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Abstract 
T and B lymphocytes are crucial in the immune response to infections. T cells are organized 
in highly specialized subsets displaying distinct functions. Helper T cells are well-known 
orchestrators of the adaptive immune response, as they provide help to another group of T 
cells, referred to as cytotoxic, which recognize and eliminate virus-infected or tumor cells. 
Moreover, helper T cells also support antibody production by B cells. T and B lymphocyte are 
characterized by the expression of a particular receptor which is able to recognize antigen, 
referred to as TCR (T-cell receptor) and BCR (B-cell receptor), respectively. The antigen 
receptor is not only mandatory for the recognition of pathogens and the initiation of the 
immune response, but it is also essential for lymphocyte development and homeostasis. The 
question how a single receptor can interpret different signals and translate them into specific 
cellular outcomes has fascinated many researchers. It is now clear that the antigen receptor is 
endowed with different sets of molecules, which adjust the intensity of the signal, control its 
duration, and regulate its localization. Quantitative and qualitative differences in the nature of 
the signal will activate a different set of genes and will ultimately result in the appropriate 
cellular response. Defects in signal transduction may lead to unwanted responses which result 
in autoimmunity or immunodeficiency. Thus, the study of how signaling via antigen receptors 
is initiated, propagated, coordinated, and translated into a cellular response is important for 
the understanding not only of physiological processes, but also of the molecular mechanisms 
underlying human diseases. 
My work focuses on how signaling via the antigen receptor is regulated, integrated, and 
translated into a cellular response. I have investigated with particular emphasis the function of 
transmembrane adaptor molecules in T and B cells. By using knockout mice, we have 
successfully demonstrated that TRAPs (Transmembrane Adaptor Proteins) are indeed 
important modulators of signals that regulate lymphocyte development, activation and 
homeostasis. Our study on SIT (SHP-2-interacting transmembrane adaptor protein) has 
revealed that SIT is required for setting the signaling threshold during thymocyte selection. 
We have further shown that SIT is a negative regulator of TCR-mediated signaling which 
inhibits the phosphorylation of TCRζ and ZAP-70 (zeta-chain-associated protein of 70 kDa). 
Moreover, we have also found that SIT regulates tolerance, thus preventing autoimmunity. 
Finally, we showed that SIT, LAX (linker for activation of X cells), and TRIM (T-cell 
receptor interacting molecule) possess redundant functions. By generating double-knockout 
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mice, we have demonstrated that SIT and LAX cooperatively regulate CD4+ T-cell activation 
and prevent autoimmunity, while SIT together with TRIM controls T-cell fate. 
More recently, my focus has shifted from the characterization of TRAPs to the analysis of 
how signaling networks are regulated in primary human T cells. In fact, I believe that it is a 
necessary goal for the future to characterize how signaling networks work during 
physiological responses and how they are integrated with upstream inputs and parallel 
signaling pathways in human T cells. This is important for truly understanding of the 
molecular events that trigger not only cellular responses, but also diseases.  
We have analyzed how the Ras-Erk cascade is regulated in primary human T lymphocytes. 
Based on studies performed in cell lines, it has been postulated that Erk activation depends on 
the cooperative action of RasGRP1 and Grb2/Sos. Using RNAi approaches in primary cells, 
we found that TCR-mediated Erk activation requires RasGRP1, but not Grb2/Sos. Thus, 
conversely to the current model, our data demonstrate that Sos and Grb2 do not link the TCR 
to Ras-Erk activation in primary T cells. However, when we analyzed Erk activation 
downstream of the IL-2R, we found that Grb2/Sos are required to activate Erk. Collectively, 
our data suggest that RasGRP1 and Grb2/Sos function as insulators of signals leading to Ras 
activation induced by different stimuli rather than to cooperate downstream of the TCR. Our 
aim is to further investigate biochemical mechanisms underlying T-cell activation not only in 
normal processes (i.e. infections), but also in pathological modifications occurring in human 
diseases i.e. cancer, autoimmunity and chronic inflammation.  
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Zusammenfassung 
T- und B-Lymphozyten sind Schlüsselzellen der spezifischen Immunantwort gegen 
Krankheitserreger. T-Lymphozyten koordinieren die spezifische Immunantwort und erkennen 
und zerstören virusinfizierte Zellen. Demgegenüber stehen B-Zellen, die für die humorale 
Immunantwort zuständig sind und Antikörper bilden, welche Antigene binden und 
eliminieren. T- und B-Lymphozyten stammen von unreifen Vorläuferzellen des 
Knochenmarks ab. B-Zellen reifen vollständig im Knochenmark aus, wohingegen die 
Vorläuferzellen der T-Zellen in den Thymus einwandern und dort ihre Entwicklung 
abschließen. Die Reifung der Lymphozyten ist ein komplexer schrittweiser Prozess, während 
dem sie Selektionsprozesse durchlaufen, die für eine Prüfung der Funktionalität der Zellen 
notwendig sind. T- und B-Lymphozyten besitzen an ihrer Oberfläche Antigenrezeptoren 
(TCR auf T- und BCR auf B-Zellen). Diese sind verantwortlich für die Antigen-Erkennung, 
die Auslösung der Immunantwort als auch für die Reifung der Lymphozyten. Darüber hinaus 
spielen Antigenrezeptoren auch eine wichtige Rolle bei der Lymphozytenhomöostase. 
Eine zentrale Frage, die Immunologen immer noch fasziniert, ist: Wie entstehen aus dem 
Signal eines einzigen Rezeptors verschiedene zelluläre Antworten? In den letzten Jahren ist 
klar geworden, dass der Antigenrezeptor mit unterschiedlichen regulatorischen Molekülen 
zusammenarbeitet, welche die Intensität und die Dauer des Signals beeinflussen und dessen 
Lokalisierung kontrollieren. Quantitäts- und Qualitätsunterschiede in der Art des Signals 
werden im Zellkern durch die Aktivierung verschiedener Gene interpretiert, die 
schlussendlich die passende zelluläre Entscheidung fällen. Fehler in der Regulation der 
Antigenrezeptor-Signalübertragung können unerwünschte zelluläre Antworten auslösen, die 
in Autoimmunerkrankungen oder Immundefiziten resultieren. Deshalb ist die Erforschung, 
wie die Antigenrezeptor-Signalübertragung initiiert, weitergeleitet, koordiniert und 
letztendlich interpretiert wird, wichtig; nicht nur um die Grundlagen physiologischer Prozesse 
zu verstehen, sondern auch für das Verständnis der molekularen Mechanismen, die 
Krankheiten zu Grunde liegen. 
In den letzten Jahren habe ich mich mit den Fragen beschäftigt, wie die Antigenrezeptor-
Signalübertragung während der Lymphozytenentwicklung, -aktivierung und -homöostase 
reguliert wird und wie zelluläre Entscheidungen getroffen werden. Insbesondere, habe ich die 
Funktion der non-raft-assoziierten transmembranösen Adaptorproteine (TRAPs) in T- und B-
Lymphozyten untersucht. Mittels Knockout-Mausmodellen habe ich mit meiner 
  9
Arbeitsgruppe demonstriert, dass TRAPs wichtige Modulatoren der Antigenrezeptor-
Signalübertragung sind und dadurch die Entwicklung, Aktivierung und Homöostase von 
Lymphozyten regulieren. Unsere Arbeit über das transmembranöse Adaptorprotein SIT (SHP-
2-interacting transmembrane adaptor protein) hat ergeben, dass SIT für die T-Zellentwicklung 
nötig ist und dass SIT die Signalschwelle des TCR senkt. Die Stärke des Signals spielt bei der 
Thymozytenentwicklung die entscheidende Rolle um festzulegen wie die Zelle auf einen 
spezifischen Liganden reagiert. SIT-defiziente Thymozyten zeigen einen hyperaktiven 
Phänotyp, erkennbar durch erhöhte CD69 und CD5 Expression. Daraus folgt, dass die 
Selektionsprozesse im Thymus der SIT-/--Mäuse verändert sind und, wie an Hand TCR-
transgener Mausmodelle gezeigt, die positive Selektion in negative Selektion umgewandelt 
wird. SIT-/--Mäuse zeigen auch eine defekte T-Zell-Homöostase. Mittels adoptiven Transfers 
von T-Zellen in lymphopenische Empfänger-Mäuse haben wir gezeigt, dass SIT die 
homöostatische Proliferation hemmt. Schlussendlich demonstrieren unsere Studien auch, dass 
SIT eine wichtige Rolle bei der Aufrechterhaltung der Selbsttoleranz spielt. Tatsächlich sind 
SIT-defiziente Mäuse anfälliger für die Entwicklung experimenteller und spontaner 
Autoimmunerkrankungen im Vergleich zum Wildtyp. Darüber hinaus haben wir mittels RNAi 
in peripheren T-Zellen gezeigt, dass SIT ein negativer Regulator der TCR-vermittelten 
Signaltransduktion ist, welcher die Phosphorylierung von TCRζ und ZAP-70 (zeta-chain-
associated protein of 70 kDa) inhibiert.  
Zusätzlich haben wir untersucht, ob SIT mit anderen transmembranösen Adaptorproteinen 
eine redundante Funktion aufweist. Zu Beginn haben wir getestet, ob SIT und TRIM (T-cell 
receptor interacting molecule) funktionell überlappen. SIT und TRIM besitzen eine sehr 
ähnliche molekulare Struktur und sind beide in Thymozyten sehr stark exprimiert. Durch 
Generierung von SIT/TRIM Doppel-Knockout (DKO) Mäusen konnten wir feststellen, dass 
SIT und TRIM gemeinsam die Thymozytendifferenzierung regulieren. Die Selektionprozesse 
im Thymus von DKO-Mäusen sind komplett gestört. Tatsächlich wird die Non-Selektion in 
positive Selektion und die positive Selektion in negative Selektion umgewandelt. 
Anschließend haben wir getestet, ob SIT funktionell mit dem Adaptorprotein LAX (linker for 
activation of X cells) überlappt. Im Gegensatz zu SIT und TRIM haben wir festgestellt, dass 
SIT und LAX gemeinsam die Funktion peripherer T- und B-Zellen regulieren. SIT/LAX-
DKO-Mäuse zeigen eine erhöhte Anzahl aktivierter CD4+-T-Zellen sowie der B1-Zellen, eine 
Subpopulation der B-Lymphozyten die den größten Teil des IgM produzieren. B-Zellen, in 
denen SIT und LAX ausgeknockt wurde, proliferieren stärker als Wildtyp B-Zellen. Als 
Konsequenz ist auch die humorale Immunantwort in SIT/LAX-DKO-Mäusen verstärkt. Die 
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Veränderung der Funktion von T- und B-Zellen resultiert letztendlich in der spontanen 
Entwicklung einer Glomerulonephritis Autoimmunerkrankung in SIT/LAX-DKO-Mäusen. 
Zusammenfassend konnten wir demonstrieren, dass die non-raft-assoziierten 
transmembranösen Adaptorproteine SIT, TRIM und LAX eine wichtige Rolle bei der 
Lymphozytendifferentierung, -aktivierung und -homöostase spielen.  
In den letzten Jahren habe ich meine Studien auf die Analyse der TCR-vermittelten 
Signalnetzwerke in peripheren menschlichen T-Zellen fokussiert. Ich glaube, dass es für die 
Zukunft notwendig sein wird, die detaillierte Funktionsweise von 
Signaltransduktionskaskaden zu bestimmen und ebenso zu charakterisieren, wie 
Signalmodule mit vorgeschalteten Inputs und parallelen Signaltransduktionswegen 
Informationen integrieren. Die Nutzung primärer humaner T-Zellen als experimentelles 
System sind von Vorteil, da sich manche menschliche biologische Prozesse oder Krankheiten 
in Tiermodellen oder Zelllinien nur teilweise widerspiegeln. Als ersten Aspekt haben wir 
untersucht, wie die Aktivierung der Ras-Erk Signalkaskade in peripheren humanen T-Zellen 
reguliert wird. Andere Arbeitsgruppen haben gezeigt, dass die TCR-vermittelte Aktivierung 
von Ras-Erk von der kooperativen Aktion zweier Aktivatoren abhängt, nämlich RasGRP1 
und Grb2/Sos. Dieses Modell basiert auf Ergebnissen aus Zelllinien, deshalb ist noch nicht 
bekannt, ob bei primären T-Zellen sowohl RasGRP1 als auch Grb2/Sos notwendig sind, um 
Ras-Erk zu aktivieren. Vermittels RNAi haben wir demonstriert, dass die TCR-vermittelte 
Aktivierung von Ras-Erk in peripheren T-Zellen nur von RasGRP1, aber nicht von Grb2/Sos 
abhängt. Darüber hinaus haben wir gezeigt, dass Grb2/Sos, aber nicht RasGRP1 eine wichtige 
Rolle bei der IL-2-vermittelten Ras-Erk-Aktivierung spielt. Zusammengefasst 
veranschaulichen unsere Daten, dass RasGRP1 und Grb2/Sos keine kooperative Aktion bei 
der Aktivierung von Ras-Erk „downstream“ des TCR vermitteln. Beide Moleküle 
funktionieren unabhängig voneinander „downstream“ von wichtigen Rezeptoren der T-Zellen 
(TCR und IL-2R), die die Aktivierung und Proliferation von T-Zellen regulieren und damit 
eine effiziente Immunantwort erlauben. Dies unterstützt unsere Ansicht, dass sich primäre T-
Zellen durch Zelllinien nur ungenügend repräsentiert lassen. Daher ist es unser Ziel die 
weitere Untersuchung der TCR-vermittelten Signalübertragung in primären T-Zellen während 
physiologischer bzw. pathologischer Prozesse wie Krebs, Autoimmunität und chronischen 
Entzündungen durchzuführen. 
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1. An introduction to the immune system 
The constant selection pressure of microbes on multicellular organisms has led to the 
evolution of an orchestra of defense mechanisms, known as the immune system. Over the past 
several decades it has become clear that the immune system is a very complex network of 
proteins, cells, tissues, and organs that work together to protect the body not only against 
infectious agents (i.e. virus, bacteria, fungi, and parasites) and foreign substances (i.e. toxins) 
that can cause tissue damage and diseases, but also against tumor cells. Physical and chemical 
barriers, which include the skin, mucous membranes, tears, earwax, and stomach acid, are 
considered the first line of defense of the body. When pathogens eventually overcome the 
physico-chemical barriers, the immune system operates throughout the body to eliminate 
invaders. There are certain sites within the body where the immune system is organized into 
specific structures where the immune response (i.e. the reaction of the immune system against 
invaders) is initiated. These are called secondary lymphoid organs (e.g. lymph nodes, spleen, 
mucosa-associated lymphoid tissue). There are also primary lymphoid organs (i.e. bone 
marrow and thymus), which are the sites where the cells of the immune system are generated.  
The immune system can be subdivided into two parts: the innate or non-specific and the 
adaptive, which is also referred to as acquired or specific immunity. Innate immunity is 
phylogenetically older than acquired immunity. The two branches of the immune system are 
composed of both cellular (i.e. neutrophils, macrophages, eosinophils, dendritic cells, and NK 
cells for the innate; T and B lymphocytes for the adaptive immune system) and humoral 
components (e.g. proteins of the complement for the innate and antibodies for the adaptive 
immunity). Each of these two branches of the immune system protects the body from 
pathogen attacks and possesses particular mechanisms of action. First, the components of the 
innate immune response are constitutively present in the body and are ready to be mobilized 
within minutes upon infection. Therefore, innate immunity is the first line of defense against 
invading organisms. Conversely, adaptive immunity needs to be induced and, hence, it acts as 
a second line of defense. The innate system recognizes pathogen-associated molecular 
patterns (PAMPs) present on bacteria, fungi, parasites and viruses (e.g. components of 
bacterial cellular walls, peculiar modifications of DNA and RNA, or viral double-stranded 
RNA). Thus, innate immunity is not specific and reacts equally well against a variety of 
organisms. In contrast, the adaptive immune system is antigen specific. This means that it 
reacts only to the specific microorganism causing an infection. Finally, once that the pathogen 
has been eradicated, the non-specific immune response ceases and the innate defense 
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mechanisms return to their previous state, without being altered by the infection. Conversely, 
the specific response develops ‘memory’. In other words, when the same pathogen is 
encountered for a second time, the specific response will be faster and more effective. Despite 
the fact that the two arms of the immune system have distinct mechanisms of actions, they are 
not separated, but rather integrated by cytokines and hormones into a complex multilayered 
network. One of the most representative examples of a crosstalk between the adaptive and the 
innate immune system is antigen presentation. In fact, T cells initiate the adaptive immune 
response only when parts of the pathogens (antigens) are presented by antigen presenting cells 
(APCs), such as dendritic cells and macrophages, which belong to the innate immune system. 
One of the most distinguishing features between the innate and adaptive immune system is the 
nature of the receptors that immune cells use to recognize pathogens. The innate immune 
system employs pattern recognition receptors (PRRs), which are encoded by separate genes 
and recognize groups of related molecules characteristic of microbes (the above mentioned 
PAMPs). In contrast, cells of the adaptive immune system, such as B and T lymphocytes, are 
endowed with a unique repertoire of diverse receptors (the B-cell receptor, BCR, and the T-
cell receptor, TCR, respectively), which are generated de novo in each individual by the 
random recombination of gene segments. The repertoire of adaptive immune receptors has the 
possibility to recognize a numberless variety of antigens and is generated during the 
development of T and B cells in the primary lymphoid organs. During development, the 
antigen receptor repertoire is further selected for specificity to antigens and for lack of 
reactivity against self molecules. 
The BCR and the TCR can be structurally divided in two modules: (i) an extracellular unit 
that recognizes and binds antigens and (ii) cytoplasmic subunits possessing signal-transducing 
capability. Signals emanating from these receptors are crucial not only for the activation and 
differentiation of T and B cells (and hence for the immune response), but are also necessary 
for their development and homeostasis. 
 
2. Development of the immune system 
All immune cells are derived from a common precursor, called the pluripotent hematopoietic 
stem cell (HSC) that reside in the bone marrow. HSCs differentiate into two intermediate stem 
cells: (i) the common myeloid progenitor (CMP), which is the precursor for the cells of the 
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innate immune system, such as granulocytes, macrophages, mast cells, and dendritic cells, and 
(ii) the common lymphoid progenitor (CLP), which can differentiate into lymphocytes, the 
key cells of the adaptive immune system.  
Here, I will focus on the development of lymphocytes as these cells are the subject of my 
investigations. As mentioned above, lymphocytes originate from common lymphoid 
progenitors in the bone marrow. Cells destined to become B lymphocytes continue maturation 
in this organ, whereas precursors of T cells exit the bone marrow and enter the thymus, where 
they become irreversibly committed toward development in the T-cell lineage by the action of 
the master differentiation gene Notch1 (Radtke et al., 1999). 
2.1. T-cell development 
The development of T cells proceeds through discrete stages (Figure 1) (for a review see Starr 
et al., 2003). Early T-lymphocyte precursors are defined as double negative (DN or CD4-CD8-
) since they do not express either CD4 or CD8. DN thymocytes can be further subdivided into 
four distinct developmental stages defined by the expression of CD44 and CD25 (IL2Rα). 
DN1 thymocytes (CD44+CD25-) are still pluripotential and can give rise to T, B, and NK 
cells. DN1 cells mature into DN2 cells (CD44+CD25+) possessing a more limited 
differentiation potential. DN2 further differentiate into DN3 thymocytes (CD44−CD25+), 
which are committed thymocytes that have undergone rearrangements of the gene segments 
coding for the TCR. These cells also express additional molecules characteristic of the T-cell 
lineage such as the CD3/TCRζ chains, Lck, ZAP-70, LAT, SLP-76 and others. However, 
DN3 thymocytes do not possess a functional αβTCR instead they express a complex called 
the pre-TCR. The TCR and the pre-TCR share many similarities (Figure 2). They both 
include CD3 εγ and εδ heterodimers, a TCR ζζ homodimer, and a fully rearranged TCRβ 
chain. Nevertheless, the pre-TCR does not contain the TCRα chain, but rather a surrogate 
chain called pTα.  
The pre-TCR dictates the fate of developing DN3 thymocytes. In fact, mice lacking CD3 
chains or TCRβ expression show a developmental arrest at the DN3 stage. The pre-TCR does 
not have a known ligand and appears to signal in a ligand-independent fashion. Signaling via 
the pre-TCR controls the transition from the DN3 to the DN4 stage (CD44−CD25-). During 
this process, known as “β-selection” (Figure 1), DN3 cells are rescued from apoptosis, 
proliferate, and stop recombination of the other TCRβ locus (allelic exclusion), thus ensuring 
that only one functional TCRβ is expressed on the surface of each T cell. The importance of
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Figure 1. Schematic representation of T-cell development in the thymus.
Upon entering the thymus, lymphoid precursor cells undergo commitment to the T-cell 
lineage by the action of Notch. Early T-cell precursors express neither CD4 nor CD8 and 
are called double negative (DN) cells. The DN stage can be subdivided further into four 
discrete stages (DN1–4) by the expression of CD44 and CD25. DN2 thymocytes start to 
rearrange the TCRβ gene. DN3 cells express the pre-TCR which is required for successful 
transition to the DN4 stage (TCRβ-selection checkpoint). At DN4, thymocytes enter 
division and start to express the CD4 and CD8 genes, thus becoming double positive (DP) 
cells. DP thymocytes initiate the rearrangement of TCRα and hence replace the pre-TCR 
with the mature αβTCR. Finally, DP thymocytes undergo positive and negative selection
(αβTCR selection). Positive selection results in the differentiation into CD4+ or CD8+ single 
positive (SP), whereas negative selection culminates with the elimination of the autoreactive 
clones by apoptosis.
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Figure 2. Structure of the pre-TCR and the αβTCR.
A schematic structure of the pre-TCR (left) and the αβTCR (right) is shown. The pre-TCR 
complex is composed of a TCRβ chain paired with surrogate preTα, two CD3ε chains, one 
dimerizing with a CD3γ chain, the other with a CD3δ chain, and a TCRζ homodimer. The 
pre-TCR and the αβTCR are very similar. The only difference is that the αβTCR express a 
TCRα chain instead of the surrogate preTα. ITAMs are indicated with white boxes.
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pre-TCR-mediated signaling in DN3 development has been highlighted in LAT-/- or SLP-76-/- 
mice (Pivniouk and Geha, 2000). In these mice the pre-TCR is uncoupled from the activation 
of downstream signaling pathways and hence thymic development is arrested at the DN3 
stage. At the end of β-selection, thymocytes further mature from DN4 to the double positive 
(DP) stage. During this transition, DN4 cells upregulate the coreceptors CD4 and CD8 and 
start to recombine the TCRα locus.  
At the DP stage, thymocytes express a fully assembled αβTCR and undergo a second major 
developmental checkpoint (TCR αβ selection, see Figure 1). At this stage, the fate of DP 
thymocytes is determined by the avidity/affinity of the αβTCR for MHC/self-peptides (Figure 
3). Thymocytes expressing a non-functional αβTCR complex that does not bind self-
peptide/MHC complexes or that is unable to signal are rapidly eliminated (non-selection). 
About 90% of DP thymocytes die during this process, which is known as “death by neglect”. 
On the other hand, DP thymocytes that express a functional αβTCR undergo either positive or 
negative selection. This process is dictated by the affinity of the TCR for MHC+self peptide 
complexes (Figure 3). If DP thymocytes carry TCRs with intermediate affinities they will 
undergo positive selection. This means that thymocytes will complete the differentiation 
program and become mature T cells. If DP thymocytes bear TCRs with strong affinity for self 
peptides they will undergo negative selection, a process required to eliminate thymocytes 
expressing self reactive TCRs.  
At the end of thymic selection, only about 5% of thymocytes complete maturation to become 
CD4+ or CD8+ T cell. Thymic selection ensures the generation of a normal TCR repertoire 
showing strong reactivity against pathogenic peptides, but lacking overt reactivity against self 
proteins. For this reason this process is also known as central tolerance. However, thymic 
selection is not completely safe and some potentially autoreactive T cells do escape negative 
selection and migrate into the periphery. Therefore, the body possesses a second layer of 
safety mechanisms, called peripheral tolerance, which prevents the activation of autoreactive 
T cells in the periphery. These mechanisms include the induction of anergy (i.e. refractory 
state), immunoregulation (e.g. inhibition of activation by regulatory T cells), expression of 
antigens in organs which are not accessible to T cells (immune privilege), and others. 
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Figure 3. Relationship between TCR affinity, signaling potential, and the outcome of 
thymic selection.
Upon TCR/MHC+self peptide interactions, DP thymocytes undergo selection processes. 
TCRs that fail to recognize ligand generate signals of insufficient strength which are unable 
to induce selection and thymocytes die of neglect. Intermediate-strength signals lead to 
positive selection, which will result in the maturation of DP cells into CD4+ or CD8+ single 
positive T cells. Conversely, strong signals lead to deletion of autoreactive DP thymocytes.
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2.2. B-cell development 
B cells develop in the bone marrow from a common lymphoid progenitor. Similar to T-cell 
development, the development of B lymphocytes also occurs through a multistep process, 
which includes the ordered expression of different genes (Figure 4) (LeBien and Tedder, 
2008). The earliest B lineage-committed progenitors are referred to as pro-B cells, which can 
be distinguished by the expression of B220 and CD43. These cells show recombination at the 
heavy chain locus. Once the immunoglobulin heavy chain genes are successfully rearranged 
and a heavy chain is expressed at the plasma membrane together with both the surrogate light 
chains and the signaling components Igα/β (forming the pre-BCR), pro-B cells undergo 
proliferation and clonal expansion. At this stage, pro-B cells are called large pre-B cells. 
Subsequently, large pre-B cells stop proliferating and start to rearrange the light chain locus. 
These cells are known as small pre-B cells.  
Similar to the pre-TCR, also the expression of the pre-BCR is crucial for the differentiation of 
B cells. In fact, gene knockout mice that fail to express the pre-BCR display a developmental 
block at the pro-B cell stage (Martensson et al., 2010). Once functional light chains have been 
successfully synthesized and paired with the μ heavy chains, small pre-B cells develop into 
surface IgM+ immature B cells. At this stage, immature B cells undergo negative selection 
and die if they bind to self antigens in the bone marrow. Conversely, if immature B cells do 
not bind self antigen, then they start to express the δ chain and will display both IgM and IgD 
at the plasma membrane. These cells are called transitional 1 B cells and migrate from the BM 
to the secondary lymphoid organs. Transitional 1 (T1) B cells, are IgMhi and IgDlo and further 
differentiate into transitional 2 (IgMhiIgDhi) in the spleen. Finally, these cells develop into 
mature B cells (IgMloIgDhi).  
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Figure 4. Schematic representation of B-cell development.
The development of B cells begins in the bone marrow and completes in the spleen. The 
stages of B-cell maturation can be defined by the expression of surface markers. Early B-
cell precursors (pro-B) consist of cells that are negative for cell-surface immunoglobulin 
(IgM), but positive for the B-cell-lineage marker B220 and CD43. Pro-B cells switch on the 
expression of the Rag genes, which are responsible for the rearrangement of the Igµ locus 
(IgH). This in turn results in the expression of the Igµ heavy chain, which associates with 
the surrogate light chain (SLC) to form the pre-B-cell receptor (pre-BCR). Signaling 
through the pre-BCR promotes a proliferative burst and proliferating pro-B cells are defined 
as large pre-B cells. Successively, large pre-B cells stop proliferating and switch on the 
expression of the light chain (IgL) (small pre-B cells). Finally, B-cell precursors express the 
BCR, which will control the next stages of B-cell development.
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3. Subpopulations of peripheral lymphocytes 
Peripheral lymphocytes are not a homogeneous population, but rather exist in multiple 
subsets. Here, I shall briefly describe T- and B-cell subpopulations. 
3.1. T-cell subsets 
Peripheral T cells are subdivided into two distinct groups one expressing the αβ TCR (αβ T 
cells) and the other bearing the γδ TCR (γδ T cells). 
αβ T cells, which represent the majority of T lymphocytes, can be further subdivided in CD4+ 
and CD8+ T lymphocytes. These two subpopulations are functionally distinct. Whereas CD4+ 
T cells coordinate the adaptive immune response and are, therefore, called T-helper cells, 
CD8+ T cells display cytotoxic activity and are able to kill virus-infected or tumor cells.  
CD4+ T cells orchestrate the adaptive immune response and perform their helper function 
mainly by secreting a variety of cytokines. T-helper cells are divided into T-helper (Th) 
subsets, which are defined according to the cytokines they secrete (Zhu and Paul, 2008). A 
growing number of Th subsets have been identified: Th1 cells, which produce IL-12, IL-18, 
and IFNγ support cell-mediated immune responses; Th2 cells, which secrete IL-4, IL-5, and 
IL-13 coordinate humoral immune responses; Th9 cells, which produce IL-9 may play a role 
against helminth infection; Th17, which secrete IL-17 have an anti-microbial function and are 
also implicated in the pathogenesis of many autoimmune diseases. Beside the Th types, CD4+ 
T cells also include another important subset called regulatory T cells (Tregs). Tregs are 
characterized by the expression of the transcription factor Foxp3 and CD25 and play a pivotal 
role in peripheral tolerance. 
Conversely to αβ T cells, γδ T lymphocytes represent a small subset of the T-cell pool which 
usually does not express the coreceptors CD4 or CD8 (for a Review see Bonneville et 
al.,2010). γδ T cells develop in the thymus at the DN2-DN3 stage. In the periphery, they are 
particularly abundant in the gut mucosa and in the skin. Their function is still largely 
unknown and antigen recognition by γδ T cells is very unique as it does not require MHC 
class I or class II molecules. The γδTCR repertoire is very limited and γδTCRs appear to 
recognize conserved molecules, similarly to pattern recognition receptors (the receptors of the 
cells of the innate immunity). γδ T cells appear to function as non-classical T cells and can 
contribute to both adaptive and innate immunity. In addition to a strong cytotoxic activity, γδ 
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T cells have also regulatory functions and produce large amounts of proinflammatory 
cytokines such as IFNγ and IL-17. 
3.2. B-cell subsets 
Mature B cells are divided into (i) follicular (FO) B cells (also called conventional or B-2 
cells), which represent the majority of the mature B cells in the secondary lymphoid organs 
and (ii) marginal zone (MZ) B cells (for a review see LeBien and Tedder, 2008). These two 
B-cell subsets are functionally distinct. In fact, whereas FO B cells take part in both T-cell 
dependent and T-cell independent immune responses, MZ B cells play an important role in T-
independent immune responses. 
An additional B-cell subset called B-1 cells has been identified. In adult mice, B-1 cells are 
found mainly in the peritoneal and pleural cavity. On the basis of the expression of surface 
markers, B-1 cells can be defined as CD5+CD23+CD43+IgMhiIgDlo. The origin of B-1 cells 
remains still unknown. One hypothesis proposes that B-1 cells and conventional B cells 
originate from distinct precursors. Conversely, a second model postulates that both B-1 and 
conventional B cells derive from a common precursor (Figure 5). According to this 
hypothesis, the strength of BCR signaling in B-cell precursors will dictate the developmental 
outcome. If the signal via the BCR is strong, B-cell precursors will develop into B-1 cells. 
Conversely, if the BCR signaling is more moderate, B cells will differentiate into 
conventional B cells. This hypothesis is based on the observation that genetically engineered 
mutant mice lacking important positive regulators of BCR-mediated signaling display a strong 
reduction in B-1 cell numbers. On the contrary, mice lacking negative regulators (e.g. CD22 
or SHP-1) show an increase in B-1 cell numbers (Figure 5). This hypothesis is also 
corroborated by our recent data. In fact, we found that mice lacking both SIT and LAX, two 
inhibitory transmembrane adaptor proteins, display increased B-1-cell numbers (App.19 and 
sections 6.1., 6.3., and 6.4.).  
From a functional point of view, B-1 cells are responsible for the production of most of the 
non-immune serum IgM (natural antibodies) and contribute substantially to the production of 
IgA and IgG3. Similar to MZ B cells, B-1 cells are important during T-independent immune 
responses. 
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Figure 5. Development of B1 cells.
B-cell precursors can potentially differentiate into either conventional (B2) or B1 cells. The 
strength of the BCR-mediated signaling dictate the developmental outcome. Weak BCR 
signaling will support B2-cell development. Conversely, a stronger signaling via the BCR 
will result in the development of B1 cells. As demonstrated in many mouse models, 
alterations of the BCR signaling strength will in turn affect B1 cell development (Hardy and 
Hayakawa, 2001; App.19).
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4. Lymphocyte homeostasis 
T and B lymphocytes are the key players of the adaptive immune response. Therefore, the 
preservation of the size of the peripheral lymphocyte pool throughout life is a precondition for 
an effective immunity. Different strategies are used by the body to regulate the number of 
peripheral lymphocytes. These include expansion of mature cells, cell death, and the 
regulation of cell production. Together these processes are referred to as homeostasis (for a 
review see Grossman et al., 2004). 
The homeostasis of different lymphocyte subsets appears to be independently regulated. In 
fact, T cells are found in normal numbers in B-cell deficient mice and vice versa. Similarly, 
naïve T cells cannot be replaced by expanding memory T cells and the peripheral memory 
pool cannot be displaced by an enhanced generation of new cells in the thymus. The fact that 
lymphocytes possess independent homeostatic control is a prerequisite (i) to safeguard a 
diverse repertoire of the antigen receptors and (ii) to preserve immunological memory against 
previously encountered pathogens. 
Here, I would like to further focus on how homeostasis of naïve T cells is regulated. In young 
individuals, the pool of naïve peripheral T cells is initially generated through the continuous 
emigration of SP thymocytes into the blood stream. Successively, the number of naïve T cells 
in the periphery is kept constant by the balance between loss (i.e. death or gradual 
differentiation in the memory compartment after antigen encounter) and replacement (i.e. by 
the thymic output). In adults, as thymic output diminishes, naïve T-cell numbers are 
maintained by survival signals (i.e. MHC/self peptides and IL-7) (Figure 6A) and, when 
clones are lost, by antigen-independent cell divisions of the remaining T-cell clones 
(homeostatic proliferation) (Figure 6B).  
One of the major achievements in our understanding of how homeostasis is regulated was the 
discovery that cytokines (e.g. IL-7 for naïve T cells) and TCR/MHC+self peptide interactions 
deliver homeostatic signals. The primary function of cytokines and self peptides/MHC 
molecules is to support T-cell survival (Figure 6A), as their absence results in T-cell loss. 
However, these homeostatic signals can also trigger proliferation under conditions in which 
the size of the T-cell pool is reduced (lymphopenia) (Figure 6B). Under lymphopenic 
conditions, residual T cells proliferate in the attempt to repopulate the void. Lymphopenia 
may occur after chemotherapy, during viral infections, or in patients suffering from 
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immunodeficiency. Under particular circumstances, however, lymphopenia may also provide 
the basis for the development of autoimmunity (Figure 6B). This may occur when T-cell 
depletion persists or is progressively repeated, or when lymphopenia arises concomitantly 
with an inflammation. In this scenario, T cells may be overstimulated or the T-cell repertoire 
may be skewed to a one enriched in self-reactive clones. In this regard, we found that SIT-
deficient mice develop autoimmunity along with an enhanced homeostatic expansion 
(Posevitz et al., 2008/App.11; Arndt et al., 2011/App.16). 
Homeostasis has been extensively studied in different experimental models. One of the most 
well-established methods to study homeostatic expansion is the adoptive transfer of T cells 
into lymphopenic recipients. Sublethally irradiated mice or Rag1/Rag2-deficient mice are 
frequently used as recipients. Studies employing these models have revealed that the strength 
of TCR signaling is a crucial determinant for homeostatic expansion. T cells expressing TCRs 
with higher affinity display homeostatic advantage over T cells carrying TCRs with lower 
affinity. Our studies have further empathized the importance of modulators of TCR signaling 
in the regulation of T-cell homeostasis (Posevitz et al., 2008/App.11). We have shown that 
mice lacking SIT, a transmembrane adaptor that inhibits TCR-mediated signaling, showed an 
enhanced lymphopenia-induced homeostatic expansion. One observation of our study was 
that the loss of SIT enables HY TCR transgenic T cells to undergo homeostatic proliferation. 
This is a striking effect as HY TCR transgenic T cells, due to the very low affinity of the 
TCR, are unable to undergo homeostatic proliferation in lymphopenic hosts. 
An important issue that has been recently addressed is whether homeostatic TCR signals 
inducing survival are qualitatively different from those inducing expansion (Seddon and 
Zamoyska, 2003). It appears that Lck and Fyn, the most proximal signaling molecules in the 
TCR signaling cascade, are key discriminators between T-cell survival and expansion. In fact, 
whereas the expression of Lck is not required for the survival of naïve T cells, Lck expression 
is absolutely mandatory for TCR signals that induce homeostatic proliferation upon 
lymphopenia. Conversely, Fyn plays no role in lymphopenia-induced homeostatic expansion, 
but rather it mediates T-cell survival. 
In addition to TCR signals, also cytokines (especially IL-7) play a crucial role in T-cell 
homeostasis (Fry and Mackall, 2005). Studies utilizing IL-7Rα deficient mice or blocking 
antibodies have shown that IL7Rα-mediated signaling is essential for the homeostatic 
proliferation and the survival of naïve T cells. 
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Figure 6A. Regulation of T-cell homeostasis under normal conditions.
Selection processes in the thymus generate T cells with a broad spectrum of affinities for 
self peptides. After emigrating into the periphery, these cells are kept alive (quiescent 
survival) by continuous signals generated upon TCR/MHC+self petides and by soluble 
factors (i.e. IL-7). Competition for soluble factors and MHC+self peptides limits the size of 
the peripheral T-cell pool and avoid uncontrolled homeostatic expansion (modified from 
Theofilopoulos et al., 2001).
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Figure 6B. Regulation of T-cell homeostasis under lymphopenic condition.
Reduction of T-cell numbers increases the availability of stimulatory signals (i.e. 
MHC+peptides and cytokines) resulting in homeostatic expansion. Lymphopenia-induced 
homeostatic proliferation is usually an innocuous process, and expanding T cells express 
some activation/memory markers without acquiring effector functions. However, when 
other pathological conditions are met (e.g. recurrence of lymphopenia, inflammation, etc,), 
T cells may become over reactive and the T-cell repertoire may be skewed. This may lead 
to the development of autoimmune diseases (modified from Theofilopoulos et al., 2001).
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In summary, the homeostasis of naïve T cells depends on signals mediated by both 
TCR/MHC+self pepdide and IL7/IL7R interactions. It is the availability of these factors that 
limits the size of the different lymphocyte subpopulations. The relative contribution of the 
two signaling pathways to the activation of the homeostatic program has not yet clearly 
determined and may depend on both the characteristics of individual T-cell clones and the 
environmental conditions (e.g. the degree of the lymphopenia). 
T cells undergoing homeostatic expansion do not upregulate activation markers such as CD69 
or CD25 and keep the expression of the naive T-cell marker CD62L. Therefore, they are 
clearly distinguishable from activated T cells. Nevertheless, they upregulate memory markers 
such as CD44 and CD122, and also their functional responses resemble those of memory 
cells. Thus, T cells undergoing homeostatic proliferation are also referred as to memory-like T 
cells. 
 
5. TCR-mediated signaling: an overview 
As discussed above, signals transduced via the TCR are crucial for the development, the 
activation, and homeostasis of T cells. Therefore, in this section, I will discuss how TCR-
mediated signaling is initiated, regulated, and propagated to the nucleus, where the cellular 
program is ultimately executed.  
One of the first events induced upon TCR ligation is the aggregation of the receptors. 
Subsequently, Lck and Fyn, two members of the Src family of tyrosine kinases, come into 
play. The question of how the signaling cascade is initiated by Src kinases has fascinated 
many researchers. To date, however, a clear answer to this question is still missing and 
several models have been postulated. The current tenet suggests that Src kinases are activated 
upon TCR triggering. In turn, Lck and Fyn phosphorylate a variety of downstream molecules, 
thus allowing propagation of the signal to the nucleus. However, a recently proposed model 
has challenged this view (Nika et al., 2010). According to the studies of Nika et al., a pool of 
Lck, the Src kinase playing a major role in TCR signaling, is constitutively active. Therefore, 
the initiation of signaling does not require de novo activation of Lck, but rather the 
redistribution of the active pool of Lck to the TCR and other signaling molecules at the 
plasma membrane.  
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Nevertheless, Src-family tyrosine kinases are crucial for the propagation of the signal as they 
phosphorylate the two tyrosine residues of the ITAMs (immunoreceptor tyrosine-based 
activation motifs) located within the cytoplasmic tails of the antigen receptor-associated 
subunits (i.e. CD3 γ, δ, ε, and ζ in T cells). Fully phosphorylated ITAMs provide binding sites 
for ZAP-70, a protein tyrosine kinase with two tandem SH2 domains, which propagates the 
signal further. Recruitment of ZAP-70 to the ITAMs results in its phosphorylation and 
subsequent activation by Lck. Activated ZAP-70 in turn phosphorylates two adaptor proteins 
LAT and SLP-76, which form the backbone of a signaling complex that activates multiple 
downstream signaling pathways (e.g. MAPK, NFAT, NFkB etc.) leading to T-cell activation 
and proliferation (Smith-Garvin et al., 2009). T cells also possess a number of counter 
regulating mechanisms that fine-tune and shutdown signaling (Acuto et al., 2008; Linnemann 
et al., 2009/App.14; Marinari et al., 2003/App.3). 
A central question in TCR-mediated signaling seeks to understand how the TCR produces 
diverse cellular outcomes (e.g. proliferation, differentiation, or apoptosis) in response to 
different stimuli by activating a limited number of signaling modules. During the last decades 
efforts have been made in order to answer this question and several hypotheses have been 
formulated. Recent progress emphasizes that variations in the magnitude or in the duration of 
activation of signaling cascades determine the specificity of the signaling output and of the 
consequent cellular outcome (Ebisuya et al., 2005). In the following subsections, I shall 
discuss two current models for signal discrimination. 
5.1 Regulation of TCR-mediated signaling: signal amplification at the proximal level 
The TCR/CD3 complex has an unique configuration compared to other antigen receptors as it 
contains ten ITAMs. As mentioned above, ITAMs are critical for the initiation of signaling 
following ligand engagement. It has been additionally proposed that ITAMs could also 
provide quantitative and/or qualitative contributions to the specific cellular response (Love 
and Hayes, 2010). In fact, the high number of ITAMs in the TCR signaling machinery can 
allow the generation of different signaling degrees, ranging from weak to strong, depending 
on the number of phosphorylated ITAMs and hence on available ZAP-70 molecules. 
Differences in the signal amplitude will be then translated into the nucleus, where diverse sets 
of responding genes will be activated, which will in turn dictate the specific cellular response.  
A large body of evidence indicates that the ITAM-mediated signal amplification plays a 
critical role in T-cell development. ITAMs appear to be important at both the DN to DP and 
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the DP to SP transitions, as well as for the αβ/γδ T lineage choice. In fact, the attenuation of 
the γδTCR signaling potential by reducing the number of ζ ITAMs results in the diversion 
from the γδ to the αβ T-cell lineage. Additional studies have revealed that TCRζ-/- mice 
transgenically reconstituted with ζ chains lacking one or more ITAMs have a defect in thymic 
development (Love et al., 2000; Watanabe et al., 2000). Interestingly, the severity of the 
developmental defect is in close correlation with the number of inactivated ITAMs. Both 
positive and negative selection are affected in these mice (Figure 7). Positive selection is 
reduced or diverted to non-selection, whereas negative selection is converted to positive 
selection (Shores et al., 1997; Yamazaki et al., 1997). These alterations may potentially lead 
to the generation of autoreactive T cells. In summary, these data demonstrate that 
amplification of the TCR signal at a very proximal level determines the right signal intensity 
for the specific developmental outcome.  
We have further explored how the TCR-mediated signaling is regulated during T-cell 
development. In particular, we have analyzed the function of the two transmembrane adaptor 
molecules SIT and TRIM. It has been shown that TRIM is an integral component of the 
TCR/CD3 complex (Bruyns et al., 1998; Kirchgessner et al., 2001). Similarly, SIT was 
identified as a protein co-immunoprecipitating with CD3ε (Marie-Cardine et al., 1999). Thus, 
both SIT and TRIM are physically located at the plasma membrane either as a part of or in 
close proximity to the TCR and hence may be involved in the regulation of TCR-mediated 
signaling. Indeed, we have demonstrated that SIT and TRIM function as suppressors of signal 
amplification and regulate thymic selection (Simeoni et al., 2005a/App.5; Koelsch et al., 
2008/App.13). By generating SIT and TRIM single or double knockout mice, we found that 
the loss of SIT and TRIM converts non selection into positive selection (Figure 7). Using 
TCR transgenic models (i.e. HY and P14), we found that the loss of SIT alone is sufficient to 
induce a more efficient positive selection and a partial shift to negative selection, whereas the 
loss of both SIT and TRIM results in a complete conversion from positive to negative 
selection (Figure 7). Interestingly, the effects of SIT/TRIM double-deficiency on thymocyte 
development are opposite to those observed in mice carrying mutations in the TCR-associated 
ζ chain. On the basis of these observations, we propose a model whereby signal amplification 
by multiple ITAMs within the TCR/CD3 complex appears to be counter regulated by an 
inhibitory system based on several TBSMs within transmembrane adaptors (Koelsch et al., 
2008/App.13).  
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Figure 7. Model of thymic selection outcomes.
The model shows the effects of altering signal intensity on the selection of thymocytes 
expressing TCRs with increasing affinity/avidity for the ligand. The effects of SIT (black 
dotted line) or SIT and TRIM (black dashed line) deletions on selection outcomes are 
compared with those obtained by TCR-ζ mutants carrying only 1 ITAM (gray dotted line) 
or no ITAMs (gray dashed line) (from Koelsch et al., 2008/App.13)
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5.2 Regulation of TCR-mediated signaling: signal amplification at the level of Ras 
The Ras-Erk cascade is essential for cell-fate decisions in many cell types including T 
lymphocytes (Yasuda and Kurosaki, 2008). In T cells it is the magnitude of Erk activity that 
appears to be involved in cell-fate specification triggered via the TCR (Daniels et al., 2006; 
Prasad et al., 2009). For example, it was shown that strong Erk activation at the plasma 
membrane induces apoptosis (negative selection), whereas moderate Erk activation in 
intracellular compartments induces differentiation (positive selection) of immature T cells. A 
similar mechanism of Erk activation exists also in mature peripheral T cells. In fact, we have 
previously shown that in OT-I T cells strong Erk activation correlates with apoptosis, 
whereas, weak Erk activity corresponds with proliferation (Wang et al., 2008/App.12). More 
recently, we have shown that the duration of Erk activation may also play a role in cell-fate 
decisions in human T cells. In fact, transient Erk activation correlates with an unresponsive, 
anergic-like state, whereas sustained Erk activity corresponds with proliferation (App.18). 
Upon ligation of the TCR, the activation of the Erk cascade is thought to occur through the 
action of two distinct GEFs, RasGRP1 and Sos1 (Figure 8A) (Roose and Weiss, 2000). 
RasGRP1 is activated by DAG, which is produced by PLCγ1 upon cleavage of PIP2. PLCγ1 is 
activated upon binding to phosphorylated LAT, a transmembrane adaptor protein crucial for 
T-cell activation (Wange, 2000). Phosphorylated LAT also recruits the GADS/SLP-76 
complex, which binds and further activates PLCγ1 by recruiting the tyrosine kinase Itk. 
Additionally, phosphorylated LAT is also required to recruit the Grb2/Sos complex to the 
plasma membrane. Thus, LAT may activate Ras via two distinct pathways: (i) PLCγ1-DAG-
RasGRP1 and (ii) Grb2-Sos (Figure 8A) (Roose and Weiss, 2000). 
A key finding on Ras-Erk regulation in T cells came from recent studies based on lymphoid 
cells, thymocytes and in silico simulations showing that Ras activation is further controlled by 
an unusual interplay between RasGRP1 and Sos (Das et al., 2009; Roose et al., 2007). These 
studies proposed that, upon initial receptor triggering, Ras is exclusively activated via 
RasGRP1 (Figure 8A). Once a certain threshold of Ras activation has been reached, RasGTP 
(active Ras) will prime Sos, thus triggering a feedback loop that results in the full activation 
of the Ras-Erk cascade. This mechanism relies on an allosteric pocket found in Sos crystal 
structure that is specific for RasGTP (Margarit et al., 2003). In fact, it has been shown that 
upon loading of the allosteric pocket of Sos with RasGTP, the GEF activity of Sos is 
significantly enhanced. 
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Figure 8. Models of Ras-Erk activation in T cells. 
A) Model proposed by Das et al. 2009. Weak TCR ligands induce only a partial 
phosphorylation of LAT, which in turn activates Ras only via RasGRP1 (left), whereas 
strong ligands induces full LAT phosphorylation that will result in Ras activation through 
the coordinated action of RasGRP1 and Sos1 (right). The different strength of Erk activation 
will in turn regulate the cellular outcome. B) Alternative Ras-Erk activation model 
(Warnecke et al., 2012/App.17). TCR- and IL2-mediated pathways activate Ras-Erk by 
utilizing two independent mechanism, one involving RasGRP1, the other Grb2/Sos.  
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Thus, the current model postulates that the coordinated action of RasGRP1 and Sos1 regulates 
the magnitude of Ras-Erk activation (Figure 8A). Consequently, the magnitude of the Ras-Erk 
signaling is interpreted by the cells through the activation of a network of immediate-early 
genes, thus allowing the generation of the appropriate response.  
However, it has not yet been demonstrated whether this model for TCR-mediated Ras-Erk 
activation is also valid in primary T cells. Given the central role of Erk activation in cell-fate 
specification processes induced by TCR triggering, we have further assessed the validity of 
this model in primary human T cells (Warnecke et al., 2012/App.17). Initially, we suppressed 
Grb2/Sos1 and RasGRP1 expression using siRNA. We found that, in primary T cells, neither 
the suppression of Sos1 nor Grb2 impairs TCR-mediated Erk activation. Conversely, 
suppression of RasGRP1 confirmed that RasGRP1 is the major activator of Ras-Erk in 
primary T cells. However, when we assessed the contribution of Grb2/Sos and RasGRP to 
Erk activation downstream of the IL-2 receptor, which is also required for T-cell activation, 
we found that only Grb2/Sos are required for IL2-mediated Erk activation. Consistent with 
previously published data (Priatel et al., 2010), we found that the downregulation of RasGRP1 
did not affect IL-2-mediated Erk activation. Thus, RasGRP1 and Grb2/Sos do not function as 
integrators of signals to Ras downstream of the TCR, but rather they appear to function as 
insulators of signals that lead to Ras activation induced by different stimuli (Figure 8B). 
 
6. Adaptor molecules 
A major step in our understanding of lymphocyte development and activation has been 
achieved through the functional characterization of a group of molecules called adaptor 
proteins (Simeoni et al., 2005b; Simeoni et al., 2008). Adaptors function as linkers between 
the antigen receptor, which senses changes in the extracellular environment, and the 
cytoplasmic effectors, which transmit the signal to the nucleus. These proteins are involved in 
the regulation of many signaling cascades and can be divided into two main groups: 
TRansmembrane Adaptor Proteins (TRAPs), which are integral transmembrane proteins such 
as LAT, TRIM, SIT, PAG/Cbp, NTAL/LAB (Brdicka et al., 2002/App.2), LIME (Brdickova 
et al., 2003/App.4), and LAX (for a review see Lindquist et al., 2003; Horejsi et al., 2004) and 
Cytoplasmic Adaptor Proteins (CAPs) such as Grb2, Gads, SLP-76, ADAP, SKAP-55, 
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SKAP-HOM (Togni et al., 2005/App.6) etc., localized within the cytoplasm (for a review see 
Simeoni et al., 2004; Simeoni et al., 2005b).  
Adaptor molecules are proteins that exhibit no intrinsic enzymatic or transcriptional activities. 
However, they possess a variety of signaling domains including Src-homology 2 and 3 
domains (referred to as SH2 and SH3 domains respectively), phosphotyrosine binding (PTB) 
domains, pleckstrin homology (PH) domains, and many others (Simeoni et al., 2004). They 
also possess tyrosine-based signaling motifs (TBSMs), which interacts with SH2 or PTB 
domains. It is by virtue of their modular structure that adaptors couple proximal biochemical 
events initiated by ligation of the TCR to distal signaling pathways. Adaptors also play an 
important role in inside-out signaling and link the TCR to integrin activation (Horn et al., 
2009/App.15). 
The function of TRAPs is to ensure the proper positioning of signaling elements at the plasma 
membrane (Simeoni et al., 2005b). Upon antigen receptor stimulation, protein tyrosine 
kinases phosphorylate key tyrosine residues within TBSMs, which is the predominant 
signaling motif characterizing this group of adaptors. Tyrosine phosphorylation creates 
binding motifs that recruit signaling molecules containing SH2 or PTB domains to the plasma 
membrane. The group of transmembrane adaptors can be further subdivided into TRAPs that 
are raft-associated (LAT, PAG, LIME, and NTAL/LAB) and those that are not (SIT, TRIM, 
and LAX) (see Figure 9).  
A large body of work derived from different laboratories supports the idea that LAT is an 
essential TRAP in T cells (Wange, 2000). In fact, LAT-deficient cell lines have a severe 
defect in the activation of important signaling cascades including Ca2+ and Ras. To 
specifically address the role of LAT in vivo, LAT-knockout and -knockin mice were 
generated (for a review see Malissen et al., 2005). The characterization of LAT-knockout 
mice has clearly demonstrated that LAT is essential for T-cell development, as LAT-/- mice 
display a developmental block at the DN3 stage.  
In contrast to LAT, which is clearly crucial for T-cell functions, the other TRAPs such as 
LAX, NTAL, and SIT rather appear to function as signal attenuators, and thus participate in 
the fine-tuning of antigen receptor-mediated signaling. Recent data suggest that LAX (Zhu et 
al., 2005; App.19), NTAL (Zhu et al., 2006a), and SIT (Posevitz et al., 2008/App.11) regulate 
lymphocyte homeostasis and peripheral tolerance. Despite intense scrutiny, the in vivo 
function of other TRAPs, such as PAG (Dobenecker et al., 2005; Xu et al., 2005), TRIM
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Figure 9. The three non-raft transmembrane adaptor proteins. SIT (SHP2-interacting 
transmembrane adaptor protein), TRIM (T-cell-receptor-interacting molecule), and LAX 
(linker for activation of X cells, where X denotes an as yet unidentified cell) are the TRAPs 
that do not localize to lipid rafts. All have short extracellular domains, typical 
transmembrane α-helices and long cytoplasmic tails that contains several potential 
phosphorylation sites known as tyrosine-based signaling motifs (TBSMs) (     ). The primary 
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the SH2-domain-containing molecules (indicated in parenthesis). Mw, molecular weight; 
Ex, tissue expression.
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(Kolsch et al., 2006/App.8), and LIME (Gregoire et al., 2007/App.10) remains still elusive. 
Here, I will primarily focus upon the non raft-associated transmembrane adaptors SIT, TRIM 
and LAX.  
6.1. SIT (SHP-2-Interacting Transmembrane adaptor protein) 
SIT has the typical structural organization of TRAPs, which consists of a short extracellular 
domain (18 aa), a single segment of hydrophobic amino acids representing the transmembrane 
region (20 aa), and a long cytoplasmic tail (136 aa) (Figure 9). However, SIT is a unique 
molecule among TRAPs, as (i) it is one of two expressed at the plasma membrane as a 
disulfide linked homodimer (this property is shared with TRIM) and (ii) it is heavily 
glycosylated on a single asparagine residue (N26) in the extracellular domain. This 
glycosylation accounts for approximately 20 kDa of the molecular weight and may represent a 
binding site for an extracellular ligand, which, however, has yet to be identified.  
The cytoplasmic domain of SIT is characterized by the presence of five TBSMs: Y90GNL, 
Y127TSL, Y148SEV, Y169ASV, and Y188ANS respectively (Figure 9). Upon TCR stimulation, 
these TBSMs can be phosphorylated by the coordinated action of both Src and Syk families 
tyrosine kinases. Tyrosine Y90 (YGNL) and Y169 (YASV) are strongly phosphorylated, 
whereas residues Y127 (YTSL), Y148 (YTSL), and Y188 (YANS) represent only minor 
phosphorylation sites. It has been shown that SIT binds the tyrosine phosphatase SHP-2 and 
the tyrosine kinase Csk through the phosphorylated Y148SEV and Y169ASV motifs, 
respectively (Marie-Cardine et al., 1999; Pfrepper et al., 2001/App.1). Additionally, SIT also 
binds the adaptor protein Grb2 via phosphorylated tyrosines Y90GNL and Y188ANS (Figure 
9). By acting as a scaffold, SIT may influence T-cell activation by recruiting signaling 
molecules to the plasma membrane. Previous experiments performed in the Jurkat T-cell line 
demonstrated that SIT is indeed involved in the regulation of TCR-mediated signaling (Marie-
Cardine et al., 1999). Overexpression of full length SIT exerted a strong inhibitory effect on 
the TCR- and PHA-mediated transcriptional activity of NFAT. As reported above, SIT binds 
the inhibitory molecule SHP-2 via Y148SEV, which is an immunoreceptor tyrosine-based 
inhibition motif (ITIM) and hence may inhibit T-cell activation via SHP-2. However, a SIT-
mutant containing an amino acid substitution (Y to F) in the ITIM still inhibited TCR-
mediated NFAT activation, despite the fact that the SHP-2 binding to SIT was largely lost. 
These results indicate that the binding of SHP-2 to SIT is not required for negative regulation 
of TCR signaling. Additional experiments revealed that the Y169ASV motif mediates the 
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inhibition of TCR-induced NFAT activation. Pulldown assays performed on pervanadate 
treated T cells initially suggested that the tyrosine kinase Csk binds to the YASV motif and 
thus might mediate the inhibitory effect of SIT on TCR signaling (Pfrepper et al., 
2001/App.1). Csk is the major negative regulator of Src protein tyrosine kinases that inhibits 
TCR-mediated signaling by several mechanisms (Marinari et al., 2003/App.3). However, so 
far we could not show an association between SIT and Csk in human or mouse T-cells under 
more physiological conditions of stimulation (e.g. CD3 mAb instead of pervanadate).  
Recently, we have re-addressed the question of how SIT regulates TCR-mediated signaling by 
using RNAi (Arndt et al., 2011/App.16). We have found that suppression of SIT expression 
by siRNA in both Jurkat and primary T cells enhances proximal TCR signaling, thus 
confirming our initial hypothesis that SIT is a negative regulator. A more detailed analysis 
revealed that the loss of SIT also resulted in an enhanced TCRζ phosphorylation and ZAP-70 
association. Collectively, these data suggest that SIT negatively regulates proximal TCR 
signaling at the level of TCRζ/ZAP-70. We propose that SIT influences the activation of 
signaling molecules, such as Lck, located in the apical part of the TCR signaling cascade. 
However, how SIT regulates TCR-mediated signaling requires further investigations. 
SIT is strongly expressed in thymocytes. Additionally, SIT is abundant in peripheral T cells 
and is also expressed in B cells and in plasma cells, albeit at a much lower level. This 
expression pattern suggests that SIT may play a role in T-cell development and function. In 
fact, the analysis of thymic development in SIT-/- mice demonstrated that SIT inhibits 
selection processes, as the loss of SIT converted positive to negative selection in class-I-
restricted HY and P14 TCR transgenic mice (Simeoni et al., 2005a/App.5). Moreover, SIT-
deficient thymocytes are hyperactivated and overexpress the activation markers CD5 and of 
CD69, a similar phenotype to that observed in thymocytes from mice lacking negative 
regulatory cytosolic adaptors such as c-Cbl or SLAP (Naramura et al., 1998; Sosinowski et 
al., 2001).  
Similarly to thymocytes, also SIT-deficient peripheral T cells are hyperactivated as they 
proliferate stronger to CD3 stimulation compared to wild-type cells and also produce more 
cytokines (Simeoni et al., 2005a/App.5). Moreover, in aged SIT-deficient mice T cells 
spontaneously activate and upregulate CD69 and CD40L (App.19). Collectively, these data 
emphasize the role of SIT as a negative regulator of TCR-mediated signaling and T-cell 
activation. 
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As SIT appears to be an inhibitor of T-cell activation, we have investigated whether SIT is 
required for the immune response. We tested different infection models including Listeria and 
Toxoplasma and also standard immunizations with T-dependent and T-independent antigens. 
However, in none of the conditions tested did it appear that the loss of SIT impaired the 
immune responses. We next investigated other processes that depend on TCR signals and 
found that SIT regulates T-cell homeostasis (see section 4) (Posevitz et al., 2008/App.11). 
SIT-deficient mice display an accumulation of CD8+ T cells expressing high level of CD44, 
CD122, and CD62L, but normal levels of CD25 and CD69. These cells phenotypically 
resemble memory-like T cells, which are believed to be cells undergoing homeostatic 
proliferation. When we performed adoptive transfer experiments into lymphopenic hosts, we 
indeed found that SIT-deficient naïve CD8+ T cells expand more vigorously than their wild 
type counterparts and acquire a memory-like phenotype. In addition SIT also appears to 
regulate the homeostasis of γδTCR+ lymphocytes, as SIT-/- mice displayed a marked increase 
in the absolute numbers of this T-cell subset in lymph nodes, spleen, Payer’s patches, and 
bone marrow (Simeoni et al., 2005a/App.5).  
Collectively, the data suggest that SIT negatively regulates both thymic selection and 
peripheral T-cell homeostasis. As both processes are regulated through signals triggered by 
low affinity self peptide/MHC complexes, it is likely that SIT is an important component of 
the machinery that translates low-affinity stimuli into a cellular outcome. 
Alterations in T-cell development and homeostasis may compromise both central and 
peripheral tolerance and hence may enhance the susceptibility to develop autoimmune 
diseases. When we explored this possibility, we found that SIT-deficient mice spontaneously 
develop pathological features of a Lupus-like syndrome, which include anti-nuclear 
antibodies (ANAs) in the serum, an increase in glomerular size and cellularity, thickening of 
capillary walls, an augmented mesengial matrix with PAS-positive deposits, and proteinurea 
(App.19). Moreover, SIT-deficient mice were also more susceptible to the induction of 
experimental autoimmune encephalomyelitis (EAE) (Simeoni et al., 2005a/App.5), a 
prototypical T cell-mediated autoimmune disease. In summary, the data demonstrate that SIT 
is an important negative regulator of T-cell activation that controls thymic selection, inhibits 
homeostatic proliferation, and limits autoimmunity. 
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6.2. TRIM (T-cell Receptor Interacting Molecule) 
TRIM was initially isolated as a molecule that specifically associated with the TCR/CD3 
complex (Bruyns et al., 1998; Kirchgessner et al., 2001). The protein is structurally organized 
as follow: (i) it has a 8 amino acid extracellular domain, (ii) a 19 amino acid transmembrane 
region and (iii) a 159 amino acid cytoplasmic tail (Figure 9). The interaction between TRIM 
and the TCR complex occurs preferentially with the TCRζ chain and most of cellular TRIM is 
associated with the TCR/CD3 complex at the plasma membrane. From a functional point of 
view, this close association seems to be required to regulate TCR expression. In fact, 
overexpression of TRIM increased the levels of the TCR/CD3 complex on the cell surface by 
inhibiting spontaneous TCR internalization (Kirchgessner et al., 2001). 
More recently, it has been shown that TRIM is also important for regulating the expression of 
CTLA-4 (Valk et al., 2006), a potent inhibitor of T-cell activation. Indeed, TRIM associates 
with CTLA-4 and leads to enhanced CTLA-4 surface expression in T cells. Collectively, the 
available data suggest that TRIM functions as a chaperone in modulating both TCR/CD3 and 
CTLA-4 expression.  
Similarly to SIT, TRIM is expressed in T cells as a disulfide-linked homodimer (Figure 9). 
Three TBSMs (Y63GNL, Y79EQM, Y110ASL) are located within the cytoplasmic tail of 
TRIM. Upon TCR-induced phosphorylation, tyrosine Y79, which is located within a YxxM 
consensus motif, interacts with the p85 regulatory subunit of PI3K. The phosphorylation of 
TRIM appears to be mediated only by Src family tyrosine kinases, such as Lck and Fyn, and 
not by members of the Syk family. Overexpression of TRIM in Jurkat T cells resulted in a 
two fold elevation of calcium mobilization upon TCR stimulation. However, this phenomenon 
likely represents a consequence of higher TCR expression on the cell surface and not an effect 
of TRIM on TCR-mediated signaling (Kirchgessner et al., 2001). Indeed, overexpression of a 
TRIM mutant carrying Y to F substitutions in the TBSMs was still able to enhance calcium 
flux and to inhibit TCR internalization similarly to wild type TRIM. Transfection of TRIM in 
DC27.10 hybridoma T cells or peripheral blood lymphocytes enhanced the inhibitory effect of 
CTLA-4 on anti-CD3 mediated proliferation and IL-2 production (Valk et al., 2006). 
However, also these results reflect the regulatory activity of TRIM on CTLA-4 expression 
rather than a direct effect of TRIM on TCR-mediated signaling. Thus, it remains still unclear 
whether TRIM may also function as a signaling molecule during T-cell activation. 
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Despite the fact that TRIM has been shown to regulate TCR/CD3 expression and to facilitate 
CTLA-4 transport to the plasma membrane, TRIM-deficient mice possess normal TCR/CD3 
and CTLA-4 levels (Kolsch et al., 2006/App.8). Additionally, TRIM-/- mice also do not show 
defects in T-cell development even though TRIM is strongly expressed in CD4+CD8+ 
thymocytes. Moreover, immune functions are unaffected in TRIM-deficient mice. The lack of 
an evident phenotype in TRIM-/- mice could indicate that loss of TRIM has been compensated 
by other transmembrane adaptors. In fact, we have found that together SIT and TRIM regulate 
thymic development (see section 5.1.). 
6.3. LAX (Linker for Activation of X cells, where X indicates “to be defined”) 
LAX is another non-raft associated transmembrane adaptor expressed in T cells, B cells, 
monocytes, and bone marrow-derived mast cells. It contains eight tyrosine residues within its 
cytoplasmic domain (Zhu et al., 2002; Zhu et al., 2006b). Upon BCR and TCR stimulation, 
LAX is rapidly tyrosine phosphorylated. The four membrane distal residues (Y193, Y268, Y294, 
Y373) associate with Grb2, GADS, and PI3K (Figure 9).  
LAX was identified as a LAT-like molecule. In fact, similarly to LAT, LAX binds the 
cytosolic adaptors Grb2 and GADS via its distal TBSMs. Moreover, LAX and LAT both 
become phosphorylated by Src- and Syk-family tyrosine kinases after T-cell activation. 
However, despite the structure similarity to LAT, LAX has no palmitoylation motif and is not 
localized to the lipid rafts. The functional difference between LAX and LAT was shown in 
experiments where LAX was expressed in LAT-deficient cells. In fact, LAX failed to 
reconstitute TCR-mediated signaling in LAT-deficient cells. Overexpression experiments in 
the Jurkat T-cell line finally demonstrated that LAX is a negative regulator of antigen receptor 
signaling rather than a positive one. The molecular mechanisms of this phenomenon are yet to 
be defined. However, it has been suggested that LAX may inhibit T-cell activation via the 
cytosolic adaptor ALX, a negative regulator of T-cell activation (Perchonock et al., 2006; 
Shapiro et al., 2008). Alternatively, it is conceivable that LAX acts by sequestering Grb2, 
GADS, or even PI3K away from the lipid rafts where they are required to link the TCR to 
downstream signaling pathways. 
The generation and characterization of LAX-deficient mice confirmed that LAX is also a 
negative regulator in lymphocyte signaling in vivo. Indeed, LAX-/- T or B lymphocytes 
showed enhanced tyrosine phosphorylation and calcium flux upon BCR or TCR stimulation 
(Zhu et al., 2005). Analysis of the PI3K and MAPK pathways revealed that LAX-deficient 
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lymphocytes display also enhanced PKB, Erk, and p38 activation. Collectively, these data 
indicate that LAX-/- T and B cells are hyperresponsive. However, it appears as if the loss of 
LAX does not directly increase lymphocyte proliferation, but rather inhibits cell death.  
Despite the fact that LAX-deficient lymphocytes are hyperresponsive to BCR- or TCR-
mediated stimulation, LAX-/- mice display only modest alterations of immune function in vivo 
(Zhu et al., 2005). However, we have found that aged LAX-/- mice develop a mild Lupus-like 
disease (App.19). Thus, LAX may regulate signals required to limit autoimmunity.  
6.4. Non-raft TRAPs: a group of molecules with redundant function 
The lack of an evident phenotype in the immune system of TRIM-deficient mice and the 
modest phenotype observed in SIT- and LAX-deficient mice could indicate that there is a 
high degree of redundancy among the non-raft TRAPs. To explore the possibility, we have 
generated SIT/TRIM and SIT/LAX double-deficient mice.  
The idea that SIT and TRIM could have redundant function is further supported by several 
structural similarities. First, SIT and TRIM are both homodimeric proteins located outside of 
the lipid rafts. Second, SIT shares two TBSMs with TRIM, YGNL and YASV/L whose order 
with respect to the membrane is conserved (see Figure 9). As reported above, these two motifs 
represent the major regulatory sites within the SIT cytoplasmic tail. Finally, both are strongly 
expressed in thymocytes.  
The generation of SIT/TRIM double-deficient mice revealed that SIT and TRIM are indeed 
redundant and negatively regulate TCR-mediated signals in the thymus (Koelsch et al., 
2008/App.13). CD4+CD8+ thymocytes from SIT/TRIM double-deficient mice show a more 
activated phenotype than SIT-/- mice, as they strongly upregulate TCRβ, CD5, and CD69. 
Moreover, thymic development is severely altered in these mice (see section 5.1.). Thus, SIT 
and TRIM together regulate the fate of developing thymocytes (Figure 7). 
The characterization of SIT/LAX double-deficient mice showed that SIT and LAX together 
negatively regulate immune functions at different levels (App.19). First, SIT/LAX double-
deficient mice show increased number of B1 cells, a particular B-cell subset associated with 
autoimmune diseases and also with malignant transformation (Kantor and Herzenberg, 1993; 
Kasaian and Casali, 1993), and activated CD4+ T cells. Moreover, basal immunoglobulin 
levels and the titer of ANAs are increased in the double-knockout as compared with LAX or 
SIT single-mutant mice. Finally, aged SIT/LAX double-deficient mice develop 
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gromerulonephritis at a higher frequency as compared to SIT-/- mice. Collectively, the data 
suggest that SIT and LAX appear to restrain cellular and humoral responses that lead to 
autoimmunity. 
 
Concluding remarks 
Signaling via the TCR is a highly organized and tightly regulated process that is crucial for an 
immune response. Defects in signal transduction may lead to either T-cell 
hyperresponsiveness or impaired T-cell activation, which results in autoimmunity or 
immunodeficiency, respectively. Thus, the study of how TCR signaling is initiated, 
propagated, coordinated, and translated into a cellular response is important for the 
understanding not only of physiological processes, but also of the molecular mechanisms 
underlying human disease. 
However, most of our knowledge on TCR-mediated signaling is based on data obtained from 
T-cell lines, hybridoma, and lymphoblasts. The extensive use of such a variety of different 
cellular systems has often led to conflicting results and to the identification of pathways that 
may not be active in resting primary T cells (see section 5.2.). Additionally, the use of several 
non-physiological stimuli (e.g. phorbol esters, cross-linked CD3, or anti-TCR antibodies) to 
analyze signaling events upon TCR engagement has also contributed to the generation of data 
that may not reflect physiological conditions (App.18). Finally, also the data generated using 
a variety of animal models have not taken into account the possible differences in the 
signaling mechanisms between human and mouse T cells.  
Therefore, one of the major goals for the future is to understand how TCR-mediated signaling 
is regulated in primary human T cells under conditions mimicking physiological stimulation. 
One of the major problems is that antigen-specific stimulation can only be employed to 
trigger T cells expressing a transgenic TCR, hence this applies only to murine models. Thus, 
the availability of a method that mimics antigen-specific systems is of particular importance 
to study primary human T-cells, which cannot be stimulated on a large scale by antigen-
specific systems. We have recently started to characterize which of the currently available 
systems to stimulate human T cells more closely reproduces physiological stimulation 
(App.18). We found that CD3xCD28 agonistic mAbs immobilized on beads mimics signaling 
induced by antigen-specific (physiologic) systems and also induce a functional outcome 
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(proliferation). Conversely to immobilized antibodies, antibodies applied in solution induce a 
transient signal and an abortive response. We further show that TCR activation kinetics and 
feedback regulation under proliferation-inducing conditions (immobilized mAbs) are 
markedly different from those leading to unresponsiveness (soluble mAbs). Thus, we 
concluded that immobilized mAbs are better suited than soluble mAbs for signaling studies. 
We believe that, by further employing immobilized mAbs, it may be possible to reveal new 
mechanistic insights into the regulation of TCR signaling in primary human T cells, which 
may additionally have important implications for understanding the molecular mechanisms of 
human diseases. This will also be helpful for the generation of maps of the TCR signaling 
network and will contribute to developing dynamic models (Saez-Rodriguez et al., 
2007/App.9; Klamt et al., 2006/App.7). 
Although antibody-coated beads represent an attractive and easy to use system, they clearly 
have limitations. Microbeads have rigid surfaces and lack the fluidity of biological 
membranes, whereby the analysis of the combined effects of different receptors is limited. 
Therefore, it will be necessary for the future to develop new stimulation methods that are 
better suited to mimic physiological cell-cell interactions.  
With regard to the future of transmembrane adaptor molecules, it will be important to assess 
whether functional redundancy might apply to all TRAPs. In fact, the structural similarities 
between LAX and TRIM (both molecules are capable of binding PI3K and are strongly 
expressed in CD4+ T cells) or between NTAL and LAX (which both carry several Grb2-
binding site and both are expressed in B cells and mast cells) are suggestive of the existence 
of sophisticated and redundant mechanisms that regulate antigen receptor-mediated signaling. 
Interestingly, it has been published that aged NTAL-deficient mice show hyperactivation of 
CD4+ T cells, possess anti-nuclear antibodies, and develop a lupus-like autoimmune disease 
(Zhu et al., 2006a). This phenotype strikingly resembles the alterations of the immune system 
that we observe in the SIT/LAX double-deficient mice. It will now be important to assess 
whether SIT/LAX/NTAL-triple deficient mice show an even more aggravated autoimmune 
phenotype. Similarly, the generation of additional double or triple knockout mice will help to 
assess how TRAPs control the intricate signal transduction network within immune cells. 
Recently, two new members have been added to the family of transmembrane adaptors. Grb2-
binding adaptor protein transmembrane (GAPT), which is expressed in B cells and myeloid 
cells (Liu and Zhang, 2008) and proline rich 7 (PRR7), which is readily upregulated in 
activated human peripheral blood lymphocytes (Hrdinka et al., 2011). The function of these 
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new TRAPs has not yet been completely clarified. Whereas GAPT appears to be involved in 
B-cell activation, PRR7 seems to inhibit TCR-mediated signaling and induce apoptosis in the 
Jurkat T-cell line. 
A long-lasting question regarding TRAPs is whether B cells possess a LAT-like molecule that 
links the BCR to downstream signaling pathway. This question has been raised as T and B 
cells express many homologous signaling molecules and utilize conserved pathways to 
transduce signals from their respective antigen receptors. As mentioned above, LAT and SLP-
76 are indispensable for the activation of NFAT, AP1, and NFκB upon TCR triggering. B 
cells are known to express only SLP-65, also referred as to BLNK, which is a cytosolic 
homolog of SLP-76 (Yablonski and Weiss, 2001), but they do not express a LAT-like 
molecule, which recruit SLP-65 to the plasma membrane. Therefore, how the BCR is linked 
to the activation of downstream signaling cascades still remains unknown. It was though that 
NTAL/LAB, which together with LAT arise from a duplication of a primordial gene, was the 
long searched LAT-like molecule in B cells (Brdicka et al., 2002/App.2; Janssen et al., 2003). 
Indeed, one of the name given to this TRAP is LAB (linker for activation of B cells) alluding 
to its desired function in BCR-mediated signaling (Janssen et al., 2003). However, further 
studies have clearly shown that NTAL/LAB is functionally different from LAT, as it 
functions as a negative regulator of antigen-receptor mediated signaling (Zhu et al., 2006a). 
Also LIME (Brdickova et al., 2003/App.4) and LAX, two other TRAPs, have been proposed 
to be LAT-like molecules (Ahn et al., 2006; Zhu et al., 2002). However, also in these cases in 
vivo studies clearly demonstrated that BCR-mediated signaling is not significantly affected in 
both LIME-/- and LAX-/- mice (Gregoire et al., 2007/App.10; Zhu et al., 2005). Thus, it will be 
important to understand how the BCR is linked to the activation of the transcriptional 
program leading to humoral immune responses. This may be important for the development 
of specific clinical therapeutics which would allow the manipulation of immune responses. 
The role of TRAPs in human diseases has now just begun to be investigated. The fact that 
different TRAPs knockout mice develop autoimmunity is suggestive of their potential role in 
regulating tolerance. Recent studies have shown that TRAPs are differently expressed in 
leukemic cells (Svec et al., 2005; Svojgr et al., 2009; Svojgr et al., 2012; Tedoldi et al., 2006). 
However, whether TRAPs play a role in cancer or rather represent markers for the diagnosis 
and the identification of lymphoma cells requires further study.  
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Structural and functional dissection of the
cytoplasmic domain of the transmembrane adaptor
protein SIT (SHP2-interacting transmembrane
adaptor protein)
Klaus-Ingmar Pfrepper1, Anne Marie-Cardine2, Luca Simeoni3, Yasuhiro Kuramitsu1,
Albrecht Leo1, Jiri Spicka1, Ivan Hilgert4, Jeanette Scherer1 and Burkhart Schraven3
1 Immunomodulation Laboratory of the Institute for Immunology, Ruprecht-Karls University
Heidelberg, Heidelberg, Germany
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3 Institute for Immunology, Otto-von-Goernicke University Magdeburg, Magdeburg, Germany
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SIT (SHP2-interacting transmembrane adaptor protein) is a recently identified transmembrane
adaptor protein, which is expressed in lymphocytes. Its structural properties, in particular the
presence of five potential tyrosine phosphorylation sites, suggest involvement of SIT in TCR-
mediated recruitment of SH2 domain-containing intracellular signaling molecules to the
plasma membrane. Indeed, it has recently been demonstrated that SIT inducibly interacts with
the SH2-containing protein tyrosine phosphatase 2 (SHP2) via an immunoreceptor tyrosine-
based inhibition motif (ITIM). Moreover, SIT is capable to inhibit TCR-mediated signals proxi-
mal of activation of protein kinase C. However, inhibition of T cell activation by SIT occurs
independently of SHP2 binding. The present study was performed to further characterize the
molecular interaction between SIT and intracellular effector molecules and to identify the pro-
tein(s) mediating its inhibitory function. We demonstrate that SIT not only interacts with SHP2
but also with the adaptor protein Grb2 via two consensus YxN motifs. However, mutation of
both Grb2-binding sites also does not influence the inhibitory function of SIT. In contrast,
mutation of the tyrosine-based signaling motif Y168 ASV completely abrogates the ability of SIT
to inhibit T cell activation. Co-precipitation experiments revealed that the tyrosine kinase
p50csk could represent the negative regulatory effector molecule that binds to this motif.
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kinase SH: Src-homology SHP: SH2-containing protein
tyrosine phosphatase SHIP: SH2-domain containing inosi-
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1 Introduction
Among the earliest intracellular events that occur after
engagement of the T cell receptor (TCR) complex are
tyrosine phosphorylations of numerous proteins which
result from activation of protein tyrosine kinases (PTK) of
the Src (e. g. Lck, Fyn), Syk (ZAP-70, Syk) and Tec (e. g.
ltk) family (for recent reviews see [1–4]). It is now well
established that these initial phosphorylations are a pre-
requisite to allow coupling of the TCR to intracellular sig-
naling pathways such as the Ras/Raf/MAPK pathway or
the calcineurin/NF-AT pathway. Moreover, it is well doc-
umented that TCR-mediated tyrosine phosphorylations
are accompanied by and are required for the transloca-
tion of intracellular signaling molecules (e. g. Grb2,
SHP2, SLP-76 and others) from the cytosol to the inner
leaflet of the plasma membrane. The precise molecular
mechanisms whereby these cytoplasmic effector and
adaptor molecules are targeted to the plasma membrane
after TCR engagement were until recently only poorly
understood. Major progress in solving this puzzle has
been achieved through the identification of a novel group
of proteins that has been termed transmembrane adap-
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tor proteins. These polypeptides are characterized by
very short extracellular domains and comparatively long
cytoplasmic tails, which contain several tyrosine-based
signaling motifs (between five and ten). Upon phosphor-
ylation by Src and/or Syk-PTK the tyrosine-based sig-
naling motifs become rapidly phosphorylated and then
serve as docking sites for SH2 domain-containing intra-
cellular signaling molecules (reviewed in [4, 5]).
The so far best characterized transmembrane adaptor
protein is LAT (linker for activation of T cells) [6, 7]. LAT is
a type III transmembrane protein that carries 10 tyrosine
residues in its cytoplasmic tail, among which 6 represent
potential tyrosine-based signaling motifs. LAT becomes
rapidly tyrosine phosphorylated after T cell activation by
ZAP-70 and then directly interacts with the SH2-
domains of Grb2, Gads and PLC + 1 and indirectly with
other intracellular signaling molecules including PI3-
kinase, SLP-76 and Cbl [6, 7]. Compelling evidence that
LAT is required for the propagation of TCR-mediated sig-
nals was provided by the analysis of LAT-deficient Jurkat
variants. These cells exhibit severe defects in TCR-
mediated phosphorylation and activation of PLC + 1,
generation of calcium fluxes, activation of the Ras path-
way and IL2-gene expression [8, 9]. Moreover, LAT-
deficient mice show an arrest in thymic development at
the CD4–CD8– stage that results in a loss of mature
peripheral blood T-cells [10]. All these data suggest that
LAT is indispensable for T cell activation and T cell devel-
opment.
Shortly after the identification of LAT, the molecular clon-
ing of three additional transmembrane adaptor proteins,
TRIM (T cell receptor interacting molecule) [11], SIT
(SHP2-interacting transmembrane adaptor protein) [12]
and PAG/Cbp (protein associated with GEMs/Csk bind-
ing protein) [13, 14] has been reported.
TRIM has been initially indentified as a T cell-specific
disulfide-linked homodimer which associates and co-
modulates with the TCR/CD3/ ´ complex [15, 16]. TRIM
becomes tyrosine phosphorylates by Src kinases and
then associates with the 85-kDa subunit of PI3-kinase
via a typical consensus YxxM motif and possibly via its
YGNL and/or YASL motifs with two additional so far
non-identified polypeptides of 43 and 50 kDa. However,
the function of TRIM remains elusive.
The most recently identified transmembrane adaptor
protein PAG/Cbp is a type III transmembrane protein
with an extracellular domain of 16 amino acids (aa) and a
397 aa cytoplasmic tail [13, 14]. In contrast to the other
transmembrane adaptor proteins known so far, PAG is
ubiquitously expressed. In its cytoplasmic tail it carries
a total of 10 potential tyrosine-based signaling motifs
among which at least one (Y317 in human PAG) mediates
an association with the PTK Csk, the major negative regu-
lator of Src-family kinases. Thus, PAG/Cbp could be
involved in negative regulation of T cell activation by
recruiting Csk to the plasma membrane followed by
down-regulation of T cell activation. Accordingly, overex-
pression of PAG in COS or 293T cells attenuates the
kinase activity of Src and Fyn via a mechanism that
involves binding of Csk [13, 14]. In resting peripheral
blood T cells PAG is expressed as a constitutively
tyrosine-phosphorylated polypeptide that recruits Csk to
the membrane. Perhaps more importantly, immediately
after T cell activation PAG becomes dephosphorylated by
an unknown protein tyrosine phosphatase and releases
Csk [13]. These data suggest that one function of PAG
might be to down-regulate the enzymatic activities of Src
kinases in resting T cells by recruiting Csk and thus to par-
ticipate in keeping the cells in a quiescent state.
SIT is a disulfide-linked homodimeric polypeptide which
is exclusively expressed in lymphocytes. In contrast to
the other transmembrane adaptor proteins known so far,
SIT is a heavily glycosylated polypeptide [12]. This could
indicate that SIT possesses an external ligand that mod-
ulates its function. The cytoplasmic domain of SIT con-
tains five potential tyrosine phosphorylation sites among
which one is an ITIM. This motif mediates an inducible
interaction with the tyrosine phosphatase SHP2. Impor-
tantly, overexpression of SIT in Jurkat T cells inhibits
TCR-mediated activation of the nuclear factor of T cells
(NF-AT) via a mechanism that is likely located upstream
of the activation of phospholipase C (PLC) and protein
kinase C (PKC). However, mutation of the tyrosine resi-
due within the ITIM does not prevent SIT-mediated inhi-
bition of NF-AT activity although it almost completely
abrogates the interaction between SIT and SHP2 [12].
These data suggest that SIT exerts its inhibitory function
via a mechanism that does not involve SHP2 or the ITIM.
The present study was conducted to better understand
the molecular mechanisms leading to tyrosine phosphor-
ylation of SIT and to elucidate the structural basis for its
negative regulatory function during T cell activation.
2 Results
2.1 Identification of the sites of tyrosine
phosphorylation within the cytoplasmic
domain of SIT
The cytoplasmic domain of SIT carries a total of five
potential sites of tyrosine phosphorylation. These
are Y90GNL, Y128TSL, VKY148SEV (ITIM), Y168ASV and
Y188ANS. To assess which of these five tyrosines repre-
sent in vivo phosphorylation sites, we generated a series
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Fig. 1. Identification of the tyrosine phosphorylation sites within in the cytoplasmic domain of SIT. (A) Amino acid sequence of
human SIT. The five tyrosine-based signaling motifs are underlined. The amino acids that are conserved between human SIT and
Dok-3 (see Sect. 3) are double underlined. (B) A cDNA construct coding for a chimeric molecule encompassing the extracellular
and transmembrane domain of human CD8 fused to the cytoplasmic portion of SIT was generated and cloned into the pEF-Bos
eukaryotic expression vector. The wild-type CD8/CD8/SIT construct was then used as a template to generate the depicted vari-
ants in which individual tyrosine residues ( > ) were replaced by phenylalanines (F). (C) cDNA constructs encoding the SIT chime-
ras depicted in (B) were transiently expressed in Jurkat T cells by electroporation. Following overnight incubation, the cells were
activated for 2 min with pervanadate (PV). Subsequently cells were lysed in NP 40-containing buffer and subjected to CD8 immu-
noprecipitation. Following SDS-PAGE, proteins were subjected to sequential anti-PTyr anti-SHP2 and anti-SIT Western blotting.
of chimeric SIT molecules in which the cytoplasmic tail of
SIT was fused to the transmembrane and the extracellu-
lar domains of CD8. The cytoplasmic domains of the
individual CD8/CD8/SIT chimeras corresponded either
to wild-type SIT or carried mutations of four of the five
potential tyrosine phosphorylation sites. A scheme
depicting the various CD8/CD8/4F chimeras that we
used in these experiments is shown in Fig. 1 B.
The individual cDNA contructs were transfected into Jur-
kat T cells by electroporation. Following overnight incu-
bation the expression of the chimeras was assessed by
FACS analysis (see e. g. Fig. 4) and by anti-SIT Western
blotting (Fig. 1 C). Subsequently, the transfectants were
either left untreated or were briefly treated with pervana-
date, lysed in NP40-containing buffer, subjected to CD8
immunoprecipitation followed by anti-phosphotyrosine
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Fig. 2. TCR stimulation of Jurkat cells results in the recruit-
ment of Grb2 and SHP2 to SIT. (A) Jurkat cells (4 × 107) were
stimulated with C305 mAb for the indicated periods of time
at 37 °C. Lysates were subjected to immunoprecipitation
using anti-SIT antibodies, separated on a SDS-10 % PAGE,
and immunoblotted with the anti-PTyr mAb 4G10 (upper
panel). The membrane was subsequently stripped and
reprobed with anti-SHP2 (middle panel) and anti-Grb2
(lower panel) mAbs. (B) Densitometric analysis of the bands
corresponding to SHP2 and Grb2 shown in (A).
(PTyr) Western-blotting. Fig. 1 C demonstrates that
under these experimental conditions the CD8/CD8/SIT,
the CD8/CD8/4F+YGN and the CD8/CD8/4F+YAS chi-
meras became strongly tyrosine phosphorylated,
whereas the phosphorylation of the CD8/CD8/4F+YTS,
the CD8/CD8/4F+ITIM and the CD8/CD8/4F+YAN chi-
meras was much weaker. The overall level of tyrosine
phosphorylations was YGNL n YASV G YTSL G ITIM
G YANS. The data indicate that the major sites of SIT
tyrosine phosphorylation are the YGNL and the YASV
motifs. However, the YTSL, the ITIM and the YANS
motifs likely also become tyrosine phosphorylated after
T cell activation. Indeed, when we analyzed the individ-
ual CD8 immunoprecipitates shown in Fig. 1 C for co-
precipitation of SHP-2, we observed that SHP2 was
recruited by the wild-type CD8/CD8/SIT chimera and
the CD8/CD8/4F+ITIM chimera but not by any of the
other mutants tested (Fig. 1 C, middle panel). This con-
firms our previous data which had suggested that the
ITIM represents the in vivo phosphorylation site mediat-
ing the association between SIT and SHP2 ([12] and see
also below).
2.2 SIT associates with SHP2 and Grb2 after
T cell activation
The YGNL motif of SIT represents a potential binding site
for the SH2 domain of the cytosolic adaptor protein Grb2
[17]. Given the above finding that this motif likely repre-
sents a major site of tyrosine phosphorylation we next
assessed whether SIT, besides recruiting SHP2, would
also associated with Grb2 after T cell activation. To this
end Jurkat cells were stimulated for increasing periods of
time with the clonotypic anti-TCR mAb C305 and then
lysed in NP40-containing buffer. Subsequently, anti-SIT
immunoprecipitates were prepared and analyzed for SIT
tyrosine phosphorylation and co-precipitation of SHP2
and Grb2 by Western blotting. The upper panel of
Fig. 2 A demonstrates that an increase in SIT phosphoty-
rosine content is already detectable after 1 min of TCR-
mediated activation of Jurkat T cells and that it remains
detectable for at least 1 h. As previously reported [12],
the rapid increase in SIT phosphorylation is accompa-
nied by an association between SIT and SHP2 (Fig. 2 A,
middle panel). Perhaps more importantly, a time-
dependent interaction of SIT with Grb2 was also detect-
able (Fig. 2 A, lower panel). Densitometric analysis of the
blots revealed that the interaction between SIT and
SHP2 or Grb2 was peaking at approximately 5 min after
TCR engagement, and then slowly declined (Fig. 2 B).
These results demonstrate that SIT not only associates
with SHP2 but also with Grb2 upon T cell activation.
2.3 Grb2 binds to the YGNL and YANS motifs
of SIT
To assess whether the inducible association between
SIT and Grb2 is mediated via the YGNL motif we overex-
pressed CD8/CD8/SIT chimeras in Jurkat T-cells in
which single tyrosine residues were mutated to phenylal-
anine (see Fig. 3 A for a schematic representation of the
individual cDNA constructs). Again, the transfectants
were left unstimulated or were treated with pervanadate.
Subsequently, NP40 lysates were prepared and sub-
jected to anti-CD8 immunoprecipitation. Immunoprecipi-
tates were then analyzed for the presence of SHP2 and
Grb2 by Western blotting (Fig. 3 B). These experiments
revealed that the YTSL, the ITIM and the YASV motif are
dispensable for the association between SIT and Grb2
since almost identical amounts of Grb2 were detect-
able in CD8 precipitates prepared from transfectants
expressing these three mutants compared to cells
expressing wild-type SIT (Fig. 3 B).
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Fig. 3. The YANS and YGNL motifs of SIT mediate the association with Grb2. (A) Schematic representation of the cDNA con-
structs used for the experiments shown in this figure as well as those shown in Fig. 4 (see legend of Fig. 1 for nomenclature). (B)
Jurkat cells were transfected with empty pEF-Bos vector (Bos) or with the indicated constructs. After 18 h, 2 × 106 cells were left
unstimulated (−) or treated with pervanadate (+) for 2 min. NP40 lysates were subjected to anti-CD8 immunoprecipitation fol-
lowed by anti-pTyr Western blot analysis. The blot was then stripped and re-probed with anti-SIT, anti-SHP2 or anti-Grb2 anti-
bodies, as indicated.
In marked contrast, mutation of the YGNL motif resulted
in an impaired ability of SIT to recruit Grb2 following T
cell activation (arrow in Fig. 3 B), indicating that this motif
represents a Grb2 binding site. However, we observed
that the CD8/CD8/YAN chimera also had a reduced abil-
ity to associate with Grb2 despite the above observation
that this motif apparently does not represent a major site
of tyrosine phosphorylation. Moreover, concomitant
mutation of the YGNL and the YANS motif (CD8/CD8/
YGN+YAN chimera) resulted in a complete loss of Grb2
binding while the association with SHP2 was unaffected.
These data strongly suggest that the association
between SIT and Grb2 occurs on two different sites,
namely YGNL and YANS (with YGNL being the major
binding site).
2.4 Inhibition of T cell activation by SIT requires
an intact YASV motif
Previous data had suggested that SIT might exert an
inhibitory function during T cell activation. This hypothe-
sis was based on the finding that overexpression of wild-
type SIT or a CD8/CD8/SIT chimera in Jurkat T cells
strongly impaired induction of the transcriptional activity
of NF-AT after recruitment of the TCR [12]. However, inhi-
bition of T cell activation by SIT is apparently not medi-
ated via SHP2 since a SIT-ITIM mutant or a CD8/CD8/
ITIM chimera which had largely lost their ability to bind to
SHP2 still inhibited TCR-mediated induction of NF-AT
activity [12].
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Fig. 4. The YASV-motif is responsible for SIT-mediated inhibition of TCR/CD3-induced NF-AT activation. (A) Jurkat cells were
co-transfected with empty vector (pEF-Bos), a cDNA encoding the CD8/CD8/SIT chimera (WT) or the indicated SIT-variants,
together with a NF-AT driven luciferase reporter construct. Eighteen hours later, cells were stimulated with crosslinked anti-TCR
(C305) or CD3 4 (OKT3) mAb for 6 h and then analyzed for luciferase activity as described in Sect. 4. The luciferase units obtained
after stimulation of cells transfected with the empty vector were set as 100 %. Shown is the relative inhibition of the response of
each transfectant in comparison to the response of the vector transfectant. Equal levels of expression of the individual chimeras
were verified by anti-SIT Western blotting and by FACS analysis using an anti-CD8 mAb (not shown but see e. g. Fig. 4 B). (B)
Cells were transfected with the indicated constructs as described in (A). Transfectants were subsequently stimulated with cross-
linked anti-TCR mAb C305 alone or with a combination of crosslinked C305 and CD8 mAb (MEM-31). The luciferase units after
stimulation with crosslinked C305 alone were set as 100 %. Shown is the relative inhibition/amplification of this response follow-
ing co-crosslinking of the CD8-chimera with the TCR. The following equation was used: normalized luciferase units after TCR ×
CD8 co-stimulation divided by normalized luciferase units after TCR-stimulation alone. The expression of the constructs was ver-
ified by anti-SIT immunoblotting (lower panel) and by indirect immunofluorescence using mAb MEM-31.
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To examine further the molecular mechanisms underly-
ing the inhibitory function of SIT, the wild-type CD8/
CD8/SIT chimera or tyrosine mutants thereof (see
Fig. 3 A for details) were transiently overexpressed in Jur-
kat cells together with a luciferase reporter gene con-
struct that is driven by a triplicated NF-AT binding site of
the IL-2 promoter. A truncated version of the CD8/CD8/
SIT chimera lacking the entire cytolasmic tail of SIT
(CD8/CD8/STOP), a CD8/CD8/SIT chimera in which all
five tyrosine phosphorylation sites were mutated to
phenlyalanine (CD8/CD8/5F) as well as a chimeric TRIM
molecule consisting of the extracellular domain of
human HLA-A2 fused to a full-length TRIM molecule
(Ch–F), served as negative controls. Following transfec-
tion, cells were allowed to rest for 18 h and were then
stimulated for 6 h using either the anti-TCR mAb C305 or
the CD3 4 mAb OKT3. Subsequently, the TCR-mediated
induction of NF-AT activity was determined.
As shown in Fig. 4 A, overexpression of the CD8/CD8/
SIT chimera induced the previously described decrease
in TCR- and CD3 4 -mediated activation of NF-AT. Dele-
tion of the entire intracellular domain of SIT (CD8/CD8/
STOP) or mutation of all five tyrosine residues (CD8/
CD8/5F) abrogated the ability of the chimera to inhibit
NF-AT activation. In addition, overexpression of Ch–F
did not influence TCR-mediated activation of NF-AT, as
previously reported [15]. These data demonstrate that i)
inhibition of T cell activation is a specific property of SIT,
ii) SIT-mediated inhibition of T cell activation requires an
intact cytoplasmic domain and iii) it involves one or more
of the five cytoplasmic tyrosine residues of SIT.
As reported previously, overexpression of the CD8/CD8/
ITIM-chimera, which is strongly impaired in its ability to
bind SHP2 (see e. g. Fig. 3 B and [12]) still inhibited T cell
activation. The same was true for CD8/CD8/SIT chime-
ras in which the two Grb2-binding sites (CD8/CD8/YGN
or CD8/CD8/YAN chimera) were mutated individually or
concomitantly, as well as for the CD8/CD8/YTS chimera.
These findings suggested that the YGNL, YTSL, ITIM or
YANS motifs do not mediate the inhibitory signal exerted
by SIT. In marked contrast, all CD8/CD8/SIT chimeras in
which the YASV motif was mutated either alone (arrow)
or in combination with other tyrosine residues were
strongly impaired in their ability to inhibit TCR responses.
Similar data as shown in Fig. 4 A were obtained when the
individual CD8/CD8/SIT chimeras were co-ligated with
the TCR (Fig. 4 B). Under these experimental conditions
the wild-type CD8/CD8/SIT and the CD8/CD8/ITIM chi-
mera induced an approximately 60–70 % inhibition of
NF-AT activity. Perhaps more importantly, an identical
down-regulation of NF-AT activity was produced by the
CD8/CD8/4F+YAS chimera (in which only the YASV
motif is intact), whereas co-crosslinking of the CD8/
CD8/4F+ITIM chimera did not influence induction of NF-
AT activity. From this experiment as well as from the data
shown in Fig. 4 A we conclude that the inhibitory function
of SIT is exclusively mediated via the YASV motif.
Surprisingly, we observed that the CD8/CD8/YAS chi-
mera even up-regulated NF-AT activity when it was co-
ligated with the TCR. This suggested that in the absence
of a functional YASV motif, SIT can provide a positive –
rather than a negative – regulatory signal for T cell activa-
tion rather (Fig. 4 B). To investigate, which of the remain-
ing four tyrosine residues that are present in the CD8/
CD8/YAS chimera is responsible for up-regulation of T
cell activation in the absence of YASV, we overexpressed
the individual CD8/CD8/4F chimeras in Jurkat T cells
and assessed their influence on induction of NF-AT
activity after co-crosslinking with the TCR. As shown in
Fig. 5 A the CD8/CD8/4F+YTS, the CD8/CD8/4F+ITIM
and the CD8/CD8/4F+YAN chimeras had no major
impact on NF-AT activity after co-ligation with the TCR.
In marked contrast, co-engagement of the CD8/CD8/
4F+YGN chimera strongly up-regulated the response
under conditions where the CD8/CD8/SIT and the CD8/
CD8/4F+YAS chimeras inhibited NF-AT activity. Thus, in
the absence of a phosphorylatable YASV motif SIT can
exert a positive regulatory function for T cell activation
which is mediated via the YGNL motif.
2.5 The PTK Csk binds to the YASV motif
Given the above data indicating a critical role for the
YASV motif for SIT-mediated inhibition of T cell activa-
tion, we were interested to identify the molecule that
binds to this motif. To this end we established Jurkat var-
iants stably expressing the CD8/CD8/SIT or the CD8/
CD8/YAS chimera, respectively. The individual transfect-
ants as well as the parental (CD8–) Jurkat cell line were
metabolically labeled with a mixture of 35S-cysteine and
35S-methionine and subjected to brief pervanadate treat-
ment. Subsequently, CD8 immunoprecipitates were pre-
pared from postnuclear lysates, subjected to two-
dimensional gel electrophoresis and analyzed by auto-
radiography. By using this approach we repeatedly
observed a 45–50-kDa polypeptide (p45) with an esti-
mated isoelectric point of 7.0 co-precipitating with the
CD8/CD8/SIT chimera but not with the CD8/CD8/ITIM
chimera (not shown).
Both the molecular weight of p45 as well as its isoelectric
point are similar to those of the PTK p50csk, the major
negative regulator of src PTK. Moreover, the YASV motif
of SIT shows striking similarities to the tyrosine-based
signaling motif Y314SSV which has recently been shown
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Fig. 5. The YASV – motif is responsible for SIT-mediated
inhibition of TCR/CD3-induced NF-AT activation. (A) The
same experiment as shown in Fig. 4 B using the CD8/CD8/
4F-chimeras. (B) Jurkat cells stably expressing the CD8/
CD8/SIT or the CD8/CD8/YAS chimeras were briefly treated
with pervanadate. Subsequently, cells were lysed in NP40
containing buffer and subjected to CD8 immunoprecipita-
tion. The tyrosine phosphorylation status of the chimeras as
well as the presence of Csk and SHP2 in the immunoprecipi-
tates were assessed by sequential Western -blotting (anti-
Ptyr 1 anti-Csk 1 anti-SHP-2 1 anti-SIT).
to represent the major bindig site for the SH2 domain of
Csk within the cytoplasmic domain of the transmem-
brane adapter protein PAG/Cbp [13, 14]. Therefore we
argued that p45 is identical to Csk and that SIT might
recruit Csk via the YASV motif. To assess this question
we performed anti-Csk Western blot analysis of CD8
immunoprecipitates prepared from the above Jurkat var-
iants after treatment with pervanadate. As shown in
Fig. 5 B large amounts of Csk co-precipitated with the
CD8/CD8/SIT but not with the CD8/CD8/YASV chimera
under these experimental conditions. Thus, Csk is the
primary candidate for being the negative regulatory mol-
ecule that binds to YASV and mediates the inhibition of
T cell activation by SIT.
3 Discussion
During the last years major efforts have been made to
understand better the molecular mechanisms controlling
the quality of an immune response after engagement of
the TCR. The recent identification of a novel group of
integral membrane proteins that carry multiple tyrosine-
based signaling motifs in their cytoplasmic domains has
offered new perspectives to explain how TCR-mediated
signals are coupled to intracellular signaling pathways to
yield an appropriate cellular response. This group of sig-
naling molecules has collectively been termed trans-
membrane adaptor proteins and so far comprises LAT,
TRIM, PAG/Cbp and SIT.
While it is meanwhile well established that the expres-
sion and tyrosine phosphorylation of LAT is essential for
T cell activation and T cell development, the cellular
functions of TRIM, PAG/Cbp and SIT are less well
defined. We thought that one way to better understand
the roles of these novel adaptor proteins during T cell
activation might be to identify their sites of tyrosine
phosphorylation as well as the signaling proteins that
inducibly bind to their cytoplasmic domains. In this study
we have performed a structure-function analysis of SIT.
The cytoplasmic domain of SIT contains five potential
sites of tyrosine phosphorylation. These are Y90GNL,
Y128TSL, Y148SEV, Y168ASV and Y188ANS. Overexpression
of CD8/CD8/SIT chimeras in Jurkat T cells in which four
of these five sites were mutated to phenylalanine (CD8/
CD8/4F chimeras) revealed that under optimal condi-
tions (pervanadate stimulation) all five tyrosines can
serve as substrates for protein tyrosine kinases. How-
ever, the levels of tyrosine phosphorylation of the individ-
ual 4F chimeras were quite different. Thus, the YGNL and
the YASV motifs clearly seem to represent the preferred
phosphorylation sites whereas YTSL, ITIM and YANS
become phosphorylated to a much lesser extent (the
overall order seems to be: YGNL n YASV G YTSL G
ITIM G YANS). At present we do not know whether these
differences in tyrosine phosphorylation indeed reflect the
in vivo situation or whether the lower levels of tyrosine
phosphorylation of the YTSL, the ITIM and the YANS
motifs are due to the fact that their full phosphorylation
can only be achieved after YGNL and YASV have been
phosphorylated. This possibility cannot be excluded
because our previous experiments had suggested that,
although the Syk-PTK ZAP-70 and Syk alone cannot
induce detectable tyrosine phosphorylation of SIT in a
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COS cell system, optimal tyrosine phosphorylation of
SIT apparently requires co-expression of both Src and
Syk PTK [12]. Moreover, our previous data as well as the
experiments described in this report clearly demonstrate
that, besides YGNL and YASV, at least the ITIM and the
YANS motifs can bind intracellular effector molecules
(SHP2 and Grb2) after T cell activation (Fig. 3).
Based on the studies performed by Songyang et al. [17],
we argued that the YGNL motif could mediate an inter-
action between SIT and the cytoplasmic adaptor mole-
cule Grb2. Indeed, an analysis of SIT immunoprecipi-
tates prepared from TCR-stimulated Jurkat T cells not
only corroborated an activation-induced association
between SIT and SHP2 but also revealed an interaction
between SIT and Grb2 (Fig. 2). By using chimeric CD8/
CD8/SIT constructs in which individual tyrosine residues
were mutated to phenylalanine we confirmed that
Y188GNL represents a Grb2 binding site (Fig. 3 B). How-
ever, we also observed that mutation of this site only par-
tially abolished the association between SIT and Grb2.
This suggested the existence of at least one additional
Grb2 binding site within the cytoplasmic domain of SIT,
which we identified as the Y188 ANS motif. Thus, simulta-
neous mutation of both YGNL and YANS motifs
completely ablated the ability of SIT to recruit Grb2
whereas single mutation of either motif only partially
interfered with the association between the two mole-
cules (Fig. 3 B). These data suggest that after T cell acti-
vation Grb2 can interact with SIT via two different sites,
namely Y90 GNL and Y188 ANS.
Previous studies had indicated that overexpression of
SIT in Jurkat cells leads to down-regulation of the TCR/
CD3-induced activation of NF-AT and that this inhibitory
function is dependent on the presence of its cytoplasmic
domain. We here extended these initial observations by
demonstrating that the inhibitory function of SIT is
dependent on tyrosine phosphorylation. Thus, a CD8/
CD8/SIT chimera in which all five tyrosines were
mutated to phenylalanine (CD8/CD8/5F chimera) had
completely lost its capability to inhibit T cell activation
(Fig. 4 A).
By mutational analysis we identified the Y168 ASV motif
as the phosphorylation site that seems to be responsible
for SIT mediated inhibition of T cell activation. Overex-
pression of a CD8/CD8/SIT chimera in which only the
YASV motif was mutated (CD8/CD8/YAS chimera) fully
rescued the NF-AT response following T cell activation,
whereas chimeras carrying mutations in the YGNL, the
ITIM, the YTSL or the YANS motifs had no influence on
the ability of SIT to inhibit T cell responses (Fig. 4 A).
Moreover, co-ligation of a CD8/CD8/SIT chimera, which
only contained the YASV motif (CD8/CD8/4F+YAS) with
the TCR-inhibited activation of NF-AT in an identical
fashion as the wild-type protein (Fig. 4 B). All these data
suggest that the inhibitory function of SIT is exclusively
mediated via the YASV motif.
However, mutation of the YASV motif has no obvious
impact on the binding of SHP2 and/or Grb2 to SIT
(Fig. 3 B). Therefore we proposed the existence of a SH2
domain containing negative regulatory effector molecule
that selectively binds to the phosphorylated YASV motif
and mediates the inhibitory effect on T cell activation.
Two-dimensional analysis of CD8 immunoprecipitates
prepared from metabolically labeled Jurkat T cells stably
expressing either the CD8/CD8/SIT or the CD8/CD8/
YAS chimera resulted in the identification of a 45-kDa
polypeptide (p45) with an estimated isoelectric point of
about 7.0 that specifically co-precipitated with the wild-
type chimera but not with the YASV mutant. We argued
that p45 may be the tyrosine kinase Csk, which pos-
sesses the appropriate molecular weight and isoelectric
point. In addition, Csk has recently been demonstrated
to bind via a YSSV motif (which is very similar to the
YASV-motif of SIT) to human and rat homologoues of the
transmembrane adapter protein PAG/Cbp [13, 14].
Based on these molecular properties of Csk it was not
surprising that we identified endogenous Csk in CD8
immunoprecipitates prepared from the CD8/CD8/SIT
transfectants but not in those obtained from Jurkat T
cells expressing the CD8/CD8/YAS mutant (Fig. 5 B).
Collectively, these findings suggest that Csk could repre-
sent the negative regulatory protein that binds to the
YASV motif and mediates the negative regulatory effect
exerted by SIT on TCR-induced NF-AT activity.
The obvious question emerging from the finding that Csk
is capable to bind to SIT is which TCR-mediated signal-
ing pathway(s) leading to activation of NF-AT is/are con-
trolled by this interaction. In this regard it is important
to remember that overexpression of SIT in the Jurkat var-
iant J.HM1.2.2 (which co-expresses a TCR and the
human muscarinic receptor type 1) does not inhibit
induction of NF-AT activity after triggering of G-protein
coupled receptors [12]. This suggests that SIT controls
signaling processes mediated via ITAM-containing
immunoreceptors. Moreover, we had demonstrated that
the inhibitory effect of SIT on TCR-mediated induction of
NF-AT activity can be bypassed by treatment of SIT
transfectants with a combination of a phorbol ester and
ionomycin (which indicates that SIT likely exerts its func-
tion upstream of activation of PKC).
However, so far our attempts to show inhibition of (a)
proximal tyrosine phosphorylation event(s) as an indica-
tor of Csk-mediated inhibition of Src kinase activity in
cells overexpressing SIT have not been successful. For
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example we did not observe significant alterations of the
global TCR-mediated tyrosine phosphorylation of cellu-
lar proteins after overexpression of SIT (either transiently
or stably). In addition, tyrosine phosphorylation of TCR ´ ,
LAT, PLC + and also phosphorylation of Erk after TCR
triggering seem to occur normally in cells overexpressing
SIT. Collectively, these findings suggest that at least the
initial activation of Src kinases occurs normally in cells
overexpressing SIT. Therefore, further studies are
required to elucidate the question which TCR-mediated
signaling pathway(s) is/are controlled by SIT.
It is important to note that the functional activities of SIT
show striking similarities to those that have recently been
described for the negative regulatory adaptor protein
Dok-3 [18]. Like SIT Dok-3 inducibly associates with Csk
and down-regulates BCR-mediated activation of NF-AT
via an unknown mechanism. The inhibitory effect of Dok-
3 depends on the presence of the C-terminal tail of the
molecule which contains four potential tyrosine-based
signaling motifs among which one is likely responsible
for recruitment of Csk [18]. Interestingly, the same YASV
motif that mediates the association between SIT and
Csk is also expressed in Dok-3 and the amino acids
flanking both motifs are well conserved between the two
molecules (see Fig. 1 A). It is therefore tempting to spec-
ulate that the YASV motif of Dok-3 also mediates its
association with Csk and that this motif is involved in the
inhibition of BCR-mediated signaling. Furthermore, the
overall functional similarities between the two molecules
might suggest that they control the same pathways of
immunoreceptor-mediated signaling in different types of
cells.
Previously we have demonstrated that the cytoplasmic
tyrosine phosphatase SHP2 binds to the ITIM within the
cytoplasmic domain of SIT. In T cells it is believed that
SHP2 is involved in regulation of the MAPK pathway
leading to activation of the transcription factor AP-1 [19].
The NF-AT reporter construct that we used in this study
contains an AP-1 binding site and therefore we thought
that, if SIT-associated SHP2 regulated AP-1 activity, then
the CD8/CD8/4F-ITIM chimera should be capable to
upregulate NF-AT when overexpressed in T cells. How-
ever, this is clearly not the case. Even co-ligation of the
CD8/CD8/4F+ITIM chimera with the TCR failed to exert
any measurable effect on the activity of the NF-AT
reporter construct, although the chimera was capable to
bind SHP2 (Fig. 1 C). From these data we conclude that
the SIT-associated fraction of SHP2 regulates an
(unknown) pathway of T cell activation that does not
result in activation of AP-1.
An interesting observation during this study was that the
functional effect of the individual CD8/CD8/SIT chime-
ras could be best demonstrated when the chimeras were
co-crosslinked with the TCR using a CD8 antibody
(Figs. 4 B and 5 A). As already mentioned above SIT rep-
resents a heavily glycosylated molecule that could pos-
sess an external ligand. One possibility to explain our
results would be that the CD8 antibody mimics the func-
tion of this putative ligand. In this scenario engagement
of SIT by its ligand would bring SIT in close proximity of
the TCR, thus allowing the down-regulation of TCR-
mediated signals. However, whether SIT indeed has an
external ligand and whether this putative ligand regu-
lates its function requires further investigations.
We also would like to point out that, although our previ-
ous studies as well as the experiments described in this
report, support the view that SIT represents a negative
regulatory adaptor protein, the possibility cannot be
excluded that under particular conditions of T cell activa-
tion SIT exerts a positive rather than a negative regula-
tory function.
As shown in Figs. 2 and 3, SIT is capable of recruiting
Grb2 via the YGNL motif following T cell triggering. In
addition, it seems that YGNL represents a preferred tyro-
sine phosphorylation site (Figs. 1 and 3). Finally, our
experiments using the CD8/CD8/YASV and the CD8/
CD8/4F+YGN chimera indicate that in the absence of
phosphorylatable YASV, SIT enhances TCR-mediated
activation of NF-AT (Figs. 4 B and 5 A). This effect is
mediated via the YGNL motif and thus likely involves a
Grb2-controlled signaling pathway (Fig. 5 A).
One could imagine a situation in which a preferential (or
even exclusive) phosphorylation of YGNL occurs in vivo,
for example after TCR triggering by a weak agonist.
Thus, depending on its state of phosphorylation SIT (as
well as other transmembrane and cytosolic adaptor pro-
teins) could serve as a multifunctional protein that helps
to integrate the quality of an externally applied signal into
an appropriate cellular response. For the further under-
tanding of SIT function it will be important to elucidate
the question whether the phosphorylation status of SIT
as well as its association with cytosolic effector mole-
cules is influenced by the quality of an externally applied
signal. Moreover, it will be important to identify the mole-
cule(s) that bind to the SIT/Grb2 complex. Potential can-
didates are SOS [20, 21], SLP-76 [22], Dynamin [20],
TNF-R1 [23] and SHIP [24] which all have been demon-
strated to bind one or two of the Grb2-SH3 domains.
Experiments are underway to assess these questions.
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4 Materials and methods
4.1 Cells and antibodies
Jurkat cells were maintained in RPMI 1640 supplement-
ed with 10 % FCS, 2 % glutamin and 1 % penicillin-
streptomycin (Gibco BRL, Germany). The Jurkat variants
stably expressing the CD8/CD8/SIT and the CD8/CD8/YAS
chimeras were generated and propagated as previously
described [11]. The anti-SIT polyclonal antiserum was raised
by immunizing rabbits with a KLH-coupled synthetic peptide
corresponding to amino acids 96–114 [12]. After affinity
purification on peptide-coupled protein A-Sepharose beads,
antibodies were used at 2 ? g/ml for Western blotting. Anti-
bodies against SHP2, phosphotyrosine (4G10) (Upstate Bio-
technology Inc.), Grb2 (Santa Cruz) and Csk (Santa Cruz)
were diluted at 1 ? g/ml for immunoblotting. For immunopre-
cipitation experiments, protein A-Sepharose-purified anti-
CD8 mAb AICD8.1 or MEM-31 mAb were covalently cou-
pled to CNBr-activated Sepharose beads (6 mg mAb/ml of
packed beads).
4.2 Immunoprecipitation and Western blotting
Untransfected Jurkat T cells (4 × 107 for the experiment
shown in Fig. 2) or Jurkat cells (2 × 106) that had been tran-
siently transfected with cDNA encoding the various CD8/
CD8/SIT chimeras (see below) were stimulated with culture
supernatant of C305 mAb (provided by Dr. A. Weiss, Univer-
sity of California, San Francisco, CA) for the indicated period
of time, or with a mixture of 0.1 mM vanadate plus 1 mM
H2O2 for 2 min, at 37 °C. Immunoprecipitations were per-
formed using the crude polyclonal rabbit antiserum directed
at SIT (1:100 v/v) followed by collection of the immune com-
plexes using protein A-Sepharose or by using 15 ? l of
packed beads coupled with protein A-purified CD8 mAb.
After several washes, the precipitates were subjected to
SDS-PAGE and further processed for Western blot analysis
using standard procedures, as described elsewhere [12, 16].
4.3 cDNA constructs and transfection
Generation of the chimeric CD8/CD8/SIT molecule and its
cloning into the eukaryotic pEF-Bos expression vector have
been previously described [12]. Point mutation of the tyro-
sine residues (replaced by phenylalanine) within selected
signaling motif(s) has been performed using the Quick
Change site-directed Mutagenesis kit from Stratagene
according to the manufacturer’s recommendations.
4.4 Luciferase reporter gene assay
Jurkat cells were transiently transfected by electroporation
using 30 ? g of the indicated cDNA construct together with
10 ? g of the NF-AT reporter construct and 1 ? g of a rennilla
luciferase reporter gene. Cells were allowed to recover for
18 h and incubated in duplicates (7 × 104 cells/well) with
medium, immobilized anti-TCR (C305) or anti-CD3 (OKT3)
mAb, or PMA (10–8 M) plus ionomycin (1 ? g/ml) in a 96-well
plate (U96 Maxisorp, Nunc). After 6 h of stimulation, cells
were harvested, washed twice in PBS and lysed for 15 min
at room temperature. The normalized luciferase activity of
the NF-AT reporter gene was measured in each supernatant
using the dual luciferase assay system from Promega.
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Abstract
 
A key molecule necessary for activation of T lymphocytes through their antigen-specific T cell
receptor (TCR) is the transmembrane adaptor protein LAT (linker for activation of T cells).
Upon TCR engagement, LAT becomes rapidly tyrosine phosphorylated and then serves as a
scaffold organizing a multicomponent complex that is indispensable for induction of further
downstream steps of the signaling cascade. Here we describe the identification and preliminary
characterization of a novel transmembrane adaptor protein that is structurally and evolution-
arily related to LAT and is expressed in B lymphocytes, natural killer (NK) cells, monocytes,
and mast cells but not in resting T lymphocytes. This novel transmembrane adaptor protein,
termed NTAL (non–T cell activation linker) is the product of a previously identified 
 
WBSCR5
 
gene of so far unknown function. NTAL becomes rapidly tyrosine-phosphorylated upon cross-
linking of the B cell receptor (BCR) or of high-affinity Fc
 

 
- and Fc
 

 
-receptors of myeloid
cells and then associates with the cytoplasmic signaling molecules Grb2, Sos1, Gab1, and c-Cbl.
NTAL expressed in the LAT-deficient T cell line J.CaM2.5 becomes tyrosine phosphorylated
and rescues activation of Erk1/2 and minimal transient elevation of cytoplasmic calcium level
upon TCR/CD3 cross-linking. Thus, NTAL appears to be a structural and possibly also func-
tional homologue of LAT in non–T cells.
Key words: lipid rafts • membrane microdomains • antigen receptors • Fc gamma receptor • 
Fc epsilon receptor
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Introduction
 
Immunoreceptors (TCR, B cell receptor [BCR],
 
*
 
 most
Fc-receptors) initiate, upon binding of their agonist ligands,
signaling pathways based on an inducible activation of Src-,
Syk-, and Tec-family protein tyrosine kinases (1–3). Even-
tually this leads to activation of further downstream signal-
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phosphatidylinositol 3-kinase; PLC
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, phospholipase C
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; PTK, protein
tyrosine kinase; P-Tyr, phosphotyrosine.
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ing molecules such as phospholipase C
 

 
 (PLC
 

 
), phos-
phatidylinositol 3-kinase (PI3-K), and other proteins
regulating activities of small G-proteins of Ras and Rho
families. A key component of the TCR signaling pathway
is a transmembrane adaptor protein linker for activation of
T cells (LAT) which becomes tyrosine phosphorylated by
activated ZAP-70 (4) and then binds several other mole-
cules including PLC
 

 
, Grb2, SLP-76, PI3-K, and Gads (5).
LAT is expressed in T cells as a palmitoylated protein and is
a characteristic component of detergent-resistant mem-
brane microdomains (6, 7), also called membrane rafts or
glycosphingolipid-enriched membrane domains (GEMs)
enriched in glycosylphosphatidylinositol (GPI)-anchored
proteins, glycosphingolipids, cholesterol, and several spe-
cies of signaling molecules including Src-family kinases and
heterotrimeric G-proteins (8). Association of the ligated
TCR (as well as other immunoreceptors) with GEMs
seems to be indispensable for the initiation of cellular acti-
vation as it facilitates the phosphorylation of immunorecep-
tor-associated tyrosine-based activation motifs by GEM-
associated Src-kinases and several other early signaling steps
(9, 10). T cells devoid of LAT are defective in TCR signal-
ing and LAT
 

 
/
 

 
 mice lack mature T cells as their develop-
ment in thymus is blocked at an early stage (11).
In marked contrast to T cells, B cells of LAT
 

 
/
 

 
 mice
are functionally normal because LAT is not expressed in
these cells. Furthermore, myeloid and NK cells develop
apparently normally in the LAT-deficient animals and at
least some aspects of signaling through their Fc-receptors
remain functional (11–13). The latter data indicate that
another LAT-like molecule may be expressed in non–T
cells. Therefore, we were looking for a molecule which
might possibly play a LAT-like role in BCR and Fc-recep-
tor signaling.
 
Materials and Methods
 
Cells and Antibodies.
 
Human T, B, NK cells, and monocytes
were obtained from buffy coats by Ficoll centrifugation and pre-
parative cell sorting using a FACS Vantage™ flow cytometer
(Becton Dickinson) and PE-conjugated mAbs to CD3 and CD19
(Serotec), biotinylated anti-CD14 (Serotec), fluoresceinated
streptavidin (BD Biosciences), unlabeled CD56 mAb MEM-188
(product of the Prague laboratory), and fluorescein-conjugated
F(ab)
 
2
 
 fragments of goat anti–mouse Ig (Caltag). Mouse spleno-
cytes (an unseparated washed suspension containing 
 

 
40% B
cells) used in functional experiments with B cells were obtained
from C57/BL6 mice. Human blood monocytes used in the func-
tional experiments were obtained by preparative cell sorting based
solely on their characteristic side and forward scatter properties
(i.e., without any antibody staining). Bone marrow mast cells
(BMMCs) of wild-type and Lyn
 

 
/
 

 
 mice (14) were provided by
Dr. M. Hibbs (Ludwig Institute for Cancer Research, Mel-
bourne, Australia). B cell line Ramos, myeloid cell line THP-1,
T cell line Jurkat, and 293T cells were from the cell line collec-
tion of the Institute of Molecular Genetics. Jurkat T cell line mu-
tant J.CaM2.5 deficient in the transmembrane adaptor protein
LAT (15) was donated by Dr. A. Weiss (University of California
at San Francisco, San Francisco, CA).
 
Antiserum to non–T cell activation linker (NTAL) was pro-
duced in the Prague laboratory by immunization of rabbits with
bacterially expressed cytoplasmic fragment of human NTAL
(amino acids 89–243), mouse mAbs to NTAL were prepared us-
ing standard techniques from splenocytes of mice immunized
with the same bacterially produced NTAL fragment; some of
them cross-reacted also with mouse homologue (unpublished
data). In addition, anti-peptide mAbs were prepared directed to
the peptide comprising residues 196 to 210 of the human mole-
cule (purchased from Genemed Synthesis Inc.) conjugated to
keyhole limpet hemocyanin using a commercial kit (Pierce
Chemical Co.). Rabbit polyclonal antibodies to Erk1/2 and
phospho-Erk1/2 were from Promega and New England Biolabs,
Inc., respectively.
The sources of the other antibodies used were as follows: Jur-
kat TCR (IgM mAb C305, provided by Dr. A. Weiss), CD28
(IgM mAb 248.23.2; reference 16), Grb2 (mouse mAb; Trans-
duction Laboratories), Sos1 (rabbit polyclonal; Santa Cruz Bio-
technology, Inc.), c-Cbl (rabbit polyclonal; Santa Cruz Biotech-
nology, Inc.), Gab1 (Upstate Biotechnology), ubiquitin (rabbit
polyclonal; Sigma-Aldrich), phosphotyrosine (mAbs P-Tyr-01
and P-Tyr-02 prepared in the Prague laboratory; PY-20-horse-
radish peroxidase conjugate; Transduction Laboratories), CD59
(mAb MEM-43), and CD3
 

 
 (mAb MEM-92), both prepared in
Prague laboratory.
 
In Vitro Kinase Assay, Immunoprecipitation, and Other Biochemical
Methods.
 
Detergent-resistant microdomains (GEMs) were im-
munoisolated and in vitro kinase assays performed as described
previously (17). Briefly, cells were solubilized with ice-cold iso-
tonic lysis solution containing 1% detergent Nonidet P-40 (NP-
40), the postnuclear supernatants containing GEMs were incu-
bated in plastic wells coated with mAb MEM-43 (antibody to a
major protein component of GEMs, GPI-anchored pro-
tein CD59). After washing, the kinase solution containing
[
 

 
32
 
P]ATP (ICN Biomedicals) was added and the proteins
phosphorylated by GEMs-associated kinases were resolved by
SDS-PAGE and autoradiography. Sucrose density gradient-based
GEMs isolation was performed as described previously (18).
NTAL and NTAL-containing complexes were immunopre-
cipitated using postnuclear supernatants of cells solubilized by a
detergent effectively disrupting GEMs (laurylmaltoside [n-dode-
cyl 
 

 
-D-maltoside]; Calbiochem; lysis buffer: 1% laurylmaltoside
in 20 mM Tris [pH 7.5], containing 100 mM NaCl, 10% glyc-
erol, 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride, 10 mM
EDTA, 50 mM NaF, 1 mM Na
 
3
 
VO
 
4
 
) and CNBr-Sepharose
beads (Amersham Biosciences) coupled with mAbs purified by
Protein A-Sepharose affinity chromatography. These lysates were
passed through minicolumns (30–50 
 

 
l packed volume) of such
immunosorbents; after washing with 10 column volumes of lysis
buffer, bound proteins were eluted with 2 column volumes of
2
 

 
 concentrated SDS-sample buffer and the flow-through and
eluted fractions were analyzed by SDS-PAGE followed by West-
ern blotting. In some experiments the cells were solubilized in
2
 

 
 concentrated SDS-sample buffer, ultracentrifuged (250,000 
 
g
 
,
30 min) and the supernatant analyzed by SDS-PAGE and West-
ern blotting. Biosynthetic labeling with [
 
3
 
H]palmitate, SDS-
PAGE, and Western blotting were performed as described (18).
For enhanced detection of polyubiquitinated NTAL, the blot was
autoclaved before immunostaining (19).
 
Isolation of NTAL and Its Identification by Peptide Mass Map-
ping.
 
Large-scale isolation of GEMs from NP-40-solubilized
THP-1 cells by sucrose density gradient ultracentrifugation and
separation of their protein components by two-dimensional
 1619
 
Brdi ka et al.cˇ
 
PAGE was performed essentially as described earlier for analogous
isolation of the transmembrane adaptor protein PAG (18). Two
silver stained spots comigrating with the radioactively labeled in
vitro phosphorylated spots were digested directly in the gel by
trypsin (Promega) and the resulting peptide mixtures were ana-
lyzed on a Bruker BIFLEX II (Bruker-Franzen) MALDI-TOF
mass spectrometer equipped with a nitrogen laser (337 nm) and a
delayed extraction ion source. A saturated solution of 
 

 
-cyano-
4-hydroxycinnamic acid in aqueous 50% acetonitrile and 1%
acetic acid was used as a MALDI matrix. 1 
 

 
l of the sample and 1
 

 
l of the matrix solution were mixed on the target and allowed
to dry at the ambient temperature. Positive-ion mass spectra of
peptide maps were measured in the reflectron mode. Spectra
were externally calibrated by using the monoisotopic [M
 
	
 
H]
 
	
 
ion of peptide standard (somatostatin; Sigma-Aldrich).
 
DNA Constructs, Transfections.
 
The coding region of human
NTAL was amplified from human leukocyte cDNA library
(CLONTECH Laboratories, Inc.; primers: 5
 


 
 CAGTTCTTG-
GAAACCCACTCGAG 3
 


 
 and 5
 


 
 GATGTCGACTAGGCT-
TCTGTGGCTGCCAC 3
 


 
). The PCR product was blunted and
cloned into EcoRV site of pBluescript SK vector (Stratagene), the
coding sequence was then cut out with HindIII and SmaI, gel-
purified, and cloned into the HindIII/EcoRV digested eukaryotic
expression vector pFLAG-CMV 5a (Sigma-Aldrich), and se-
quenced. For stable transfections NTAL coding sequence was
subcloned into EcoRI site of pEFIRES-N vector (provided by
Dr. S. Hobbs, Institute of Cancer Research, London, UK; refer-
ence 20). The FLAG-NTAL construct encoding the full length
NTAL containing the COOH-terminal FLAG tag was produced
from the pFLAG-CMV 5a construct by site-directed mutagenesis
using the QuikChange™ site-directed mutagenesis kit (Strat-
agene) according to the manufacturer’s instructions and the
FLAG-NTAL insert was eventually subcloned into the pE-
FIRES-N vector. The analogous FLAG-LAT construct was ob-
tained from a previously described construct (21) by subcloning
the FLAG-LAT insert into the pEFIRES-N vector. The FLAG-
TRIM construct in pEF-BOS vector was described earlier (21).
For transient transfection of 293T cells, Lipofectamine 2000™
reagent (Invitrogen) was used according to manufacturers instruc-
tions. For transfection experiments in 293T cells the following
cDNA constructs were used: Myc-tagged Lck or ZAP-70 in-
serted into pcDNA3 vector (donated by Dr. R. Abraham, Mayo
Clinic, Rochester, MN), Syk cloned into the pRK5 vector
(provided by Dr. W. Kolanus, Gene Center, Munich, Germany),
Myc-tagged Lyn in pcDNA3.1 vector (provided by Dr. S. Wat-
son, University of Oxford, UK), and FLAG-tagged Hck in
pcDNA1 vector (provided by Dr. G. Langsley, Institut Pasteur,
Paris, France). For bacterial expression, the NTAL intracellular
fragment corresponding to amino acids 89–243 was cloned to
BamHI site of pET-15b expression vector (Novagen), generating
a construct with NH
 
2
 
-terminal histidine tag.
J.CaM2.5 cells (Jurkat T cell line mutant deficient in the trans-
membrane adaptor protein LAT) were transfected with non-
tagged or FLAG-tagged NTAL, LAT, and TRIM constructs in
the above described expression vectors by electroporation; stable
transfectants expressing NTAL were selected by growing in 96-
well plate in selective medium containing 1 mg/ml G418 (Cal-
biochem). After 3 wk oligoclonal G418-resistant populations were
expanded and checked for NTAL expression by Western blot-
ting. Four independent clones (three expressing high amount of
NTAL and one of very low expression) were analyzed in detail.
All these clones expressed only trace amounts of LAT (just like
the parental J.CaM2.5 cells) and all of them had the same high
 
expression of CD3 as the parental J.CaM2.5 cells or wild-type
Jurkat cells (unpublished data). In relevant figures a representative
of the NTAL high-expressing clones (which all gave similar re-
sults) is compared with wild-type Jurkat cells and to a parental
J.CaM2.5 cell line (which behaves essentially identically as the
NTAL-low expressing clone).
 
Mouse Genomic Clones.
 
LAT genomic clones were isolated
from a 129/Ola phage library and sequenced. The GenBank/
EMBL/DDBJ accession no. corresponding to mouse LAT is
AJ438435. Part of the sequence of the mouse 
 
LAT
 
 gene can be
found on a contig present in the Ensembl Gene report (Ensembl
gene ID: ENSMUSG00000030742; http://www.ensembl.org/
Mus_musculus/), allowing the location of the 
 
LAT
 
 gene to chro-
mosome 7.
 
Confocal Microscopy.
 
THP-1 cells and J.CaM2.5-NTAL
transfectants were spun on coverslips coated with poly-L-lysine
(Sigma-Aldrich), fixed, and permeabilized 3 min in 
 

 
20
 

 
C
methanol and then 5 s in cold acetone. After washing in PBS
the slides were blocked with PBS containing 1% bovine serum
albumin and 20% human AB serum and incubated for 45 min
with mouse mAb to NTAL (NAP-7, 50 
 

 
g/ml), followed by
45 min incubation with Alexa 488 goat anti–mouse IgG (Mo-
lecular Probes, 500
 

 
 diluted). Nuclei were stained with pro-
pidium iodide (10 min, 0.5 
 

 
g/ml). The samples were mounted
in PBS and viewed with a Laserscan microscope (Leica TCS
SP). Incubation with irrelevant primary antibody served as a
negative control.
 
Tissue Section Immunostaining.
 
Sample of intestinal tissue bi-
opsy from a colorectal carcinoma patient (including a normal tis-
sue with local lymph nodes) was fixed with 10% neutral buffered
formalin, embedded into parafin, and 4-
 

 
m thick tissue sections
were cut. The preparation was dipped into citrate buffer pH 6.0
and treated in a microwave oven (2 
 

 
 5 min; 750 W). After
blocking endogenous peroxidase activity by 1.5% H
 
2
 
O
 
2
 
 in meth-
anol for 20 min, tissue sections were incubated sequentially with
hybridoma supernatant containing anti-NTAL mouse mono-
clonal antibody, biotinylated anti–mouse antibody (Jackson Im-
munoResearch Laboratories), streptavidin-conjugated horserad-
ish peroxidase (Biogenex), and 3,3-diaminobenzidine.
 
Cell Activation.
 
THP-1 cells were incubated 30 min on ice
with an irrelevant mouse IgG2a monoclonal antibody (50 
 

 
g/ml
in HBSS) which binds in the monomeric form selectively to the
human high affinity IgG receptor (Fc
 

 
RI; CD64; reference 22)
and then 20 min at 37
 

 
C in culture medium. Ligated Fc
 

 
-recep-
tors were then cross-linked with polyclonal goat anti–mouse an-
tibody (Sigma-Aldrich; 20 
 

 
g/ml; 2 min at 37
 

 
C), cooled down
in ice-water bath for 1 min, spun down 1 min at 2
 

 
C, and imme-
diately detergent solubilized. In some experiments THP-1 cells
were stimulated in the presence of kinase inhibitors. Purified
monocytes were stimulated using a similar protocol, except that
they were first incubated with human AB serum and the ligated
Fc
 

 
-receptors were then cross-linked with polyclonal rabbit anti–
human Ig antibody (Jackson ImmunoResearch Laboratories).
BMMCs from wild-type mice or from mice with a genetically
disrupted Lyn gene (BMMC-Lyn
 

 
/
 

 
) were sensitized with mono-
clonal IgE (IGEL b4 1; 1 
 

 
g/ml) and the ligated Fc
 

 
RIs were ag-
gregated with 2,4,6-trinitrophenyl (TNP)-BSA conjugate (1 
 

 
g/
ml; 5 min at 37
 

 
C) as described elsewhere (23). Ramos B cells
were activated by incubation for 2 min at 37
 

 
C with F(ab)
 
2
 
 frag-
ments of goat anti–human IgM (Jackson ImmunoResearch Labo-
ratories). Mouse B cells present in the unseparated splenocyte sus-
pension (10
 
8
 
 cells/ml) were stimulated 30 s with F(ab)
 
2
 
 fragments
of goat anti–mouse IgM (20 
 

 
g/ml; Jackson ImmunoResearch
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Laboratories). In vitro activation of Jurkat T cells, J.CaM2.5 mu-
tants, and J.CaM2.5-NTAL stable transfectants was performed us-
ing soluble IgM anti-CD3 mAb MEM-92 (100–250
 

 
 diluted as-
citic fluid containing approximately 8 mg/ml mAb, at 37
 

 
C for 5
min). Activated (phosphorylated) Erk1/2 was determined by im-
munoblotting of the total cell lysates using phospho-Erk specific
antibody (New England Biolabs, Inc.). J.CaM2.5 cells transiently
transfected with the FLAG-tagged LAT, NTAL, or TRIM con-
structs were 18 h after the transfection stimulated for 2 min with a
combination of anti-TCR (C305) and anti-CD28 IgM mAbs
(hybridoma supernatants) and phospho-Erk1/2 and FLAG
epitope were determined in their detergent lysates by Western
blotting.
 
Flow Cytometry Analysis of Calcium Mobilization.
 
Jurkat,
J.CaM2.5, and J.CaM2.5-NTAL cells were loaded with fluores-
cent Ca
 
2
 
	
 
 indicators Fura Red and Fluo-4 (9.2 
 
M and 3.6 M,
respectively; Molecular Probes) in HBSS containing 10 mM
HEPES (Sigma-Aldrich) and 4 mM Probenecid (Sigma-Aldrich),
for 20 min in dark and at room temperature. The cells were
washed twice in HBSS containing 10 mM HEPES and 1% fetal
calf serum (HBSS/FCS), resuspended to final concentration of
106 per ml, rested for 15 min in dark, and preheated for 15 min at
37C before the measurement performed at 37C. After 1 min,
anti-CD3 (MEM-92) mAb (100 diluted ascitic fluid containing
approximately 8 mg/ml mAb) at 10 g/ml final concentration
was added and the measurement was continued for additional 5
min. Finally, adequacy of cellular loading was verified by treating
the cells with ionomycin (Sigma-Aldrich; 2 g/ml final concen-
tration). Data were acquired on FACSort™ flow cytometer (Bec-
ton Dickinson) at 500 ms time points and ratiometric analysis was
performed with Flow Jo software (Tree Star).
Results
NTAL Is a Transmembrane Adaptor Protein Similar to
LAT. In vitro kinase assays performed on GEMs immu-
noprecipitated from myeloid cell lines HL-60 and THP-1
revealed the presence of an unidentified 30 kD phospho-
protein (pp30) which was not detectable under similar
conditions in T cells (Fig. 1 A). To further characterize this
protein, the in vitro labeled proteins were mixed with
GEMs prepared from 5  108 THP-1 cells as described
previously (18). This mixture was then subjected to two-
dimensional gel electrophoresis and a doublet of acidic
protein spots of 29–30 kD visualized by silver staining was
found to colocalize with radiolabeled pp30 (Fig. 1 B). The
spots were excised, digested in-gel with trypsin, and re-
sulting peptides were analyzed by mass spectrometry
(MALDI-TOF). Database searching revealed that six of the
peptides (Table I) fit precisely to those predicted for a so far
uncharacterized protein encoded by a previously cloned
full-length cDNA corresponding to a broadly expressed
human gene termed WBSCR5 which is located on human
chromosome 7 (7q11.23; references 24 and 25). The
WBSCR5 cDNA codes for a polypeptide of 243 amino
acid residues (Fig. 2) and a predicted molecular weight of
26.550 daltons while the predicted mouse homologue is
shorter by 40 amino acid residues and is encoded by a gene
residing on chromosome 5 (25). The protein resembles in
its general organization the GEM-associated transmem-
brane adaptor proteins PAG/Cbp (18, 26) and LAT (4).
Thus, it consists of a very short NH2-terminal extracellular
peptide (6aa), a single putative hydrophobic transmem-
brane domain which is followed by a potential palmitoyla-
tion site (a CxxC motif). The predicted cytoplasmic do-
main contains a total of 10 tyrosines but no other clearly
recognizable motifs. Importantly, the mouse LAT and
WBSCR5 genes show a strikingly similar organization.
Both of them are composed of 11 exons that split the re-
spective coding sequence in a very similar manner (Fig. 3).
The two genes (residing on different chromosomes) also
display the same splice frame diagrams (Fig. 3) further sug-
gesting that they are closely related and likely are derived
from a common ancestor (see Discussion). Because of the
structural similarity to LAT and its broad expression we
termed to the novel protein NTAL.
Based on the published cDNA sequence of human
WBSCR5, a full length NTAL cDNA was obtained by
PCR from human leukocyte cDNA library and subcloned
into bacterial (pET-15b) or eukaryotic (pEFIRES-N) ex-
pression vectors. Rabbit polyclonal and mouse monoclonal
antibodies raised to the bacterially produced major part of
the cytoplasmic domain of NTAL detected a band of the
appropriate size in the LAT-deficient Jurkat variant
JCaM2.5 following expression of NTAL (Fig. 4 A).
Western blotting further demonstrated absence of
NTAL in peripheral blood T cells, moderate expression in
monocytes, and strong expression in peripheral blood B
lymphocytes and NK cells (Fig. 4 B); NTAL is also strongly
expressed in B cell lines Raji and Ramos and myeloid lines
Figure 1. NTAL isolation. (A) Proteins
of myeloid cell (HL-60) vs. T cell (Jurkat)
membrane microdomains (GEMs) phos-
phorylated under the conditions of the in
vitro kinase assay; a pattern very similar to
that of HL-60 was observed also in the case
of the THP-1 cell preparation (unpublished
data). (B) Proteins of THP-1 GEMs were
mixed with the preparation obtained by in
vitro kinase assay, separated by 2-dimen-
sional gel electrophoresis and detected by
silver staining or autoradiography. Arrows
indicate the position of pp30.
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THP-1 and HL-60 but not in T cell lines HPB-ALL and
Jurkat (unpublished data). Immunohistochemical staining
of paraffin tissue sections revealed a particularly strong ex-
pression in germinal centers of human lymph nodes (Fig. 5
A). As expected, NTAL is mostly present in buoyant
GEMs (Fig. 5 B), it can be biosynthetically labeled by 3H-
palmitate (Fig. 5 C), and clearly localizes to the plasma
membrane (Fig. 5 D).
NTAL Is Tyrosine-phosphorylated after FcRI, FcRI, or
BCR Cross-linking and Becomes Associated with Other Signal-
ing Proteins. The overall similarity of NTAL to LAT and
the results of in vitro kinase assay indicated that NTAL
might be inducibly tyrosine-phosphorylated after triggering
of immunoreceptors. Indeed, NTAL became tyrosine-
phosphorylated and associated with additional phosphopro-
teins following cross-linking of the high-affinity IgG-
receptor (FcRI/CD64) on human THP-1 myeloid cells and
blood monocytes, the high-affinity IgE-receptor (FcRI)
on mouse BMMCs, and the BCR on human Ramos and
mouse splenic B cells (Fig. 6 A).
The major proteins inducibly associating with NTAL in
cells activated via the BCR or the FcRI were identified as
Table I. Tryptic Peptides Identified by Mass Spectrometry
Position of peptide
in the polypeptide
chain
Measured masses
[M	H]	
Calculated masses
[M	H]	
146-161
	C2H3ON@Cysa 1,677.7 1,677.8
80–94 1,722.8 1,722.9
78–94 1,965.9 1,966.0
57–76 2,131.0 2,131.1
57-76
	O@Metb 2,147.0 2,147.1
57-76
	20@Metc 2,163.0 2,163.1
57–77 2,259.0 2,259.1
57-77
	O@Metb 2,275.0 2,275.1
57-77
	2O@Metc 2,291.0 2,291.1
104–123 2,400.9 2,401.0
104-123
	O@Metb 2,416.9 2,417.0
104-123
	2O@Metc 2,432.9 2,433.0
The six peptides and their derivatives shown in the table fit
unequivocally to the WBSCR5 gene product (AAF74978) and covered
30% of its predicted sequence.
aCarbamidomethylation of cysteine (due to iodoacetamide present in
the lysis buffer).
bMono-oxidation of methionine.
cDi-oxidation of methione.
Figure 2. Predicted amino acid sequence of human NTAL (product of
the WBSCR5 gene). The putative transmembrane region is boxed, the
potential palmitoylation sequence, the tyrosine-x-asparagine motifs, and
all other tyrosines are in bold and underlined. These sequence data are
available from GenBank/EMBL/DDBJ under accession no. AAF74978.
Figure 3. Comparison of the exon-intron organization and of the
splice frame diagrams of the mouse genes encoding LAT and NTAL, re-
spectively. Exons are shown by boxes; the positions of the initiation
(Start) and termination (Stop) codons are indicated by vertical arrows.
Based on splice frame junctions, three types of introns can be distin-
guished in a given gene: phase 0 intron interrupts the reading frame be-
tween two consecutive codons, whereas phase 1 and phase 2 introns in-
terrupt the reading frame between the first and the second nucleotide of a
codon or between the second and the third nucleotide of a codon, re-
spectively (reference 40). According to that classification, the phase class
of each intron is indicated by a solid circle on the diagram shown below
each gene. For the sake of clarity, the length of introns is not drawn to
scale. The structure of the mouse NTAL (WBSCR5) gene is reported in
(reference 25) and that of LAT in this paper.
Figure 4. Expression of NTAL. (A) cDNA encoding human NTAL
was expressed in J.CaM2.5 cells and the protein product was visualized by
Western blotting of the transfectants detergent lysate as compared with
Ramos cells (expressing endogenous NTAL). (B) Western blotting of the
indicated subpopulations of human peripheral blood cells (immunostain-
ing for NTAL or Erk; the latter was used as a loading control).
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Grb2, Sos1, and Gab1 (in both Ramos and THP-1 cells)
and c-Cbl (only in THP-1; Fig. 6 B). A fraction of the
NTAL protein immunoprecipitated from detergent lysate
of anti-BCR–stimulated Ramos cells exhibited strongly
decreased electrophoretic mobility indicative of possible at-
tachment of multiple ubiquitin residues. This was con-
firmed directly by Western blotting of NTAL immunopre-
cipitates prepared from BCR-triggered Ramos cells (Fig. 6
C). Maximum level of NTAL tyrosine phosphorylation in
Ramos cells was observed already after 15 s of stimulation,
whereas the maximal ubiquitinylation was seen after 3
min (unpublished data).
To determine which protein tyrosine kinases (PTKs) are
able to phosphorylate NTAL, we treated THP-1 cells with
the Src-family PTK inhibitor PP2 or the Syk-family PTK
inhibitor piceatannol and then stimulated them via FcRI
cross-linking. As shown in Fig. 7 A, both inhibitors sup-
pressed tyrosine phosphorylation of NTAL. Coexpression
of NTAL with Src-family kinases Lck, Lyn, Hck, or Yes
and/or Syk or ZAP-70 in 293T-cells indicated that NTAL
was, similarly as LAT, most strongly phosphorylated in the
presence of simultaneously expressed Lck and ZAP-70 or
Lck and Syk (Fig. 7 B). Furthermore, no tyrosine phosphor-
ylation of NTAL was observed in Lyn/ mouse BMMCs
stimulated via FcRI (compare Fig. 6 A for the wild-type
BMMCs) indicating that Lyn is directly or indirectly re-
sponsible for NTAL inducible phosphorylation in these
cells (unpublished data).
Expression of NTAL Can Partially Compensate for LAT
Deficiency in T Cells. To assess whether NTAL could ex-
ert a LAT-like function, NTAL was stably expressed in the
LAT-deficient Jurkat variant J.CaM2.5 (which also does
not express NTAL). After stimulation of the transfectants
with an agonistic CD3 mAb, NTAL became rapidly ty-
rosine-phosphorylated and associated with Grb2, Sos1, and
c-Cbl (Fig. 8 A) but not with SLP-76 or PLC1 (unpub-
lished data). CD3 stimulation was accompanied by a mini-
mal (but reproducible) and transient increase in cytoplasmic
calcium level (Fig. 8 B) and a partial rescue of Erk1/2
phosphorylation (Fig. 8 C). To compare semiquantitatively
the effects of NTAL expression with that of LAT,
J.CaM2.5 cells were transiently transfected with expression
constructs encoding FLAG-tagged LAT, NTAL, TRIM,
or with the vector only and activation of Erk1/2 was fol-
lowed after anti-CD3 plus anti-CD28 stimulation. As
shown in Fig. 8 D, NTAL partially rescued activation of
Figure 5. Tissue and subcellular localization of NTAL. (A) Paraffin
section of lymphoid tissue immunoperoxidase stained for NTAL; the ma-
jor positive structures are germinal centers. (B) Localization of NTAL in
buoyant detergent-resistant microdomains (GEMs). THP-1 cells were
solubilized in the presence of 3% nonionic detergent Brij-58 or 1% lau-
rylmaltoside (LM; a detergent known to disrupt GEMs) and subjected to
sucrose density gradient ultracentrifugation; the fractions (numbered from
top to bottom) were analyzed by Western blotting. (C) Biosynthetic la-
beling of NTAL with [3H]palmitate; NTAL immunoprecipitate was ana-
lyzed by SDS-PAGE followed by fluorography of the gel. (D) Plasma
membrane localization of NTAL (green) as determined by confocal mi-
croscopy in THP-1 cells and J.CaM2.5-NTAL transfectants; nuclei are
shown in red.
Figure 6. Induction of NTAL tyrosine phosphorylation and association
with cytoplasmic signaling proteins. (A) THP-1 cells or purified human
monocytes were stimulated via their FcRI receptors, Ramos cells or
murine B lymphocytes via BCR, and mouse BMMC via FcRI recep-
tors. NTAL was immunoprecipitated from unstimulated () or stimu-
lated (	) cells and analyzed by SDS-PAGE and Western blotting using
anti-phosphotyrosine antibody to visualize tyrosine-phosphorylated
NTAL (top panel). The bottom panel represents immunostaining of
NTAL in the same samples and in the same position of the blot (around
30 kD). (B) The same NTAL immunoprecipitates as shown in part A
were analyzed by Western blotting using antibodies to the indicated asso-
ciated molecules. (C) Blots of NTAL immunoprecipitates from unstimu-
lated () or anti-BCR-stimulated (	) Ramos cells were immunostained
by antibodies to NTAL or ubiquitin (Ubq.). Only the relevant parts of
the blots are shown in parts A and B, corresponding to the size of the
relevant proteins.
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Erk1/2 when expressed at a level comparable to that of
LAT under the same conditions while expression of TRIM
had no effects even at much higher expression level. Thus,
the ectopically expressed NTAL can partially restore at least
some aspects of TCR signaling in LAT-deficient mutants.
Discussion
The new transmembrane adaptor protein NTAL de-
scribed in this paper (a product of the previously described
gene WBSCR5; references 24 and 25) appears to be struc-
turally closely related to the critical component of the
TCR signaling pathway, LAT (4). Moreover, the organiza-
tion of the genes encoding LAT and NTAL, respectively, is
also similar, indicating they probably have a common evo-
lutionary origin. Interestingly, the expression pattern of
NTAL in lymphocytes is largely complementary to that of
LAT: while LAT is predominantly found in T but not B
lymphocytes, the reverse is true for NTAL. Among the im-
portant features of the structure of NTAL is a potential
palmitoylation site (CxxC) adjacent to the transmembrane
domain that is presumably responsible for targeting the
protein to membrane microdomains (rafts, GEMs). Fur-
thermore, there are five potential Grb2 binding motifs
(YxN). Our data using PTK inhibitors (Fig. 7) and coex-
pression of NTAL and PTKs in 293T cells indicate that
NTAL, again similarly to LAT, is phosphorylated by con-
certed action of Src- and Syk-family kinases (presumably
the Src-family kinases are needed for activation of the Syk
family kinases).
Induction of NTAL tyrosine phosphorylation after BCR
cross-linking is reminiscent of the phosphorylation of LAT
that is induced by TCR ligation (4). Similar to LAT in
activated T cells, NTAL immunoprecipitated from BCR-
stimulated B lymphocytes is associated with the cytoplas-
mic linker protein Grb2 and the nucleotide exchange fac-
tor of the small G-protein Ras, Sos1 (27). Surprisingly, and
in clear contrast to LAT, we never observed an inducible
association of NTAL with PLC or another cytoplasmic
adaptor protein, SLP-76 (or its B cell analogue SLP-65/
BLNK; references 28 and 29), both of which are key com-
ponents of the multicomponent complex that is organized
by activated (tyrosine-phosphorylated) LAT (5). This could
suggest that the role of NTAL in BCR signaling differs
from that of LAT in the TCR signaling; namely, that
NTAL may be involved only in activation of the Grb2/
Sos1-initiated pathway(s) but not in activation of the
PLC-Ca2	 pathway. The finding of the adaptor protein
Gab1 in the NTAL immunoprecipitates may further sug-
gest that the NTAL-Grb2-Gab1 complex possibly regulates
the activity of PI3-K in stimulated cells (30–32), but this
remains a speculation at this moment.
The lack of association of SLP-65 and PLC with phos-
phorylated NTAL may further indicate that SLP-65 does
not require a LAT-like molecule in B cells for being tar-
geted to the plasma membrane. Indeed, recent data sug-
gested that SLP-65 binds directly with its Src-homology 2
(SH2)-domain to a highly conserved non-ITAM tyrosine
motif within the cytoplasmic domain of CD79a (Ig; refer-
ences 33 and 34). Moreover in contrast to SLP-76, phos-
phorylated SLP-65 binds SH2 domains of PLC2 (35).
Thus, it is tempting to speculate that the multiple functions
that LAT exerts in T cells are shared in B lymphocytes be-
tween NTAL and other molecules, for example, CD79a.
Similarly to the situation in B cells, NTAL becomes
strongly tyrosine phosphorylated after cross-linking of Fc-
RI and FcRI and then associates with Grb2 and Sos1
(but again not with PLC and also not with SLP-76).
Thus, also in these cells NTAL seems to be involved in
linking the activated immunoreceptors to the Grb2/Sos
pathway. In contrast to activated B cells, NTAL also inter-
acts with c-Cbl in activated THP-1 cells (Fig. 6). LAT has
been shown to be important for processing of the FcRI
and FcRI mediated signals; however, FcRI and FcRI
signaling in LAT/ cells is still partially functional (12,
13). It is therefore tempting to speculate that this residual
Fc-receptor signaling capacity in myeloid cells is due to the
presence of NTAL. It is important to note that FcRI
(CD64) is the only human Fc-receptor that binds soluble
monomeric murine antibodies of the IgG2a isotype with
sufficient affinity (22). This indicates that under the used
experimental conditions only this Fc-receptor became ac-
tivated in our experiments with the THP-1 cells. Further-
more, an identical pattern of NTAL phosphorylation was
observed in the THP-1 cells when FcRI (CD64) was di-
Figure 7. Kinases phosphorylating NTAL. (A) Inhibition of NTAL ty-
rosine phosphorylation in THP-1 cells stimulated via FcRI by the indi-
cated PTK inhibitors. NTAL immunoprecipitates prepared from the
treated and control cells were analyzed by Western blotting to detect P-Tyr
or NTAL, respectively. (B) Phosphorylation of NTAL coexpressed in
293T cells with various Src- and Syk-family kinases. Total cell lysates
were analyzed by SDS-PAGE and Western blotting to detect the indi-
cated molecules.
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rectly cross-linked by a CD64-specific monoclonal anti-
body; in contrast, no phosphorylation was observed after
direct mAb-mediated cross-linking of FcRII (CD32) or
FcRIII (CD16) in these cells (unpublished data).
Our experiments provide preliminary evidence for a
functional LAT-like role of NTAL in immunoreceptor sig-
naling: ectopic expression of this protein in LAT-deficient
J.CaM2.5 Jurkat T cells partially rescues TCR/CD3-medi-
ated signaling, namely activation of Erk1/2 (Fig. 8). The
minimal calcium response accompanying the CD3-medi-
ated stimulation may be in agreement with the observed
lack of coprecipitation of PLC and SLP-76 with activated
NTAL in these transfectants, as discussed above. The strik-
ing conservation of the exon-intron organization of the
genes encoding LAT and NTAL, respectively (Fig. 3), sug-
gests that they probably derive from a duplication of an an-
cestral gene. As reported for other gene families, in the
course of evolution, the original position of the exon bor-
ders has been blurred by splice junction sliding (36). It is
important to note that the exon-intron organization and
splice frame diagram of genes encoding other transmem-
brane adaptor proteins involved in immunoreceptor signal-
ing, e.g., SIT (37) or TRIM (38) differ totally from the dis-
tinctive organization found in the genes enconing LAT and
NTAL. A similar relationship of gene organization was
previously noted for the functionally closely related signal
transducing subunits of several immunoreceptors (39).
Thus, NTAL appears to be structurally, evolutionarily and
probably also functionally related to the transmembrane
adaptor protein LAT.
We would like to thank Drs. R. Abraham, M. Hibbs, S. Hobbs,
W. Kolanus, G. Langsley, S. Watson, and A. Weiss for kindly pro-
viding us with cells and constructs as specified in Materials and
Methods.
This work was supported from the projects Center of Molecular
and Cellular Immunology (LN00A026) and grant no. 1131000001
from Ministry of Education, Youth and Sports of the Czech Re-
Figure 8. Functional analysis of NTAL in LAT-defective J.CaM2.5 transfectants. (A) NTAL immunoprecipitates obtained from unstimulated () or
anti-CD3 stimulated (	) J.CaM2.5 mutants and J.CaM2.5-NTAL transfectants were analyzed by Western blotting for the presence of the indicated mol-
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stimulated by anti-CD3 IgM mAb (added at time points indicated by arrows) and increase of cytoplasmic Ca2	 was measured. (C) Wild-type Jurkat,
J.CaM2.5, and J.CaM2.5-NTAL transfectants were stimulated by optimally diluted anti-CD3 IgM mAb and after 5 min of activation Erk1/2 was de-
tected in the cell lysates by Western blotting using anti-phospho Erk antibody; bottom panel represents control staining by anti-Erk. (D) J.CaM2.5 cells
transiently transfected with the indicated FLAG-tagged constructs were stimulated for 2 min by anti-CD3 and anti-CD28 mAbs and activation of Erk1/2
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The activation of Csk by CD4 interferes with
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CD4-Lck recruitment to TCR/CD3, as well as Lck activation is essential for T cell activation.
Indeed, the blockage of CD4-Lck recruitment to TCR during antigen recognition exerts a
drastic inhibitory effect on T cell activation by interfering with both early and late phases of
T cell signaling. In the present work, we report a novel inhibitory mechanism by which CD4
can shut down proximal T cell-activating signals. Indeed, we show that upon ligation of CD4
by antibodies the inhibitory kinase, p50csk, is strongly induced and prolonged during the
time. In contrast, p50csk was not activated when TCR and CD4 were properly engaged by
their ligands. We also demonstrate that anti-CD4 treatment stimulated Csk kinase associ-
ated to the membrane adapter, PAG/Cbp, without affecting the total amount of Csk bound to
PAG/Cbp. As a consequence, early tyrosine phosphorylation events as well as downstream
signaling pathways leading to IL-2 gene expression induced by TCR were inhibited in anti-
CD4 pretreated cells. We suggest a new model to explain the activation of negative signals
by CD4 molecule.
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1 Introduction
The coreceptor molecule CD4 plays a crucial role in the
early events of T cell activation by contributing to both
MHC recognition and intracellular signal transduction.
CD4 binds to both engaged TCR and non-polymorphic
regions of MHC class II molecules [1, 2], and its cyto-
plasmic tail interacts with the Src family tyrosine kinase
p56lck [3] that is necessary to initiate the immunoreceptor
signaling. The earliest event induced by TCR recognition
of peptide-MHC molecules is the phosphorylation of
tyrosine residues in the immunoreceptor tyrosine-based
activation motifs (ITAM) of the CD3 subunits and TCR-
associated ´ chain, which leads to the recruitment and
activation of ZAP-70 kinase [4]. CD4-associated p56lck
contributes to the initial tyrosine phosphorylation of ITAM
and interacts with the ´ /ZAP-70 complex, mechanisms
proposed to favor CD4 recruitment to the activated TCR
[5]. Moreover, p56lck is also involved in the phosphoryla-
tion and activation of ´ -associated ZAP-70, which in turn
phosphorylates several adapter proteins (i.e. LAT and
SLP-76) resulting in the activation of downstream signal-
ing events that lead to functional T cell responses [6].
In addition to initiate immunoreceptor signaling, CD4-
associated p56lck can also have inhibitory roles. Indeed,
CD4 ligation by mAb or HIV gp120 transmits negative
signals able to both inhibit TCR signaling [7, 8] and acti-
vate apoptotic programs [9, 10]. Several mechanisms
have been proposed for the CD4-mediated inhibitory
effects, including sequestration of p56lck to the actin-
cytoskeleton [11] or sequestration of key components of
the TCR/CD3 by the CD4-Lck complexes [8]. A still open
question is whether the modulation of CD4-associated
Lck kinase activity modifies TCR-dependent kinase sig-
naling cascades by transforming activatory signals into
suppressive ones.
Lck kinase activity is regulated by an inhibitory C-
terminal tyrosine residue (Tyr505) that when phosphory-
lated associates with the SH2 domain of p56lck itself,
thus leading to the down-regulation of its catalytic activ-
ity [12, 13]. A balance between phosphorylated and
dephosphorylated p56lck at this C-terminal residue must
be maintained to avoid hypo– as well as hyper-reactivity
in response to TCR engagement. The tyrosine kinase
Csk phosphorylates the inhibitory Tyr505 residue,
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Fig. 1. CD4 engagement by Leu3a inhibits TCR-induced NF-
AT and IL-2 promoter activity. (A, B) Jurkat cells were trans-
fected with 10 ? g NF-AT (A) or IL-2 (B) luciferase reporter
constructs. Cells were then pre-cultured for 15 min in the
presence or absence of Leu3a (1:100 dilution) and then
stimulated for 8 h with 5-3.1/B7 cells pulsed with different
concentrations of SEE. The results are expressed as fold
induction over the basal luciferase activity after normaliza-
tion to g -galactosidase values. The results express the mean
± SD of three different experiments.
whereas the CD45 tyrosine phosphatase antagonizes
Csk by dephosphorylating this inhibitory residue [14].
p50csk is a cytoplasmic tyrosine kinase expressed ubiqui-
tously, albeit in greater amounts in hemopoietic cells
[15]. p50csk contains an SH3 domain, an SH2 domain and
a C-terminal kinase domain. Elimination of p50csk in thy-
mocytes abrogates the requirement for preTCR-
mediated signals for the development of mature § g T
cells [16]. p50csk overexpression strongly inhibits TCR
signaling, an effect correlated with its ability to phos-
phorylate and inactivate Lck and Fyn [17]. More recently,
a cooperation between p50csk and the associated
proline-enriched protein tyrosine phosphatase PEP, in
inhibiting Src kinase mediated signals in T cells, has
been described [18]. To negatively regulate Src kinase
activities, p50csk must translocate from the cytoplasm to
the membrane, specifically to the glycosphingolipid-
enriched domains or lipid rafts, which play an important
role for the initiation of receptor-mediated signaling, and
where the majority of Src kinases are localized [19–21].
One mechanism that has been proposed relies on the
interaction of p50csk with a recently cloned phosphopro-
tein associated with glycosphingolipid-enriched micro-
domains (PAG) or Csk binding protein (Cbp) [22, 23].
Indeed, in resting normal T cells p50csk is present in lipid
rafts through interaction with tyrosine phosphorylated
PAG/Cbp, thus inducing a tonic inhibition of T cell activa-
tion. The dephosphorylation of PAG/Cbp induced by
TCR engagement leads to the dissociation of Csk from
lipid rafts and to Lck activation [24]. Therefore, the sig-
nals that activate Csk and at the same time inhibit its dis-
sociation from membrane PAG/Cbp may interfere with
Lck activation by blocking TCR activating signaling.
Here we report a novel inhibitory mechanism by which
CD4 can shut down proximal T cell activating signals.
Indeed, we show that upon ligation of CD4 p50csk kinase
activity was strongly induced and prolonged during the
time. On the contrary, p50csk was not activated when
TCR was properly stimulated. We also demonstrate that
anti-CD4 treatment induced PAG/Cbp-associated Csk
kinase activity without affecting the total amount of Csk
bound to PAG/Cbp. As a consequence, TCR-mediated
early tyrosine phosphorylation events as well as down-
stream signaling pathways, which lead to IL-2 gene
expression, were inhibited in anti-CD4 pretreated cells.
These results support data on the negative effects medi-
ated by Csk, and provide a new model to explain the
activation of negative signals by CD4 molecule.
2 Results
2.1 CD4 dissociation from TCR inhibits
both earliest and late TCR-mediated
signaling events in staphylococcal
enterotoxin E-stimulated Jurkat cells
To elucidate the molecular mechanisms regulating anti-
CD4 antibodies-mediated inhibition of T cell responses,
we used CD3+CD4+CD28+ Jurkat cells that, when stimu-
lated with staphylococcal enterotoxin E (SEE) presented
by B7+ HLA-DR1-expressing cells (5-3.1/B7) or EBV-B
cells, provide a good physiological model of T cell acti-
vation [10]. CD4 ligation by Leu3a mAb separately from
TCR inhibited both NF-AT- and IL-2-luciferase activities
induced by SEE (Fig. 1A, B). The tyrosine phosphoryla-
tion of TCR-associated CD3 subunits and ´ chains is one
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Fig. 2. CD4 engagement by Leu3a inhibits TCR-induced
ZAP-70 tyrosine phosphorylation. Jurkat cells were pre-
cultured for 15 min in the presence or absence of Leu3a
(1:100 dilution) and then stimulated with EBV-B cells pulsed
with 1 ? g/ml SEE. ZAP-70 was immunoprecipitated and
anti-phosphotyrosine Western blotting was performed
(upper and middle panels). Each sample was analyzed by
Western blotting with anti ZAP-70 antibodies (lower panel).
Sizes are indicated in kilodaltons. The results are represen-
tative of three independent experiments.
of the earliest events that precede the activation of the
downstream signaling pathways regulating T cell activa-
tion. Tyrosine phosphorylated ´ chains in turn recruit
ZAP-70 that is itself tyrosine phosphorylated by the
receptor-associated src kinases, and activated [4]. To
determine whether the inhibition of NF-AT and IL-2 pro-
moter activity reflected a blockage of early TCR signal-
ing, Jurkat cells were both untreated or treated with
Leu3a and then stimulated with EBV-B cells pre-pulsed
with an optimal concentration of SEE. ZAP-70 was then
immunoprecipitated and tyrosine phosphorylation was
analyzed by Western blotting. As shown in Fig. 2, Leu3a
treatment inhibited the tyrosine phosphorylation of both
ZAP-70 (upper panel) and coprecipitating ´ chain (middle
panel, lane 4 vs. 2). Similar to that observed in primary T
cells [25], CD4 engagement before TCR triggering inhib-
its in Jurkat cells the earliest TCR-induced tyrosine
phosphorylation events necessary for IL-2 gene expres-
sion.
2.2 CD4 engagement by antibodies induces
Csk kinase activity
In most T cells, immunoreceptor signaling is dependent
on full activation of Src family tyrosine kinases [4]. In
contrast, the activation of Csk inhibits TCR signaling
[17]. Thus, we verified whether the inhibitory signals
induced by dissociating CD4 from TCR following Leu3a
treatment were associated to the activation of p50csk. To
test this hypothesis, Jurkat cells were treated with Leu3a
for different times and both p56lck and p50csk kinase
activities were measured in vitro. Fig. 3A shows that
cross-linking of CD4 by Leu3a results in a twofold
increase of Lck kinase activity that rapidly decreased to
nearly the basal level after 15 min of stimulation (upper
panel, lanes 1–4). In contrast, CD4 engagement induced
a high and sustained activation of Csk (Fig. 3A upper
panel, lanes 5–8). CD4-induced activation of Csk was
independent of Lck as demonstrated by the absence of
any detectable Lck in anti-Csk immunoprecipitates
(Fig. 3B, lower panel), and was also observed using a
second anti-Csk antiserum (Fig. 3C, upper panel, lanes
1–4). Similar results were obtained in primary CD4+ T
cells (Fig. 3D), indicating that CD4-mediated activation
of Csk was not peculiar to Jurkat cells but was also a
feature of normal T lymphocytes.
Although Leu3a mAb was an IgG1, with a low binding
affinity for protein A, and lysates were subjected to two
preclearing steps with protein A-Sepharose beads
before Csk immunoprecipitation, we ensured that the
kinase activity observed was exclusively due to immuno-
precipitated Csk. Thus, we performed in vitro competi-
tion assays using the Csk peptide used for generating
the anti-Csk antibodies. The anti-Csk antibodies were
incubated overnight at 4°C with a saturating concentra-
tion of blocking peptide, and anti-Csk immunoprecipita-
tions were performed in unstimulated or Leu3a-activated
Jurkat cells. As shown in Fig. 4A, the addition of blocking
peptide strongly reduced the total amount of immuno-
precipitated Csk (lower panel, lanes 3 and 4 vs. 1 and 2)
as well as the kinase activity observed in Leu3a stimu-
lated Jurkat cells (upper panel, lanes 3 and 4 vs.1 and 2).
In contrast, the same peptide did not inhibit either CD4-
associated Lck activity (Fig. 4A, upper panel, lane 6 vs.
5) or the amount of CD4-bound Lck (lower panel). The
ability of Csk to undergo strong autophosphorylation in
vitro has been previously shown [26], but no obvious
sites of tyrosine autophosphorylation were found in Csk.
Thus, we verified whether the robust autophosphoryla-
tion of Csk induced by anti-CD4 antibodies was also
accompanied by an increase of its ability to phosphory-
late a specific exogenous substrate. CD4 stimulation
increased Csk kinase activity on the exogenous sub-
strate pEY (Fig. 4B, upper panel). This peptide has been
previously described to be highly specific for Csk [26].
Indeed, pEY was not phosphorylated by CD4-
associated Lck (Fig. 4C, upper panel lanes 3 and 4),
despite the strong Lck kinase activity observed in anti-
CD4 immunoprecipitates (Fig. 4C, upper panel, lanes 1
and 2). Altogether these data clearly demonstrate that
CD4 stimulation of both Jurkat cells and primary CD4+ T
cells induced the activation of Csk.
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Fig. 3. Csk kinase activity is induced following CD4 engagement in T cells. (A) Jurkat cells were stimulated for different times with
Leu3a and in vitro kinase assays were performed in anti-p56lck (lanes 1–4) or anti-p50csk (lanes 5–8) immunoprecipitates. (B) Jur-
kat cells were stimulated for 5 min with Leu3a and Csk was immunoprecipitated by using sc-286 antibody (lanes 1–2). The kinase
activities of immunoprecipitated Csk was evaluated in vitro (upper panel). (C) Jurkat cells were stimulated for 5 min with Leu3a
and Csk was immunoprecipitated by using sc-286 antibody (lanes 1–2) or anti-Csk antiserum from A. Veillette’s Laboratory (AV,
lanes 3–4). The kinase activities of immunoprecipitated Csk were evaluated in vitro (upper panel). (D) Primary CD4+ T cells were
stimulated for 5 min with Leu3a and the kinase activities of Lck and Csk were measured as in (A). Fold induction over the basal
kinase activity (F.I.) was quantitated by phosphorimager. Each IP was analyzed for Lck or Csk content using specific antibodies
followed by peroxidase-conjugated protein A. The results are representative of three independent experiments.
We next examined the effect of CD4 cross-linking on Csk
kinase activity in TCR stimulated Jurkat cells. Jurkat
cells were pretreated for 15 min with Leu3a and then
stimulated with 5-3.1/B7 cells pulsed with an optimal
dose of SEE. Consistent with several lines of evidence
that for an efficient TCR signaling Csk must not be active
[17, 18], SEE stimulation did not induce a significant up-
regulation of Csk kinase activity (Fig. 5, upper panel,
lanes 1–4). No Csk activity was observed when Jurkat
cells were stimulated with an optimal concentration of
SEE (10 ? g/ml, data not shown). In contrast, when Leu3a
engaged CD4 before SEE stimulation, Csk kinase activ-
ity increases of at least 23-fold (Fig. 5, upper panel, lanes
5–7). Similar results were obtained in normal CD4+ T cells
stimulated with anti-CD3 Ab (data not shown). These
data demonstrate that the inhibitory signals elicited by
CD4 engagement, separately from TCR, are associated
at a very early step with the induction of Csk kinase
activity, which through the negative regulation of Src
kinases abolishes TCR activation.
2.3 Leu3a treatment induces Csk kinase activity
associated to PAG/Cbp without affecting the
ratio of PAG/Cbp-Csk complexes
The relocation of Csk to the lipid rafts, where Src kinases
are active, is essential for its role as negative regulator of
TCR signaling. Indeed, the identification of lipid rafts-
associated protein PAG/Cbp, which when tyrosinephos-
phorylated binds Csk [22, 23] and up-regulates its kinase
activity [27], has suggested a mechanism by which Csk
may turn off the signaling events initiated by Src kinases.
PAG/Cbp was immunoprecipitated from both Jurkat
cells and primary CD4+ T cells treated with Leu3a, and
Csk kinase activity was measured. CD4 engagement by
Leu3a increased PAG/Cbp-associated Csk autophos-
phorylation (Fig. 6A, upper panel). We were sure that the
autophosphorylated band was PAG/Cbp-associated
Csk and not CD4-bound Lck on the basis of their differ-
ent migration mobility on 7% SDS-PAGE (data not
shown). The increase of in vitro PAG/Cbp-associated
Csk autophosphorylation was also accompanied by an
increase of Csk kinase activity on the exogenous sub-
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Fig. 4. CD4 engagement increases Csk kinase activity on exogenous substrates. (A) Jurkat cells were stimulated for 5 min with
Leu3a, Csk and CD4 were immunoprecipitated with specific antibodies (upper panel, lanes 1, 2 and 5) or specific antibodies
incubated overnight with a tenfold excess of Csk blocking peptide (CskP) (upper panel, lanes 3, 4 and 6) and in vitro kinase
assays were performed. (B) Csk was immunoprecipitated from both unstimulated or anti-CD4 activated Jurkat cells and the
kinase activity was measured on the exogenous substrate poly(Glu, Tyr) (pEY). Position of molecular weight markers (mw) are
shown in kDa. (C) CD4 was immunoprecipitated from both unstimulated or anti-CD4 activated Jurkat cells and in vitro kinase
assays for Lck activity (upper panel, lanes 1, 2) or on the exogenous substrate pEY (upper panel, lanes 3, 4) were performed. F.I.
and IP were determined as in legend for Fig. 3. The results are representative of three independent experiments.
Fig. 5. CD4 ligation before TCR engagement induces Csk
kinase activity. Jurkat cells were pre-cultured for 15 min in
the presence or absence of Leu3a and then stimulated with
adherent 5-3.1/B7 cells prepulsed with 1 ? g/ml SEE for the
indicated times. Csk was immunoprecipitated and the
kinase activity was measured by in vitro kinase assays. F.I.
and IP were determined as in legend for Fig. 3. The results
are representative of three independent experiments.
strate pEY (Fig. 6B, upper panel). Similar results were
obtained in primary CD4+ T cells (Fig. 6C). The induction
of Csk kinase activity induced by Leu3a was not associ-
ated to an increase of Csk binding to PAG/Cbp as dem-
onstrated by the equal amounts of Csk coprecipitated
with PAG/Cbp in both unstimulated and Leu3a-treated
cells (Fig. 6, middle panels). We next examined if CD4
treatment before TCR engagement was also able to acti-
vate PAG/Cbp-associated Csk activity. Jurkat cells were
pretreated for 15 min with Leu3a and then stimulated for
different times with 5-3.1/B7 cells prepulsed with an
optimal concentration of SEE. As shown in Fig. 7, SEE
stimulation did not affect PAG/Cbp-associated Csk
kinase activity (upper panel, lanes 1–3). It is interesting to
note that in contrast to the results obtained using anti-
CD3 and anti-CD28 mAb as stimulators [22], the amount
of PAG/Cbp-associated Csk did not change in Jurkat
cells physiologically activated with SEE presented by
B7+ APC (Fig. 7, middle panel). Interestingly, PAG/Cbp-
associated Csk kinase activity was up-regulated in SEE-
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Fig. 6. CD4 ligation induces the activation of PAG/Cbp-associated Csk without affecting the amount of Csk bound to PAG/Cbp.
(A) Jurkat cells were activated with Leu3a for the indicated times. Cells were lysed in buffer containing n-octyl g -glucopiranoside,
PAG/Cbp was immunoprecipitated using specific antibodies and in vitro kinase assays were performed. (B) Jurkat cells were
activated with Leu3a for 5 min and Csk activity was measured in anti-PAG/Cbp immunoprecipitates using pEY as substrate. (C)
Primary CD4+ T cells were activated with Leu3a for 5 min and PAG/Cbp-associated Csk kinase activity was evaluated as in (A).
Each IP was analyzed for Csk and PAG content using specific antibodies followed by peroxidase-conjugated protein A. The
results are representative of three independent experiments.
Fig. 7. CD4 engagement separately from TCR increases
PAG/Cbp-associated Csk kinase activity. Jurkat cells were
pre-cultured in the presence or absence of Leu3a and then
stimulated with adherent 5-3.1/B7 cells prepulsed with 1 ? g/
ml SEE. Csk kinase activity in anti-PAG/Cbp immunoprecipi-
tates was measured. Each IP was analyzed for Csk or PAG/
Cbp content using specific antibodies. The results are repre-
sentative of three independent experiments.
stimulated Jurkat cells pretreated with Leu3a (upper
panel, lanes 5–7 vs. 1–4). Thus, CD4 engagement was
able to up-regulate PAG/Cbp-associated Csk kinase
activity also in SEE-stimulated cells without affecting the
amount of Csk bound to PAG/Cbp.
To assess the significance of Csk activation by CD4 in
inhibiting TCR-mediated signaling, Jurkat cells were
transfected with a NF-AT-luciferase reporter construct
together with a Csk mutant lacking its kinase activity
(Csk KR). Overexpression of Csk (KR) increased NF-AT
basal activity (at least tenfold) and completely reverted
Leu3a-mediated inhibition of NF-AT activity in SEE-
stimulated Jurkat cells (Fig. 8, panel A).
3 Discussion
The reorganization of surface receptors and signaling
molecules at the T cell/APC interface plays a key role in
T cell activation. This process, known as immunological
synapse (IS) formation, co-ordinates engagement of the
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Fig. 8. Expression of dominant negative Csk (KR) restores
TCR-induced NF-AT activation in Leu3a-treated cells. (A)
Jurkat cells were transfected with NF-AT luciferase reporter
construct together with vector control or dominant negative
Csk (KR) mutant and after 24 h cells were stimulated for
additional 8 h with SEE-pulsed 5-3.1/B7 cells. The results
are expressed as the mean of arbitrary units of the luciferase
activity ± SD. The data represent at least four independent
experiments. (B) The overexpression of Csk (KR) mutant was
analyzed by western blotting using anti-Csk antibodies.
TCR by peptide/MHC complex, thus facilitating signaling
through the TCR. Recent models suggest that the main
role of CD4 is to “boost” TCR recognition [28], facilitating
the rapid recruitment of Lck to TCR/CD3, an event that is
essential to initiate signaling and trigger the early phase
of T cell activation [29]. Indeed, Lck is autophosphory-
lated and activated during IS formation, an event that
require both CD4 and CD28 [29]. The blockage of CD4-
Lck recruitment to TCR by anti-CD4 antibodies or HIV
gp120 during antigen recognition exerts a drastic inhibi-
tory effect on T cell activation by interfering with both
early and late phases of T cell signaling [7, 30]. Several
mechanisms have been proposed to explain the inhibi-
tory effects mediated by CD4 on TCR signaling, such as
decreased cellular levels of p56lck [31], sequestration of
CD4-associated p56lck to the cytoskeleton [11], or
sequestration of crucial components of the TCR/CD3
signaling pathway to the CD4-p56lck complexes [8]. Less
is known about the regulation of p56lck kinase activity fol-
lowing CD4 engagement separately from TCR. Here we
present evidence that a mechanism regulating p56lck
activity relies on the induction of Csk kinase activity by
CD4.
p56lck kinase activity is regulated by a conserved tyrosine
residue, Tyr505, within the C-terminal tail that, when
phosphorylated, inhibits kinase activity. CD45, a trans-
membrane tyrosine phosphatase expressed by all hemo-
poietic cells, appears to be required for activation of
p56lck by dephosphorylating its inhibitory site [32]. In
contrast, the tyrosine kinase p50csk phosphorylates the
Tyr505, thus inhibiting p56lck kinase activity [15]. CD45
and Csk are both constitutively active enzymes. How-
ever, data from CD45-deficient mice indicate that the
balance between CD45 and Csk is a net dephosphoryla-
tion of the inhibitory site at the steady state [33]. A cur-
rent model proposes that, under resting conditions,
CD45 maintains a basal level of CD4-Lck activity that is
responsible for generating the p21 ´ phosphoisoform
associating inactive ZAP-70 [34]. Engagement of TCR by
peptide-MHC molecules brings CD4-Lck into closer
proximity of CD3/TCR- ´ , thus leading to the generation
of p23 ´ phosphoisomer, and phosphorylation and acti-
vation of ´ -bound ZAP-70 by p56lck [35]. The subsequent
interaction between ZAP-70 and p56lck will result in the
activation of both proteins [36, 37]. In this model, if the
balance between CD45 and Csk will shift in favor of Csk,
the dominance of Tyr505-phosphorylated p56lck species
in a “closed” conformation and with a reduced ability of
their SH2/SH3 domains to dock with the TCR/ZAP-70
complex will be induced. Indeed, we show that CD4
engagement by anti-CD4 mAb induced a reduction of
both ZAP-70 and ZAP-70-associated TCR- ´ tyrosine
phosphorylations (Fig. 2). These events were associated
to a transient increase of Lck kinase activity. In contrast,
CD4 stimulation induced a stronger and persistent
increase of Csk kinase activity that was not observed
when cells were correctly stimulated through TCR
(Fig. 5). Although, a direct correlation between CD4-
induced Csk activation and the impairment of TCR-
mediated signaling cannot be made, our data on the loss
of CD4-mediated inhibition of TCR signaling in kinase-
deficient Csk-overexpressing cells, strongly support this
hypothesis. Moreover, it is intriguing that the reduction in
TCR- ´ phosphorylation and ZAP-70 recruitment in anti-
CD4-treated cells is similar to that observed in Csk-
overexpressing cells [18].
Similarly to the Src kinases, Csk consists of an SH3
domain, an SH2 domain and a kinase domain, but lacks
the C-terminal regulatory tyrosine residue as well as the
N-terminal myristoylation signal for targeting to lipid
rafts. Recently, a transmembrane protein known as PAG
or Cbp has been identified that, when phosphorylated,
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can recruit Csk via its SH2 domain to the membrane lipid
rafts where the Src kinases are located [22, 23]. PAG/
Cbp is involved not only in the membrane recruitment of
Csk but also in Csk-mediated inhibition of Src, by
directly activating Csk [27]. In unstimulated T cells, PAG/
Cbp is constitutively tyrosine phosphorylated and asso-
ciated to Csk. TCR engagement by antibodies has been
described to induce the rapid dephosphorylation of
PAG/Cbp, thus leading to a transient displacement of
Csk from lipid rafts. This event has been reported to
allow a stronger and prolonged activation of Src kinases
and sustained TCR signaling [22, 24]. Physiological stim-
ulation of Jurkat cells by SEE presented on B7+ APC did
not affect either the amount of PAG/Cbp-associated Csk
or PAG/Cbp-associated Csk kinase activity. The failure
to see PAG dephosphoryation in Jurkat cells following
TCR stimulation may be due to the fact that Jurkat
express not very much PAG/Cbp but a lot of phospha-
tases, which results in a constitutive dephosphorylation
of PAG/Cbp. Indeed, when the expression levels of PAG/
Cbp are raised, PAG becomes dephosphorylated after
TCR stimulation also in Jurkat cells [38]. In contrast, CD4
engagement alone or before TCR stimulation was able to
activate PAG/Cbp-associated Csk kinase activity, again
without modifying the total amount of Csk bound to
PAG/Cbp (Fig. 6, 7). It may be possible that Lck acti-
vated by Leu3a phosphorylates PAG, thus inducing an
increase of Csk recruitment and activation. However, our
results showing that Leu3a did not change the amount of
Csk associated with PAG suggest that Csk kinase activ-
ity may be regulated by another mechanism. Csk has
also been described to down-regulate Src activity by
redistributing to sites of Src activation through a direct
interaction with tyrosine phosphorylated GTPase-
activating protein (GAP)-associated p62dok [39, 40]. In T
cells, p62dok is tyrosine phosphorylated following CD2
[41] or CD28 stimulation [42]. Recent data from Nemorin
et al. have shown that p62dok tyrosine phosphorylation is
mediated by Lck [41] and that p62dok overexpression
impairs both CD3- and CD2-induced NF-AT activation
and IL-2 secretion [43]. Thus, the transient increase of
Lck kinase activity induced by Leu3a may lead to the
tyrosine phosphorylation of p62dok, which in turn may
recruit and activate Csk thus leading to the termination
of Lck activity. CD4 engagement by Leu3a induced in
Jurkat cells the tyrosine phosphorylation of a ˚ 62 kDa
protein that may be p62dok (data not shown). Experi-
ments are in progress to verify this hypothesis.
A disregulation between CD3- and CD4-mediated sig-
nals has been observed following exposure of T lympho-
cytes to IL-16, a natural ligand of CD4 [44], or in lympho-
cytes derived from HIV-1-infected patients. Moreover,
binding of HIV gp120 with CD4 separately from TCR
results in the activation of programmed cell death [9, 45].
An increase of Csk kinase activity has also been
observed in T cells committed to apoptosis [46]. Our
data represent the first demonstration that CD4 may reg-
ulate the activity of an inhibitory kinase that, altering the
proximal signaling events generated by TCR, gives rise
to a dominant negative signals that, in some circum-
stances, may contribute to the death of T cells [47]. This
characterizes a novel biological role for CD4 that may
contribute to a greater understanding of TCR signaling
both in normal and pathological conditions.
4 Materials and methods
4.1 Cell lines, antibodies and reagents
CD4+ Jurkat T cell line was maintained in RPMI 1640 supple-
mented with 10% FCS, L-glutamine, penicillin and strepto-
mycin (Gibco). The L cell transfectants expressing HLA-
DRB1*0101 (5-3.1) and co-transfected with human B7.1 (5-
3.1/B7) were previously described [45]. Human peripheral
blood CD4+ T cells were purified by negative selection using
an indirect magnetic cell sorting kit (Miltenyi Biotec, Auburn,
CA). Mouse anti-CD4 mAb (Leu3a) was from Becton Dickin-
son (Mountain View, CA). Mouse anti-p56lck (3A5), rabbit
anti-p56lck, rabbit anti-p50csk antibodies and the Csk block-
ing peptide were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Rabbit anti-Csk antiserum was kindly pro-
vided by A. Veillette (IRCM, Montreal, Canada). Anti-human
ZAP-70 and ´ chain mAb were from Upstate Biotechnology
(Lake Placid, NY). Anti-PAG antibodies were generated as
previously described [22]. SEE was purchased from Toxin
Technology (Sarasota, FL).
4.2 Plasmids, cell transfection, activation and
luciferase assay
The NF-AT luciferase reporter construct containing the lucif-
erase gene under the control of the human IL-2 promoter
NF-AT binding site was kindly provided by C. Baldari (Uni-
versity of Siena, Siena, Italy). The IL-2 luciferase construct
[48] was kindly provided by J.F. Peyron (Faculte´ de Medicine
Pasteur, Nice, France). Kinase-dead Csk, Csk (K222R), was
kindly provided by A. Veillette (IRCM). The pSV g -gal vector
(Promega Corp., Madison, WI) contains the g -galactosidase
gene driven by the SV40 promoter/enhancer.
Transient transfections were performed by electroporating
(at 260 V, 960 ? F) 107 Jurkat cells in 0.5 ml RPMI 1640 sup-
plemented with 20% FCS with 10 ? g of the indicated
reporter constructs together with 20 ? g pSV- g gal plasmid,
keeping the total amount of DNA constant (50 ? g) with
empty vector. At 24 h after transfection 105 cells were pre-
treated for 15 min with medium or Leu3a (1:100 dilution) at
37°C and then stimulated for 8 h with confluent 5-3.1/B7
cells cultured overnight with the indicated concentration of
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SEE in round-bottom 96-well plates. g -Galactosidase and
luciferase assays were performed according to the manu-
facturer’s instruction (Promega). Luciferase activity, deter-
mined in triplicates samples using an automated lumino-
meter (Lumat LB 9501, EG&G Berthold, Wildbad, Germany)
was expressed as fold induction over the basal activity of
cells cultured with medium alone or in arbritary units (AU)
after normalization to the g -galactosidase values.
4.3 Cell stimulation, immunoprecipitation and in vitro
kinase assay
Jurkat cells were washed twice, resuspended in medium
(108/ml) and incubated at 37°C in the presence or absence
of Leu3a mAb for different times. When indicated, Leu3a
pretreated cells were then stimulated with adherent 5-3.1/B7
cells pulsed with different concentration of SEE. At the end
of incubation, cells were harvested and lysed for 30 min on
ice in 1% NP40 lysis buffer containing 20 mM Tris-HCl pH
7.5, 150 mM NaCl, 1 mM EGTA in the presence of inhibitors
of proteases and phosphatases: 10 ? g/ml leupeptin, 10 ? g/
ml aprotinin, 1 mM Pefabloc-sc, 50 mM NaF, 10 mM
Na4P2O7 and 1 mM NaVO4. Cells were lysed in buffer con-
taining 60 mM N-octyl g -glucopiranoside (Sigma) instead of
1% NP-40 for co-immunoprecipitation experiments of PAG/
Csk complexes. Post-nuclear lysates were subjected to two
rounds of preclearing with protein A-Sepharose beads
before immunoprecipitations with anti-Csk, or anti-Lck or
anti-PAG antibodies preadsorbed on protein A-Sepharose
beads. In the competition assays with the Csk blocking pep-
tide, the anti-Csk antibodies were incubated overnight at
4°C with a tenfold excess of peptide before immunoprecipi-
tation. The kinase activity of immunoprecipitated p56lck or
p50csk was assayed at 30°C for 15 min in 25 ? l p56lck kinase
buffer (1 mM Tris-HCl pH 7.5, 7.5 mM NaCl, 25 mM Hepes
pH 7.3, 10 mM MnCl2, 0.05% NP-40) or p50csk kinase buffer
(50 mM Hepes, pH 7.4, 5 mM MgCl2, 0.05% NP-40) in the
presence of 10 ? Ci [ + –32P]ATP (10 Ci/mmol). Similar assays
with the same buffer were performed with the synthetic
polyamino acid poly(Glu, Tyr) 4:1 (Sigma), abbreviated pEY
(0.5 ? g), as substrate of Csk. The reactions were terminated
with 2× Laemmli sample buffers. Samples were analyzed by
sodium dodecylsulfate-polyacrylamide gel electrophoresis
(SDS-PAGE). Gels were fixed, treated with 1 M KOH for 1 h
at 55°C to remove the alkali-labile phosphate groups from
serine and threonine-phosphorylated proteins, dried and
autoradiographed. Radioactivity in the phosphorylated pro-
teins was quantitated by a phosphorimager. Immunoblotting
and detections of proteins by enhanced chemiluminescence
(Amersham Pharmacia Biotech) were performed as previ-
ously described [5]. For anti-Csk and anti-Lck Western blot-
ting, peroxidase-conjugated protein A was used instead of
secondary Ab to avoid Ig heavy chain nonspecific binding.
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Abstract
 
Lymphocyte membrane rafts contain molecules critical for immunoreceptor signaling. Here, we
report identification of a new raft-associated adaptor protein LIME (Lck-interacting molecule)
expressed predominantly in T lymphocytes. LIME becomes tyrosine phosphorylated after cross-
linking of the CD4 or CD8 coreceptors. Phospho-LIME associates with the Src family kinase Lck
and its negative regulator, Csk. Ectopic expression of LIME in Jurkat T cells results in an increase
 
of Csk in lipid rafts, increased phosphorylation of Lck and higher Ca
 
2
 

 
 response to CD3 stim-
ulation. Thus, LIME appears to be involved in regulation of T cell activation by coreceptors.
Key words: membrane microdomains • Lck • Csk • signal transduction • phosphorylation
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Introduction
 
Membrane microdomains, also called lipid rafts or glycolipid-
enriched microdomains, are small areas of cell membranes
that can be distinguished from the rest of the membrane by
unique lipid and protein composition. They are enriched
in lipids containing long saturated fatty acid residues
(mainly sphingomyelin and glycosphingolipids) and choles-
terol, glycosylphosphatidylinositol-anchored proteins, and
several cytoplasmic proteins associated with the inner leaflet
of the membrane via covalently attached fatty acid residues.
Among these cytoplasmic proteins are, e.g., Src family kinases
(possessing NH
 
2
 
-terminal double acylation) and heterotri-
meric G proteins. The integrity of membrane rafts seems to
be maintained by lateral interactions of their constituent
lipids which form, together with cholesterol, a more orga-
nized “liquid ordered” phase in the membrane. Membrane
rafts can be easily isolated due to their relative insolubility
in solutions of common mild detergents of the polyoxyeth-
ylene type (such as Triton X-100, Brij series, NP-40) at
low temperature and their ability to float when such detergent
lysates are ultracentrifuged in sucrose density gradient.
Conversely, membrane rafts are readily solubilized by
alkyl-glycosidic type of detergents (for general review on
 
the rafts and their role in immunoreceptor signaling see
references 1–3). Most transmembrane proteins are excluded
from lipid rafts, exceptions being few molecules palmitoy-
lated on cytoplasmic membrane-proximal cysteine residues,
such as the pre-TCR (4), the CD4 and CD8 coreceptors
(5, 6), and the three recently discovered transmembrane
adaptor proteins, linker for activation of T cells (LAT) (7, 8),
phosphoprotein associated with glycosphingolipid-enriched
microdomains (PAG) (9), or Csk-binding protein (Cbp)
(10) and non–T cell activation linker (NTAL) (11) or
linker for activation of B cells (LAB) (12).
Because of the presence of several key signal-transducing
molecules (Src family kinases, transmembrane adaptor proteins
LAT, NTAL/LAB, and PAG/Cbp), membrane rafts have
been shown recently to play an essential role in initiation of
immunoreceptor (TCR, BCR, FcR) signaling (1–3). To
identify novel lipid raft-associated transmembrane adaptor
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Abbreviations used in this paper:
 
 Cbp, Csk-binding protein; LAT, linker for
 
activation of T cells; LAB, linker for activation of B cells; LIME, Lck-
interacting molecule;
 
 
 
NTAL, non–T cell activation linker; PAG, phos-
phoprotein associated with glycosphingolipid-enriched microdomains;
 
PBL, peripheral blood leukocytes; PHA, phytohemagglutinin; PLC
 

 
,
 
phospholipase C
 

 
; PTK, protein tyrosine kinase; P-Tyr, phosphotyrosine;
SH Src homology; TRAP, transmembrane adaptor protein; TRIM,
TCR-interacting molecule.
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proteins, we have searched public databases for molecules
sharing the structural features characteristic of raft-targeted
transmembrane adaptor proteins. One of the proteins
identified by this approach was Lck-interacting molecule
(LIME), a molecule of unknown function whose amino
acid sequence has been deposited in the databases since
1998. In the present study we describe the first biochemical
and functional characterization of LIME.
 
Materials and Methods
 
Cells and Antibodies.
 
T, B, and NK cells and monocytes were
obtained from buffy coats by Ficoll centrifugation and preparative
cell sorting using a FACS Vantage
 
TM
 
 flow cytometer (Becton
Dickinson) and PE-conjugated mAbs to CD3 and CD19 (Sero-
tec), biotinylated anti-CD14 (Serotec), fluoresceinylated (FITC)
streptavidin (BD Biosciences), unlabeled CD56 mAb MEM-188,
and fluorescein-conjugated F(ab)
 
2
 
 fragments of goat anti–mouse
Ig (Caltag). Single-positive (CD4
 

 
8
 

 
, CD4
 

 
8
 

 
), double-positive
(CD4
 

 
8
 

 
), and double-negative (CD2
 

 
CD4
 

 
CD8
 

 
CD19
 

 
)
thymocytes were isolated by flow sorting using anti–CD4-FITC
(MEM-241), anti–CD8-PE (BD Biosciences), anti–CD2-PE
(Immunotech), anti–CD4-biotin (Serotec), anti–CD8-biotin (Se-
rotec), anti–CD19-biotin (Serotec), and Streptavidin-FITC (BD
Biosciences) mAbs. Purity of all sorted thymocyte subpopulations
used in subsequent experiments was 
 

 
99%. In some experiments,
the peripheral blood leukocytes (PBLs) obtained by Ficoll centrif-
ugation were passed through nylon wool column, the nonadher-
ing T and NK cells were recovered and are referred to as periph-
eral blood T cells. 293T cells were from the cell line collection of
the Institute of Molecular Genetics. T cell line J77 (CD4
 

 
 Jurkat)
was provided by Dr. O. Acuto (Institut Pasteur, Paris, France).
Antiserum to LIME was produced in the Prague laboratory by
immunization of rabbits with bacterially expressed and Talon
purified (CLONTECH Laboratories, Inc.) cytoplasmic fragment
of human LIME (described under constructs), and mouse mAbs
to LIME were prepared using standard techniques from spleno-
cytes of mice immunized with the same bacterially produced
LIME fragment. In addition, antipeptide mAbs were prepared
against the COOH-terminal peptide comprising residues 281–
296 of the human molecule (purchased from PolyPeptide Labo-
ratories) conjugated to keyhole limpet hemocyanin using a com-
mercial kit (Pierce Chemical Co.). Rabbit antiserum to LAT
(13) was provided by Dr. L. Samelson (National Institute of
Child Health and Human Development, National Institutes of
Health, Bethesda, MD).
The sources of the other antibodies used were as follows: mAb
to phosphotyrosine (4G10; UBI), rabbit polyclonal antibodies to
Erk1/2 (Promega), phospho-Lck (Tyr
 
505
 
) and phospho-Src fam-
ily (Tyr
 
416
 
) (New England Biolabs, Inc.), Csk (Santa Cruz Bio-
technology, Inc.), mAbs to CD3 (OKT3; Ortho), CD28 (IgM
isotype; provided by Dr. U. Moebius, University of Heidelberg,
Germany), and CD4 (B66.1; donated by Dr. C.T. Baldari, Uni-
versity of Siena, Siena, Italy). mAbs to Lck (LCK-01), CD4
(MEM-16, MEM-115, MEM-241), CD8 (MEM-31), CD3
 

 
(MEM-92, MEM-57), CD20 (MEM-97), and CD56 (MEM-
188) were all prepared in the Prague laboratory.
 
Immunoprecipitation, In Vitro Kinase Assay, and Other Biochemical
Methods.
 
LIME and LIME-containing complexes were immu-
noprecipitated from postnuclear supernatants of cells solubilized
by a detergent effectively disrupting lipid rafts (laurylmaltoside
[
 
N
 
-dodecyl 
 

 
-D-maltoside]; Calbiochem) (lysis buffer: 1% lau-
 
rylmaltoside in 20 mM Tris, pH 7.5, containing 100 mM NaCl,
10% glycerol, 1 mM 4-[2-aminoethyl]-benzenesulfonyl fluoride,
10 mM EDTA, 50 mM NaF, 1 mM Na
 
3
 
VO
 
4
 
) using CNBr-
Sepharose beads (Amersham Biosciences) coupled with mAbs pu-
rified by protein A–Sepharose affinity chromatography. The
lysates were passed through minicolumns (30–50 
 

 
l packed vol-
ume) of such immunosorbents; after washing with 10 column
volumes of lysis buffer, bound proteins were eluted with 2 col-
umn volumes of 2
 
	
 
 concentrated SDS sample buffer and the
flow-through, and eluted fractions were analyzed by SDS-PAGE
followed by Western blotting.
In vitro kinase assays were performed as described before (14).
Briefly, cells were solubilized in ice cold 1% laurylmaltoside lysis
buffer (see previous paragraph), and the postnuclear supernatants
were incubated in plastic wells coated with appropriate mAbs.
After washing, the kinase solution (20 mM Hepes, pH 7.4, 5 mM
MgCl
 
2
 
, 5 mM MnCl
 
2
 
, 0.1% detergent Igepal [Sigma-Aldrich])
containing 0.1 
 

 
Ci [
 

 
-
 
32
 
P]ATP (ICN) per well was added, and
the proteins phosphorylated by kinases present in the immuno-
precipitates were resolved by SDS-PAGE followed by autora-
diography and immunoblotting. In some cases, purified cytoplas-
mic domain of TCR-interacting molecule
 
 (
 
TRIM) protein (15)
(30 
 

 
g/ml) was used as an exogenous Lck substrate and added to-
gether with 0.5 
 

 
Ci [
 

 
-
 
32
 
P]ATP per well. At the end of the test,
the content of the wells was taken and processed for SDS-PAGE
and autoradiography. For control, the wells were then washed,
and phosphorylated proteins in immunoprecipitates were re-
solved as in the standard kinase assay. Lipid raft separation by su-
crose gradient ultracentrifugation was performed essentially as
described before, using 3% Brij-58 detergent for membrane solu-
bilization; the density gradient fractions were analyzed by SDS
PAGE and Western blotting (9). In some experiments, cells were
directly solubilized in 2
 
	
 
 concentrated SDS sample buffer, ultra-
centrifuged (250,000 
 
g
 
, 30 min), and the supernatant was ana-
lyzed by SDS-PAGE and Western blotting. Biosynthetic labeling
with 
 
3
 
H-palmitate, SDS-PAGE, and Western blotting were per-
formed as described (11).
 
PCR.
 
Nested PCR with two sets of primers (first 5
 


 
-
GAGAATTCTGCACAAAGACCTTCCTGG-3
 


 
 plus 5
 


 
-GAG-
AATTCACAGGTCCTTGAGTGTTCAG-3
 


 
 and then the same
5
 


 
 end primer plus 5
 


 
-GCAGCACCCTAGAACCCAGA-3
 


 
primer) was used to detect the LIME cDNA in the Multiple Tis-
sue Panels I and II and the Immune System Panel (CLONTECH
Laboratories, Inc.).
 
DNA Constructs and Transfections.
 
The coding region of hu-
man LIME was amplified from human leukocyte cDNA library
(CLONTECH Laboratories, Inc.) (primers: 5
 


 
-GAGAATTCT-
GCACAAAGACCTTCCTGG-3
 


 
 and 5
 


 
-GAGAATTCACAG-
GTCCTTGAGTGTTCAG-3
 


 
). The PCR product was cloned
into EcoRI site of pBluescript SK vector (Stratagene) and se-
quenced. For bacterial expression, the LIME intracellular frag-
ment corresponding to aa 141–295 was cloned into XhoI and
BamHI sites of pET-15b expression vector (Novagen), generat-
ing a construct with NH
 
2
 
-terminal histidine tag. For expression
in eukaryotic cells, LIME coding sequence was subcloned into
EcoRI site of pEFIRES-N vector (16) (provided by Dr. S.
Hobbs, Institute of Cancer Research, London, UK). For transient
transfection of 293T cells, Lipofectamine 2000™ reagent (Invi-
trogen) was used according to manufacturer’s instructions. For
transfection experiments in 293T cells, the following cDNA con-
structs were used: Flag-tagged Lck and Myc-tagged ZAP-70 in-
serted into pcDNA3 vector (donated by Dr. R. Abraham, Mayo
Clinic, Rochester, Minnesota), Fyn cloned in pSR
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vector (provided by Dr. A. da Silva, Dana Farber Cancer Insti-
tute, Boston, MA), Csk in pEF-BOS vector (9), Syk cloned into
the pRK5 vector (provided by Dr. W. Kolanus, Gene Center,
Munich, Germany), Myc-tagged Lyn in pcDNA3.1 vector (pro-
vided by Dr. S. Watson, University of Oxford, Oxford, UK), and
Flag-tagged Hck in pcDNA1 vector (provided by Dr. G. Langs-
ley, Institut Pasteur, Paris, France).
J77 cells (Jurkat T cell line expressing CD4; essentially devoid
of endogenous LIME expression) were transfected with the
LIME-pEFIRES-N construct by electroporation, and stable
transfectants were selected by growing the cells in 96-well plate
in selective medium containing 1 mg/ml G418 (Calbiochem).
After 3 wk, oligoclonal G418-resistant populations were ex-
panded and checked for LIME expression by Western blotting.
Single Tyr
 
→
 
Phe mutants were produced by site-directed mu-
tagenesis using the QuickChange XL Site-Directed Mutagenesis
kit (Stratagene) according to the manufacturer’s protocol.
COOH-terminally FLAG-tagged NTAL was produced by site-
directed mutagenesis using the same kit; FLAG-tagged LIME
construct was generated by PCR using the primer containing se-
quence for FLAG. All mutated nucleotide sequences were veri-
fied by full-length sequencing and subcloned to pEFIRES-N.
For overexpression in peripheral blood T cells, LIME was sub-
cloned into EcoRI site of pXJ41 vector (17), and the transfection
was performed using the nucleofector apparatus and human T cell
nucleofector kit (Amaxa Biosystems) according to the manufac-
turer’s instructions.
 
Confocal Microscopy.
 
J77-LIME transfectants were spun on
coverslips coated with poly-
 
l
 
-lysine (Sigma-Aldrich), and fixed
and permeabilized 3 min in 
 

 
20
 

 
C methanol and then 5 s in cold
acetone. After washing in PBS, the slides were blocked in PBS
containing 1% BSA and incubated 45 min with mouse mAb to
LIME (LIME-1, 50 
 

 
g/ml), followed by 45 min incubation with
Alexa 488 goat anti–mouse IgG (Molecular Probes, 500
 
	
 
 di-
luted). Nuclei were stained with propidium iodide (Molecular
Probes, 10 min, 0.5 
 

 
g/ml). The samples were mounted in PBS
and viewed on a Laserscan microscope (Leica TCS SP). Incuba-
tion with irrelevant primary antibody and staining of nontrans-
fected J77 cells served as a negative control.
 
Cell Activation.
 
Peripheral blood T cells were stimulated by 2
min incubation with anti-CD3 (MEM-92) or anti-CD4 (MEM-
16) IgM mAbs (
 

 
10 
 

 
g/ml) at 37
 

 
C. In some experiments, a
combination of anti-CD4 mAbs (MEM-16 
 

 
 MEM-115
[IgG] 
 

 
 MEM-241 [IgG]; 
 

 
10 
 

 
g/ml each) for 2 min at 37
 

 
C
was used. When IgG mAbs alone were used (anti-CD4 [MEM-
241], anti CD8 [MEM-31]), the cells were first preincubated 30
min on ice with the primary antibody (
 

 
10 
 

 
g/ml), washed with
ice cold medium, and stimulated by cross-linking with 10 
 

 
g/ml
goat anti–mouse polyclonal antibody (ICN) for 2 min at 37
 

 
C.
The cells were then lysed, subjected to LIME immunoprecipita-
tion, and LIME phosphorylation was determined by anti-phos-
photyrosine (P-Tyr) immunoblotting. In some experiments the
cells were pretreated for 7–20 min with 2.5–10 
 

 
g/ml of the Src
kinase family inhibitor PP2 (Calbiochem).
For long term activation, culture dishes were precoated with
purified sterile anti-CD3 mAb MEM-57 (IgG2a; final concentra-
tion 10 
 

 
g per ml of 0.1 M Tris, pH 9.5) for 4 h at 37
 

 
C. Dishes
were washed three times with RPMI medium without serum,
and 5 million T cells, resuspended in 5 ml RPMI supplemented
with FCS and 500 IU IL-2 (Chiron), were seeded per 5-cm dish.
Cells were then cultured, harvested, and lysed at indicated time
points. Where indicated, cells were removed from the anti–CD3-
coated dish, washed, and cultured in a new uncoated dish in the
 
presence of IL-2 (100 IU/ml). For phytohemagglutinin (PHA)
stimulation, PBLs were cultured for 3 d in RPMI medium with
10% FCS and PHA (Wellcome Reagents; commercial stock solu-
tion diluted for optimal activity 50
 
	
 
).
To measure Ca
 
2
 

 
 response to anti-CD3 activation, J77 cells
were electroporated either with FLAG-tagged LIME or NTAL
expression constructs or with an empty pEFIRES-N vector. After
48 to 72 h in culture, the cells were transferred to Hepes-buffered
Hank’s balanced salt solution with 1% FCS and loaded with Fluo-
4 and Fura Red dyes (Molecular Probes, each 1 
 

 
g/100 
 

 
l con-
taining 10
 
6
 
 cells) for 20 min at room temperature. The cells were
washed in the same buffer incubated for 10 min at room tempera-
ture and then warmed for 10 min at 37
 

 
C. The measurement was
performed on the FACSort™ flow cytometer (Becton Dickinson)
in a heated holder (37
 

 
C); after measuring the baseline, the anti-
CD3 IgM mAb MEM-92 (10
 
5
 
 diluted ascitic fluid) was added,
and eventually, when the response subsided the calcium iono-
phore ionomycin (Molecular Probes) was used to determine the
absolute maximal response. The analysis was performed using the
FlowJo program (Tree Star, Inc.). From a kinetic curve con-
structed from ratios of Fluo-4 to FuraRed fluorescence, the aver-
age baseline, the maximum after anti-CD3 stimulation, and the
average response to ionomycin were deduced.
 
Results
LIME, A Novel Lipid Raft-Associated Transmembrane
Adaptor Protein. Public databases were searched for pro-
teins possessing the following structural features: (a) an
NH2-terminal peptide consisting of 5–50 amino acids fol-
lowed by a transmembrane helix; (b) a palmitoylation motif
(CxxC) starting 0–4 amino acids downstream from the
transmembrane helix; and (c) at least one tyrosine-based
motif (Yxx[I/L/V]) in the COOH-terminal (presumably
cytoplasmic) portion of the protein. This approach yielded
a number of candidate proteins, most of them being false
positives (e.g., proteins with NH2-terminal signal pep-
tide). However, the search identified also the already
known transmembrane adaptors PAG/Cbp and NTAL/LAB.
Among several other potentially interesting molecules we
identified a protein carrying the GenBank/EMBL/DDBJ
accession no. BAA91148. BLAST search revealed that the
sequence of its murine homologue, LIME (standing for
“Lck interacting molecule”) is also available under Gen-
Bank/EMBL/DDBJ accession no. AAG35210. Although
Hur et al. (18) submitted the sequence to the database al-
ready in 1998, no biochemical or functional characteriza-
tion of LIME has been reported up to now.
The human LIME cDNA codes for a strongly basic
polypeptide (predicted pI 9.7) of 295 amino acid residues
and a predicted molecular weight of 31,229 daltons (Fig. 1).
The leaderless type III protein consists of a very short NH2-
terminal extracellular peptide (4 aa), a single putative hydro-
phobic transmembrane domain (23 aa), which is followed
by a potential palmitoylation site (a CxxC motif) and two
arginine residues. The predicted cytoplasmic domain con-
tains a total of five tyrosines, all potentially phosphorylated
by Src family kinases. Two of the tyrosine-based signaling
motifs (Y200 and Y235, respectively) potentially represent im-
munoreceptor tyrosine-based inhibition motifs.
T
h
e 
Jo
u
rn
al
 o
f 
E
xp
er
im
en
ta
l 
M
ed
ic
in
e
Transmembrane Adaptor Protein LIME1456
LIME transcripts were detected by PCR in cDNA pre-
pared from PBLs, various lymphoid tissues, and liver but
not other tissues (Fig. 2, A and B). In Western blotting ex-
periments, both polyclonal and monoclonal antibodies di-
rected to COOH-terminal fragments of LIME recognized
a zone of the appropriate size in peripheral blood T cells,
which strongly increased in intensity after overexpression
of LIME (Fig. 2 C). Strong expression of LIME was also
observed in purified CD56 cells (mixture of NK cells and
NK T cells). However, when further separated NK cells
(CD3-negative) were found to express only little LIME
compared with NK T cells (unpublished data). Similarly,
purified blood B lymphocytes express only low amounts of
LIME, and the molecule seems to be absent in monocytes
(Fig. 2 D). In addition, all thymocyte subsets (double nega-
tive, double positive, single positive) contained comparable
amounts of LIME, and no marked differences in the level
of LIME expression could be detected in purified subsets of
peripheral blood T cells (CD4, CD8, CD45RA,
CD45RO, CD4CD25, CD4CD25,  Tcells; not
depicted). Among the T cell lines tested (Jurkat, HPB ALL,
HUT-78, SupT1, Molt-4, and CEM), only Jurkat cells are
essentially negative for LIME protein expression (not de-
picted). Expression of LIME strongly decreased when pe-
ripheral blood T cells were activated in vitro for several
days using PHA or plastic-immobilized CD3 mAb (Fig. 2,
E and F). When the stimulated T cells were transferred in
new culture dishes and cultivated further in the absence of
external stimuli, LIME became rapidly and strongly reex-
pressed (Fig. 2 F). These data suggest that expression of
LIME in peripheral blood T cells is controlled by external
stimuli mediated via the TCR (or other PHA-responsive
cell surface receptors).
As shown in Fig. 3, LIME is mostly present in buoyant
lipid rafts (Fig. 3 A) and can be biosynthetically labeled by
3H-palmitate (Fig. 3 B), indicating that the membrane-
proximal putative palmitoylation motif is used for targeting
the protein into lipid rafts. Moreover, LIME clearly local-
izes to the plasma membrane as judged from confocal mi-
croscopy of Jurkat T cells stably overexpressing the mole-
cule (Fig. 3C). Collectively, these data suggest that LIME
represents an integral membrane protein associated with
lipid rafts.
Figure 1. Predicted amino acid sequence of human LIME. The putative
transmembrane region is boxed, and the potential palmitoylation sequence
and tyrosine motifs are in bold and underlined.
Figure 2. Expression of LIME. (A) Presence of LIME mRNA in various
tissues as detected by PCR from the Multiple Tissue cDNA Panels I and
II (CLONTECH Laboratories, Inc.) and (B) the Immune System Panel
(CLONTECH Laboratories, Inc.). (C) Western blotting of vector- and
LIME-transfected peripheral blood T cells (immunostaining for LIME
and LAT; the latter was used as a loading control). (D) Western blotting of
indicated subpopulations of human peripheral blood cells (immunostaining
for LIME and Erk1/2; the latter was used as a loading control). (E) Western
blotting of resting and PHA-activated peripheral blood T cells (immunostain-
ing for LIME and LAT; the latter was used as a control). (F) Kinetics of
LIME downmodulation in peripheral blood T cells stimulated by immo-
bilized anti-CD3 mAb and LIME reexpression after removal of the cells
from anti-CD3–coated wells (after day 3) and further culturing in the
presence of IL-2. Cell lysates were analyzed by Western blotting for the
presence of LIME and LAT. The same results were obtained when IL-2
was not added to the culture medium (not depicted).
Figure 3. Subcellular localization of LIME. (A) Localization of LIME
in buoyant detergent-resistant microdomains (lipid rafts). Peripheral
blood T cells were solubilized in the presence of 3% nonionic detergent
Brij-58 and subjected to sucrose density gradient ultracentrifugation; the
fractions (numbered from top to bottom) were analyzed by Western blotting.
(B) Biosynthetic labeling of LIME with 3H-palmitate; LIME immunopre-
cipitate was analyzed by SDS-PAGE followed by fluorography of the gel
(the 56-kD zone corresponds probably to associated Lck). (C) Plasma
membrane localization of LIME (green) as determined by confocal mi-
croscopy in J77-LIME.
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Engagement of the CD4 or CD8 Coreceptors Induces Tyrosine
Phosphorylation of LIME and Its Association with Protein Tyro-
sine Kinases Lck and Csk. The overall similarity between
LIME, LAT, PAG/Cbp, and NTAL/LAB indicated that
LIME might be inducibly tyrosine phosphorylated after li-
gation of some cell surface receptor(s). To identify such re-
ceptors, a broad screening involving antibody-mediated
cross-linking of multiple lymphocyte surface molecules was
performed. This approach revealed that LIME becomes ty-
rosine-phosphorylated exclusively after antibody-mediated
engagement of the CD4 or CD8 coreceptors (Fig. 4)
but not after triggering CD2, CD3, CD5, CD7, LFA-1,
CD43, CD45, or MHC class I (not depicted). Cocross-
linking of CD4 and CD3 consistently produced lower lev-
els of LIME tyrosine phosphorylation than CD4 cross-link-
ing alone (not depicted).
As shown in Fig. 4 C, after cross-linking of CD4 phos-
phorylation of LIME was maximal after 2 min and slowly
declined thereafter. LIME became also tyrosine phosphory-
lated after cross-linking of CD4 on the surface of anti-CD3
activated, IL-2–propagated T cell blasts (not depicted).
To determine which protein tyrosine kinases (PTKs)
might be responsible for phosphorylation of LIME, we
treated human peripheral blood T cells with the Src family
PTK inhibitor PP2 before CD4 cross-linking. As shown in
Fig. 4 D, pretreatment with PP2 strongly suppressed the
CD4-mediated tyrosine phosphorylation of LIME. In
agreement with this result, coexpression of LIME with the
protein tyrosine kinases Fyn, Lck, Lyn, Hck, Csk, Syk, or
ZAP-70 in 293T-cells revealed that LIME represents a sub-
strate for PTKs of the Src family, in particular Lck or Lyn
(Fig. 4 E).
The next series of experiments was performed to assess
molecular interactions between LIME and other signaling
molecules expressed in T cells. These experiments indi-
cated that the Src family kinase Lck and the negative regu-
lator of Src kinases, the Csk kinase, specifically associate
with phosphorylated LIME in CD4-stimulated T lympho-
cytes (Fig. 5 A). Analysis of the LIME immunoprecipitates
using phosphospecific antibodies further suggested that
LIME-associated Lck was phosphorylated on both the
COOH-terminal inhibitory and the activating tyrosine res-
idues (Y505 and Y394, respectively; Fig. 5 A). The inducible
association of LIME with PTK activity was also demon-
strated by an in vitro kinase assay using LIME immunopre-
cipitates prepared from unstimulated or anti-CD4–stimu-
lated T cells (Fig. 5 B).
Strikingly, when stably expressed in the CD4-positive
Jurkat T cell line (J77), LIME displayed constitutive strong
tyrosine phosphorylation and bound Lck, Csk, and also
Fyn (Fig. 6) even without CD4 cross-linking; constitutive
tyrosine phosphorylation of LIME was observed also in all
Figure 4. Induction of LIME
tyrosine phosphorylation. (A) Pe-
ripheral blood T cells were left
unstimulated () or stimulated
via CD3 or CD4, and LIME was
immunoprecipitated from lauryl-
maltoside lysates and analyzed by
Western blotting to visualize
tyrosine-phosphorylated LIME
(top) and total LIME (bottom).
(B) As in A but using purified
CD8 T cells stimulated by
mAbs to CD4 (negative control),
CD8, or not stimulated (). (C)
Kinetics of LIME phosphoryla-
tion after T cell stimulation via
CD4; stimulation was stopped
after the indicated times (0–30
min). Immunoprecipitated LIME
was analyzed by Western blotting
using antibodies to P-Tyr (top)
or LIME (bottom). (D) Inhibition of anti–CD4-induced LIME phosphorylation in T cells by the inhibitor of Src kinases PP2. LIME immunoprecipitates
were analyzed by Western blotting for P-Tyr and LIME. (E) Kinases phosphorylating LIME were examined by cotransfection of constructs encoding
LIME, and the indicated kinases in 293T cells; total cell lysates were analyzed by Western blotting using antibodies to P-Tyr (top) or LIME (bottom).
Expression of all the kinases was verified separately (not depicted).
Figure 5. Proteins associated with phosphorylated LIME. (A) LIME
immunoprecipitates prepared from unstimulated (left) or anti–CD4-
stimulated (right) T cells (solubilized under raft-dissociating conditions)
were analyzed by Western blotting using antibodies to the indicated
molecules. (B) In vitro kinase assay of the LIME immunoprecipitates
obtained from unstimulated and anti–CD4-stimulated T cells; as a neg-
ative control (Ctr.) an irrelevant antibody (anti-CD20) was used for the
immunoprecipitation.
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T cell lines expressing LIME naturally [unpublished data]).
Moreover, the level of LIME phosphorylation and its asso-
ciation with Lck and Csk, respectively, did not change sig-
nificantly in these transfectants after CD4 cross-linking.
However, brief pretreatment of these transfectants with the
Src family PTK inhibitor PP2 led to a substantial decrease
of the constitutive phosphorylation of LIME; in such pre-
treated cells, LIME rephosphorylation could be achieved
by cross-linking of CD4 by antibodies or recombinant
HIV-derived gp120 (not depicted). The reason for the
constitutive tyrosine phosphorylation of LIME in J77 is un-
clear at present but might be due to a deregulation of the
membrane-proximal signaling pathways in the transformed
cells (see Discussion).
To assess which tyrosine residues of LIME mediate its
interaction with Lck and Csk, respectively, a series of stable
J77 transfectants were generated expressing tyrosine mu-
tants of LIME. It could be demonstrated that Y254 repre-
sents the binding site for Lck (and Fyn) (Fig. 6). Indeed,
this site corresponds to a high stringency binding site for
Lck and Fyn as predicted by the scansite program (http://
scansite.mit.edu) (19). In contrast, phosphorylated Y167 and
potentially also Y200 appear to mediate the interaction be-
tween LIME and Csk. These tyrosine-based signaling mo-
tifs readily fit the consensus sequence that is found in vari-
ous Cbps and the consensus sequence selected from peptide
libraries (Table I).
Further analysis of the J77-LIME transfectant indicated
that the amounts of lipid rafts-associated Lck and Csk are ei-
ther slightly (in the case of Lck) or strongly increased (in the
case of Csk) in these cells compared with WT J77 cells (Fig.
7 C). These data confirm that tyrosine-phosphorylated
LIME is capable of targeting Lck and Csk to lipid rafts.
The data shown in Fig. 7 A demonstrate that in J77-
LIME transfectants the LIME-associated fraction of Lck is
more strongly phosphorylated on the inhibitory tyrosine
Y505 compared with the total pool of Lck. In addition, an in
vitro kinase assay of Lck immunoprecipitates prepared from
J77-LIME cells results in a much stronger phosphorylation
of Lck than in WT J77 cells (Fig. 7 B). Furthermore, LIME-
associated Lck was even stronger phosphorylated than Lck
immunoprecipitated from the total pool of Lck in the J77-
LIME cells (Fig. 7 B). This could be either due to a higher
enzymatic activity of the LIME-associated Lck (resulting in a
higher level of autophosphorylation) or due to an increased
phosphorylation of Lck by LIME-associated Csk.
Figure 6. Identification of the P-Tyrs involved in binding of Lck, Fyn,
and Csk. LIME immunoprecipitates from lysates of J77 cells stably trans-
fected with the indicated Tyr to Phe mutants of LIME were analyzed by
Western blotting for the presence of the indicated molecules.
Table I. Comparison of Published Csk Binding Sequences
Protein name and binding site position Csk binding sequence Reference
LIME Y167 V A E Y A R V Q K R K This paper
LIME Y200 D V L Y S R V C K P K This paper
Paxillin Y118 E H V Y S F P N K Q K 39
Caveolin Y14 G H L Y T V P I R E Q 40
PTP-HSCF Y354 A D T Y A V V Q K R G 41
PTP-HSCF Y381 T P I Y S Q V A P R A 41
IGF-IR Y943 G V L Y A S V N P E Y 42
IGF-IR Y1316 R Q P Y A H M N G G R 42
InsulinR Y1322 H I P Y T H M N G G K 42
p62dok Y449 S A L Y S Q V Q K S G 43
PAG Y317 S A M Y S S V N K P G 9
SIT Y169 P E L Y A S V C A Q T 44
Hic-5 Y60 D H L Y S T V C K P R 45
Peptide library Y[T/A/S][K/R/Q/N][M/I/V/R] 46
Critical tyrosines are bolded, other amino acids participating in the putative consensus motif are underlined.
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To distinguish between these possibilities, we assessed
the capability of Lck to phosphorylate an exogenous sub-
strate (the cytoplasmic domain of the transmembrane adap-
tor protein TRIM, which has been shown to be an excel-
lent substrate for Lck in vivo [20]). As shown in Fig. 7 B
(top), the ability of Lck to phosphorylate TRIM appears to
be the same in J77-LIME cells and in J77 cells transfected
with an empty vector. These data collectively support the
hypothesis that the higher levels of tyrosine phosphoryla-
tion of LIME-associated Lck primarily result from phos-
phorylation of Y505 by the LIME-associated Csk. More-
over, they suggest that expression of LIME in Jurkat T cells
leads to increased phosphorylation of Lck by Csk without
dramatically altering the enzymatic activity of Lck. This
finding can be best explained by the fact that the Src ho-
mology (SH)2 domain of Lck is not available for interac-
tion with phospho-Y505 because it is engaged by phosphor-
ylated LIME (Y254), and therefore, the closed inactive
conformation of Lck cannot be formed.
LIME Increases Ca2 Response After Stimulation of J77
Cells. Transient expression of LIME in J77 cell leads to a
significantly higher Ca2 response to anti-CD3 stimulation
compared with cells transfected with an empty vector,
whereas another raft-associated transmembrane adaptor
protein NTAL, expressed at the same level, does not
change this response significantly (Fig. 8).
Discussion
Transmembrane adaptor proteins (TRAPs) are emerging
as important molecules involved in coupling immunore-
ceptors to intracellular signaling pathways (1–3). Two types
of TRAPs can be distinguished, namely those that are ex-
cluded from the rafts (TRIM [20], SHP2-interacting trans-
membrane adaptor [21], and linker for activation of X
[LAX] [22]) and those that are targeted to rafts via jux-
tamembrane palmitoylation of a di-cysteine motif CxxC
(LAT [7, 8], PAG/Cbp [9, 10], NTAL/LAB [11, 12],
and LIME). The increasing number of the raft-associated
TRAPs is in agreement with the currently recognized im-
portance of membrane rafts in receptor signaling and other
cellular processes (1–3). LAT and NTAL/LAB are in-
volved in signaling initiated by immunoreceptors (TCR
and BCR or Fc receptors, respectively [11, 12, 23]),
whereas PAG/Cbp participates more generally in negative
regulation of Src family kinases and thus indirectly controls
immunoreceptor signaling (9, 10, 24–26).
LIME, the novel TRAP described herein, appears not to
be a direct target of immunoreceptor-mediated signaling
events. Rather, its phosphorylation and association with in-
tracellular signaling and effector molecules (Lck and Csk)
seems to be controlled in primary T cells by the corecep-
tors CD4 and CD8. Csk and Lck (plus Fyn) also associate
with LIME when the molecule is expressed in the J77 Jur-
kat T cell line; notably, in these transfectants LIME is con-
stitutively tyrosine phosphorylated, and its phosphorylation
status apparently does not change upon CD4 (nor CD3)
cross-linking. Importantly, the Lck molecules that associate
with phosphorylated LIME are phosphorylated both on the
COOH-terminal negative regulatory Y505 and on the posi-
tive regulatory Y394 and exhibit somewhat paradoxically an
increased autophosphorylation activity. It seems likely that
the inhibitory phospho-Y505 is unable to exert its inhibitory
Figure 7. Effects of LIME on Lck and Csk in J77-LIME stable trans-
fectants. (A) The concentration of directly immunoprecipitated Lck was
adjusted to equate on the Western blot to the amount of Lck coprecipi-
tated with LIME (top), and the blot was then stained with antibody spe-
cifically recognizing the phosphorylated Tyr505. (B) In vitro kinase assay
was performed using purified cytoplasmic domain of TRIM protein as an
exogenous substrate for Lck immunoprecipitated from J77-LIME trans-
fectants or from cells transfected with an empty vector. The phosphorylated
proteins in immunoprecipitates were also resolved to check content (immu-
noblotting) and phosphorylation status (autoradiography) of Lck. The
dividing lines in the TRIM panel indicate that these lanes were not adjacent
in the original gel, and the far right-hand lane is from a different gel, which
was processed simultaneously. (C) Localization of Lck and Csk in lipid
rafts of J77-LIME transfectants or cells transfected with an empty vector.
Cells were solubilized in the presence of 3% nonionic detergent Brij-58
and subjected to sucrose density gradient ultracentrifugation; the fractions
(numbered from top to bottom) were analyzed by Western blotting.
Figure 8. Effects of LIME on anti–CD3-induced Ca2 response. J77
cells transiently transfected with the indicated constructs were stimulated
by cross-linking of CD3. The results are presented as a proportion of the
peak anti-CD3 response to the maximum response induced by Ca2 ion-
ophore ionomycin after correction for basal level. The results are repre-
sentative of three independent experiments and show the mean and SD of
four measurements. The observed increase is statisticaly significant at the
5% level (Student’s t test). The right panel shows the comparable level of
LIME and NTAL expression as determined by Western blotting and
immunostaining of FLAG tag.
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function, since the Lck SH2 domain is bound to the phos-
pho-LIME (see further discussion of this point below).
Interestingly, despite the presence of two putative im-
munoreceptor tyrosine-based inhibition motifs in the cyto-
plasmic tail of LIME, so far we could not detect any SH2
domain containing phosphatase (SHP-1, SHP-2, or SHIP)
in LIME immunoprecipitates prepared from activated
(even pervanadate-treated) cells.
What are possible biological functions of this novel raft-
associated adaptor? Induction of tyrosine phosphorylation
and association with Lck and Csk after CD4 or CD8 cross-
linking strongly indicates that LIME plays a role in regula-
tion or propagation of coreceptor signaling.
The roles of the coreceptors (so far studied mainly for
CD4) may be twofold, depending on whether the corecep-
tor is coengaged with the TCR or cross-linked separately.
Cocross-linking of CD4 with the TCR generally potenti-
ates TCR-mediated signaling events, obviously due to
bringing the CD4-associated fraction of Lck into the prox-
imity of the cytoplasmic tails of the CD3 complex and the
 chains (27, 28). LIME might play a potentiating role in
this physiological signaling. This view is supported by our
observation that transient overexpression of LIME in J77
Jurkat T cells increases Ca2 responses after CD3 stimula-
tion. Moreover, when stably expressed in J77 cells LIME is
expressed as a constitutively phosphorylated protein. This
could correspond to the situation that occurs in primary T
cells after coreceptor engagement.
In contrast to coengagement with the TCR, separate
cross-linking of CD4 either by antibodies to suitable CD4
epitopes or by HIV gp120 is known to inhibit or markedly
modify the outcome of the subsequent signaling induced
by TCR engagement (29, 30). Moreover, in rodent mod-
els selective ligation of CD4 in vivo by certain antibodies
results in remarkably robust alloantigen-specific immuno-
suppression and induction of specific transplantation toler-
ance, which is apparently mediated by regulatory T cells
secreting suppressive cytokines (31, 32). Finally, CD4 sig-
naling may also modify LFA-1–dependent adhesivity (33).
Little is known about the molecular mechanisms underly-
ing these inhibitory functions of CD4. However, CD4
cross-linking alone can induce signaling pathways similar to
those triggered by TCR (activation of Lck and Fyn, initia-
tion of the Ras-Raf-MAPK, and phospholipase C-PKC-
Ca2 pathways, resulting in activation of the NF AT,
NFB, and AP-1 transcription factors) (34, 35). The final
result of signaling mediated solely via CD4 may be either
induction of apoptosis or presensitization of T cells to
CD3-mediated apoptosis (34, 36, 37).
It is tempting to speculate that LIME is involved in these
inhibitory aspects of CD4 signaling: it may, for example,
compete with CD4 for Lck and at the same time it may
bring more Csk to membrane rafts (Fig. 7 C). This could
eventually result in inhibition of Src family kinases, which
are needed for TCR signaling. This model of LIME func-
tion is, however, not very well compatible with our obser-
vation that Lck isolated from J77-LIME transfectants and
LIME-associated Lck (which is more phosphorylated on
the COOH-terminal inhibitory tyrosine) has a kinase ac-
tivity comparable to Lck from control cells. Nevertheless, it
is possible to propose the following model for LIME func-
tion (Fig. 9): cross-linking of CD4 induces aggregation or
reorganization of lipid rafts containing LIME, CD4-Lck,
and free Lck. By this, Lck (free or CD4-associated) is
brought into proximity of LIME and phosphorylates the
adaptor. Now, cytoplasmic Csk and free Lck bind to tyro-
sine-phosphorylated LIME via their SH2 domains. In the
resulting complex, Csk phosphorylates Lck on Y505 (either
on the same LIME adaptor or on a different LIME mole-
cule in close proximity). However, the Lck phosphorylated
on Y505 remains enzymatically active because its SH2 do-
main is bound to phospho-LIME and thus cannot be
engaged by phospho-Y505 (with the consequence that
the inactivating “closed” conformation of Lck cannot be
formed). LIME-associated, “open” Lck could phosphory-
late additional molecules thus propagating the CD4-medi-
ated signal. In addition (or alternatively), phospho-Y505 of
LIME-bound Lck could serve as a docking site for addi-
tional signaling proteins (including Lck or Fyn). Recruit-
ment of these molecules to the LIME–Csk–Lck complex
could further amplify the CD4-mediated signal. Subse-
quently, the phosphorylated Lck may dissociate from
LIME, assume the “closed” conformation, and remain in-
active in the lipid raft. A model in which LIME-associated
Lck recruits and activates lipid raft-associated Fyn might
explain the recent report that the activation of Fyn within
the lipid microdomains is preceded (and requires) translo-
cation of Lck to lipid rafts (38).
A remarkable feature of LIME is its downmodulation in
T cells after stimulation with PHA or immobilized anti-
CD3 antibodies and its reappearance after removal of the
stimulating agents. A plausible explanation could be that
down-regulation of LIME serves to limit CD3/TCR-
Figure 9. Hypothetical mechanism of LIME involvement in regulation
of Lck activity.
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mediated activation processes by blunting coreceptor sig-
naling. Such a mechanism could help to prevent hyperacti-
vation of T cells that have already seen antigen and start to
differentiate into effector T-lymphocytes.
In summary, we suggest that the newly described lipid
raft-associated transmembrane adaptor protein LIME may
have regulatory function(s) in T cells. At the beginning of
an immune response where coreceptor signaling is required
to activate T cells, LIME rapidly becomes tyrosine-phos-
phorylated, transiently increases the activity of Lck by
blocking formation of its inactive conformation, and thus
amplifies TCR-mediated signals. Upon prolonged stimula-
tion, LIME helps to accumulate inhibited Lck in lipid rafts,
thereby preventing hyperactivation of T cells. In the case of
antigen persistence, T cells down-regulate expression of
LIME. This may be a mechanism to prevent premature ter-
mination of the immune response by blunting membrane
recruitment of enzymatically active Lck. Furthermore, one
may speculate that strongly positive nonphosphorylated
LIME may possibly interact with membrane phospholipids
or other negatively charged cytoplasmic molecules (e.g.,
phosphoproteins) and thereby modify their interactions
with other signaling molecules. To fully understand the role
of LIME during T cell activation, it will be necessary to ex-
plore its possible functional interactions with PAG/Cbp,
another raft-associated transmembrane adaptor that regulates
the activity of Src kinases by recruiting Csk (10, 11). More-
over, more definitive answers regarding the physiological
role of LIME in T cell activation should be provided by
LIME knock-out mice, currently under construction.
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SIT is a transmembrane adapter protein that modulates signals emanating from the T-cell receptor (TCR).
Here, we have used gene-targeted mice to assess the role of SIT for T-cell development and peripheral T-cell
functions. SIT/ double-positive thymocytes show an upregulation of the activation markers CD5 and CD69,
suggesting that SIT negatively regulates TCR-mediated signals at the CD4 CD8 stage of thymic develop-
ment. This assumption is further supported by the observation that in female H-Y TCR transgenic mice,
positive selection is enhanced and even converted to negative selection. Similarly, mature peripheral T cells are
hyperresponsive towards TCR-mediated stimuli and produce larger amounts of T-helper 1 (TH1) cytokines,
and SIT-deficient mice show an increased susceptibility to develop experimental autoimmune encephalomy-
elitis, a mouse model of multiple sclerosis. These results demonstrate that SIT is a critical negative regulator
of TCR-mediated signaling and finely tunes the signals required for thymic selection and peripheral T-cell
activation.
The recognition of specific antigen/major histocompatibility
complex (MHC) complexes by the clonotypic T-cell receptor
(TCR) initiates a number of signaling cascades which ulti-
mately culminate in gene transcription. The proper function of
these signal transduction pathways requires the coordinated
action of many molecules. During the last years, the under-
standing of the membrane-proximal signaling events leading to
T-cell activation has significantly advanced. For example, it has
been demonstrated that the activation of protein tyrosine ki-
nases belonging to the Src, Syk, and Tec families are among the
earliest biochemical events that initiate cellular activation
upon antigen recognition (reviewed in references 12 and 37)
Also, major progress was made in elucidating how Src and Syk
kinase-mediated signals are further processed to induce appro-
priate cellular responses. In this regard, the identification of a
novel group of integral membrane molecules named trans-
membrane adapter proteins (TRAPs) was a major achieve-
ment (18).
All TRAPs known to date have a common molecular struc-
ture. They possess very short extracellular domains and com-
paratively long cytoplasmic tails containing several (up to 10)
tyrosine-based signaling motifs (TBSMs) (18). After immuno-
receptor engagement, the core tyrosine residues within the
TBSMs become rapidly phosphorylated and thereby serve as
docking sites for cytoplasmic signaling proteins carrying SH2
domains. By recruiting SH2 domain-containing proteins to the
plasma membrane, the TRAPs function as molecular biochips
which sort and coordinately propagate externally applied sig-
nals into the cell. Thus, the identification of the TRAPs has
clarified the question of how signal-transducing receptors such
as the TCR are connected with intracellular signaling path-
ways.
Presently, the family of TRAPs includes LAT, LAX, LIME,
NTAL/LAB, PAG/Cbp, SIT, and TRIM. LAT represents the
most well-characterized transmembrane adapter protein and
appears to be primarily involved in positively regulating TCR-
mediated signaling. By recruiting cytoplasmic signaling mole-
cules such as Grb2, GADS, SLP-76, and phospholipase C- to
the plasma membrane, LAT assembles a signaling complex
that is required for coupling the T-cell receptor to the major
intracellular signaling pathways leading to transcription of the
T-cell growth factor interleukin-2 (16, 34, 48). The generation
of LAT-deficient mice has further revealed the indispensable
role of this transmembrane adapter protein for T-cell devel-
opment (49).
Conversely to LAT, the transmembrane adapter proteins
LAX and PAG seem to exert negative regulatory functions on
TCR-mediated signaling either by recruiting the most impor-
tant negative regulator of Src kinase activity, the cytosolic
protein tyrosine kinase Csk, to the plasma membrane (PAG)
(8, 22, 43) or by inhibiting TCR-mediated activation of p38
mitogen-activated protein kinase (LAX) (50).
In addition to the regulation of antigen receptor signaling, it
appears that some transmembrane adapters may regulate sig-
nals initiated after coreceptor engagement. This has most re-
cently been shown for the lipid raft-associated transmembrane
adapter protein LIME, which exclusively becomes phosphory-
lated after external engagement of the CD4 or CD8 corecep-
tors (9, 21). However, the biological relevance of this phos-
phorylation has not yet been revealed.
Two transmembrane adapters, TRIM and SIT, differ from
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the other TRAPs known so far as they represent disulfide-
linked homodimers. TRIM associates with the TCR complex,
preferentially through an interaction with the TCR- chain,
and when overexpressed in Jurkat T cells, TRIM inhibits the
spontaneous internalization of the TCR (10, 26). However, the
precise function that TRIM plays during T-cell activation re-
mains elusive.
SIT has been reported to act as a modulator of TCR-medi-
ated signaling (29, 35). Indeed, when overexpressed in Jurkat T
cells, wild-type (wt) SIT exerts strong negative regulatory ef-
fects upon TCR-mediated activation of the transcription factor
NF-AT (29, 35) This inhibitory effect seems to be exclusively
mediated via a single TBSM within the SIT cytoplasmic do-
main (YASV) that binds a still-to-be-defined ligand. In con-
trast, overexpression of a SIT mutant lacking the YASV motif
strongly amplifies TCR signals. This effect is mediated via
another tyrosine-based signaling motif, YGNL, which seems to
control a Grb2-mediated signaling pathway (35). Collectively,
the currently available data suggest that SIT serves as a mul-
tifunctional adapter that finely tunes signals emanating from
the TCR.
The aim of the present study was to assess the role of SIT
during T-cell development and T-cell activation using an in
vivo model. To this end, we generated SIT-deficient mice. Our
data confirm that SIT primarily acts as a negative regulator of
TCR-mediated signals and sets signaling thresholds necessary
for positive selection within the thymus. In addition, SIT seems
to be involved in the maintenance of peripheral T-cell ho-
meostasis, as demonstrated by the hypersensitivity of SIT-de-
ficient T cells in response to TCR stimulation and increased
susceptibility of SIT-deficient mice to autoimmunity in a mu-
rine model of multiple sclerosis.
MATERIALS AND METHODS
Mice. The targeting construct was transfected into 129-derived embryonic
stem cells. Targeted embryonic stem clones were selected and processed as
previously described (2). Positive clones were injected into C57BL/6 blastocysts.
Animals containing the disrupted SIT allele were crossed onto C57BL/6 (Charles
River) for more than 10 generations. Genotype was determined by PCR using a
mixture of three primers, 5 SIT (CCT GAC TCT CAC ACC AGC AGC), 3 SIT
(GGT CCA CTG GGA CAA GAG TGC AGC C), and 3 NEO (GAC GTG
CTA CTT CCA TTT GTC ACG TCC) (BioTeZ Berlin-Buch GmbH). OT-I and
OT-II TCR transgenic (tg) mice were kindly provided by Percy Knolle, P14 mice
were provided by Thomas Kammerthoens, and H-Y TCR transgenic mice were
kindly provided by Gary Koreztky. For TCR transgenic studies, SIT/ mice 
TCR tg mice were obtained by crossing SIT/ mice with SIT/ mice for TCR
heterozygote transgenics. All mice analyzed were between 5 and 10 weeks of age.
Flow cytometry. For each sample, 1  106 cells were stained with antibodies
and analyzed on a FACSCalibur using the CellQuest software (Becton Dickin-
son). All antibodies were purchased from BD Biosciences except for H-Y–
fluorescein isothiocyanate (clone T3.70; eBioscience). For flow cytometric de-
termination of extracellular signal-regulated kinase (ERK) activation,
thymocytes were surface labeled with anti-CD4-CyChr and anti-CD8-phyco-
erythrin, fixed, and permeabilized in phosphate-buffered saline (PBS) containing
3.7% formaldehyde and 0.2% saponin for 15 min at room temperature. After
being washed in PBS containing 0.1% saponin, 0.1% NaN3, and 0.2% BSA/c,
cells were stained with anti-phospho-p44/42 mitogen-activated protein kinase
(Cell Signaling) in PBS supplemented with bovine serum albumin (10 mg/ml),
0.2% BSA/c, 0.1% saponin, and 0.1% NaN3 for 45 min at room temperature.
Bound antibody was detected with fluorescein isothiocyanate-conjugated anti-
rabbit immunoglobulin G (IgG) (Jackson ImmunoResearch Laboratories).
Apoptosis assay. Thymocytes (5  105) were cultured in 96-well flat-bottomed
plates coated with 10 g/ml anti-CD3 (145-2C11; BD Biosciences) or 10 g/ml
anti-CD3 plus 10 g/ml anti-CD28 (37.51; BD Biosciences). For concanavalin A
(ConA) stimulation, a final concentration of 1 g/ml was used. Samples were
then incubated at 37°C for 24 h before analysis. After harvesting, the living cells
were analyzed by forward scatter and side scatter flow cytometry parameters.
Cells were also harvested, washed, and stained with annexin V and propidium
iodide according to the manufacturer’s instructions (Bender MedSystems).
Proliferation assay and cytokine determination. T-cell purification was per-
formed using a Pan T-cell Isolation kit and an AutoMacs magnetic separation
system (Miltenyi Biotec). Purified T cells (2.5  104 cells/well) were cultured in
RPMI medium (supplemented with 10% fetal calf serum, antibiotics, and 2--
mercaptoethanol) in a U-bottomed 96-well plate (Costar) in the presence of
plate-bound anti-mouse CD3ε (145-2C11; BD Biosciences) or phorbol myristate
acetate (PMA) and ionomycin. Cells were cultured for 72 h and labeled with 0.5
Ci/well of [3H]thymidine during the last 6 h. Supernatants from anti-CD3-
stimulated T cells were collected after 48 h and assessed for cytokines by cyto-
metric bead array (BD Biosciences).
Induction of active EAE. Myelin oligodendrocyte glycoprotein (MOG) p35-55,
corresponding to the mouse sequence MEVGWYRSPFSRVVHLYRNGK, was
synthesized by standard 9-fluorenylmethoxycarbonyl chemistry and purified by
high-performance liquid chromatography. Active experimental autoimmune en-
cephalomyelitis (EAE) was induced in 8- to 12-week-old mice by immunization
with 200 g of MOG p35-55 in complete Freund’s adjuvant (Sigma-Aldrich,
Taufkirchen, Germany) containing 800 g of killed Mycobacterium tuberculosis
(Difco Laboratories, Detroit, MI). In addition, 200 ng of pertussis toxin (List
Biological Laboratories, Campbell, CA) dissolved in 200 l PBS was injected
intraperitoneally on the day of immunization and again 2 days postimmunization.
Statistics. Statistical analyses were performed using GraphPad Prism (Graph-
Pad Software Inc., San Diego, CA). P values were determined by an unpaired
two-tailed Student’s t test.
RESULTS
SIT is expressed predominantly in thymocytes. Previously,
we have shown that SIT is selectively expressed in lymphoid
cell lines (29). To assess the expression of SIT in primary cells
from different murine lymphoid organs, anti-SIT Western blot-
ting was performed. As shown in Fig. 1A, the highest levels of
SIT protein expression are detectable in the thymus, and lower
levels are detected in spleen. We next analyzed whether SIT
expression is different in T lymphocytes compared to B lym-
phocytes and whether immature T cells express different
amounts of SIT than mature T cells. Figure 1A shows that SIT
expression is much higher in purified CD3 splenic T cells than
in B220 B cells. In addition, the expression of SIT within the
thymus (containing approximately 80% immature T cells) is
much higher than in mature splenic T cells. Conversely, SIT is
not expressed in the Gr-1 myeloid lineage in the bone mar-
row (data not shown). In conclusion, SIT is expressed at the
highest levels in immature thymocytes.
SIT/ mice show normal B-cell but altered T-cell develop-
ment. To elucidate the function of SIT within the immune
system, we generated SIT-deficient mice by homologous re-
combination. The SIT gene was disrupted in embryonic stem
cells by using a standard gene-targeting strategy. As shown in
Fig. 1B, the entire coding sequence of the SIT gene (19) was
replaced with a neomycin resistance cassette, and the expected
mutation was confirmed by PCR (Fig. 1C) and anti-SIT West-
ern blotting (Fig. 1D).
SIT-deficient mice are born at the expected Mendelian fre-
quency, and they are viable, are fertile, show normal growth,
and present no obvious abnormalities. Flow cytometry analysis
further revealed that the distribution of B-cell subsets in the
bone marrow, spleen, and lymph nodes is normal (Table 1 and
Fig. 2). B-cell precursor fractions such as pro-B cells (B220
CD43), immature B cells (B220 IgM), and recirculating
mature B cells (B220high IgM) from SIT/ bone marrow are
comparable to those of wt mice (Fig. 2A). In the spleen, the
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total B-cell distribution (B220 IgM) as well as the percent-
ages of B-cell subpopulations such as immature (IgMhigh
IgDlow), transitional (IgMhigh IgDhigh), and mature (IgMlow
IgDhigh) are also not affected by SIT deficiency (Fig. 2F).
Moreover, B1 lymphocytes (CD5 B220) in the peritoneal
cavity also show a normal distribution (Fig. 2C). In addition,
basal immunoglobulin levels as well as those obtained after
immunization of SIT-deficient mice were normal (data not
shown). Collectively, these data suggest that SIT is dispensable
for normal B-cell development and peripheral B-cell functions.
To address the question of whether SIT plays a role in T-cell
development, we investigated single-cell suspensions of thymo-
cytes from wild-type animals and SIT-deficient littermates by
FIG. 1. Expression of SIT in mouse lymphocytes and generation of
SIT-deficient mice. (A) Lysates prepared from freshly isolated thymo-
cytes (T), splenocytes (S), purified splenic T cells (CD3), or purified
splenic B cells (B220) were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and blotted with an anti-SIT MAb.
To demonstrate equal amounts of protein loading, the blot was
stripped and reprobed with an anti-Erk polyclonal antibody. (B) Par-
tial restriction map of the SIT locus and the targeting cassette. Filled
boxes represent exons. Restriction sites are indicated as follows: N,
NotI; B, BamHI; M, MluI; P, PstI; X, XbaI. Abbreviations: NEO,
neomycin resistance cassette; TK, thymidine kinase. (C) PCR analysis
of SIT wild-type (/), heterozygous (/), and homozygous (/)
mutant alleles. (D) Anti-SIT Western blot analysis showing absence of
SIT protein in SIT/ mice. Postnuclear lysates were prepared from
thymocytes, separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, and blotted with an anti-SIT MAb. The blot was
successively stripped and reprobed with an anti-ERK1/2 antibody as a
loading control.
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FIG. 2. Lymphocyte development in SIT-deficient mice. Bone marrow cells (A), lymph nodes cells (B), peritoneal cavity cells (C), thymocytes
(D), double-negative thymocytes (E), and splenocytes (F) from 5- to 8-week-old mice were stained with MAbs for CD43, B220, IgM, CD4, CD8,
TCR-, CD44, CD25, 
TCR, IgD, and CD5 and analyzed by flow cytometry. Numbers represent the percentages of cells that fall into the
indicated boxes or quadrant areas of total gated living cells.
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flow cytometry. Table 1 shows that the cellularity of SIT-defi-
cient thymi is moderately increased. Fluorescence-activated
cell sorter analysis further revealed an alteration in the com-
position of thymocyte subpopulations (Fig. 2D), with clearly
reduced proportions of both CD4 and CD8 mature single-
positive (SP) thymocytes and an increase of CD4 CD8 (dou-
ble-positive [DP]) immature thymocytes in SIT/ mice. In
agreement with this observation, a significant decrease of thy-
mocytes expressing high levels of TCR (as a measure of ter-
minal maturation) was found in the knockout animals (Fig.
2D). Due to the increase in total thymic cellularity, we calcu-
lated the absolute numbers of the individual thymocyte sub-
sets. As summarized in Table 1, SIT/ mice show an approx-
imate 40% increase in the total number of immature DP
thymocytes and a slight reduction in the number of mature SP
thymocytes. In contrast, the numbers of double-negative thy-
mocytes (Table 1) as well as their CD25/CD44 fluorescence-
activated cell sorter profiles are normal (Fig. 2E). The latter
finding suggests that SIT is dispensable during the earliest
steps of thymic development. Thus, the higher total numbers of
thymocytes in SIT-deficient mice are primarily caused by an
increase in the DP subset. The alteration in the DP/SP ratio
suggests a subtle defect in thymic selection.
Upregulation of cell surface molecules involved in thymic
selection processes on SIT/ DP thymocytes. To obtain fur-
ther insight into the molecular mechanism underlying the al-
tered thymic development in SIT/ mice, we analyzed the
expression levels of surface markers whose expression is known
to be regulated during thymic development.
The expression of CD5 has been reported to directly corre-
late with the intensity of pre-TCR- and TCR-mediated signals
(5, 6). Thus, high levels of CD5 expression are found in thy-
mocytes of transgenic mice which express TCRs with a high
affinity/avidity for their selecting ligands (5, 6) or on DP thy-
mocytes of mice lacking negative regulatory cytosolic adapters
such as c-Cbl or SLAP (32, 38). Therefore, it appears that CD5
serves as a negative-feedback regulator of TCR-mediated sig-
nals and that its expression is required to regulate signaling
processes during thymocyte selection (5, 6, 42). As shown in
Fig. 3, the expression of CD5 is upregulated on SIT-deficient
DP thymocytes, indicating an enhanced signaling capability of
the TCR in the absence of SIT.
CD69 is another maturation marker that becomes upregu-
lated after TCR engagement by ligands presented by thymic
stromal cells during both negative and positive selection (4, 31,
41, 47). Similar to CD5, DP thymocytes of SIT-deficient mice
express higher levels of CD69 than wt littermates (Fig. 3). This
further corroborates our hypothesis that TCR-mediated sig-
naling is augmented in SIT-deficient thymocytes. In contrast to
CD5 and CD69, the expression profiles of CD4, CD8, heat-
stable antigen (HSA), CD45RB, and CD62L are normal in
SIT/ thymocytes (data not shown).
SIT deficiency alters positive selection in H-Y and P14 TCR
transgenic mice. Within the thymus, the majority of cells be-
long to the DP stage. Moreover, it is during this stage that
autoreactive thymocytes are eliminated by negative selection,
while thymocytes with the appropriate specificity for self-pep-
tide/MHC complexes are positively selected and further de-
velop to the SP stage. It is known from multiple studies that
TCR transgenic mice expressing a defined TCR are well
suited to study thymic selection processes (13, 27). Given the
above-described findings, which suggested that loss of SIT af-
fects thymic development by enhancing TCR-mediated signals,
we wished to obtain a more detailed insight into SIT-mediated
regulation of thymic selection processes. To this end, we
crossed SIT/ mice with mice expressing transgenic TCRs
(P14, H-Y, OT-I, and OT-II) and evaluated the effect of SIT
deficiency on selection processes.
As shown in Fig. 4A, higher levels of CD5 are expressed on
DP and in particular on positively selected CD8 SP H-Y tg
thymocytes of SIT/ mice than in their SIT/ counterparts.
Since CD5 expression on mature SPs has been proposed to
result from TCR-mediated signals that are delivered during
the selection processes (6), the enhanced expression of CD5 on
SIT/ SP cells indicates that, similar to the situation seen in
the non-TCR tg mice, loss of SIT also enhances signaling via
the TCR in the H-Y TCR tg model.
Figure 4A further demonstrates that the positively selected
CD8 SP TCR tg cells express strikingly lower levels of HSA
than the corresponding cells from SIT/ animals. This indi-
cates that SIT-deficient CD8 SP cells are more mature than
SIT/ cells, likely because of enhanced positive selection (see
below).
According to the currently proposed model, the activation/
phosphorylation status of the dual-specificity kinase ERK di-
rectly correlates with the efficiency of positive selection (7, 23,
28, 33). Figure 4B depicts that ex vivo phosphorylation of ERK
in DP thymocytes of SIT-deficient mice is stronger than in the
corresponding SIT-positive animals (mean fluorescence inten-
sity [MFI] of 59.5 versus 30.4). In contrast, the levels of Erk
phosphorylation are similar after in vitro stimulation with
PMA (MFI of 170 versus 183), which rules out the possibility
that the cells express different amounts of phosphorylatable
Erk. Note that the histograms shown in Fig. 4B were obtained
from cells that had not been activated in vitro; thus, the ex-
FIG. 3. Enhanced expression of CD5 and CD69 on SIT/ DP
thymocytes. Ungated (total) or CD4 CD8-gated (DP) thymocytes
were assessed for surface expression of CD5 and CD69. The histo-
grams represent profiles of cells from a representative SIT/ (shaded)
and SIT/ (thick lines) mouse. All data are representative of a min-
imum of 10 individual experiments.
VOL. 25, 2005 SIT NEGATIVELY REGULATES TCR-MEDIATED SIGNALS 7561
pression levels of phospho-ERK indeed reflect the in vivo
situation within the thymus. Since the H-Y TCR is known to
signal rather inefficiently (36), it is therefore not surprising that
the mean peaks of fluorescence (as a sign of Erk phosphory-
lation) are not very high. Nevertheless, both the more mature
phenotype of SP cells and the enhanced activation of ERK on
DP thymocytes strongly suggest that loss of SIT enhances the
efficiency of positive selection in female H-Y TCR tg mice.
This assumption is even further supported by the finding
that the proportions of non-TCR tg T cells are strongly de-
creased in SIT-deficient mice (Fig. 4C). The non-TCR tg pool
in the H-Y mice is composed of CD4 cells in which the trans-
genic TCR- chain is paired with an endogenous (non-tg)
TCR- chain (Fig. 4C). This pairing occurs in the H-Y tg mice
because the transgenic TCR has only a weak affinity for the
selecting ligands, and therefore, it transduces a weak signal
that is not sufficient to properly suppress the rearrangement of
the Tcra locus (20). The enhanced ratio of tg (CD8 H-Y) to
non-tg (CD4 H-Y) T cells in SIT/ mice therefore indicates
that in the absence of SIT, the H-Y TCR signals stronger,
resulting in a more efficient suppression of the rearrangement
of the endogenous TCR- chain.
Besides the above-described signs of enhanced positive se-
lection, we also observed a significant reduction in the total
number of H-Y–TCR tg DP thymocytes in SIT-deficient mice
(Fig. 5A). This finding could indicate that the loss of SIT not
only enhances the efficiency of positive selection but even par-
tially converts positive selection to negative selection. Impor-
tantly, similar data as shown in Fig. 5A for the H-Y TCR tg
model were found in a second TCR tg model, P14 (Fig. 5B).
However, in the P14 TCR tg system, loss of SIT resulted in an
even more dramatic reduction of thymic cellularity. This could
suggest that in this system, the conversion from positive to
negative selection caused by loss of SIT is even stronger than
in the H-Y TCR tg model. In any case, both TCR tg models
demonstrate that the loss of SIT alters thymic selection pro-
cesses, likely by enhancing positive selection and also by par-
tially converting positive selection to negative selection. In
FIG. 4. Enhanced positive selection in the absence of SIT. (A) Thymocytes from H-Y female mice were stained with CD4 and CD8 and
assessed for the expression of CD5 and HSA on gated DP and CD8 SP cells. The histograms represent overlaid profiles of cells from a
representative SIT/ (shaded) and SIT/ (thick lines) mouse. (B) Enhanced ERK1/2 activation in SIT/ H-Y thymocytes. Single-cell
suspensions from thymi were immediately fixed and stained for CD4, CD8, and phospho-ERK1/2. Numbers indicate MFI from one representative
experiment out of four. Dotted lines indicate the levels of staining with the secondary antibody alone. (C) Representative dot plots of the
expression of the clonotypic transgenic TCR chain (T3.70) and transgenic TCR (F23.1) (upper panels) or CD4 and CD8 (lower panels) in lymph
node cells. Numbers indicate the percentages of cells in each subset.
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contrast to the H-Y and the P14 system, SIT deficiency did not
alter the outcome of selection processes in a class I-restricted
TCR tg model with higher affinity (OT-I) and class II-re-
stricted TCR tg models (OT-II) (data not shown).
Normal negative selection in the absence of SIT. We also
investigated whether SIT deficiency would directly influence
negative selection. To assess this question in vivo, we took
further advantage of the H-Y TCR transgenic model (27). In
male H-Y TCR transgenic mice, the CD4 CD8 DP thymo-
cytes are efficiently depleted by negative selection, and there-
fore, mature CD8 SP cells are barely detectable. However,
some CD8 SP thymocytes downregulate the CD8 coreceptor
and escape negative selection, thus permitting a small popula-
tion of thymocytes to colonize the periphery. Figure 6A dem-
onstrates that loss of SIT does not alter the cellular composi-
tion of the thymus in male H-Y TCR tg mice. Similarly, no
differences were observed in the periphery of SIT-deficient
H-Y TCR tg male mice (data not shown). These data strongly
suggest that negative selection proceeds normally in the ab-
sence of SIT.
However, since the deletion process in the H-Y male model
occurs at a very high efficiency and only extremely low numbers
of DP cells are detectable in the mice, it is difficult to unmask
augmented negative selection in this system. To circumvent
this problem, we mimicked negative selection in vitro by stim-
ulating freshly isolated thymocytes with CD3 and CD3 plus
CD28 monoclonal antibodies (MAbs) or with the polyclonal
mitogen ConA. Figure 6B shows that the survival rates of the
in vitro-activated thymocytes were comparable between wild-
type and SIT/ mice. Thus, SIT seems to be dispensable for
negative selection within the thymus as well as for in vitro
deletion of immature T lymphocytes.
Alterations of the peripheral T-cell pools in SIT/mice. To
obtain further insight into the consequences of SIT deficiency,
we examined the cellular composition of the peripheral lym-
phoid system. These experiments revealed normal sizes, archi-
tectures, and cellularities of spleen, Peyer’s patches, and bone
marrow (data not shown). Moreover, the numbers of B
(B220), T (TCR), CD4, CD8, and NK (NK1.1) cells
were also unaffected in the absence of SIT (Fig. 2F and data
not shown). In marked contrast, both superficial and mesen-
teric lymph nodes of SIT/ mice show an approximate 50%
decrease in total cellularity (Table 1). Anatomical analysis of
these lymph nodes did not show alterations in global architec-
ture. However, a significant reduction in the number of
FIG. 5. The absence of SIT partially converts positive selection to
negative selection. Flow cytometric analysis of positive selection in
thymus is shown. Thymocytes from H-Y (A) and P14 (B) TCR SIT/
or SIT/ transgenic mice were analyzed for transgenic TCR expres-
sion by staining with T3.70, a clonotypic antibody specific for H-Y
TCR chain, or V2, the P14 TCR chain. The dot plots show CD4
and CD8 profiles of cells gated on TCRhigh. Numbers indicate per-
centages of cells in each subset. One representative animal for each
group is shown. The graphs show the mean cellularity of TCR trans-
genic thymocyte subsets from seven SIT/ and seven SIT/ H-Y tg
mice and three SIT/ and three SIT/ P14 tg mice.
FIG. 6. SIT is dispensable for negative selection. (A) Flow cyto-
metric analysis of CD4/CD8 profiles of the T3.70 population in H-Y
TCR transgenic male mice. (B) DP thymocyte deletion in response to
TCR cross-linking. Thymocytes were cultured in 24-well plates coated
with anti-CD3 or anti-CD3 plus anti-CD28 or in the presence of ConA
for 24 h, and their viability was determined. One of two independent
experiments is shown, each using three pairs of mice. Black and open
bars represent wild-type and knockout mice, respectively.
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TCR lymphocytes in both the CD4 and CD8 subpopula-
tions (Table 1 and Fig. 2B) was found by flow cytometry,
whereas the numbers of B and NK cells as well as the expres-
sion levels of CD24, CD25, CD44, CD45RB, CD62L, and
CD69 cells (Table 1, Fig. 2B, and data not shown) were all
normal. Thus, the decrease in total cellularity of lymph nodes
is due to a selective reduction in conventional TCR T
lymphocytes.
Further analysis of the secondary lymphatic organs revealed
an increase in both the distribution and the absolute numbers
of 
TCR lymphocytes in SIT-deficient lymph nodes, spleen,
Peyer’s patches, blood, and bone marrow (Table 1, Fig. 2B, and
data not shown). Moreover, the SIT/ 
 T-cell subset con-
tains a higher proportion of CD44low, CD45RBhi, and
CD62Lhi cells which correspond with a naive phenotype (25,
44) (Fig. 7A). 
 T cells develop very early in the thymus
during embryonal life through a unique developmental path-
way (3, 17). The first two waves of 
 T cells lack junctional
diversity and migrate to the skin and to mucosal tissue. At the
end of the fetal life, a third wave of 
 cells is produced. After
exiting the thymus, these cells populate the spleen and the
lymph nodes of adult mice. To assess whether SIT deficiency
alters 
 T-cell development, we analyzed thymocyte suspen-
sions from newborn and adult mice by flow cytometry. These
experiments revealed no alteration of the numbers of CD3

TCR cells within the thymus of SIT-deficient mice (Fig.
7B). Similarly, the distribution of intraepithelial gut lympho-
cytes, which are also mostly 
 T cells, was found to be unaf-
fected in SIT-deficient mice (not shown). Collectively, these
data suggest that SIT regulates the expansion of peripheral

T cells rather than being involved in the homing of these
cells to the gut or in their thymic development.
SIT negatively regulates peripheral T-cell responses. The
altered distribution of peripheral T-cell subpopulations in SIT-
deficient mice prompted us to investigate whether T cells func-
tion normally in the absence of SIT. To this end, we analyzed
proliferation of purified splenic T cells that were stimulated
with different concentrations of plate-bound anti-CD3 MAb by
means of [3H]thymidine incorporation. As shown in Fig. 8A,
compared to wild-type littermates, T cells of SIT/ mice ex-
hibit a 50% enhancement in proliferation upon CD3 stimu-
lation that is most evident at intermediate antibody concentra-
tions. Similarly, SIT-deficient T cells produce strikingly higher
amounts of gamma interferon, interleukin-2, and tumor necro-
sis factor alpha after CD3 stimulation (Fig. 8B), strongly sug-
gesting that SIT deficiency skews the peripheral T-cell reper-
toire towards the TH1 (T-helper 1) lineage.
To assess whether the altered peripheral T-cell function of
SIT-deficient mice primes the organism for the development of
autoimmune diseases, we investigated the clinical course of
EAE in wild-type and SIT/ mice. EAE is a T-cell-mediated
autoimmune disease of the central nervous system that is char-
acterized by inflammation, demyelination, and relapsing/remit-
ting courses of paralysis (30). It represents a well-established
animal model for multiple sclerosis and is believed to primarily
be a TH1-mediated disease. As shown in Fig. 8C, analysis of
the clinical EAE score following immunization with MOG
shows a more severe disease in SIT/ mice than in control
animals. Thus, the absence of SIT not only affects selection
processes within the thymus and peripheral T-cell functions
but also aggravates the susceptibility of the organism to de-
velop autoimmune diseases. Surprisingly, however, even a de-
tailed biochemical analysis of most important membrane-prox-
imal signaling events of SIT-deficient T cells (e.g., global
FIG. 7. 
 T-cell populations in SIT/ mice. (A) Proportion of CD3 
 TCR lymph node cells expressing CD44, CD45RB, and CD62L.
Ten mice for each genotype were included in the groups. ***, P  0.0003; **, P  0.0038; *, P  0.0352. (B) 
 T-cell distribution in thymi from
adult or newborn mice. Black bars and open boxes represent wt and SIT-deficient mice, respectively.
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tyrosine phosphorylation; TCR-mediated Ca2 flux; LAT
phosphorylation; activation of ERK, June N-terminal protein
kinase, and p38; IB degradation, etc.) did not reveal any
significant changes compared to wt littermates (data not
shown). Thus, the mechanisms by which SIT controls T-cell
function remain elusive, although the biochemical analysis of
TCR-mediated signals within the thymic compartment sug-
gests that SIT primarily regulates TCR-mediated activation of
Erk.
DISCUSSION
In this study, we report the characterization of mice lacking
the transmembrane adapter molecule SIT. Our findings sup-
port our previous hypothesis that SIT primarily acts as a neg-
ative regulator of TCR-mediated signaling (29, 35). Because
SIT is most highly expressed in thymocytes, we initially inves-
tigated the function of SIT during thymic selection processes.
Non-TCR transgenic SIT-deficient thymocytes showed higher
levels of CD5 and CD69 than wild-type animals. Upregulation
of these two activation markers has been proposed to reflect
the activation status of the cells within the thymus, and the
expression levels of CD5 on thymocytes have been shown to
directly correlate with the strength of TCR-mediated signals
(6, 32, 38). Therefore, the enhanced expression of CD5 on
SIT-deficient thymocytes suggests that not only in Jurkat T
cells (29, 35) but also in vivo, SIT primarily acts as a negative
regulator of T-cell activation. Furthermore, it indicates that
one physiologic function of SIT is to finely tune signals that
emanate from the TCR during thymic development. Clearly,
the possibility that SIT directly regulates the expression levels
of CD5 or CD69 cannot be completely ruled out. However, the
observation that the expression levels of CD5 and CD69 are
normal in SIT-deficient OT-I and OT-II TCR transgenic mice
(data not shown) makes this possibility unlikely.
The enhanced expression of CD5 and CD69 (together with
the slightly increased thymic cellularity) in non-TCR tg mice
initially suggested that loss of SIT enhances TCR-mediated
FIG. 8. Altered peripheral T-cell function in SIT/ mice. (A) Enhanced T-cell proliferation. Purified splenic T cells were stimulated in 96-well
plates coated with anti-CD3 antibody or PMA and ionomycin (PI), pulsed with [3H]thymidine, and processed for standard scintillation counting.
Results from seven wild-type and nine knock-out mice are shown as mean counts per minute (cpm). One of two independent experiments is shown.
*, P  0.01; **, P  0.007. (B) Augmented cytokine production by anti-CD3-stimulated SIT/ T cells. T cells were purified and stimulated with
0.3 g/ml anti-CD3 or PMA and ionomycin (PI). Results from 8 wild-type and 10 knockout mice are shown. IL-2, interleukin-2; IFN-, gamma
interferon; TNF-, tumor necrosis factor alpha. *, P  0.02; **, P  0.005. (C) Increased incidence of EAE in the absence of SIT. Mice were
examined daily for signs of disease and graded on a scale of increasing severity from 0 to 5 as follows: 0, no signs; 0.5, partial tail weakness; 1, limp
tail or slight slowing of righting from supine position; 1.5, limp tail and slight slowing of righting; 2, partial hind-limb weakness or marked slowing
of righting; 2.5, dragging of hind limb(s) without complete paralysis; 3, complete paralysis of at least one hind limb; 3.5, hind-limb paralysis and
slight weakness of forelimbs; 4, severe forelimb weakness; 5, moribund or dead.
VOL. 25, 2005 SIT NEGATIVELY REGULATES TCR-MEDIATED SIGNALS 7565
signals, thereby leading to subtle alterations of the thymic
selection processes. This hypothesis was confirmed in the low-
affinity H-Y TCR tg model system, where we demonstrated
that in female H-Y TCR tg animals, loss of SIT apparently
enhances the efficiency of positive selection. This hypothesis
was deduced from different observations. First, SIT-deficient
CD8 SPs show enhanced expression of CD5 (as a sign of
enhanced TCR-mediated signaling during the selection pro-
cesses [6]). Second, the positively selected CD8 SP cells in the
female mice are more mature than their SIT-expressing coun-
terparts (as assessed by lower levels of HSA expression). Third,
ex vivo-isolated thymocytes show enhanced constitutive phos-
phorylation of the dual-specificity kinase ERK, whose activity
has been reported to directly correlate with the efficiency of
positive selection (1, 36, 40). Fourth, loss of SIT induces a
more efficient silencing of the TCR locus that results in a
decrease of non-TCR tg CD4 SP T-cells (20). Thus, the H-Y
data are compatible with the hypothesis that loss of SIT en-
hances TCR-mediated signals and thereby facilitates positive
selection. It is interesting that similar effects on positive selec-
tion as shown here for SIT have previously been observed in
mice lacking expression of CD5 (in the H-Y and the P14 TCR
tg models [5, 42]). Thus, it appears as if negative regulators
such as SIT and CD5 serve to set the signaling thresholds for
positive selection during thymic development.
In addition to enhanced positive selection, we found a de-
crease in DP cells in female H-Y TCR tg mice. This could
suggest that in the H-Y system (and even more pronounced in
the P14 system), loss of SIT not only enhances positive selec-
tion but even partially converts positive selection to negative
selection. Although further experiments are required to prove
this hypothesis, the idea that loss of SIT partially converts
positive selection to negative selection is strongly supported by
recent data that we obtained in our laboratory using female
H-Y TCR tg SIT/TRIM double-knockout mice. TRIM is a
second non-lipid-raft transmembrane adapter protein with un-
known function that carries similar tyrosine-based signaling
motifs in its cytoplasmic domain as SIT (10).
Importantly, the thymi of the female H-Y TCR tg TRIM/
SIT double-knockout mice are almost indistinguishable from
the thymi of wild-type male H-Y TCR tg animals, in which
almost all DP thymocytes are eliminated by negative selection
(due to expression of the endogenous male autoantigen). Thus,
in the female H-Y TCR tg mice, concomitant loss of both
TRIM and SIT completely converts positive selection to neg-
ative selection (L. Simeoni et al., unpublished data). The fact
that this conversion is only incomplete in SIT-single-deficient
mice (note that loss of TRIM by itself has a null effect on
thymic development in either male or female H-Y TCR tg
mice [Simeoni et al., unpublished]) suggests that the loss of
SIT is partially compensated for by other transmembrane
adapter proteins, TRIM being one potential candidate (see
below).
It is also possible that SIT may regulate thymocyte survival.
However, two observations argue against this hypothesis. First,
the thymic cellularity in the OT-I and OT-II transgenic systems
is normal. Second, we did not observed any differences in the
survival rate of thymocytes after treatment with various apo-
ptotic stimuli (e.g., dexamethasone, etoposide, and anti-Fas).
Compensatory mechanisms might also explain why SIT de-
ficiency does not enhance positive selection (or convert posi-
tive selection to negative selection) in the OT-I and OT-II
TCR transgenic models. Alternatively, it simply might suggest
that the fine-tuning function of SIT becomes negligible beyond
a certain strength of the TCR-mediated input signal. In line
with a gatekeeper function of SIT only in low-strength signal-
ing systems might be the finding that the loss of SIT apparently
does not influence negative selection processes in any model
that we investigated (i.e., the strong TCR-mediated signals that
induce negative selection apparently can no longer be influ-
enced by SIT).
Besides regulating thymic development, SIT seems to par-
tially control the size of the peripheral T-cell pool. Thus, the
loss of SIT leads to an expansion of 
 T cells in peripheral
lymphoid organs without enhancing the production of 
 T
cells within the thymus or impairing their homing to the gut. In
addition, SIT-deficient mice show diminished numbers of  T
cells, selectively in lymph nodes. The latter finding could be
due either to a reduced production of  T cells within the
thymus or to a defect in peripheral T-cell homeostasis or to
both. The mild reduction in the numbers of SP thymocytes in
nontransgenic SIT/ mice could in fact be partially responsi-
ble for the reduced numbers of mature peripheral T cells.
However, it is also known that similarly to immature thymo-
cytes, naive T cells require continuous contact with self-pep-
tide/MHC molecules (low-affinity signals) to prevent death by
neglect (15, 39). Thus, low-affinity ligands dictate positive se-
lection in immature thymocytes and survival in naive periph-
eral T cells. Loss of a negative regulatory molecule such as SIT
could enhance the strength of TCR-mediated signaling in the
presence of low-affinity peptides, thereby altering the survival/
death rate of peripheral T cells.
Independently of the mechanism that underlies altered ho-
meostasis of the peripheral T-cell pool, the absence of SIT
results in hyperreactivity of peripheral T cells towards TCR-
mediated stimuli, with the consequence of enhanced produc-
tion of the TH1 cytokines tumor necrosis factor alpha and
gamma interferon in vitro. In line with this, loss of SIT signif-
icantly enhances the clinical course of EAE, a TH1-mediated
autoimmune disease of the central nervous system.
How SIT regulates peripheral T-cell functions and how it
balances TH1 versus TH2 T-helper cells in the periphery is not
known at present. Indeed, despite considerable effort, we could
not reveal significant alterations of membrane-proximal signal-
ing events in SIT-deficient peripheral T cells. One possibility to
explain the hyperreactivity of peripheral T cells was based on
our previous observation that in Jurkat T cells, SIT exerts its
negative regulatory function via the tyrosine-based signaling
motif YASV (29, 35). Moreover, in the Jurkat system, it was
shown that upon pervanadate stimulation, the tyrosine kinase
Csk, the major negative regulator of Src protein tyrosine ki-
nases, is capable of binding to this motif. Therefore, Csk rep-
resented an attractive candidate for mediating the inhibitory
function of SIT on TCR signaling. However, so far, we could
not show an association between SIT and Csk in human or
mouse T cells under more physiological conditions of stimula-
tion (e.g., CD3 MAb instead of pervanadate [data not shown]).
Similarly, we did not observe an upregulation of the enzymatic
activity of Lck, a crucial substrate of Csk in peripheral T cells
of SIT/ mice. Furthermore, CD3-mediated phosphorylation
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of the TCR- chain is not impaired in SIT-deficient thymo-
cytes. Collectively, these data suggest that SIT is not involved
in the inhibition of Src kinases (either directly or indirectly by
recruiting Csk).
Another possibility to explain the negative regulatory role of
SIT was based on our previous observation that SIT is capable
of recruiting cytosolic protein tyrosine phosphatases (e.g.,
SHP2) to the plasma membrane (29). However, extensive bio-
chemical analysis of SIT-deficient T cells did not reveal alter-
ation of TCR-mediated membrane targeting of SHP1 or SHP2
(data not shown). This largely rules out the possibility that
impaired membrane targeting of SHP1 or SHP2 underlies the
enhanced signaling capacity of SIT/ T cells. Nevertheless,
the fact that SIT-deficient T cells react normally after stimu-
lation with PMA and ionomycin suggests (and confirms our
previous data) that SIT exerts its negative regulatory role up-
stream of activation of protein kinase C and production of IP3.
Although the molecular mechanism(s) underlying SIT-me-
diated inhibition of signaling is still unknown, it appears as if
SIT would negatively regulate TCR-mediated activation of
ERK in thymocytes. Indeed, ex vivo-isolated H-Y transgenic
SIT-deficient thymocytes show enhanced phosphorylation of
ERK1/2, and SIT/ DP thymocytes display higher expression
levels of CD5 and CD69, both molecules whose expression is
regulated via the ERK-dependent transcription factors Ets-1
(14, 45) and AP-1 (11, 24). In light of these observations, it is
important that we have previously demonstrated that SIT can
bind the cytosolic adapter protein Grb2, an upstream activator
of Erk, via a membrane-proximal YGNL motif. However,
when overexpressed in Jurkat T cells, a CD8/CD8/SIT chimera
(extracellular domain/transmembrane domain/intracellular
domain) that carries an isolated YGNL motif does not inhibit
T-cell functions (35). Rather, when this chimera is co-cross-
linked with the TCR, it strongly upregulates TCR-mediated
activation of the transcription factor NFAT. This suggests a
positive rather than a negative regulatory role of the YGNL
motif. However, further experiments are required to assess the
role of the YGNL motif for SIT-mediated T-cell function.
Another possibility to explain enhanced TCR-mediated sig-
naling in the absence of SIT would be to assume that SIT
exerts its negative regulatory role in normal cells through se-
questration of key signaling molecules from the lipid raft to the
nonraft fraction, thereby limiting the numbers of signaling
molecules in the lipid rafts. Loss of SIT within the nonraft
fraction could then result in a redistribution of these signaling
molecules to the lipid rafts. This would then permit enhanced
signaling. A redistribution of molecules from nonrafts to rafts
has most recently been proposed to cause the augmented
FcεRIII-mediated signaling in NTAL/LAB-deficient mast cells
(46, 51).
However, another recent report suggested that when present
in the nonraft fraction of chicken DT-40 cells, Grb2 inhibits
B-cell receptor (BCR)-mediated signals via an unknown mech-
anism (38a). Targeting of Grb2 to the lipid rafts (e.g., by
ectopic expression of the lipid raft-associated transmembrane
adapter NTAL) rescues the BCR from the Grb2-mediated
inhibitory signal, thus facilitating BCR-mediated responses. If
this model would also apply for T cells, then it would be
reasonable to assume that SIT inhibits TCR-mediated signal-
ing by enhancing the inhibitory pool Grb2 in the nonraft frac-
tion. The fact that we did not observe major alterations of
biochemical signaling events following CD3 stimulation of
SIT-deficient peripheral T cells does not necessarily contradict
this hypothesis, simply because the subtle changes that are
induced by loss of SIT might be too weak to be detected by
standard biochemical techniques. In addition, loss of SIT
might be to a large extent compensated by other non-raft-
associated transmembrane adapter proteins exerting similar
functions, such as TRIM and LAX.
Although the molecular mechanism(s) underlying SIT func-
tion is still elusive, it is obvious that SIT controls signaling
pathways at different levels within the immune system. First,
SIT-mediated signals are required to maintain a proper T-cell
repertoire; second, they are mandatory to maintain the com-
position of the peripheral T-cell pools; third, they regulate the
activation thresholds of peripheral T cells; and fourth, they
control cytokine production/expansion of particular peripheral
T-cell populations. In all cases, SIT seems to act as a fine tuner
of TCR-mediated signaling processes.
The only mild alterations of thymic selection processes as
well as the rather moderate hyperreactivity of peripheral T
cells in SIT-deficient mice might be due to a functional redun-
dancy among those transmembrane adapter proteins that serve
as negative regulators during TCR-mediated signaling. In this
regard, other nonraft transmembrane adapter proteins, for
example, TRIM and LAX, might compensate for the loss of
SIT. TRIM shares not only structural properties with SIT
(both molecules are disulfide-linked homodimers) but also two
tyrosine-based signaling motifs (YGNL and YASV, which is
YASL in TRIM) (18). Similarly, LAX is also capable of bind-
ing, e.g., Grb2, and has been reported to negatively regulate
TCR-mediated signals via an unknown mechanism (50).
Therefore, the analysis of the SIT/LAX or SIT/TRIM double
knockout or the SIT/LAX/TRIM triple knockout will possibly
help to elucidate the biochemical pathways that are controlled
by these transmembrane adapter proteins. Nevertheless, it is
tempting to speculate that SIT as well as other transmembrane
adapter proteins play important roles in priming the organism
for the development of autoimmune diseases either by regu-
lating peripheral tolerance or by altering the generation of an
appropriate T-cell repertoire. In this regard, it will be impor-
tant to assess the genetic status and the phosphorylation status
of SIT and other negative regulatory transmembrane adapter
proteins in patients suffering from autoimmune disease.
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SKAP-HOM is a cytosolic adaptor protein representing a specific substrate for the Src family protein
tyrosine kinase Fyn. Previously, several groups have provided experimental evidence that SKAP-HOM (most
likely in cooperation with the cytosolic adaptor protein ADAP) is involved in regulating leukocyte adhesion. To
further assess the physiological role of SKAP-HOM, we investigated the immune system of SKAP-HOM-
deficient mice. Our data show that T-cell responses towards a variety of stimuli are unaffected in the absence
of SKAP-HOM. Similarly, B-cell receptor (BCR)-mediated total tyrosine phosphorylation and phosphorylation
of Erk, p38, and JNK, as well as immunoreceptor-mediated Ca2 responses, are normal in SKAP-HOM/
animals. However, despite apparently normal membrane-proximal signaling events, BCR-mediated prolifer-
ation is strongly attenuated in the absence of SKAP-HOM/. In addition, adhesion of activated B cells to
fibronectin (a ligand for 1 integrins) as well as to ICAM-1 (a ligand for 2 integrins) is strongly reduced. In
vivo, the loss of SKAP-HOM results in a less severe clinical course of experimental autoimmune encephalo-
myelitis following immunization of mice with the encephalitogenic peptide of MOG (myelin oligodendrocyte
glycoprotein). This is accompanied by strongly reduced serum levels of MOG-specific antibodies and lower
MOG-specific T-cell responses. In summary, our data suggest that SKAP-HOM is required for proper
activation of the immune system, likely by regulating the cross-talk between immunoreceptors and integrins.
Adaptor proteins are multifunctional signaling molecules
which are capable of coupling engaged immunoreceptors (e.g.,
the T-cell receptor [TCR] or the B-cell receptor [BCR]) to
intracellular signaling pathways and effector systems. In gen-
eral, adaptor proteins do not exert enzymatic or transcriptional
activities. Rather, they contain a variety of modular domains
that mediate constitutive or inducible protein-protein or pro-
tein-lipid interactions after engagement of signal-transducing
receptors.
Several cytosolic adaptor proteins have been identified dur-
ing the last years which appear to be involved in reorganization
of the cytoskeleton and/or integrin-mediated adhesion after
external engagement of immunoreceptors. In T cells, these
include the cytosolic adaptor proteins ADAP (adhesion and
degranulation promoting adaptor protein) (27) and SKAP55
(Src-kinase-associated phosphoprotein of 55 kDa) (31).
ADAP was among the first adaptor proteins shown to trans-
late TCR stimulation to avidity modulation of 1 and 2 in-
tegrins (a mechanism called inside-out signaling). Thus, de-
spite almost normal proximal signaling events (global tyrosine
phosphorylation, TCR-mediated increases in intracellular cal-
cium, Erk activation, actin polymerization, and TCR cluster-
ing), TCR-mediated clustering of integrins and the adhesion of
T cells to the 1 and 2 integrin ligands fibronectin and
ICAM-1 were found to be strongly impaired in ADAP-defi-
cient T cells. The failure to activate integrins via inside-out
signaling leads to a defect in TCR-mediated proliferation, in-
terleukin-2 (IL-2) production, and a strongly impaired T-cell
response in vivo (9, 27).
While ADAP is expressed in T cells and myeloid cells,
SKAP55 is expressed exclusively in T lymphocytes (5, 20).
SKAP55 comprises a pleckstrin homology domain, a C-termi-
nal SH3 domain, and an interdomain that carries three ty-
rosine-based signaling motifs (21). Overexpression experi-
ments in Jurkat T cells suggested that SKAP55 interacts with
the protein tyrosine phosphatase CD45 and possibly regulates
the mitogen-activated protein kinase pathway (32, 33). More
recently it was demonstrated that SKAP55 is capable of regu-
lating integrin-mediated adhesion, conjugate formation be-
tween T cells, and antigen-presenting cell (APC)- and TCR-
mediated clustering of LFA-1 in mouse T cells (15, 31). Thus,
the functional effects of SKAP55 and ADAP seem to be sim-
ilar.
In line with this assumption is the observation that in pri-
mary T cells and in the Jurkat T-cell line, SKAP55 tightly
associates with ADAP. This interaction involves the SH3 do-
main of SKAP55 and a proline-rich segment in ADAP (17, 21).
Biochemical analysis had further suggested that all SKAP55
molecules expressed in T lymphocytes associate with ADAP.
All these data indicate that in T lymphocytes, SKAP55 and
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ADAP form a functional unit and that a role of this unit is to
modulate T-cell adhesion after engagement of the TCR/CD3
complex. However, it is still unknown whether regulation of
adhesion is the only task that is fulfilled by SKAP55 and ADAP
during an ongoing immune response.
In contrast to SKAP55, the cytosolic adaptor SKAP-HOM
(SKAP55 homologue) or SKAP55R (SKAP55 related) is an
adaptor protein that is more widely expressed within the he-
matopoetic system (4, 16, 23). SKAP-HOM comprises an al-
most identical structure as SKAP55, except for a unique N-
terminal putative coiled-coil region and only two tyrosine-
based signaling motifs in the interdomain. Similar to SKAP55,
SKAP-HOM has been reported to associate with ADAP via its
SH3 domain and to represent a specific substrate for the Src
family protein tyrosine kinase p59Fyn (17, 23).
An involvement of SKAP-HOM in integrin-mediated signal-
ing was initially suggested by the analysis of murine bone
marrow-derived macrophages (BMM) in which tyrosine phos-
phorylation of SKAP-HOM (and of ADAP) was induced after
adhesion to fibronectin (1, 30). Moreover, in BMM from mice
homozygous for the “motheaten” (me) mutation (these me/me
mice lack expression of the cytosolic tyrosine phosphatase
SHP-1), ADAP and SKAP-HOM were found to be expressed
as constitutively tyrosine phosphorylated proteins, and this
augmented phosphorylation correlates well with the known
hyperadhesiveness of me/me macrophages (28, 30). Finally,
enteropathogenic species of Yersinia enterocolitica exert resis-
tance to phagocytosis by injecting the virulence factor YopH, a
protein tyrosine phosphatase, into host cells. In these cells
YopH apparently dephosphorylates ADAP and SKAP-HOM.
Either by itself or in concert with other mechanisms, this leads
to abrogation of the phagocytic process and causes cellular
detachment and rounding up (1, 6). Thus, not only ADAP and
SKAP55 but also SKAP-HOM seem to be involved in integrin-
mediated signaling pathways. However, the function of SKAP-
HOM within the immune system remains elusive.
To gain further insight into the physiologic role of SKAP-
HOM, we investigated the immune system of SKAP-HOM-
deficient mice. T-cell, platelet, and macrophage functions ap-
pear to be unaffected by loss of SKAP-HOM. In marked
contrast, despite apparently normal membrane-proximal sig-
naling events, both in vitro and in vivo B-cell responses are
impaired in the absence of SKAP-HOM. Indeed, after anti-
body-mediated stimulation of the BCR, SKAP-HOM-deficient
B cells show reduced in vitro proliferation and an impaired
capability to adhere to either fibronectin or ICAM, two phys-
iologic ligands for 1 and 2 integrins. Moreover, when chal-
lenged in vivo, SKAP-HOM-deficient mice display a decrease
in clinical severity of experimental autoimmune encephalomy-
elitis (EAE) and a strongly reduced production of MOG (my-
elin oligodendrocyte glycoprotein)-specific immunoglobulins.
Taken together, our findings indicate an important role for
SKAP-HOM in regulating homeostasis of the immune system.
Moreover, they suggest that SKAP-HOM might be an attrac-
tive target for therapeutic intervention in autoimmune diseases
such as multiple sclerosis.
MATERIALS AND METHODS
Mice strains. The SKAP-HOM-deficient mouse was generated by retrovirus-
based gene trap technology (Lexicon Genetics Inc.) (34). Mice were backcrossed
to C57BL/6JBom (Taconics) for a minimum of six generations. In all experi-
ments, 8- to 12-week-old littermate mice were used. All procedures were con-
ducted according to protocols approved by the local authorities. Mice were
genotyped by two independent PCRs using the following primer sequences:
neomycin sense, 5GAT GCC GCC GTG TTC C; neomycin antisense, 5GCC
CCT GAT GCT CTT CGT C; SKAP-HOM sense, 5CCT GCG GCC TTT GAT
GGT G; SKAP-HOM antisense, 5ACT GCT TTG CTG GGG GTG GTG TT.
Determination of hematological parameters. To measure blood cell parame-
ters, whole blood was collected by heart puncture in tubes containing heparin
and analyzed on an automatic hematology counter (Cell-Dyn 1600; Abbott).
Cell preparations. The spleens were passed through a fine mesh filter to obtain
a single cell suspension. In all assays, total splenocytes were isolated, and B and
T cells were purified by negative selection using mouse B-cell isolation kits or
mouse T-cell isolation kits and AutoMACS (Miltenyi Biotec), respectively. CD4-
and CD8-positive splenocytes were prepared by positive selection using anti-CD4
or anti-CD8 microbead-coupled antibody and AutoMACS. Purity was 90% as
checked by flow cytometry. The cells were cultured in RPMI 1640 medium
supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100 g/ml strep-
tomycin (all from Biochrom AG), and 50 M 2-mercaptoethanol.
Adhesion assay. For fibronectin binding, the central area of a 35-mm diameter
tissue culture dish (Falcon) was coated with 50 l fibronectin (100 g/ml; Roche
Diagnostics) for 90 min at room temperature. For ICAM-1 binding, tissue cul-
ture dishes were precoated for 16 h at 4°C with goat anti-human immunoglobulin
G (IgG) Fc fragment (7.2 g/ml; Dianova) to allow directional coating. After
washing, dishes were coated with 12.5 g/ml recombinant murine ICAM-1 hu-
man Fc chimera (R&D Systems) for 90 min at room temperature. After coating,
dishes were washed three times with phosphate-buffered saline (PBS) (without
Ca2 or Mg2) and blocked with 1% bovine serum albumin (BSA) in PBS for an
additional 2 h.
Cells (5  106) were washed with Hanks balanced salt solution (HBSS) and
either left unstimulated or stimulated with tetradecanoyl phorbol acetate (50
ng/ml), MnCl2 (2 mM), or anti-mouse IgM F(ab)2 (2 g/ml) for 30 min at 37°C.
Cells were plated on the dishes and incubated at 37°C for 30 min. Nonadherent
cells were removed by washing the dishes three times with HBSS. Cell adhesion
was measured by counting six independent fields by microscopy using an ocular
counting reticule. Specific adhesion was expressed as the increase over unstimu-
lated control samples.
Proliferation assay. Freshly isolated mouse cells were resuspended in com-
plete medium and seeded in quadruplicate at 1  105 cells in 96-well round-
bottomed microtiter plates (Costar). Cells were either left unstimulated or stim-
ulated for 72 h at 37°C with the indicated concentrations of affinity-purified goat
anti-mouse IgM or the corresponding F(ab)2 fragment (Jackson ImmunoRe-
search), lipopolysaccharide (LPS; 2.5 g/ml; Sigma), IL-4 (20 ng/ml; Peprotech
Inc.), anti-mouse CD40 (1 g/ml; Pharmingen), phorbol myristate acetate
(PMA) (2  108 M; Sigma), and ionomycin (500 ng/ml; Calbiochem). For the
last 8 h, 0.5 Ci [3H]thymidine was added to the cultures. After harvesting, the
radioactivity incorporated into the DNA was measured by liquid scintillation
counting (1450 MicroBeta Trilux; PerkinElmer Wallac GmbH). The stimulation
index was calculated as the ratio of counts per minute (cpm) of stimulated to
unstimulated proliferation.
Measurement of bone marrow-derived macrophage proliferation in response
to macrophage colony-stimulating factor (M-CSF) and granulocyte-macrophage
colony-stimulating factor (GM-CSF). BMMs from mice of the indicated geno-
types were differentiated ex vivo as previously described (10) with some modifi-
cation. Specifically, bone marrow cells were preplated for 48 h on tissue culture
plates, and cells remaining in suspension were enumerated. Cells (1  106) were
seeded onto 35-mm petri plates. The cells were incubated at 37°C in Dulbecco’s
modified Eagle medium containing 10% heat-inactivated serum supplemented
with either 10 ng/ml M-CSF or 20 ng/ml of GM-CSF (Peprotech). Cells were fed
every 2 days. At the indicated time, cells were rinsed with PBS, harvested in
trypsin-EDTA, and counted using a Z2 Coulter Counter.
FcR and complement receptor-mediated phagocytosis. To opsonize sheep red
blood cells (RBCs) with IgG, RBCs were washed and resuspended in veronal-
buffered saline (Sigma-Aldrich) containing 1:2,500 rabbit anti-RBC serum and
incubated at 37°C for 1.5 to 2 h. To opsonize RBCs with complement, RBCs were
incubated with anti–sheep RBC IgM for 1 h (1:5,000), followed by incubation
with 10% C5-deficient serum (Sigma-Aldrich) for 20 min. Opsonized RBCs were
washed with veronal-buffered saline and resuspended in DMEM at 5  107
RBCs/ml. BMMs (7 to 8 days old) were seeded in 24-well plates (3  105/well)
for 24 h, starved for 2 h, and incubated with 0.4 ml of opsonized RBCs at 37°C
for 20 min. Phagocytosis was terminated by lysing nonphagocytosed RBCs with
H2O for 40 s, and BMMs were fixed in 4% paraformaldehyde. To visualize
internalized RBCs, the cells were permeabilized with 0.5% Triton X-100 for 5
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min, rinsed three times in PBS, pH 7.4, and incubated with rabbit anti-RBC
serum (1:10,000) and rhodamine phalloidin. After washing, the cells were incu-
bated in fluorescein isothiocyanate (FITC)-conjugated anti-rabbit Ig and washed
three times prior to being photographed using a Zeiss microscope. Four-hundred
cells were counted in three randomly chosen fields. The percentage of active cells
(greater than 3 RBCs/cell) and the average number of RBCs per active cell were
determined for each field.
Flow cytometry. The cells were stained with the following antibodies: anti-
CD3, anti-CD5, anti-CD11a, anti-CD18, anti-CD21, anti-CD23, anti-CD29, anti-
CD45R/B220, anti-CD49d, anti-IgM, and anti-IgD (all from Pharmingen). Flow
cytometry was performed on a FACSCalibur using CellquestPro software (Bec-
ton Dickinson).
Western blotting. Western blotting was performed as previously described
(22). For immunodetection, the following primary antibodies were used: anti-
phospho-Tyr (4G10; Upstate Biotechnology), anti-phospho-Erk1/2, anti-Erk1/2,
anti-phospho-JNK, anti-JNK, anti-phospho-p38, anti-p38, anti-phospho-Akt
(Cell Signaling Technology, Inc.), and anti-SKAP55 (BD Biosciences). Goat
polyclonal anti-ADAP sera were previously described (25). Affinity-purified rab-
bit polyclonal anti-SKAP-HOM antiserum was prepared as described elsewhere
(23). Specific binding was detected using peroxidase-conjugated goat anti-mouse
or goat anti-rabbit antibodies by applying the enhanced chemiluminescence
system (Amersham Biosciences) according to the manufacturer’s protocol.
Calcium flux. Purified splenic B cells were resuspended at 1  106 cells/ml in
RPMI 1640 without phenol red, supplemented with 10% fetal calf serum, and
loaded with 3.75 M indo-1 acetoxymethyl ester (Molecular Probes) for 45 min
at 37°C. Cells were washed, resuspended in the same RPMI medium, and
incubated for an additional 30 min at 37°C. After establishing a stable baseline
level, B cells were stimulated with 10 g/ml affinity-purified goat anti-mouse IgM
F(ab)2 fragment (Jackson ImmunoResearch). Equal loading of samples was
checked by treatment of cells with 100 nM ionomycin (Calbiochem). The ratio of
indo-1 violet/blue was analyzed by flow cytometry using LSR (Becton Dickinson).
Data analysis was performed using FloJo software (Tree Star).
Enzyme-linked immunosorbent assays (ELISAs). For the determination of
spontaneous levels of IgM and IgG isotypes, microtiter plates (MaxiSorb; Nunc,
Wiesbaden, Germany) were coated with 3.6 g/ml goat anti-mouse IgG plus IgM
(heavy plus light chains) (Dianova, Hamburg, Germany) at 4°C overnight and
blocked with 1% BSA. Sera were serially diluted in duplicate. Isotype-specific
antibodies were detected with the respective alkaline phosphatase-conjugated
goat anti-mouse antibodies to IgG1, IgG2a, IgG2b, IgG3, or IgM (Southern
Biotechnology Associates, Inc.). The substrate p-nitrophenyl phosphate (Sigma
Aldrich) was used for color development, and after 30 min the absorbance was
read at 405 nm on an ELISA plate reader (Dynatech). Immunoglobulin concen-
trations were calculated by interpolation from a standard curve using the respec-
tive isotype controls from mouse myeloma (Sigma-Aldrich).
For the determination of specific anti-2,4-dinitrophenyl (DNP) and anti-MOG
p35-55, IgG and IgM plates were coated with 3 g/ml DNP-BSA or 10 g/ml
MOG in bicarbonate buffer, respectively, overnight at 37°C. After blocking with
1% BSA, the plates were incubated with serial dilutions of mouse serum over-
night at 4°C. Specific binding was detected using alkaline phosphatase-labeled
goat anti-mouse IgM ( chain specific; Serotec) or goat anti-mouse IgG (sub-
classes 1 plus 2a plus 2b plus 3; Fc	 fragment specific; Dianova).
Immunization of mice. Twelve-week-old mice were immunized intraperitone-
ally (i.p.) with 100 g of 2,4-dinitrophenyl-conjugated keyhole limphet hemocy-
anin (DNP-KLH; Calbiochem) in complete Freund’s adjuvant (CFA; Sigma-
Aldrich, Taufkirchen, Germany) and were boosted 21 days later. Mice were bled
before and after boosting (day 21 and day 28), and hapten-specific serum anti-
body levels were measured by ELISA (see above). Also, mice were immunized
i.p. with 100 g of 2,4,6-trinitrophenyl (TNP)-LPS in saline. Mice were bled
before and 5 and 10 days after immunization, and hapten-specific serum antibody
levels were measured by ELISA.
Induction of EAE and clinical evaluation. MOG p35-55 corresponding to a
mouse sequence (MEVGWYRSPFSRVVHLYRNGK) was synthesized on a
peptide synthesizer by standard 9-fluorenylmethoxycarbonyl chemistry and pu-
rified by high-performance liquid chromatography (HPLC). Active EAE was
induced in 8- to 12-week-old mice by immunization with 200 g MOG p35-55
emulsified in complete Freund’s adjuvant (CFA; Sigma-Aldrich, Taufkirchen,
Germany) containing 800 g of heat-killed Mycobacterium tuberculosis (Difco
Laboratories, Detroit, Mich.). The emulsion was administered subcutaneously as
four 50-l injections into the flanks of each leg. In addition, 200 ng of pertussis
toxin (List Biological Laboratories, Campbell, CA) dissolved in 200 l PBS was
injected i.p. on days 0 and 2. Mice were weighed daily, monitored for clinical
signs of EAE, and graded on a scale of increasing severity from 0 to 5 by blinded
investigators as described earlier (29). Daily clinical scores were calculated as the
average of all individual disease scores of each group, including mice not devel-
oping clinical signs of EAE.
Cytokine concentration. Levels of cytokines in culture supernatants were de-
termined using the mouse inflammatory cytometric bead array kit (Becton Dick-
inson).
Conjugation assay. Splenic B cells obtained from wild-type or knock-out
littermates were cultured at a concentration of 2  106 cells/ml in RPMI 1640
medium supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100 g/ml
streptomycin (all from Biochrom AG), and 50 M 2-mercaptoethanol for 16 h
with (loaded) or without (unloaded) 0.2 mg/ml chicken ovalbumin 323-339 pep-
tide (OVA323-339). Cells were then washed and set to 1 106 cells/ml in the same
medium. T cells enriched by negative selection using a T-cell kit (Miltenyi
Biotec) obtained from OT-II mice were loaded with 5 (and 6-)-carboxfluorescein
diacetate succinimidyl ester (CFSE). After loading, T cells were diluted to 1 
106 cells/ml RPMI 1640 medium supplemented with 10% fetal calf serum, 100
U/ml penicillin, 100 g/ml streptomycin (all from Biochrom AG), and 50 M
2-mercaptoethanol. Peptide-loaded or unloaded B cells (100 l) were mixed with
equal volume of T cells in a 96-well plate. After coincubation for 8 h, cells were
fixed by adding 200 l of 4% paraformaldehyde. After 20 min at 37°C, cells were
carefully transferred into Falcon tubes and measured by a fluorescence-activated
cell sorter. Events with positive CFSE staining and increased forward scatter
were counted as conjugates.
Actin polymerization. Purified splenic B cells (100 l; 2  106 cells/ml in PBS)
were stimulated with 10 g/ml affinity-purified goat anti-mouse IgM F(ab)2
fragment. At the end of the stimulation, 100 l 4% formaldehyde, 0.2% saponin,
and 100 l FITC-phalloidin (5 g/ml) were added. The tubes were vortexed and
kept at room temperature for 15 min. After washing, cells were resuspended in
300 l paraformaldehyde. Actin polymerization was measured by flow cytometry
and expressed as an increase in mean fluorescence intensity.
Statistical analysis. Values are expressed as the means 
 standard errors of
the means (SEM) of at least three independent experiments. One-way analysis of
variance was used to assess the statistical significance of the differences. Proba-
bility (P) values of 0.05 (*) and 0.01 (**) were considered significant.
RESULTS
Expression of SKAP-HOM within the hematopoietic system.
In order to asses the in vivo function of SKAP-HOM, we
generated SKAP-HOM/ mice by a retrovirus-based gene
trap technology (Lexicon Genetics Inc.) (Fig. 1A). SKAP-
HOM deficiency was confirmed by PCR and by anti-SKAP-
HOM Western blotting (Fig. 1B and C). SKAP-HOM/ mice
were born healthy at the expected Mendelian frequency and
did not show any obvious abnormalities. Moreover, the total
numbers of leukocytes or of different leukocyte subsets (lym-
phocytes, monocytes, and granulocytes) were normal in the
peripheral blood of SKAP-HOM-deficient animals (Table 1).
Similarly, the numbers of splenocytes, thymocytes, and lymph
node cells were unaffected in the absence of SKAP-HOM.
Platelet counts were slightly (but not significantly) lower in
SKAP-HOM-deficient mice compared to wild-type animals.
Within the lymphatic organs of wild-type mice, SKAP-HOM
was found to be expressed in T cells, B cells, CD4 T cells,
CD8 T cells, and, to a lesser extent, thymocytes (Fig. 1D).
Unfortunately, we could not analyze the expression pattern of
SKAP-HOM within the T-cell compartment in more detail
(e.g., whether SKAP-HOM is selectively expressed in particu-
lar T-cell subsets), because the polyclonal antiserum we used
for Western blotting was not suitable for flow cytometry or for
microscopy.
Recently it had been demonstrated that loss of ADAP in the
T-cell line Jurkat induces a concomitant loss of its binding
partner SKAP55, likely because SKAP55 is subjected to deg-
radation when not complexed with ADAP (13). Since SKAP-
HOM is also expressed in T-cells and, similar to SKAP55, is
capable of associating with ADAP, we had to formally exclude
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the possibility that loss of SKAP-HOM/ in T and/or B cells
influences the expression levels of either ADAP or SKAP55.
Figure 1E shows that this is not the case. Indeed, T-cells of
SKAP-HOM-deficient mice express normal amounts of both
ADAP and SKAP55. While these data exclude the possibility
that the expression of ADAP or SKAP55 is dependent on
SKAP-HOM, they also indicate that loss of SKAP-HOM
within the T-cell compartment could be compensated for by
the ADAP/SKAP55 complex. In contrast to T cells (and as
reported previously), B lymphocytes express SKAP-HOM but
not ADAP or SKAP55 (5, 20, 23).
Lymphocyte populations of spleen, lymph nodes, and bone
marrow of SKAP-HOM-deficient mice were further analyzed
by flow cytometry with a panel of lineage- and stage-specific
monoclonal antibodies. The number and distribution of T cells
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FIG. 1. Scheme showing the retroviral insertion into the SKAP-HOM locus, the expression pattern of SKAP-HOM in lymphoid organs, and
the loss of SKAP-HOM protein in SKAP-HOM-deficient mice. (A) The VICTR20 retroviral insertion site in the SKAP-HOM locus was
determined by restriction site mapping and comparing the wild-type and retroviral-targeted alleles. PCR products generated by oligonucleotide
primers (a to c; also used for genotyping) positioned as shown were sequenced to identify the precise site of retroviral integration. Only the first
4 out of 12 coding exons are shown. (B) Mice were genotyped by PCR detecting the wild-type SKAP-HOM allele and the recombinant allele
containing the neomycin resistance cassette. (C) Postnuclear lysates of total splenocytes of knock-out, wild-type, and heterozygous animals were
resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by blotting onto nitrocellulose sheets. Immunoblots were probed
with a polyclonal rabbit anti-SKAP-HOM antiserum. (D) Total splenocytes and thymocytes were prepared from wild-type animals. Splenic B cells
and T cells were obtained by negative selection with microbeads. CD4 T cells and CD8 T cells were obtained by positive selection with
microbeads. Postnuclear lysates were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the resulting blots were probed
as for panel C. (E) Loss of SKAP-HOM does not affect expression of ADAP and SKAP55 in the T-cell compartment. Postnuclear lysates of
purified splenic T- and B-cell populations were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by anti-SKAP-
HOM, anti-ADAP, and anti-SKAP55 Western blotting. LTR, long terminal repeat; KO, knockout; WT, wild-type; HT, heterozygous.
TABLE 1. Hematopoietic cellularity in 8- to 12-week-old wild-type
and SKAP-HOM-deficient littermatesa
Hematopoietic cellularity
Mouse
Wild type (n  12) SKAP-HOM
/
(n  10)
Splenocyte number (106) 148 
 15 182 
 30
Thymocyte number (106) 154 
 12 184 
 18
Lymph node cells (106)
(inguinal  axillary)
12 
 2 11 
 2
White blood cells (103 cells/l) 4.4 
 0.5 4.5 
 0.7
Lymphocytes (103 cells/l) 3.6 
 0.4 3.9 
 0.5
Monocytes (103 cells/l) 0.4 
 0.1 0.3 
 0.1
Granulocytes (103 cells/l) 0.4 
 0.1 0.3 
 0.1
Platelets (103 cells/l) 555 
 105 442 
 102
a Note that the differences in platelet counts did not reach statistical signifi-
cance as assessed by one-way analysis of variance.
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in the various immunological organs (thymus, spleen, lymph
nodes, and bone marrow) as well as the CD4/CD8 ratio was
normal in SKAP-HOM/ mice. Also, developmental and
maturation markers of B cells (including marginal zone B cells
and B1 cells) showed no abnormalities in bone marrow, spleen,
lymph nodes, and the peritoneal cavity (Fig. 2 and data not
shown). Thus, although SKAP-HOM is ubiquitously expressed
within the hematopoietic system, its absence is either dispens-
able for normal hematopoietic cell development or can be
compensated for by other molecules.
Impaired B-cell responses in SKAP-HOM/mice. We next
assessed the consequences of SKAP-HOM deficiency in vari-
ous hematopoietic cell populations known to express SKAP-
HOM. These experiments revealed that T-cell proliferation (as
judged by [3H]thymidine incorporation) towards a variety of
different stimuli (anti-TCR, anti-CD3ε, PMA plus ionomy-
cin) was comparable between SKAP-HOM-deficient mice and
control animals (Fig. 3A). Note that the apparent hyperprolif-
eration of PMA-ionomycin-stimulated T cells is due to vari-
ability within the different samples and did not reach signifi-
cance. There was also no difference in the production of tumor
necrosis factor , IL-4, IL-5, gamma interferon, and IL-2 by
stimulated T cells between knock-out and wild-type mice (data
not shown). This strongly suggests that loss of SKAP-HOM
FIG. 2. Normal T- and B-lymphocyte differentiation in SKAP-HOM-deficient mice. (A) Thymic T-cell precursors, splenic T cells, and lymph
node T cells were analyzed by flow cytometry after staining with CD4-FITC and CD8-phycoerythrin. (B) Bone marrow B-cell precursors, splenic
B cells, and lymph node B cells were analyzed after staining with B220-FITC and IgM-phycoerythrin. The percentages of cells within each
lymphocyte population are indicated. BM, bone marrow; LN, lymph node.
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does not alter in vitro T-cell functions, possibly because its loss
is compensated for by the ADAP/SKAP55 complex (see
above).
Similar to T cells, stimulation of SKAP-HOM deficient
platelets with collagen-related peptide (a ligand for the ITAM-
coupled receptor glycoprotein VI [GPVI]) or thrombin (which
activates the G protein-coupled receptors protease-activated
receptors 3 and 4 [PAR3 and PAR4]) exhibited normal aggre-
gation and -granule secretion. Platelet spreading on collagen
and fibrinogen was also normal in SKAP-HOM-deficient mice.
Likewise, tyrosine phosphorylation of LAT, SLP-76, and
PLG	2 after stimulation of GPVI with collagen-related pep-
tide was unaffected (data not shown). These findings suggest
that SKAP-HOM is also dispensable for platelet function.
SKAP-HOM is expressed in macrophages, and previous
overexpression studies had suggested that in myeloid cells it
negatively regulates cytokine-mediated growth (2, 4). To assess
whether loss of SKAP-HOM alters growth of ex vivo-isolated
myeloid cells, we measured M-CSF-induced proliferation of
BMM prepared from wild-type, heterozygous, and SKAP-
HOM-deficient mice. As shown in Fig. 3B, BMMs of SKAP-
HOM/ mice and wild-type mice showed almost identical
growth rates after stimulation with M-CSF and GM-CSF (data
not shown). Thus, SKAP-HOM does not seem to play a major
role in regulating cytokine-mediated growth of BMMs. More-
over, analysis of SKAP-HOM-deficient BMMs did not reveal
significant differences in Fc- or complement receptor-mediated
phagocytosis of IgG- or IgM-coated sheep red blood cells (Fig.
3C and D).
In marked contrast to T cells, platelets, and macrophages,
the proliferative responses of anti-IgM stimulated B lympho-
cytes were significantly decreased in SKAP-HOM/ mice
(Fig. 4A). Similarly, the response to LPS, which is mediated via
toll-like receptor 4 (TLR4), was strongly impaired (Fig. 4B). In
contrast, the same cells responded normally after stimulation
with PMA-ionomycin or a combination of CD40 monoclonal
antibody (MAb) plus IL-4, ruling out a general defect in the
capability of B cells to become activated (Fig. 4C). These
results were confirmed with CFSE staining, excluding the pos-
sibility that the decreased proliferation observed was due to
increased apoptosis (data not shown). Rather, the data suggest
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FIG. 3. Normal T-cell and BMM proliferation and normal Fc- and
complement receptor-mediated phagocytosis in SKAP-HOM-deficient
mice. (A) Purified splenic T cells were stimulated with increasing
concentrations of CD3ε MAbs or with a combination of PMA plus
ionomycin. Data of quadruplicate cultures are shown as means 

SEM; n 5. (B) BMMs isolated from wild-type or knockout mice were
cultured for 2 days and then plated in replicates in the presence of 10
ng/ml M-CSF. Cells were harvested at the indicated times and counted.
(C) BMMs were incubated with sheep red blood cells opsonized with
either IgG or IgM and C5-deficient (def.) sera. BMMs were scored for
the percent of phagocytically active cells and for the ability of active
cells to phagocytize RBCs (D). Results are representative of three
separate experiments.
FIG. 4. Impaired B-cell proliferation in SKAP-HOM-deficient
mice. (A) Purified splenic B cells from wild-type or SKAP-HOM-
deficient mice were stimulated with the indicated concentration of
soluble anti-IgM F(ab)2 or soluble anti-IgM; n 10; results are means

 SEM. The mean counts per minute of maximally IgM F(ab)2-
stimulated wild-type B cells was 7,045 
 893 cpm versus 407 
 69 cpm
of unstimulated cells. For SKAP-HOM-deficient B cells, the mean
counts per minute was 6,417 
 663 versus 628 
 60, respectively.
(B) Purified splenic B cells were stimulated with the indicated concen-
tration of LPS (0.31 to 20 g/ml). (C) Purified splenic B cells were
activated with either anti-CD40IL-4, LPS (2.5 g/ml), or PMA plus
ionomycin (Ion.). The stimulation index was calculated as the ratio of
counts per minute (cpm) of stimulated to unstimulated proliferation.
Nonstimulated B cells are shown as controls; n  8; shown are means

 SEM. *, P  0.05; **, P  0.01.
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that SKAP-HOM is involved in the regulation of BCR- and
TLR4-mediated activation of B lymphocytes.
In summary, the data shown in Fig. 3 and 4 indicate that loss
of SKAP-HOM primarily alters B-cell functions.
Reduced levels of serum immunoglobulins in SKAP-
HOM/ mice. The impaired proliferative in vitro response of
SKAP-HOM-deficient B cells prompted us to assess the spon-
taneous and induced production of immunoglobulins in wild-
type and SKAP-HOM-deficient animals. As shown in Fig. 5,
considerably lower concentrations of constitutive serum immu-
noglobulins were found in SKAP-HOM/ mice compared to
wild-type littermates. This was in particular true for the IgM,
IgG2a, and IgG2b isotypes (Fig. 5A).
To investigate the humoral response after in vivo immuni-
zation, wild-type and SKAP-HOM-deficient animals were im-
munized with a T-dependent (DNP-KLH) or a T-independent
model antigen (TNP-LPS). In the former case, the primary
immune response was measured 21 days after the first immu-
nization. On the same day the mice received a second immu-
nization (boostering), and the secondary immune response was
assessed 7 days later. As shown in Fig. 5B, the magnitude of
DNP-KLH-specific IgM, IgG1, IgG2a, and IgG3 was similar in
wild-type and SKAP-HOM/ animals with regard to both the
primary and the secondary immune response. Moreover, DNP-
KLH and mitogen-induced in vitro proliferation of splenocytes
after the second immunization was unaffected in SKAP-HOM-
deficient animals (Fig. 5C).
Similar to the response after immunization with DNP-KLH,
SKAP-HOM-deficient mice responded normally after immu-
nization with the T-independent antigen TNP-LPS (data not
shown). Collectively, these data indicate that loss of SKAP-
HOM affects basal immunoglobulin production, whereas
SKAP-HOM-deficient mice are able to mount normal nitro-
phenyl-specific primary and secondary responses to all immu-
noglobulin isotypes.
Normal proximal signaling in SKAP-HOM/ B cells. De-
spite the apparently normal B-cell response after immuniza-
tion with T-dependent and T-independent antigens, the im-
paired B-cell proliferation following anti-IgM and LPS
stimulation suggested that loss of SKAP-HOM results in a
subtle failure(s) of the BCR to be coupled to intracellular
signaling pathways. To further elucidate the molecular mech-
anism underlying the functional alterations of SKAP-HOM-
deficient B cells, we analyzed membrane-proximal signaling
events downstream of the BCR. First, we assessed the ability of
SKAP-HOM/ B cells to elicit a calcium response upon stim-
ulation with an anti-IgM MAb. As shown in Fig. 6A, at an
antibody concentration at which impaired B-cell proliferation
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FIG. 5. Constitutive serum immunoglobulin levels and humoral immune responses in SKAP-HOM-deficient mice. (A) Constitutive serum
immunoglobulin levels in nonimmunized wild-type and SKAP-HOM-deficient animals; n  11; shown are means 
 SEM. (B) Humoral immune
response after immunization with the T-dependent antigen DNP-KLH. Twelve-week-old mice were injected at days 0 and day 21 intraperitoneally
with DNP-KLH. Mice were bled before boostering (on day 21, corresponding to primary response) and after boostering (on day 28, corresponding
to secondary response). Anti-DNP-specific levels of IgM, IgG1, IgG2a, and IgG3 were measured by ELISA. Four animals were investigated for
each group. (C) Proliferative response of splenocytes after the secondary immunization to DNP-KLH. Lymphocytes isolated from the spleen at
day 28 (after boostering) were stimulated with the indicated concentrations of DNP-KLH for 72 h. Results are given as the mean stimulation index
of three independent experiments (means 
 SEM). Ion., ionomycin.
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of SKAP-HOM deficient B-cells was clearly evident, no differ-
ences in BCR-mediated calcium flux were discernible between
splenic B cells of wild-type and SKAP-HOM/ mice. Simi-
larly, BCR stimulation did not reveal any significant differences
in global tyrosine phosphorylation (Fig. 6B) as well as in the
phosphorylation of Erk1/2, JNK, p38, and PKB/Akt after
short-time (up to 10 min) as well as after long-time stimulation
(up to 60 min; data not shown). Thus, loss of SKAP-HOM does
not affect the major membrane-proximal signaling events
downstream of the BCR.
Impaired adhesion of SKAP-HOM/ mice B cells. A
strongly reduced proliferation after immunoreceptor engage-
ment in combination with almost normal membrane-proximal
signaling events is reminiscent of the situation that has been
described for T cells lacking the cytosolic adaptor protein
ADAP (9, 27). ADAP/ T cells are severely compromised in
their ability to adhere to ligands of 1 and 2 integrins, such as
ICAM-1 and fibronectin. Similarly, downregulation of
SKAP55 (e.g., by RNA interference) has the same effect (15
and S. Kliche and B. Schraven, unpublished data).
To assess whether loss of SKAP-HOM alters B-cell adhe-
sion, purified splenic B lymphocytes were stimulated via the
BCR and then allowed to adhere to fibronectin (a ligand of the
1 integrin VLA-4) or to ICAM-1 (a ligand of the 2 integrin
LFA-1). As shown in Fig. 7A and B, BCR-induced adhesion to
both fibronectin and ICAM-1 was strongly attenuated in
SKAP-HOM/ B cells. In contrast, treatment of the same
cells with manganese chloride (which induces a conformational
change of the extracellular domain of integrins, thereby switch-
ing them to the high-affinity state) or phorbol ester (which
induces the high-affinity state of the integrins via inside-out
signaling by bypassing membrane-proximal signaling events)
induced adhesion comparable to that of wild-type cells. The
latter finding excludes the possibility that loss of SKAP-HOM
generates an intrinsic functional defect of either 1 or 2
integrins. Moreover, flow cytometry analysis did not reveal
alterations in cell surface expression of CD11a/CD18 (LFA-1)
and CD49d/CD29 (VLA-4) in SKAP-HOM/ B cells (data
not shown), which rules out the possibility that loss of adhe-
siveness of SKAP-HOM-deficient B cells is caused by blunted
expression of integrins. Rather, it appeared that, similar to
ADAP/SKAP55 in T cells, SKAP-HOM is involved in coupling
the BCR to integrin activation.
To investigate whether the adhesion defect of SKAP-
HOM/ B cells could be attributed to impaired dynamics of
the actin cytoskeleton, we compared BCR-induced actin poly-
merization in wild-type and SKAP-HOM-deficient B cells. To
this end, activated B cells were permeabilized with saponin and
subsequently stained with phalloidin-tetramethyl rhodamine
isocyanate, a probe specifically reacting with polymerized F-
actin. The amount of polymerized F-actin within the cells was
subsequently determined by flow cytometry. Figure 7C depicts
that actin polymerization occurs normally in the absence of
SKAP-HOM, which suggests that SKAP-HOM is dispensable
for BCR-mediated reorganization of the cytoskeleton.
The 2 integrin LFA-1 has been shown to be involved in the
formation of the immunological synapse in T cells and in
conjugate formation between B and T cells at the onset of an
immune response (12). To assess whether loss of SKAP-HOM
impairs conjugate formation, we loaded freshly isolated splenic
B cells with the model peptide OVA323-339 and then incubated
the peptide-loaded B cells with T cells of OT-II TCR-trans-
genic mice. Subsequently, conjugate formation between T and
B cells was evaluated by flow cytometry. Figure 7D shows that
conjugate formation is not impaired in SKAP-HOM-deficient
B lymphocytes. In addition, the formation of the B-cell synapse
and the clustering of LFA-1 after MAb-mediated activation of
the BCR also seem to occur normally in the absence of SKAP-
HOM (F. Batista, personal communication). Thus, SKAP-
HOM seems to be dispensable for conjugate formation be-
tween T cells and APCs and for formation of the
immunological synapse after antibody-mediated triggering of
the BCR.
Decreased severity of EAE in SKAP-HOM/ mice. Al-
though EAE is considered to primarily represent a Th1-medi-
ated autoimmune disease, a number of studies have suggested
a role for B cells and autoantibodies in EAE (7, 8, 14). To asses
the consequences of SKAP-HOM deficiency in this autoim-
mune model, wild-type mice and SKAP-HOM/ mice were
immunized with the encephalitogenic peptide MOG 35-55.
FIG. 6. Normal proximal BCR-mediated signaling in the absence
of SKAP-HOM. (A) Freshly isolated, indo-1-loaded splenic B cells
were stimulated with anti-IgM F(ab)2 (10 g/ml) or, as a positive
control, with ionomycin (100 nM). Intracellular calcium levels were
measured by flow cytometry. (B) Purified splenic B cells were left
unstimulated or treated with soluble anti-IgM F(ab)2 (10 g/ml) for
the indicated minutes. Cellular lysates were resolved by sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis, and blots were probed
with anti-phosphotyrosine (anti-pTyr) MAb 4G10. The expression lev-
els of total Erk1 and Erk2 are shown as loading controls in the lower
panel (additional data not shown). KO, knockout; WT, wild type.
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Figure 8A demonstrates that both groups of mice showed
maximal disease scores at days 15 to 17 after immunization,
which was followed by a remission phase. However, despite the
fact that the first clinical signs of disease appeared somewhat
earlier in SKAP-HOM/ animals (Fig. 8A and the inset ta-
ble), the mean clinical score of EAE was clearly more severe in
wild-type animals (mean score of 2.2 in wild-type animals ver-
sus 1.2 in SKAP-HOM/ animals at day 17, respectively; P 
0.05). Thus, SKAP-HOM/ mice are not only impaired in
their ability to activate B lymphocytes in vitro but also show a
blunted immune response after immunization with the enceph-
alitogenic peptide MOG in vivo.
To further elucidate the mechanisms underlying the altered
response of SKAP-HOM-deficient mice in the EAE model, we
measured the in vivo levels of the MOG-specific autoantibod-
ies at day 15 after immunization. Figure 8B shows that the
levels of MOG-specifc IgG and, to a lesser extent, MOG-
specifc IgM antibodies in the serum were much lower in
SKAP-HOM/ mice compared to wild-type animals. In ad-
dition, a decreased MOG-specific proliferation of lymph node
cells was observed (Fig. 8C). These findings suggest that loss of
SKAP-HOM within the hematopoietic system leads to an at-
tenuated clinical course of EAE which is accompanied by re-
duced production of MOG-specific immunoglobulins as well as
a reduced MOG-induced T-cell response.
DISCUSSION
In this study we investigated the immune system of mice
deficient in expression of the cytosolic adaptor protein SKAP-
HOM. SKAP-HOM represents the ubiquitously expressed ho-
mologue of the T-cell-specific adaptor protein SKAP55, a
physiological binding partner of the integrin-regulating adap-
tor ADAP (17, 21). Mice lacking SKAP-HOM/ are viable
and fertile and exhibit no obvious abnormalities. Therefore, it
is likely that SKAP-HOM/ is not required during develop-
ment of the growing organism or the hematopoietic system.
Although no anatomic abnormalities were observed in the
primary and secondary lymphoid organs, SKAP-HOM/
mice showed reduced levels of spontaneous immunoglobulins
in the serum. The constitutive defect in the production of IgM,
IgG2a, and IgG2b apparently does not result from loss of a
particular B-cell population but rather is due to a reduced
ability of SKAP-HOM-deficient B cells to proliferate after
stimulation of the BCR or TLR4.
Our attempts to identify the signaling defect(s) underlying
FIG. 7. Attenuated BCR-mediated adhesion but normal F-actin polymerization and conjugate formation of SKAP-HOM-deficient B cells.
(A) Purified splenic B cells were stimulated with anti-IgM F(ab)2 and then allowed to adhere to tissue cell culture dishes coated with either
fibronectin (A) or recombinant murine ICAM-1 (B). Adherent cell numbers were determined by microscopy. Results are expressed as means 

SEM of six independently performed experiments. (C) Purified B cells were treated with anti-IgM F(ab)2, permeabilized with saponin, and then
stained with FITC-phalloidin. The cellular F-actin polymerization was assayed by flow cytometry after 1, 5, and 10 min. Results are expressed as
percent increase of mean fluorescence intensity (MFI). The shown graph is representative of five independently performed experiments.
(D) Purified B cells were loaded with OVA peptide overnight. T cells of OT-II TCR-transgenic mice were loaded with CFSE and coincubated with
the peptide-pulsed B cells for 8 h. Conjugate formation was subsequently assessed by flow cytometry. Results are expressed as percentages of
loaded B cells conjugated with T cells. The shown graph is representative of four independently performed experiments. unstim., unstimulated.
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the reduced ability of SKAP-HOM-deficient B cells to respond
to external stimuli did not reveal significant alterations of
BCR-mediated global tyrosine phosphorylation, calcium flux,
or activation of the mitogen-activated protein kinase pathways.
These data collectively suggest that the major membrane-prox-
imal signaling events regulating B-cell activation are not im-
paired in the absence of SKAP-HOM. However, we found that
the lack of SKAP-HOM results in a severely compromised
ability to couple the BCR to regulation of 1 and 2 integrins,
thereby causing reduced adhesion of B cells to fibronectin and
to ICAM-1. It is tempting to speculate that these adhesion
defects are the major reason for the observed alterations of
both the in vivo and in vitro B-cell responses that we see in the
SKAP-HOM/ mice.
Both SKAP-HOM and SKAP55 are reported to form a
complex with the cytosolic adaptor protein ADAP (17, 21). In
T cells, the association between SKAP55 and ADAP has been
shown to be mediated via the SH3 domain of SKAP55 and the
proline-rich domain of ADAP (17, 21). Moreover, loss of
ADAP in T cells results in a failure of integrin-mediated ad-
hesion as well as impaired T-cell proliferation after TCR stim-
ulation (9, 27). Preliminary data obtained by RNA interference
approaches in the T-cell line suggest a similar adhesion-regu-
lating function for SKAP55 (15 and S. Kliche and B. Schraven,
unpublished). Moreover, a recent report had demonstrated
that overexpression of SKAP55 augments both T-cell adhesion
to fibronectin and ICAM-1 as well as conjugate formation
between T cells and APCs (31). Thus, it appears as if in T cells
ADAP and SKAP55 form a functional unit that couples the
TCR to integrin activation, thereby regulating T-cell adhesion.
Our finding that B-cell adhesion is impaired in SKAP-HOM-
deficient mice strongly suggests that SKAP-HOM fulfils a sim-
ilar function in B lymphocytes as SKAP55 and ADAP in T-
cells. One of the major challenges for the future will be to
assess whether a B-cell homologue of ADAP (ADAP-HOM)
exists that constitutively interacts with SKAP-HOM in B lym-
phocytes and couples the BCR to integrin activation.
It is, however, important to note that the adhesion defect
caused by loss of SKAP-HOM is apparently less severe than
the T-cell adhesion defect that is observed in ADAP-knockout
mice. This could indicate that ADAP regulates adhesion not
only via SKAP55 but also through another, as yet unidentified
signaling molecule(s). Alternatively, the possibility has to be
considered that loss of SKAP-HOM in B cells is partially
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FIG. 8. SKAP-HOM-deficient mice show reduced severity of EAE. (A) EAE was induced following immunization with MOG 35-55 (200 g
MOG in CFA). The severity of EAE is presented as mean clinical scores (means 
 SEM; n  9). The accompanying table in the box shows the
incidence of EAE within the experimental groups at days 7, 10, and 15, respectively. The shown graph is representative of three independently
performed experiments. The difference in the mean clinical score was significant at days 7, 8, 13, 15, and 17 (P  0.05). (B) Serum levels of
anti-MOG-specific antibodies in sera collected at day 14 after immunization of mice with MOG 35-55. Concentration of specific IgM and IgG were
measured by ELISA. (C) Proliferative response to MOG 35-55 of lymphocytes isolated from draining lymph nodes at day 14 following
immunization with MOG 35-55 (n  5). Lymph node cells were cultured with or without MOG 35-55 for 72 h. The mean counts per minute of
maximally MOG-stimulated wild-type lymph node cells was 4,431 
 856 cpm versus 1,059 
 211 cpm of unstimulated cells. For SKAP-HOM/
lymph node cells, the mean cpm was 1,969 
 860 versus 610 
 191, respectively. WT, wild type; KO, knockout.
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compensated for by another protein(s) that regulate(s) B-cell
adhesion.
Although additional studies are required to solve this puzzle,
it appears as if the impaired adhesion of B cells in vitro does
not affect the ability of B cells to populate the different lym-
phoid organs in vivo. This could be explained by the fact that
the regulated induction of adhesion and migration in vivo
results from complex interactions of different signaling path-
ways and that in the orchestra of events regulating, e.g., hom-
ing of lymphocytes, the absence of one player can be compen-
sated for by others. In line with this hypothesis is the finding
that also in ADAP/ mice (in which T cells show a strongly
impaired adhesion to ICAM-1 and ICAM-2, VCAM-1, and
fibronectin after TCR engagement) the colonization of the
lymphoid organs appears to be almost normal (9, 27).
The unaltered response of the SKAP-HOM-deficient ani-
mals after immunization with DNP-KLH versus the clearly
reduced in vitro response of SKAP-HOM-deficient B lympho-
cytes and the lower levels of anti-MOG antibodies after im-
munization of the animals with MOG-peptide seem to be con-
tradictory. However, it is important to note that the DNP-KLH
immunization for inducing a humoral immune response and,
e.g., the immunization with MOG peptide that is used for
induction of EAE are not directly comparable. The different
nature of antigen (hapten plus carrier versus peptide), the
different routes of application (intraperitoneal versus subcuta-
neous), and the different immunization protocols (booster
dose versus single application) may explain these diverging
results.
In this regard, an elegant recent in vitro study showed that
integrin (e.g., LFA-1)-mediated adhesion is primarily impor-
tant for B-cell activation under suboptimal conditions of stim-
ulation (e.g., when either low-affinity antigens are used for
stimulation or when the concentration of the activating peptide
is very low) (3). Possibly, in terms of the B-cell response,
subcutaneous immunization with MOG peptide represents a
“suboptimal” condition in which the contribution of integrin-
mediated adhesion is important to allow appropriate B-cell
activation. In contrast, i.p. immunization with optimal doses of
high-affinity T-dependent or T-independent antigens might re-
flect conditions of stimulation in which the contribution of
integrin-mediated adhesion is less important. The elucidation
of these possibilities requires immunization of the animals with
different doses of T-dependent or T-independent antigens and
subsequent monitoring of the B-cell response. Additionally, or
alternatively, SKAP-HOM-deficient mice could be crossed
with mice carrying a transgenic BCR, as described previously
(3). Ex vivo-isolated B cells from such double transgenic ani-
mals could be stimulated with different concentrations of pep-
tide or with altered peptides, followed by analysis of B-cell
functions (microscopic analysis of the B-cell synapse and/or
functional readouts such as CD86 expression). We are cur-
rently preparing to assess these possibilities.
Nevertheless, the impaired in vitro response of SKAP-
HOM-deficient B lymphocytes, the lower constitutive concen-
trations of serum immunoglobulins, and the strongly reduced
antibody response in the EAE model suggest that SKAP-HOM
plays an important role in the generation of an appropriate
immune response after challenge with particular antigens (see
also below).
Loss of SKAP-HOM attenuates the clinical course of EAE.
This is accompanied by a decreased synthesis of MOG-specific
antibodies and a reduced secondary MOG-specific prolifera-
tion of lymph node cells. The apparently normal in vitro func-
tions of SKAP-HOM-deficient T cells might suggest that the
attenuated course of EAE is mainly due to an altered B-cell
response. However, EAE is primarily considered to represent
a Th1-mediated autoimmune disease, and the pathophysiolgic
role of B cells and autoantibodies is controversial. For exam-
ple, B-cell-deficient mice immunized with rodent MOG 35-55
develop a course of EAE that is indistinguishable from that of
wild-type mice. This suggests that B cells do not play a major
role in EAE (11). By contrast, passive transfer of activated B
cells or serum from wild-type mice immunized with MOG
restores the susceptibility of B-cell-deficient mice to develop
EAE. This indicates that MOG-specific B cells and anti-MOG
antibodies seem to contribute to the pathology of EAE (18, 19,
26). In line with the latter assumption is a recent report by
Filatreau et al. which clearly showed a role of B cells in regu-
lating the clinical course of EAE (7). Thus, further studies are
required to assess whether impaired B-cell responses alone are
responsible for the altered outcome of EAE in SKAP-HOM-
deficient mice.
Indeed, it might well be that not only blunted B-cell func-
tions but also an altered cooperation between T and B cells
results in an incomplete T-cell activation leading to an atten-
uated MOG-specific immune response in SKAP-HOM-defi-
cient mice. In addition (or alternatively), the possibility cannot
be excluded that the altered course of EAE in the SKAP-
HOM/ mice is in part (if not primarily) due to an impaired
cooperation between dendritic cells (DC), macrophages, and T
cells. Although further experiments are required to precisely
assess the functions of SKAP-HOM/ DCs and macrophages,
two preliminary pieces of evidence argue against a severe func-
tional alteration of antigen-presenting cells in the absence of
SKAP-HOM. First, we did not find significant impairments of
Fc- or complement receptor-mediated phagocytosis in SKAP-
HOM-deficient macrophages, which suggests that antigen uptake
(at least via these receptors) is not dependent on SKAP-HOM.
Moreover, conjugate formation between OVA323-339-loaded
DCs and the corresponding OT-II TCR transgenic T cells is
not affected in the absence of SKAP-HOM. However, whether
it also applies for DCs loaded with MOG or other (suboptimal)
peptides requires further analysis.
Finally, despite apparently normal functions in vitro (which
might be due to the fact that loss of SKAP-HOM is compen-
sated for by the presence of SKAP55, whose expression is not
affected in T cells of SKAP-HOM-deficient mice), the possi-
bility cannot be excluded that SKAP-HOM-deficient T cells
are also slightly impaired in their ability to respond to specific
antigens (such as MOG) in vivo. In summary, further studies
(including the analysis of microglia cells which express SKAP-
HOM) are required to answer the question of how loss of
SKAP-HOM attenuates the clinical course of EAE. In addi-
tion, it will be necessary to assess the question of whether loss
of SKAP-HOM exclusively alters the clinical outcome of EAE
or whether it also affects the course of other model diseases
(e.g., infection with Yersinia enterocolitica). Experiments are
under way to address these questions.
Nevertheless, we have shown here that loss of SKAP-HOM
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attenuates B-cell functions and that it impairs the cross-talk
between the BCR and integrins. These findings might be im-
portant in light of recent data showing that the 4 integrin
(VLA-4) antagonistic monoclonal antibody Natalizumab re-
duces the development of brain lesions in murine EAE as well
as in controlled clinical trials with patients suffering from mul-
tiple sclerosis (24). VLA-4 is expressed on activated T cells, B
cells, and monocytes. Our data demonstrating loss of adhesion
to the VLA-4 ligand fibronectin in SKAP-HOM-deficient B
lymphocytes and attenuated EAE in SKAP-HOM-deficient
mice might suggest that the beneficial effect of Natalizumab is
partially due to an inhibition of B-cell invasion into the central
nervous system. Although further histopathological studies are
required to analyze the nature and the numbers of infiltrating
immunocompetent cells in the central nervous system of wild-
type and SKAP-HOM-deficient mice during EAE, our data
indicate that interference with SKAP-HOM functions might be
an attractive new avenue for pharmaceutical intervention in
autoimmune diseases such as multiple sclerosis.
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Abstract
Background: Structural analysis of cellular interaction networks contributes to a deeper understanding
of network-wide interdependencies, causal relationships, and basic functional capabilities. While the
structural analysis of metabolic networks is a well-established field, similar methodologies have been
scarcely developed and applied to signaling and regulatory networks.
Results: We propose formalisms and methods, relying on adapted and partially newly introduced
approaches, which facilitate a structural analysis of signaling and regulatory networks with focus on
functional aspects. We use two different formalisms to represent and analyze interaction networks:
interaction graphs and (logical) interaction hypergraphs. We show that, in interaction graphs, the
determination of feedback cycles and of all the signaling paths between any pair of species is equivalent to
the computation of elementary modes known from metabolic networks. Knowledge on the set of signaling
paths and feedback loops facilitates the computation of intervention strategies and the classification of
compounds into activators, inhibitors, ambivalent factors, and non-affecting factors with respect to a
certain species. In some cases, qualitative effects induced by perturbations can be unambiguously predicted
from the network scheme. Interaction graphs however, are not able to capture AND relationships which
do frequently occur in interaction networks. The consequent logical concatenation of all the arcs pointing
into a species leads to Boolean networks. For a Boolean representation of cellular interaction networks
we propose a formalism based on logical (or signed) interaction hypergraphs, which facilitates in particular
a logical steady state analysis (LSSA). LSSA enables studies on the logical processing of signals and the
identification of optimal intervention points (targets) in cellular networks. LSSA also reveals network
regions whose parametrization and initial states are crucial for the dynamic behavior.
We have implemented these methods in our software tool CellNetAnalyzer (successor of FluxAnalyzer) and
illustrate their applicability using a logical model of T-Cell receptor signaling providing non-intuitive results
regarding feedback loops, essential elements, and (logical) signal processing upon different stimuli.
Conclusion: The methods and formalisms we propose herein are another step towards the
comprehensive functional analysis of cellular interaction networks. Their potential, shown on a realistic T-
cell signaling model, makes them a promising tool.
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Evolution has equipped cells with exquisite signaling sys-
tems which allow them to sense their environment,
receive and process signals in a hierarchically organized
manner and to react accordingly [1]. The complexity of
the corresponding molecular machineries, in accordance
with the complicated tasks they have to perform, is over-
whelming. In the last few years, as a key element to the
growing popularity of systems biology, mathematical
tools have been applied to the analysis of signaling data
[2]. Ordinary differential equations relying on kinetic
descriptions of the underlying molecular interactions are
arguably the most used approach for modeling signaling
networks (e.g. [3-6]). A number of theoretical methods
have been devised and employed for the reconstruction
(reverse engineering) of signaling or, more generally,
interaction networks (which may represent signaling but
also other types or abstractions of cellular networks such
as genetic regulatory networks) based on perturbation
experiments [7]. The approaches rely on methods ranging
from Bayesian networks (e.g. [8]) to metabolic control
analysis [9,10].
Relatively few methods have been proposed so far for ana-
lyzing the structure of a given signaling (or any interac-
tion) network. This is somewhat surprising since
structural analysis of metabolic networks is a well-estab-
lished field and proved to be successful to recognize rela-
tionships between structure, function, and regulation of
metabolic networks [11]. Structural analysis will be partic-
ularly useful in large signaling networks, where a simple
visual inspection is not possible and at the same time the
construction of precise quantitative models is practically
infeasible due to the huge amount of required, but gener-
ally unknown, kinetic parameters and concentration val-
ues. However, the reconstruction of large signaling
networks is still in its first stages [2,12].
Structural or qualitative approaches that have been
employed for interaction networks include statistical
large-scale analyses in protein-protein networks (e.g.
[13]). These studies are important for examining statisti-
cal properties of the interaction graph and for understand-
ing its global organization but they provide relatively few
insights into the function of the network. Papin and co-
workers [14,15] were the first to adapt methods from the
constraint-based approach (frequently used for structural
analysis of metabolic networks [11]) to analyze stoichio-
metric models of signaling pathways. Recently, graph-the-
oretical descriptions of signaling networks have been
examined [16-18]. Finally, Boolean networks as discrete
approximations of quantitative models have been used
for logical analyses of small signaling networks e.g. [19].
However, the majority of studies relying on the Boolean
approach deal with genetic interaction networks, many of
which have a relatively small size (ca. 10 species; e.g.
[20,21]), however, recently more complicated networks
have also been investigated [22,23].
In this contribution, we propose formalisms for represent-
ing signaling and other interaction networks mathemati-
cally and present a collection of methods facilitating
structural analysis of the respective network models.
Rather than introducing completely new concepts, we will
systematize and adapt existing formalisms and methods,
often motivated from structural analyses of metabolic net-
works, towards a functional analysis of the structure of a
signaling network. Issues that can be addressed with the
proposed methods include:
• check of the plausibility and consistency of the network
structure
• identification of all or particular signaling pathways,
feedback loops and crosstalks
• network-wide functional interdependencies between
network elements
• identification of the different modes of (logical) input/
output behavior
• predicting responses (phenotypes) after changes in net-
work structure
• finding targets and intervention points in the network
for repressing or provoking a certain behavior or response
• analysis of structural network properties like redun-
dancy and robustness
Structural analysis is not based on quantitative and
dynamic properties and can thus only provide qualitative
answers. However, some insights into the dynamic prop-
erties can nevertheless often be obtained, because funda-
mental properties of the dynamic behavior are often
governed by the network structure [24]. While we will
focus on signaling networks, the methods can be easily
applied to any kind of interaction network, including
gene regulatory systems. Apart from a toy model, we will
exemplify our methods on a model of signaling pathways
in T-cells.
Results and discussion
Mass and signal flows in cellular interaction networks
The reader familiar to the structural analysis of stoichio-
metric networks may notice that, in the case of metabolic
networks, many of the issues in the task list of the previ-
ous section have been handled by the constraint-based
approach [11]. For example, the identification of func-Page 2 of 26
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put (products) behavior of stoichiometric reaction
networks is facilitated by elementary-modes analysis
[25,26]. Flux Balance Analysis is another related tech-
nique often used for phenotype predictions of metabolic
mutants [11,27]. Recently, the concept of minimal cut sets
has been introduced for identifying targets in metabolic
networks [28,29]. Therefore, it seems reasonable to apply
these methods to signaling networks. However, some fun-
damental differences in the way the network elements
interact may complicate a direct transfer:
(1) The constraint-based framework assumes steady-state,
while in signaling networks a transient behavior can often
be observed. (However, as will be discussed below, many
useful insights of signaling networks can be obtained
from using a static approach.)
(2) In stoichiometric networks, any arrow (reaction) lead-
ing from educts to products can be seen as an "activating"
(producing) connection for the products. Therefore,
employing stoichiometric framework it is difficult or only
indirectly possible to express an inhibitory action of a spe-
cies onto another.
(3) Probably the most significant difference is that the
edges (i.e. the connections between the species) in meta-
bolic networks carry flows of mass whereas edges in sign-
aling networks may carry mass and/or information
(signal) flow. Of course, at the molecular level, any inter-
action between species in the cell can be written as a stoi-
chiometric equation. However, whereas mass flow is
connected to a real consumption of participating com-
pounds, signal flow is usually characterized by a recycling
of certain species (e.g. enzymes) so that these species can
mediate the signal transfer continuously (until they are
degraded).
A typical example, namely the activation of a receptor
tyrosine kinase (Figure 1(a)) [30], illustrates the simulta-
neous occurrence of mass and signal flow. A ligand (Lig)
binds to the extracellular domain of a receptor (Rec) yield-
ing a receptor-ligand complex which can undergo further
changes (e.g. by autophosphorylation or/and dimeriza-
tion). We denote the outcome by RecLig*. This complex is
now able to phosphorylate another molecule (M).
Accordingly, M binds to RecLig* and becomes phosphor-
ylated (M-P) by the expense of ATP. At the end, M-P is
released, recycling also the activated receptor-ligand com-
plex RecLig*.
The first step in this scheme can be considered as a mass
flow. However, the cycle in which RecLig* phosphorylates
M, is a mass flow with respect to M and ATP, but a signal-
ing flow with respect to RecLig*, as the latter is indeed
required for driving this cycle but not consumed (because
recycled) in the overall stoichiometry.
In performing a structural analysis we are interested in
extracting signaling paths from the network scheme.
Therefore, it may seem reasonable to compute elementary
modes, which typically represent pathways in reaction
networks with mass flow [25]. A basic property of elemen-
tary modes is that the (relative) mass flow represented by
an elementary mode keeps the "internal" species in a bal-
anced state. Internal species (here: RecLig*, RecLig*-M,
RecLig*-M-P) are within the system's boundary, whereas
the external species (here: Rec, Lig, M, M-P, ADP, ATP) are
considered as pools which are balanced by processes lying
outside the system's boundaries. Computing the elemen-
tary modes from the respective stoichiometric model of
Figure 1(a) gives exactly one mode which reflects the dis-
cussed role of RecLig* as a kinase (Figure 1(b)): in its net
stoichiometry, this elementary mode converts the external
species M and ATP into M-P and ADP, whereas RecLig* is
recycled. Since RecLig* is neither consumed nor produced
in the overall process, the first step (building the receptor-
ligand complex) is not involved in this mode simply
because a continuous synthesis of RecLig* would lead to
an accumulation of this species, which is inconsistent
with the steady-state assumption of elementary modes.
Thus, the causal dependency of M-P from the availability
of Rec and Lig is not reflected by the mass flow concept of
elementary modes. Note that exactly the same conceptual
problem would arise when enzymes and enzyme synthe-
(a) Example of a typical signaling pathway where mass and signal flow occur simultaneosly (Rec = receptor; Lig = ligand; RecLig* = (a tive) re eptor-ligand- omplex; M = olecule; M-P = phospho ylated m lecule M)Figure 1
(a) Example of a typical signaling pathway where mass and 
signal flow occur simultaneosly (Rec = receptor; Lig = ligand; 
RecLig* = (active) receptor-ligand-complex; M = molecule; 
M-P = phosphorylated molecule M). (b) The (only) elemen-
tary mode in this example which follows when M, M-P, ADP, 
ATP, Rec and Lig are considered as external (boundary) spe-
cies. The involved reactions are indicated by green, thick 
arrows. In its net stoichiometry, this elementary mode con-
verts M and ATP into M-P and ADP, whereas RecLig* is recy-
cled in the overall process. Importantly, the mandatory 
process of building the receptor-ligand-complex RecLig* 
(hence, the causal dependeny of M-P from the availability of 
Rec and Lig) is not reflected by this mode.Page 3 of 26
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ies of metabolic networks.
The example demonstrates that we require a framework
with the ability to account for mass and signal flows. Han-
dling both mass and signal flows formally equivalent as
interactions could be a suitable approach. Interpreting Fig-
ure 1(a)) as a diagram of interactions we could redraw it
as depicted in Figure 2(a). The dashed arrow indicates that
RecLig* catalyzes the phosphorylation of M to M-P. If we
assume that ADP, ATP, and M are always present, we get
the simple chain shown in Figure 2(b) expressing that Rec
and Lig are required to obtain RecLig* (or to activate
RecLig*), and that RecLig* is required to get M-P. If we do
not further distinguish between the two types of arrows
and thus consider mass and signal flows as formally
equivalent, the causal connections between the species
would, nevertheless, still be captured correctly. This
abstract representation of different types of interactions
will thus be used herein.
The following two sections will deal first with interaction
graphs and later with the more general (logical) interac-
tion hypergraphs. The basic difference between these two
related approaches can be illustrated by how they deal
with a connection such as "Rec + Lig" in Figure 2(b). If we
interpret it as "Rec activates RecLig* and Lig activates
RecLig*" then the concept of interaction graphs is applica-
ble (discussed in the following section). However, it
would be more accurate to say that "Rec AND Lig are
required simultaneously for building RecLig*", and it is this
more refined approach that leads to the concept of inter-
action hypergraphs, which will be discussed in further
details later on.
Analyzing interaction graphs
Definition of interaction graphs
Interaction (or causal influence) graphs are frequently
used to show direct dependencies between species in sig-
naling, genetic, or protein-protein interaction networks.
The nodes in these graphs may represent, depending on
the network type and the level of abstraction, receptors,
ligands, effectors, kinases, genes, transcription factors,
metabolites, proteins, and other compounds, while each
edge describes a relation between two of these species. In
signaling and gene regulatory networks, two further char-
acteristics are usually specified for each edge: a direction
(which species influences which) and a sign ("+" or "- ",
depending on whether the influence is activating (level
increasing) or inhibiting (level decreasing)). Formally, we
represent a directed interaction or causal influence graph
as a signed directed graph G = (V, A), where V is the set of
vertices or nodes (species) and A the set of labeled
directed edges [31,32]. Directed edges are usually called
arcs and an arc from vertex i (tail) to j (head) is denoted by
an ordered tuple {i,j,s} with i, j ∈ V and s ∈ {+,- }.
Sometimes, for example in protein-protein interaction
networks, the directions of the edges remain unspecified.
We will not consider such undirected interaction graphs
explicitly, however, many of the issues discussed in the
following can be transferred to undirected graphs (e.g. by
representing an undirected edge by two (forward and
backward) arcs).
The structure of a signed graph can be stored conveniently
by an m x q incidence matrix B in which the columns cor-
respond to the q arcs (interactions) and the rows to the m
nodes (species), similar as in stoichiometric matrices of
metabolic reaction networks [33]. For the k-th arc {i, j, s}
a (-1) is stored in the k-th column of B for the tail vertex
(i) and (+1) for the head vertex (j) of arc k. Hence, Bi,k = -
1 and Bj,k = 1 and Bl,k = 0 (l≠ i, j). For storing the signs, a q-
vector s is introduced whose k-th element is (+1) if arc k is
positive and (-1) if k is negative.
Self-loops (arcs connecting a species with itself) are not
considered here but could be stored in a separate list since
they would appear as a zero column in the incidence
matrix.
Note that, as far as the memory requirement is concerned,
the structure of a graph can be stored more efficiently than
by an incidence matrix, e.g. by using adjacency lists [34].
However, since we will present methods directly operat-
ing on the incidence matrix, we refer herein to this repre-
sentation.
Signal transduction networks are usually characterized by
an input, intermediate, and output layer (cf. [16]). The
Interpretation of Figure 1 as an interaction networkFigure 2
Interpretation of Figure 1 as an interaction network.Page 4 of 26
(page number not for citation purposes)
BMC Bioinformatics 2006, 7:56 http://www.biomedcentral.com/1471-2105/7/56input domain consists only of species having no predeces-
sor, which can thus not be activated from other species in
the graph. Such sources (typical representatives are recep-
tors and ligands) are starting points of signal transduction
pathways and can easily be identified from the incidence
matrix since their corresponding row contains no positive
entry. In contrast, the output layer consists only of nodes
having no successor. These sinks, usually corresponding to
transcription factors or genes, are identifiable as rows in B
which have no negative entry. The set of source and sink
nodes define the boundaries of the network under inves-
tigation. They play here a similar role as the external
metabolites in stoichiometric studies [33]. The intermedi-
ate layer functions as the actual signal transduction and
processing unit. It consists of the intermediate species, all
of which have at least one predecessor and at least one
successor, i.e. they are influenced and they influence other
elements. Such species contain both -1 and +1 entries in
the incidence matrix. In reconstructed signaling networks,
the detection of all sink and source species may help to
detect gaps in the network, e.g. when a species should be
an intermediate but is classified as a sink or source.
The presence of sinks and sources are a consequence of
setting borders to the system of interest. Sometimes there
are no sinks or/and no sources, especially in models of
gene regulatory networks (see e.g. the networks studied in
[21]), but this does not impose limitations to the
approaches presented here.
A toy example of a (directed) interaction graph that will
serve for illustrations throughout this paper is given in
Figure 3. This interaction graph, called TOYNET, consists
of two sources (I1, I2), two sinks (O1, O2), 7 intermediate
species (A,..., G), two inhibiting (arcs 2 and 7) and 11 acti-
vating interactions. Incidence matrix B of TOYNET reads
(the sign vector s is given on the top of B):
 
Identification of feedback loops
Even though some analysis methods (e.g. Bayesian net-
works) rely on acyclic networks where feedbacks are not
allowed, one of the most important features of signaling
and regulatory networks are their feedback loops
[3,5,18,21,35-38]. Positive feedbacks are responsible and
even required [39] for multiple steady state behavior in
dynamical systems. In biological systems, multistationar-
ity plays a central role in differentiation processes and for
epigenetic and switch-like behavior. In contrast, negative
feedback loops are essential for homeostatic mechanisms
(i.e. for adjusting and maintaining levels of system varia-
bles) or for generating oscillatory behavior [35].
Most reports demonstrating the role and consequences of
feedback loops analyze relatively small networks where
the cycles can be easily recognized from the network
scheme but rather few works address the question of how
feedback cycles can be identified systematically. This is
particularly important in large interaction graphs, where a
detection by simple visual inspection is impossible, espe-
cially when feedback loops overlap.
A feedback loop is, in graph theory, a directed cycle or cir-
cuit. A circuit is defined as a sequence C = {a1,...,aw} of arcs
that starts and ends at the same vertex k and visits (with
the exception of k) no vertex twice, i.e. C = {a1,...,aw} =
{{k, l1}, {l1,l2},..., {lw-1,k}} such that all nodes k, l1, l2 ...
lw-1 are distinct. The parity of the number of negative signs
of the arcs in C determines whether the feedback loop is
negative (odd number of negative signs) or positive
(even). In the example TOYNET two feedback loops can
be found: (i) the arc sequence {4,5,6,7} which is negative
(since one negative arc (7) is involved), and (ii) the
sequence {10,11}, which is positive (because the signs of
both arcs in this circuit are positive). Obviously, sinks and
sources (and all arcs connected to these nodes) can never
be involved in any circuit.
Computing all directed cycles in large graphs is computa-
tionally a difficult task. Algorithms that can be found in
the literature usually rely on backtracking strategies (e.g.
[16,40]). Here, we introduce a different approach where
the circuits are identified as elementary modes establish-
ing a direct link to metabolic network analysis. Circuits
can be formally represented by a q-vector c in which ci = 1
if arc i is involved in the circuit and ci = 0 otherwise. A cir-
cuit vector fulfills the equation
B c = 0 (2)
and hence, lies in the null space of the incidence matrix of
the graph [32,41]. Generally, any vector c obeying (2) ful-
fills a so-called conservation law and is called a circulation
which may be envisioned as a flow cycling around in the
network [42]. Eq. (2) is strongly related to the mass bal-
ance equation of metabolic networks in steady state. In
fact, considering the graph as a reaction network with the
B =
+ − + + + + − + + + + + +
− −
−
−
1 1 0 0 0 0 0 0 0 0 0 0 0
0 0 1 0 0 0 0 0 0 0 0 0 0
0 0 0 1 0 0 0 0 0 0 0 01
1
1
0 0 1 1 0 0 0 0 0 0 0 0
0 0 0 0 1 1 0 0 0 0 1 0
0 0 0 0 0 1 1 0 0 0 0 0 0
0 1 1 0 0 0 0 1 1 0 0 0
−
− −
−
− − 0
0 0 0 0 0 0 0 0 1 1 1 0 0
0 0 0 0 0 0 0 0 0 1 1 0 1
0 0 0 0 0 0 0 0 0 0 0 1 0
0 0 0 0 0 0 0 0 0 0 0 0 1
−
− −

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dence matrix would be equivalent to the stoichiometric
matrix and any circulation would be equivalent to a sta-
tionary flux distribution. Note that not all circulations are
circuits: the linear combinations of circuit vectors do also
yield circulations but are not (elementary) circuits. Pre-
cisely, circuits are special circulations having two addi-
tional properties. First, they must be admissible with
respect to the directions of the involved arcs, i.e. only non-
negative values are allowed for c:
ci≥ 0 for all i.  (3)
Second, circuits are non-decomposable circulations, i.e. the
set of arcs building up the circuit c, expressed by P(c) = {i:
ci > 0}, is irreducible:
There is no non-zero vector d fulfilling eqs. (2) and (3)
and P(d)⊂ P(c) (4)
Eqs. (2) and (3) and condition (4) close the complete
analogy to elementary modes. In fact, cycles or circuits are
the elementary modes in the special case of graphs (ele-
mentary modes are defined for any matrix in eq. (2), not
only for the very special shape of incidence matrices
related to graphs). Any feasible stationary flux vector in a
metabolic network can be obtained by non-negative lin-
ear combinations of elementary modes. Equivalently, any
circulation vector can be decomposed into a non-negative
linear combination of circuit vectors. Note that, multiply-
ing a (circuit) vector c, that fulfills (2)-(4), by a scalar b>0
yields another vector v = bc which represents the same cir-
cuit because the same arcs compose it (are unequal to
zero). Moreover, all non-zero components in a circuit vec-
tor are equal to each other. Therefore we can always nor-
malize the vector in such a way that we obtain the binary
representative of this circuit where all components are
either "1" or "0".
In metabolic networks, elementary modes reveal not only
internal cycles but also, even with higher relevance, meta-
bolic pathways connecting input and output species. Con-
tinuing with the analogy to interaction graphs, in the next
subsection we will see that elementary modes can be used
to identify not only feedback loops but also signaling
paths.
Signaling (influence) paths between two species
When the interaction graph is very large it becomes diffi-
cult to see whether a species S1 can influence (activate or
inhibit) another species S2 and via which distinct path-
ways this can happen. Computing the complete set of
directed paths between a given pair (S1, S2) of species is
therefore often desirable. A path P = {a1,...,aw} is, similarly
to a feedback circuit, a sequence of arcs where none of the
nodes is visited more than once, but in the case of a sign-
aling path the start node S1 is distinct from the end node
S2, i.e. P = {a1,...,aw} = {{S1,l1}, {l1,l2}, ..., {lw-1,S2}} such
that all nodes S1, S2, l1, l2 ... lw-1 are distinct.
To obtain the signaling pathways from S1 to S2 we pro-
ceed as follows (Figure 4(a)): we add an "input arc" for S1
(i.e. a new column in the incidence matrix B containing
only zeros except a (+1) for S1) and an "output arc" for S2
(another new column in B containing only zeros except a
(-1) for S2. Then, computation of the elementary modes
in this network will provide the original feedback loops
without participation of the input and the output arc (as
shown above) and additionally all paths starting with the
input arc at S1 and ending with the output arc at S2, with
the latter revealing all possible routes between S1 and S2.
Admittedly, the introduced input and output arcs have no
tail or no head, respectively, and would therefore not be
edges in the graph-theoretical sense, but this has no con-
sequence for the analysis described within this contribu-
tion. In fact, this procedure is equivalent to adding in the
incidence matrix a "dummy" node representing the envi-
ronment (ENV), an "input arc" from ENV to S1 and an
"output arc" from S2 to ENV (Figure 4(b)). Computing
the elementary modes from the resulting incidence matrix
would produce the feedback circuits as well as the circuits
running over ENV. The latter represent the paths leading
from S1 to S2. In the procedure described above ENV is
simply removed from the incidence matrix leading to the
same results.
In order to obtain only the paths from S1 to S2 (without
the feedback loops), one can enforce the input and output
arc to be involved by using an extension of the algorithm
for computing elementary modes [43].
Example of a directed interaction graph (TOYNET)Figure 3
Example of a directed interaction graph (TOYNET). Arcs 2 
and 7 indicate inhibiting interactions, while all others are acti-
vating.Page 6 of 26
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edges simultaneously. For example, if we are interested in
all the paths connecting the input layer with the output
layer, i.e. all routes leading from a source to a sink node,
we add to each source an input edge and to each sink an
output edge and compute the elementary modes (and,
optionally, discard the feedback circuits where neither a
source nor a sink participates). In this way we obtain the
same set of signaling paths as if the elementary modes
would be computed separately for each possible pair of
source and sink nodes. Figure 5 shows the complete set of
signaling paths connecting the input with the output layer
of TOYNET.
Analogously to the feedback loops, we assign to each sig-
naling path an "overall sign" indicating whether A acti-
vates (+) or inhibts (-) B along this path. Again, the parity
of the signs of the arcs in the path determine whether the
influence is positive (even number of negative signs) or
negative (odd number of signs).
To sum up, feedback loops and influence paths in interac-
tion graphs can be identified as elementary modes (or,
equivalently, as extreme rays of convex cones [44]) from
the respective incidence matrix. Similar conclusions have
recently been drawn by Xiong et al. [45], albeit the authors
computed paths only between sink and source nodes and
only within unsigned graphs (i.e. they did not consider
inhibitory effects). Feedback circuits were also not consid-
ered. Hence, here we extend and generalize those results.
The equivalence of signaling paths and loops to elemen-
tary modes allows one the advantage to use the highly
optimized algorithms for computing elementary modes
[43,44,46].
Combinatorial studies on signaling paths
The computation of all paths between a pair of species
helps us to recognize all the different ways in which a sig-
nal can propagate between two nodes. In metabolic path-
way analysis, a statistical or combinatorial analysis of the
participation and co-occurrences of reactions in elemen-
tary modes proved to be useful for obtaining system-wide
properties, such as the detection of essential reactions/
enzymes or correlated reaction sets (enzyme subsets)
[11,26,47].
In principle, similar features are of interest also for signal-
ing paths and feedback loops. However, two important
issues arise in interaction graphs that require a special
treatment. First, we have two different types of pathways,
positives and negatives. Owing to their opposite mean-
ings we often need to analyze them separately in statistical
assessments. Second, in metabolic networks we are partic-
ularly interested in the reactions (edges), because they cor-
respond to enzymes that are subject to regulatory
processes and can be knocked-out in experiments. In con-
trast, in interaction graphs we are usually more interested
in the nodes, since they are often knocked-out in experi-
ments or medical treatments, either via mutations, siRNA
or by specific inhibitors. An edge in signaling networks
represents mostly a direct interaction between a pair of
species and has therefore no mediator. In some cases, an
edge can directly be targeted by e.g. a mutation at the cor-
responding binding site of one of the two nodes species
involved. Here, we will focus on species participation,
albeit similar computations can be made for the edges.
As mentioned several times, in signaling networks we are
often interested in all the different ways by which a certain
transcription factor (or any other species from the output
layer) can be activated or inhibited by signals arriving the
input layer. For this purpose, we compute all signaling
paths leading from source nodes located in the input layer
down to a certain sink species s of interest. We denote the
set of all these paths by Is, which can be dissected in the
two disjoint subsets of activating and inhibiting paths: I =
 ∫ . Each source species i can then be classified into
one of the following four influence classes with respect to
s:
(1) activator of s (i is involved in at least one path of 
and in no path of )
(2) inhibitor of s (i is involved in at least one path of 
and in no path of )
Is
+ Is
−
Is
+
Is
−
Is
−
Is
+
Computation of all signaling paths between two species (here: between I1 and O1)Figure 4
Computation of all signaling paths between two species 
(here: between I1 and O1). (a) via the incorporation of a 
"simplified" input and output arc; (b) with explicit introduc-
tion of an ENV („environment") node. Computing the ele-
mentary modes from the respective incidence matrix for (a) 
and (b) yields basically the same result, namely all paths 
between I1 and O1, as well as the two feedback circuits in 
the intermediate layer.Page 7 of 26
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(inhibiting) path of  and in at least one (activating)
path of )
(4) without any influence on s (i is not involved in any
path of Is)
In TOYNET, we see from Figure 5 that I2 is a pure activator
and I1 an ambivalent factor for O1. With respect to O2, I1
is an inhibitor and I2 again an activator. The qualitative
response of s after perturbing the level of a non-affecting
species, or of an inhibitor or activator can be predicted
unambiguously (namely unchanged or decreasing or
increasing, respectively) as long as the network has no
negative feedback loop. Negative feedback loops limit
such qualitative predictions for activators (or inhibitors):
if there is any path from an activator (inhibitor) to s that
touches a negative feedback loop (i.e. at least one species
on the path is involved in a negative feedback) then the
resulting effect in perturbation experiments can not be
predicted uniquely (cf. [36]). This case occurs in TOYNET
for I2 with respect to O1: I2 is an activator of O1 but the
only connecting path (P5 in Figure 5) goes through spe-
cies C which participates in the negative feedback circuit.
Thus, although at least a transient increase in O1 can be
expected after up-regulating I2, we cannot exclude that the
negative feedback drives the level of O1 below its initial
level at a certain time point after increasing the level of I2.
We therefore call an activator (inhibitor) p of s a total acti-
vator (total inhibitor) of s if there is no path from p to a spe-
cies in a negative feedback circuit that is in turn connected
to s.
Positive feedbacks do not limit these qualitative up/
down-predictions because they cannot change the mono-
tone effect of the respective input signal, e.g. when
increasing the level of I2 in TOYNET we can expect an
increase in the level of O2 after some time.
To summarize, regarding the influence of a species p on
another species s we have 6 possible cases: total and non-
total activator, total and non-total inhibitor, ambivalent
factor and non-influencing species. Note that, by comput-
ing the connecting signaling paths, this classification pro-
cedure can be applied not only between a source and a
sink node but also between any pair of species, e.g.
between a source and an intermediate, an intermediate
and a sink, and two intermediates. In TOYNET, for exam-
ple, F is a total activator of O2 and has no influence on
O1, whereas D is an inhibitor but not a total one of O1
because it is connected to (even involved in) a negative
feedback circuit.
Additionally, as the complement of incoming paths, we
can also determine the paths starting in a certain species s
showing us which nodes and arcs are reachable from (and
influenceable by) s. As a further generalization, sets of
incoming and/or outgoing paths can also be defined not
only for a single species s but also for a set S of species.
This might be useful, for example, when we are interested
in all paths ending (starting) in a certain subset of the sink
(source) nodes.
Investigations of influence and signaling paths as pro-
posed above provide, apart from pair-pair relationships
(e.g. "a is a (total) activator of b" or "a has no influence on
b"), global properties (e.g. a is a (total) activator of all sink
species). Some other useful structural features and con-
straints can be detected by a statistical or combinatorial
analysis of certain path sets (partially, similar ideas have
been proposed by [14] for stoichiometric models of sign-
aling networks):
• Essential species (arcs): When focussing on a specific sig-
naling event, e.g. the activation of a certain species by sig-
nals from the input layer, we may identify essential
species (or arcs) with respect to this event. For example,
species E and arc 9 are essential for activating O2 but non-
essential for the activating paths leading to O1 in
TOYNET.
• Species (arc) participation: A more quantitative measure
can be obtained by giving percentages of all those activat-
ing and/or inhibiting pathways, in which the species or
Is
−
Is
+
All signaling paths linking the input layer (source species) with the output layer (sink species) in TOYNETFigure 5
All signaling paths linking the input layer (source species) with the output layer (sink species) in TOYNET.Page 8 of 26
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tion to the paths where the respective species or arc is
involved or to the complete set of paths. For example, I2
is involved in 50% of all positive paths coming from the
input layer and activating O1, while I2 is involved in
100% of all paths activating O2 (but only 50% of the
paths coming from I2 lead to O2). Arc 9 is involved in one
activating and one inhibiting path leading to O2. Thus,
only 50% of the paths running over this arc are activating,
however, it is involved in all (100%) activating paths con-
necting sources with O2. Similar considerations can be
done regarding feedback loops: in TOYNET, species D and
A as well as arcs 6, 7 and 11 are not involved in paths con-
necting input with output layers and have thus a special
importance in establishing the negative (D, A, arcs 6 and
7) and positive (arc 11) feedback. (Note that a similar
measure for the importance of a species or arc is between-
ness centrality [48]. This importance measure is well-
known in graph theory and checks how many shortest
paths between pairs of nodes are running over the respec-
tive node or arc.)
• Redundancy: The total number of paths activating
(inhibiting) a species is a measure for the redundancy in
the system.
• Path length: The length distribution of signaling paths
provides a rough idea on the compactness of the network
[18].
• Crosstalk: Using our framework, crosstalk might be
defined as a place (node) where paths from different
source nodes cross each other for the first time. For exam-
ple, E is a crosstalk species in TOYNET (signals of I1 and
I2 cross) whereas F and G are not. In some cases, however,
crosstalk is a more complex phenomenon where different
nodes are involved. For example, at species C a path com-
ing from I1 via B and another path from I2 via E meet each
other. However, I1 and I2 have also met earlier in E and,
additionally, the action of I1 on C via B is already influ-
enced by I2 in species B since I2 can act on B via the path
visiting E, C, D and A.
Distance matrix and dependency matrix
Some applications presented in this section require
exhaustive enumerations of signaling paths becoming
computationally challenging in large networks. However,
in some cases we only want to know whether any activat-
ing and/or any inhibiting path between two nodes exists
or whether there is any positive or any negative feedback
circuit in which a certain species is involved. For such
"existence questions" we can often apply standard meth-
ods from graph theory. A very useful object is the distance
matrix D which can be obtained with low computational
demand by computing the shortest distances (shortest
path lengths) between each pair of species (e.g. Dijkstra's
algorithm [32]). D has dimension m × m and the element
Dij stores the length of the shortest path for traveling from
node i to node j, being Dij = ∞ if no paths exists between i
and j. The distance matrix shows immediately
• which elements can be influenced by species i (the i-th
row of D)
• which nodes can influence species i (i-th column of D)
• whether feedback circuits exist: if the distance Dii from a
node i back to itself is finite, then i is involved in at least
one feedback loop. Furthermore, if Dij and the transposed
element Dji are finite, Dij, Dji≠∞, then a feedback between
species i and j exists.
By an extension of the usual shortest path algorithm (not
shown), we may also compute separately a matrix Dpos for
the shortest positive paths and another Dneg for the shortest
negative paths. Table 1 shows the distance matrices Dpos
and Dneg from TOYNET.
Table 1: Shortest length of positive/negative paths in TOYNET (∞= no path exists). Values in the diagonal indicate whether the 
respective element is involved in a positive/negative feedback loop. See also the dependency matrix in Figure 6.
I1 I2 A B C D E F G O1 O2
I1 ∞/∞ ∞/∞ 4/4 1/∞ 2/2 3/3 ∞/1 ∞/2 ∞/3 3/3 ∞/4
I2 ∞/∞ ∞/∞ ∞/4 ∞/5 2/∞ 3/∞ 1/∞ 2/∞ 3/∞ 3/∞ 4/∞
A ∞/∞ ∞/∞ ∞/4 1/∞ 2/∞ 3/∞ ∞/∞ ∞/∞ ∞/∞ 3/∞ ∞/∞
B ∞/∞ ∞/∞ ∞/3 ∞/4 1/∞ 2/∞ ∞/∞ ∞/∞ ∞/∞ 2/∞ ∞/∞
C ∞/∞ ∞/∞ ∞/2 ∞/3 ∞/4 1/∞ ∞/∞ ∞/∞ ∞/∞ 1/∞ ∞/∞
D ∞/∞ ∞/∞ ∞/1 ∞/2 ∞/3 ∞/4 ∞/∞ ∞/∞ ∞/∞ ∞/4 ∞/∞
E ∞/∞ ∞/∞ ∞/3 ∞/4 1/∞ 2/∞ ∞/∞ 1/∞ 2/∞ 2/∞ 3/∞
F ∞/∞ ∞/∞ ∞/∞ ∞/∞ ∞/∞ ∞/∞ ∞/∞ 2/∞ 1/∞ ∞/∞ 2/∞
G ∞/∞ ∞/∞ ∞/∞ ∞/∞ ∞/∞ ∞/∞ ∞/∞ 1/∞ 2/∞ ∞/∞ 1/∞
O1 ∞/∞ ∞/∞ ∞/∞ ∞/∞ ∞/∞ ∞/∞ ∞/∞ ∞/∞ ∞/∞ ∞/∞ ∞/∞
O2 ∞/∞ ∞/∞ ∞/∞ ∞/∞ ∞/∞ ∞/∞ ∞/∞ ∞/∞ ∞/∞ ∞/∞ ∞/∞Page 9 of 26
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Dneg, D can be obtained. Moreover, the two matrices Dpos
and Dneg, whose computation is reasonably possible in
very large networks, are sufficient to classify all species
into (total/non-total) activators, (total/non-total) inhibi-
tors, ambivalent factors, and non-influencing nodes with
respect to a certain compound y. The reason is that this
classification requires only knowledge on the existence of
positive and negative paths between species pairs and on
the existence of negative feedback loops. For example, a
species x is a total activator of y if (i) at least one positive
path from x to y exits (  ≠ ∞) and if (ii) no negative
path from x to y exists (  = ∞) and if (iii) for any spe-
cies z that is influenced by x (Dx, z ≠ ∞) and connected to y
(Dz, y ≠ ∞) it holds, that z is not involved in a negative feed-
back (  = ∞).
For representing species dependencies in a compact man-
ner, we introduce the dependency matrix M, which shows
all the pair-wise dependencies, e.g. by using 6 different
colors (for the 6 possible cases). Thereby, the color of
matrix element Mxy indicates whether species x is a total/
non-total activator or a total/non-total inhibitor or an
ambivalent factor or a non-influencing node for species y.
Again, x = y is allowed, indicating feedbacks. Figure 6
shows the dependency matrix for TOYNET.
Although the distance and dependency matrices store a
wealth of structural information in a very condensed
manner, some applications still require a full enumera-
tion of all available signaling paths. One case is the sys-
tematic determination of minimal cut sets.
Minimal cut and intervention sets in interaction graphs
Searching for intervention strategies in signaling networks
is of high relevance in experimental and, in particular,
medical applications. Recently, the concept of minimal cut
sets has been introduced, which facilitates the identifica-
tion of efficient intervention strategies (cuts) and, at the
same time, the recognition of potential failure modes in a
given biochemical reaction network [28,29]. Basically, in
the most general version, a minimal cut set (MCS) is
defined as a minimal (irreducible, non-decomposable)
set of cuts (or failures) of edges or/and nodes that
represses a certain functionality or behavior in the system
[29]. For example, assume we want to prevent the activa-
tion of the sink node O1 in TOYNET. By removing nodes
{B, E} one can be sure that an activation of O1 by an
external stimulus becomes infeasible. The set {B, E}
would thus be a cut set for preventing the activation of
O1. Moreover, it is minimal since neither the removal of
only B nor the removal of only E can guarantee that the
"inhibition task" is achieved. Another minimal cut set
would be {C}. C is thus essential for activating O1, as
would be confirmed by participation analysis of all paths
activating O1. A general algorithmic scheme for a system-
atic enumeration of MCSs in stoichiometric networks was
given in [29]:
(i) Define a deletion task
(ii) Compute all minimal functional units (elementary
modes) and specify the set of target modes that have to be
attacked in order to achieve the deletion task
(iii) Compute the so-called minimal hitting sets of the tar-
get modes
We could proceed here in a similar way. First, a deletion
task specifying the goal of our intervention is defined. In
our example, the deletion task is "Prevent the activation of
O1 by any external input". Hence, the signaling paths
from the input layer to O1 are computed, which are P1,
P2, and P5 (see Figure 5). However, according to our dele-
tion task, the target set comprises only the paths P1 and
P5, because only these two activate O1. Finally, the mini-
mal hitting sets of the target paths have to be computed,
which are the MCSs [26,29]. When cutting species, a hit-
ting set T is a set of species that "hits" all target paths in a
minimal way, i.e. for each target path there is at least one
species that is contained in T and in the path. To be a min-
imal hitting set, no proper subset of T fulfills the hitting set
condition. The minimal hitting sets of the target paths and
hence the MCSs of our deletion task would be: {C}, {B,
E}, {I2, B}, {I1, E} and {I1, I2}. Deletion tasks may be
more complicated: for example, in TOYNET we might be
interested to repress the activation of O1 and O2. Accord-
ingly, the target paths would increase by one (P4 in Figure
5) resulting in another set of MCSs.
This example might suggest that we can use the same pro-
cedure as in metabolic networks, namely computing the
minimal hitting sets with respect to the target paths. This
naive approach works indeed for the case where the target
paths do only involve positive arcs (as in our example). It
can also be applied for interrupting any set of feedback cir-
cuits. For example, removing {A} interrupts the negative
feedback circuit and deleting {D, F} interrupts both feed-
back circuits in TOYNET. However, in general, negatively
signed arcs occurring in interaction graphs require a spe-
cial treatment. Even the following simple activating path
leading from a source species I to a sink species O contains
pitfalls:
. If the activation of O
is to be repressed, the signal flow along this path must be
Dx y
pos
,
Dx y
neg
,
Dz z
neg
,
I A B C O+ − − + →  →  →  →Page 10 of 26
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be sufficient. However, not all nodes are allowed to be cut.
If species B is removed, its negative action on C would be
interrupted, enabling in turn C to activate O. The reason
is that B, according to the definitions, is an inhibitor of O
and is therefore not a proper cut candidate. In fact, we
could add (constitutively provide or activate) B to stop an
activation of O. Generally, for attacking an activating path,
only the species that have an activating effect on the end
node of this path are proper cut candidates, whereas spe-
cies inhibiting the end node should instead be kept at a
high level to prevent an activation along this path. Hence,
as a generalization of (minimal) cut sets, we define (min-
imal) intervention sets (MISs) in interaction networks as
(minimal) sets of elements that are to be removed or to be
added in order to achieve a certain intervention task. By
allowing only the removal of elements, the set of MISs
coincides with the MCSs.
The computation of the MISs (or the smaller set of MCSs)
for a set of activating target paths that involve negatively
signed arcs is a more difficult task than computing only
minimal hitting sets. Indeed, each MIS will still represent
a hitting set, because at least one species in each target
path must be removed or constitutively provided. The dif-
ficulty arises by ambivalent factors which have in some
target paths an activating and in others an inhibitory effect
upon the end node. We could therefore restrict the inter-
ventions to those species that are either pure activators
with respect to the target paths (these are allowed to be
removed) or pure inhibitors (these are allowed to be
added). Using only these species, the MISs could again be
computed as the minimal hitting sets.
However, for computing MISs that may also act on ambiv-
alent factors, we present a more general algorithm (here
for a given set of activating target paths):
(1) In each target path, the involved nodes are labeled by
+1 (if the species influences the end node of the respective
path positively) or by -1 (if the species has a negative influ-
ence on the end node of the respective path).
(2) Combinations Ci of one, two, three, ... distinct
removed or activated species are constructed systemati-
cally. For each combination Ci, it is checked for each target
path whether the signal flow from the start node to the
end node is interrupted properly. A requirement is that at
least one of the positive (+1) species of each path is
removed or at least one negative (-1) species is provided
(added) by Ci (hitting set property). If, for a certain path,
Ci contains several nodes that are visited by this paths then
it is only checked whether the node closest to the end
node is attacked properly. When all paths have been
attacked (hit) properly by a combination Ci, then a new
MIS has been found. When constructing further combina-
tions of larger cardinality, the algorithm has to ensure that
none of the new combinations contains an earlier found
MISs completely.
Of course, this enumerative algorithm is even more time
consuming than computing minimal hitting sets and it
will become infeasible to compute all MISs in large net-
works. We may then restrict ourselves to MISs of low car-
dinality and/or to the subset of MCSs. Besides, the
determination of MISs can become even more compli-
cated: it might happen that a MIS attacks all activating tar-
get paths correctly but simultaneously destroys an
inhibiting path (not contained in the set of target paths)
which might then become an activating path. The MCS
{I1, I2} of our example represents such a problematic
case: it hits the two activating paths to O1 as demanded,
but it also attacks the inhibiting path leading from I1 to
O1. Thus, the inhibition of E through I1 would be inter-
rupted and it could be sufficient to retain E in an active
state enabling the activation of O1. Hence, we would not
be sure about the activation status of O1 after removing
this cut set. To avoid such side-effects, we may extend our
algorithm given above by checking also the consequence
of each intervention Ci with respect to the non-target
paths and exclude combinations that do not fulfill certain
criteria.
In a completely analogous fashion, we can also determine
MCSs or MISs that repress inhibitory paths. For example,
removing {I1} is a MCS that attacks the only inhibiting
path to O1, alternatively we might use the MISs {#E} or
{#C}, where # stands for "constitutively provided". The
same issues as discussed above must be taken into account
when interrupting a negative path: here, in each target
path, only the inhibiting species of the final sink source
should be removed whereas the activating nodes can be
added. Furthermore, we may also define more compli-
cated intervention tasks, e.g. where some activating and
some inhibiting paths are selected as target paths.
Jacobian matrix and interaction graph
Several works have highlighted the strong relationships
between interaction graphs and the Jacobian matrix J, the
latter obtained from a dynamical model of the network
under investigation [10,35,39]. A dynamic model of a sig-
naling (or any kind of interaction) network is usually
described by a system of ordinary differential equations
that model the evolution of the m network components x1
... xmwith the time:Page 11 of 26
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tives of F with respect to x:
 
The sign of Jik(x) tells whether xk has a (direct) positive or
negative influence on xi and sign(J(x)) can thus be seen as
the adjacency matrix of the underlying interaction graph.
In an adjacency matrix Y, a non-zero entry for Yik indicates
an edge from node i to k. Adjacency and incidence matrix
are equivalent for describing a graph structure and can be
converted into each other: each non-zero element Yik gets
a corresponding column in the incidence matrix.
The sign structure of the Jacobian matrix is, in biological
systems, typically constant and reflects, despite its very
qualitative nature, fundamental properties of the dynamic
system. For example, multistationarity can only occur if a
positive circuit exists in the associated interaction graph
[39]. Methods for the detection of multistability in a spe-
cial class of dynamical systems – monotone I/O systems –
have been developed by Sontag et al. [36]. Monotone I/O
systems possess a monotonicity property that can be
checked from the interaction graph spanned by the Jaco-
bian matrix. In fact, having one source species and one
sink species, the required monotonicity property is equiv-
alent to our definition of a total activator of the sink node.
Thus, the methods developed in the previous section may
support such studies, where the structure of the Jacobian
matrix is analyzed. Having the absolute values of the Jaco-
bian matrix available (which change over time), arcs,
paths, and feedback circuits could be assigned an interac-
tion strength useful to identify key elements in the net-
work.
Boolean networks and (logical) interaction hypergraphs
Definitions
The methods described above consider an interaction as a
dependency between two species allowing to employ
tools from graph theory. However, in cellular networks,
an interaction (edge) often represents a relationship
among more than two species (nodes). A typical example
is a bimolecular reaction of the form A+B→ C, where three
species are involved. The binding of the ligand to the
receptor in Figure 2(b) (Rec+Lig→ RecLig*) is such a
bimolecular interaction. Using an interaction graph, this
reaction is modeled with two arcs (Figure 7(a)), namely
Rec→ RecLig* and Lig→ RecLig*, capturing correctly that
Rec and Lig have an influence on RecLig*. However, this
relaxed representation has shortcomings for a functional
interpretation of the network. To exemplify this, consider
the minimal cut sets repressing the phosphorylation of M
in Figure 7(a). As explained in the previous section, we
need to attack all positive paths leading to M-P. There are
two positive paths, one starting from Rec and the other
from Lig and, thus, {Rec, Lig} would be a minimal cut set.
But, intuitively, this cut set is not minimal for the real sys-
tem because both Rec and Lig are required for activating
M, and removing only one of the two species is thus suffi-
cient to interrupt the activation of M. (In other words, the
existence of a signaling path in an interaction graph does
not ensure that a signal can flow along this path.)
This example reveals that a proper consideration of AND-
connections between species is required. However, AND-
relationships are not possible in graphs but in hyper-
graphs, which are generalizations of graphs. Similar to a
directed graph, a directed hypergraph H=(V, A) consists of
a set V of nodes and a set A of hyperarcs (= directed hyper-
edges [49]). A hyperarc aconnects two subsets of nodes: a
= {S,E}; S,E⊂ V. S comprises the tail (start) nodes and E
the head (end) nodes of the connection. S and E can have
arbitrary cardinality, and a graph is a special case of a
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Dependency matrix of TOYNETFigure 6
Dependency matrix of TOYNET. The color of a matrix ele-
ment Mxy has the following meaning: (i) dark green: x is an 
total activator of y; (ii) light green: x is a (non-total) activator 
of y; (iii) dark red: x is a total inhibitor of y; (iv) light red: x is 
a (non-total) inhibitor of y; (v) yellow: x is an ambivalent fac-
tor for y; (vi) black: x does not influence y;Page 12 of 26
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edges.
In our context, without loss of generality, we will usually
have only one end node in E and we interpret a hyperarc
as an interaction in which the compound contained in E
is activated by a combined action of the species contained
in S. Figure 7(b) depicts the example with the receptor-lig-
and-complex as a hypergraph in which a hyperarc cap-
tures now the AND-connection between Rec and Lig
yielding RecLig*.
AND connections facilitate a refined representation of sto-
ichiometric conversions within interaction networks,
albeit the precise stoichiometric coefficients are not cap-
tured here. Apart from stoichiometric interactions, AND
connections allow the description of other dependencies,
for example, the case where only the presence of an acti-
vator AND the absence of an inhibitor leads to the activa-
tion of a certain protein.
In TOYNET, the four nodes (B, C, E, F) have more than
one incoming arc (Figure 3). In these nodes it is undeter-
mined how the different stimuli are combined, e.g.
whether B AND E are required to activate C or whether
one of both is sufficient (B OR E).
We could therefore concatenate all incoming edges in a
node by logical operations leading to Boolean networks
[21,31]. An assumption underlying Boolean networks is
to consider only discrete (concentration/activation) levels
for each species; in the simplest case a species can only be
"off" (= 0 = "inactive" or "absent") and "on" (= 1 =
"active" or "present"). Hence, each species is considered
as a binary (logical) variable. Next, a Boolean function fi
is defined for each node i which determines under which
conditions i is on or off, respectively. fi depends only on
those nodes in the interaction graph from which an arc
points into species i. In general, for constructing a Boolean
function, all logical operations like AND, OR, NOT, XOR,
NAND can be used. However, here we express each
Boolean function by a special representation known as
sum of products (SOP; also called (minimal) disjunctive
normal form (DNF)) which is possible for any Boolean
function [50]. SOP representations require only AND, OR
and NOT operators. In a SOP expression, literals, which
are Boolean variables or negated Boolean variables, are
connected by AND's giving clauses. Several such AND
clauses are then in turn connected by OR's. Using the
usual symbols '·' for AND, '+' for OR and '!' for NOT, an
example of a SOP expression would be: fi = x·y·z + x·!z
stating that fi gets value "1" if (x AND y AND z are active)
OR (if x is active AND z is NOT) and "0" else. The SOP
expression fi = x·!y + !x·y mimics an XOR gate.
In our context, writing a Boolean function as a SOP has
several advantages. First, many biological mechanisms
that lead to the activation of a species correspond directly
to SOP representations. Second, by using SOPs, the struc-
ture of a Boolean network can be represented and
depicted intuitively as a hypergraph: each hyperarc point-
ing into a node i is an AND clause of other nodes and rep-
resents one way of activating i; hence, all hyperarcs ending
in i are OR'ed together. A hyperarc carries a signal flow to
its end node and the binary value of the flow depends on
the state of all its start nodes. In the following, such a
hypergraph induced by a minimal SOP representation of
a Boolean network will be called a logical interaction hyper-
graph (LIH).
In Figure 8 a possible instance of a LIH compatible with
the interaction graph of TOYNET in Figure 3 is depicted.
In each of the four nodes with more than one incoming
arc, the logical concatenation has now been specified. For
example, B is now activated if A AND I1 are active simul-
taneously (hyperarc "1&4"). In contrast, C is activated if B
OR E is present (active), and F is active if E OR G are in an
active state. Hence, C and F retain their graph-like struc-
ture.
Inhibiting arcs in the interaction graph are interpreted in
the corresponding LIH as NOT-operations. Thus, arc 7 is
now interpreted as "A is active if D is not present". Since
arc 2 and 3 in Figure 3 have been combined with an AND
in Figure 8, we interpret this new hyperarc as "E becomes
activated if I2 is present AND I1 NOT". Hence, in contrast
to inhibiting arcs in interaction graphs, in general we do
not assign a minus sign (a NOT) to the complete hyperarc,
but to its negative branches (see hyperarc 2&3 in Figure
8), whereas all other branches get positive signs. Due to
the assignment of signs LIHs can formally be seen as
signed directed hypergraphs.
The pure logical description of a signaling or regulatory
network works well when the activation (inhibition) of a
species by others follows a sigmoid curve [21]. Problems
that might arise while describing a real network within the
logical framework and possible solutions are discussed in
a later section.
LIHs can be formally represented and stored in a similar
way as interaction graphs. The underlying hypergraph is
stored by an m × n incidence matrix B in which the rows
correspond to the species and the columns to the n hyper-
arcs. If species i is contained in the set of start (tail) nodes
of a hyperarc k then Bik = -1, if i is the endpoint (head) of
hyperarc k then Bik = 1, and if i is not involved in k we have
Bik = 0. For storing the NOTs operating on certain species
in a hyperarc we may use another m × n matrix U that
stores in Uik a "1" if species i enters the hyperarc k with itsPage 13 of 26
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matrix B for the LIH of TOYNET (Figure 8) reads
 
To be concise, the two non-zeros entries of U are indicated
by an asterisk in the incidence matrix.
Representing a Boolean network as a LIH we can easily
reconstruct the underlying interaction graph from the
matrices B and U: we simply split up the hyperarcs having
more than one start node (or/and more than one end
node in the general case). Thus, a hyperarc with d start and
g end nodes is converted into d·g arcs in the interaction
graph. The sign of each arc in the graph model can be
obtained from U. The reverse, the reconstruction of the
LIH from the interaction graph, is not possible in a unique
manner underlining the non-deterministic nature of
interaction graphs.
Time in Boolean networks
A logical interaction hypergraph describes only the static
structure of a Boolean network. However, it is the dynamic
behavior of Boolean networks that has been analyzed
intensely in the context of biological (especially genetic)
systems [21,31,51]. For studying the evolution of a logical
system we need to introduce the (discrete) time variable t
and a state vector x(t) that captures the logical values of
the m species at time point t. Two fundamental strategies
exist to derive the new state vector x(t+1) from the current
state x(t). In the synchronous model, the logical value of
each node i is updated by evaluating its Boolean function
fi with the current state vector: xi (t+1) = fi(x(t)). Synchro-
nous models are deterministic but assume for all interac-
tions the same time delay which is often too unrealistic for
biological systems [21]. In the asynchronous model, we
select any (but only one) node i whose current state is
unequal to its associated Boolean function: xi (t) ≠ fi(x(t)).
Only this node switches in the next iteration. Since there
are, in general, degrees of freedom in choosing the switch-
ing node, this description is non-deterministic. The
advantage is that the complete spectrum of potential tra-
jectories is captured, albeit the graph of sequences is usu-
ally very dense, complicating its analysis in large systems.
The asynchronous description becomes (more) determin-
istic if time delays for activation and inhibition events are
known [21].
We are now approaching the main part of this section.
Logical steady-state analysis
An important characteristic of the dynamic behavior of
Boolean networks, which is equivalent for both asynchro-
nous and synchronous descriptions, is the set of logical
steady states (LSSs). LSSs are state vectors xs obeying  =
fi(xs) for all nodes i. Hence, in LSS, the state of each node
is consistent with the value of its associated Boolean func-
tion and, therefore, once a Boolean network has moved
into a logical steady state, it will stop to switch and then
retain this state.
In the following, we will focus on logical steady state anal-
ysis (thus circumventing any interpretation problems that
might arise by choosing synchronous or asynchronous
description), which suffices for a number of applications,
especially for predicting potential functional states in sig-
naling or regulatory networks.
Given a Boolean network we may enumerate all possible
LSSs [52]. However, this is computationally difficult in
large networks. Besides, we are often interested in particu-
lar LSSs that can be reached from a given initial state x0. In
some cases, we only know a fraction of all initial node val-
ues. For example, a typical scenario in signaling networks
would be that initial values from species in the input layer
are known (specifying which external signals reach the
cell and which not), and we would like to know how the
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nals generate a certain logical pattern in the output layer.
Of course, we have to "wait" until the signals reach the
bottom of the network and, for obtaining a unique
answer, there should be a time point from which the states
will not change in the future. This is equivalent to deter-
mining the LSS in which the network will run from a given
starting point.
In a possible scenario for TOYNET, the initial values of the
source species I1 and I2 might be known to be  = 0 and
 = 1, whereas the initial states of all other nodes are
unknown (Figure 9(a)). The states of I1 and I2 will not
change anymore because I1 and I2 have no predecessor in
the hypergraph model. Assuming that each interaction
has a finite time delay, E must become active and B inac-
tive. From these fixed values we can conclude that C and
F will definitely become active (by E) at a certain time
point and not change this state in the future. Proceeding
further in the same way, we can resolve the complete LSS
resulting from the given initial values of I1 and I2 (Figure
9(b)).
The last example illustrated that partial knowledge on ini-
tial values, especially from the source nodes, can be suffi-
cient to determine the resulting LSS uniquely. However, in
general, several LSSs might result from a given set of initial
values or a LSS may not exist at all. For example, if we only
know  = 1 in TOYNET nothing can be concluded
regarding a LSS (except that I2 will retain its state). If no
complete LSS can be concluded uniquely from initial val-
ues, there might nevertheless be a subset of nodes that will
reach a state in which they will remain for the future. For
example, setting  = 1 E will definitely become inacti-
vated after some time (again, finite time delay is
assumed). Since in this scenario nothing further can be
derived for other nodes, we would say that xI1 = 1 and xE =
0 are partial LSSs for the initial value set {  = 1}. Note
that these two partial steady states would not change
when we specified more or even all initial values.
We have conceived an algorithm which derives partial
LSSs that follow from a given set of initial values (if for
each node a partial LSS can be found, then a unique and
complete LSS exists for the set of initial values). The itera-
tive algorithm uses the following rules in the logical
hypergraph model:
• initial values of source nodes will not change in the
future, hence, are partial LSSs
• if species i has a proved partial LSS of 0, all hyperarcs in
which i is involved with its non-negated value have a zero
flow
• if species i has a proved partial LSS of 1, all hyperarcs in
which i is involved with its negated value have a zero flow
• if all hyperarcs pointing into node i have a zero flow,
then i has a partial LSS of 0
• if all start nodes of a hyperarc have a partial LSS of 1 (or
of 0 for those start nodes entering the hyperarc with the
negated value) then a partial LSS of 1 follows for the end
node of this hyperarc
• knowing all the positive feedback circuits in the system,
we can check whether there is a "self-sustaining" positive
circuit where the known initial state values of the involved
nodes guarantee a partial LSS for all the nodes in this cycle
(see comments below)
In each loop, the algorithm tries to identify new partial
LSSs (following from the current set of partial LSSs already
identified) until no further ones can be found. Setting ini-
tial values in the input layer, this can be envisioned as a
propagation of signals through the interaction network
xI1
0
xI2
0
xI2
0
xI1
0
xI1
0
Table 3: All negative and positive feedback loops in the T-cell model as determined by CellNetAnalyzer. Negative influences are 
indicated by "", positive influences are expressed by "→".
1 (negative) TCRbind → TCRphos → ZAP70 → cCbl  TCRbind
2 (negative) TCRbind → Fyn → TCRphos → ZAP70 → cCbl  TCRbind
3 (negative) TCRbind  PAGCsk  Lck → ZAP70 → cCbl  TCRbind
4 (negative) TCRbind  PAGCsk  Lck → TCRphos → ZAP70 → cCbl  TCRbind
5 (negative) PAGCsk  Lck → Fyn → PAGCsk
6 (negative) TCRbind  PAGCsk  Lck → Fyn → TCRphos → ZAP70 → cCbl  
TCRbind
7 (negative) cCbl  ZAP70 → cCbl
8 (positive) TCRbind → Fyn → PAGCsk  Lck → TCRphos → ZAP70 → cCbl  
TCRbind
9 (positive) TCRbind → Fyn → PAGCsk  Lck → ZAP70 → cCbl  TCRbindPage 15 of 26
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is not sufficient to derive a unique LSSs.
Generally, in logical interaction hypergraphs where the
underlying interaction graph has no feedback loop (i.e. is
acyclic), specification of the initial values of all the source
nodes will always result in a unique and complete LSS
since the signals can be propagated step by step from top-
down to the output layer. In general, if all initial values are
known for the input layer, non-uniqueness or even non-
existence of partial LSSs can only be generated by feedback
loops. The partial LSSs of nodes involved in positive feed-
backs do often depend on the initial values of all the
nodes in this loop. For example, defining  = 0 we can
conclude a partial LSSs of zero for E in TOYNET (Figure
8), but, among others, the values of F, G and O2 remain
unknown although the only connection to a source node
leads via E. The reason is that F and G build up a positive
feedback loop which cannot be resolved without knowl-
edge on further initial values. If we know, additionally to
 = 0, that  = 1 then F and G will always keep
each other activated so that we can infer a partial LSS of 1
for F, G and O2 (this is the last rule in the list given
above). If we have instead  = 0, we derive a 0 for
the partial LSS of these three nodes. If one of the two
nodes F and G has an initial value of 1 and the other 0,
nothing can be derived since the positive loop might
become fully activated or fully deactivated. However,
what can be confirmed in these simple examples is that
positive feedback loops induce multistationarity. It is
noteworthy that continuous dynamic models of networks
with positive feedbacks will depend, apart from kinetic
parameters, in a similar fashion on initial state values.
In contrast, negative feedback loops are not sensitive
against initial values but they can be the source of oscilla-
tions, preventing hence the existence of LSSs. In TOYNET
we have one negative feedback loop which can potentially
generate oscillations, for example, when we set  = 1.
Then, C cannot be activated via E. Assuming an initial
value of 0 for C (the same conclusion would be drawn
with 1), D becomes deactivated and thus A actived. Due
to the partial LSS of 1 for I1 we get an activation of B and
then of C and D which in turn inhibits A leading in the
next round to a deactivation of B, C and D and so on. The
logical states within this circuit and downstream of it
(O1) will thus never reach a steady state. As shown in
[21], oscillatory behavior in logical models corresponds
to oscillations or a stable equilibrium (lying somehow
between the fully activated and fully inactivated level) in
the associated continuous model, depending on the cho-
sen parameters. Negative feedback loops can thus impede
predictions on the basis of logical steady states, but they
also point to network structures whose parametrization
will have great impact on the dynamic behavior.
Note that feedback loops do not always prevent predic-
tions on (partial) LSSs as can be seen by the example in
Figure 9, it depends on the given initial values.
Such a logical steady state or "signal flow" analysis (SFA)
as presented herein shares similarities with the established
method of metabolic flux analysis [53]. In MFA, uptake
and excretion rates of cells are measured in order to recon-
struct the intracellular flux distribution within a metabolic
network. MFA relies on the quasi-steady state assumption,
similarly as SFA relies on LSS. However, whereas MFA tries
to reconstruct the reaction rates along the edges and noth-
ing can be said on the states of the species, the goal of SFA
is to determine the steady states of the nodes (belonging
to a given activation scheme) from which then the signal
flows along the edges follow. It is noteworthy that the cal-
culability of unknown reaction rates in MFA depends only
on the set of known rates [54], whereas in SFA the set of
given initial states and their respective values determine the
unique calculability of (partial) LSSs.
Applications of logical steady state analysis
The LSS analysis introduced herein offers a number of
applications for studying functional aspects in cellular
interaction networks:
xI2
0
xI2
0 x xF G
0 0
=
x xF G
0 0
=
xI1
0
Logical interaction hypergraph of TOYNET (compare with interact on graph in Figure 3)Fi ure 8
Logical interaction hypergraph of TOYNET (compare with 
interaction graph in Figure 3).Page 16 of 26
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Imposing different patterns of signals in the input layer
one may check which species become activated or inhib-
ited in the intermediate and, in particular, in the output
layer. This can also be simulated in combination with dif-
ferent initial state values for certain intermediate nodes,
albeit this will have an influence on the LSS only in con-
nection with positive feedbacks, as shown above.
Mutants and interventions
The changes in signals flows and in the input-output
behavior occurring in a manipulated or malfunctioning
network can be studied by removing or adding elements
or by fixing the states of certain species in the network. In
TOYNET, for example, if we want to study the effect of a
mutant missing F (or the effect of adding an inhibitor for
F) we may remove species F from the network (or, equiv-
alently, fix the state of F to zero) and compute then the
partial LSSs again. We will see that, independently of a
given pattern in the input layer, G and O1 will be assigned
a partial LSS of 0. Removing elements often changes not
only the values, but also the determinacy of partial LSSs.
Minimal cut sets (MCSs) and minimal intervention sets (MISs)
The definiton of MCSs and MISs in logical interaction
hypergraphs is similar as in interaction graphs: a MCS is a
minimal (irreducible) set of species whose removal will
prevent a certain response or functionality as defined by
an intervention goal. In the more general MISs we permit,
additionally to cuts, also the constitutive activation of cer-
tain compounds. Two examples in TOYNET: removing F
is a MCS for repressing an activation of G and O2. Assum-
ing an initial state of zero for the species in the intermedi-
ate layer, adding I1 and removing B would be a proper
MIS for repressing the activation of O1 and O2. Note that
in the interaction graph of TOYNET, this intervention
would not suffice to attack all activating paths leading
from the input layer to O1 and O2 (path P4 not attacked,
Figure 5). This example underscores again that MCSs and
MISs in interaction hypergraphs are usually smaller than
those obtained from the underlying interaction graph,
simply because more constraints are added by logical
combinations. However, the determination of MCSs, and
let alone MISs, in logical interaction hypergraphs is com-
binatorially complicated as in interaction graphs, in par-
ticular when negative signs (NOTs) occur. Here, we can
only propose a "brute-force" approach where the LSS
analysis serves algorithmically as an oracle: we check sys-
tematically for each combination of one, two, three ...
knocked out (for MISs also of permanently activated)
nodes in the network how this affects the (partial) LSSs,
possibly in combination with a given scenario of initial
states. From the resulting partial LSSs we can decide
whether our intervention goal has been achieved or not.
To compute only minimal cut or intervention sets, further
combinations with a cut or intervention set already satis-
fying our intervention goal have to be avoided. The algo-
rithm can be stopped when a user-given maximum
cardinality for the MCSs/MISs has been reached.
Backward propagation
The methods described above compute partial LSSs actu-
ally only by forward propagation of signals, but one may
also do the opposite, e.g. fixing values in the output layer
and tracing back the required states of nodes in the inter-
mediate and input layer using similar rules as for forward
propagation.
Network expansion methods
There is an interesting relationship between our LSS anal-
ysis and network expansion methods proposed by Eben-
höh et al. [55]. Network expansion allows for checking
which metabolites can in principle be produced from a
provided set of start species within a metabolic (stoichio-
metric) reaction network. This is a special case in our log-
ical framework. Briefly, metabolic networks are per se
hypergraphs and can thus be represented as a LIH by using
only AND's (each reaction is an AND clause of its reac-
tants; stoichiometric coefficients are not considered) and
OR's. Hence, no inhibiting interactions exist. We may
then put the supplied set of available species in the input
layer, set the initial values of all other species to zero and
compute then the LSS. Note that, according to the expla-
nations given above, a complete LSS will always be found
since all initial values are given and no negative feedback
circuit exists. Therefore, the computed LSS indicates
which species can be produced from the input set and
which not.
Extensions for the logical description of interaction networks
Several extensions and refinements of the logical frame-
work can be introduced which allow a more appropriate
description of real signaling and regulatory networks:
(1) As already proposed and applied by Thomas et al.
[21], the discretization in more than two levels is in prin-
ciple possible. This mimics the fact, that in reality multi-
ple relevant threshold values for a species may exist. A
refined discretization could be relevant, for instance, for a
species that activates/inhibits more than one species (with
different threshold levels). Another relevant situation
occurs if a species can be activated via two paths (con-
nected by an OR; see species C in TOYNET): the activation
via both paths might be significantly stronger than by only
one. However, considering several activation levels for a
certain species forces one to often consider multiple levels
for elements downstream or/and upstream of this species,
increasing hence the complexity of the network, and
requiring detailed knowledge which is often not available.Page 17 of 26
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dictability in LSS analysis. However, in cellular networks,
negative feedbacks become activated often upon a certain
time period after an activation event occurs, for example,
when gene expression is involved. This might be consid-
ered by classifying species and/or hyperedges by assigning
a discrete time constant (or time scale) τ to each element
telling us whether this network element appears in an
early (τ = 1) or late (τ = 2) state. Using the sub-network
with all elements having a time constant of τ = 1 for the
first simulation and then using the computed LSSs as ini-
tial values for computing the second round (where the
complete network is considered) leads often to more real-
istic results. As in the case of multiple levels, this extension
requires a more detailed knowledge about the network
under consideration. An example in TOYNET (Figure 8):
we may assume that D is a factor that is transcriptionally
regulated by C, thus, arc 6 has a time constant of τ = 2 and
all others have τ = 1. Setting the initial values I1 = 1, I2 =
0 and D = 0 and computing the LSSs for τ = 1 activation of
C and O1 occurs. We can then fix the state of D (D = 1)
and get then a complete deactivation of C and O1.
(3) In real signaling and regulatory networks, it is some-
times difficult to decide whether arcs from the interaction
graph have to be linked by an AND or an OR in the inter-
action hypergraph. For example, in TOYNET, species E is
inhibited by factor I1 and activated by factor I2. If I1 has
a very strong inhibiting effect on E we may formulate the
hyperarc as done in Figure 8, suggesting that I1 must not
be active for activating E. However, if the interaction
strength of both I1 and I2 with respect to E is at the same
level (i.e. additive) neither "NOT(I1) OR I2" nor
"NOT(I1) AND I2" would reflect the real situation.
Indeed, this is a recurring situation in signaling networks,
where often a balance between different signals deter-
mines the activation of a certain element. At this point it
could be helpful to use logical operations that have a par-
tially incomplete truth table. In the latter example we
could say that E is active if (NOT(I1) AND I2) and E is
inactive if (I1 AND NOT(I2)). For the other two possible
cases, no decision could be made along this hyperedge. Of
course, modeling uncertainty in this way will limit the
determinacy but on the other hand a determined result
with this model allows a safer interpretation.
Analyzing interaction networks using CellNetAnalyzer
We have integrated many of the methods and algorithms
described herein in our software tool CellNetAnalyzer,
which is a MATLAB package and the successor of FluxAna-
lyzer [56]. Whereas FluxAnalyzer was originally developed
for structural and functional analysis of metabolic net-
works, CellNetAnalyzer extends these capabilities conse-
quently to the structural analysis of signaling and
regulatory networks. Apart from stoichiometric (meta-
bolic) reaction networks, CellNetAnalyzer supports now
also the composition of logical interaction hypergraphs
using AND, OR and NOT connections. Whenever needed,
the underlying interaction graph can be deduced from the
interaction hypergraph. Alternatively, by using only OR's
and NOT's, arbitrary interaction graphs can be con-
structed. As in FluxAnalyzer, the network model can be
linked with externally created graphics visualizing the net-
work. User interfaces (text boxes) enable data input and
output directly in these interactive maps (see screenshot
in Figure 10). New functions for graph-theoretical and
logical analysis have been integrated into the user menu;
the results from computations are directly displayed
within the interaction maps or in separate windows. The
functions include:
• large-scale computation of all (positive and negative)
signaling paths connecting inputs with outputs or of all
signaling paths between a given pair of nodes; statistical
analysis of these paths
• large-scale computation of all (positive and negative)
feedback loops; statistical analysis of these routes
• computation of minimal cut sets for a given set of paths
or/and loops
• computation of distance (shortest paths) matrices – sep-
arately for positive and negative paths
• large-scale dependency analysis: identification of (total)
activators, (total) inhibitors and ambivalent factors for a
given species; display of the dependency matrix
• computation of (partial) logical steady states from a
given set of initial state values
• computation of (logical) minimal cut sets repressing or
provoking a user-defined behavior in the logical network
Example of a logical steady state in TOYNET resulting from a particular set f initial states in the input layeFigure 9
Example of a logical steady state in TOYNET resulting from a 
particular set of initial states in the input layer.Page 18 of 26
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complex signaling networks, we have set-up and analyzed
in CellNetAnalyzer a logical model of T-cell activation (Fig-
ure 10), which will be discussed in the next section.
CellNetAnalyzer is free for academic purposes (see web-site
[57]).
Logical model of T-cell activation
T-cell activation and the molecular mechanisms behind
T-lymphocytes play a key role within the immune system:
Cytotoxic, CD8+, T-cells destroy cells infected by viruses or
malignant cells, and CD4+ helper T-cells coordinate the
functions of other cells of the immune system, such as B-
lymphocytes and monocytes [58]. Loss or dysfunction,
especially of CD4+ T-cells (as it occurs e.g. in the course of
HIV infection or in immuno-deficiencies) has severe con-
sequences for the organism and results in susceptibility to
viral and fungal infections as well as in the development
of malignancies. The importance of T-cells for immune
homeostasis is due to their ability to specifically recognize
foreign, potentially dangerous, agents and, subsequently,
to initiate a specific immune response that is aimed at
eliminating them. T-cells detect foreign antigens by means
of their T-Cell Receptor (TCR) which recognizes peptides
only when presented on MHC (Major Histocompatibility
Complex) molecules. The peptides that are recognized by
the TCR are typically derived from foreign (e.g. bacterial,
viral) proteins and are generated by proteolytic cleavage
within so called antigen presenting cells (APCs). Subse-
quent to their production the peptides are loaded onto the
MHC-molecules and the assembled peptide/MHC-com-
plex is then transported to the cell surface of the APC were
it can be recognized by T-cells. The whole process of anti-
gen uptake, proteolytic cleavage, peptide loading onto
MHC, transport of the peptide/MHC complex to the sur-
face of the APC and the recognition of the peptide/MHC-
complex by the TCR is called antigen presentation and
provides the molecular basis for the fine specificity of the
adaptive immune response.
The binding of peptide/MHC to the TCR, and the addi-
tional binding of a different region of the MHC molecules
to so called co-receptors (CD4 in the case of helper T-cells
and CD8 in the case of cytotoxic T-cells), initiates a pleth-
ora of signaling cascades within the T-cell. As a result, sev-
eral transcription factors – most importantly, AP1, NFAT
and NFκB – are activated. These transcription factors, in
turn, control the cell's fate, e.g. whether it becomes acti-
vated and proliferates [59] or not.
In the following, a logical model describing some of the
main steps involved in the activation of CD4+ helper T-
cells (also applicable for CD8+ cytotoxic T-cells) will be
briefly introduced and analyzed (see Figure 10 and Table
2). Several players, in particular, some whose role and
activation is not completely understood, are not included
in our model and thus their effects are not considered or
lumped with others. Additionally, in several, currently
still controversial cases, we have assumed one of the pos-
sible hypotheses; however, this does not mean that we
propose this to be the correct description of the TCR-
induced signaling network; we just want to demonstrate
Screenshot of the CellNetAnalyzer model for T-cell activationFigure 10
Screenshot of the CellNetAnalyzer model for T-cell activation. 
Each arrow finishing on a species box represents a hyperarc 
and all the hyperarcs pointing into a species box are OR con-
nected. In the shown "early-event" scenario, the feedbacks 
were switched off whereas all input arcs are active. The 
resulting logical steady state was then computed. Text boxes 
display the signal flows along the hyperarcs (green boxes: 
fixed values prior computation; blue boxes: hyperarcs acti-
vating a species (signal flow is 1); red boxes: hyperarcs which 
are not active (signal flow is 0)).Page 19 of 26
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case. It is out of the scope of this paper to analyze the com-
plete, highly-complex signaling machinery of a T-cell.
Here, the biochemical steps included in the signaling
pathway will be described briefly; for a detailed descrip-
tion we refer the reader to reviews such as [59,60] and the
references therein:
• Upon binding of peptide/MHC to the TCR, the first
main step in the TCR-mediated signaling cascade is the
activation of the Src-family protein tyrosine kinase p56lck
(in the following termed Lck), although the exact mecha-
nism is still unclear. We have included one well accepted
mechanism [61], which probably plays a major role but
may be combined with others (cf. Figure 10):
 In resting T-cells, the major negative regulator of Lck,
the protein tyrosine kinase Csk (C-terminal Src-kinase) is
bound via a SH2-domain to the constitutively tyrosine
phosphorylated transmembrane adaptor protein PAG
(Protein Associated with Glycosphingolipid enriched
microdomains) and consequently inhibits membrane-
bound Lck by phosphorylating a C-terminal negative reg-
ulatory tyrosine residue of the Src kinase.
 Upon ligand binding, PAG is dephosphorylated by a so
far unknown protein tyrosine phosphatase, thereby lead-
ing to the detachment of Csk from PAG, and hence releas-
ing Lck from the inhibitory effect of Csk. The release of
Csk from PAG, together with the activity of the membrane
associated tyrosine phosphatase CD45 (which dephos-
phorylates Lck on the same inhibitory residue that is
phosphorylated by Csk), and the concomitant binding of
the MHC molecule to the coreceptor CD4, leads to full
activation of Lck (see Figure 10).
 However, both CD4 and the TCR can also be stimulated
individually, e.g. by using monoclonal antibodies specifi-
cally directed at either of the molecules or using cell lines
expressing mutated forms of CD4 that cannot bind MHC
or cannot transmit signals.
 A regulation of the enzymatic activity of CD45 is not
included in the model (basically because it is not yet clear
how CD45 is regulated in vivo), but, since CD45 is an
important regulatory element for T-cells, it is included as
an input signal, allowing the analysis of its effect and the
performance of CD45 knock-out experiments.
 After a few minutes, PAG is rephosphorylated [62],
probably by the Src-kinase Fyn, and subsequently Csk is
re-recruited to PAG inhibiting Lck again.
• Activated Lck can phosphorylate another member of the
Src-protein kinases, p59fyn, in the following termed Fyn
(Fyn can probably also be activated in a Lck-independent,
TCR-dependent manner [63]). Additionally, Lck phos-
phorylates the so called ITAMs (Immunoreceptor Tyro-
sine-based Activation Motifs) that are present in the
cytoplasmic domains of the TCR-complex (the latter if the
TCR is close to Lck, i.e., if there is a concurrent activation
of the TCR). Subsequently, the Syk-family protein tyrosine
kinase ZAP70 (Zeta Associated Phosphoprotein of 70
kDa) binds to the phosphorylated ITAMs and, if Lck is
active, becomes activated by Lck-mediated tyrosine phos-
phorylation. Thus, during the initial phase of signal trans-
duction via the TCR three tyrosine kinases become
activated in a sequential manner, first Lck and Fyn and
then ZAP70. Together these three kinases propagate the
TCR-mediated signal by phosphorylating a number of
membrane associated and cytosolic signaling proteins.
• Active ZAP70 can phosphorylate LAT (Linker for Activa-
tion of T-cells), a second transmembrane adapter protein,
at four different tyrosine residues. Subsequently, cytoplas-
mic signaling molecules containing SH2-domains,
including the scaffolding proteins Grb2, Gads, and the
lipid kinase PLCγ1 (Phospholipase gamma 1), can bind to
phosphorylated LAT. Additionally, Grb2 binds to the
?
?
?
?
?
Dependency matrix for the T-cell modelFigure 11
Dependency matrix for the T-cell model. The meaning of the 
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Sos in one activation step), and Gads to the adapter pro-
tein SLP76. The latter, upon phosphorylation by ZAP70,
can bind to the Tec-family tyrosine kinase Itk. Binding to
SLP76 and additional phosphorylation by ZAP70 acti-
vates Itk.
• For the activation of PLCγ1, the following conditions
have to be fulfilled: PLCγ1 is bound to LAT, SLP76 bound
to Gads, ZAP70 is activated (which hence phosphorylates
SLP76, allowing PLCγ1 to bind to SLP76), and Itk is
active, and hence is able to phosphorylate and thereby to
fully activate PLCγ1. Since all these conditions are needed,
a logical AND was included in the model (see Figure 10).
Rlk, another Lck-dependent Tec-family tyrosine kinase,
can also phosphorylate PLCγ1, hence Rlk has a redundant
role to Itk with regard to the activation of PLCγ1 [64].
• Activated PLCγ1 hydrolyses phosphatidyl-inositol-4,5
biphosphate (PIP2), which is considered an ubiquitous
membrane associated phospholipid and is therefore not
modeled, thereby generating the second messenger mole-
cules diacyloglycerol (DAG) and inositol trisphosphate
(IP3) [59,61].
• IP3 mediates calcium flux. Calcium (together with cal-
modulin) activates the serine phosphatase calcineurin,
which dephosphorylates the cytosolic form of the tran-
scription factor NFAT (Nuclear Factor of Activated T-
cells). The calcineurin-mediated removal of phosphate
groups allows NFAT to translocate to the nucleus and to
regulate gene expression.
• The second messenger DAG activates PKCθ and
(together with PKCθ[65]) activates the nucleotide
exchange factor RasGRP1.
• RasGRP1 and Sos (the latter if it is close to the mem-
brane, that is, if it is bound to LAT by means of Grb2), can
activate Ras, which in turn activates the Raf/MEK/ERK
MAPK Cascade.
• PKCθ is involved in the activation of JNK, as well as the
essential transcription factor NFκB (via phosphorylation
and subsequent degradation of the NFκB inhibitor, Iκ B,
by the PKCθ-activated Iκ B-kinase, IKK).
• ERK, activated by the Ras/Raf/MEK cascade, activates the
transcription factor CRE and (together with JNK) the
essential transcription factor AP1.
• The E3 ubiquitin ligase cCbl is important for shutting off
TCR-mediated signaling processes by ubiquitination of
key proteins, which are subsequently targeted for degrada-
tion [66]. One important target of cCbl is ZAP70; upon
tyrosine phosphorylation of ZAP70, cCbl binds to ZAP70,
leading to ZAP70's ubiquitination and degradation as
well as to the downregulation of the TCR.
From these biological facts we constructed a logical hyper-
graph model, containing 40 nodes and 49 hyperarcs, and
implemented it in CellNetAnalyzer (Figure 10). The model
is summarized in Table 2.
Remarks on the logical T-cell activation model
Note that a species can represent different states of a mol-
ecule: for example, CD45 refers to the availability of
CD45 to act on its substrates (Lck and Fyn), PLCg(bind)
refers to PLCγ1 bound to LAT, and PLCg(act) to the active
(bound to LAT and phosphorylated) form of PLCγ1. It is
also important to realize that several steps can be lumped
together or expressed in higher detail; for example, the
formation of the complex LAT:Grb2:Sos is considered as
one step, but intermediate steps could be considered. This
would be reasonable, for example, if Grb2 would have
other functions apart from binding Sos. Similarly, the two
steps of cCbl's effect (ubiquitination and degradation) are
lumped in the hyperarcs pointing to its targets ZAP70 and
TCR.
Also note that some of the logical operators could be
modeled in a different manner, as in the case of Sos and
Dependency matrix for the T-cell model for the early event sc nario (τ = 1: he feedback loops are not active)Figure 12
Dependency matrix for the T-cell model for the early event 
scenario (τ = 1: the feedback loops are not active). The meaning 
of the different colors is the same as in Figure 6.Page 21 of 26
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since both can independently activate Ras, although both
(AND) may be needed for full Ras activation).
Furthermore, our model describes the full activation of
the cascade which leads to proliferation; it is known that
e.g. stimulation of TCR with antibodies against its CD3
subunits produces a certain activation of the cascade
(where probably Fyn overtakes Lck's role [63]) but does
not lead to full activation. Therefore, in our model, as an
approximation, activated Fyn can phosphorylate the
ITAMs of the TCR, but is not able to activate ZAP70. Here
a model with more than 2 levels could be envisioned,
where activation of Fyn would be enough to produce a
weak (level 1) activation of ZAP70 and hence the whole
cascade downstream, while full activation via Lck would
activate the cascade to a level 2 (full activation).
The model has two extracellular input signals (one for the
TCR and one for the coreceptor CD4). Additionally, an
input arc for CD45 is included because the regulation of
CD45 is not modeled, as described above. Therefore,
mathematically speaking, the model contains 3 elements
in the input layer. On the other hand, the output layer
contains 4 transcription factors (CRE, AP1, NFAT and
NFκB).
As explained in the theoretical section, one reasonable
way to deal with the effect of negative feedbacks is to con-
sider the different time scales of the processes. Hence,
since PAG rephosphorylation takes place after a few min-
utes [62], and cCbl mediated degradation is an even
slower process, we can define several scenarios:
-τ = 0, resting-state (no inputs, no feedbacks),
-τ = 1, early-events (input(s), no feedbacks), and
-τ = 2, mid-time events (input(s), feedbacks). Here, the
state of the feedback loops (activation of PAG/Csk by Fyn
and recruitment of cCbl to phosphorylated ZAP70) will
depend on the state of the respective activators at τ = 1.
This can be considered either by fixing manually the state
values of cCbl and PAG/Csk for τ = 2 upon inspection at τ
= 1 (as was done herein) or by inclusion of a positive self-
loop.
We use the term mid-time event since one can also envi-
sion a long-term scenario (τ = 3), where slow gene expres-
sion mechanisms (not considered here) are active.
Analysis of the T-cell signaling cascade
In the interaction graph underlying the hypergraphical
model, there are 1158 paths from the input to the output
layer and 9 (7 negative and 2 positive) feedbacks loops,
which are listed in Table 3. cCbl is involved in most
(88%) of the loops, in accordance to its important role in
the regulation of the signaling cascade. Not surprisingly,
since the only feedback mechanisms included are the
effect of cCbl on ZAP70 and TCR and of Fyn on PagCsk,
no loop goes downstream of ZAP70, and a suitable mini-
mal cut set attacking all the feedback loops would consist
of Fyn and cCbl.
We further analyze the interaction graph by computing
the dependency matrix (Figure 11). Since downstream of
ZAP70 there are only positive connections (except at node
IκB), all the elements downstream of ZAP70 are total acti-
vators (except of IκB, which is a total inhibitor of NfκB)
with respect to the transcription factors in the output
layer, that is, they can have only positive effects. Therefore,
for these species, a negative intervention via e.g. inhibitors
or iRNA would unambiguously lead to a decrease in the
activation levels of the transcription factors. For consider-
ing the early-events scenario (τ = 1: the feedback loops are
not active), we recompute the dependency matrix where
the action of Fyn on PAGCsk and of ZAP70 on cCbl is not
considered (Figure 12). Then, all inputs (CD45, TCRlig
and CD4) are total activators for all species in the output
layer. This is not the case when the feedbacks become
active (Figure 11): TCRlig and CD45 become then ambiv-
alent factors, i.e. have negative connections to the sink
species, whereas CD4 is still an activator but no longer a
total one, as it is now connected to a negative feedback
loop.
Simulation results of LSS analysis of key elements of the T-cell model using the two time- cales xplained in the t xtFig re 13
Simulation results of LSS analysis of key elements of the T-
cell model using the two time-scales explained in the text. 
Blue line: upon TCR+CD4+CD45 activation; dashed red line: 
only TCR+CD45 activation.Page 22 of 26
(page number not for citation purposes)
BMC Bioinformatics 2006, 7:56 http://www.biomedcentral.com/1471-2105/7/56A further analysis of the interaction graph provides that
there is no minimal cut set containing only one (essential)
species whose removal would interrupt all the positive
paths to all the outputs. In fact, all minimal cut sets satis-
fying this intervention task would contain at least two spe-
cies, for example MCS1 = {Rlk, ZAP70} and MCS2 =
{LAT, PLCg(act)}. The latter examples agree only partially
with biological knowledge: removal of MCS1 or MCS2
would indeed prevent the activation of any output, how-
ever, from experimental observations one knows that for
example LAT alone is essential in TCR signaling [60].
Thus, MCS2 would not be minimal.
Interpreting the hypergraphical (logical) model (Figure 10)
reveals that, due to several AND connections, the addi-
tional removal of PLCg(act) would indeed be redundant
Table 2: The hyperarcs of the logical T-cell signaling model (see Figure 10). Exclamation mark ('!') denotes a logical NOT and dots 
within the equations indicate AND operations.
→ CD45
→ CD8
→ TCRlig
AP1 →
Ca → Calcin
Calcin → NFAT
CRE →
CREB → CRE
DAG → PKCth
ERK → Fos
ERK → Rsk
Fyn → PAGCsk
Fyn → TCRphos
Gads → SLP76
Grb2Sos → Ras
!IkB → NFkB
!IKKbeta → IkB
IP3 → Ca
JNK → Jun
Jun·Fos → AP1
LAT → Gads
LAT → Grb2Sos
LAT → PLCgbind
Lck·CD45 → Fyn
Lck → Rlk
MEK → ERK
NFAT →
NFkB →
!PAGCsk·CD8·CD45 → Lck
PKCth·DAG → RasGRP1
PKCth → IKKbeta
PKCth → SEK
PLCg(act) → DAG
PLCg(act) → IP3
Raf → MEK
Ras → Raf
RasGRP1 → Ras
Rsk → CREB
SEK → JNK
TCRbind·CD45 → Fyn
TCRbind·Lck → TCRphos
!TCRbind → PAGCsk
TCRlig·!cCbl → TCRbind
TCRphos·Lck·!cCbl → ZAP70
ZAP70·SLP76·PLCg(bind)·Itk → PLCg(act)
ZAP70·SLP76 → Itk
ZAP70 → cCbl
ZAP70 → LAT
ZAP70·SLP76·Rlk·PLCg(bind) → PLCg(act)Page 23 of 26
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removed. This example illustrates the limitations of
graph-based methods and we computed therefore the
(logical) minimal cut sets from the logical interaction
hypergraph revealing that not only LAT, but also ZAP70,
Lck, TCR, the ligand for the TCR, TCRphosp, CD4 and
CD45 are essential for full T-cell activation. This result is
in good agreement with the current knowledge: the T-cell
receptor, its ligand, and the ability of the receptor to get
phosphorylated are required for T-cell activation; and
CD4 (since it binds Lck thus recruiting it to the mem-
brane) and CD45 (which dephosphorylates Lck inhibi-
tory regulatory site) are required for the activation of the
essential kinase Lck.
Next we performed a logical steady state analysis for the
different time scales given above. These simulations pro-
vide a rough approximation to the dynamics of the sign-
aling cascade. Figure 10 shows the particular situation in
the early-event scenario (τ = 1) as displayed in CellNetAn-
alyzer. Figure 13 summarizes the logical steady state values
of important components obtained for the three different
time scales. The blue line shows the case for
TCR+CD4+CD45 stimulation, whereas the dashed red
line represents the case when only TCR+CD45 is stimu-
lated in the input layer. Similar analysis can be performed
using different scenarios, for example, in a cell where a
certain element has been knocked-out.
Conclusion
In this contribution we have presented a collection of
methods for the functional analysis of the structure of cel-
lular signaling and regulatory networks. As discussed in
the theoretical sections, different abstractions and formal-
isms can be used to encode and analyze the topology of
interaction networks. The simplest representations are
interaction graphs, which are restricted to one-to-one rela-
tionships but do yet capture important functional and
causal dependencies in the system under study. We have
shown that arguably the most important features of inter-
action graphs, namely feedback circuits and signaling (or
influence) pathways, can systematically be identified by
the concept and algorithm of elementary modes known
from stoichiometric (metabolic) network analysis. Feed-
back cycles are mainly responsible for the dynamic behav-
ior of the system, whereas signaling paths reveal network-
wide dependencies between species. In some cases, analy-
sis of feedback cycles and signaling paths may allow one
to predict unambiguously the qualitative effect upon per-
turbations of certain species (independently of kinetic
parameters and mechanisms). Falsification experiments
may then be used to identify missing or incorrect interac-
tions. Knowledge on all the signaling paths also facilitates
a systematic identification of optimal intervention strate-
gies. Again, a concept known from metabolic networks,
minimal cut sets, can be adapted and employed here.
However, inhibitory actions make this kind of analysis
more complicated and we therefore generalized the for-
malism of minimal cut sets leading to minimal interven-
tion sets.
The applicability of tools from metabolic network analy-
sis to interaction graphs relies on the fact that metabolic
networks are hypergraphs, which in turn are generaliza-
tions of graphs. In our opinion, the importance of hyper-
graphs in structural analyses of cellular interaction
networks has been underestimated. In fact, whenever
AND-connections occur in interactions of species, hyper-
graphical approaches become essential.
Boolean networks describe interaction networks in a more
constrained and deterministic manner than interaction
graphs, enabling discrete simulations. Herein we have
demonstrated that signed directed hypergraphs are capa-
ble to represent the logical structure of any Boolean net-
work. The hypergraphical coding of Boolean networks,
which relies on the sum-of-product representation of
Boolean networks (using only AND, OR and NOT opera-
tions), has several advantages: it is rather intuitive, it
mostly corresponds to the underlying molecular mecha-
nisms, and it is easy to store and to handle. A hypergraph-
ical representation of a Boolean network also establishes
a direct link to the corresponding (underlying) interaction
graph which can easily be derived from the hypergraph.
Finally, it facilitates a logical signal flow (or steady state)
analysis in Boolean networks which, as demonstrated in
this report, is useful for studying and predicting the qual-
itative input-output behavior of signaling networks with
respect to a given, possibly incomplete, set of initial state
values. This can be achieved here without an explicit enu-
meration and/or simulation of all possible trajectories.
In general, Boolean networks rely on stronger assump-
tions and knowledge than interaction graphs and a pure
logical description of all interactions is not always possi-
ble. We have suggested extensions of the Boolean frame-
work, such as incomplete truth tables of logical
operations, to handle these problems.
As pointed out by many authors (e.g. [67-69]) the logical
description and analysis of large signaling networks has a
strong relationship to electrical circuit analysis; however,
there still seems to be a large potential in employing the-
oretical and software tools from electrical engineering and
Boolean logic for investigating interaction networks. Sig-
nal flow analysis as introduced herein might be another
step in this direction.
Describing signal and mass flows equivalently as interac-
tions, as done herein, offers high flexibility and enablesPage 24 of 26
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metabolic, signalling or regulatory ones) into one frame-
work. However, the higher level of abstraction comes with
the price that some molecular mechanisms are not always
precisely represented, as, for instance, the stoichiometric
coefficients in mass flows.
The potential of the introduced methods were demon-
strated on a model of a small part of the signaling machin-
ery of T-cells. The size and complexity of the model was
chosen so that the methods could be tested on a case study
of real size and complexity, while at the same time the
results could be (at least in part) intuitively understood
and proofed. If enough information is available, similar
models could be set up for any other signaling network.
Certainly, these tools will be especially useful in larger
interaction networks. Our current and future work aims to
expand and subsequently analyse the T-cell model, with
hopes that further understanding of this complex network
can improve current knowledge about important ill-
nesses, such as autoimmune diseases and leukemia. This
is certainly a challenging task, but the potential described
here makes it a worthy endeavour.
Availability and requirements
For academic purposes,CellNetAnalyzer can be obtained
for free via the website
http://www.mpi-magdeburg.mpg.de/projects/cna/
cna.html
Note that CellNetAnalyzer requires MATLAB® version 6.1
or higher.
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The transmembrane adaptor molecule TRIM is strongly expressed within thymus and in peripheral CD4
T cells. Previous studies suggested that TRIM is an integral component of the T-cell receptor (TCR)/CD3
complex and might be involved in regulating TCR cycling. To elucidate the in vivo function of TRIM, we
generated TRIM-deficient mice by homologous recombination. TRIM/ mice develop normally and are
healthy and fertile. However, the animals show a mild reduction in body weight that appears to be due to a
decrease in the size and/or cellularity of many organs. The morphology and anatomy of nonlymphoid as well
as primary and secondary lymphoid organs is normal. The frequency of thymocyte and peripheral T-cell
subsets does not differ from control littermates. In addition, a detailed analysis of lymphocyte development
revealed that TRIM is not required for either positive or negative selection. Although TRIM/ CD4 T cells
showed an augmented phosphorylation of the serine/threonine kinase Akt, the in vitro characterization of
peripheral T cells indicated that proliferation, survival, activation-induced cell death, migration, adhesion,
TCR internalization and recycling, TCR-mediated calcium fluxes, tyrosine phosphorylation, and mitogen-
activated protein family kinase activation are not affected in the absence of TRIM. Similarly, the in vivo
immune response to T-dependent and T-independent antigens as well as the clinical course of experimental
autoimmune encephalomyelitis, a complex Th1-mediated autoimmune model, is comparable to that of wild-
type animals. Collectively, these results demonstrate that TRIM is dispensable for T-cell development and
peripheral immune functions. The lack of an evident phenotype could indicate that TRIM shares redundant
functions with other transmembrane adaptors involved in regulating the immune response.
Upon ligation of the T-cell receptor (TCR) by peptide/major
histocompatibility complex complexes, a plethora of signaling
cascades are initiated within T cells that finally result in T-cell
activation. It is well established that the TCR itself is not
capable of transducing signals, as it possesses only a short
intracellular tail that lacks any known signaling motif. Rather,
signal transduction via the TCR is accomplished by the invari-
ant CD3, CD3, CD3ε, and  subunits, which all possess
particular amino acid motifs named ITAMs (immunoreceptor
tyrosine-based activation motifs) in their cytoplasmic domains
(17, 35). Overall, the TCR/CD3/ complex is organized in
dimers (CD3ε and CD3ε dimers that noncovalently associ-
ate with the TCR heterodimer and the TCR homodimer)
and contains in total 10 ITAMs: 1 in each of the CD3, CD3,
and CD3ε subunits and 3 in each of the two TCR chains.
Upon phosphorylation by Src family kinases, the ITAMs are
converted into high-affinity binding sites for the cytosolic pro-
tein tyrosine kinase ZAP-70, which is in turn recruited from
the cytosol to the activated TCR by its tandem SH2 domains.
After binding to the phosphorylated ITAMs, ZAP-70 serves as
a substrate for Src kinases and becomes activated by phosphory-
lation. The biochemical cascade originating from the ligated
TCR is then further propagated by the transmembrane adap-
tor protein LAT (linker for activation of T cells) which links
the TCR to the mitogen-activated protein kinase (MAPK) and
Ca2 pathways after phosphorylation by ZAP-70 (12, 37).
In addition to being the signal transducing subunits of the
TCR, the CD3 and TCR chains are also required for the
correct expression of the TCR at the plasma membrane (for a
review, see reference 1). TCR assembly begins in the endo-
plasmic reticulum with the pairing of CD3ε with either CD3
or CD3. Once the ε and ε heterodimers are formed, they
noncovalently associate with the TCR/ heterodimer. The
last component to be incorporated in the complex is the TCR
homodimer, which overrides an endoplasmic reticulum reten-
tion signal within the CD3ε chain, thus allowing the complex to
be transported to the plasma membrane (9).
Recent findings have indicated that the invariant chains of
the TCR/CD3 complex might associate with a variety of addi-
tional molecules. For example, the TCR chain has been pro-
posed to interact with SLAP-2 (26), TRIM (4, 20), CTLA4 (7),
and Unc119 (5, 14), while CD3ε apparently complexes with
CAST (36) and Nck (13). The physiological relevance of these
interactions is so far not completely understood. However, it
has been proposed that they could serve to integrate or regu-
late the signal capability of the TCR/CD3 complex or to mod-
ulate the expression levels of the T-cell receptor.
The nonraft transmembrane adaptor protein TRIM (T-cell
receptor interacting molecule) is exclusively expressed in T
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lymphocytes. TRIM has been shown to coprecipitate with the
TCR/CD3 complex under mild detergent conditions, and, sim-
ilar to the TCR, its expression is downregulated after TCR
triggering (4). A recent study demonstrated that TRIM pref-
erentially interacts with the TCR complex via the TCR chain
and that all three domains of TRIM (extracellular, transmem-
brane, and cytoplasmic domains) are required for this interac-
tion (20).
The functional relevance of the association between TRIM
and TCR has been addressed by overexpressing TRIM in the
Jurkat T cell line (20). These experiments revealed that cells
overexpressing TRIM show a considerable increase in cell sur-
face expression of TCR and CD3ε caused by TRIM-medi-
ated inhibition of spontaneous TCR internalization (20). As
expected, the enhanced expression levels of the TCR in TRIM
transfectants concomitantly lead to an increased TCR-medi-
ated Ca2 flux. Based upon these data, it was proposed that
TRIM regulates TCR-mediated signaling by modulating the
expression levels of the TCR on the cell surface.
TRIM possesses three tyrosine-based signaling motifs
(TBSMs) within its cytoplasmic domain that are potentially
involved in regulating TCR-mediated signal transduction. One
of these motifs (YEQM) represents a consensus motif for the
p85 subunit of phosphatidylinositol 3-kinase (PI3K) and, in-
deed, TRIM is capable of binding p85 via the YEQM motif
after phosphorylation by Src kinases (4). Similarly, the two
other TBSMs also become phosphorylated upon TCR engage-
ment, but the molecules binding to these motifs are yet to be
identified (20).
To study the function of TRIM in vivo, we generated TRIM-
deficient mice by homologous recombination. Collectively, the
functional and biochemical characterization of TRIM/ mice
suggest that TRIM is dispensable for the development and the
function of the immune system.
MATERIALS AND METHODS
Mice. TRIM/ mice were generated by homologous recombination by replacing
a part of exon 1 (including ATG) and exon 2 (coding for the entire transmembrane
region) with a NEO cassette. The linearized targeting construct was transfected into
SVJ129-derived embryonic stem cells, and G418-selected clones were transferred
into C57BL/6 blastocysts as previously described (2). Germ line mutated animals
were backcrossed onto the C57BL/6 background for more than 10 generations in a
conventional animal facility. Animals were genotyped by PCR using the following
primers: 5TRIM (CGT CTC TGC TTC TCT ACA TAG TGG), 3TRIM (GCT
CTG GAT GCC CCT TCT TCC), and 3Neo (GAC GTG CTA CTT CCA TTT
GTC ACG TCC) (BioTez GmbH).
OT-I and OT-II TCR transgenic mice were kindly provided by Percy Knolle,
P14 mice were provided by Thomas Kammerthoens, and H-Y TCR transgenic mice
were provided by Gary Koreztky. For TCR transgenic studies, TRIM/ mice
crossed with TCR transgenic mice were obtained by crossing TRIM/ mice with
TRIM/ mice with TCR heterozygote transgenics.
Flow cytometry analysis. Single-cell suspensions were obtained from thymus,
lymph nodes, spleen, and bone marrow by dissociation of isolated tissues through
a 70-	m mesh. Cells were stained with fluorescence-labeled monoclonal anti-
bodies against CD3 (145-2C11), CD4 (RM4-5), CD5 (53-7.3), CD8 (53-6.7),
CD25 (7D4), CD44 (IM7), CD45RB (363.16A), CD62L (MEL-14), CD69
(H1.2F3), TCR (H57-597), TCR (GL3), B220 (RA3-6B2), and TCRV2
(B20.1), all obtained from BD Biosciences, or with fluorescein isothiocyanate
(FITC)-labeled HY-TCR (T3.70) (eBiosciences) for 30 min at 4°C. Cell-associ-
ated fluorescence was analyzed by a FACSCalibur and Cell Quest Pro software
(BD Biosciences).
Immunoblotting. For all biochemical analyses, CD4 T cells were purified by
an AutoMACS magnetic isolation system according to the manufacturer’s in-
structions (Miltenyi). Cells were either left unstimulated, stimulated with 10
	g/ml of biotinylated CD3ε antibody (145-2C11; BD Biosciences), or stimulated
with CD3 plus 10 	g/ml of biotinylated CD28 (BD Biosciences) monoclonal
antibody (MAb) followed by cross-linking with 25 	g/ml of streptavidin
(Dianova) at 37°C. Cells were lysed in lysis buffer containing 1% NP-40, 1%
laurylmaltoside (N-dodecyl -D-maltoside), 50 mM Tris, pH 7.5, 140 mM NaCl,
10 mM EDTA, 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 1 mM
Na3VO4. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, transferred onto polyvinylidene difluoride or nitrocellulose
membranes, and blotted with the following antibodies: anti-phosphotyrosine
(4G10), anti-ERK1/2 (pT202/pT204), anti-JNK (pT183/pY185), anti-p38
(pT180/pT182), anti-phospho-Akt (S473), anti-Akt, all from Cell Signaling, and
anti-ZAP70 (clone Z24820; Transduction Laboratories), anti-ERK1/2 (Cell Sig-
naling), or -actin (Sigma). Where PI3K inhibitor was used, CD4 T cells were
preincubated with 100 nM wortmannin (Calbiochem) for 30 min at 37°C prior to
stimulation.
Ca2 flux. For Ca2 measurement, cells were incubated for 30 min with 3.75
	g/ml indo-1-AM (Molecular Probes) in phenol red-free RPMI 1640 medium
(GIBCO BRL) containing 10% fetal calf serum (FCS). After washing, the cells
were incubated for 30 min at 37°C in RPMI 1640 and stained with CD4 and CD8
and incubated with 10 	g/ml biotinylated CD3 (145-2C11) MAbs at 4°C. Calcium
fluxes were induced by cross-linking the TCR/CD3 complex with 75 	g/ml
streptavidin and were measured using an LSR flow cytometer (BD Biosciences).
Proliferation assay. CD4 T cells were purified from single-cell suspensions of
splenocytes by an AutoMACS magnetic isolation system according to the man-
ufacturer’s instructions (Miltenyi). Cells were stimulated for 72 h with either the
indicated concentrations of plate-bound CD3 MAb (145-2C11), 4 	g/ml con-
canavalin A (ConA) (Calbiochem), or 2.5 	g/ml staphylococcal enterotoxin B
(SEB; Sigma), or with 2 
 109 M phorbol-12-myristate-13-acetate (PMA)
(Calbiochem) and 0.5 	g/ml ionomycin (Calbiochem) in 96-well U-bottomed
plates (Corning Costar) at a density of 25 
 104 cells per well in 200 	l of RPMI
medium supplemented with penicillin, streptomycin, -mercaptoethanol, and
10% FCS. Cells were pulsed with 1 	Ci [3H]thymidine per well during the last
8 h.
Cell survival assays. Thymocytes or purified splenic CD4 T cells were incu-
bated for 24 h in the presence of the following stimuli: plate-bound CD3 MAb
(145-2C11), CD3 CD28 MAb (37.51), 1 	M etoposide (Sigma), 1 	g/ml Fas
MAb (BD Biosciences) plus 30 	g/ml cycloheximide (Calbiochem), or 2 nM
dexamethasone (Sigma). Cells were harvested and stained with annexin V and
propidium iodide (BenderMedSystem) according to the manufacturer’s instruc-
tions. Apoptotic cells were defined as annexin V-positive and propidium iodide-
negative cells.
For activation-induced cell death (AICD), 2 
 106 CD4 lymphocytes were
stimulated with 5 	g/ml plate-bound CD3 MAb in RPMI in flat-bottomed
24-well plates (Corning Costar) for 2 days. Cells were then grown in medium
containing 5 IU/ml recombinant human interleukin-2 (rIL-2) (PeproTech) for an
additional 2 days in flat-bottomed 24-well plates, and 1 
 106 cells were restim-
ulated overnight with 5 	g/ml plate-bound CD3 MAb in new 24-well plates with
medium containing 5 IU/ml rIL-2. Apoptosis was measured as described above.
Migration assay. Cell migration was performed in a 24-well Transwell plate
(Corning Costar) with 3-	m-pore polycarbonate filters. Freshly isolated lymph
node cells were resuspended at a density of 4 
 107 cells/ml in RPMI containing
0.5% bovine serum albumin (BSA). One hundred microliters of cell suspension
was placed in the upper chamber, and 600 	l of medium was placed in the lower
chamber. After equilibration at 37°C for 1 h, 50 nM of mouse recombinant
SDF1 (PeproTech) was added to the wells, and the plates were incubated for an
additional 3 h. Cells were then harvested, stained with anti-CD4 and anti-CD8,
and counted by fluorescence-activated cell sorting (FACS). Duplicates were used
for each condition.
Mouse immunization and ELISA. Two- to 3-month-old mice were immunized
intraperitoneally with 20 	g/animal 2,4-dinitrophenyl (DNP)–keyhole limpet he-
mocyanin (KLH) (Calbiochem) in 200 	l complete Freund’s adjuvant (Sigma)
and were boosted 10 days later with 20 	g/animal DNP-KLH in 200 	l incom-
plete Freund’s adjuvant (Sigma). Before and after immunization, mice were bled
and the amount of hapten-specific immunoglobulins was determined by enzyme-
linked immunosorbent assay (ELISA) as previously described (31). Briefly,
plates were coated with 3 	g/ml DNP-BSA in bicarbonate buffer overnight at
4°C. Nonspecific binding was prevented by blocking the plates with 1% BSA for
2 h at room temperature. Serial dilutions of mouse sera were incubated overnight
at 4°C, and the specific binding was detected using alkaline-phosphatase-labeled
goat anti-mouse immunoglobulin M (IgM; Serotec) or goat anti-mouse IgG
(subclasses 1, 2a, 2b, 3; Dianova).
Basal levels of immunoglobulins were measured as previously described (31).
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TCR internalization and recycling. For TCR internalization assays, 2 
 106
lymph node cells were precoated for 30 min at 4°C with phycoerythrin (PE)-
labeled TCR (H57-597) MAb in RPMI containing 10% FCS, 50 	M -mer-
captoethanol, penicillin, and streptomycin. After washing, cells were plated in
96-well plates at a density of 1 
 106 cells per 200 	l of medium and incubated
at 37°C for the indicated times. TCR internalization was measured as previously
described (10). Briefly, TCR internalization was stopped by washing the cells in
ice-cold phosphate-buffered saline (PBS) containing 0.1% sodium azide and 1%
BSA. The surface-bound antibody was removed by washing lymphocytes in
stripping buffer (100 mM Glycin, 100 mM NaCl, pH 2.5). The intracellular
fluorescence was measured by FACS. To distinguish the different lymphocyte
subsets, cells were stained with CD4-FITC and CD8-CyChrome MAbs after
stripping. Internalization of the TCR was calculated according to the following
equation, as previously published (10, 16, 32): % internalization  100 
 [(acid-
resistant fluorescence at t  cellular autofluorescence)/(fluorescence of cells
stained with TCR-PE MAb  cellular autofluorescence)], where t is time.
A TCR recycling assay was performed as reported previously (24). Briefly, 4 

106 freshly isolated lymph node cells were stained at 37°C with 1 	g/ml PE-
labeled anti-TCR for 1 h. After washing, surface-bound antibody was stripped
as reported above. To allow reexpression of the internalized receptor, cells were
then incubated at 37°C for different times, washed in ice-cold PBS containing
0.1% sodium azide and 1% BSA, and again stripped in low-pH buffer. Lympho-
cytes were stained for CD4 and CD8 and analyzed by FACS. Recycled TCR was
calculated using the following formula: % recycled  100 
 [(acid-resistant
fluorescence after second low-pH buffer treatment  autofluorescence)/(acid-
resistant fluorescence after first low-pH buffer treatment)].
EAE. Experimental autoimmune encephalomyelitis (EAE) was induced and
scored as previously described (28, 31).
RESULTS AND DISCUSSION
Generation of TRIM-deficient mice. To assess the role of
TRIM within the immune system, the TRIM gene was dis-
rupted by homologous recombination in embryonic stem (ES)
cells (Fig. 1A). The targeting vector replaced part of exon 1
and exon 2 of the TRIM gene with a neomycin selection cas-
sette. The deleted region contained the translation start site as
well as the entire extracellular and transmembrane regions of
TRIM. The linearized targeting vector was introduced into ES
cells by electroporation, and cells were selected with G418 and
ganciclovir. Successfully targeted ES clones were injected into
C57BL/6 blastocysts. To avoid potential phenotypic bias due to
inbred genetics, germ line-competent chimeric mice were
backcrossed on a C57BL/6 genetic background for more than
10 generations. Mutation of the TRIM gene was confirmed by
genomic PCR (Fig. 1B). To ensure that the targeted allele
results in loss of protein, lysates were prepared from thymo-
cytes of null and wild-type mice and analyzed by anti-TRIM
Western blotting with two different monoclonal or two poly-
clonal anti-TRIM reagents, all directed at particular regions of
the cytoplasmic tail of TRIM. Under all conditions tested, we
did not detect any anti-TRIM-reactive product, corresponding
either to the full-length or to a truncated (cytoplasmic) form in
TRIM/ thymocytes (Fig. 1C and data not shown). These
data demonstrate that the TRIM gene was indeed successfully
inactivated. Analysis of genotypes at weaning revealed that the
mutated allele segregates with the expected Mendelian fre-
quency, thus indicating that TRIM does not cause embryonic
lethality. Indeed, among the 608 viable offspring obtained by
breeding TRIM/ mice, 149 (24.5%) were TRIM/, 290
(47.7%) were TRIM/, and 169 (27.8%) were TRIM/.
TRIM/ mice are viable and fertile but display a smaller
body size. Anatomical and histological analysis of hematoxylin-
eosin sections of liver, muscle, smooth muscle from heart,
brain, testis, gut, and primary and secondary lymphoid organs
such as thymus, spleen, and lymph nodes from TRIM-deficient
mice did not reveal any detectable abnormalities (data not
shown). Moreover, TRIM/ mice were viable and fertile.
However, compared to sex-matched wild-type littermates,
TRIM-deficient mice displayed a mild reduction (about 10 to
20%) in body weight which became evident at 3 weeks of age
and remained constant throughout the aging process (Fig. 1D).
Accordingly, we found a decrease (about 10 to 20%) in the size
of several organs, such as thymus, spleen, lymph nodes, liver,
kidney, and heart (data not shown). Because TRIM/ and
TRIM/ mice maintain constant organ-to-body-mass ratios,
the difference in body weight could be due to an overall re-
duction in cell size or in cellularity.
Analysis of lymphoid organs (thymus, lymph nodes, spleen,
and bone marrow) revealed that cell sizes were normal,
whereas cell numbers within the organs were significantly re-
duced (about 20% [Tables 1 and 2 and data not shown]). This
indicates that loss of TRIM results in a reduction of organ
cellularity and consequently in body mass. Since TRIM ap-
FIG. 1. Generation of TRIM-deficient mice. (A) Partial restriction
map of the TRIM locus and the targeting construct. Exons are repre-
sented by filled boxes. Neo, neomycin resistance cassette; Tk, thymi-
dine kinase. (B) PCR analysis of TRIM wild type, heterozygous, and
knockout mice. (C) Western blot analysis of cell lysates prepared from
wild-type and TRIM/ thymocytes. The blot was probed with the
monoclonal anti-TRIM antibody TRIM04 and with the polyclonal
anti-ERK1/2 antibody to show equal loading. (D) TRIM-deficient
mice display lower body weights. Shown are growth curves of female
and male TRIM/ or TRIM/ animals (n  15 mice per group).
Statistically significant differences are indicated: , P  0.05; , P 
0.005; , P  0.001.
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pears to be exclusively expressed in T cells, the reason for this
unexpected observation remains elusive. At present, it is not
known whether the immune system is directly involved in the
regulation of body weight (particularly in healthy animals such
as TRIM-deficient mice, which also do not show any histolog-
ical signs of chronic inflammation that could be responsible for
reduced body weight). A decrease in body mass has been
observed in several knockout strains of mice in which mole-
cules that are expressed in T cells (3, 6, 8, 15, 22, 23) were
eliminated. However, in these models, the reduction in body
weight is caused by alterations of organ development or by
altered hormone action (as the molecules under investigation
are also expressed outside of the hematopoietic system) but
not by impaired immune functions. One possible explanation
for our observation, therefore, could be that TRIM is not only
expressed in T cells but also in other types of cells, e.g., hor-
mone-producing cells. In this regard it is worth mentioning
that Ikaros, a well-known lymphoid transcription factor, has
recently been found to be expressed in cells of the pituitary
gland (11). It appears that Ikaros is required not only for the
development of the immune system but also for the regulation
of the endocrine pituitary-adrenocortical system and body
weight (11). Possibly a similar situation holds true for TRIM.
Experiments are in progress to assess this possibility.
TRIM-deficient T cells show normal TCR/CD3 surface lev-
els and normal TCR dynamics. Previously, we had shown that
overexpression of TRIM in Jurkat T cells enhances the expres-
sion levels of the TCR on the cell surface by altering sponta-
neous TCR internalization (4, 20). To address the question of
whether TRIM exerts a similar function in nontransformed
primary mouse T cells, we investigated the expression levels of
the TCR on thymocytes and peripheral T cells of wild-type and
TRIM-deficient mice by flow cytometry. As shown in Fig. 2A
and B, the absence of TRIM had no impact on the expression
levels of the TCR (or CD3ε [data not shown]). We next inves-
tigated whether internalization of the TCR or TCR recycling
after antibody-mediated internalization was affected in TRIM/
T lymphocytes. Figure 2C shows that the internalization of the
TCR in peripheral lymph node T cells and in thymocytes (data
not shown) occurred at normal rates in the absence of TRIM.
In addition, the reexpression kinetics of the internalized TCR
pool at the cell surface was comparable in wild-type and
TRIM-deficient T cells (Fig. 2D). These data suggest that in
contrast to Jurkat T cells, TRIM is dispensable for both the
internalization and the recycling of the TCR in primary mouse
T cells. A possible explanation could be that the regulation of
TCR expression-downregulation-internalization by TRIM can
only be observed in an overexpression system or in trans-
formed cell lines, such as Jurkat. Alternatively, it might be that
primary T cells possess other molecules that compensate for
the absence of TRIM.
Normal T-cell development in TRIM/ mice. To assess the
role of TRIM during T-cell development, flow cytometric anal-
yses of lymphocyte suspensions prepared from thymus, spleen,
and lymph nodes (Tables 1 and 2 and Fig. 3) were performed.
As depicted in Table 1, the total cellularity of the thymus was
found to be slightly reduced in TRIM/ mice. However, the
distribution of thymic subpopulations, as defined by CD4 and
CD8 coreceptor expression, was similar between TRIM/ ani-
mals and control littermates Fig. 3A. Moreover, we did not
observe a significant alteration in the CD4/CD8 ratio (Table
1), and there was also no difference in CD25 and CD44 ex-
pression within the double negative thymocyte population (Fig.
3B). Collectively, these findings suggest that TRIM is dispens-
able for thymic development.
To corroborate this assumption and, in particular, to rule
out subtle alterations in the selection processes in the absence
of TRIM, we crossed TRIM/ mice onto different TCR
transgenic backgrounds. As shown in Fig. 4, the loss of TRIM
did not influence positive selection in class I (HY)- or class II
(OT-II)-restricted TCR transgenic models. We also tested pos-
itive selection using OT-I and P14 class I-restricted TCRs,
which possess higher affinities for the selecting ligands than the
HY TCR, and again we did not observe any alteration in
TRIM-deficient animals (data not shown). Thus, TRIM ap-
pears to be dispensable for positive selection. Similarly, the
loss of TRIM had no influence on the efficiency of negative
selection in TRIM/ HY male animals (Fig. 4C) or when
negative selection was mimicked by intraperitoneal injection of
the CD3ε MAb 145-2C11 (data not shown). In addition, the
TABLE 1. T-cell subsets in thymusa
TRIM status n Total no. ofcells (106)
No. of cells with indicated phenotype CD4/CD8
ratioCD4 CD8 CD4 CD8 CD4 CD8
TRIM/ 19 119.8 (9.7) 3.9 (0.4) 11.8 (1.1) 3.4 (0.4) 100.6 (8.3) 3.8 (0.2)
TRIM/ 20 92.0 (9.2) 2.8 (0.3) 8.9 (1.2) 2.7 (0.3) 77.5 (8.0) 3.5 (0.2)
a The numbers of lymphocyte subsets were determined on the basis of the total cell count and flow cytometric analysis shown in Fig. 2. Data represent means and
standard errors of the means (in parentheses).
TABLE 2. T-cell subsets in peripheral lymph nodesa
TRIM status n Total no. ofcells (106)
No. of cells with indicated phenotype CD4/CD8
ratio
CD3/B220
ratioCD4 CD8 CD3 B220
TRIM/ 11 28.3 (3.5) 10.8 (1.3) 10.4 (1.7) 21.1 (2.7) 6.2 (0.7) 1.12 (0.1) 3.38 (0.2)
TRIM/ 12 20.3 (2.5) 7.0 (0.7) 7.9 (1.1) 15.5 (2.0) 4.1 (0.5) 0.92 (0.04) 3.78 (0.3)
a The numbers of lymphocyte subsets were determined on the basis of the total cell count and flow cytometric analysis shown in Fig. 2. Data represent means and
standard errors of the means (in parentheses).
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survival of TRIM/ thymocytes after in vitro application of
different apoptotic stimuli was found to be normal (Fig. 4D).
Finally, membrane-proximal TCR-mediated signaling events
(global tyrosine phosphorylation and calcium fluxes) in thymo-
cytes were also unaffected in TRIM/ thymocytes (data not
shown). In summary, these data corroborate that TRIM is
dispensable for both positive and negative selection as well as
for thymocyte responses to either TCR-mediated or TCR-
independent apoptotic stimuli.
We next analyzed peripheral lymphocyte populations prepared
from secondary lymphoid organs. Similar to the situation within
the thymus, TRIM/ mice showed slightly reduced numbers of
all lymphocyte subsets in the spleen and lymph nodes (Table 2
and data not shown), while the distributions of T- and B-cell
subsets were normal (Fig. 3C and D and data not shown). In
addition, we did not observe major alterations in the CD4/CD8 or
the T-cell/B-cell ratios (Table 2) in TRIM/ animals. A detailed
expression analysis of a variety of lineage- and activation-specific
markers (including CD5, CD25, CD44, CD45RB, CD62L, CD69,
TCR, TCR, and NK1.1) also did not reveal any differences
between TRIM/ animals and control littermates. Similarly,
TRIM deficiency had no influence on the expression levels of the
accessory receptor CD28 or of the negative regulatory receptor
CTLA4 (data not shown). Together, these results indicate a non-
essential role for TRIM in the development, maturation, and
distribution of peripheral T lymphocytes.
Analysis of in vitro and in vivo peripheral lymphocyte func-
tions. We have previously reported that TRIM is exclusively
expressed in lymphoid organs (thymus, lymph node, and
spleen) (4, 19). As shown in Fig. 5A, within the T-cell com-
partment TRIM is strongly expressed in thymocytes and in
mature peripheral CD4 T cells, whereas mature CD8 cells
express only minute amounts of the protein. These findings are
in line with a recent report showing higher expression levels
of TRIM mRNA in human and mouse CD4 peripheral T
lymphocytes than CD8 T cells (29) (http://symatlas.gnf.org
/SymAtlas/).
To assess whether TRIM deficiency affects the function of
peripheral CD4 T cells, we investigated membrane-proximal
TCR-mediated signaling events. Figures 5B and C demon-
FIG. 2. TCR expression, internalization, and recycling are normal
in TRIM-deficient mice. Thymocytes (A) and lymph node cells
(B) were stained with anti-TCR MAb and analyzed by flow cytom-
etry. The histograms represent profiles of cells from representative
TRIM/ (shaded) and TRIM/ (thick lines) mice. (C) Measure-
ment of TCR internalization. Lymph node T cells were incubated with
PE-labeled anti-TCR antibody (H57-597) for 30 min on ice. Cells
were then washed to remove unbound antibody and placed at 37°C for
0, 30, 60, 90, and 180 min. Surface-bound antibody was removed by
low-pH washes, and internalized antibody in CD4 cells was quantified
by flow cytometry. (D) Reexpression of previously internalized anti-
TCR antibody. To label an internalized pool of TCR, lymph node T
cells were stained with PE-labeled anti-TCR antibody, cultured for 90
min at 37°C (to allow optimal TCR internalization), and stripped at
low pH to remove cell surface TCR-bound antibody as described for
panel C. Cells were then incubated at 37°C for various time points.
TCR/anti-TCR-PE complexes recycling to the cell surface of CD4
cells were quantified as the fluorescence lost after a second low-pH
wash at the indicated time point and the fluorescence at time zero.
FIG. 3. Development of lymphoid organs in TRIM-deficient mice.
Thymocytes (A), double negative thymocytes (B), and peripheral
lymph node cells (C and D) from 6- to 10-week-old mice were stained
with MAbs for CD3, CD4, CD8, CD25, CD44, and B220 and analyzed
by flow cytometry. Numbers represent percentages of cells falling into
the indicated quadrant of total living cells.
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strate that TCR-mediated global tyrosine phosphorylation, the
activation of MAPKs, and the elevation of intracellular cal-
cium ions are all normal in TRIM/ CD4 T cells. Since
TRIM has been shown to recruit the p85 regulatory subunit of
PI3 kinase (4) and, therefore, may be involved in the regulation
of PI3K activity, we also investigated TCR-mediated activa-
tion-phosphorylation of the serine/threonine kinase Akt/pro-
tein kinase B as a surrogate marker of PI3K activity. Surpris-
ingly, TRIM-deficient T lymphocytes showed an augmented
and prolonged phosphorylation of Akt compared to control
cells. Since wortmannin treatment completely abolished Akt
phosphorylation in both wild-type and TRIM-deficient CD4
T cells (Fig. 5D), we conclude that PI3K activity is indeed
augmented in TRIM/ T lymphocytes.
The PI3 kinase/Akt pathway is involved in many biological
processes, including cell survival, proliferation, differentiation,
and migration (25). To assess whether the augmented activity
of Akt in the absence of TRIM would alter apoptotic re-
sponses, we stimulated mature peripheral CD4 T cells with
CD3 MAbs, corticosteroids, CD95 MAbs, ConA, or etoposide.
Figure 6A shows that the survival of TRIM/ T cells is indis-
tinguishable from that of control T cells. To further investigate
whether TRIM deficiency alters apoptosis of preactivated T
cells (a phenomenon known as AICD), CD4 T cells were
FIG. 4. Positive and negative selection in TRIM/ mice. Normal
positive selection in female HY (A) and OT-II (B) TCR transgenic
(tg) mice. Thymocytes were stained with anti-HY (T3.70) and anti-V2
antibodies, and the CD4/CD8 profiles of transgenic TCR-gated cells
are shown in panels A and B, respectively. (C) Normal negative selec-
tion in HY TCR tg TRIM/ male mice. Profiles of thymocytes gated
on T3.70 cells and then examined for CD4 and CD8 expression. (D)
Response to death-inducing signals within the thymocyte population.
Freshly isolated thymocytes were incubated for 24 h in 24-well plates
and were stimulated with 10 	g/ml plate-bound CD3 plus CD28 MAbs
or incubated either with etoposide, anti-Fas plus cycloheximide
(aFasCHX), or dexamethasone (Dexa). Cell viability was measured
by annexin V and propidium iodide staining.
FIG. 5. TCR-mediated signaling in TRIM-deficient CD4 T cells.
(A) TRIM expression in T cells. Postnuclear lysates were prepared
from freshly isolated thymocytes, lymph node cells (LN), or purified
CD4 and CD8 splenocytes, separated on sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, and blotted with TRIM04 MAb.
The blot was reprobed with anti-Erk1/2 to demonstrate equal loading.
Numbers below the blot represent relative TRIM expression compared
to the lowest. (B) Global tyrosine phosphorylation and MAP family
kinase activation are normal, but Akt phosphorylation is enhanced in
TRIM-deficient mice. Purified CD4 splenic T cells were stimulated
for the indicated periods of time with the CD3 MAb 145-2C11. The
cells were lysed and processed for Western blot analysis. The blots
were probed with anti-phosphospecific antibodies and then stripped
and reprobed with anti-Erk1/2, anti-ZAP-70, and anti-Akt to show
equal loading. Data are representative of five separate experiments.
(C) Analysis of Ca2 mobilization. Purified splenic CD4 cells were
loaded with indo-1-AM and incubated with 10 	g/ml of biotinylated
anti-CD3 (145-2C11). The arrows indicate the addition of streptavidin
and ionomycin (Iono), respectively. (D) TRIM regulation of Akt phos-
phorylation depends on PI3K activity. Purified CD4 splenic T cells
were stimulated for 2 min with CD3 MAb alone or with CD3 plus
CD28 MAbs in the presence or absence of the PI3K inhibitor wort-
mannin. The level of Akt activation was measured by using a phos-
phospecific anti-Akt antibody and the equal loading by using an anti-
Akt antibody. stim., stimulation.
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stimulated in CD3 MAb-coated wells for 2 days. The activated
cells were then grown in the presence of IL-2 for an additional
2 days and finally restimulated overnight with CD3 MAbs. The
induction of apoptosis was subsequently measured by staining
the cells with annexin V and propidium iodide. The data shown
in Fig. 6B demonstrate that the absence of TRIM does not
influence AICD.
We next assessed the in vitro proliferative response after
stimulation with a variety of mitogenic stimuli, such as CD3
MAbs, ConA, SEB, and CD3/CD28 costimulation. As shown
in Fig. 6C, TRIM-deficient CD4 T cells responded as effi-
ciently as wild-type T cells to all applied stimuli. Similarly, the
concentrations of IL-2, IL-4, tumor necrosis factor , and
gamma interferon in the culture supernatants were found to be
normal (data not shown). Note that similar results were ob-
tained when unfractionated splenic T cells were analyzed in-
stead of purified CD4 T cells (data not shown).
To investigate whether TRIM regulates the migration of pe-
ripheral T lymphocytes, we used a transwell system and allowed
lymphocytes to migrate through fibronectin-coated polycarbonate
meshes in response to the chemokine SDF1. Again, TRIM/
T cells migrated with an efficiency similar to that of wild-type
lymphocytes (Fig. 6D). Similarly, the constitutive and the CD3-
mediated adhesion of 1 and 2 integrins to fibronectin or
ICAM-I-coated plastic dishes were normal in TRIM/ mice
(data not shown). Collectively, these data suggest that the absence
of TRIM does not influence T-cell proliferation, survival, migra-
tion, and adhesion.
In summary, the data shown in Fig. 6 demonstrate that
despite the enhanced activity of PI3K in TRIM/ mice, T-cell
functions are unaffected under a variety of experimental con-
ditions. A possible explanation for this somewhat unexpected
observation could be that the slight augmentation of PI3K
activity that occurs in the absence of TRIM is, per se, not
sufficient to significantly alter downstream signaling cascades
and thus cellular responses. It is also possible, however, that
the augmented PI3K activity in TRIM/ cells is partially
compensated for by another nonraft transmembrane adaptor
protein(s) exerting similar functions, the transmembrane adap-
tor protein LAX being a likely candidate. LAX also binds the
p85 regulatory subunit of PI3K (40), and similar to the situa-
tion described here, LAX/ T cells show a slightly augmented
PI3K activity after TCR engagement (39). Thus, it appears as
if both TRIM and LAX jointly regulate PI3K activity in pe-
FIG. 6. T-cell responses in vitro and in vivo. (A) Normal survival of peripheral CD4 T cells upon stimulation with CD3 MAb (aCD3), ConA,
etoposide, anti-Fas plus cycloheximide (aFas/CHX), or dexamethasone (Dexa). One representative out of two experiments is shown. (B)
Activation-induced cell death (AICD). CD4 T cells were stimulated in CD3 MAb-coated plates, grown in IL-2, and restimulated overnight with
CD3 antibody. Apoptosis was measured by annexin V and propidium iodide staining. The data are expressed as induction of apoptosis relative to
control samples that were not restimulated. (C) Normal T-cell proliferation in TRIM-deficient mice. Purified CD4 splenic T cells were stimulated
in CD3 MAb-coated 96-well plates or with ConA, SEB, or PMA plus ionomycin (Iono) for 72 h, pulsed with [H3]thymidine, and processed for
standard scintillation counting. One out of five independent experiments is shown. Three mice of each genotype were included in each experiment.
(D) Migration assay. Freshly isolated lymph node cells were added to the insert of a transwell plate, with the lower chamber containing medium
alone or medium supplemented with SDF1. After 3 h, cells that had migrated into the lower wells were collected and counted by flow cytometry.
The data shown are representative for three independently performed experiments. The migration is expressed as induction relative to that of
control samples incubated with medium alone. (E) Serum immunoglobulin titers. The concentration of serum immunoglobulins was measured by
ELISA. Bars represent mean values. (F and G) Humoral immune response. Mice were immunized with the T-dependent antigen DNP-KLH, and
DNP-specific immunoglobulins were analyzed at day 10 (F), or they were reimmunized at day 14 with the same antigen and DNP-specific
immunoglobulins were measured at day 28 (G) as described in Materials and Methods.
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ripheral T cells. Combined deletion of the TRIM and LAX
genes will be required to assess whether both molecules indeed
share redundant functions with regard to the TCR-mediated
activation of PI3K or not.
One possibility to explain the enhanced activity of PI3K in
the absence of either TRIM or LAX could be that in normal T
cells both molecules are involved in sequestering the p85 sub-
unit of PI3K from the lipid rafts to the nonraft fraction. Loss of
TRIM or LAX might then cause a redistribution of PI3K from
the nonraft to the raft fraction, thereby enhancing its activity.
It is important to note that a similar “redistribution” phenom-
enon has recently been proposed to underlie the augmented
response of mast cells that lack expression of the transmem-
brane adaptor protein NTAL/LAB (33).
The impact of TRIM deficiency on in vivo immune functions
was further tested by challenging TRIM/ mice and control
littermates with the T-dependent antigen DNP-KLH at days 0
and 21. The levels of hapten-specific IgG1, IgG2a, IgG2b,
IgG3, and IgM antibodies were measured 10 and 28 days after
immunization. As shown in Fig. 6, both the primary (Fig. 6F)
and the secondary (Fig. 6G) humoral responses of mutant and
wild-type mice were comparable, indicating that T-helper func-
tions are not affected in TRIM/ mice.
To finally study the immune function of TRIM-deficient T
cells in a disease model, we assessed the clinical course of
experimental autoimmune encephalomyelitis (EAE), a murine
model of multiple sclerosis, in wild-type and TRIM-deficient
animals. EAE is a well-established Th1-mediated disease that
can be induced in C57BL/6 mice by immunization with
MOG(35-55) peptide. The pathophysiology of EAE is charac-
terized by T-cell-mediated demyelinization of axons in the
central nervous system, which is followed by a progressive
paralysis of the tail and the limbs (21). Due to the complex
nature of the disease, which integrates many aspects of T-cell
function, EAE represents a sensitive model system to detect
even subtle alterations of immune functions. Indeed, we re-
cently could show clear differences in the clinical course of
EAE in knockout mice in which both T-dependent and T-
independent immune responses were unaffected (28, 31).
To induce EAE, matched groups of TRIM/ and wild-type
mice were immunized with MOG(35-55) peptide, and the clin-
ical score of EAE was assessed over time in a blinded study. As
shown in Table 3, TRIM-deficient mice showed a normal
course of EAE both with regard to the onset of disease as well
as with regard to the clinical score, which ranged between 1.7
and 1.9 in both TRIM/ and TRIM/ mice. Together with
the normal response after immunization with T-dependent
antigens, these data suggest a nonessential role of TRIM
within the immune system.
Normal B-cell development and B-cell functions in TRIM-
deficient mice. Although TRIM expression has been reported
to be limited to T lymphocytes (4), we also investigated the
generation and the functions of B cells in TRIM/ animals.
These experiments were aimed to exclude the possibility
that TRIM is expressed as a functional protein in particular
B-cell subsets or in B-cell precursors as had previously been
shown for the transmembrane adaptor protein LAT and the
tyrosine kinase ZAP-70 (27, 30). However, the development
of B cells within the bone marrow as well as the in vitro
proliferation of purified splenic B cells after anti-IgM, lipo-
polysaccharide, anti-CD40, and IL-4 stimulation was not af-
fected by loss of TRIM (data not shown). Similarly, the serum
Ig levels (Fig. 6E) and the humoral immune response after
immunization with the T-independent antigen DNP-lipopoly-
saccharide was normal in TRIM/ mice (data not shown).
Thus, in contrast to LAT, TRIM is not involved in regulating
B-cell development and B-cell functions both in vivo and in
vitro.
Concluding remarks. Among the seven TRAPs known to
date, LAT clearly represents the master switch that critically
regulates T-cell development and peripheral T-cell activation
(12, 37, 38). In contrast, other transmembrane adaptors such as
LAX, NTAL, and SIT rather appear to be involved in the
fine-tuning of antigen receptor-mediated signaling within im-
mune cells (28, 34, 39). The same seems to apply for the nonraft
transmembrane adaptor protein investigated here, TRIM.
TRIM is strongly expressed in thymocytes and, as shown
here, in peripheral CD4 T cells. Previous reports suggested
that TRIM might be involved in the regulation of TCR expres-
sion in Jurkat T cells (4, 20). In addition, TRIM was shown to
undergo tyrosine phosphorylation after T-cell activation and to
recruit the p85 regulatory subunit of PI3K to the plasma mem-
brane (4, 20). Together, these observations suggested that
TRIM might represent an important regulator of T-cell devel-
opment and T-cell responses. However, the data presented in
this report suggest that TRIM does not play an essential role
within the (murine) immune system.
Although our study did not reveal major alterations of im-
mune functions in the absence of TRIM, we certainly cannot
exclude the possibility that TRIM regulates immunological
processes that we have not investigated (for example, TRIM
could be involved in pathways that emerge from signaling re-
ceptors distinct from the TCR). However, given the fact that
several in vivo models (immunization with T-dependent anti-
gens as well as induction of the autoimmune disease EAE) did
not show abnormalities in TRIM-deficient animals, we believe
this possibility to be unlikely.
To date, seven TRAPs have been identified: LAT, LAX,
LIME, NTAL/LAB, PAG/CBP, SIT, and TRIM (for a review,
see reference 18). Among them, LAX, SIT, and TRIM are
localized in the nonraft fraction of the plasma membrane.
Recently published data showed that both LAX and SIT
function as negative regulators of antigen receptor-mediated
signaling. Thus, LAX-deficient T and B lymphocytes are hy-
perresponsive to CD3- or anti-IgM-mediated stimuli (39). Sim-
ilarly, we have most recently shown that SIT functions as a
negative regulator of TCR-mediated signaling (28). The mo-
TABLE 3. Clinical observations of MOG peptide-induced EAEa
Group Incidenceof EAE Avg score
No. of
deaths
Wild type 26/32 1.95  0.2 10/32
TRIM/ 25/33 1.75  0.2 8/33
a Disease severity was scored according to a scale from 0 to 5: 0, no signs; 0.5,
partial tail weakness; 1, limp tail or slight slowing of righting from supine
position; 2, paresis of hind limb or marked slowing of righting; 2.5, dragging of
hind limb(s) without complete paralysis; 3, complete paralysis of hind limb; 4,
severe forelimb paralysis; 5, moribund or dead. In respect of the animal protec-
tion laws, mice were killed when they reached a score of 3 and received this last
score until the end of the experiment.
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lecular mechanisms underlying LAX- and SIT-mediated neg-
ative regulation of TCR signaling are still unclear. One possi-
bility is that LAX and SIT affect signaling within T cells by
sequestering cytoplasmic effector molecules from the lipid rafts
to the nonraft fraction or that they blunt T-cell responses by
recruiting negative regulatory molecules to the plasma mem-
brane.
The very mild phenotypes of the SIT and LAX knockout
mice plus the almost nonexistent phenotype of the TRIM
mouse described in this report indicate that each of the non-
raft-associated TRAPs by itself plays a rather subtle role within
the immune system. However, the orchestrated activities of all
negative regulatory transmembrane adaptor proteins might
play a major role in controlling cell growth and differentiation.
The apparent redundancy among the different nonraft TRAPs
may serve as a safety mechanism to guarantee the integrity of
the system even when one component is missing or altered. In
this regard, the analysis of TRIM/SIT double-deficient mice
(note that TRIM and SIT share two tyrosine-based signaling
motifs within their cytoplasmic tails, YGNL and YASV/L), of
TRIM/LAX double-deficient mice (as both molecules are ca-
pable of binding PI3K and each of the single knockouts shows
augmented activity of PI3K), or even of triple knockouts (as all
three molecules carry YXN motifs that might bind the cytoso-
lic adaptor protein Grb2) might shed further light onto the
question of how TRAPs regulate homeostasis within the im-
mune system.
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Cellular decisions are determined by complex molecular interaction networks. Large-scale signaling networks are
currently being reconstructed, but the kinetic parameters and quantitative data that would allow for dynamic
modeling are still scarce. Therefore, computational studies based upon the structure of these networks are of great
interest. Here, a methodology relying on a logical formalism is applied to the functional analysis of the complex
signaling network governing the activation of T cells via the T cell receptor, the CD4/CD8 co-receptors, and the
accessory signaling receptor CD28. Our large-scale Boolean model, which comprises 94 nodes and 123 interactions and
is based upon well-established qualitative knowledge from primary T cells, reveals important structural features (e.g.,
feedback loops and network-wide dependencies) and recapitulates the global behavior of this network for an array of
published data on T cell activation in wild-type and knock-out conditions. More importantly, the model predicted
unexpected signaling events after antibody-mediated perturbation of CD28 and after genetic knockout of the kinase
Fyn that were subsequently experimentally validated. Finally, we show that the logical model reveals key elements
and potential failure modes in network functioning and provides candidates for missing links. In summary, our large-
scale logical model for T cell activation proved to be a promising in silico tool, and it inspires immunologists to ask new
questions. We think that it holds valuable potential in foreseeing the effects of drugs and network modifications.
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Introduction
Understanding how cellular networks function in a holistic
perspective is the main purpose of systems biology [1].
Dynamic models provide an optimal basis for a detailed study
of cellular networks and have been applied successfully to
cellular networks of moderate size [2–5]. However, for their
construction and analysis they require an enormous amount
of mechanistic details and quantitative data which, until now,
has been often lacking in large-scale networks. Therefore,
there has been considerable effort to develop methods based
exclusively on the often well-known network topology [6,7].
One may distinguish between studies on the statistical
properties of graphs [8–10] and approaches aiming at
predicting functional or dysfunctional states and modes.
For the latter, a large corpus of methods has been developed
for metabolic networks mainly relying on the constraints-
based approach [11,12]. However, for signaling networks,
methods facilitating a similar functional analysis—including
predictions on the outcome of interventions— have been
applied to a much lesser extent [6].
Here we demonstrate that capturing the structure of
signaling networks by a recently introduced logical approach
[13] allows the analysis of important functional aspects, often
leading to predictions that can be veriﬁed in knock-out/
perturbation experiments. Logical networks have until now
been used for studying artiﬁcial (random) networks [14] or
relatively small gene regulatory networks [15–18]. In contrast,
herein we study a large-scale signaling network, structured in
input (e.g., receptors), intermediate, and output (e.g., tran-
scription factors) layers. Compared with gene regulatory
networks, the behavior of signaling networks is mainly
governed by their input layer, shifting the interest to input–
output relationships. Addressing these issues requires parti-
ally different techniques, as compared with gene regulatory
networks. We use a special and intuitive representation of
logical networks (called logical interaction hypergraph (LIH); see
Methods), which is well-suited for this kind of input–output
analysis. By applying logical steady state analysis, one may
predict how a combination of signals arriving at the input
layer leads to a certain response in the intermediate and the
output layers. Additionally, this approach facilitates predic-
tions of the effect of interventions and, moreover, allows one
to search for interventions that repress or provoke a certain
logical response [13]. Furthermore, each logical network has a
unique underlying interaction graph from which other
important network properties such as feedback loops,
signaling paths, and network-wide interdependencies can be
evaluated.
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Importantly, we consider here a logical model to be
constructed by collecting and integrating well-known local
interactions (e.g., a kinase phosphorylates an adaptor
molecule). The logical model is then employed to derive
global information (e.g., stimulation of a receptor leads to the
activation of a certain transcription factor via several logical
connections). Thus, the available data on the global network
behavior is not used to construct the model; instead, it is used
to verify the model. The model may then be employed to
predict global responses that have not yet been studied
experimentally.
Here, we apply the logical framework to a carefully
constructed model of T cell receptor (TCR) signaling. T-
lymphocytes play a key role within the immune system:
cytotoxic, CD8þ, T cells destroy cells infected by viruses or
malignant cells, and CD4þ T helper cells coordinate the
functions of other cells of the immune system [19]. The
importance of T cells for immune homeostasis is due to their
ability to speciﬁcally recognize foreign, potentially danger-
ous, agents and, subsequently, to initiate a speciﬁc immune
response. T cell reactivity must be exquisitely regulated as
either a decrease (which weakens the defense against
pathogens with the consequence of immunodeﬁciency) or
an increase (which can lead to autoimmune disorders and
leukemia) can have severe consequences for the organism.
T cells detect foreign antigens by means of the TCR, which
recognizes peptides only when presented upon MHC (Major
Histocompatibility Complex) molecules. The peptides that
are recognized by the TCR are typically derived from foreign
(e.g., bacterial, viral) proteins and are generated by proteo-
lytic cleavage within so-called antigen presenting cells (APCs).
Binding of the TCR to peptide/MHC complexes and the
additional binding of a different region of the MHC
molecules by the co-receptors (CD4 in the case of T helper
cells and CD8 in the case of cytotoxic T cells), together with
costimulatory molecules such as CD28, initiates a plethora of
signaling cascades within the T cell. These cascades give rise
to a complex signaling network, which controls the activation
of several transcription factors. These transcription factors,
in turn, control the cell’s fate, particularly whether the T cell
becomes activated and proliferates or not [20]. Therefore, we
chose to focus on a limited number of receptors that are
known to be central to the decision making process. The high
number of kinases, phosphatases, adaptor molecules, and
their interactions give rise to a complex interaction network
which cannot be interpreted via pure intuition and requires
the aid of mathematical tools. Since no sufﬁcient basis of
kinetic data is available for setting up a dynamic model of this
network, we opted to use logical modeling as a qualitative and
discrete modeling framework. Note that there are kinetic
models dealing with a smaller part of the network (e.g.,
[5,21,22]), as well as models of the gene regulatory network
governing T cell activation [23].
We recently introduced our approach for the logical
modeling of signaling networks [13], and, to exemplify it, we
presented a small logical model for T cell activation (40
nodes). However, this model only served to demonstrate
applicability and was too incomplete to address realistic
complex input–output patterns. In contrast, the model
presented herein has been signiﬁcantly expanded to 94 nodes
and reﬁned by a careful reconstruction process (see below). It
is thus realistic enough to be veriﬁed with diverse exper-
imental data and to test its predictive power.
In this report, the large-scale logical model describing T
cell activation and the analysis performed therewith will be
presented. First we will show that a number of important
structural features can be identiﬁed with this model. Then we
will show that the model not only reproduces published data
on wet lab experiments, but it also predicts non-intuitive and
previously unknown responses.
Results
Setup of a Curated, Comprehensive Logical Model of T
Cell Receptor Signaling
We have constructed a logical model describing T cell
signaling (see Methods and Figure 1), which comprises the
main events and elements connecting the TCR, its corecep-
tors CD4/CD8, and the costimulatory molecule CD28, to the
activation of key transcription factors in T cells such as AP-1,
NFAT, and NFjB, all of which determine T cell activation and
T cell function. In general, the model includes the following
signaling steps emerging from the above receptors: the
activation of the Src kinases Lck and Fyn, followed by the
activation of the Syk-related protein tyrosine kinase ZAP70,
and the subsequent assembly of the LAT signalosome, which
in turn triggers activation of PLCc1, calcium cascades,
activation of RasGRP, and Grb2/SOS, leading to the activa-
tion of MAPKs [20]. Additionally, it includes the activation of
the PI3K/PKB pathway that regulates many aspects of cellular
activation and differentiation, particularly survival. For the
activation of elements that play an important role, but whose
regulation is not well-known yet (e.g., Card11, Gadd45), an
external input was added. These elements can be considered
as points of future extension of the model.
As mentioned above, our model, which is documented in a
detailed manner in Tables S1 and S2, is based upon local
interactions (e.g., kinase ZAP70 phosphorylates the adaptor
molecule LAT) that are well-established for primary T cells in
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Author Summary
T-lymphocytes are central regulators of the adaptive immune
response, and their inappropriate activation can cause autoimmune
diseases or cancer. The understanding of the signaling mechanisms
underlying T cell activation is a prerequisite to develop new
strategies for pharmacological intervention and disease treatments.
However, much of the existing literature on T cell signaling is related
to T cell development or to activation processes in transformed T
cell lines (e.g., Jurkat), whereas information on non-transformed
primary T cells is limited. Here, immunologists and theoreticians
have compiled data from the existing literature that stem from
analysis of primary T cells. They used this information to establish a
qualitative Boolean network that describes T cell activation
mechanisms after engagement of the TCR, the CD4/CD8 co-
receptors, and CD28. The network comprises 94 nodes and can be
extended to facilitate interpretation of new data that emerge from
experimental analysis of T cell activation. Newly developed tools and
methods allow in silico analysis, and manipulation of the network
and can uncover hidden/unforeseen signaling pathways. Indeed, by
assessing signaling events controlled by CD28 and the protein
tyrosine kinase Fyn, we show that computational analysis of even a
qualitative network can provide new and non-obvious signaling
pathways which can be validated experimentally.
A Logical Model of T Cell Receptor Signaling
the literature. We did not use the known global information
(e.g., stimulation of a receptor leads to the activation of a
certain transcription factor) for the model construction.
Instead, in simulations, the local interactions give rise to a
global behavior which can be compared with available
experimental observations (and was thus used to verify the
model).
Each component in the logical model can be either ON
(‘‘1’’) or OFF (‘‘0’’). We consider a compound to be ON only if
it is fully activated and able to trigger downstream events
properly; otherwise, it is OFF. Furthermore, we consider two
timescales [13]: early (s ¼ 1) and late (s ¼ 2), involving
processes occurring during or after the ﬁrst minutes of
activation, respectively (the time-scale for each interaction is
given in Table S2). Some key regulatory processes such as the
degradation of signaling proteins mediated by the E3
ubiquitin ligase c-Cbl [24–26] occur after a certain time,
and are thus assigned s¼ 2. Therefore, as will be shown later,
analysis of signal propagation during the early events reveals
which elements become activated, and the consideration of
the late events allows a rough approximation to the dynamic
behavior (sustained versus transient) of the network.
The model comprises 94 different compounds and 123
interactions that give rise to a complex map of interactions
(Figure 1). It is, to the best of our knowledge, the largest
Boolean model of a cellular network to date.
Interaction-Graph-Based Analyses
The ﬁrst step in our analysis was to examine the interaction
graph underlying the logical model. The former can be easily
derived from the latter when a special representation of
Boolean networks is used (see Methods). The interaction
graph is less constrained than the Boolean network since it
only captures direct (positive or negative) effects of one
Figure 1. Logical Model of T Cell Activation (Screenshot of CellNetAnalyzer)
Each arrow pointing at a species box is a so-called hyperarc representing one possibility to activate that species (see Methods). All the hyperarcs pointing
at a particular species box are OR connected. Yellow species boxes denote output elements, while green ones represent (co)receptors. In the shown
‘‘early-event’’ scenario, the feedback loops were switched off, and only the input for the costimulatory molecule CD28 is active (scenario in column 2 of
Table 1). The resulting logical steady state was then computed. Small text boxes display the signal flows along the hyperarcs (blue boxes: fixed values
prior to computation; green boxes: hyperarcs activating a species (signal flow is 1); red boxes: hyperarcs which are not active (signal flow is 0)).
doi:10.1371/journal.pcbi.0030163.g001
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molecule upon another. Thus, unlike the logical model, the
interaction graph cannot describe how different causal
effects converging at a certain species are combined. For
example, in an interaction graph we may say that A and B
have a positive inﬂuence on another node C; the logical
network is more precise because it expresses that A AND B
(or A OR B) are required to activate C. Accordingly,
compared with the logical model, an interaction graph
requires less a priori knowledge about the network under
study which comes at the price that functional predictions
are limited. Nevertheless, as demonstrated in this section, a
number of important functional features can be revealed
from the graph model.
First we studied global properties of the graph. As
expected, the graph is connected (i.e., neglecting the arc
directions, there is always a path from one node to all others).
However, the directed graph contains as a core one strongly
connected component with 33 nodes (i.e., for each pair (a,b)
of nodes taken from this component there is a path from a to
b and from b to a). This structural organization is related with
the bow-tie structure found in other cellular networks (e.g.,
[7,27]) and implies that the rest of the network (not contained
in the strongly connected component) mainly consists in
relatively simple input and output layers (including branch-
ing cascades) feeding to and from this component.
We continued the interaction-graph-based analysis by
computing the feedback loops. Feedback loops are of major
importance for the dynamic behavior and functioning of
biological networks. Negative feedback loops control homeo-
static response and can give rise to oscillations, while positive
feedbacks govern multistable behavior (connected to irrever-
sible decision-making and differentiation processes) [15,28–
30]. The interaction graph underlying the logical T cell model
has 172 feedback loops, 89 thereof being negative. Remark-
ably, all feedback loops are only active in the second timescale
because each loop contains at least one process of the second
timescale. The elements of the MAPK cascade are involved in
92% of the feedback loops. This is due to the fact that there is
a connection from ERK to the phosphatase SHP1 from the
bottom to the top of the network [5]. Due to this connection,
the resulting feedback can return to ERK via many different
paths, thereby leading to a high number of loops. Indeed, if
the ERK ! SHP1 connection is not considered, the number
of loops is reduced dramatically from 172 to 13 (with only 11
being negative), all located in the upper part of the network.
c-Cbl is involved in ;85% of them, thus underscoring the
importance of c-Cbl in the regulation of signaling processes
[25,26].
There are 4,538 paths, each connecting one of the three
compounds from the input layer (TCR, CD4/CD8, CD28) with
one compound in the output layer (transcription factors and
other elements controlling T cell activation). The high
number of negative paths (2,058) can be traced back to the
presence of two negative connections (via DGK and Gab2). In
fact, considering the early signaling events within the
network, where DGK and Gab2 are not active yet, the
number of paths is reduced to 1,530, with only six of them
being negative. These paths are from the TCR and CD28 to
negative regulators of the cell cycle (p21, p27, and FKHR),
having thus a positive effect on T cell proliferation. These
and other global effects can be graphically inspected via the
dependency matrix [13,31], depicted in Figure 2. Importantly,
when considering the timescale s¼ 1, there is no ambivalent
effect (i.e., via positive and negative paths) between any
ordered pair (A,B) of species, i.e., A is either a pure activator
of B (only positive paths from A to B), or a pure inhibitor of B
(only negative paths from A to B), or has no direct or indirect
inﬂuence on B at all. For example, during early activation, the
TCR can only have a positive effect upon AP1 (the array
element (TCRb, AP1) in Figure 2 is green). Note that this
changes for timescale s ¼ 2 where, in several cases, a
compound inﬂuences another species in an ambivalent
manner.
Analysis of the Logical Model
An important aspect that can be studied with a logical
model is signal processing and signal propagation and the
corresponding response (activation/inactivation) of the nodes
upon external stimuli and perturbations (see Methods). One
starts the analysis of a scenario by deﬁning a pattern of input
stimuli, possibly in combination with a set of nodes that are
knocked-out or knocked-in. Then, by an iterative evaluation
of the Boolean rules in each node, the signal is propagated
through the network, switching each node ON or OFF,
respectively (see [13] and Methods). For example, since CD28
(an input) is (permanently) ON in the scenario shown in
Figure 1, it will (permanently) activate node X, which will in
turn (permanently) activate Vav1, and so forth. In the same
scenario, since the input CD4 is OFF, Lckp1 and therefore
Abl, ZAP70, and other components cannot become activated
and therefore are in the OFF state. In the ideal case, each
node can be assigned a uniquely determined state that follows
from a given input pattern. In terms of Boolean networks, the
set of determined node values then represents a logical steady
state. In some cases, in particular when negative feedback
loops are active, only a fraction of the elements can be
assigned a unique steady state value, whereas other (or even
all) nodes might oscillate [15]. However, since in the T cell
model all negative feedback loops become active only during
timescale s¼ 2 (as described above), a complete logical steady
state follows for arbitrary input patterns when considering s
¼ 1.
Using this kind of logical steady state analysis, we ﬁrst
analyzed the activation pattern of key elements upon differ-
ent stimuli (activation of the TCR and/or CD4 and/or CD28;
Table 1) for timescale s¼ 1. The model was able to reproduce
data from both the literature and our own experiments,
providing a holistic and integrated interpretation for a large
body of data. The model also predicted a non-obvious
signaling event, namely that the activation of the costimula-
tory molecule CD28 alone leads not only to the activation of
PI3K—which is to be expected from a large body of literature
dealing with CD28 signaling showing that PI3K binds to the
motif YxxM of CD28 [32,33]—but also to the selective
activation of JNK, but not ERK. The model predicts a
pathway from CD28 to JNK which gives a holistic explanation
for this result: the pathway does NOT involve the LAT
signalosome, activation of PLCc1, and Calcium ﬂux, but
clearly depends on the activation of the nucleotide exchange
factor Vav1 which activates MEKK1 via the small G-protein
Rac1 (Figure 1). Clearly, the activating pathway shown in
Figure 1 could be identiﬁed by a visual inspection of the map
(note that we have intentionally drawn the network in such a
way that this route can be easily seen). However, in large-scale
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networks the identiﬁcation of long-distance pathways by
simply following all possible routes becomes infeasible and is
particularly complicated if AND connections are involved.
Furthermore, since the CD28-induced JNK activation path-
way was not expected, one would probably not have searched
speciﬁcally for this pathway, while the algorithm reveals the
whole response of the network.
The prediction made by the model is particularly surpris-
ing in light of published data which either suggest that CD28
stimulation alone does NOT activate JNK [34,35] or induces
only a weak activation [36]. Driven by this surprising
prediction, we performed the corresponding experiments in
vitro. As shown in Figure 3A, stimulation of mouse primary T
cells with a non-superagonistic CD28 antibody induced an
evident and sustained JNK phosphorylation, thus conﬁrming
almost perfectly the predicted binary response. Note, the
model also predicted that JNK activation does not depend on
the activation of PI3K. Again, this prediction was veriﬁed by
applying a pharmacological inhibitor of PI3K (Figure 3D).
The discrepancies with the literature could be due either to
the different cellular systems (primary T cells versus T cell
lines) or to the different stimulation conditions.
The nature of the kinase involved in CD28-mediated
signaling remains unclear. Indeed, application of the Src-
kinase inhibitor PP2 that inactivates both Lck þ Fyn [37],
showed that Src-kinases, which were proposed to mediate
CD28 signaling [38], are dispensable for the CD28-mediated
activation of JNK (Figure 4). To ﬁt the Src-kinase inhibitor
data with the model, it would have been possible to simply
bypass the Src-kinase and to draw a causal connection from
CD28 to Vav. Such a connection would indeed be justiﬁed
since it is well established that triggering of CD28 leads to the
activation of Vav ([39]; for more details, see Table S2,
reactions 35 and 48). However, we preferred to include a
to-be-identiﬁed kinase X that gets activated by CD28 (Figure
1), in order to keep within the model the information that
there is a component to be identiﬁed. Potential candidates
for kinase X would be members of the Tec-family of PTKs.
However, it is difﬁcult to study the signaling properties of
these kinases in primary non-transformed cells since speciﬁc
inhibitors for Tec kinases are not yet available and the
corresponding knock-out mice show defects in thymic
development. Therefore, as we focused during model
generation on well-established data from primary T cells
and excluded data obtained from knockout mice showing
alterations of thymic development, we did not include it.
Figure 2. Dependency Matrix of the Logical T Cell Signaling Model (Figure 1) for the Early Events Scenario (s ¼ 1)
The color of a matrix element Mxy has the following meaning [13]: (i) dark green: x is a total activator of y; (ii) dark red: x is a total inhibitor of y; (iii) white:
no (direct or indirect) influence from x on y.
doi:10.1371/journal.pcbi.0030163.g002
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The ability of the model to recapitulate the T cell
phenotype of a variety of previously described knock-out
mice was also tested (Table 1). Indeed, the model could
reproduce the phenotype of several knock-outs and again
reported a rather unexpected result: activation of the TCR in
Fyn-deﬁcient cells selectively triggers the PI3K/PKB pathway.
This prediction was subsequently tested using peripheral
primary T cells prepared from spleen of Fyn-deﬁcient mice.
As shown in Figure 3B, the wet-lab experiments corroborated
the model result again.
However, there was an experimental result which the
model could not reproduce: TCR-mediated JNK activation is
blocked by an inhibitor of PI3K (Figure 3C). In fact, this result
is not in accordance with the network because PI3K has no
inﬂuence upon JNK (see dependency matrix, Figure 2).
To identify potential connections that would explain the
experimental data, we applied the concept of Minimal
Intervention Sets (MISs; see Methods). A MIS is a irreducible
collection of actions (e.g., activation or inactivation of certain
compounds), that, if applied, guarantees that a certain goal (a
desired behavior) is fulﬁlled [13]. Here, we computed the MISs
by which JNK becomes activated under the experimentally
obtained constraint (see Figure 3C) that PI3K is OFF
(describing the effect of the PI3K inhibitor), ZAP70 is ON,
and that the TCR has been activated. These MISs (Table 2)
thus provide a list of minimal combinations of elements that
should be directly or indirectly affected by PI3K and thus
allow us to explain the observed response of JNK upon
inhibiting PI3K. Some of them are obvious, e.g., the ﬁrst MIS
in Table 2 suggests that JNK activation could be directly
interacting with PI3K or elements that are located down-
stream of PI3K (e.g., PIP3). There is currently no convincing
experimental evidence for an effect of PI3K on JNK, though.
Other MISs in Table 2 suggest that a PI3K-mediated activation
of Vav (both 1 and 3 isoforms) is involved, which would be an
attractive possibility to explain the experimental data.
Indeed, Vav possesses a PH domain which can bind to PIP3,
and this mechanism could be important for Vav activation
[40], thus making it a reasonable extension of the model.
Another molecule that could be involved in PI3K-mediated
Table 1. Summary of Predicted Activation Pattern upon Different Stimuli and Knock-Out Conditions
Input/
Output
WT WT WT PI3K PI3K PI3K SLP76 Fyn Fyn Fyn Rlk and
Itk
Lck and
Fyn
Lck and
Fyn
Lck and
Fyn
Input TCR 1 0 1 1 0 1 1 1 1 1 1 1 0 1
CD4 0 0 0 0 0 0 0 0 1 0 0 0 0 0
CD28 0 1 1 0 1 1 0 0 0 1 0 0 1 1
Output ZAP 1 0 1 1 0 1 1 0 1 0 1 0 0 0
LAT 1 0 1 1 0 1 1 0 1 0 1 0 0 0
PLCga 1 0 1 0 0 0 0 0 1 0 0 0 0 0
ERK 1 0 1 0 0 0 0 0 1 0 0 0 0 0
JNK 1 1 1 1 1 1 1 0 1 1 1 0 1 1
PKB 1 1 1 0 0 0 1 1 1 1 1 0 1 1
AP1 1 0 1 0 0 0 0 0 1 0 0 0 0 0
NFKB 1 0 1 0 0 0 0 0 1 0 0 0 0 0
NFAT 1 0 1 0 0 0 0 0 1 0 0 0 0 0
Reference Figure
3A, 3C
Figure
3A, 3D
Figures
3A, 4
Figure 3C Figure 3D Figure 4 [49] Figure
3B, [50]
Figure
3B, [50]
Figure
3B, [50]
[51] Figure 4 Figure 4 Figure 4
The headings denote the perturbed (switched-off) element. In the case of PI3K and Lck and Fyn, the perturbation was done via a chemical inhibitor, and for the rest it was through a
genetic knock-out. The ‘‘Input’’ rows show the stimuli, and ‘‘Output’’ the predictions of the model for key elements of the network. Here, blue numbers denote results corroborated by
published data, while green ones were confirmed by our own data. The red number shows a discrepancy between model and experiment (see discussion in the main text). Finally, the row
labeled Reference indicates the Figure where the experimental results are shown or points to the literature reference.
doi:10.1371/journal.pcbi.0030163.t001
Figure 3. In Vitro Analysis of Model Predictions
(A) Activation of ERK and JNK upon CD28, TCR (CD3), or TCRþ CD28 stimulation in mouse splenic T cells.
(B) Activation of PKB upon TCR, TCRþ CD4, and TCR þ CD28 stimulation in Fyn-deficient and heterozygous splenic mouse T cells.
(C) Inhibition of PI3K with both Ly294002 and Wortmannin blocks the phosphorylation of PKB, ERK, and JNK, but not ZAP-70 in human T cells.
(D) Inhibition of PI3K with both Ly294002 and Wortmannin blocks the phosphorylation of PKB, but not of JNK in human T cells upon CD28 stimulation.
As a control, the total amount of ZAP70 (A) or b-actin (B–D) was determined. One representative experiment (of three) is shown.
doi:10.1371/journal.pcbi.0030163.g003
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activation of JNK is the serine/threonine kinase HPK1 (see
Figure 1 and Tables S1 and S2). Interestingly, HPK1 is
phosphorylated by Protein Kinase D1 (PKD1) [41], a kinase
whose activation depends on PKC (which in turn is depend-
ent on DAG, downstream of PI3K) for activation. Since the
regulation and functional roles of both PKD1 and PKC (with
the exception of the h isoform) are not yet well-established in
T cells, we did not include them in the model, but a
connection PI3K ! PIP3 ! Itk ! PLCc ! DAG ! PKC !
PKD1 ! HPK1 would be plausible (in which the path from
PKC to HPK1 via PKD1 would be new). An alternative could
be a Rac-dependent activation of HPK1 [42]; however, this is
again a not-well-established connection and thus was not
considered.
Deﬁnitely, the model requires a direct or indirect
connection from PI3K to JNK, and additional experiments
are required to assess which of the candidate links predicted
by the MISs are relevant in peripheral T cells. This particular
example illustrates another useful and important application
of our approach: the model not only reveals that a link is
missing, but also suggests candidates that can be veriﬁed
experimentally. Thus, MIS analysis is capable of guiding the
experimentalist and helps to plan the corresponding experi-
ments.
As an additional application of MISs, we computed
combinations of failures (constitutive activation or inactiva-
tion of elements caused for example by mutations) which lead
to sustained T cell activation without external stimuli. These
failure modes would cause uncontrolled proliferation and
thus may be connected to diseases such as leukemia or
autoimmunity. Interestingly, components occurring in the
MISs with few elements (Table 3) are in fact known
oncogenes: ZAP70 [43], PI3K [44], Gab2 [45], and PLCc1
[46] (and SLP76 is directly involved in PLCc1 activation).
Robustness and Sensitivity Analysis of the Logical Model
Strongly related to the idea of MISs is a systematic
evaluation of the network response if the model is confronted
with failures. By considering a failure as something that
happens to the cell by an internal or external event (e.g., a
mutation), we may assess the robustness—one of the most
important properties of living systems [47]—of the network.
In contrast, if we consider the failure as an error that has
been introduced during the modeling process (due to
incomplete knowledge), then we are assessing the sensitivity
of the model with respect to the predictions it makes.
Accordingly, to study robustness and sensitivity issues, we (i)
removed systematically each single interaction from the
network, (ii) recomputed the scenarios given in Table 1, and
(iii) compared the new predictions with the 126 original
predictions (Table 1), ranking the interactions according to
the number of introduced changes produced (Table 4). As an
average value, 4.76 errors were introduced per simulated
failure, which corresponds to 3.78% of the total numbers of
predictions. The most sensitive interactions are mainly
located in the upper part of the network and activate
components such as the T cell receptor (TCRb), ZAP70,
LAT, Fyn, or Abl. It is intuitively clear that the network is very
Figure 4. In Vitro Analysis of Src-Kinase Inhibition
Inhibition of Src-Kinases (Lck and Fyn) with PP2 blocks TCR-induced but affects only moderately CD28-induced PKB and JNK activation in human T cells;
therefore, we concluded that CD28 signaling is not strictly Src-kinase– dependent. The effect was compared with PI3K inhibition via Wortmannin (ccf.
Figure 3C and 3D), which blocks the phosphorylation of PKB but not of JNK. b-actin was included as the loading control. One representative experiment
(of three) is shown.
doi:10.1371/journal.pcbi.0030163.g004
Table 2. Application of the Minimal Intervention Sets To Identify
Candidates To Fill the Gap between PI3K and JNK
MIS
jnk
hpk1 rac1r
hpk1 sh3bp2
mekk1 mkk4
mekk1 mlk3
hpk1 mekk1 rac1p1
hpk1 mekk1 vav1
hpk1 mkk4 rac1p2
hpk1 mlk3 vav3
hpk1 rac1p1 rac1p2
hpk1 rac1p1 vav3
hpk1 rac1p2 vav1
hpk1 vav1 vav3
hpk1 mlk3 rac1p2
The MISs of maximal size 3 to obtain JNK off under the conditions (i) TCR on, (ii) PI3K off,
and (iii) ZAP70 on (as shown in the experiment, see Figure 3D and Table 1) were
computed, setting the rest of conditions to the standard values for the early events. Here,
each MIS represents one set of molecules that should be influenced by PI3K in order to be
consistent with the fact that PI3K inhibition blocks JNK activation. For species
abbreviations, see Tables S1 and S2.
doi:10.1371/journal.pcbi.0030163.t002
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sensitive to failures (again, caused either by internal/external
events or modeling errors) in these upper nodes because all
pathways branching downstream are governed by them.
Accordingly, the validation of our model (with the data from
Table 1) is most sensitive to modeling errors in the upper part
of the network. We also note that species that can be
activated by more than one interaction (e.g., PI3K) are
signiﬁcantly less sensitive to single interaction failures since
alternative pathways exist. Regarding robustness, it is worth
emphasizing that in the worst case about 30% of the original
predictions are affected after removal of an interaction,
indicating that there is no ‘‘all-or-nothing’’ interaction in the
network.
We have also performed the same analysis for the removal
of a species (instead of an interaction) which basically led to
the same results (unpublished data). However, the removal of
a node can be seen as a stronger intervention in the network
than deleting an interaction, as the former simulates the
simultaneous removal of all interactions pointing at that
species. Accordingly, deleting nodes implies some stronger
deviations from the original predictions.
Qualitative Description of the Dynamics
So far we have analyzed which elements within the
signaling network get activated upon signal triggering (i.e.,
for the ﬁrst timescale s¼1). This is due to the fact that a large
corpus of data for these conditions is available (see Table 1).
However, it is important to note that the model is also able to
roughly predict the dynamics upon different stimuli and
conditions.
The modus operandi goes as follows: ﬁrst, one computes
the steady state values with no external input (s ¼ 0).
Subsequently, the steady state for s ¼ 1 is computed as
described above. Finally, one computes the state of the ‘‘slow’’
interactions (those only active at s ¼ 2) as a function of the
values at s¼1, and subsequently recomputes the steady states.
This provides the response at late events, s ¼ 2. The results
obtained can be plotted in a time-dependent manner (Figure
5). Here, one can also investigate the effect of different
knock-outs. For example, the absence of PAG has no effect on
key downstream elements of the cascade, due to the
redundant role of other negative regulatory mechanisms
(speciﬁcally, the degradation via c-Cbl and Cbl-b, and Gab-2–
mediated inhibition of PLCc1). Only a multiple knock-out of
these regulatory molecules leads to sustained activation of
key elements. Thus, these results point to a certain degree of
redundancy in negative feedbacks for switching off signaling.
This sort of qualitative analysis of the dynamics shows the
ability of the Boolean approach to reproduce the key
dynamic properties (transient versus sustained) of a signaling
process.
Discussion
In this contribution, a logical model describing a large
signaling network was established and analyzed. We set up a
Table 4. Robustness Analysis: Ranked List of the Most Sensitive
Interactions
Interaction Caused Errors
if Removed
!ccblp1 þ tcrlig ! tcrb 39
!ccblp1 þ tcrp þ abl ! ¼ zap70 34
zap70 ! lat 27
tcrb þ lckr ! fyn 26
tcrbþfyn ! tcrp 26
fyn ! abl 26
pi3k þ !ship1 þ !pten ! pip3 21
lat ! plcgb 15
zap70 þ !gab2 þ gads ! slp76 15
lat ! gads 15
pip3 ! pdk1 13
lckp2 þ !cblb ! pi3k 11
lckr þ tcrb ! lckp2 11
!ikkab ! ikb 11
zap70 þ lat ! sh3bp2 10
plcgb þ !ccblp2 þ slp76 þ zap70 þ vav1 þ itk ! plcga 10
pdk1 ! pkb 10
pip3 þ zap70 þ slp76 ! itk 10
zap70 þ sh3bp2 ! vav1 10
!dgk þ plcga ! dag 9
!shp1 þ cd45 þ cd4 þ !csk þ lckr ! lckp1 8
cd28 ! x 8
tcrb þ lckp1 ! tcrp 8
lckp1 ! abl 8
mek ! erk 6
ras ! raf 6
ca ! cam 6
dag ! rasgrp 6
ip3 ! ca 6
lat ! grb2 6
grb2 ! sos 6
plcga ! ip3 6
raf ! mek 6
sos þ !gap þ rasgrp ! ras 6
x ! vav1 5
mkk4 ! jnk 5
mlk3 ! mkk4 5
rac1p1 ! mlk3 5
rac1r þ vav1 ! rac1p1 5
Each single non-input interaction was removed from the network followed by a
recomputation of the scenarios given in Table 1. The number of deviations from the 126
predictions made in Table 1 is shown. For abbreviations and comments on the
interactions, see Tables S1 and S2.
doi:10.1371/journal.pcbi.0030163.t004
Table 3. Minimal Intervention Sets To Produce the Full
Activation Pattern in T Cells
MIS
!gab2 pi3k zap70
!gab2 pip3 zap70
pi3k plcga zap70
pi3k slp76 zap70
pip3 slp76 zap70
pip3 plcga zap70
pdk1 plcga zap70
The MISs of maximal size 3 that induce sustained full activation (namely: ap1, bcat, bclxl,
cre, cyc1, nfkb, p70s, sre, and nfat are on, whereas fkhr, p21c, and p27k are off) of T cells
without external stimuli. The MISs were computed using CellNetAnalyzer. Note that the
exclamation mark ‘‘!’’ denotes ‘‘deactivation’’; species without this symbol have to be
activated (constitutively). Interestingly, the compounds involved in these MISs are
involved in oncogenesis (ZAP70, PI3K, Gab2, and PLCc1 are oncogenes, and SLP76 is
directly involved in PLCc1 activation, see Figure 1 and main text). Note that since PIP3 is a
second messenger and not ‘‘mutable’’, for the purpose of this analysis the MISs involving
its activation can be considered equivalent to those involving its activator PI3K (i.e., these
MISs are equivalent).
doi:10.1371/journal.pcbi.0030163.t003
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comprehensive Boolean model describing T cell signaling and
performed logical steady state analyses unraveling the
processing of signals and the global input–output behavior.
Moreover, by converting the logical model into an interaction
graph, we extracted further important features, such as
feedback loops, signaling paths, and network-wide interde-
pendencies. The latter can be captured in a dependency
matrix (as in Figure 2) which provides thousands of
qualitative predictions that can be falsiﬁed in perturbation
experiments. The logical model reproduces the global
behavior of this complex network for both natural and
perturbed conditions (knock-outs, inhibitors, mutations, etc.).
Its validity has been proven by reproducing published data
and by predicting unexpected results that were then veriﬁed
experimentally. Table 1 summarizes the results of 14 different
scenarios, in which the logical model predicted 126 states. For
44 of them, experimental data was available (15 from
literature and 29 from our own experiments) conﬁrming
the predictions, except in the case discussed above.
Furthermore, we clearly show that the concept of inter-
vention sets allows one (a) to identify missing links in the
network, (b) to reveal failure modes that can explain the
effects of a physiological dysfunction or disease, and (c) to
search for suitable intervention strategies, while keeping
track of potential side effects, which is valuable for drug
target identiﬁcation.
Compared with a kinetic model based on differential
equations, a Boolean approach is certainly limited regarding
the analysis of quantitative and dynamical aspects, and it
certainly cannot answer the same questions. However, to
establish such a model requires mainly the topology and only
a relatively small amount of quantitative data; hence, a
combination of information which is currently available in
large-scale networks. Although the model itself is qualitative
(i.e., discrete), it enables us not only to study qualitative
aspects of signaling networks, but it can also be validated by
semi-quantitative measurements such as those in Figures 3
and 4. In summary, with the network involved in T cell
activation as a case study, our approach proved to be a
Figure 5. Considering Different Time Scales, a Rough Description of the Dynamics Can Be Obtained
The activation of key elements upon activation of the TCR, the coreceptor CD4, and the costimulatory molecule CD28 is represented at the resting state,
s¼ 0 (no inputs); early events s¼ 1 (input(s), no feedback loops); and later-time events, s¼ 2 (input(s), feedback loops). The black lines correspond to a
wild type while the green ones to a PAG KO. Note that the absence of PAG has no effect on key downstream elements of the cascade, due to the
redundant role of other negative regulatory mechanisms (degradation via c-Cbl and Cbl-b, Gab-2 mediated inhibition of PLCc1). Multiple knock-out of
these regulatory molecules leads to sustained activation of key elements (red lines).
doi:10.1371/journal.pcbi.0030163.g005
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promising in silico tool for the analysis of a large signaling
network, and we think that it holds valuable potential in
foreseeing the effects of drugs and network modiﬁcations.
Although sometimes the results of a logical model may
(afterward) appear to be obvious (as in the case of the CD28-
mediated JNK connection), it enables an exhaustive and
rigorous analysis of the information processing taking place
within a signaling network. Such a systematic analysis
becomes infeasible for a human being in large-scale systems.
In addition, the LIH can represent the situation of varying
cofactor functions; for example, that two substances A AND B
are required to activate a third substance C, but activation of
C in the presence of A and a fourth substance D requires B
not to be present.
Certainly, the logical model for T cell activation is far from
complete. We are just at the beginning of the reconstruction
process and other receptors and their pathways need to be
included. However, we feel that already in its current state,
the model may prove useful to inspire immunologists to ask
new questions which may ﬁrst be answered in silico.
Furthermore, the model may also provide a framework for
those who may endeavor to quantitatively model TCR
signaling.
Methods
Logical network representation and analysis. We began construc-
tion of the signaling network for primary T cells by collecting data
from the literature and from our own experiments providing well-
established connections (Tables S1 and S2). As a ﬁrst (intermediate)
result, we obtain an interaction graph. Interaction graphs are signed
directed graphs with the molecules (such as receptor, phosphatase, or
transcription factor) as nodes and signed arcs denoting the direct
inﬂuence of one species upon another, which can either be activating
(þ) or inhibiting (). For example, a positive arc leads from MEK to
ERK because the ﬁrst phosphorylates and thereby activates the
second (Figure 1). From the incidence matrix of an interaction graph
we can identify important features such as feedback loops as well as
signaling paths and network-wide interdependencies between pairs
of species (e.g., perturbing A may have no effect on B as there is no
path connecting A to B). Algorithms related to these analyses are
well-known [48] and were recently presented in the context of
signaling networks [13]. However, from interaction graphs we cannot
conclude which combinations of signals reaching a species along the
arcs are required to activate that species. For example, in Figure 1,
Jun AND Fos are required to form active AP1.
For a reﬁned representation of such relationships, we use a logical
(or Boolean) model in which we introduce discrete states for the
species (here the simplest (binary) case: 0¼ inactive or not present; 1
¼ active or present) and assign to each species a Boolean function.
Here we use a special representation of Boolean functions known as
disjunctive normal form (DNF, also called ‘‘sum of product’’
representation) which uses exclusively AND, OR, and NOT oper-
ators. A Boolean network with Boolean functions in disjunctive
normal form can be intuitively drawn and stored as a hypergraph
(LIH) [13], which is well-suited for studying the information ﬂows
and input–output relationships in signal transduction networks
(Figure 1). In this hypergraph, each hyperarc connects its start nodes
with an AND operation (indicated by a blue circle in Figure 1) and
each hyperarc represents one possibility for how its end node can be
activated or produced (note that hyperacs may also have only one
start node, i.e., they are then ‘‘graph-like’’ arcs). Red branches
indicate species that enter the hyperarc with their negated value. For
example, PLCc-1 (PLCga in Figure 1) AND NOT DGK activates DAG
(see Figure 1). Note that each LIH has a unique underlying
interaction graph (which can be easily derived from the LIH
representation by splitting the AND connections), whereas the
opposite is, in general, not true.
Within this logical framework we may study the effect of a set of
input stimuli (typically ligands) on downstream signaling by comput-
ing the logical steady state [13] that results by propagating the signals
through the network from the input to the output layer. It seems
worthwhile to remark that the updating assumption (synchronous
versus asynchronous [14,15])—which must usually be made when
dealing with dynamic Boolean networks—is not relevant here as we
focus on the logical steady states, which are equivalent in both cases.
Sometimes a logical steady state is not unique or does not exist due to
the presence of feedbacks loops. However, many feedback loops
become active only in a longer timescale justifying setting them OFF
in the ﬁrst wave of signal propagation (allowing them to be switched
ON for the second timescale). This has been used here for several
feedback loops (see main text and Table S2). The effect of knocking-
out a species can be tested by re-computing the (new) logical steady
state for the respective stimuli. MISs satisfying a given intervention
goal can be computed by systematically testing sets of permanently
activated or/and deactivated nodes [13,31].
All mathematical analyses and computations have been performed
with our software tool CellNetAnalyzer [31], a comprehensive user
interface for structural analysis of cellular networks. CellNetAnalyzer
and the T cell model can be downloaded for free (for academic use)
from http://www.mpi-magdeburg.mpg.de/projects/cna/cna.html.
Immunoblotting. Human or mouse T cells were puriﬁed using an
AutoMACS magnetic isolation system according to the manufac-
turer’s instructions (Miltenyi, http://www.miltenyibiotec.com). Mouse
T cells were stimulated with 10 lg/ml of biotinylated CD3e (a subunit
of the TCR) antibody (145–2C11, BD Biosciences, http://www.
bdbiosciences.com/), 10 lg/ml of biotinylated CD28 antibody (37.51,
BD Biosciences), CD3 plus CD28 mAbs, or with CD3 plus 10 lg/ml of
biotinylated CD4 (GK1.5, BD Biosciences) followed by crosslinking
with 25 lg/ml of streptavidin (Dianova, http://www.dianova.de) at 37
8C for the indicated periods of time. Human T cells were stimulated
with CD3e mAb MEM92 (IgM, kindly provided by Dr. V. Horejsi,
Prague, Czech Republic) or with CD3 plus CD28 mAbs (248.23.2).
Cells were lysed in buffer containing 1% NP-40, 1% laurylmaltoside
(N-dodecyl b-D-maltoside), 50 mM Tris pH 7.5, 140 mM NaCl, 10mM
EDTA, 10 mM NaF, 1 mM PMSF, 1 mM Na3VO4. Proteins were
separated by SDS/PAGE, transferred onto membranes, and blotted
with the following antibodies: anti-phosphotyrosine (4G10), anti-
ERK1/2 (pT202/pT204), anti-JNK (pT183/pY185), anti-phospho-Akt
(S473) (all from Cell Signaling, http://www.cellsignal.com/), anti-
ZAP70 (pTyr 319, Cell Signaling), anti-ZAP70 (cloneZ24820, Trans-
duction Laboratories, http://www.bdbiosciences.com/), or against b-
Actin (Sigma, http://www.sigmaaldrich.com/). Where PI3K and src-
kinase inhibitors were used, T cells were treated with 100 nM
Wortmannin (Calbiochem, http://www.emdbiosciences.com) or 10 lM
PP2 (Calbiochem) for 30 min at 37 8C prior to stimulation. All
experiments have been repeated three times and reproduced the
shown results.
Supporting Information
Table S1. List of Compounds in the Logical T Cell Model
Model name corresponds to the name in Figure 1 and Table S2.
Common abbreviations are those usually used in the literature, while
name is the whole name. Type classiﬁes the molecules, if applies, as
follows: K ¼ Kinase, T ¼ Transcription Factor, P ¼ Phosphatase, A ¼
Adaptor Protein, R ¼ Receptor, G ¼ GTP-ase. In the case where two
pools of a molecule were considered, a ‘‘reservoir’’ was included
which was required for both pools. This allows us to perform a
simultaneous knock-out of both pools.
Found at doi:10.1371/journal.pcbi.0030163.st001 (56 KB PDF).
Table S2. Hyperarcs of the Logical T Cell Signaling Model (see Figure
1 and Methods)
Exclamation mark (‘‘!’’) denotes a logical NOT, and dots within the
equations indicate AND operations. The names of the substances in
the explanations are those used in the model and Figure 1; the
biological names are displayed in Table S1. In the case where two
pools of a molecule were considered (e.g., lckp1 and lckp2), a
‘‘reservoir’’ (lckr) was included which was required for both pools.
This allows us to perform a simultaneous knock-out of both pools
acting on the reservoir.
Found at doi:10.1371/journal.pcbi.0030163.st002 (183 KB PDF).
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LIME (Lck-interacting membrane protein) is a transmembrane adaptor that associates
with the Lck and Fyn protein tyrosine kinases and with the C-terminal Src kinase (Csk).
To delineate the role of LIME in vivo, LIME-deficient mice were generated. Although
Lime transcripts were expressed in immature and mature B and T cells, the absence of
LIME impeded neither the development nor the function of B and T cells. TCR
transgenic mice deprived of LIME showed, however, a 1.8-fold enhancement in positive
selection. Since B cells and activated Tcells express LIME and the related adaptor NTAL,
mice lacking both adaptors were generated. Double-deficient mice showed no defect in
the development and function of B and Tcells, and the lack of LIME had no effect on the
autoimmune syndrome that develops in aged NTAL-deficient mice. In contrast to a
previous report, we further showed that this autoimmune syndrome develops in the
absence of T cells. Therefore, our in vivo results refute all the previous roles postulated
for LIME on the basis of studies of transformed B and Tcells and demonstrate that LIME
has no seminal role in the signaling cassette operated by antigen receptors and
coreceptors.
Introduction
Transmembrane adaptor proteins (TRAP) represent a
group of molecules participating in immunoreceptor
signaling. They possess a short extracellular domain, a
transmembrane region, and a long cytoplasmic tail
carrying up to ten potential tyrosine phosphorylation
sites. In contrast to the signaling subunits that are
associated with immunoreceptors and that contain
immunoreceptor tyrosine activation motif (ITAM), the
knownTRAP carry no ITAM and do not associate directly
with immunoreceptors. So far four TRAP have been
identified as components of membrane lipid rafts and
denoted as 'linker of activation of T cells' (LAT, also
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called LAT1), phosphoprotein associated with glycoli-
pid-enriched membranes (PAG, also known as Cbp),
non-T cell activation linker (NTAL, also called LAB or
LAT2), and Lck-interacting membrane protein (LIME)
(reviewed in [1]). These TRAPpossess twopalmitoylated
cysteine residues in the membrane proximal segment of
their cytoplasmic tail that target them to lipid rafts.
Upon tyrosine phosphorylation, which is mostly due to
Src- and Syk-family protein tyrosine kinases, TRAP bind
several SH2 domain-containing cytoplasmic signaling
molecules. This results in the assembly of membrane
proximal complexes that regulate immunoreceptor
signaling in a positive or negative manner.
So far little is known about the biological functions of
LIME [2–4]. In humans, LIME is expressed predomi-
nantly in T cells and becomes tyrosine phosphorylated
by Src-family kinases. This phosphorylation occurs
exclusively after cross-linking of the CD4 and CD8 co-
receptors by antibodies, or by the HIV glycoprotein 120
in the case of CD4 [3]. Overexpression of LIME in Jurkat
T cells amplifies TCR-mediated calcium flux, phosphor-
ylation of Erk and transcriptional activation of the IL-2-
gene promoter [3]. It is therefore possible that LIME
plays a positive role in the sequential activation of Lck
and Fyn that occurs in the lipid rafts of T cells [5].
Considering that inhibitory signals are induced when
CD4 is cross-linked in the absence of TCR engagement
[6], the ensuing tyrosine phosphorylation of LIME could
also generate inhibitory signals. Finally, LIME may also
account for the remarkable ability of certain anti-CD4
antibodies to induce a state of antigen-specific tolerance
through the induction of regulatory T cells [7].
The published data on mouse LIME are somewhat
different. High expression of LIME was observed in the
lung. In T cells, LIME expression was rapidly up-
regulated following TCR-cross-linking and LIME was
localized at the contact site between T cells and antigen-
presenting cells (APC) [2]. A recent report further
indicated that LIME might be involved in BCR-mediated
B cell activation [4]. Suppression of LIME expression by
siRNA resulted in inhibition of BCR-mediated activation
of MAPK, PI3K, calcium flux, NFAT, and NF-jB. To
further elucidate the function of LIME in vivo, we have
generated LIME-deficient mice and have analyzed them
for the development and function of B and T
lymphocytes.
Results
LIME expression in mouse B and T cells
Previous studies contain several inconsistencies with
regards to the pattern of expression of LIME [2, 8]. To
settle this issue, populations corresponding to several
stages of mouse B and T cell differentiation were
prepared by cell sorting and analyzed by quantitative
RT-PCR for their relative levels of Lime transcripts
(Fig. 1A). The same cell populations were also analyzed
for the presence of Lat and Ntal transcripts. As shown in
Fig. 1A, CD4+CD8+ thymocytes expressed Lime tran-
scripts at lower levels than mature, resting CD4+ and
CD8+ T cells. A recent study analyzing whole B cells
isolated from the spleen showed that LIME is expressed
in mouse B cells [4]. To more precisely determine the
pattern of LIME expressionwithinmature B cells, splenic
B cells were sorted according to IgM and IgD expression.
IgMhigh IgDlow or transitional 1 (T1) cells, are recent
immigrant from the bone marrow that develop into
IgMhigh IgDhigh transitional 2 (T2) cells, some of which
differentiate further into mature IgMlow IgDhigh, or
follicular recirculating B cells [9]. As shown in Fig. 1,
Lime transcripts were expressed in T1, T2, and mature
B cells, albeit at lower levels than in mature T cells.
Plasma cells also expressed Lime transcripts at levels
comparable to those found in their direct follicular B cell
precursors (Fig. 1A). Moreover, Lime transcripts were
expressed during early stages of B cell differentiation in
the bone marrow (Fig. 1A).
T cell development in LIME-deficient mice
To explore the role of LIME in B and T cell development
and function, we generated mice deprived of LIME. As
depicted in Fig. 2, our knockout approach resulted in the
replacement of the whole LIME coding sequence with a
loxP sequence. Mice homozygous for this mutation,
Lime–/–, were born at the expected Mendelian frequen-
cies and were deprived of detectable LIME protein
(Fig. 2F). Analysis of Lime–/– mice showed that their
thymi, spleens, and lymph nodes were of normal size.
Monitoring CD4, CD8, CD44, CD25, CD62L, CD5,
TCRab, TCRcd and CD49b (DX5) expression, showed
no major alteration in the T cell, NK T cell, and NK cell
populations from thymus and secondary lymphoid
organs (Fig. 3 and data not shown). T cell proliferation
and IL-2 production in response to graded concentra-
tions of anti-CD3 antibody, or to a suboptimal dose of
anti-CD3 antibody in combination with increasing
concentrations of anti-CD28 antibody were similar in
LIME-sufficient and -deficient T cells (Fig. 4A and B).
Upon CD3 cross-linking, Lime–/– thymocytes and CD4+
Tcells showed calcium responses of the same magnitude
as those observed in wild-type counterparts (Fig. 4D and
data not shown). In line with these data, the clinical
course of experimental autoimmune encephalitis (EAE),
a mouse model of human multiple sclerosis, was not
influenced by the absence of LIME (data not shown). We
also evaluated whether the loss of LIME affects the
ability of the CD4 molecule to deliver inhibitory signals
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when cross-linked prior to the engagement of the TCR.
When CD4 expressed on LIME-sufficient and -deficient
T cells was cross-linked for 45 min before stimulation
with anti-CD3 antibodies, the same inhibitory signals
were delivered by the cross-linked molecules CD4
(Fig. 4C and D). Therefore, the absence of LIME does
not detectably affect a large panel of events associated
with T cell development and function.
LIME deficiency improves positive selection of
Marilyn TCR transgenic thymocytes
To analyze with a higher sensitivity the effect of the
Lime-deficiency on intrathymic positive and negative
selection events, Lime–/– mice were backcrossed into
transgenic mice expressing an MHC class II-restricted
TCR and maintained on a RAG-deficient background.
We used the Marilyn TCR transgenic line because it
expresses a monoclonal population of Vb6+ CD4+ Tcells
specific for Dby, a male H-Y antigen presented by I-Ab
molecules, and permits positive and negative selection
among the same littermates to be readily analyzed [10].
Moreover, since in vitro experiments showed that LIME
is heavily tyrosine phosphorylated after CD4 cross-
linking [3], using the Marilyn TCR transgenic line we
could gauge the role of LIME in a CD4-dependent
physiological set-up. Comparison of the thymi of LIME-
sufficient and -deficient Marilyn female mice for their
cellularity, CD4-CD8 staining profile, and levels of CD3
and of Vb6+ TCR showed that LIME deficiency improves
the selection of mature CD4+ SP cells expressing
transgenic TCR (Fig. 5A). Lime–/– Marilyn female mice
showed a 1.8-fold increase in the number of clonotype-
positive CD4+ SP cells [15.1  4.5  106 in wild-type
Marilyn female thymi (n=4) versus 27.5  2.1  106 in
Lime–/– Marilyn female thymi (n=6)]. Consistent with
this observation, comparison of the spleen from LIME-
deficient and -sufficient Marilyn female mice showed
that the absence of LIME resulted in a threefold increase
in the number of clonotype-positive CD4+ cells
[1.6  0.5  106 in wild-type Marilyn female spleen
(n=4) versus 5.2  1.6  106 in Lime–/– Marilyn female
spleen (n=6)]. In LIME-sufficient, Marilyn male mice,
negative selection results in the absence of TCRhigh DP
and of CD4+ SP cells, and, as a consequence, the
periphery is deprived of clonotype-positive CD4+ Tcells.
As shown in Fig. 5A, in LIME-deficient, Marilyn male
mice, the lack of LIME had no measurable impact on
negative selection. As documented in other TCR
transgenic model, a minute population of clonotype-
Figure 1. Comparative expression of Lime, Lat and Ntal transcripts
throughout mouse B and T cell development. (A) RNA samples were
prepared fromwild-typemice and analyzed by quantitative RT-PCR for the
presence of Lat,Ntal and Lime transcripts. Results are expressed as relative
units of Lat, Ntal and Lime mRNA normalized using Hprt transcripts.
Negative control samples are shown on lane 11 and corresponds to total
spleen cells isolated from Lat–/– (Lat panel), Ntal–/– (Ntal panel) or Lime–/–
(Lime panel) mice. (B) RNA sampleswere prepared from CD4+ Th2 effectors
freshly isolated from LatY136F mice and from wild-type CD4+ T cells that
were left unstimulated (resting) or stimulated (activated) with anti-CD3
plus anti-CD28 antibodies for 40 h prior to analysis by quantitative RT-PCR
for the presence of Ntal transcripts. Positive (+) and negative (-) control
samples correspond to mature B cells isolated from wild-type or Ntal–/–
mice. Data shown are representative of two independent experiments.
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positive, CD4–CD8– T cells is found in the periphery of
Marilynmalemice and is not affected by the lack of LIME
(Fig. 5A). Despite the presence of slightly lower levels of
clonotypic TCR on their surface (Fig. 5A), the mature
CD4+ cells found in the periphery of Lime–/– Marilyn
femalemice were capable of proliferating and producing
IL-2 in response to their cognate antigen, and slightly
higher responses were even observed in the absence of
LIME (Fig. 5B and C).
B cell development and function in LIME-deficient
mice
Although LIME is expressed in immature and mature
B cells, analysis of splenic B cell populations showed that
they are capable of properly reaching the T1, T2, and
follicular stages in the absence of LIME (Fig. 6A).
Consistent with these results, basal levels of IgG1, IgG2a,
IgG2b, IgG3 and IgE, and antibody responses to a
T-dependent antigen were normal in LIME-deficient
mice (data not shown). Importantly, NTAL, another raft-
associated TRAP is expressed in T1, T2, and follicular
B cells [11]. Young mice deprived of NTAL showed no
defect in B cell differentiation and function [11, 12].
Because NTAL and LIME are coincidently expressed in
immature and mature B cells (Fig. 1), the product of the
other may have backed up the function of the missing
one. Therefore, to analyze whether some redundancy
exists between NTAL and LIME in mouse B cells, Lime–/–
and Ntal–/– mice were bred to generate double-deficient
mice. Analysis of the B cell compartment in Lime–/–
Ntal+/+, Lime+/+ Ntal–/–, and Lime–/– Ntal–/– mutant
mice revealed no major difference with wild-type
littermates (Fig. 6A). Moreover, mature B cells isolated
from wild-type, Lime–/– Ntal+/+, Lime+/+ Ntal–/–, and
Lime–/– Ntal–/–mutant mice showed similar proliferative
responses upon stimulation with F(ab0)2 fragments of an
anti-IgM antibody or lipopolysaccharide (Fig. 6B and
data not shown), and similar Ca2+ influx following BCR
cross-linking (Fig. 6C and data not shown). Thus, single
or combined deletions of LIME and NTAL do not
detectably affect B cell development and function.
Lack of autoimmunity in LIME-deficient mice
Even though NTAL is barely detectable in naive Tcells, it
could be detected in activated T cells [13]. As shown in
Fig.1B,Ntal transcripts are indeed expressed in activated
T cells, including Th2 effector cells from LatY136F mice,
albeit at lower levels than inmatureBcells. Therefore, the
NTAL and LIME TRAP are coincidently expressed in
activated T cells. However, combined deletions of LIME
andNTALdonot detectably affect early and late events of
T cell activation (Fig. 6D and E).
Aged (>6 -month-old) Ntal–/– mice showed hyper-
activated Tcells that were thought to activate B cells and
thus be responsible for the presence of anti-DNA
antibodies in the sera of these mice [13]. Using an
independently derived line of Ntal–/– mice [14], we
failed to document an enlargement of the spleen and the
presence of hyperactivated T cells in 25–30-week-old
Ntal–/– mice (Fig. 7A and data not shown). However, we
confirmed the presence of anti-nuclear antibodies when
the sera of 6-month-old Ntal–/– mice were used to stain
fixed HEp-2000 cells. The presence of anti-nuclear
Figure 2. Generation and identification of Lime deficient mice.
(A–D) Strategy used to delete the Lime gene. (A) Partial
restriction map of the wild-type Lime gene. Exons are shown
as filled boxes. Exons containing the initiation (ATG) and stop
codon are specified (E: EcoRI, H: HindIII). (B) Targeting vector
used for the deletion of exons 1–5. Shaded and open boxes
correspond to the thymidine kinase gene (TK) and to the loxP-
flanked-Cre-Neor cassette, respectively. LoxP sites are shown
as triangles. (C) Structure of the targeted allele following
homologous recombination. (D) Final structure of the targeted
allele after self-excision of the Cre-Neor cassette. The 50 and 30
single-copy probes used to verify 50 and 30 targeting events are
indicated. Theposition of the PCRprimers used to genotype the
resulting mice are indicated by arrows. (E) PCR genotyping of
Lime-deficient and -sufficient littermates using primers in-
dicated in (D). (F) Lack of LIME expression in T cells from Lime–/–
mice as detected by Western blotting. Total cell lysates were
processed under reducing (R) or non-reducing (NR) conditions,
and revealed with a rabbit antiserum directed at mouse LIME.
The position of LIME (29 kDa) and of a non-specifically reactive
protein of 35 kDa is indicated. The intensity of this last band
demonstrates that each lane was loaded with comparable
amounts of total proteins.
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antibodies in the absence of hyperactivated T cells
questions the contribution of NTAL-deficient T cells to
the development of anti-nuclear antibodies. Considering
that Ntal–/– Lat–/– mice lack T cells but possess a normal
B cell compartment [11], we further analyzed the sera of
6-month-old Ntal–/– Lat–/– mice for the presence of anti-
nuclear antibodies. As shown in Fig. 7E, anti-nuclear
antibodies were readily detected in the sera of 6-month-
old Ntal–/– Lat–/– mice. Therefore, in contrast to the
conclusions reached by Zhu and colleagues [13], NTAL
has an intrinsic negative regulatory role within B cells
that contributes to regulate their activity in aged mice.
Importantly, aged Lime–/– mice showed no sign of T or
B cell activation and their sera contained no detectable
anti-DNA antibodies (Fig. 7E). Furthermore, the ab-
sence of LIME was without effect on the development of
anti-nuclear antibodies that occurs in aged Ntal–/– mice
(Fig. 7E).
Discussion
By assembling signalosomes, the four raft-associated
TRAP (LAT, NTAL, PAG and LIME) coordinate intracel-
lular programs that control the development and
activation of immunocytes. Consistent with these views,
LAT plays a seminal role during T cell development and
function and is also critical for FceRI signaling in mast
cells [15–17]. In contrast, it has been difficult to define
the role of the three other raft-associated TRAP and
deletion of their genes resulted in either subtle or no
detectable phenotype. NTAL functions primarily as a
negative regulator of FceRI-, BCR- and TREM-1-
mediated signaling [11, 12, 14, 18]. Despite a wealth
of biochemical data supporting an important role of PAG
in regulation of Src-family protein tyrosine kinases, PAG
appears dispensable for Tcell development and function
[19, 20].We report here that LIME is also dispensable for
the development and function of B and T cells. The only
robust effect due to the lack of LIME was noted when a
null mutation of the Lime gene was bred into mice in
which ab TCR variability was neutralized by expressing
a TCR transgene previously calibrated in a LIME-
sufficient thymus. Under those conditions, the loss of
LIME enhanced both positive selection and the number
of mature T cells found in the periphery. Therefore,
under sensitized conditions LIME likely contributes to
dampening TCR signals.
The loss of C-terminal Src kinase (Csk) at early stages
of T cell development unleashed the activity of Lck and
Fyn, and resulted in TCR-deficient T cells that accumu-
late in peripheral lymphoid organs [21]. Considering
Figure 3. Flow cytometric analysis of T cell populations in thymus and spleen of 7-week-oldwild-type and Lime–/–mice. Single-cell
suspensions were stained with the indicated antibodies and analyzed by flow cytometry. Numbers indicate the percentages of
cells in the specified quadrants or gates. In the single-color histograms representing CD5 staining on splenocytes, the values in
italic correspond to themean fluorescence of CD5+ cells. The thymocytes analyzed in the TCRb versus TCRd dot plot corresponded
to CD3high cells. The total number of thymocytes and splenocytes are shown above dot plots (averaged from three experiments).
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that the SH2 domain of Csk could bind both PAG and
LIME [1], it remains possible that some functional
complementation exists between LIME and PAG and
thus accounts for the different phenotype observed in
mice that lack Csk or have a deletion of the Pag or Lime
gene. In that regard, generation ofmice with a combined
deletion of Lime and Pag should be particularly
informative.
In this study, besides a 1.8-fold enhancement in
T cell-positive selection, we have failed to document any
blatant effect resulting from the loss of LIME as well as
from the combined loss of LIME and NTAL. These results
obtained using in vivo assays or freshly isolated T and
B cells contrast with previous results obtained using
transformed B and T cell lines and refute all the roles
postulated for LIME on the basis of the analysis of
transformed cell lines. In contrast, using a wealth of in
vivo sensitized experimental conditions, LIMEwas found
to have no seminal role in the signaling cassette operated
by antigen receptors and coreceptors.
Materials and methods
Mice
Mice deficient in recombination activation gene 2 (Rag2–/–
mice) [22], in CD3e (Cd3D5/D5 mice) [23], in LAT (Lat–/– mice)
[24] and in NTAL (Ntal–/– mice) [11] have been described.
Mice homozygous for a mutation that replaced tyrosine 136 of
LAT with phenylalanine (LatY136F mice) have been described
[25]. The Marilyn TCR transgenic line was obtained from O.
Lantz [10]. Mice have been crossed onto a C57BL/6 back-
Figure 4. Proliferative responses, IL-2 production, and Ca2+ responses in lymph node T cells from wild-type and Lime–/– mice. (A)
T cells purified from 7-week-old wild-type and Lime–/– mice were stimulated with graded concentrations of anti-CD3 antibody.
After 72 h, the extent of T cell proliferation was measured by determining levels of [3H]thymidine uptake. (B) Purified T cells were
stimulatedwith a fixed concentration (1 lg/mL or 0.1 lg/mL) of anti-CD3 antibody with or without graded concentrations of anti-
CD28 antibody. Also shown is the level of T cell proliferation obtained following stimulation with phorbol-myristate-acetate and
ionomycin (PMA/Iono). (C) CD4+ T cells purified fromwild-type and Lime–/–micewere stimulatedwith anti-CD3 antibodies. When
specified [a-CD4 (prelig)], CD4molecules were cross-linked for 45 min before stimulation with anti-CD3 antibodies. The extent of
proliferation was measured after 72 h of culture. Values have been normalized as % of the proliferation value observed following
stimulation with PMA and Iono. In A–C, the data shown are representative of five independent experiments and the values
correspond to the mean  SD from quadruplicate samples. (D) Calcium flux analysis in response to TCR stimulation in wild-type
and Lime–/– lymph node CD4+ T cells. The diagram depicts calcium flux (y axis) as a function of time (x axis). Arrows indicate the
time point of addition of streptavidin (SAV) to cross-link the biotinylated anti-CD3 antibody, or of ionomycin (Iono). In the right
panels, CD4moleculeswere cross-linked for 45 min prior to stimulation with anti-CD3 antibodies. Data shown are representative
of four independent experiments.
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Figure 5.T cell development inwild-type and Lime–/–mice expressing theMarilyn transgenic TCR. (A) Thymocytes and splenocytes
from LIME-sufficient (WT) and -deficient (Lime–/–) female or male mice expressing the Marilyn transgenic TCR were analyzed by
flow cytometry for expression of CD4, CD8, and CD3e. The genotypes and the total number of cells in the thymus or spleen
[averaged from 4 (WT) and 6 (Lime–/–) age-matched mice] are indicated above dot plots. The percentages of cells within each
quadrants or gates are indicated. Single-color histograms represent CD3e staining on total thymocytes and splenocytes. The
percentage of CD3eint and CD3ehigh thymocytes are indicated. In the case of the spleen, the percentage and mean fluorescence
(italicizedvalues) of CD3+ cells are indicated. All themiceweremaintained on a Rag-2–/–-deficient background, andwere between 6
and 8 weeks of age. (B, C) CD4+ T cells found in the periphery of WT and Lime–/– Marilyn female mice were analyzed for their
capacity to proliferate (B) and produce IL-2 (C) after stimulationwith graded concentrations of agonistic peptide. CD4+ T cellswere
purified from secondary lymphoid organs and incubatedwith Ab-positive APC prepulsedwith the Dby agonist peptide. The extent
of cell proliferation (B) and IL-2 content (C) were determined after 40 h and 24 h, respectively. Data shown in (B) and (C) are
representative of three independent experiments.
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Figure 6. Analysis of B and T cell development and function in mice with single and combined deletion of LIME and NTAL. (A)
Splenocytes from wild-type (WT), LIME-deficient (Lime–/–), NTAL-deficient (Ntal–/–) mice and mice lacking both LIME and NTAL
(Lime–/– Ntal–/–) were stained with the indicated antibodies and analyzed by flow cytometry. Genotypes are specified over the dot
plots. In the CD19 versusMHCclass II staining, the percentages of B cells (CD19+MHCII+) are indicated. In the IgM versus IgD staining
profiles, CD19+MHCII+-gated B cells were categorized into IgMhigh IgDlow, IgMhigh IgDhigh, and IgMlow IgDhigh cells. (B) Spleen B cells
frommice of the specified genotypeswere left unstimulated (0) or stimulatedwith lipopolysaccharide (LPS, 10 lg/mL), goat F(ab0)2
anti-mouse IgMantibody (IgM, 10 lg/mL), orwith phorbolmyristate acetate and ionomycin (P/I). After 40 h of culture, the extent of
cell proliferation was determined. (D) Spleen T cells frommice of the specified genotype were left unstimulated (0) or stimulated
with anti-CD3e antibody at two different doses (1 lg/mLand 5 lg/mL), andwith amix of anti-CD3e and anti-CD28 antibodies. After
40 h of culture, the extent of cell proliferation was determined. (C, E) Calcium responses analysis following to antigen receptor
stimulation of B (C) and T (E) cells isolated from mice of the specified genotypes.
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ground for at least seven generations, and housed in a specific
pathogen-free animal facility. All procedures were in accor-
dance with protocols approved by French Laws and the
European Directives.
Vector construction
The targeting construct used for disruption of the Lime gene is
shown in Fig. 2. The 50 homologous sequences correspond to a
gene segment encompassing nucleotide positions 8079–9024
(sequence available from GenBank/EMBL/DDBJ under acces-
sion number F131462). The 30 homologous sequences
correspond to a gene segment encompassing nucleotide
positions 13 800–18 812 (sequence available from Gen-
Bank/EMBL/DDBJ under accession number F131462). In
the targeting vector, exons 1–5 of the Lime gene were replaced
by a loxP-flanked, Cre-Neor auto-deleter cassette [26].
Isolation of recombinant embryonic stem cell clones
and production of mutant mice
After electroporation of CK35 129/Sv embryonic stem cells
[27] and selection in G418 and gancyclovir, colonies were
screened for homologous recombination by Southern blot
analysis. The 50 single-copy probe corresponds to a 392-bp
fragment that encompasses nucleotide position 6857–7249. It
was amplified using the following oligonucleotides: 50-CGG
AAT TCG TGG CAC CAC ACT GTA GAG AG-30 and 50-GCT CTA
GAC TGT GCA CAC TCC TGA CAA CTC-30. When tested on
HindIII-digested DNA, it hybridized either to a 7.4-kbwild-type
fragment or to a 2.7-kb recombinant fragment. The presence of
an appropriate homologous recombination event at the 30 side
was assessed using a 357-bp fragment encompassing nucleo-
tide positions 19201–19558. It was amplified using the
following oligonucleotides: 50-CGG AAT TCT GGC TGC AGA
CAT GAA CAC AC-30 and 50-GCT CTA GAT TGT AGG AAG GCT
ATT TCA GG-30. When tested on EcoRI-digested DNA, this
fragment hybridized either to a 16.6-kb wild-type fragment or
to a 9.6-kb recombinant fragment. A Neo probe was also used
to ensure that adventitious non-homologous recombination
Figure 7. Lime-deficient mice do not develop autoimmune syndrome and splenomegaly upon aging. Spleen from 25- to 30-week-
old wild-type (WT), LIME-deficient (Lime–/–), NTAL-deficient (Ntal–/–), LIME-NTAL double-deficient (Lime–/– Ntal–/–) mice were
assayed for total cellularity (A) and for their content in CD4+ T cells (B) and in B cells (C). Sera from the samemicewere analyzed for
the concentration of total IgG (D). Data shown are representative of three to nine animals as indicated in parenthesis. (E) Sera from
25- to 36-week-old mice of the specified genotype were used at a 1:80 dilution to stain HEp-2000 cells. The presence of nuclear
antibodies was revealed using a FITC-conjugated goat F(ab0)2 anti-mouse IgG. All sera from wild-type (n=4) and Lime
–/– (n=7) mice
gaveno staining of HEp-2000 cells. Sera fromNtal–/–mice gave fluorescence signals themagnitude ofwhich is similar to the signals
obtained with sera of LatY136F mice that develop early-onset autoantibodies [29, 30]. In line with a previous report [13], some
interindividual variationswere observed in the content of autoantibodies. In the case of sera from Ntal–/– (n=7) mice: four showed
strong positive fluorescence signals, one gave clearly positive signals, and two sera gave no detectable staining. Ntal–/– Lat–/– (n=6)
and Ntal–/– Lime–/– (n=6) mice showed the same frequency of animals containing anti-nuclear antibodies as Ntal–/– mice.
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events had not occurred in the selected clones. Screening of
mice for the presence of the Lime null mutation was performed
by PCR using the following oligonucleotides: (a): 50-ACC TGC
TTTGTTCACCTC ATTAATGGGTAT-30, (b): 50-ACAGCC AGG
AAG ATC TTT GTG GGC TGC TGG-30, and (c): 50-GTG ACC
ACC CTG TCC TGC CCA ACC TAG AGG-30. The wild-type Lime
allele is visualized as a 229-bp fragment using the a-b pair of
oligonucleotides, whereas the mutant allele is visualized as a
530-bp fragment using the a-c pair of oligonucleotides.
Immunoblotting
Splenocytes fromwild-type or Lime–/–mice were solubilized in
the presence of 1% laurylmaltoside. Lysates were subjected to
SDS/PAGE followed by Western blotting. The blot was
immunostained with a rabbit antiserum directed to the
cytoplasmic domain of mouse LIME (amino acids 86–202),
followed by goat anti-rabbit Ig conjugated to horseradish
peroxidase.
Flow cytometry and intracellular staining
Lymphocyte suspensions were prepared from thymus or
lymphoid peripheral organs and stained with the specified
antibodies (BD Pharmingen and Caltag laboratories). Cells
were analyzed on FACSCalibur and BDTM LSRI flow cytometers
(Becton Dickinson). Data acquisition and analysis were
performed using CellQuest (Becton Dickinson) or FlowJO
(Treestar) software.
RNA preparation and quantitative RT-PCR
Purification of immature and mature B and T cell fractions,
RNA isolation and real-time RT-PCR were performed as
described [11]. The pairs of primers used to amplify the Hprt,
Lat, and Ntal transcripts have been reported [11]. Lime
transcripts were amplified with the following oligonucleotides:
Lime sense, 50-GAA GCA CAA AGG GAC AGA GC- 30 and Lime
antisense, 50-CAG GTT CAG CTG GTC TGT GA- 30. Relative
expression values were expressed as 2–DCT where DCT is the
difference between the mean CT value of duplicates of the test
sample and of the endogenous HPRT control.
Cell purification
Splenic T cells were purified by negative selection using
magnetic cell sorting (Miltenyi Biotec). Purity was analyzed by
flow cytometry and was >90%.
Ca2+ flux measurement
For B cells, Ca2+ flux measurements were as described [11],
and data acquisition and analysis were performed with
CellQuest (Becton Dickinson) or FlowJO (Treestar), respec-
tively. Tcells were incubated for 30 minwith 3.75 lg/mL indo-
1-AM (Molecular Probes) in phenol red-free RPMI 1640
medium (GIBCO BRL) containing 10% fetal calf serum. Cells
were subsequently stained with CD4 and CD8 and incubated
with 10 lg/mL biotinylated anti-CD3 antibody (clone
145–2C11) at 4C. Calcium fluxes were induced by cross-
linking the TCR/CD3 complex with 75 lg/mL streptavidin and
were measured using an LSR flow cytometer (BD Biosciences).
In some instances, prior to stimulation with anti-CD3
antibodies, CD4 molecules were cross-linked for 45 min using
a biotinylated rat anti-mouse CD4 antibody (clone RM 4–5)
and streptavidin.
Proliferative responses and IL-2 production of T cells
Purified T cells were cultured in 96-well round-bottom plates
(2.5  104 cells per well) and stimulated with graded
concentrations of rat anti-mouse CD3 antibodies. After 72 h,
plates were pulsed for 8 h with 0.5 lCi [3H]thymidine per
well. Incorporation of [3H]thymidine into DNA was measured
by liquid scintillation counting (1450 MicroBeta Trilux, Perkin
Elmer Wallac GmbH). To assess the effect of CD28 costimula-
tion, graded concentrations of anti-CD28 antibodies were
added to T cells stimulated with a fixed concentration (0.1 or
1 lg/mL) of rat anti-mouse CD3 antibodies. When specified,
Tcells were stimulated with PMA (0.05 lg/mL) and ionomycin
(2 nM). In the case of Marilyn TCR transgenic T cells, antigen-
induced proliferation was measured using I-Ab-positive, spleen
cells from Cd3D5/D5 mice as APC. Spleen cells were irradiated
and pulsed with various concentration of the Dby peptide [28].
Purified CD4+ cells (5  104) were stimulated with 5  105
antigen-pulsed APC. After 40 h, cultures were assayed for their
content of ATP. Briefly, 100 lL CellTiterGlo reagent (Promega)
was added to the culture and the resulting luminescence,
which is proportional to the ATP content of the culture, was
measured with a Victor2 luminometer (Wallac, Perkin Elmer
Life Science). The level of IL-2 contained in the supernatant
after 20 h was determined using the CTL-L line. Values were
converted into IL-2 units using a recombinant mouse IL-2
standard (Pharmingen).
B cell responses and ELISA
They were performed as described [11].
Detection of anti-nuclear antibodies
The presence of anti-nuclear antibodies was determined using
human HEp-2000 cells (Immunoconcepts). HEp-2000 cells
were incubated with the indicated mouse serum dilution for
30 min. Slides were then washed and incubated for 30 min
with a FITC-labeled goat F(ab0)2 anti-mouse IgG antibody
(Beckman-Coulter). Slides were analyzed by fluorescence
microscopy.
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Regulation of T Cell Homeostasis by the Transmembrane
Adaptor Protein SIT1
Vilmos Posevitz, Boerge Arndt, Tina Krieger, Nicole Warnecke, Burkhart Schraven,
and Luca Simeoni2
The transmembrane adaptor protein SIT is a negative regulator of TCR-mediated signaling. However, little is known about the
functional role of SIT in mature T cells. In this study, we show that mice deficient for SIT display a decreased number of naive
CD8 T cells and a progressive accumulation of memory-like (CD44high) CD8 T lymphocytes that resemble cells undergoing
homeostatic proliferation. Indeed, when transferred into lymphopenic hosts, SIT/ naive CD8 T cells undergo enhanced
homeostatic proliferation and express a higher level of CD44 in comparison to wild-type T cells. By using class-I-restricted TCR
transgenic models with different ligand affinity/avidity, we show that lymphopenia-induced homeostatic proliferation is more
pronounced in cells carrying low-affinity TCRs. Strikingly, the loss of SIT induces homeostatic proliferation of HY TCR transgenic
cells, which are normally unable to proliferate in lymphopenic mice. Collectively, these data demonstrate that SIT negatively
regulates T cell homeostasis. Finally, we show that SIT-deficient T cells develop a mechanism analogous to sensory adaptation as
they up-regulate CD5, down-regulate the coreceptor, and display impaired TCR-mediated ZAP-70 activation. The Journal of
Immunology, 2008, 180: 1634–1642.
T he number of mature T cells is kept constant throughoutthe life by a tightly regulated process termed peripheralhomeostasis (1). Over the past several years, studies have
demonstrated that different mechanisms contribute to the mainte-
nance of the pool of peripheral T lymphocytes. In the days fol-
lowing birth, the periphery is filled with naive cells emigrating
from the thymus. Once these naive cells have colonized the pe-
riphery, they undergo a cell division program called homeostatic
proliferation (2). Both processes, namely emigration from the thy-
mus and expansion in the periphery, determine the initial size of
the peripheral T cell pool. Prolonged survival and homeostatic
proliferation of peripheral T lymphocytes allow to keep cell num-
bers constant during adulthood when the thymus involutes and
thymic output strongly decreases. Homeostatic proliferation is also
necessary to replenish the peripheral T cell pool following abnor-
mal cell depletion caused by e.g., irradiation, chemotherapy, or
infection (3–5).
Signals emanating from the TCR as well as from IL receptors
(e.g., IL-7, IL-15, among others) critically regulate lymphocyte
homeostasis (6–8). Several groups have addressed the role of the
TCR in maintaining the peripheral T cell pool. The TCR has the
ability “to sense” differences in ligand affinity and in turn is able to
translate these different input signals into distinct cellular re-
sponses. The most explicit example of this phenomenon is thymic
selection, where thymocytes expressing TCRs with high affinity
for self-peptide/MHC complexes are negatively selected whereas
those expressing TCRs with lower affinity are positively selected
and mature into CD4 or CD8 cells (9, 10). Experimental evi-
dence also suggests that interaction with self-peptide/MHC serves
the additional purpose of maintaining cell survival in the periphery
and of triggering homeostatic proliferation of mature T lympho-
cytes (11, 12). The essential role of signal strength in T cell ho-
meostasis highlights the importance of those molecules that are
able to modulate TCR-mediated signaling.
In this regard, adaptor proteins, a group of molecules that or-
ganize signaling complexes at the plasma membrane, play a piv-
otal role as they represent important regulators of lymphocyte ho-
meostasis. Previously, we have shown that Src homology domain
containing tyrosine phosphatase 2-interacting transmembrane
adaptor protein (SIT),3 a transmembrane adaptor strongly ex-
pressed on thymocytes and peripheral T cells, represents a multi-
functional regulator of TCR-mediated signaling (13–15). The char-
acterization of SIT-deficient mice demonstrated that SIT regulates
selection processes within the thymus by setting TCR-mediated
activation thresholds (13). Indeed, positive selection was partially
converted to negative selection and the expression level of CD5
was strongly elevated on SIT/ CD4CD8 immature thymo-
cytes. CD5 is a molecule whose expression is directly proportional
to the affinity of the TCR for self-peptide/MHC ligands (16). Col-
lectively, our data had demonstrated that SIT negatively regulates
TCR-mediated signal strength. As the maintenance of the periph-
eral T cell pool is also strictly dependent upon TCR-mediated sig-
naling, we here investigated the role of SIT in peripheral T cell
homeostasis. To date, the number of molecules that have been
shown to regulate homeostatic proliferation is surprisingly limited
and nothing is known about the role that transmembrane adaptor
proteins play in this process.
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We report that SIT is required for proper homeostasis of pe-
ripheral T cells and negatively regulates homeostatic proliferation
in lymphopenic hosts. SIT-deficient T cells further develop sensory
adaptation and display impaired ZAP-70 activation. Collectively, the
data shown in this study demonstrate that SIT is a critical modulator
of the signaling threshold and regulates T cell development and pe-
ripheral homeostasis in a similar fashion.
Materials and Methods
Mice
SIT/ mice were previously described (13). All mice used in this study
were between 1 and 5 mo of age, when not otherwise indicated. OT-I TCR
transgenic mice were provided by Dr. Percy Knolle, P14 by Dr. Thomas
Kammerthoens, and HY TCR transgenic mice by Dr. Gary Koreztky. SIT-
deficient mice carrying TCR transgenes were generated as previously de-
scribed (13). All experiments involving mice were performed according to
the guidelines of the State of Sachsen-Anhalt.
Flow cytometry
For FACS analysis, single cell suspensions were prepared and 1  106 cells
were stained with indicated Abs and analyzed on a FACS Calibur using the
CellQuest software (Becton Dickinson). All Abs were purchased from BD
Biosciences except for HY (clone T3.70; eBioscience) as previously reported
(13). For apoptosis determination, splenocytes and lymph node cells were
harvested, washed, and stained with Annexin V-PE (BD Biosciences).
Intracellular staining
Intracellular Bcl-2 staining was performed by using a Bcl-2 FITC set (BD,
Biosciences) according to the manufacturer’s instructions.
BrdU labeling and analysis
Steady-state proliferation of T cells was measured by BrdU incorporation.
Mice were fed with 0.8 mg/ml BrdU (Sigma-Aldrich) given in their drinking
water. Intracellular staining for BrdU was performed by using a FITC BrdU kit
(BD Biosciences) in accordance with the manufacturer’s instructions.
T cell isolation
Splenic T cells were purified using a Pan T cell isolation kit (Miltenyi
Biotec), while CD4CD8 thymocytes were enriched by using anti-FITC
microbeads (Miltenyi Biotec) after staining with a FITC-labeled CD8 mAb
(clone CT-CD8a, Caltag) on an AutoMACS magnetic separation system.
The purity of CD4CD8 thymocytes was 97%. CD8 SP thymocytes
were enhriched by negative selection using CD4 microbeads (Miltenyi
Biotec) on an AutoMACS magnetic separation system.
Adoptive transfer
Total lymph node cells or enriched CD8 SP thymocytes were isolated
from mutant and control mice, washed, counted, and resuspended at 5 
106 cells/ml in ice cold PBS. Cells were then labeled with 0.1 M CFSE
(Molecular Probes) for 10 min at 37°C. Before i.v. injection, cells were
washed with ice cold PBS containing 5% FCS and subsequently resus-
pended in PBS at 10  106/ml. Recipient B6.SJL (CD45.1) mice were
irradiated (950 rad) using a BioBeam 8000 (STS Steuerungstechnik &
Strahlenschutz GmbH) 1 day before adoptive transfer and injected i.v. with
200 l (2  106 cells) of cell suspension. After irradiation, mice were
treated with 2 mg/ml neomycin sulfate (Sigma-Aldrich). Tissues were har-
vested on day 3 or 7 and analyzed for the intensity of CSFE and other cell
surface markers.
Immunoprecipitation, immunoblotting, in vitro kinase assay
For all biochemical analysis, lymphocytes were either left unstimulated or
stimulated with 10 g/ml biotinylated anti-CD3 Ab (145-2C11; BD Bio-
sciences) alone or in combination with biotinylated CD4 (GK1.5; BD Bio-
sciences) or CD28 (37.51; BD Biosciences) followed by crosslinking with
25 g/ml streptavidin at 37°C. Cells were lysed in lysis buffer containing
1% Nonidet P-40, 1% laurylmaltoside (N-dodecyl--D-maltoside), 50 mM
Tris (pH 7.5), 140 mM NaCl, 10 mM EDTA, 10 mM NaF, 1 mM phenyl-
methylsulfonylfluorid, and 1 mM Na3VO4. The supernatants of the lysates
were subjected to immunoblotting, or immunoprecipitated with Abs spe-
cific for linker for activation of T cells (LAT) (Transduction Laboratories),
ZAP-70 (Santa Cruz Biotechnology), or TCR- (Santa Cruz Biotechnol-
ogy). Abs were captured using protein A-Sepharose. Proteins were sepa-
rated by SDS-PAGE, electrotransferred to polyvinylidene difluoride mem-
branes, and blotted with the following Abs: anti-phosphotyrosine (4G10),
anti-ERK1/2 (Cell Signaling Technology), anti-JNK (Cell Signaling Tech-
nology), anti-p38 (Cell Signaling Technology), anti-phosphoLAT (Y171,
Cell Signaling Technology; Y191, Cell Signaling Technology; Y226, Up-
state Biotechnology), anti-LAT (a gift from Dr. Weiguo Zhang) anti-
phosphoZAP-70 (Y319, Y493, Cell Signaling Technology), and anti-
ZAP-70 (Transduction Laboratories).
For the determination of ZAP-70 kinase activity, 40  106 thymocytes
were stimulated with 10 g/ml biotinylated anti-CD3 (145-2C11, BD Bio-
sciences) plus 10 g/ml anti-CD4 Abs (GK1.5, BD Biosciences) and
crosslinked with 25 g/ml streptavidin at 37°C. Anti-ZAP-70 immuno-
complexes were assayed for kinase activity as previously described (17).
Ca2 flux
For Ca2-measurement, cells were incubated for 30 min with 3.75 g/ml
indo-1-AM (Molecular Probes) in phenol red-free RPMI 1640 medium
(Invitrogen Life Technologies) containing 10% FCS. After washing, the
cells were incubated in the presence of CD4-FITC, CD8-PE, and 10 g/ml
biotinylated CD3 (145-2C11; BD Biosciences) mAbs at 4°C. Calcium
fluxes were induced by crosslinking the TCR/CD3 complex with 75 g/ml
streptavidin and were measured using a LSR flow cytometer (BD
Biosciences).
Statistics
Statistical analysis were performed using GraphPad Prism (GraphPad Soft-
ware). Mean values  SEM are shown in each graph. Asterisks represent
p values of an unpaired two-tailed Student’s t test.
Results
SIT/ mice show a reduction of CD44low and an
accumulation of CD44high CD8 T cells
We have previously shown that SIT deficiency resulted in a se-
lective decrease in the numbers of T, but not B cells in lymph
nodes. This deficit seems to affect particularly the CD8 T cell
pool (Fig. 1A and Ref. 13). To further elucidate this phenomenon,
we investigated the survival rate and steady-state proliferation of
peripheral T cell subpopulations. To this end, we firstly measured
the expression of Bcl-2, an antiapoptotic molecule whose expres-
sion is regulated by survival signals (6, 18). Fig. 1B shows that
intracellular expression of this protein was not affected in the ab-
sence of SIT. Furthermore, the survival rate after in vitro culture
(data not shown) or Annexin V expression on ex vivo isolated
CD8 T cells (Fig. 1C) were not altered in the absence of SIT.
Hence, it appears as if loss of SIT does not affect the survival of
CD8 as well as CD4 T cells (data not shown).
We next measured steady-state proliferation by determining
BrdU incorporation in CD8 T cells. However, we found sim-
ilar turnover rates between SIT/ and wild-type (WT) mice
(Fig. 1D).
Collectively, these data suggest that loss of SIT does not alter T
cell numbers by affecting their survival or steady-state
proliferation.
To shed further light onto this phenomenon, we characterized
the expression of differentiation markers in lymphoid organs of
SIT-deficient and WT mice by flow cytometry.
We initially assessed the expression of CD44, a cell surface
marker that is generally used to distinguish between naive
(CD44low) and memory cells (CD44high). Fig. 2A shows that
CD8 T cells from SIT/ mice display a dramatic alteration of
the CD44 profile. Calculation of absolute numbers revealed a se-
lective and marked decrease in the number of naive CD8 T cells
in secondary lymphoid organs from SIT-deficient mice (Fig. 2B).
Conversely, CD4 T cells showed only a mild alteration in the
CD44 profile (Fig. 2A) and, accordingly, a slight reduction in the
number of the naive fraction (Fig. 2C). The expression of the ac-
tivation markers CD25 and CD69 was not altered on T cells from
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SIT-deficient mice (data not shown), thus indicating that the acti-
vation status of the cells is normal. These results demonstrate that
the paucity of mature CD8 T cells observed in the lymph nodes
of SIT/ mice can be exclusively attributed to the loss of the
naive CD8 subset.
Furthermore, SIT-deficient mice also accumulate high numbers
of CD44high CD8 and to a lesser extent of CD4 T lymphocytes
in the spleen (Fig. 2, B–C).
In summary, these data show that SIT regulates the differenti-
ation status of T cells.
We have previously shown that SIT/ mice generate less
CD8 SP thymocytes (13). In agreement with these data, the num-
ber of naive CD8 T cells is already severely reduced in young
SIT/ mice in which cells released from the thymus significantly
contribute to the peripheral T cell pool (Fig. 3A). Moreover, we
also found that the fraction of CD8 cells expressing the E integrin
(CD103) (Fig. 3B) and the chemokine receptor CCR9 (data not
shown), which have been shown to correspond to a peripheral
naive T cell subset that directly originates from recent thymic em-
igrants (19, 20), are severely reduced in mice lacking SIT. Thus, a
decrease in the generation of thymic precursors represents a mech-
anism to explain the reduction of naive CD8 T cells in
SIT-deficient mice.
We next investigated the mechanisms responsible for the accu-
mulation of CD44high T cells in SIT-deficient mice. CD44high cells
are usually referred to as memory cells. However, it appears that
they represent a pool of cells with different origins including not
only Ag-experienced T lymphocytes but also cells undergoing ho-
meostatic proliferation. Indeed, it has been shown that during ho-
meostatic expansion, naive T cells up-regulate CD44 and persist in
the secondary lymphoid organs of adult mice, thus contributing to
the CD44high lymphocyte pool (21). Therefore, as CD44high cells
do not only represent memory cells, we referred to them as mem-
ory-like cells.
FIGURE 1. Normal survival and steady-state proliferation of CD8 T
cells in SIT/ mice. A, Lymph node cells were isolated from SIT/ and
SIT/ mice and stained with CD4 and CD8 mAbs. Bar graphs indicate
mean values  SEM from seven SIT/ and nine SIT/ mice. , p 
0.0217; , p 0.0001. B, Intracellular Bcl-2 expression in CD8 T cells
from lymph nodes of SIT/ (filled histogram) and SIT/ (empty histo-
gram) mice. Isotype control is shown as dotted line. C, Lymph node (LN)
cells and splenocytes were stained with Annexin V and CD8 mAb. The
mean percentage  SEM of Annexin V within CD8 T cells from six
SIT/ and seven SIT/ mice is shown. D, BrdU incorporation was mea-
sured for CD8 T cells in lymph nodes (LN) and spleen. Numbers in
quadrants indicate percentages of CD8 T cells. The results shown are
representative of three independent experiments.
FIGURE 2. Altered distribution of CD8 T cell subsets in the periphery
of SIT/ mice. A, Representative CD44 expression profile within CD4
and CD8 T cells from lymph nodes (LN) and spleen of SIT-deficient and
control mice. Absolute numbers of CD8CD44low and CD8CD44high (B)
or CD4CD44low and CD4CD44high (C) T cells from spleens and lymph
nodes (LN) of 5-mo-old SIT knockout and control mice were calculated.
Filled squares and triangles represent SIT/ mice, while empty squares
and triangles represent SIT/ mice.
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We focused our further investigations on CD8 T cells as they
appear to be more affected by the loss of SIT than CD4 T cells.
To characterize in more detail CD8CD44high T cells in SIT-de-
ficient mice, we measured the expression of additional markers of
cell differentiation. Fig. 3C shows that CD62L and CD122 were
both highly expressed on CD8CD44high T lymphocytes thus
further indicating a memory-like phenotype (Fig. 3C). As
CD8CD44highCD62LhighCD122high lymphocytes resemble cells
undergoing homeostatic proliferation (22–24), the data shown in
Fig. 3C suggest that homeostatic expansion is enhanced in SIT-
deficient mice. To explore this possibility, we performed adoptive
transfer experiments.
Loss of SIT lowers the activation threshold and enhances
homeostatic proliferation of CD8 T cells
Adoptive transfer of CFSE-labeled lymph node cells into lym-
phopenic mice is a well-established experimental system to study
homeostatic mechanisms. To investigate whether the loss of SIT
resulted in enhanced T cell homeostatic proliferation, we adop-
tively transferred enriched CD8 SP thymocytes, as a source of
naive T cells, in irradiated recipient mice. Fig. 4A shows that SIT-
deficient CD8 T cells undergo a faster homeostatic proliferation
compared with WT control T cells. As it has been shown that
during homeostatic proliferation naive T cells up-regulate CD44
expression (21), we measured the level of this differentiation
marker on CD8 T cells from SIT-knockout and control mice
recovered after homeostatic proliferation. In agreement with the
enhanced homeostatic expansion, we found that SIT-deficient na-
ive CD8 T cells also up-regulate CD44 at a higher level than their
WT counterparts (Fig. 4B). Fig. 4B also shows that the amount of
CD44 expressed on CD8 SP thymocytes from knockout and WT
mice before adoptive transfer is comparable. This observation in-
dicates that the loss of SIT does not result in a general up-regu-
lation of CD44 expression. In summary, our data demonstrate that
the loss of SIT enhances both the homeostatic proliferation of
naive T cells and the generation of memory-like T cells in lym-
phopenic mice. And, therefore, we believe that a similar mecha-
nism is responsible for the accumulation of memory-like T cells in
SIT-deficient mice.
As the TCR affinity is reported to correlate with the ability of T
cells to undergo homeostatic proliferation in lymphopenic host, we
performed adoptive transfer using donor cells derived from three
TCR transgenic mouse lines, HY, P14, and OT-I, expressing TCRs
with different affinities for self-peptides/MHC (Fig. 4C). This ex-
perimental design allowed us, first, to study the behavior of ho-
mogeneous naive T cell populations and, second, to grade the po-
tential effects of SIT on TCR-mediated signal strength and in turn
on homeostatic proliferation.
Because we had previously shown that signaling via the low-
affinity HY TCR is particularly affected in SIT-deficient thymo-
cytes, we performed our initial investigations using the HY TCR
transgenic system (13). It has been shown that HYCD8 T cells
prepared from female mice do not undergo homeostatic prolifer-
ation in lymphopenic hosts, likely because of too low TCR affinity
that is not sufficient to trigger expansion of T cells in the periphery
(12, 25). To assess whether loss of SIT affects the homeostatic
behavior of HYCD8 T lymphocytes, CFSE-labeled lymph node
cells from WT and SIT/ female HY transgenic mice were adop-
tively transferred into irradiated female recipient animals. At day
7 after transfer, spleens were isolated and cells analyzed for the
number of divisions based on CFSE content. As expected, WT
HYCD8 T cells did not proliferate in lymphopenic female mice
(Fig. 4C). In marked contrast, loss of SIT enabled HY TCR trans-
genic CD8 T cells to undergo vigorous homeostatic expansion
(Fig. 4C). Similar results were obtained when we performed adop-
tive transfer in a second lymphopenic model, RAG1/ mice (data
not shown). In both systems, SIT/HYCD8 T cells underwent
at least two cell divisions, thus indicating that the proliferation is
not a radiation-induced effect, i.e., triggered by cytokines, which
are released upon irradiation (26).
The hypothesis that SIT regulates homeostasis primarily via the
TCR is further supported by the fact that the in vitro response of
T lymphocytes to recombinant cytokines such as IL-7 and IL-15
(which play an important role in peripheral T cell homeostasis;
Refs. 7, 8, 18) was comparable in SIT/ and WT CD8 T cells
(data not shown).
We next tested whether SIT also exerts a negative regulatory
effect on CD8 T cells carrying the P14 TCR, which possesses
higher affinity than the HY TCR. Fig. 4C shows that, similarly to
the HY TCR transgenic model, the absence of SIT enhanced the
homeostatic proliferation of P14 CD8 T cells.
Finally, we investigated whether SIT has any regulatory effect
on the homeostatic capability of CD8 T cells expressing a high
affinity TCR, such as OT-I. In agreement with previously pub-
lished data, Fig. 4C shows that OT-I TCR transgenic cells strongly
proliferate in lymphopenic mice (25). However, Fig. 4 also dem-
onstrates that the kinetics of homeostatic proliferation were com-
parable between SIT/ and SIT/ OT-I CD8 T cells. These
data suggest that beyond a certain threshold of affinity for self-
peptides/MHC complexes, SIT is dispensable for the regulation of
FIGURE 3. Reduced numbers of naive T cells in young SIT/ mice.
A, Number of naive CD8 T cells from lymph nodes (LN) and spleen of
1-mo-old SIT/ and SIT/ mice. Filled squares and triangles represent
SIT/ mice, while empty squares and triangles represent SIT/ mice.
Expression of CD44 together with CD103 (B), or CD122 and CD62L (C)
is shown on CD8 splenocytes. Numbers indicate percentages of cells in
each quadrant.
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TCR-mediated signaling. Collectively, these data demonstrate that
SIT-deficiency lowers TCR-mediated activation threshold and en-
hances homeostatic proliferation.
Sensory adaptation of SIT-deficient T cells
Despite the lower threshold for activation, CD8 T cells from
SIT-deficient mice do not display a fully activated phenotype.
Therefore, it is conceivable that SIT/ cells develop compen-
satory mechanisms to avoid improper activation. Indeed, recent
observations suggest that T cells are endowed with adaptation
mechanisms and may reprogram the activation threshold in re-
action to strong signals (27). To assess this point, we investi-
gated the expression of CD5, which is well established to di-
rectly correlate with the strength of TCR engagement.
Moreover, the expression of CD5 is required to dampen strong
TCR signaling (28). CD5 function appears to be of particular
importance in CD4CD8 thymocytes, whose maturation crit-
ically depends upon the TCR-mediated activation threshold. In
fact, we and others have previously shown that thymocytes
lacking negative regulatory molecules express higher levels of
CD5 as compared with WT cells (13, 29, 30). Surprisingly, we found
that CD5 expression remained elevated even on peripheral SIT/
FIGURE 4. SIT negatively regu-
lates homeostatic proliferation of
CD8 T cells in lymphopenic hosts.
Homeostatic proliferation of CD8 T
cells after adoptive transfer in lym-
phopenic mice. CFSE-labeled en-
riched CD8 SP thymocytes (A) and
lymph node cells carrying transgenic
TCRs (HY, P14, or OT-I) (C) from
SIT/ and SIT/ mice (CD45.2)
were adoptively transferred into irra-
diated recipient mice (CD45.1). Af-
ter 7 days (CD8 SP, HY, P14) or 3
days (OT-I), splenocytes were stained
with CD8 and CD45.1 (CD8 SP,
P14, and OT-I) or with T3.70 and
CD8 (HY) mAbs. Histograms in A
and C show CFSE profiles of donor
derived CD45.1 CD8 (CD8 SP,
P14, OT-I) or T3.70 CD8 (HY)
from a representative mouse. Num-
bers indicate cell divisions. Bar
graphs in A and C show statistical
analysis of homeostatic proliferation
of enriched CD8 SP thymocytes
from 5 SIT/ and 5 SIT/ mice (A)
and of lymph node cells from four
OT-I, four P14, and six HY from WT
or SIT-deficient mice (C). B, Histo-
gram overlays compare the expres-
sion of CD44 on CD8 SP thymo-
cytes from SIT/ (filled histograms)
and SIT/ (empty histograms) mice
before (upper panel) and after (lower
panel) adoptive transfer. Statistical
analysis of CD44high expressing
CD8 SP cells from five SIT/ and
five SIT/ mice after adoptive trans-
fer is shown in the bar graph below.
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CD8 T cells either in TCR transgenic or nontransgenic genetic
backgrounds (Fig. 5A and our unpublished data). This observa-
tion corroborates the hypothesis that in addition to thymocytes,
peripheral CD8 T lymphocytes receive constantly stronger
signals via the TCR in the absence of SIT.
To further characterize the existence of mechanisms that would
allow tuning of the activation threshold in SIT/ mice, we in-
vestigated the expression of the coreceptor CD8. Recent data sug-
gested that down-regulation of CD8 is a mechanism that allows T
cells to regulate the threshold of T cell activation (31). Thus in
addition to upregulating CD5, modulation of T cell responsiveness
by downregulating the CD8 coreceptor represents a mechanism for
sensory adaptation that prevents the activation of autoreactive T
cells in the presence of persistent stimulation.
Analysis of SIT/ peripheral CD8 T cells revealed signifi-
cantly lower levels of CD8 expression compared with control mice
(Fig. 5A). As CD8 single positive thymocytes express normal
level of CD8 (data not shown), the down-regulation of the core-
ceptor in the periphery is likely induced by signals received by
mature T cells. A similar coreceptor down-regulation was detected
in SIT-deficient mice carrying the HY and P14 TCRs (data not
shown). Moreover, HY and P14 SIT/ mice also displayed un-
usually high numbers of transgenic TCR CD4CD8 lympho-
cytes in the periphery (Fig. 5B), thus likely indicating that a com-
plete down-regulation of the coreceptor has occurred in some cells.
In addition to CD8 T cells, SIT-deficient CD4CD8 thymo-
cytes show a similar phenotype and up-regulate CD5 while down-
regulating CD4 (data not shown). Taken together, these observa-
tions are in line with the concept that SIT-deficient T cells
counterbalance the stronger TCR-mediated stimulation by adjust-
ing the expression of positive and negative regulatory molecules,
thus reprogramming the activation threshold.
Impaired proximal signaling in SIT/ T cells
The existence of compensatory mechanisms in SIT-deficient mice
was further supported by the observation that thymocytes and pe-
ripheral T cells displayed impaired proximal signaling events upon
in vitro stimulation with CD3 or CD3 plus CD28 Abs (Fig. 6A and
our unpublished data). The data depicted in Fig. 6A show that
tyrosine phosphorylation of several proteins is reduced in SIT-
deficient thymocytes. In particular, we consistently observed a
marked reduction of TCR-mediated tyrosine phosphorylation of
LAT either assessed by global anti-phosphotyrosine immunoblot-
ting (Fig. 6A), LAT immunoprecipitation, or by using phosphosite
specific Abs (Fig. 6B).
Given the strong reduction in LAT phosphorylation it was nec-
essary to investigate whether the activation of signaling molecules
downstream of LAT is also reduced in SIT/ thymocytes. Fig. 6A
shows that TCR-mediated activation of ERK1/2 is significantly
impaired in SIT-deficient mice whereas the activations of JNK/
SAPK and p38 are normal. In agreement with these data, further
biochemical analyses revealed that TCR-mediated phosphoryla-
tion of PLC1 and calcium-flux are reduced in SIT-deficient T
cells (Fig. 6C).
ZAP-70 is believed to represent the major tyrosine kinase re-
sponsible for LAT phosphorylation (32). To assess whether the
reduced levels of LAT phosphorylation in SIT-deficient mice is
due to an impaired activation of ZAP-70 we investigated the phos-
phorylation status and the enzymatic activity of ZAP-70. In line
with blunted LAT phosphorylation we found that TCR-mediated
phosphorylation of two critical tyrosine residues of ZAP70, Y319,
and Y493 is reduced in SIT/ thymocytes (Fig. 6D). Simi-
larly, in vitro kinase assays of ZAP-70 immunoprecipitates
showed attenuated enzymatic activity of ZAP 70 in the absence
of SIT (Fig. 6D).
ZAP-70 activation requires the tyrosine phosphorylation of
ITAM motifs of the CD3 and TCR--chains (33). Phosphorylation
of the ITAMs provides docking sites for the two SH2 domains
within ZAP-70, thus positioning this kinase in the TCR/CD3 com-
plex closed to its upstream activator Lck. Therefore, to elucidate
the mechanisms responsible for impaired ZAP-70 activation in
SIT-deficient T cells, we investigated TCR- phosphorylation and
TCR-/ZAP-70 association. Fig. 6E shows that complete tyrosine
phosphorylation of TCR- upon CD3-crosslinking, which is detect-
able as a phospho-protein migrating at 23kDa, is comparable between
SIT-deficient and WT T cells (Fig. 6E). Furthermore, analysis of
immunoprecipitated TCR- show that the association with ZAP-70
is also normal in SIT/ T cells (Fig. 6E), thus suggesting that the
phosphorylation of TCR- and the recruitment of ZAP-70 to the
TCR/CD3 complex are intact in SIT-deficient mice. Overall, our
findings indicate the existence of a molecular mechanism that ren-
ders SIT-deficient T cells refractory to TCR-mediated stimulation
by reducing ZAP-70 activation.
FIGURE 5. Expression of CD5 and CD8 in SIT/ T cells. A, Histo-
gram overlays compare the expression of CD5 and CD8 on CD8-gated
splenic and lymph node T cells from SIT/ (filled histograms) and
SIT/ (empty histograms) mice. Statistical analysis of CD5 and CD8
mean fluorescence intensity is shown below. B, Splenocytes from HY and
P14 TCR transgenic mice were stained with CD4, CD8, and TCR (T3.70
for HY and V2 for P14) mAbs and numbers of transgenic TCRCD4
CD8 were calculated. The mean  SEM of TCRCD4CD8 cells
from seven SIT/ and seven SIT/ mice in each TCR transgenic model
is shown.
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Discussion
The data presented in this study reveal that SIT, a nonraft-associ-
ated transmembrane adaptor, acts as a critical regulator of the pe-
ripheral T cell pool. We demonstrate that SIT contributes to the
maintenance of the peripheral CD8 T cell in at least two different
ways. First, by regulating the number of precursors generated
within the thymus and, second, by modulating homeostatic prolif-
eration in the periphery. Our data suggest that SIT lowers the T
cell-activation threshold whereby signals that normally should pro-
mote survival may become overtly stimulatory in the absence of
FIGURE 6. Impaired TCR-medi-
ated signaling in SIT/ T cells. A,
Thymocytes were stimulated for the
indicated times and assayed for the
induction of total tyrosine phosphory-
lations (p-Tyr) or the activation of
ERK1/2, JNK and p38. B, LAT phos-
phorylation was analyzed by blotting
total cell lysates with phospho-spe-
cific Abs or by blotting anti-LAT im-
munoprecipitates with an anti-
phosphotyrosine Ab. C, Purified T
cells were stimulated for the indicated
times and assayed for PLC1 phos-
phorylation. The panel below shows
calcium flux from CD4- and CD8-
gated splenocytes of SIT/ and WT
mice. The arrows indicate Ab
crosslinking (Ab) and ionomycin
(iono.), respectively. D, Thymocytes
were stimulated and processed for im-
munoblotting. Phosphorylation of
ZAP-70 was analyzed by immuno-
blotting total cell lysates directly.
ZAP-70 immunoprecipitates were
subjected to in vitro kinase assay. E,
Thymocytes were stimulated and
TCR was immunoprecipitated. Sub-
sequently, tyrosine phosphorylation
levels and association with ZAP-70
were analyzed by western blotting.
Equal loading is shown by reprobing
immunoblots with Abs specific for
ERK1/2, JNK, and p38 (A), LAT (B),
PLC-1 (C), and ZAP-70 (D) or
TCR (E).
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SIT and may induce naive CD8 and CD4 lymphocytes to un-
dergo a continuous slow-rate homeostatic proliferation. During
this expansion, naive cells seem to progressively acquire the mem-
ory-like phenotype.
Despite the fact that SIT is expressed in both cell types, SIT-
deficiency more prominently affects CD8 than CD4 T cells.
Similarly, mice lacking the adaptor protein GADS, which, like
SIT, is expressed in both T-lymphocyte subsets, show an impaired
homeostasis in CD4 but not in CD8 T cells (34). These results
are in line with the idea that homeostasis in CD8 T cells is reg-
ulated differentially than in CD4 T cells.
We propose that SIT represents a modulator of T cell homeosta-
sis. Conversely to other molecules such as LAT or CTLA-4 that
have been shown to regulate the expansion of activated T cells
(35–38) SIT and the recently published human lymphocyte acti-
vation Ag 3 (39) and B and T lymphocyte attenuator (BTLA) (40)
appear to be the only negative regulatory molecules known so far
that selectively affect peripheral T cell homeostasis without alter-
ing the activation status of T cells.
One mechanism of action could be that SIT recruits tyrosine
phosphatases such as SHP-1 and SHP-2 to the plasma membrane
in a similar fashion to other negative regulatory molecules pos-
sessing ITIMs, such as CD5 (41), PD-1 (42), and BTLA (43).
Indeed, SIT knockout mice share many similarities with CD5-,
PD-1-, and BTLA-deficient mice. Like SIT/ mice, CD5/
mice also show a conversion from positive to negative selection in
the HY and P14 systems (28, 44). Moreover, similar to SIT-defi-
cient mice, PD-1/ mice display increased numbers of
TCRCD4CD8 peripheral T cells (45) and develop glomeru-
lonephritis (46). Finally, both SIT and BTLA knockout mice show
an increase in memory-like CD8 T cells and enhanced lymphope-
nia-induced homeostatic proliferation (40).
Survival and homeostatic proliferation of peripheral T cells both
require the expression of self-peptide/MHC molecules (47). This
requirement parallels the need for MHC restriction during Ag-
specific proliferation. However, unlike Ag-induced proliferation,
homeostatic proliferation does not require costimulation (23, 48)
and does not result in the differentiation of effector cells (11, 23).
Compelling evidences further suggest that homeostatic expansion
of peripheral T cells has similarities to T cell development. Indeed,
two groups have recently shown that the peptides initiating posi-
tive selection in the thymus also drive homeostatic proliferation in
the periphery (11, 12). Therefore, self peptides appear to be key
factors for determining cell fate. Upon TCR ligation, they rescue T
lymphocytes from a default cell death pathway, thus initiating pos-
itive selection in the thymus, and, further, they induce homeostatic
proliferation in the periphery. Consequently, TCR-ligand affinity
plays a pivotal role in the regulation of the efficiency of these
processes. In fact, transgenic T cells carrying the low affinity HY
TCR undergo inefficient positive selection and show no homeo-
static proliferation, whereas mice expressing TCRs with higher
affinities, such as P14, 2C, and OT-I, show a more efficient positive
selection and robustly proliferate in lymphopenic mice (25, 49).
Thus, it is likely that thymic selection and homeostatic prolifera-
tion share similar regulatory mechanisms. How a T cell senses the
degrees of TCR-ligand affinity and sorts them into specific cellular
outcomes is largely unknown. However, the data presented in this
study as well as our previous study on SIT/ mice (13) demon-
strate that SIT is an important component of the signaling machin-
ery that translates analog inputs into digital outputs and suggest
that SIT functions as a fine-tuner of the translation process. To our
knowledge, SIT is the only molecule that has been shown so far to
regulate both thymic development and homeostatic proliferation.
Our data suggest that SIT regulates T cell homeostasis primarily
via the TCR. However, we cannot exclude the possibility that in
vivo SIT could also regulate signal transduction from other recep-
tors such as ILs receptors or even a cross-talk between the TCR
and ILs receptors.
We also show that SIT-deficient T cells develop sensory adap-
tation, most likely in an attempt to compensate the enhanced TCR-
mediated signaling. At the molecular level, SIT/ T cells show
an impaired ZAP-70 activity that in turn affects the activation of
other downstream signaling molecules. Therefore, the perturbation
of ZAP-70 activity is the most apical defect in the TCR-mediated
pathway that is affected by SIT. How does loss of SIT impair
ZAP-70 activation? We propose two mechanisms to answer this
question. First, as SIT-deficient T cells down-regulate coreceptor
expression, the amount of Lck that is activated upon TCR/core-
ceptor coengagement is reduced. The defective Lck activation
could in turn result in a selective reduction of ZAP-70 activation.
As we did not notice changes in TCR- phosphorylation, it is likely
that src-kinase activity associated with the TCR is not affected in
SIT-deficient T cells. Alternatively, tyrosine phosphatases such as
SHP-1, which are known to mediate dephosphorylation and inac-
tivation of ZAP-70 (50) are more active in SIT-deficient T cells. In
agreement with this hypothesis would be our finding that the ex-
pression of inhibitory receptors such as CD5, a molecule that
down-regulates the TCR-mediated signal transduction pathway by
recruiting SHP-1 to the plasma membrane (41) are enhanced in
SIT/ T lymphocytes.
The development of compensatory mechanisms could serve to
prevent autoimmunity or chronic inflammatory processes and
hence to preserve an appropriate immune competence of T cells
even in the absence of SIT. Indeed, immune responses against Ags,
Toxoplasma, and Listeria, as well as rejection of allograft trans-
plantations were all normal in SIT-deficient mice (our own unpub-
lished observations). However, despite the apparently normal im-
mune response, it appears as if the sensory adaptation is not
completely effective. In fact, we have recently shown that SIT-
deficient mice spontaneously develop antinuclear Abs, glomerulo-
nephritis, and accumulate activated CD4 T cells in secondary lym-
phoid organs (our unpublished results). Additionally, we showed
previously that SIT-deficient mice display a more severe clinical
course during Experimental autoimmune encephalomyelitis, a
mouse model of multiple sclerosis (13). Individuals in which T
cells undergo enhanced lymphopenia-induced homeostatic prolif-
eration such as patients affected by immunodeficiencies (i.e.,
AIDS) or treated with chemo/radio therapy suffer from different
autoimmune diseases (51, 52). Moreover, it has been demonstrated
that T cells undergoing homeostatic expansion are more suscepti-
ble to becoming autoreactive (53). On the basis of these observa-
tions, we propose that the susceptibility of SIT/ mice to develop
autoimmunity is likely caused by the enhanced homeostatic pro-
liferation of SIT-deficient T cells. In conclusion, our observations
suggest that SIT plays an important role in maintaining T cell
homeostasis and that alterations of SIT expression or function in
humans may lead to enhanced homeostatic proliferation and to an
increased susceptibility to develop autoimmune diseases.
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Dynamics of Proximal Signaling Events after
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Engagement of the TCR can induce different functional outcomes such as activation, proliferation, survival, or apoptosis. How the
TCR-mediated signaling cascades generating these distinct cellular responses are organized on the molecular level is so far not
completely understood. To obtain insight into this question, we analyzed TCR/CD8-mediated signaling events in mature OT-I TCR
transgenic T cells under conditions of stimulation that lead to either proliferation or apoptosis. These experiments revealed major
differences in the phosphorylation dynamics of LAT, ZAP70, protein kinase B, phospholipase C-1, protein kinase D1, and
ERK1/2. Moreover, input signals leading to apoptosis induced a strong, but transient activation of ERK1/2 mainly at sites of
TCR-engagement. In contrast, stimuli promoting survival/proliferation generated a low and sustained activation of ERK1/2, which
colocalizes with Ras in recycling endosomal vesicles. The transient activation of ERK1/2 under pro-apoptotic conditions of stim-
ulation is at least partially due to the rapid polyubiquitination and subsequent degradation of ZAP70, whereas the sustained
activation of ERK1/2 under survival promoting conditions is paralleled by the induction/phosphorylation of anti-apoptotic mol-
ecules such as protein kinase B and Bcl-xL. Collectively, our data provide signaling signatures that are associated with prolifer-
ation or apoptosis of T cells. The Journal of Immunology, 2008, 180: 6703–6712.
S timulation of the TCR/CD3/-complex can result in a va-riety of different cellular responses such as differentiation,cytokine secretion, survival, proliferation, or apoptosis.
According to the currently accepted model, signaling downstream
of the engaged TCR is initiated after ITAMs within the TCR-
associated CD3/-complex have been phosphorylated by the Src-
family protein kinases Lck and Fyn (1). Phosphorylation of the
ITAMs induces the recruitment of ZAP70, which is in turn phos-
phorylated and activated by Lck and Fyn (2). Activated ZAP70
then phosphorylates several downstream molecules, including the
key adapter proteins LAT and SLP-76 (3, 4). The formation of a
signalosome containing LAT and the adapter proteins Gads and
SLP-76 provides a membrane-associated signaling platform that
facilitates the recruitment and activation of PLC-1 which subse-
quently converts phosphatidylinositol 4,5-bisphosphate to diacyl-
glycerol (DAG)3 and inositol 1,4,5-trisphosphate. 1,4,5-trisphos-
phate mediates the release of Ca2 from intracellular stores
whereas DAG activates PKC as well as RasGRP, a nucleotide
exchange factor for Ras (5). GTP-loaded Ras (active form) binds
to and activates the serine/threonine kinase Raf-1 which subse-
quently activates the MEK1/2-ERK1/2 pathway (6, 7).
The kinetics of ERK1/2 activation after receptor engagement
have been correlated with specific functional outcomes, including
differentiation, proliferation, survival, or apoptosis (7). During thy-
mocyte development, the fate of DP thymocytes is determined by
a single receptor, which can differentially modulate ERK1/2 ac-
tivity, depending on the affinity of the ligand. TCR-engagement by
either positive selecting (low-affinity) peptide ligands induces a
weak but sustained activation of ERK1/2 correlating with differ-
entiation and survival of thymocytes, whereas negative selecting
(high-affinity) peptides generate a strong but transient activation of
ERK1/2 presumably responsible for the induction of thymocyte
apoptosis (8, 9). Recently, it was shown that the different kinetics
of ERK1/2 activation also correlate with distinct subcellular local-
ization of this kinase. Thus, negative selecting ligands appear to
target activated ERK1/2 to the plasma membrane whereas positive
selecting ligands induce the recruitment of activated ERK1/2 to the
Golgi apparatus (10). However, it is currently not clear whether
different localization and/or activation kinetics of ERK1/2 are in-
deed directly responsible for regulating positive vs negative
selection.
Abs recognizing site-specific phosphorylation motifs of key
molecules have been successfully used to study the kinetics and
sequence of early events leading to T cell activation. During the
past years several research groups have addressed the question
how the TCR regulates the activation of intracellular signaling
cascades. Experimental systems included in vitro stimulation of
primary T cells or Jurkat T cell lines with either soluble or immo-
bilized Abs that recognize the TCR-associated CD3-chains, pep-
tide-loaded APCs, or MHC-I/MHC-II tetramers carrying high- or
low-affinity peptides. However, the number of detailed studies that
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correlate phosphorylation kinetics of key molecules involved in T
cell activation with different cellular responses is very low
(10–12).
In the present study, we have addressed the question how dif-
ferent T cell responses (proliferation vs apoptosis) correlate with
intracellular signaling events in mature OT-I TCR-transgenic
CD8 T cells. Stimulation conditions were chosen in a way that
engagement of the TCR and the CD8 coreceptor either induces
proliferation/survival or cell death/apoptosis. We show that these
two conditions of stimulation lead to dynamically distinct patterns
of phosphorylation/activation of key molecules involved in T cell
activation. Furthermore, we also demonstrate that these different
cellular responses correlate with distinct subcellular localizations
of ERK1/2 in peripheral T cells.
Materials and Methods
Mice, T cell purification, and activation
OT-I TCR transgenic (tg) mice were provided by Percy Knolle (University
of Bonn, Bonn, Germany). Perforin knock out (perforin/) mice were
obtained from Jackson Laboratories. The mice were maintained in patho-
gen free conditions. All experiments involving mice were performed ac-
cording to the guidelines of the State of Sachsen-Anhalt, Germany. Splenic
CD8 T cells from OT-I TCR tg mice were purified using a pan T cell
isolation kit and AutoMacs magnetic separation system (Miltenyi Biotec)
according to the manufacturer’s instructions. Purification of splenic CD8
T cells from wild-type (WT) or perforin/ mice was performed using
CD8 T cell isolation kit (Miltenyi Biotec). Cells were stimulated with
biotinylated anti-mouse CD3 (10 g/ml) mAb and biotinylated anti-
mouse CD8 (10 g/ml) mAb (both from BD Biosciences) and cross-
linked with streptavidin (50 g/ml; Dianova). Before stimulation of cells
with streptamers, either PE-conjugated or nonconjugated Strep-Tactin was
incubated with recombinant monomeric biotinylated-MHC-I (1 g/reac-
tion) (IBA GmbH) at 4°C according to the manufacturer’s instructions.
Recombinant monomeric biotinylated H-2Kb molecules presenting the
OVA SIINFEKL peptide specific for the OT-I-tg TCR were used in this
study.
Flow cytometry and TCR internalization
CD8 T cells were stained with FITC-labeled mAbs against CD25 and
CD69 (BD Biosciences). Cell-associated fluorescence was analyzed on a
FACS Calibur using the Cell Quest software (BD Biosciences). To deter-
mine TCR internalization, 2  106 cells were either left untreated or stim-
ulated with CD3/CD8 mAbs or OT-I-streptamers as mentioned above at
37°C for 30–120 min. Cells were stained with FITC-conjugated TCR-
V-2 mAb (BD Biosciences) for 30 min at 4°C and analyzed by flow
cytometry.
Proliferation assay
CD8 T cells were cultured in RPMI 1640 medium containing 10% FCS
(PAN Biotech), 100 U/ml penicillin, 100 g/ml streptomycin (all from
Biochrom AG), and 50 M 2-ME in 96-well plates at a concentration of
2.5  104 cells/well. Cells were left either unstimulated or stimulated as
described above for 72 h at 37°C. Cells were then labeled with [3H]thy-
midine (0.3 Ci/well from ICN) for 8 h, harvested onto glass fiber filter
and counted with a scintillation counter (1450 MicroBeta Trilux;
PerkinElmer).
Cell survival assay and caspase-3 activity
To quantify cell survival under different stimulation conditions, T cells
were resuspended in RPMI 1640 containing supplements (as described
above) at a density of 1  106 cells/ml in a 48-well tissue culture plates.
Cells were stimulated with either CD3/CD8 mAbs or OT-I-streptamers (as
described before) at 37°C. Cells were harvested after 8 and 24 h, respec-
tively. The percentage of cells undergoing apoptosis was measured by flow
cytometry using FITC-annexin V and propidium iodide (PI) (rh annexin
V/FITC kit; Bender Medsystems) according to manufacturer’s instructions.
To detect activated caspase-3 in living cells, we used the caspase-3 detec-
tion kit according to the manufacturer’s instructions (Calbiochem). In brief,
T cells were treated as described above with OT-I-streptamers and CD3/
CD8 mAbs for 8 and 24 h, respectively. Cells were washed and 1  106
cells were incubated with 1 g FITC-conjugated DEVD-FMK in 30 l
PBS for 1 h at 37°C. After washing, the activated caspase-3 inside the cells
was analyzed by flow cytometry.
Western blotting and immunoprecipitation
CD8 T cells were either left untreated or stimulated with CD3/CD8 mAbs
or OT-I-streptamers, lysed as described in (13) and protein concentration
was determined using the Roti-Nanoquant reagent (Roth) according to
manufacturer’s instruction. The samples were analyzed by Western blot-
ting. Anti-phospho(p)-ERK1/2, anti-pS473 protein kinase (PKB) Ab, anti-
pY319ZAP70, anti-pY171LAT, anti-pS916 protein kinase D1 (PKD1) (all
from Cell Signaling Technology), anti-PLC-1, anti-pY783PLC-1, anti-
PKD1 (all from Santa Cruz Biotechnology), anti-ZAP70 (clone 1E7.2),
anti-Bcl-xL (all from BD Biosciences), anti-pTyr (clone 4G10) (Upstate
Biotechnology), and anti--actin (clone AC-15) (Sigma-Aldrich) were
used for Western blotting. The intensity of the detected bands was acquired
using the Kodak Image station 2000R and analysis was performed using ID
Image software (Kodak). To assess the ubiquitination of ZAP70, 4  107
T cells were either left unstimulated or treated with either CD3/CD8 mAbs
or OT-I-streptamers (as mentioned before) for 3 min and resuspended in
500 l lysis buffer. ZAP70 was immunoprecipitated using 2 g of rabbit
anti-ZAP70 Ab (Santa Cruz Biotechnology) in combination with 30 l
protein-A agarose beads (Santa Cruz Biotechnology) for 2 h at 4°C. Sam-
ples were analyzed by Western blotting using an anti-ubiquitin (Cells Sig-
naling Technology) and anti-ZAP70 Ab (BD Biosciences).
Calcium flux
CD8 T cells (2  107 cells/ml) resuspended in RPMI 1640 medium
(phenol-red free; Invitrogen) supplemented with 10% FCS were loaded
with 3.75 g/ml Indo-1-AM (Molecular Probes) at 37°C for 45 min. After
washing, the cells were incubated in the same medium at 37°C for an
additionally 45 min. The measurement was performed on a LSR flow cy-
tometer (BD Biosciences). Cells were incubated with CD3/CD8 mAbs at
37°C for 0.5 min to establish the baseline and cross-linked with streptavi-
din or treated with OT-I-streptamers (as mentioned before) followed by
ionomycin (10 g/ml). Data for calcium mobilization were acquired on a
LSR flow cytometer and a ratiometric analysis was performed using the
Flow Jo software (BD Biosciences).
Confocal microscopy
CD8 T cells were stimulated as described above with either OT-I-
streptamers or CD3/CD8 mAbs. Cells (2  105) were placed onto poly-
L-lysine coated slides, fixed, permeablized, and blocked as described in
(10). Cells were stained with anti-p-ERK1/2, anti Rab5 mAb (BD Bio-
sciences) or anti-pan Ras mAb (Oncogene) in combination with FITC/Cy3-
conjugated goat anti-rabbit IgG, Cy3-conjugated goat anti-mouse, FITC-
conjugated anti-TCR-V-2 mAb, or TRITC-phalloidin (Sigma-Aldrich). A
minimum of 40 cells were imaged with LEICA TCS SP2 laser-scanning
confocal system and analyzed with the LEICA software.
Results
The fate of mature CD8 T cells differs depending on the
stimuli
The aim of this study was to assess how the TCR translates dif-
ferent signals into diverse cellular responses such as proliferation
or apoptosis. For this purpose, we used purified CD8 T cells
isolated from spleens of OT-I TCR-transgenic (tg) mice and ap-
plied two different stimuli. T cells were either activated with sol-
uble biotinylated CD3 mAbs in combination with biotinylated
CD8 mAbs and subsequently cross-linked with strepavidin or
they were incubated with biotinylated H-2Kb molecules loaded
with the peptide SIINFEKL and cross-linked with Strep-Tactin
(OT-I-streptamer) (14). For this study, we used 10 g/ml each
mAb or 1 g OT-I-strepatmers to activate OT-I CD8 T cells, the
binding of 1 g OT-I- strepatmers was close to saturation under
these stimulation conditions (data not shown).
To determine whether the two stimuli induce T cell proliferation
we assessed [3H]thymidine incorporation after 72 h of in vitro
culture. Fig. 1A shows that CD8 T cells stimulated with CD3/
CD8 mAbs did not proliferate. Importantly, stimulation of the
same cells with lower doses of Abs (ranging from 10 g/ml to 1.25
g/ml) also did not induce proliferation (data not shown). Further-
more, preincubation of the cells with different concentration of
cross-linked Abs (30 min to 2 h) followed by washing (to remove
unbound antibodies) also did not result in a proliferative response
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(data not shown). Additionally, we excluded the possibility that
sodium azide present in the Ab solution might affect proliferation
(data not shown). We further examined whether the lack of pro-
liferation under the above conditions of stimulation might be due
to the fact that we used an Ab directed at the CD3-chain of the
TCR/CD3 complex. However, identical results were obtained
when cells were activated with an anti-TCR Ab in combination
with the CD8 mAb (data not shown). CD8 is expressed as a
CD8 heterodimer on MHC I-restricted TCR T cells. To ad-
dress whether the lack of proliferation is due to triggering of
CD8, we also stimulated the same T cells with either anti-CD3/
CD8 mAbs or a combination of anti-CD3/CD8/CD8 mAbs.
Like CD3/CD8-stimulation, no proliferation was observed under
these experimental conditions (data not shown). In marked contrast
to CD3/CD8 mAb stimulation, treatment of the same T cells with
peptide loaded OT-I-streptamers induced robust proliferation and
concomitantly led to strong expression of the activation markers
CD69 and CD25 (Fig. 1B).
The lack of proliferation after stimulation with CD3/CD8 Abs
could be due to T cell unresponsiveness or apoptosis. To distin-
guish between these two possibilities we assessed apoptosis of
CD3/CD8 mAb- or streptamer-stimulated cells by PI and annexin
V staining. The left panels of Fig. 1C demonstrated that already
after 8 h of stimulation with CD3/CD8 Abs 27% of the cells
showed early signs of apoptosis (annexin V and PI) and 24 h
after stimulation nearly 80% of Ab-stimulated T cells stained pos-
itive for both annexin V and PI. In contrast, only 4% of cells
were positive for annexin V and PI after streptamer stimulation.
In line with these data, stimulation with soluble CD3/CD8 Abs, but
not peptide-loaded streptamers, induced a strong activation of
caspase-3 (Fig. 1D). Notably, treatment of these cells with lower
doses of Abs (ranging from 10 g/ml to 1.25 g/ml) still induced
apoptosis whereas increasing concentrations of streptamers did not
induce cell death (data not shown). In summary, the results shown
in Fig. 1 indicate that OT-I-streptamers induced proliferation and
activation of peripheral T cells, whereas CD3/CD8 mAbs induced
apoptosis.
Activation of CD8 T cell leads to its differentiation into CTLs.
CTLs kill targeted cells mainly through the perforin/granzymes
system. To assess whether Ab induced apoptosis is mediated via
perforin, we stimulated purified CD8 T cells from WT and per-
forin/ mice with soluble anti-CD3/CD8 mAbs for 24 h and as-
sessed cell survival by propidium iodide and annexin V staining.
Fig. 1E showed that nearly 70% of Ab-stimulated T cells from WT
or perforin/ mice stained positive for propidium iodide. Con-
sistent with these data, stimulation with soluble Abs did not induce
proliferation (Fig. 1F). These data indicated that induction of ap-
optosis by soluble anti-CD3/CD8 mAbs occurred independent of
perforins.
OT-1-strepatmers induce sustained activation of PKB and
expression of Bcl-xL
The above system allowed us to compare signaling events leading
to either T cell survival or apoptosis in more detail. We first fo-
cused on PKB (also known as Akt), a serine threonine kinase,
which is critically involved in T cell survival (15). As shown in
Fig. 2A, triggering of the TCR with CD3/CD8 Abs induced a
strong, but transient phosphorylation of PKB which peaked at 3
FIGURE 1. Soluble CD3/CD8 mAb treatment in-
duces apoptosis, whereas OT-I-streptamer stimulation
leads to survival and proliferation. A, Equal cell num-
bers of purified CD8 T cells were cultured with solu-
ble CD3/CD8 mAbs or OT-I-streptamers for 72 h. Pro-
liferation was assessed by [3H]thymidine incorporation.
Data represent the averages  SEM from triplicate cul-
tures of three individual experiments. B, The expression
of CD69 or CD25 of untreated, OT-I-streptamer or
CD3/CD8 mAb stimulated (for 24 h) cells was analyzed
by flow cytometry. The histograms represent profiles of
untreated (shaded) and stimulated (thick lines) cells.
Data are representative of three individual experiments.
C, CD8 T cells were stimulated with either soluble
CD3/CD8 mAbs or with OT-I-streptamers for 8 and
24 h, respectively. Cell survival was assessed by FITC-
annexin V and PI staining. One representative experi-
ment of three individual experiments is shown here. D,
CD8 T cells were stimulated with either soluble CD3/
CD8 mAbs or OT-I-streptamers for 8 and 24 h, respec-
tively and activated caspase-3 was detected using
FITC-conjugated DEVD-FMK. One representative ex-
periment of three individual experiments is shown here.
E, Purified CD8 T cells from WT and perforin/
mice were treated with soluble anti-CD3/CD8 mAbs or
PMA/ionomycin for 24 h. Cell survival was assessed as
described in C. One representative experiment of three
individual experiments is shown here. F, T cells from
WT and perforin/ mice were stimulated with soluble
anti-CD3/CD8 mAbs and PMA/ionomycin for 72 h.
Proliferation was assessed by [3H]thymidine incorpora-
tion. Data represent the averages SEM from triplicate
cultures of three individual experiments.
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min, and rapidly declined thereafter (Fig. 2A). In contrast, OT-I-
streptamers induced a much weaker, but sustained phosphorylation
of PKB that was still detectable after 24 h of stimulation (Fig. 2,
A and B).
Previously, it was reported that expression of the anti-apoptotic
member of the Bcl2-family, Bcl-xL, prevents TCR-mediated apo-
ptosis and promotes T cell survival (16). Therefore we analyzed
whether OT-I-streptamers enhance the expression of Bcl-xL. Fig.
2C showed that this is indeed the case. Although Bcl-xL expression
was not detectable after CD3/CD8 mAb stimulation, T cells acti-
vated with OT-I-streptamers started to express Bcl-xL after 4 h of
stimulation. Bcl-xL expression was maximal at 24 h of stimulation
and was still detectable after 48 h (Fig. 2C). Thus, Ab mediated T
cell stimulation activates pro-apoptotic molecules, such as
caspase-3 and induces apoptosis whereas peptide-loaded streptam-
ers lead to the expression of anti-apoptotic molecules and promote
cell survival. Moreover, the data shown in Figs. 1 and 2 suggest
that a strong and transient activation of PKB alone is not sufficient
to protect T cells from apoptosis.
OT-I-streptamers induce sustained activation of ERK1/2
The ubiquitously expressed serine/threonine kinases ERK1/2 be-
long to the MAPK family and are important for numerous cellular
responses including proliferation and survival (7). We next inves-
tigated the kinetics of activated MAPK under survival/prolifera-
tion vs apoptosis-inducing conditions of stimulation. As shown in
Fig. 3A, CD3/CD8 mAbs induced a strong but transient phosphor-
ylation of ERK1/2 which peaked at 1 min, rapidly declined there-
after and was no longer detectable after 30 min of stimulation.
Similar kinetics of ERK1/2 phosphorylation, but with lower max-
imal intensity were observed with lower doses of the stimulating
Ab (data not shown), thus excluding the possibility of a concen-
tration effect. In contrast to Ab-mediated stimulation, engagement
FIGURE 2. OT-I-streptamers induce sustained phosphorylation of PKB
and expression of Bcl-xL. A, Purified CD8 T cells were treated with
soluble CD3/CD8 mAbs or OT-I-streptamers for the indicated time peri-
ods. Samples were analyzed by Western blotting using the indicated Abs.
The phosphorylated PKB bands were quantified using the ImageQuant
software and values were normalized to the corresponding -actin signal.
Data represent the mean  SEM of three independent experiments. B, For
long term stimulation, CD8 T cells were triggered with soluble Abs or
OT-I-streptamers and analyzed for PKB-pS473 phosphorylation as de-
scribed above. The data are representative of three independent experi-
ments. Note the expression levels of PKB were not affected either in
Ab- or streptamer-stimulated lymphocytes over the various time points
investigated (data not shown). C, Purified CD8 T cells were incubated
with soluble CD3/CD8 mAbs or OT-I-streptamers for the indicated periods
of time. The expression of either Bcl-xL or -actin was assessed by West-
ern blotting. Data are representative of three independent experiments.
FIGURE 3. OT-I-streptamers induce sustained ERK1/2 activation. A,
CD8 T cells were treated with soluble CD3/CD8 mAbs or with OT-I-
streptamers for the indicated periods of time. Lysates were prepared and
analyzed by Western blotting using the indicated Abs. The p*ERK1/2
bands were quantified using ImageQuant software and values normalized
to the corresponding -actin signal. Data represent the mean  SEM from
three independent experiments. B, For long term stimulation, CD8 T cells
were triggered with soluble CD3/CD8 Abs or OT-I-streptamers and sub-
sequently analyzed for ERK1/2 phosphorylation as described above. The
data are representative of three independent experiments. Note the expres-
sion levels of ERK1/2 were not affected either in Ab- or streptamer-stim-
ulated lymphocytes over the various time points investigated. Importantly,
phosphorylated ERK1/2 was not detected in the absence of any stimuli
after 24 h of incubation (data not shown). C, CD8 T cells were treated
with soluble CD3/CD8 mAbs or OT-I-streptamers for the indicated times.
The expression of the OT-I TCR was assessed by FITC-conjugated anti-
TCR-V-2 mAb staining analysis by flow cytometry. Data represent the
mean fluorescence intensity (MFI) of the TCR expression of three inde-
pendent experiments.
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of the TCR/CD8 with OT-I-streptamers induced a weak, but sus-
tained activation of ERK1/2 (Fig. 3A). Indeed, the level of phos-
phorylation after 30 min was as strong as after 3 min of stimula-
tion. An extended kinetic analysis revealed that ERK1/2
phosphorylation was still detectable after 24 h of streptamer stim-
ulation (Fig. 3B). It is important to note that in multiple experi-
ments we observed a substantial increase in ERK1/2 phosphory-
lation after 4 h of streptamer stimulation. The molecular basis for
the latter observation is unclear.
A rapid internalization and thus a decrease in the number of
available TCR molecules on the cell surface could explain the
transient activation of ERK1/2 after Ab stimulation. To assess this
point, we compared the expression levels of the TCR after stim-
ulation with either soluble CD3/CD8 mAbs or OT-I-streptamers
by flow cytometry. As shown in Fig. 3C, treatment of T cells
with either soluble Abs or OT-I-streptamers induced almost
identical rates of TCR-internalization (Fig. 3C). Thus, differ-
ences in TCR internalization do not account for the different
kinetics of ERK1/2 activation. In summary, the data shown in
Fig. 3 indicate that survival and proliferation of mature T cells
after streptamer stimulation correlates with a low and sustained
activation of ERK1/2.
Abs induce strong activation, ubiquitination, and rapid
degradation of ZAP70
Having excluded an altered rate of TCR internalization as the
cause of the transient phosphorylation of ERK1/2 after Ab stim-
ulation, we next investigated upstream signaling events involved in
the activation of ERK1/2. ZAP70 activation is one of the first
signaling events occurring after TCR triggering (2) and is required
for the activation of ERK1/2 (17). We assessed the activation ki-
netics of ZAP70 after Ab vs streptamer stimulation by analyzing
the phosphorylation status of pY319, which appears to be required
for TCR-mediated downstream signaling (17).
As shown in the upper panel of Fig. 4A, in terms of onset and
duration, the kinetics of ZAP70 phosphorylation were comparable
after CD3/CD8 mAb and streptamer-stimulation. In marked con-
trast to the differential activation kinetics of ERK1/2 neither of the
two stimuli induced a prolonged activation of ZAP70 (data not
shown). However, when normalized to the expression levels of
ZAP70, Ab-mediated stimulation appeared to induce a 4- to 5-fold
stronger activation of ZAP70 than streptamer-stimulation (Fig.
4B). In line with these data, we found a strikingly higher kinase
activity of immunoprecipitated ZAP70 in Ab-stimulated T lym-
phocytes compared with streptamer-stimulated cells (data not
shown).
The Western blot images depicted in Fig. 4A further showed that
besides the major band corresponding to Y319, additional ZAP70
bands displaying retarded migration in SDS-PAGE became visible
exclusively after Ab stimulation. This observation led us to suspect
that Ab stimulation not only resulted in a very strong activation of
ZAP70, but also induced its ubiquitination and subsequent degra-
dation. To address this point, T cells were stimulated for 3 min
with either CD3/CD8 Abs or with streptamers. Subsequently,
ZAP70 immunoprecipitates were obtained and analyzed by anti-
ubiquitin or anti-ZAP70 Western blotting. Fig. 4C demonstrates
FIGURE 4. Soluble CD3/CD8 mAb stimulation in-
duces ubiquitination and degradation of ZAP70 and
transient phosphorylation of LAT. A, CD8 T cells
were either incubated with soluble CD3/CD8 mAbs or
OT-I-streptamers. The phosphorylation of pY319 of
ZAP70, total ZAP70 along with the expression levels of
-actin, was determined by Western blotting. Data are
representative of three independent experiments. B, Be-
sides the main pY319 ZAP70 band as shown in A, all
bands above in Ab-stimulated cells were quantified and
the ratio between phosphorylated and nonphosphory-
lated ZAP70 was calculated for the indicated time
points. Data represent the mean  SEM from three in-
dependent experiments. C, Purified T cells were left un-
treated or incubated with soluble CD3/CD8 mAbs or
OT-I-streptamers for 3 min, respectively. ZAP70 was
immunoprecipitated and Western blot analysis was per-
formed using the indicated Abs. To control successful
stimulation, lysates were analyzed by Western blotting
for the presence of phosphorylated ERK1/2. Data are
representative of two independent experiments. D, The
total ZAP70 (middle panel shown in A) were quantified
using ImageQuant software and values normalized to
the corresponding -actin signal. Data represent the
mean  SEM from three independent experiments. E,
CD8 T cells were incubated with soluble CD3/CD8
mAbs or OT-I-streptamers for the indicated times.
Western blot analysis of cell lysates was performed us-
ing anti-phophotyrosine mAb (4G10) and the band cor-
responding to phosphorylated LAT was quantified as
described for Fig. 2. Data represent the mean SEM of
three independent experiments.
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that Ab-stimulation indeed induced a strong ubiquitination of
ZAP70 which correlated well with the rapid loss of detectable
ZAP70 protein (see Fig. 4A, middle panels and Fig. 4D for quan-
tification). In contrast, no ubiquitination of ZAP70 was observed
after streptamer-stimulation. Thus, Ab stimulation not only in-
duces a strong activation of ZAP70, but also its ubiquitination and
rapid degradation. The latter mechanism might contribute to the
transient activation of ERK1/2.
We were next interested how the differential activation/expres-
sion of ZAP70 affects the phosphorylation of its substrate the
transmembrane adapter protein LAT. To investigate this point, we
determined the phosphorylation status of LAT by Western blotting
of whole lysates using anti-phosphotyrosine Ab 4G10. Ab stimu-
lation induced an 5-fold stronger phosphorylation of LAT com-
pared with streptamer stimulation (Fig. 4E). However, the kinetics
of phosphorylation only differed slightly between the two stimuli
and neither induced a sustained phosphorylation of LAT (data not
shown). Note that similar results were obtained when we assessed
the phosphorylation status of a specific tyrosine residue within
LAT (pY 171; data not shown).
OT-I-streptamers mediate low calcium mobilization but
sustained phophorylation of PLC-1
The strikingly different magnitude of LAT or ZAP70 phosphory-
lation after Ab vs streptamer stimulation prompted us to compare
intracellular calcium flux after application of the two stimuli. As
shown in Fig. 5A, Ab stimulation generated a strong calcium sig-
nal, whereas this signal was barely detectable after streptamer
stimulation. Thus, the strong phosphorylation of LAT or ZAP70
induced by the Abs appears to correlate with a strong
Ca2-response.
Upon binding to LAT PLC-1 becomes phosphorylated on sev-
eral tyrosine residues, including Y783, which is known to be vital
for PLC-1 activity (18). To address the question whether the
strong phosphorylation of LAT and the strong induction of calci-
um-flux that occurs after Ab-mediated stimulation correlated with
the activation of PLC-1, we analyzed the phosphorylation status
of PLC-1 at Y783 by Western blotting of whole cell lysates. As
expected, CD3/CD8 mAbs induced a strong phosphorylation of
PLC-1 whereas the signal was much weaker after streptamer
stimulation (Fig. 5B). Surprisingly however, the activation of
FIGURE 5. OT-I-streptamers mediate low calcium mobilization but sustained PLC-1 and PKD1 phosphorylation. A, T cells were loaded with Indo-
1-AM and calcium release was triggered by soluble CD3/CD8 mAbs or OT-I-streptamers, respectively. Calcium influx was determined by cytometry based
on the change in the FL4/FL5 ratio. Ionomycin was added to the end of each experiment to verify proper Indo-loading. Data are representative of three
independent experiments. B, Purified splenic T cells were treated with soluble anti-CD3/CD8 mAbs or OT-I-streptamers, respectively. Cells were lysed and
equivalent amounts of protein from whole cell extracts were analyzed for phosphorylated PLC-1 (pY783) and were quantified using ImageQuant software.
Values were normalized to the corresponding -actin signal. Data represent the mean  SEM of three independently performed experiments. C, For long
term stimulation, CD8 T cells were triggered with soluble CD3/CD8 Abs or OT-I-streptamers and subsequently analyzed for PLC-1 phosphorylation
as described above. The data are representative of three independent experiments. D, CD8 T cells were either incubated with soluble CD3/CD8 mAbs
or OT-I-streptamers. The phosphorylation of serine 916 (S916) of PKD1, along with the expression level of -actin, was determined by Western blotting
and quantified as described for Fig. 2. Data represent the mean  SEM of three independent experiments. E, For long term stimulation, CD8 T cells were
triggered with soluble Abs or OT-I-strepatmers and subsequently analyzed for phosphorylation of S916 as described above. Data are representative of three
independent experiments. Note, the expression levels of PLC-1 or PKD1 were not affected either in Ab- or streptamer-stimulated lymphocytes over the
various time points investigated. Importantly, phosphorylated PLC-1 or PKD1 was not detected in the absence of any stimuli after 24 h of incubation (data
not shown).
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PLC-1 appeared to be weak but sustained after streptamer-stim-
ulation. Indeed, even after 24 h of streptamer stimulation minor
phosphorylation of Y783 was detectable (Fig. 5C). Given the fact
that neither Ab- nor streptamer-stimulation induced an extended
activation/phosphorylation of ZAP70 and LAT, these data strongly
suggest that under the experimental conditions used here, the ac-
tivation kinetics of key molecules involved in the regulation of
ERK1/2 activity bifurcate at the level of PLC-1.
The second messenger DAG is also generated by PLC-1 and is
important to activate PKC and RasGRP, which in turn leads to
activation of the Ras-ERK1/2 pathway (5). To address the ques-
tion, whether the sustained activation of PLC-1 induced after
streptamer stimulation is sufficient to produce DAG, we assessed
the phosphorylation status of PKD on pS916, which was previously
shown to be dependent upon the production of DAG (19). Stim-
ulation with CD3/CD8 mAbs induced a strong but transient phos-
phorylation of S916, whereas S916 phosphorylation was sustained,
albeit weaker, after streptamer stimulation (Fig. 5, D and E).
Therefore, although OT-I-streptamers are only weak activators of
PLC-1, they induce an extended production of DAG, which
likely contributes to the sustained activation of the Ras-ERK1/2
pathway.
Distinct subcellular localizations of ERK1/2
A recent study has shown that activated ERK1/2 resides in differ-
ent subcellular compartments when thymocytes undergo positive
vs negative selection (10). To examine whether a similar situation
also occurs in peripheral T cells undergoing apoptosis or prolifer-
ation we assessed the localization of phosphorylated ERK1/2 after
Ab or streptamer-mediated T cell activation using confocal laser
scanning microscopy. Fig. 6A demonstrates that 80% of Ab-
stimulated T cells showed an intensive localization of phosphor-
ylated ERK1/2 close to the plasma membrane after 3 min of stim-
ulation. Additional experiments revealed that under these
conditions of stimulation activated ERK1/2 colocalized to a large
extent with clustered TCR-complexes (Fig. 6B). In line with the
quantification of the Western blot analysis shown in Fig. 3A, phos-
phorylated ERK1/2 was no longer detectable after 30 min of Ab-
mediated stimulation thus confirming its transient activation under
apoptosis inducing conditions of stimulation (Fig. 6A).
Although OT-I-streptamers induced a weaker clustering of the
TCR compared with Ab-stimulation in the majority of cells, they
also led to membrane targeting of phosphorylated ERK1/2 in
80% of the cells (Fig. 6A). As expected from the quantification
of the Western blot analysis (Fig. 3A) the signal was of a much
lower intensity but even under these conditions phosphorylated
ERK1/2 partially colocalized with the transgenic TCR (Fig. 6B).
However, after 30 min and 4 h of stimulation in 60–70% of
streptamer-treated cells phosphorylated ERK1/2 was no longer
FIGURE 6. Different subcellular localization of phosphorylated
ERK1/2 after OT-I-streptamer stimulation. A, Confocal laserscanning mi-
croscopic analysis was performed on CD8 T cells stimulated with either
CD3/CD8 mAbs or OT-I-streptamers for the indicated times. Cells were
permeabilized and subjected to intracellular staining to detect phosphory-
lated ERK1/2 (green) and F-actin (red). Cells shown in each panels are
representative of at least 40 stimulated cells from two independent exper-
iments. B, Cells were either left unstimulated or treated with CD3/CD8
mAb or OT-I-streptamers for 3 min and then the localization of phosphor-
ylated ERK1/2 (red) and TCR V-2 (green) was assessed. The cells shown
in each panels are representative of 40 stimulated cells from two inde-
pendent experiments.
FIGURE 7. Phosphorylated ERK1/2 localizes in Rab5 and Ras contain-
ing recyling endosomale vesicles after OT-I-streptamer stimulation. Con-
focal laserscanning microscopic analysis was performed on CD8 T cells
stimulated with OT-I-streptamers for 30 min and 4 h, respectively and cells
were permeabilized and subjected to intracellular staining to detect phos-
phorylated ERK1/2 (green) and Rab5 or Ras (red). Cells shown in each
panels are representative of 40 stimulated cells from two independent
experiments.
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found at the plasma membrane but rather in small vesicular struc-
tures which were located close to the plasma membrane as well as
in the cytosol.
It has been described in different cellular systems that after in-
sulin receptor or TrkA receptor triggering, phosphorylated ERK1/2
accumulates in the recycling endosomes (20, 21). To address
whether the activated ERK1/2 that we detected in vesicular struc-
tures after 30 min and 4 h OT-I-streptamer stimulation localizes to
the endosomal compartment, we used Rab5 as a marker for con-
focal laser scanning microscopy. The upper two panels of Fig. 7
depicted that the vesicles indeed stained positive for Rab5, thus
identifying them as endosomes.
Other components of the ERK1/2 signaling pathway such as the
GTPase Ras have also been found in the endosomal compartment
(20, 21). In line with these data we found that Ras also colocalized
with phosphorylated ERK1/2 in Rab5-positive vesicles after
streptamer stimulation (Fig. 7, lower panels). Collectively, these
data indicate that under conditions promoting T cell survival and
proliferation activated ERK1/2 shuttles from the plasma mem-
brane to the recycling endosomes, whereas under conditions in-
ducing T cell death phosphorylated ERK1/2 only transiently ac-
cumulates at sites of TCR-engagement.
Discussion
Engagement of the TCR can result in different cellular responses
such as differentiation, survival, proliferation, or apoptosis. How-
ever, how the triggering of one receptor initiates different re-
sponses and how these responses are organized on the molecular
level is so far not understood. To address this question we used
peripheral T lymphocytes obtained from OT-I TCR-tg mice and
applied two different stimuli soluble CD3/CD8 mAbs or OT-I-
streptamers loaded with the agonistic OVA peptide SIINFEKL,
which selectively induce either apoptosis (mAbs) or proliferation
(streptamers) (Fig. 1).
Biochemical analysis of the pathways initiated by these two
types of stimuli revealed that signals inducing apoptosis produce
strong, rapid and transient phosphorylation/activation of key mol-
ecules involved in T cell activation including ZAP70, LAT, PKB,
PLC-1, PKD1, and ERK1/2. In contrast to the strong and tran-
sient signals elicited by soluble mAbs, most signals that were in-
duced by peptide loaded streptamers were of much lower intensity,
but were also more sustained. This applied to the activation of
ERK1/2 and of PLC-1, PKB, and PKD1.
Our study corroborates and extends recent experiments that had
assessed selection events in OT-I TCR-tg thymocytes (10). Hence,
it appears that independent of the system a strong and transient
activation of ERK1/2 correlates with the induction of apoptosis,
whereas a weak and sustained activation of ERK1/2 correlates
with survival and proliferation of T lymphocytes.
The molecular events that translate the different activation ki-
netics of ERK1/2 into distinct cellular responses are still unclear.
One hypothesis is that the differential localization of activated
ERK1/2 within the cells contributes to these effects. Indeed, sim-
ilar to the study performed by Daniels el al. (10) we also found the
localization of phosphorylated (and hence activated) ERK1/2 to be
markedly different under apoptosis vs proliferation inducing con-
ditions. Thus, pro-apoptotic stimuli induced rapid targeting of ac-
tivated ERK1/2 to the plasma membrane, whereas proliferation
inducing stimuli led to an accumulation of activated ERK1/2
within the recycling endosomes (Fig. 6 and Fig. 7). Localization of
activated ERK1/2 at the endosomes after insulin receptor or TrkA
receptor stimulation is a well-documented phenomenon (20, 21).
Furthermore, in insulin- or NGF-treated cells other signaling mol-
ecules required for the activation of ERK1/2 have also been de-
scribed to localize in the endosomal compartment. These include
Ras, Raf, MEK1, PLC-1, and PI3K (important for activation of
PKB) (20, 21). In line with these data, we also found Ras and
phosphorylated ERK1/2 in Rab5-containing vesicles after OT-I-
streptamer stimulation (Fig. 7). Therefore, it is reasonable to spec-
ulate that the sustained phosphorylation kinetics of PLC-1 and
PKB after OT-I-streptamer stimulation might also be due to tar-
geting of these proteins to the endosomal compartment. Unfortu-
nately, our attempts to visualize phosphorylated PLC-1 or PKB in
Rab5-containing activated ERK1/2 vesicles by confocal laserscan-
ning microscopy were so far not successful. This may be due to the
low phosphorylation status of these proteins in streptamer-treated
cells or the inaccessibility of the different phospho-specific Abs
tested for immunofluoresence. Nevertheless, our data indicated
that compartmentalization of ERK1/2 into the endosomes after
OT-I-streptamer treatment correlates with sustained activation of
this kinase. One mechanism might be that endosome-associated
ERK1/2 is protected from cytoslic or membrane associated phos-
phatases. However, how OT-I streptamer triggering of the TCR/
CD8 regulates the differential shuttling of activated ERK1/2 at the
molecular level is still unclear. Experiments are currently set up in
our laboratory to address this question.
Another important question that remains to be resolved is how
the transient activation of ERK1/2 under apoptosis-promoting con-
ditions is regulated on the molecular level. Here several possibil-
ities can be envisaged. First, we observed that stimulation of T
cells with CD3/CD8 mAbs results in a rapid poly-ubiquitiniation
and degradation of ZAP70 (Fig. 4). Moreover, the Valitiutti group
has previously demonstrated that T cell activation induces ubiq-
uitination events at the immunological synapse (22). Thus, pro-
apoptotic signals initiate a negative feedback loop that rapidly
down-regulates the input signal by eliminating ZAP70. Several
reports have shown that the ZAP70 related protein tyrosine kinase
Syk serves as a substrate for ubiquitin-ligases (23). However, to
our knowledge a TCR-mediated ubiquitination and subsequent
degradation of ZAP70 has so far not been reported. Also, the en-
zyme(s) that is/are responsible for ZAP70 ubiquitination have yet
to be determined. Obvious candidates would be members of the
Cbl family which exert E3-dependent ubiquitin ligase activity and
which have been shown to interact with ZAP70 (24). However, the
role of Cbl in ZAP70 ubiquitination and degradation is controver-
sial and further work is needed to address if and how Cbl contrib-
utes to ZAP70 ubiquitination.
In addition to the degradation of ZAP70, other mechanisms may
also contribute to the transient activation of ERK1/2 under pro-
apoptotic conditions of stimulation. One possibility would be that
the strong activation of membrane proximal tyrosine kinases (e.g.,
ZAP70, Lck, Fyn, Itk, and Rlk) not only induces the assembly of
positive-regulatory, but also of negative-regulatory signaling com-
plexes at the plasma membrane. In this regard, it is important to
mention a recent study which revealed a negative regulatory role
for Lck in T cells by showing that TCR-mediated stimuli are stron-
ger/sustained after suppression of Lck expression by siRNA in
Jurkat T cells and in primary human T lymphocytes (25). Addi-
tionally, a negative regulatory role for LAT in T cell signaling has
been suggested (26, 27). Thus, it is tempting to speculate that the
strong phosphorylation of LAT after Ab-stimulation induces the
assembly of negative regulatory complexes, which prevent a sus-
tained activation of ERK1/2. Conversely, weaker input signals (a
less strong activation of membrane proximal PTKs) would not
induce the activation of these negative regulatory loops, thus al-
lowing for a sustained activation of ERK1/2. In line with the idea
that cell fate decisions are determined at the level of the LAT
complex, would be our finding that the signaling molecules which
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are located immediately downstream of LAT (i.e., PLC-1 and
PKD1) already show markedly different phosphorylation kinetics
in our experimental system.
Finally, ERK1/2 itself could play a major role in inhibiting its
prolonged activation by inducing the phosphorylation of negative
regulatory proteins close to the membrane. Indeed, recent studies
(28, 29) have revealed the importance of serine phosphorylation of
key molecules for T cell homeostasis (SLP-76 by HPK1). Clearly,
further studies are required to elucidate the events that lead to the
transient activation of ERK1/2 under apoptosis-inducing condi-
tions of stimulation. Nevertheless, our data indicate that “optimal”
membrane proximal signals, such as a strong Ca2-flux or maxi-
mal LAT phosphorylation, may not automatically be interpreted to
mean that these events induce a productive T cell activation.
Rather, it appears that only a detailed analysis of the dynamics of
membrane proximal signaling events together with the assessment
of late events of T cell activation, such as proliferation or apopto-
sis, allows a correct interpretation of biochemical data.
It was somewhat unexpected that soluble Abs induced a rapid
apoptosis and activation of caspase-3 whereas peptide loaded
streptamers induced the expression of the anti-apoptic molecule
Bcl-xL. Although the induction of Bcl-xL expression by peptide
loaded streptamers can be explained by a sustained activation of
PKB (30), the induction of apoptosis by soluble Abs is more dif-
ficult to understand. Apoptotic T cell death and activation of
caspase-3 can be induced via the extrinsic death-receptor-mediated
pathway or through the intrinsic mitochondrial pathway (31). Cur-
rently we do not know which of the two pathways becomes acti-
vated by soluble Abs, but we clearly favor a mechanism that in-
volves the mitochondrial pathway for the following reasons. The
expression levels of CD95 were almost identical after Ab- vs
streptamer-stimulation and we also could not detect enhanced ex-
pression of CD95L after either mode of stimulation (data not
shown). Moreover, the time frame between the application of the
death-inducing stimulus and the first signs of cell death (8 h) ap-
pears to be too short to be mediated via the CD95/CD95L-system
in primary T cells. Candidate molecules that could connect the
TCR to the activation of caspase-3 via the mitochondrial pathway
are members of the BH3-only proteins that have been shown to
promote apoptosis in T cells for example Bim (32), Bid (33), or
Bad (34). Therefore, further work is needed to address which of
the BH3-only proteins contribute to Ab-induced apoptosis and
how these molecules organize pro-apoptotic pathways after Ab-
mediated apoptosis.
In multiple experiments, we observed a substantial increase of
ERK1/2 phosphorylation after 4 h of stimulation with OT-I-
streptamers (Fig. 3B). Such a “second wave” of ERK1/2 phos-
phorylation has previously been observed after long-term stimu-
lation of AND TCRtg CD4 T cells using a high-affinity peptide
(35). It might be that the production and release of cytokines, such
as IL-2, is responsible for the second wave of ERK1/2 phosphor-
ylation under survival promoting conditions of stimulation. Pre-
liminary data obtained in our laboratory indicated that IL-2 could
indeed partially contribute to the second wave of ERK phosphor-
ylation after OT-I-streptamer stimulation. Thus, in the presence of
neutralizing against IL-2 Ab, the phosphorylation of ERK1/2 was
reduced up to 50% after 4 h of stimulation with OT-I-streptamers
(data not shown). This data indicated that not only IL-2, but also
other cytokines, e.g., IL-7, may also facilitate activation, survival
and proliferation of peripheral CD8 T cells (36). Therefore, we
would speculate that the initial TCR-mediated signals leading to a
first wave of ERK1/2 activation under survival promoting condi-
tions are replaced at later time points by cytokine receptor-medi-
ated signaling events. These signals may then contribute to the
sustained activation of ERK1/2 and may also be involved in the
sustained activation of PKB thereby supporting the expression of
survival promoting molecules such as Bcl-xL.
In summary, we have shown that triggering of the same set of
receptors by different ligands can induce either survival/prolifera-
tion or apoptosis/cell death of mature CD8 T lymphocytes. We
have further demonstrated that these cellular outcomes correlate
with different activation/phosphorylation kinetics of key molecules
involved in T cell activation which seem to bifurcate at the level of
PLC-1. Our data corroborate and extend previous experiments
(10) performed in thymocytes and suggest that the molecular
mechanisms in the two systems are to a large extent comparable.
How mature T cells up-regulate TCR-mediated thresholds to con-
vert the negative selecting signal within the thymus into a prolif-
eration-inducing signal in the periphery requires further analysis.
In addition, careful kinetic and quantitative activation/phosphory-
lation studies are required to fully elucidate how transient vs sus-
tained signaling events close to the membrane are converted into
distinct cellular responses. Finally, these experiments will also
have to take the differential compartmentalization of signaling
molecules into account.
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SIT and TRIM Determine T Cell Fate in the Thymus1
Uwe Koelsch,*† Burkhart Schraven,* and Luca Simeoni2*
Thymic selection is a tightly regulated developmental process essential for establishing central tolerance. The intensity of TCR-
mediated signaling is a key factor for determining cell fate in the thymus. It is widely accepted that low-intensity signals result in
positive selection, whereas high-intensity signals induce negative selection. Transmembrane adaptor proteins have been demon-
strated to be important regulators of T cell activation. However, little is known about their role during T cell development. Herein,
we show that SIT (SHP2 Src homology domain containing tyrosine phosphatase 2-interacting transmembrane adaptor protein)
and TRIM (TCR-interacting molecule), two structurally related transmembrane adaptors, cooperatively regulate TCR signaling
potential, thereby influencing the outcome of thymic selection. Indeed, loss of both SIT and TRIM resulted in the up-regulation
of CD5, CD69, and TCR, strong MAPK activation, and, consequently, enhanced positive selection. Moreover, by crossing
SIT/TRIM double-deficient mice onto transgenic mice bearing TCRs with different avidity/affinity, we found profound alterations
in T cell development. Indeed, in female HY TCR transgenic mice, positive selection was completely converted into negative
selection resulting in small thymi devoided of double-positive thymocytes. More strikingly, in a nonselecting background, SIT/
TRIM double-deficient single-positive T cells developed, were functional, and populated the periphery. In summary, we demon-
strated that SIT and TRIM regulate cell fate of developing thymocytes, thus identifying them as essential regulators of central
tolerance. The Journal of Immunology, 2008, 181: 5930–5939.
S election of the TCR repertoire within the thymus is atightly regulated process that ensures development of Tcell clones possessing a vigorous reactivity against foreign
Ags and at the same time avoids the generation of self-reactive
cells. Decisions made in the thymus are mainly dictated by signals
transduced via the TCR upon binding MHC-self peptide com-
plexes. An established model postulates that differences in the
avidity/affinity are translated into distinct signaling strengths that
in turn determine the developmental outcome. According to this
model, strong interactions lead to apoptosis of autoreactive clones
(negative selection), and intermediate or weak associations pro-
mote thymocyte survival and maturation (positive selection),
whereas minimal or absent binding induces cell death (death by
neglect, nonselection) (1).
The data also suggest that low-intensity signals transduced via
the TCR activate the Ca2/calcineurin/NFAT and Ras/MEK/ERK
pathways and lead to positive selection, whereas high-intensity
signals leading to negative selection may also activate Grb2/Sos,
JNK, p38, and PKC (2, 3).
Transmembrane adaptor proteins (TRAPs)3 are integral mem-
brane molecules participating in proximal signaling events down-
stream of Ag receptors (4). From their position at the plasma mem-
brane, where signals transduced through the Ag receptor are sorted
and further propagated into the cell, TRAPs may play an important
role in fine-tuning TCR-mediated signal strength required to reg-
ulate positive and/or negative selection. However, with the excep-
tion of LAT (linker for activation of T cells) (5), little is known
about the role of TRAPs in thymocyte development.
Previously, we showed that the Src homology domain contain-
ing tyrosine phosphatase 2-interacting transmembrane adaptor pro-
tein (SIT) regulates thymic development by setting the signaling
threshold for positive selection (6), whereas mice lacking the TCR-
interacting molecule (TRIM) showed normal T cell development
and function (7). SIT and TRIM are structurally strongly related
proteins. Indeed, they both are non-raft-associated homodimeric
transmembrane adaptors and both possess several tyrosine-based
signaling motifs (TBSMs) within their cytoplasmic domains, two
of which are highly conserved between the two molecules (YGNL
and YASV in SIT, and YGNL and YASL in TRIM) (8, 9). Inter-
estingly, we have previously reported that the ability of SIT to
modulate TCR-mediated signaling in the Jurkat T cell line is de-
termined by these two TBSMs (10). Additionally, SIT and TRIM
are both strongly expressed in thymocytes. Based on these simi-
larities and the mild phenotype of the single knockout animals, we
proposed that SIT and TRIM adaptors can largely compensate for
each other when one of the molecules is lost. To assess this idea,
we generated SIT/TRIM double-deficient (DKO) mice. Our data
show that SIT and TRIM are indeed functionally redundant during
thymic selection. We demonstrate that concomitant loss of SIT and
TRIM results in an enhanced MAPK activation and in the conver-
sion of selection processes from nonselection to positive selection
or from positive selection to negative selection. Collectively, our
studies identified SIT and TRIM as critical regulators of central
tolerance.
Materials and Methods
Mice
SIT/ (6) and TRIM/ (7) mice were intercrossed to generate homozy-
gous DKO mice. DKO mice were further interbred with TCR transgenic
*Institute of Molecular and Clinical Immunology and †Pediatric Clinic, Otto-von-
Guericke University, Magdeburg, Germany
Received for publication August 29, 2007. Accepted for publication August 26, 2008.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by the Deutsche Forschungsgemeinschaft (DFG) (SI
861/1).
2 Address correspondence and reprint requests to Dr. Luca Simeoni, Institute of Mo-
lecular and Clinical Immunology, Otto-von-Guericke University, Leipziger Strasse
44, 39120 Magdeburg, Germany. E-mail address: luca.simeoni@med.ovgu.de
3 Abbreviations used in this paper: TRAP, transmembrane adaptor protein; SIT, Src
homology domain containing tyrosine phosphatase 2-interacting transmembrane
adaptor protein; TBSM, tyrosine-based signaling motifs; TRIM, TCR-interacting
molecule; DKO, SIT/TRIM double-deficient mice; 2m, 2-microglobulin; DP, dou-
ble positive; SP, single positive; DN, double negative.
Copyright © 2008 by The American Association of Immunologists, Inc. 0022-1767/08/$2.00
The Journal of Immunology
www.jimmunol.org
mice. OT-I TCR transgenic mice were kindly provided by Dr. Percy
Knolle, P14 by Dr. Thomas Kammerthoens, HY TCR transgenic mice by
Dr. Gary Koreztky, and F5/2-microglobulin (2m)0/RAG10 by Dr. Dimi-
tris Kioussis. OT-I (11), P14 (12, 13), HY (14), and F5/2m0/RAG10 (15–
17) were previously described. All experiments involving mice were per-
formed according to the guidelines of the State of Sachsen-Anhalt.
Flow cytometry
Single-cell suspensions were prepared, stained, and analyzed on a FACS-
Calibur using the CellQuest software (BD Biosciences) as previously re-
ported (6). The Abs for phospho-ERK1/2, phospho-JNK, and phospho-p38
were purchased from Cell Signaling Technology. Intracellular staining was
performed as previously described (6).
Proliferation assay
Lymph node cells (1  105 cells/well) were cultured in RPMI 1640 me-
dium (supplemented with 10% FCS, antibiotics, 2-ME) in U-bottom 96-
well plates (Costar) in the presence of plate-bound anti-mouse CD3 (10
g/ml, 145-2C11; BD Biosciences), anti-mouse TCR (10 g/ml, H57-
597; BD Biosciences), with Con A (2 g/ml; Calbiochem) or in the pres-
ence of 2 105 irradiated T cell-depleted splenocytes from wild-type mice
loaded with the agonist peptide NP68. Cells were pulsed with 1 Ci
[3H]thymidine per well during the last 8 h and harvested as previously
described (6).
Statistical analysis
Statistical analyses were performed using GraphPad Prism software. Mean
values  SEM are shown in each graph. Asterisks represent p-values of an
unpaired two-tailed Student’s t test.
Results
Enhanced positive selection in DKO mice
Previously, we showed that loss of SIT resulted in a partial alter-
ation of thymic selection (6), whereas the loss of TRIM had no
effect upon T cell development (7). SIT/CD4CD8 (double-
positive, DP) thymocytes expressed higher levels of CD5 and
CD69 and displayed a partial conversion from positive to negative
selection in TCR transgenic mice. To explore the possibility
whether SIT and TRIM, which appear to be structurally related,
are functionally redundant during thymocyte selection, we bred
SIT/ to TRIM/ mice to generate DKO mice. We initially
analyzed the activation markers CD5 and CD69, whose expression
was up-regulated in DP thymocytes from SIT-deficient mice (6).
As shown in Fig. 1A, CD5 and CD69 expression was notably aug-
mented on DP thymocytes lacking both SIT and TRIM when com-
pared with SIT-deficient mice. Moreover, DP cells from DKO
showed a marked up-regulation of TCR levels that was not ob-
served in either SIT/ or TRIM/ mice (Fig. 1A). Taken to-
gether, these data suggest that SIT and TRIM may compensate for
one another in lymphocyte development.
It is well established that the levels of TCR, CD5, and CD69
are strictly regulated during selection processes and that their ex-
pression reflects the intensity of the signal transduced via the TCR.
Indeed, mice lacking negative regulators of TCR-mediated signal-
ing such as c-Cbl (18) and SLAP (Src-like adaptor protein) (19)
showed up-regulation of TCR, CD5, and CD69, whereas knock-
out mice for positive regulators of intracellular signaling pathways
such as Tec-family kinases (20) or calcineurin B1 (21) show re-
duced levels of TCR, CD5, and CD69. Thus, on the basis of our
observations, it appears as if SIT and TRIM both function as neg-
ative regulators of TCR signaling strength.
Upon TCR/MHC  self peptide interaction, immature DP thy-
mocytes differentiate into mature CD4 or CD8 SP (single-pos-
itive) cells through a complex and ordered process that includes 1)
up-regulation of TCR, CD5, and CD69, 2) down-regulation of
one of the coreceptors, and 3) final commitment to either the CD4
or CD8 lineage (22–24).
To further investigate the effects of SIT and TRIM deficiency
upon T cell development, we stained thymocyte suspensions with
CD4 and CD8 mAbs. As presented in Fig. 1B, we found that DKO
mice showed a striking difference in the distribution of thymocyte
subsets in comparison to wild-type or single knockout mice. In
fact, we observed an increase in the proportion of CD4 cells
expressing low level of CD8 in DKO mice (Fig. 1B). These cells
likely represent an intermediate subset of DP thymocytes that upon
receiving a signal through the TCR is committed to the SP stage.
FIGURE 1. DKO thymocytes up-
regulate markers of positive selec-
tion. Thymocytes isolated from con-
trol, single- and double-mutant mice
were stained with Abs directed
against CD4, CD5, CD8, CD69, and
TCR and successively analyzed by
flow cytometry. A, Histograms show
expression of CD5, CD69, or TCR
on total or CD4CD8 (DP) thymo-
cytes. Expression is compared be-
tween wild-type (gray histograms)
and mutant (open histograms) mice.
B, Dot plots show CD4/CD8 staining
profiles. Numbers indicate the per-
centage of cells in each quadrant. C,
Absolute numbers of thymocyte sub-
populations of mice of each genotype
shown in B were calculated. Data de-
rive from five wild-type, three
TRIM/, six SIT/, and six DKO.
, p  0.005 and , p  0.05.
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In agreement with this assumption, we also found that DKO mice
display a 2-fold increase in the absolute number of SP thymocytes
when compared with the other genotypes (Fig. 1C). Collectively,
our data suggest that in the absence of both SIT and TRIM TCR-
mediated signaling is considerably strengthen in DP thymocytes,
resulting in a strong up-regulation of markers for positive selection
and in an augmented commitment of DP thymocytes to the SP
stage.
The number of early T cell precursors, defined by the lack of
both CD4 and CD8 expression (double-negative (DN) cells) (Fig.
1C) and the differential expression of CD25 and CD44 (data not
shown), are not affected in DKO mice. These data corroborate our
previous observation that both SIT and TRIM are dispensable dur-
ing early stages of T cell development (6, 7).
Enhanced MAPK activation in thymocytes from
SIT/TRIM/ mice
It is well established that the activation of the Ras-Raf-MEK-ERK
pathway is critical during positive selection (2). Therefore, we next
assessed whether SIT and TRIM regulate ERK activation in thy-
mocytes, by performing intracellular flow cytometric analyses us-
ing an Ab directed against the phosphorylated (and hence acti-
vated) forms of ERK1 and ERK2 (25). We analyzed DP
thymocytes expressing low CD5 levels so that ERK activation can
be solely attributed to cells that, upon TCR-MHC-self peptide en-
gagement, are initiating thymic selection and not to postselected
DP thymocytes that express CD5 at higher levels. To determine
whether the magnitude of ERK phosphorylation directly correlates
with positive selection, thymocyte suspensions prepared from mice
of each genotype were rapidly fixed in formaldehyde to preserve
the phosphorylation status of ERK. As shown in Fig. 2 and in
agreement with previous observations (26), no significant ERK
activity was detected in DP cells from wild-type or even single
mutant mice, thus indicating that relatively few thymocytes initiate
positive selection in normal mice. Conversely, we found that there
was considerably more ERK phosphorylation in DP thymocytes
from DKO mice (Fig. 2). These data show that the enhanced pos-
itive selection in DKO thymi correlate with an enhanced ex vivo
ERK phosphorylation. Importantly, we previously showed that the
more efficient positive selection/shift to negative selection ob-
served in SIT/ HY TCR transgenic female mice also correlated
with stronger ex vivo ERK activity in DP thymocytes (6). Collec-
tively, these data indicate that SIT and TRIM regulate thymic se-
lection by modulating the degree of ERK activation.
Conversion from positive to negative selection in DKO mice
Fig. 2 also shows that DKO DP thymocytes display significantly
higher levels of phosphorylated p38 and JNK when compared with
single mutant and wild-type mice. Studies performed using knock-
out mice or specific MAPK inhibitors had suggested that JNK and
p38 may be important during negative selection (2). On the basis
of these observations, higher JNK and p38 activities should result
in the conversion from positive to negative selection in DKO
thymi. This hypothesis is also supported by our previous observa-
tion that female HY TCR transgenic SIT/ mice show a partial
conversion from positive to negative selection (6).
To analyze whether loss of both SIT and TRIM resulted in an
enhanced conversion from positive to negative selection, we in-
terbred DKO mice with mice expressing transgenic TCRs. Fig. 3A
shows that the cellular pattern of positive selection in female HY
DKO mice is dramatically altered and noticeably resembles that
observed in HY TCR male mice where negative selection occurs
(Fig. 3A, upper right panel). Indeed, thymi of DKO HY TCR
transgenic female mice are completely devoid of DP cells, contain
few CD8 SP thymocytes expressing lower levels of CD8 than nor-
mal HY TCR transgenic female mice, and are comprised of almost
exclusively DN thymocytes (Fig. 3A). One result of negative se-
lection in male HY mice is the overall reduction of thymic cellu-
larity. Comparison of total cell numbers revealed another striking
similarity between DKO HY female and HY male mice. As shown
in Fig. 3B, DKO thymi are indeed markedly hypocellular like
those of male HY mice.
These results show that the concomitant deletion of SIT and
TRIM results in the complete conversion from positive to negative
selection of HY TCR thymocytes in female mice.
For some time, it was thought that elimination of autoreactive
T cells by deletion was the main pathway for the maintenance
of self-tolerance. More recent data, however, have revised this
paradigm and suggested that nondeletional pathways also con-
tribute to tolerance. For example, autoreactive T cells may es-
cape deletion by down-regulating the coreceptor (27–30). In
this way, autoreactive T cells reprogram the activation thresh-
old and become unresponsive to self Ags. Coreceptor down-
regulation has been described to take place on both thymocytes
(31, 32) and peripheral mature T cells (30, 33–35) and allows
the generation of large numbers of coreceptor low or DN pe-
ripheral T cells. The observation that CD4CD8low and
CD4CD8 TCR peripheral T cells are abundant in mice car-
rying transgenic TCRs on negatively selecting genetic back-
ground (i.e., HY TCR transgenic male mice) reinforces the idea
that coreceptor down-regulation is required to maintain toler-
ance (14, 36, 37). However, the physiological relevance of these
cells in TCR transgenic mice has been questioned due to the
premature expression of the  TCR (38).
The data shown in Fig. 3A indicate that the level of CD8 is
reduced on thymocytes from DKO HY female mice. To investigate
whether mechanisms alternative to deletion are set in motion to
reprogram the activation threshold and maintain tolerance in DKO
mice, we investigated CD8 expression levels in peripheral T cells.
Fig. 3C shows that, while HY SIT/ female mice display a partial
down-regulation of CD8, HY DKO female mice exhibit a striking
FIGURE 2. Increased MAPK activation in DKO mice. Thymocyte sus-
pensions prepared from mice of different genotypes were rapidly fixed and
stained with CD4, CD5, and CD8 mAbs and with Abs directed against the
phosphorylated forms of ERK1/2, JNK/SAPK (stress-activated protein ki-
nase), and p38 MAPKs. CD5 expression on CD4CD8 thymocytes is
shown. Preselection thymocytes expressing low levels of CD5 were gated
as indicated (left panels) and the intracellular levels of activated ERK1/2,
JNK/SAPK, and p38 are shown (right panels). Open histograms represent
cells stained with the secondary Ab alone. Numbers indicate the percentage
of cells in each gate.
5932 REGULATION OF THYMIC SELECTION BY SIT AND TRIM
down-regulation that is even more pronounced than that seen in
male HY mice (Fig. 3C, compare lower left and upper right dot
plots), and DKO females also accumulate large numbers of T3.70
DN cells (Fig. 3D). These data are in agreement with our recent
observation demonstrating that the loss of SIT markedly enhanced
the homeostatic expansion of peripheral T3.70 T cells from HY
transgenic female mice (39).
Thus, the loss of both SIT and TRIM lowers the signaling
threshold in T cells and results in a massive deletion of DP cells in
the thymus. Therefore, T3.70 T cells reprogram their activation
FIGURE 3. Positive selection is completely converted to negative selection in HY DKO female mice. A, Dot plots show CD4/CD8 staining profiles of
T3.70-gated thymocytes from wild-type, single-mutant, double-mutant female HY TCR transgenic mice (left) or male HY TCR transgenic mice (right).
One representative mouse of a minimum of five animals per group is shown. Numbers within the quadrants indicate the percentage of cells. The proportion
of T3.70 cells in total thymocytes is indicated to the right of the dot plot profiles. B, Thymocyte cell numbers from the HY TCR transgenic and mutant
mice shown in A. C, Two-color dot plots show CD4/CD8 staining on T3.70-gated lymph node cells. Numbers indicate the percentage of cells in that
quadrant. Histograms depict the expression of CD8 on T3.70-gated lymph nodes cells in wild-type (gray histograms) and mutant (open histograms) mice.
D, Absolute numbers of T3.70 T cells in lymph nodes were calculated. Data shown in B and D derive from at least four mice of each genotype. , p 
0.0002 and , p  0.009.
Table I. Thymocyte subsets in TCR transgenic micea
Genotypes
V2 V2 V2high
No. of
Mice CD4CD8
CD4
CD8
CD4
CD8
CD4
CD8
CD4
CD8
CD4
CD8
CD4
CD8
CD4
CD8
CD4
CD8
CD4
CD8
CD4
CD8
P14 4 1.06  0.2 13.2  1.6 0.6  0.1 0.4  0.05 1.5  0.2 34.7  4.3 0.2  0.04 7.9  1.2 5.9  0.7 0.1  0.01 5.6  0.8
P14 TRIM/ 4 1.15  0.2 13.2  1.2 0.7  0.1 0.4  0.02 1.2  0.2 32.3  2.1 0.2  0.02 7.3  1.3 6.1  1.8 0.1  0.03 4.8  1.5
P14 SIT/ 4 1.52  0.3 17.2  1.1 0.9  0.1 0.9  0.2 1.9  0.2 22.9  0.7 0.3  0.01 5.4  0.9 2.0  0.2 0.1  0.01 2.3  0.1
P14 DKO 4 1.81  0.3 15.8  2.2 1.6  0.2 1.0  0.3 2.0  0.9 16.5  1.1 1.3  0.3 5.1  0.4 1.3  0.04 0.4  0.05 1.1  0.2
p-values P14/
P14 DKO
NS NS 0.02 NS NS 0.007 0.02 0.02 0.0006 0.003 0.007
p-values P14
SIT//P14
DKO
NS NS NS NS NS 0.003 0.02 NS 0.04 0.002 0.008
OT-I 4 1.02  0.4 14.1  4.0 0.9  0.2 0.8  0.2 1.3  0.3 23.5  3.2 7.5  1.7 6.9  0.8 3.0  0.5 1.7  0.6 3.9  0.6
OT-I TRIM/ 4 1.34  0.4 18.2  5.1 1.1  0.3 1.1  0.2 1.2  0.3 22.7  1.8 7.4  1.7 7.2  0.6 2.1  0.2 1.8  0.1 4.2  0.6
OT-I SIT/ 6 1.55  0.8 20.1  5.2 1.1  0.7 1.0  0.7 1.5  0.7 19.4  2.7 6.6  2.6 5.7  1.1 1.6  0.2 1.6  0.2 2.2  0.1
OT-I DKO 8 1.8  0.4 19.5  4.3 1.2  0.2 1.5  0.2 1.5  0.3 10.1  2.5 4.2  1.6 1.9  0.5 0.3  0.07 0.8  0.4 0.5  0.1
p-values OT-I/
OT-I DKO
NS NS NS NS NS 0.02 0.04 0.001 0.0005 0.02 0.0001
p-values OT-I
SIT//OT-I
DKO
NS NS NS NS NS 0.02 NS 0.02 0.0006 0.02 0.0001
a All numbers are shown as  106  SEM. Statistically significant p-values are indicated.
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FIGURE 4. Partial conversion from positive to negative selection in P14 and OT-I DKO mice. Comparison of thymocytes and lymph node T cells from
wild-type, single-mutant, or SIT and TRIM double-mutant mice expressing the P14 (A–F) or the OT-I (G–L) TCRs. A and G, Histograms show expression
of the TCR transgenic -chain (V2). The gates defining V2, V2, and V2high expressing thymocytes are indicated. The number of total thymocytes
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threshold by down-regulating CD8 expression in response to a
persistent strong signal.
To further corroborate the effects of SIT and TRIM on pos-
itive selection, we used two additional TCR transgenic models
expressing either the P14 or OT-I TCRs (Fig. 4). Previously, we
showed that TRIM deficiency did not affect selection processes
in either P14 or OT-I TCR transgenic thymocytes (7), whereas
the loss of SIT modestly affected positive selection only in the
P14 TCR transgenic mice (6). In agreement with our previous
observations (6), the results in Fig. 4, A and E, show that P14
SIT/ mice show a modest reduction in the number of total
V2 and positively selected V2high thymocytes. Remark-
ably, DKO mice display a stronger decrease in the proportion
and absolute numbers of thymocytes expressing the transgenic
TCR-chain (Fig. 4, A and E). In contrast, the number of non-
transgenic V2 thymocytes are not decreased but rather
slightly increased, indicating that these cells may undergo ex-
pansion upon deletion of transgenic thymocytes. The decrease
in the total number of clonotypic TCR thymocytes appears to
be due to a reduction of both DP and CD8 SP thymocytes (Fig.
4B and Table I), thus indicating that, similar to the HY TCR
transgenic model, positive selection is likely converted to neg-
ative selection in the absence of SIT and TRIM also in the P14
system. To further corroborate this hypothesis is the observa-
tion that thymocytes from DKO mice are hyperactivated as they
up-regulate both CD5 and CD69 (Fig. 4C). In agreement with
an altered positive selection, the number of peripheral mature
V2 T cells in lymph nodes of DKO mice are also markedly
reduced in comparison to control or SIT-deficient mice (Fig. 4,
D and F). These data suggest that the loss of SIT and TRIM
results in an enhanced TCR-mediated signaling that converts
positive to negative selection.
Subsequently, we confirmed these results and analyzed selection
processes in the OT-I transgenic mice. The data presented in Fig.
4G–L demonstrate that loss of SIT and TRIM severely affects pos-
itive selection also in this TCR transgenic model. Indeed, DKO
from one representative mouse is indicated to the right of the histograms. B and H, Two-color dot plots show CD4/CD8 staining gated on V2 and on
V2high thymocytes. Numbers below the gates in A and G or within the quadrants in B and H indicate the percentage of cells. C and I, Histograms show
expression of CD5 and CD69 on V2-gated DP cells. Expression is compared between wild-type (gray histograms) and mutant (open histograms) mice.
D and J, Two-color dot plots show CD4/CD8 staining on clonotype-TCR (V2)-gated lymph node cells. Numbers indicate the percentage of cells in
that quadrant. Histograms depict the expression of CD8 on V2-gated lymph nodes cells in wild-type (gray histograms) and mutant (open histograms)
mice. E and K, Absolute numbers of total thymocytes or thymocyte subsets shown in histograms in A and G were calculated. F and L, Absolute numbers
of V2CD8 T cells in lymph nodes were calculated. Data shown derive from at least four mice per group. , p  0.0005; , p  0.005; , p  0.05.
FIGURE 5. Efficient positive selection of F5 TCR transgenic T cells by low avidity TCR-MHC interactions in DKO mice. A, Cell suspensions from
thymus were stained with CD4, CD8, CD5, and CD69 mAbs. Dot plots show CD4 and CD8 expression on thymocytes. Numbers in outlined areas represent
percentage of cells. One representative mouse of at least five animals per group is shown. Histograms show the expression of CD5 and CD69 on DP
thymocytes from wild-type mice (gray filled histograms) and mutant mice (solid lines). B, Absolute numbers of thymocyte subsets shown in A were
calculated. Data derive from five mice of the indicated genotype. , p  0.0096 and , p  0.014. C, Expression of CD4 and CD8 on lymph node cells.
Numbers within the quadrants indicate the percentage of cells. D and E, Lymph node cells isolated from mice of each indicated genotype were stimulated
with immobilized CD3 and TCR mAbs or ConA (D) or in the presence of irradiated APCs pulsed with increasing amount of NP68 peptide (E). Data shown
in D derive from three mice, whereas those presented in E derive from six mice of each genotype.
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mice showed an enhanced TCR-mediated signaling in DP cells, as
suggested by the higher levels of CD5 and CD69 expression (Fig.
4I), a marked decrease in the number of total thymocytes, total
transgenic V2 cells, and positively selected V2high thymocytes
(Fig. 4, G and K). Moreover, DP and CD8 SP thymocytes are also
markedly depleted in DKO mice (Fig. 4H and Table I). Finally, a
reduction in mature V2high lymph node CD8 T cells is also
observed in DKO mice (Fig. 4, J and L). In agreement with our
previous observations (6), the loss of SIT had only minimal affects
upon positive selection. In fact, the total number of positively se-
lected V2high thymocytes and peripheral CD8 T cells as well as
CD5 and CD69 expression are grossly unchanged in SIT/ mice.
Interestingly, both P14 and OT-I DKO mice down-regulate the
CD8 coreceptor on peripheral TCR cells (Fig. 4, D and J, right
panels). Thus, in the absence of SIT and TRIM, CD8 T cells
from TCR transgenic mice receive constantly stronger signals via
the TCR that trigger coreceptor down-regulation.
Collectively, the data obtained from three different class I-re-
stricted TCR transgenic lines suggest that the loss of SIT and
TRIM enhances TCR-mediated signaling and converts positive
into negative selection.
Conversely, when we investigated the MHC class II-restricted
OT-II TCR transgenic model we did not observe any effect on
positive selection (data not shown).
Finally, we investigated whether SIT and TRIM also affect neg-
ative selection. However, we found no differences in the CD4/CD8
profile or total cellularity of DKO thymocytes from male HY TCR
transgenic mice (data not shown). Moreover, in vitro CD3-medi-
ated deletion of DKO DP cells was normal (data not shown), thus
suggesting that SIT and TRIM do not regulate negative selection
or thymocyte survival.
In summary, these data demonstrate that SIT and TRIM coop-
eratively set the TCR signaling threshold for positive selection.
DKO thymocytes are efficiently positively selected by low avidity
TCR-MHC interactions
The data above indicate that SIT and TRIM are critical regulators
of T cell development. In all models tested, we found that positive
selection is either enhanced or converted to negative selection. The
enhanced MAPK activation, together with the up-regulation of
CD5 and CD69, is consistent with the idea that TCR-mediated
signaling is stronger in DKO mice. Therefore, we next investigated
whether the loss of SIT and TRIM enables positive selection of T
cells under experimental conditions in which TCR avidity is ab-
rogated and, thus, positive selection should not occur. As a model
system, we used 2m-deficient/RAG1-deficient mice expressing
the class I-restricted F5 transgenic TCR (F5/2m0/RAG10) (17). In
these mice, T cell development is blocked at the DP stage and
thymic selection does not occur, as class I MHC heavy chains are
expressed at extremely low levels.
To evaluate whether the loss of SIT and TRIM may alter cell
fate by diverting thymocytes from nonselection to positive selec-
tion, DKO mice were bred onto F5/2m0/RAG10 mice. As shown
in Fig. 5A, neither the loss of SIT or TRIM alone induced the
generation of mature SP thymocytes. Indeed, the CD4/CD8 pro-
files of single knockout mice resemble those of control F5/2m0/
RAG10 mice. Strikingly, however, significant numbers of CD8
SP thymocytes were found in F5/2m0/RAG10 mice lacking both
SIT and TRIM (Fig. 5, A and B). Analysis of the CD5 and CD69
expression levels (Fig. 5A) indicated that positive selection in
DKO mice is likely initiated by TCR-mediated signaling, as the
expression of both molecules is induced on DP thymocytes from
DKO mice. Even more surprisingly, we also detected mature
CD8 T cells in peripheral secondary lymphoid organs of DKO/
F5/2m0/RAG10 mice (Fig. 5C). However, the efficiency of pos-
itive selection remained very low, with 10% of the number of
CD8 T cells recovered from the lymph nodes from DKO/F5/
2m
0/RAG10 mice (0.244  106  0.021  106; n  3 mice) as
compared with F5/2m//RAG1/ mice (3.610  106 
0.215  106; n  3 mice).
Therefore, it appears that the loss of SIT and TRIM likely low-
ers the TCR-mediated signaling threshold for positive selection,
thereby enabling the maturation of T cells by TCR/low-avidity
ligand-driven signals.
To test whether the loss of SIT and TRIM might have resulted
in the spontaneous development of T cells in a TCR-independent
manner, we investigated DKO RAG-deficient mice. RAG10 and
DKO/RAG10 mice both displayed a developmental block at the
DN3 stage (data not shown), thus reinforcing the idea that the loss
of SIT and TRIM alone does not result in the autonomous matu-
ration of T cells.
FIGURE 6. Model of thymic selection outcomes. The proposed model (summarizing our data and previously published data (Refs. 41–43) shows the
effects of augmenting or diminishing signal intensity on the selection of thymocytes expressing a variety of TCRs with increasing affinity/avidity for the
ligand. The effects of SIT (black dotted line) or SIT and TRIM (black dashed line) deletions on selection outcomes are compared with those obtained by
TCR- mutants carrying only 1 ITAM (gray dotted line) or no ITAMs (gray dashed line).
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Unexpectedly, DKO/F5/2m0/RAG10 mice displayed CD4 SP
thymocytes (Fig. 5A) and peripheral CD4 T cells (Fig. 5C). In-
terestingly, also DKO mice expressing the MHC class I-restricted
P14 TCR showed an increase in the number of V2CD4 SP
thymocytes (Fig. 4B and Table I). Therefore, it is likely that the
loss of SIT and TRIM also alters T cell lineage commitment, as the
quantity of TCR-mediated signals not only influences selection
processes, but also lineage commitment (40).
Having shown that DKO/F5/2m0/RAG10 mice develop periph-
eral T cells, we next determined whether these T cells were also
functional. Initially, total lymph node cells from wild-type
C57BL6/J and DKO/F5/2m0/RAG10 mice were stimulated in the
presence of plate-bound CD3 and TCR mAbs or Con A. As
shown in Fig. 5D, DKO/F5/2m0/RAG10 cells robustly responded
to all mitogenic stimuli. Finally, to determine whether DKO/F5/
2m
0/RAG10 T cells specifically responded to the F5 TCR cognate
peptide, lymph node cells from mice of each genotype were stim-
ulated with irradiated APCs loaded with increasing amount of the
influenza virus peptide NP68. Fig. 5E shows that only lymph node
cells from DKO/F5/2m0/RAG10 and from F5/2m//RAG1/
control mice responded to the NP68 agonist peptide in a dose-
dependent manner. Collectively, our data demonstrate that DKO
F5 TCR transgenic T cells positively selected on a 2m-deficient
genetic background are functional. In summary, these results dem-
onstrate a unique joint role for SIT and TRIM as inhibitory TRAPs
that lower TCR signals, thereby directly influencing the fate of
developing thymocytes.
Discussion
To date, with the exception of LAT, deletion of any other known
transmembrane adaptors has had negligible effects on thymocyte de-
velopment. By showing that the two related transmembrane adaptor
proteins SIT and TRIM together regulate thymic selection, we re-
vealed important insights into the role of TRAPs in T cell develop-
ment and in the establishment of central tolerance. We propose that
SIT and TRIM function as suppressors of signal amplification and
regulate thymic selection by modulating the degree of MAPK acti-
vation. Furthermore, our data also show that SIT and TRIM function
in a cooperative manner, thus indicating that TRAPs may represent a
group of molecules with overlapping functions.
As summarized in Fig. 6, our data are consistent with the signaling
threshold model for thymocyte selection (41). This model postulates
that the TCR affinity/avidity for the selecting ligand is in a direct
relationship with the strength of the TCR-mediated signaling and, in
turn, with the outcome of selection. Therefore, the outcome of selec-
tion of thymocytes expressing a specific TCR can be influenced by
increasing or decreasing the TCR signal potential. Indeed, as pre-
dicted by the signaling threshold model, our data show that in a TCR
transgenic system where the avidity for the selecting ligand is thought
to be extremely low (such as in the F5/2m0/RAG10 system), the loss
of SIT and TRIM converts nonselection into positive selection (Fig.
6). Despite the fact that loss of SIT alone is not sufficient to induce the
shift into positive selection, DP thymocytes from SIT//F5/2m0/
RAG10 mice displayed enhanced CD5 levels. This observation sug-
gests that also in SIT//F5/2m0/RAG10 mice the TCR-mediated
signaling strength is potentiated, as CD5 expression is directly regu-
lated by TCR signal intensity (24). When we tested transgenic mice
expressing a TCR with a weak ligand avidity (i.e., HY), where pos-
itive selection occurs inefficiently, the loss of SIT alone is sufficient to
induce a more efficient positive selection and a partial shift to negative
selection (6), whereas the loss of both SIT and TRIM results in a
complete conversion to negative selection (Fig. 6). Positive selection
of thymocytes expressing a TCR with a higher affinity for its selecting
ligand than HY (i.e., P14) is partially converted to negative selection
by the loss of SIT alone, and the additional deletion of TRIM further
enhances the shift to negative selection (Fig. 6). Regardless of the
outcome of selection (i.e., efficient positive selection such as in OT-I
TCR transgenic mice or negative selection such as in male HY TCR
transgenic mice), over a certain level of avidity and TCR signaling
strength, SIT seems to be dispensable during selection processes and
the further deletion of TRIM converts efficient positive selection into
negative selection only in OT-I TCR transgenic mice (Fig. 6).
Models based on signal strength postulate that negative, positive,
and nonselection lie on a continuum of signals emanating from the
TCR and that amplification of the signals at a very proximal level
determines the right signal intensity for the specific developmental
outcome (40). Our data strongly support this idea and further suggest
that SIT and TRIM both function as suppressors of signal amplifica-
tion. Therefore, it is likely that they are located at the very apical part
of the TCR signaling cascade. Interestingly, the effects of SIT/TRIM
double deficiency on thymocyte development are opposite to those
observed in mice carrying mutations in the TCR-associated -chain, a
well-known amplifier of TCR-mediated signaling. Indeed, reduction
of TCR signal potential by substituting the number of ITAMs within
TCR- or by knocking out TCR- resulted in a shift from negative to
positive selection or even converted positive into nonselection (Fig. 6)
(41–44).
In light of these observations, it appears that thymocytes are pro-
vided with signaling components such as the TCR -chain or TRAPs
such as SIT and TRIM that possess opposing regulatory functions.
Therefore, signal amplification by multiple ITAMs within the TCR/
CD3 complex appears to be counterregulated by an inhibitory system
based on several TBSMs within transmembrane adaptors. In fact, in
analogy with the effects of an incremental reduction in the number of
TCR- ITAMs, our data suggest that also the sequential deletion of
TRAPs gradually affects selection processes. It appears that the co-
ordinated integration of the regulatory activity of multiple positive
and negative signaling motifs within membrane-associated proteins is
required for shaping the T cell repertoire. As this regulatory system
appears to be crucial for cell fate specifications in the thymus, it is not
surprising that the molecules controlling the process are physically
located at the plasma membrane as a part of, or in close proximity to,
the receptor. In fact, we have shown that TRIM is an integral com-
ponent of the TCR/CD3 complex (8, 45), whereas SIT was identified
as a protein co-immunoprecipitating with CD3 (9).
Surprisingly, such an elaborated system for fine-tuning TCR-
mediated signals does not seem to play a role during peripheral T
cell activation, as mutations in the number of TCR- ITAMs (41,
42) or loss of SIT and TRIM (data not shown) only minimally
affect activation of mature T cells. These observations indicate that
other regulatory mechanisms, such as those mediated by costimu-
latory molecules, are required to adjust peripheral T cell responses.
The mechanism by which SIT and TRIM regulate signaling thresh-
old remains elusive. A major obstacle encountered in elucidating this
question is the development of compensatory mechanisms in mutant
mice. Indeed, we showed that thymocytes from both SIT/ (6, 39)
and DKO mice overexpress CD5, a negative regulator that dampens
TCR-mediated signaling (24, 46–48). Changes in the level of CD5
expression is the best known example of TCR signaling tuning and
hence may indicate sensory adaptation (27, 49). It is thought that CD5
expression is regulated to modulate the activation threshold in re-
sponse to an altered signaling strength. In fact, cells that express a
high level of CD5 display a parallel lowered responsiveness to TCR
triggering (39, 47, 49). In addition to upregulating CD5, modulation
of T cell responsiveness can be also achieved by down-regulating the
CD8 coreceptor (29). Interestingly, T cells from SIT-deficient (39)
and DKO mice also down-regulate CD8. Thus, the loss of SIT and
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TRIM resulted in the development of sensory adaptation by up-reg-
ulating CD5 and down-regulating CD8.
In accordance with these observations, it is therefore not surprising
that we did not observe an enhanced TCR-mediated signaling when
DP thymocytes from DKO mice were stimulated with CD3 Ab in
vitro (data not shown). It is likely that, in these cells, the enhanced
TCR-mediated signaling caused by the loss of SIT and TRIM is coun-
terbalanced by CD5 overexpression or perhaps even by other negative
regulatory molecules. The generation of additional mouse model such
as SIT//TRIM//CD5/ triple knockouts is required to inves-
tigate how SIT and TRIM modulate TCR-mediated signaling when
the counterbalancing effects of CD5 are no longer present.
Recent observations from our laboratory suggest that SIT and
TRIM may act in concert to regulate PI3K activation. Indeed, we
found that, under particular conditions of TCR stimulation, SIT/ T
cells showed enhanced Akt phosphorylation, a measure of PI3K ac-
tivation (B. Schraven and L. Simeoni unpublished results). We have
previously shown that also T cells from TRIM/ mice displayed
enhanced Akt phosphorylation upon TCR triggering (7). It appears
that by binding the p85 regulatory subunit of PI3K, TRIM could in-
hibit PI3K activation, thus sequestering p85 outside of the lipid rafts.
However, how SIT regulates PI3K remains as yet unknown. In fact,
conversely to TRIM, SIT does not bind p85 directly. We suggest that
SIT could regulate Gab association with p85 by controlling Gab phos-
phorylation via the tyrosine phosphatase SHP-2 (50). Interestingly,
we have recently shown that SIT also shares redundant function with
the third non-raft transmembrane adaptor protein LAX (linker for ac-
tivation of X cells) in B1 cells and T lymphocytes (our unpublished
results). Similarly to TRIM, LAX binds the p85 regulatory subunit of
PI3K and the loss of LAX also resulted in an enhanced Akt phos-
phorylation in B and T lymphocytes (51). Based upon these data, we
speculate that the non-raft adaptors SIT, TRIM, and LAX may func-
tionally converge to regulate PI3K activation (52). Whereas SIT and
TRIM appear to play a major role in thymocyte development, SIT
and LAX seem to regulate B1 cell development, T cell activation, and
autoimmunity. In conclusion, our studies have begun to shed light
onto the redundant function of the non-raft adaptors in lymphocyte
development and activation. Additional efforts are now required to
reveal how these molecules regulate Ag receptor-mediated signaling
in concert.
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Introduction
T cells exert their effector function in peripheral tissues
where they contribute to the control of viral or bacterial
pathogens.1 A balanced control of immune responses
within peripheral tissues, however, is necessary to avoid
over-reactive immunity that may lead to tissue damage
and loss of organ function. Likewise, sufficient strength of
immunity has to be maintained to contain and eliminate
infectious micro-organisms. To control inflammatory
reactions in peripheral tissues numerous endogenous
anti-inflammatory factors have been described, such as
lipocortin-1,2 lipoxins3 and protectins.4 Extracellular
adenosine is a further well-described inflammatory modu-
lator of immune responses. Inflamed and damaged tissues
are characterized by high extracellular adenosine levels
induced by disruption of the local microcirculation and
subsequent onset of hypoxia.5 Hypoxia induces intracellu-
lar adenosine triphosphate (ATP) degradation, leading to
an increase in adenosine-50-monophosphate (AMP) and
adenosine concentrations in cells.6 The accumulation of
intracellular adenosine is further increased by hypoxia-
induced inhibition of adenosine kinase.7 Accumulated
adenosine is then released into the extracellular space.8
Additionally, a hypoxia-induced increase in the expres-
sion of the membrane-bound enzymes ecto-nucleoside tri-
phosphate diphosphohydrolase (NTPDase1, apyrase,
CD39) and ecto-50-nucleotidase (CD73) leads to dephos-
phorylation of adenine nucleotides to adenosine,9,10 which
further increases the extracellular adenosine concentration.
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Summary
Adenosine is a well-described anti-inflammatory modulator of immune
responses within peripheral tissues. Extracellular adenosine accumulates
in inflamed and damaged tissues and inhibits the effector functions of
various immune cell populations, including CD8 T cells. However, it
remains unclear whether extracellular adenosine also regulates the initial
activation of naı¨ve CD8 T cells by professional and semi-professional anti-
gen-presenting cells, which determines their differentiation into effector
or tolerant CD8 T cells, respectively. We show that adenosine inhibited
the initial activation of murine naı¨ve CD8 T cells after aCD3/CD28-medi-
ated stimulation. Adenosine caused inhibition of activation, cytokine pro-
duction, metabolic activity, proliferation and ultimately effector
differentiation of naı¨ve CD8 T cells. Remarkably, adenosine interfered effi-
ciently with CD8 T-cell priming by professional antigen-presenting cells
(dendritic cells) and semi-professional antigen-presenting cells (liver sinu-
soidal endothelial cells). Further analysis of the underlying mechanisms
demonstrated that adenosine prevented rapid tyrosine phosphorylation of
the key kinase ZAP-70 as well as Akt and ERK1/2 in naı¨ve aCD3/CD28-
stimulated CD8 cells. Consequently, aCD3/CD28-induced calcium-influx
into CD8 cells was reduced by exposure to adenosine. Our results support
the notion that extracellular adenosine controls membrane-proximal
T-cell receptor signalling and thereby also differentiation of naı¨ve CD8 T
cells. These data raise the possibility that extracellular adenosine has a
physiological role in the regulation of CD8 T-cell priming and
differentiation in peripheral organs.
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Adenosine itself protects tissues against damage
through different mechanisms initiated by inflam-
mation.11,12 It stimulates anti-inflammatory signalling
pathways, such as activation of cyclo-oxygenase-2 (COX-
2).13,14 A direct adenosine-mediated interference with
immune reactions in the tissue occurs by activation of
adenosine receptors on various immune cells. Among the
family of adenosine receptors, the importance of the
adenosine A2A receptor for the regulation of T cells has
been recognized as most important. Various T-cell recep-
tor (TCR) controlled effector functions are regulated by
adenosine.15–17 Based on these findings Sitkovsky and
Ohta postulated a so-called ‘2-Danger-signal’ model.18
They suggested that a first signal indicates danger caused
by the presence of pathogens and leads to the activation
of immune cells and thereby evokes defensive effector
functions. A second signal, i.e. adenosine, indicates dan-
ger from overactive immune responses and triggers
down-regulation of pro-inflammatory activities of the
immune system to prevent excessive collateral damage
and destruction of normal tissues. These reports clearly
illustrated the potent activity of adenosine to restrain the
effector function of activated T cells.
It was recently reported that naı¨ve T cells migrate
through non-lymphoid organs19 and that priming of
CD8 and CD4 T-cell responses can occur outside the
secondary lymphatic tissue by professional and non-
professional antigen-presenting cells (APC).20,21 Although
extensive investigations on the regulation of effector or
memory T-cell functions by adenosine have been pub-
lished,16,17,22 so far no clear characterization of the
direct effect of adenosine on naı¨ve murine CD8 T cells
has been reported. Therefore, we characterized the influ-
ence of adenosine on naı¨ve CD8 T-cell priming and
further elucidated the molecular mechanisms underlying
adenosine-induced inhibition of TCR-triggered T-cell
activation.
Materials and methods
Mice and reagents
All animal experiments were performed in accordance
with German law regarding the protection of animals and
complied with institution guidelines and the principles of
laboratory animal care (NIH publication 86-23, revised
1985). C57BL/6 mice were purchased from Elevage
Janvier (Strasbourg, France). H2-KbSIINFEKL-restricted
TCR-transgenic animals (OT-I), and H2-Kb-restricted
DesTCR mice (recognizing three endogenous peptides
derived from C57BL/6 background) were bred under spe-
cific pathogen-free conditions to the FELASA guidelines
in the central animal facility of the University Hospital
Bonn. OT-I mice were injected with 300 lg aNK1.1 anti-
body (clone PK136) 2 days before killing.
Antibodies for flow cytometry and enzyme-linked
immunosorbent assay (ELISA) were purchased from BD
Bioscience (Heidelberg, Germany) or eBioscience (San
Diego, CA). aKi67 antibody was kindly provided by Dr
Elmar Endl (University Hospital, Bonn, Germany). Phos-
pho-specific antibodies for Western blot analysis were
obtained from Cell Signaling (Danvers, MA) and anti-
b-actin antibody from Sigma (Deisenhofen, Germany).
Adenosine, dibutyryl-cAMP and Hoechst-33258 were pur-
chased from Sigma. 6-NBDG, Fluo-4, carboxyfluorescein
succinimidyl ester (CFSE), aCD3/CD28 beads and iono-
mycin were obtained from Invitrogen (Karlsruhe,
Germany). Streptavidin was bought at Dianova (Ham-
burg, Germany) and antibody-coated beads for magnetic
cell separation were obtained from Miltenyi Biotec (Berg-
isch Gladbach, Germany). CGS21680 was provided by
C. Mu¨ller (Bonn). The cAMP ELISA was purchased from
R&D Systems, Minneapolis, MN and used according to
the manufacturer’s protocol.
Cell isolation
Highly pure liver sinusoidal endothelial cell (LSEC) isola-
tion has been described by our group previously.20 For
separation of splenic DC, spleens were digested with
005% collagenase solution and CD11c+ cells were
isolated by immunomagnetic separation with aCD11c-
labelled magnetic antibody cell sorting (MACS)
microbeads. Splenic CD8 T cells were isolated by positive
(aCD8 MACS beads) or negative selection.
Flow cytometry
Between 1 · 103 and 1 · 106 cells were stained with spe-
cific antibodies and 10 lg/ml Fc-Block (clone 2.4G2) for
15 min on ice. For staining of intracellular antigens cells
were fixed with 4% [weight/volume (w/v)] paraformalde-
hyde in phosphate-buffered saline (PBS) for 10 min at
room temperature. Afterwards cells were permeabilized
with 05% (w/v) saponin in PBS for 15 min on ice, fol-
lowed by 30 min incubation with antibody on ice and
then analysed. Dead cells were excluded by Hoechst-
33258 staining and total cell numbers were calculated
using fluorescent labelled microbeads (BD Bioscience) as
follows: (beadstotal · cellssample)/beadssample. Acquisition
and analysis was conducted with fluorescence-activated
cell sorting CantoII (BD Bioscience) and FLOWJO software
(Tree Star Inc, Ashland, OR). For analysis of T-cell prolif-
eration, naı¨ve freshly isolated CD8 T cells were labelled
for 20 min with CFSE (1 lM) (Invitrogen) and washed
twice with PBS. After 3 days, proliferation was assessed by
flow cytometric analysis of CFSE dilution in Hoechst-
33258negative CD8 cells. Cell division index, which indi-
cates the average number of cell divisions undergone by
the responding T cells, was calculated from Hoechstnegative
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CFSE+ CD8 cells using FLOWJO software according to the
manufacturer’s protocol.
Analysis of glucose metabolism activity
After staining of 106 T cells/ml with Hoechst-33258 a base-
line was recorded for 10 seconds with a flow cytometer,
30 lM 6-NBDG was added and fluorescence was measured
for a further 60 seconds. aCD3/CD28-stimulated CD8 T
cells were activated for 24 hr, living cells were regained with
gradient centrifugation (LSM 1077 Lymphocyte; PAA, Pas-
ching, Germany) and 1 · 105 cells were seeded without
stimulation in 96-well plate in RPMI-1640 medium con-
taining 05% (w/v) bovine serum albumin over night. Sub-
sequently, the supernatant was analysed for lactate levels
with a ‘Lac’ reaction kit (Randox Laboratories, Antrim,
UK) according to the manufacturer’s guideline.
Western blot analysis
Negatively selected OT-I/RAG)/) CD8 T cells were incu-
bated with biotinylated aCD3/CD28 antibodies and cells
were activated with 40 lg/ml streptavidin, either alone or
after 5 min, before incubation with 1 mM adenosine. The
reaction was stopped by adding protein sample buffer
[058 M sucrose, 4% (w/v) sodium dodecyl sulphate,
004% (v/v) bromphenol blue, 625 mM Tris–HCl pH
68]. Equal amounts of protein were used for sodium
dodecyl sulphate–polyacrylamide gel electrophoresis (SE
600 Ruby; Amersham Biosciences, Piscataway, NJ).
Proteins were blotted on a polyvinlyidene difluoride
membrane (Hybond P; Amersham Biosciences) with
a semi-dry transfer unit (TE77 ECL; Amersham
Biosciences) and protein phosphorylation was detected
with phospho-specific antibodies and horseradish peroxi-
dase-conjugated secondary antibodies (Santa Cruz
Biotechnology Inc, Santa Cruz, CA). Blots were developed
using a chemiluminescent detection kit (AppliChem,
Darmstadt, Germany).
Determination of calcium influx
Negatively selected CD8 T cells were incubated for
45 min at 37 with phenol-red free RPMI-1640 medium
containing 10% (v/v) fetal bovine serum and 35 lM
Fluo-4 dye. Cells were washed twice and again incubated
for 45 min at 37 with phenol-red-free RPMI-1640 med-
ium/10% (v/v) fetal bovine serum. T cells were incubated
with biotinylated aCD3/CD28 antibodies for 15 min on
ice, washed and baseline fluorescence was recorded. Acti-
vation was initiated by adding 40 lg/ml streptavidin
immediately or after pretreatment with 1 mM adenosine.
Afterwards, fluorescence intensity was recorded for a fur-
ther 390 seconds. Control stimulation was performed
with 15 lM ionomycin for each sample.
Statistics
Data are shown as mean ± standard error of the mean
(SEM). For statistical analysis a Student’s t-test was used.
P-values < 005 were considered significant.
Results
Adenosine inhibits aCD3/CD28-induced activation of
naı¨ve CD8 T cells
As adenosine is known to modulate the function of vari-
ous immune cell populations, we used aCD3/CD28-
coated microbeads as ‘artificial’ APC to unequivocally
investigate the effects of extracellular adenosine on activa-
tion of naı¨ve CD8 T cells. Increased expression of activa-
tion markers, such as CD25 and CD44, within 24 hr after
aCD3/CD28 stimulation was prevented by incubation of
naı¨ve CD8 T cells with adenosine at high (1 mM) but not
at low (01 mM) concentrations (Fig. 1a). As cytokine
production is crucial for CD8 T-cell activation, expansion
and differentiation we next examined whether adenosine
influenced interleukin-2 (IL-2) and interferon-c (IFN-c)
expression. T-cell activation in the presence of 1 mM
adenosine was followed by the absence of detectable IL-2-
release (Fig. 1b) and by a dramatic reduction in IFN-
c-producing T cells (Fig. 1c). Typically, T-cell activation
is accompanied by increased metabolic function.23 We
observed that naı¨ve CD8 T cells activated in the presence
of adenosine showed a reduced increase in cell size com-
pared with untreated T cells (Fig. 1d) or naı¨ve T cells
(data not shown). Furthermore, adenosine-exposed T cells
also showed reduced glucose uptake and undetectable lev-
els of lactate production over the following 24 hr
(Fig. 1e,f), indicating that adenosine markedly influenced
metabolic activity. It is important to mention that adeno-
sine was removed before glucose uptake or lactate
production by T cells was determined.
We analysed the influence of adenosine on consecutive
events such as proliferation and expansion of T cells. A
complete inhibition of T-cell proliferation after 48 hr in
the presence of 1 mM adenosine during the initial aCD3/
CD28-stimulation was observed (Fig. 2a). As expected the
loss of proliferation correlated with a decreased percent-
age of divided cells as well as a reduced number of cell
divisions and total cell numbers (Fig. 2b). To elucidate
whether adenosine-induced inhibition of T-cell prolifera-
tion was caused by inhibition of entry into the cell cycle
or by blockade within the cell cycle, we determined the
intracellular levels of Ki67 in aCD3/CD28-stimulated
CD8 T cells. We observed a remarkable reduction in the
percentage of Ki67-positive T cells after activation in the
presence of adenosine (Fig. 2c). Therefore we concluded
that T cells did not enter the cell cycle. Inhibition of
T-cell proliferation depended on the continuous presence
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of high concentrations of adenosine, because T cells
regained the capacity to proliferate at later time-points if
adenosine was not further supplemented (data not
shown). The striking reduction in the absolute number of
living cells in the presence of adenosine after 48 hr com-
pared with the number initially added into the culture is
probably related to increased apoptotic cell death. The
induction of apoptosis is a known feature of various
nucleosides including adenosine24 and was also observed
in our experiments (data not shown).
To analyse the impact of adenosine on T-cell differenti-
ation we restimulated adenosine-exposed T cells after
72 hr of aCD3/CD28 stimulation. Notably, equal num-
bers of living T cells were subjected to aCD3 restimula-
tion for 24 hr in the absence of adenosine and effector
cytokine levels were determined in the cell culture super-
natant by ELISA. In line with our previous observations,
CD8 T cells activated in the presence of adenosine
(1 mM) showed reduced capacity to produce IFN-c and
IL-2 (Fig. 2d). This indicates a failure of T-cell differenti-
ation into effector T cells. However, CD8 T cells initially
exposed to low adenosine concentrations showed a slight
increase in IFN-c production, which may be related to a
less exhaustive state of the cells. Collectively, these experi-
ments reveal a potent inhibitory function of high concen-
trations of adenosine on the priming and differentiation
of naı¨ve CD8 T cells.
Adenosine blocks the priming of naı¨ve CD8 T cells by
APC
Initial stimulation of naı¨ve CD8 T cells by professional
APC, such as DC, or by organ-resident APC, such as
LSEC, determines differentiation into effector or tolerant
CD8 T cells, respectively.20,25 This process of tolerogenic
or immunogenic stimulation of naı¨ve CD8 T cells is dri-
ven by active signalling through either costimulatory or
coinhibitory molecules. We investigated whether adeno-
sine modulated such immunogenic as well as tolerogenic
T-cell priming. We cocultured H2-Kb-restricted DesTCR
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transgenic CD8 T cells with antigen-presenting splenic
H2-Kb+ DC or H2-Kb+ LSEC in the presence or absence
of adenosine. Expression of activation markers on CD8 T
cells was analysed after 24 hr and proliferation after
48 hr. Similar to the results of aCD3/CD28 stimulation
we observed reduced T-cell expression of CD25 and
CD44 in the presence of a high concentration of adeno-
sine after priming by antigen-presenting DC and LSEC
(Fig. 3a). After 48 hr a clear reduction in APC-induced
proliferation of T cells was observed in the presence of
adenosine (Fig. 3b). Detailed analysis revealed that the
percentage of divided cells, division index and total cell
numbers of living CD8 T cells were significantly reduced
after 48 hr, regardless of the stimulating APC (Fig. 3c).
Compared with aCD3/CD28 stimulation, the inhibitory
effects of adenosine were less pronounced, which may
have been caused by more rapid degradation of adenosine
by coculture of APC and T cells. We next investigated
whether adenosine also affected the differentiation into
effector CD8 T cells. Indeed, T cells primed by DC in the
presence of high concentrations of adenosine failed to
express IFN-c after restimulation through the TCR
(Fig. 3d). However, similar experiments to directly reveal
adenosine-mediated inhibition of tolerance induction also
demonstrated lack of IFN-c expression (data not shown)
but were not conclusive because tolerant T cells are
already non-responsive to TCR stimulation.20,26 Neverthe-
less, as induction of tolerance by LSEC is an active pro-
cess26 our observation that adenosine inhibited the initial
tolerogenic priming of T cells indicates control of
adenosine on tolerance induction. Taken together, these
results support the notion that adenosine not only
controlled priming by APC but also prevented effector
cell differentiation in T cells.
Inhibition of membrane-proximal signalling events in
TCR/CD28-induced naı¨ve CD8 T-cell activation
It was reported that adenosine increased intracellular
cAMP in T cells.15,17 We also detected an increase in
cAMP production in naı¨ve CD8 T cells within 5 min after
exposure to adenosine (Fig. 4a). To further investigate
whether increased levels of cAMP influenced T-cell stimu-
lation, we incubated aCD3/CD28-stimulated naı¨ve CD8 T
cells with a membrane-permeable cAMP analogue. The
addition of dibutyryl-cAMP (db-cAMP) was associated
with a decrease in CD25 and CD44 expression (Fig. 4b)
and a reduction in IFN-c expression in aCD3/CD28-stim-
ulated naı¨ve CD8 T cells (Fig. 4c). Moreover, in response
to the addition of db-cAMP the proliferation of aCD3/
CD28-stimulated naı¨ve CD8 T cells was dramatically
reduced (Fig. 4d). Consistent with a dominant effect of
the A2A-receptor on T-cell function and its described
capacity to induce cAMP in T cells we found that the
A2A-receptor-specific agonist CGS21680 impeded the
aCD3/CD28-induced activation of naı¨ve CD8 T cells
(Fig. 4e). These results suggested that cAMP generation
induced by adenosine interfered with signalling events in
T-cell activation. We therefore aimed to elucidate these
events in more detail.
Naı¨ve CD8 T-cell stimulation requires simultaneous
activation of TCR- and CD28-signalling pathways to
achieve full activation. We assessed classical signalling
events related to TCR/CD28 signalling. As cAMP has been
reported to inhibit TCR signalling already at the level of
the TCR–CD3 complex,27 we investigated the effects of
adenosine on tyrosine phosphorylation of membrane-
proximal signalling molecules. Adenosine treatment of
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Figure 2. Adenosine inhibits expansion and effector differentiation
of naı¨ve CD8 T cells after aCD3/CD28 activation. Naı¨ve carboxyfluo-
rescein succinimidyl ester (CFSE)-loaded CD8 T cells were activated
with aCD3/CD28 beads in the absence or presence of adenosine.
(a) After 48 hr proliferation was analysed by flow cytometry. (b) Per-
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***P < 0001.
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naı¨ve CD8 T cells clearly reduced tyrosine phosphorylation
of ZAP-70 within 5 min after aCD3/CD28 stimulation
(Fig. 5a). This is of particular relevance as ZAP-70 is a
key player in TCR signalling. Reduced levels of tyrosine
phosphorylation were also observed for Akt and ERK1/2
(Fig. 5a). We further confirmed the interception of
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Figure 3. Adenosine blocks tolerogenic and immunogenic priming of naı¨ve CD8 T cells. Antigen-presenting liver sinusoidal endothelial cells
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adenosine with proximal TCR signalling by measuring
calcium influx. Adenosine pre-treatment for 5 min signifi-
cantly reduced calcium influx into aCD3/CD28-stimu-
lated naı¨ve CD8 T cells (Fig. 5b). Taken together, these
results suggest that adenosine similar to cAMP interferes
with membrane-proximal TCR signalling events.
Discussion
Several reports have shown, that adenosine most efficiently
controls the effector functions of various immune cells
including fully differentiated effector CD8 T cells.15–17,22,28
This led to the well-established ‘2-Danger-signal’ model of
Sitkovsky and Ohta, in which adenosine acts as a modula-
tor of immune responses in peripheral tissues.12,18 Here,
we investigate the early and membrane-proximal mecha-
nisms mediating the effects of extracellular adenosine on
the priming of naı¨ve CD8 T cells.
We provide evidence that adenosine suppressed the
activation of naı¨ve CD8 T cells by inhibiting TCR signal-
ling events. We observed reduced calcium influx as well
as decreased tyrosine phosphorylation of signalling mole-
cules like ERK1/2 and Akt after TCR activation. More-
over, tyrosine phosphorylation of the TCR key kinase
ZAP-70 was strongly reduced in the presence of adeno-
sine. This argues for a membrane-proximal inhibition of
TCR signalling by adenosine. We assume that reduced
ZAP-70 tyrosine phosphorylation is a consequence of a
lack of Lck activity, which is required for recruitment of
ZAP-70 to the CD3/TCR signal transduction complex.29
Tyrosine kinase activity of Lck is under tight control of
the kinase Csk.30,31 Mustelin and Tasken have described a
model for the regulation of Lck function by Csk. In this
model, phosphorylation of Lck by Csk is a downstream
event initiated by cAMP-dependent activation of the pro-
tein kinase A (PKA) type I.32 Indeed, we also observed
induction of increased intracellular cAMP levels in CD8 T
cells after adenosine exposure. Moreover, db-cAMP treat-
ment of naı¨ve CD8 T cells before aCD3/CD28 stimulation
also inhibited ZAP-70 phosphorylation. Therefore, our
experimental data support the notion that this mecha-
nism contributes to early adenosine-induced inhibition of
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membrane-proximal TCR signalling. Nevertheless, it
remains to be determined if other PKA-dependent mech-
anisms also play a role, like inhibition of Raf, phospho-
lipase C-c or activation of cAMP-induced transcriptional
repressor ICER.33–38 It is likely that membrane-proximal
inhibition of TCR signalling by adenosine is not restricted
to naı¨ve CD8 T cells but is also operative in fully differ-
entiated effector T cells.
We and others observed cAMP induction in CD8 T
cells after adenosine exposure. Coupling to an intracellu-
lar increase in cAMP formation is a known feature of two
members of the adenosine receptor family, namely adeno-
sine A2A and A2B receptors.
15–17,39 Most likely, the
observed cAMP induction is related to activation of the
adenosine A2A receptor, which has been reported to
mediate the efficient regulation of T-cell functions.15–18,40
Support for an adenosine A2A receptor-dependent inhibi-
tion of T-cell activity in our experiments came from
observations that the A2A receptor CGS impeded activa-
tion of naı¨ve CD8 T cells and that naı¨ve CD8 T cells
derived from adenosine A2B receptor knockout mice
showed similar adenosine-induced inhibition of T-cell
activity after aCD3/CD28 stimulation (data not shown).
Additionally, in line with previous reports, we measured
reduced T-cell activation after aCD3/CD28 stimulation
in the presence of 50-(N-ethylcarboxamido) adenosine
(NECA) (data not shown), which is a known potent ago-
nist of adenosine A1, A2A and A3 receptors, and a weaker
agonist at the A2B receptor subtype, but inactive at P2
receptor subtypes, so excluding a contribution by P2
receptors.41,42 Inhibitory effects were observed for concen-
trations of 1 mM and higher (data not shown) but not of
01 mM adenosine. Measuring exact concentrations of
adenosine in tissue is difficult so it is not known what
concentrations of adenosine are actually encountered by
T cells in the tissue, and hence we cannot compare these
concentrations with tissue levels. However, we hypothe-
size that the adenosine concentrations used in our studies
are likely to be present in damaged tissue in vivo.
Taken together, these results strongly suggest that inhi-
bition of membrane-proximal signalling in naı¨ve CD8 T
cells was mediated through the adenosine A2A receptor.
The prominent role of adenosine A2A receptors in con-
trolling immune responses within peripheral tissues has
been emphasized unequivocally in several in vivo studies
using adenosine A2A receptor knockout animals. In par-
ticular, adenosine A2A receptors were shown to restrict
anti-tumour effector functions of tumour-specific CD8 T
cells giving rise to the paradox of the parallel existence of
tumour and tumour-specific CD8 T cells.39 Along the
same line, A2A receptor knockout animals develop uncon-
trolled immunity even after weak stimulation,43,44
Furthermore, A2A receptors also control IL-2 secretion
and IL-2-driven expansion of effector CD8 T cells
in vivo45 and the colitogenic function of adoptively
transferred CD45RBhi T cells.46
Here, we report experiments suggesting that adenosine
has yet another function in controlling immune
responses, i.e. the prevention of priming of naı¨ve CD8 T
cells. Under defined in vitro conditions we observed that
CD8 T-cell priming by professional antigen-presenting
DC was inhibited by adenosine. While we doubt that the
high concentrations of adenosine required for the inhibi-
tion of T-cell priming can be reached in secondary lym-
phatic tissue, we would assume that adenosine levels in
peripheral tissues are sufficient to achieve regulation.
Migration through non-lymphoid organs and priming of
naı¨ve CD8 T cells has been reported to occur outside the
lymphatic system within the bone marrow by DC or
within the liver by semi-professional LSEC or hepatocytes,
giving rise to fully activated effector or tolerant CD8
T cells, respectively.19–21,47 As tolerance induction in
peripheral tissues is often associated with clonal deletion
of potentially autoreactive CD8 T cells,48 the presence of
high concentrations of adenosine in peripheral tissue in
response to damage or infection may prevent inadver-
tent deletion of rare precursor CD8 T cells with specificity
for infectious micro-organisms. Moreover, adenosine-
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mediated inhibition of tolerogenic T-cell-priming by anti-
gen-presenting LSEC, which involves initial stimulation
and expansion of naı¨ve CD8 T cells,26 may allow for the
prevention of accidental tolerance induction towards cir-
culating antigens during situations where increased aden-
osine concentrations are caused by local infection in the
liver. Similar results were obtained recently for CD4 T
cells, where adenosine was shown to promote long-term
anergy and generation of regulatory T cells.49 Further-
more, activation of A2A receptors has been shown to
attenuate T-cell-mediated allograft rejection in vivo,50
which supports our findings that adenosine is operational
in the restriction of differentiation of naı¨ve CD8 T cells.
Taken together, our results provide evidence for the
inhibition of proximal TCR signalling events by adeno-
sine, which prevents priming and differentiation of naı¨ve
CD8 T cells and presumably is also operative in restrict-
ing effector functions of already activated CD8 T cells.
Our data raise the question of the physiological relevance
for inhibition of naı¨ve CD8 T-cell activation by adeno-
sine. Although our in vitro findings need to be examined
in appropriate in vivo models, our data suggest a poten-
tial new function for adenosine in the prevention of
peripheral CD8 T-cell priming in situations of local tissue
damage or infection.
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Src Homology 2-Domain Containing Leukocyte-Specific
Phosphoprotein of 76 kDa Is Mandatory for TCR-Mediated
Inside-Out Signaling, but Dispensable for CXCR4-Mediated
LFA-1 Activation, Adhesion, and Migration of T Cells1
Jessica Horn,2* Xiaoqian Wang,2* Peter Reichardt,* Theresia E. Stradal,† Nicole Warnecke,*
Luca Simeoni,* Matthias Gunzer,* Deborah Yablonski,‡ Burkhart Schraven,3*
and Stefanie Kliche3*
Engagement of the TCR or of chemokine receptors such as CXCR4 induces adhesion and migration of T cells via so-called
inside-out signaling pathways. The molecular processes underlying inside-out signaling events are as yet not completely
understood. In this study, we show that TCR- and CXCR4-mediated activation of integrins critically depends on the mem-
brane recruitment of the adhesion- and degranulation-promoting adapter protein (ADAP)/Src kinase-associated phospho-
protein of 55 kDa (SKAP55)/Rap1-interacting adapter protein (RIAM)/Rap1 module. We further demonstrate that the Src
homology 2 domain containing leukocyte-specific phosphoprotein of 76 kDa (SLP76) is crucial for TCR-mediated inside-out
signaling and T cell/APC interaction. Besides facilitating membrane recruitment of ADAP, SKAP55, and RIAM, SLP76
regulates TCR-mediated inside-out signaling by controlling the activation of Rap1 as well as Rac-mediated actin polymer-
ization. Surprisingly, however, SLP76 is not mandatory for CXCR4-mediated inside-out signaling. Indeed, both CXCR4-
induced T cell adhesion and migration are not affected by loss of SLP76. Moreover, after CXCR4 stimulation, the ADAP/
SKAP55/RIAM/Rap1 module is recruited to the plasma membrane independently of SLP76. Collectively, our data indicate
a differential requirement for SLP76 in TCR- vs CXCR4-mediated inside-out signaling pathways regulating T cell adhesion
and migration. The Journal of Immunology, 2009, 183: 5756 –5767.
S timulation of T cells through the TCR activates a wholeplethora of signaling pathways that collectively controlactivation, proliferation, and differentiation of T cells.
One immediate consequence of TCR engagement is the forma-
tion of a multicomponent signaling complex close to the plasma
membrane consisting of the Src homology 2-domain containing
leukocyte-specific phosphoprotein of 76 kDa (SLP76),4 the
small adapter protein Gads, and the transmembrane adapter pro-
tein linker for activation of T cells (LAT) (1). In response to
TCR engagement, LAT becomes phosphorylated on several ty-
rosine residues by the protein tyrosine kinase ZAP70 (1). This
phosphorylation leads to recruitment of Gads. Through its con-
stitutive association with Gads, SLP76 is also recruited to phos-
phorylated LAT (2). In the following, several other effector
molecules assemble with the LAT/Gads/SLP76-signaling plat-
form. These include phospholipase C1 (PLC1), the nucleo-
tide exchange factor Vav1, and the Tec family kinase IL-2-
inducible T cell kinase (Itk) (1). Together these molecules
coordinate TCR-mediated rises in intracellular calcium, up-reg-
ulation of CD69, and the activation of the Ras/ERK1/2 signal-
ing pathway (1, 3).
The importance of SLP76 for TCR-mediated signaling events
has been demonstrated in SLP76-deficient mice as well as in the
SLP76-deficient Jurkat T cell line J14. Thus, loss of SLP76 in mice
leads to a complete block at the double-negative 3 stage of thymic
development and results in an almost complete loss of mature T
cells (1). Moreover, loss of SLP76 in Jurkat T cells induces a
complete failure of the TCR to induce rises in intracellular cal-
cium, activation of the Ras/Raf/MAPK/ERK1/2 pathway, and up-
regulation of CD69 expression (3).
Besides inducing the above-mentioned signaling events, TCR
stimulation also leads to T cell adhesion, a process that is critical for
the interaction between T cells and APCs. In T cells, the 2 integrin
LFA-1 (L2) mediates adhesive events with APCs through binding
to its ligand ICAM-1. LFA-1/ICAM-1 interactions are critical for T
cell activation because they stabilize the interaction of T cells with
APCs and the formation of the immunological synapse (IS) (4, 5).
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Resting T cells are not adhesive because LFA-1 is presented in a
closed, inactive conformation. Upon triggering of the TCR or of
chemokine receptors (see below), a conformational change is
induced within LFA-1 that augments its affinity for ICAM-1. In
addition, clustering of LFA-1 molecules on the surface of T cells
enhances avidity for ICAM-1 binding. The molecular events lead-
ing to integrin activation have collectively been termed inside-out
signaling (6).
Gain-of-function and loss-of-function studies have demon-
strated that additional signaling proteins are involved in TCR-me-
diated integrin activation. These include talin (6, 7), the Wiskott-
Aldrich syndrome-Verprolin-homologous protein WAVE2 (8, 9),
Rap1 (6, 10, 11), and its downstream targets regulator of adhesion
and cell polarization enriched in lymphoid tissues or Rap1-inter-
acting adapter protein (RIAM) (12–14), adhesion- and degranula-
tion-promoting adapter protein (ADAP) (15, 16), and Src kinase-
associated phosphoprotein of 55 kDa (SKAP55) (17, 18).
Moreover, components of the LAT/Gads/SLP76 signaling plat-
form are also critically involved in TCR-mediated activation of
LFA-1. These include PLC1, Vav1, Itk, and ADAP (13, 19, 20).
How exactly these molecules orchestrate TCR-mediated activation
of integrins is not completely understood. However, we have re-
cently shown that the formation of a signaling module consisting
of ADAP/SKAP55 complex together with RIAM is required for
plasma membrane targeting of Rap1 in response to TCR stimula-
tion, and therefore for TCR-mediated activation of integrins (17,
21). In line with these data is the observation that ADAP- and
SKAP55-deficient mouse T cells show a severe defect in integrin
activation in response to TCR-mediated stimuli (15, 16, 18).
Currently, it is proposed that following T cell activation, ty-
rosine-phosphorylated ADAP binds to the Src homology 2 domain
of SLP76, thereby leading to membrane recruitment of the ADAP/
SKAP55/RIAM module and integrin activation. In line with this
idea is the observation that disruption of the interaction between
SLP76 and Gads blocks TCR-mediated adhesion to ICAM-1 (22).
Furthermore, it was shown that mutation of those tyrosine residues
within ADAP, which are believed to mediate the interaction be-
tween ADAP and SLP76, blocks TCR-mediated activation of
LFA-1 (23). Thus, it appears as if SLP76 would also play a major
role during TCR-mediated activation of integrins by facilitation
membrane targeting of the ADAP/SKAP55/RIAM module. However,
to date, an inducible interaction between endogenously expressed
ADAP/SKAP55/RIAM module and SLP76 in response to TCR en-
gagement has not been demonstrated biochemically. Hence, the mo-
lecular signaling events underlying the function of SLP76 for TCR-
mediated integrin activation are not completely elucidated.
Importantly, integrins not only become activated after stimu-
lation of the TCR, but also after triggering of chemokine re-
ceptors, such as CXCR4. Signaling via CXCR4 is induced by
stromal cell-derived factor-1 (or CXCL12) and induces affin-
ity and avidity regulation of LFA-1 (6). This process is impor-
tant for firm T cell adhesion, T cell polarization, chemokinesis,
and chemotaxis (24). Molecules involved in CXCR4-mediated
integrin activation and/or chemotaxis are talin (25), Rap1 (6,
26, 27), and its downstream targets regulator of adhesion and
cell polarization enriched in lymphoid tissues and MstI (28 –
30), Itk (20), Vav1 (20, 31, 32), Rac (31), and members of the
Wiskott-Aldrich syndrome protein family (33, 34). Moreover,
we and others have shown that overexpression of ADAP en-
hances chemotaxis of T cells in response to CXCL12 (35, 36).
These findings suggest an important role of ADAP for CXCR4-
induced migration of T cells. However, the molecular basis of
how ADAP is integrated into CXCR4 signaling is to date un-
clear. Based on its central role in TCR-mediated signaling pro-
cesses, SLP76 would be an attractive candidate that could fa-
cilitate membrane targeting of ADAP after CXCR4 stimulation.
Indeed, it was shown recently that SLP76 regulates CXCR4-
induced Ca2 flux and ERK1/2 phosphorylation (31). Con-
versely, we had demonstrated that disruption of the SLP76/
Gads association, albeit impairing TCR-mediated signaling
processes, does not affect CXCR4-induced Ca2 flux and che-
motaxis (22). Thus, it is unclear whether SLP76 is also
important for CXCR4-mediated activation of integrins and
chemotaxis.
In this study, we have addressed critical questions regarding the
function of SLP76 during TCR vs CXCR4-mediated signaling. We
show that SLP76 is indeed a critical regulator of TCR-mediated
inside-out signaling events in T cells, and we demonstrate that
SLP76 is mandatory for induction of TCR-mediated adhesion, af-
finity/avidity regulation of LFA-1, and the interaction between T
cells and B cells. Furthermore, we show that SLP76 is required for
TCR-induced Rap1 activation, Rac-mediated actin dynamics, and
recruitment of both talin and the ADAP/SKAP55/RIAM/Rap1
module to the plasma membrane and to the IS. Surprisingly, how-
ever, SLP76 is not mandatory for CXCR4-mediated activation of
LFA-1. In addition, SLP76 is dispensable for adhesion and migra-
tion of T cells in response to CXCL12. Finally, we demonstrate
that the ADAP/SKAP55/RIAM/Rap1 module is crucial for T cell
adhesion and migration in response to CXCR4 triggering, but is
recruited to the plasma membrane independently of SLP76. Our
findings show that SLP76 acts as a key player during TCR-medi-
ated inside-out signaling, whereas the adapter protein appears to be
dispensable for chemokine-dependent processes that regulate ad-
hesion and migration of T cells.
Materials and Methods
Reagents and Abs
All tissue culture reagents were from Biochrom, and all chemicals were
from Roth, unless mentioned otherwise. Staphylococcal enterotoxin B, D,
and E were purchased from Toxin Technology, respectively. Indo-1 AM,
Blue-7-amino-4-chloromethylcoumarin, DDAO-SE, and Alexa Fluor 633-
phalloidin were bought from Molecular Probes. FITC or tetramethylrho-
damine isothiocyanate (TRITC) phalloidin was from Sigma-Aldrich. PMA
was purchased from Calbiochem. Glutathione-Sepharose beads were
bought from Pharmacia. Protein A- and protein G-agarose beads were from
Santa Cruz Biotechnology. The chemokine CXCL12 was bought from
Tebu-bio, and the human Fc-tagged ICAM-1 was from R&D Systems. The
anti-RIAM rat mAbs were raised against the bacterially expressed GST-
tagged fragment of RIAM (1–420 aa), as previously described (37). Su-
pernatants of secreting hybridomas were screened by Western blotting,
immunofluorescence, and intracellular flow cytometry (FACS), and among
the various clones tested, the mAb RIAM15B7E8 was selected. The mouse
anti-CD3 mAb C305 (IgM) (38), OKT3 (ATCC), biotinylated UCHT-1
(NatuTec), or MEM92 (provided by V. Horejsi, Academy of Sciences of
the Czech Republic, Czech Republic) was used for TCR stimulation of
Jurkat T cells or human T cells. For protein surface expression analysis
by FACS, the following mAbs were used: CD18 (MEM48), CD29
(MEM101A; both provided by V. Horejsi), CD184 (CXCR4; clone
12G5; BD Biosciences), MHC class I (clone W6/32; ATCC), KIM127
(provided by N. Hogg, Cancer Research U.K. London Research Insti-
tute, London, U.K.), APC-conjugated anti-CD69 (BD Bioscience), or
FITC-conjugated MEM48 (Immunotools). The anti-SLP76 and anti-
preimmune sheep serum (39), anti-SKAP55 rabbit serum (40), or anti-
Gads rabbit serum (Upstate Biotechnology) was used for immunopre-
cipitation studies. The following Abs were used for immunoblot
analysis and/or immunofluorescence in this study: anti-SKAP55 rat
mAb (SK13B6) (17), anti-GST rat mAb (provided by C. Erk, Helm-
holtz-Zentrum fu¨r Infektionsforschung, Braunschweig, Germany), anti-
-actin mAb (Sigma-Aldrich), anti-phospho-ERK1/2 (T202, Y204) rabbit
serum and anti-Vav rabbit serum (both from Cell Signaling Technol-
ogy), anti-SLP76 mAb (Santa Cruz Biotechnology), anti-LAT mAb
(BD Biosciences), anti-ADAP sheep serum (41), anti-phospho-SLP76
mAb (pY145; BD Biosiences), anti-phospho-LAT (pY171) rabbit se-
rum and anti-phospho-ZAP70 (pY319) rabbit serum (both from Cell
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Signaling Technology), anti-Rap1 rabbit serum (Santa Cruz Biotech-
nology), anti-Rap1 mAb and anti-Rac mAb (both from BD Biosciences), and
anti-talin mAb (clone 8D4; Sigma-Aldrich). The following Abs were used for
phospho-epitope staining by FACS: anti-phospho-ZAP70 (pY319)-Alexa
Fluor 647, anti-phospho-PLC1 (pY783)-Alexa Fluor 647 (both from BD
Biosciences), and anti-phospho-ERK1/2 (pT202, pY204; clone E10; Cell Sig-
naling Technology). Streptavidin, HRP-labeled secondary Abs, and FITC-,
Cy3-, APC-, and Cy5-conjugated secondary Abs were purchased from
Dianova.
RNA interference (RNAi) of SLP76, ADAP, SKAP55, or RIAM
and cDNA constructs
For small hairpin RNA (shRNA) of SLP76, the following oligonucleotides,
shC (CCAAGTAATGTAGGATCAA; Renilla) and shSLP76 (CGAAGA
GAGGAGGAGCATC; shSLP76), were cloned into pSuper (provided by
T. Seufferlein (Universita¨tsklinik und Poliklinik fu¨r Innere Medizin I,
Halle, Germany) and pCMS3-EGFP vector (provided by D. Billadeau
(Mayo Clinic, Rochester, MN). For shRNA of ADAP and RIAM, the pre-
viously published oligonucleotides were cloned into the pCMS3 vector (12,
42). The pCMS3-EGFF construct for silencing of SKAP55 has been de-
scribed (17). The pGEX PAK-PBD was provided by T. Seufferlein. The
pGEX RalGDS-RBD was provided by J. Bos (University Medical Center,
Utrecht, The Netherlands), and the pmCherry-C1 vector was purchased from
BD Clontech.
Cell culture and transfection
Jurkat T cells (ATCC), B cells (Raji; ATCC), and SLP76-deficient/recon-
stituted Jurkat T cells (J14, J14-76-11, and J14-76-18) (3) were maintained
in RPMI 1640 medium supplemented with 10% FBS (PAN) and stable
L-glutamine at 37°C with 5% CO2. Jurkat T cells (2  107) were trans-
fected by electroporation, as previously described (17). Transfection with
the pCMS3-EGFP vector into Jurkat T cells consistently yielded in an
average of 80% GFP-expressing cell population. Primary human T cells
were prepared from healthy donors by standard separation methods using
AutoMACS (Miltenyi Biotec) maintained in RPMI 1640 medium contain-
ing 10% FBS, stable L-glutamine, and 1000 U/ml penicillin/streptomycin.
Approval for these studies was obtained from the Ethics Committee of the
Medical Faculty at the Otto-von-Guericke University. Informed consent was
obtained in accordance with the Declaration of Helsinki. For electroporation of
small interfering RNA (siRNA), human peripheral T cells (8  106) were
washed in PBS containing Ca2/Mg2 and resuspended in 200 l of Opti-
MEM (Invitrogen). siRNA smart pool against SLP76, ADAP (Dharmacon
smart pools for SLP76 or ADAP), control siRNA (siCONTROL nontargeting
smart pool from Dharmacon), Vav1.3 (31), siRNA for SLP76, or control
siRNA Renilla (see above; all purchased from Invitrogen) was added, and after
3 min cells were transfected by electroporation (square-wave pulse, 1000 V,
0.5 ms, 2 pulses (pulse interval 5 s); Bio-Rad X-cell). The cells were then
added to prewarmed cell culture medium, as described above, and cultured for
72 h before use. The knockdown efficiency of SLP76, ADAP, SKAP55,
RIAM, or Vav1 was evaluated either by Western blotting or on a single-cell
basis by intracellular flow cytometry.
Immunoprecipitation, Western blot analysis, isolation of
cytosolic and plasma membrane fractions, and GTPase assays
Cell lysis and immunoprecipitation were performed, as previously described
(17, 21). Equivalent amounts of protein (determined by Bradford assay (Roth))
were used in precipitation studies (500 g of total protein from either Jurkat T
cells or human primary T cells). Cell lysates (50g of total protein) or immune
complexes were separated by SDS-PAGE and transferred to nitrocellulose.
Western blots were conducted with the indicated Abs and developed with the
appropriate HRP-conjugated secondary Abs and the Luminol detection system
(Roth). Isolation of cytosolic and plasma membrane fractions has been de-
scribed previously (17). GTPase activity of Rap1 or Rac activity was assessed,
as previously described (17). Briefly, Jurkat T cells were either left un-
treated or stimulated for various time points with anti-CD3 mAb C305
or CXCL12 (100 ng/ml) and lysed. An aliquot of the lysate (10%) was
used as loading control. Activated GTPases were precipitated using
either glutathione-Sepharose conjugated with the GST-RalGDS fusion
protein for Rap1 (RBD) or glutathione-Sepharose coupled with the GST
fusion protein of the p21-binding domain of Pak (PBD) for Rac. Bound
GTPases were quantified by Western blotting.
Flow cytometry, calcium release, and CD69 up-regulation
To analyze the cell surface expression of 1 or 2 integrin, CXCR4, TCR,
and MHCI, cells were stained with the indicated Abs in combination with
APC-conjugated goat anti-mouse IgG and analyzed using a FACSCalibur
flow cytometer and CellQuestPro software (BD Biosciences). Soluble Fc-
ICAM-1 binding of T cells after various stimuli was assessed, as previously
described (43). Briefly, T cells suspended in binding puffer (HBSS con-
taining 2% FBS) were either left untreated or stimulated with anti-CD3
mAb, CXCL12, or Mg2/EDTA for 5 min in the presence of 20 g/ml
human rFc-ICAM-1, and bound Fc-ICAM-1 was detected by flow cytom-
etry. Intracellular staining by flow cytometry for SLP76, ADAP, SKAP55,
or RIAM was performed, as previously described (44). The specificity of
the staining for each serum or mAb was assessed using either SLP76-
deficient/reconstituted Jurkat T cells or after loss of ADAP, SKAP55, or
RIAM expression by vector-based shRNA in Jurkat T cells (please see
supplemental Fig. 1).5 To assess the F-actin content, T cells (1 105) were
left untreated or stimulated with anti-CD3 mAbs or CXCL12, and reactions
were stopped by adding PBS containing 4% paraformaldehyde (PFA), 2
g/ml FITC- or Alexa Fluor 633-phalloidin, and 0.2% Triton X-100. After
15 min, cells were washed with 1% PFA in PBS and analyzed by flow
cytometry. Measurement of TCR-induced calcium release and CD69 up-
regulation have been previously described (17). Analysis of protein phos-
phorylation with phospho-specific Abs by flow cytometry was performed,
as described (45).
Conjugate formation, adhesion, migration, and motility assays
Conjugate assays were performed, as described (21). Briefly, superantigen
(SA) mixture of staphylococcal enterotoxin B-, D-, and E-pulsed and
DDAO-SE-labeled Raji B cells were incubated with an equal number of
Jurkat T cells or CFSE-loaded human T cells for 30 min at 37°C. Non-
specific aggregates were disrupted; cells were fixed with 1% PFA, and then
analyzed by flow cytometry. The percentage of conjugates was defined as
the number of double-positive events in the upper right quadrant. Adhesion
assays were performed, as previously described (17). Briefly, Jurkat T cells
or peripheral human T cells were stimulated with OKT3, PMA, or MnCl2
for 30 min at 37°C before adhesion on Fc-ICAM-1-coated dishes. The
bound total or GFP-expressing cell fraction was determined by counting
four independent fields by microscopy using an ocular counting reticule.
To assess CXCR4-mediated adhesion, peripheral human T cells were in-
cubated for 10 min at 37°C on Fc-ICAM-1-coated dishes coimmobilized
with or without CXCL12; subsequently, nonbound cells were removed by
washing with HBSS and bound cells were counted, as described above.
Chemotaxis assays were performed, as previously described, using Tran-
swells (Costar) coated with fibronectin (35). After 2 h, the number of
migrated cells into the lower chamber was counted and the percentage of
GFP-expressing Jurkat T cells was determined by flow cytometry. For live
cell imaging of either random or CXCL12-induced motility of T cells on
Fc-ICAM-1, self-constructed imaging chambers (46) were coated with Fc-
ICAM-1 in PBS at 4°C overnight. Immediately before imaging, cells were
left untreated or stimulated with CXCL12 (100 ng/ml), and imaging was
performed on a CellR imaging workstation (Olympus) using an upright
microscope stage (BX61) with a 20 lens. Using an automated X-Y-Z
stage, at least two optical fields were chosen for each culture condition.
Images were taken every 15–60 s for 2 h. At least 30 cells per observation
field were analyzed. Tracking analysis of migrating cells to determine the
velocity was done by computer-assisted cell tracking using the Software
CellTracker (46).
Immunofluorescence microscopy
For B cell/T cell conjugates, SA- and Blue-7-amino-4-chloromethylcou-
marin-loaded Raji B cells were incubated for 30 min at 37°C with human
T cells on poly(L-lysine)-coated coverslips and fixed with 3.5% PFA in
PBS for 10 min. Cells were permeabilized with 0.1% Triton X-100 in PBS,
blocked with 5% horse serum in PBS, and incubated with the indicated Abs
or phalloidin. Coverslips were mounted in Mowiol 488 and imaged with a
LEICA TCS SP2 laser-scanning confocal system (Leica Microsystems)
using a plan apochromatic oil emerging 63 objective (NA 1.4). Figure
constructions of images were performed in COREL Photopaint. For quan-
tification of recruitment of proteins and F-actin at the contact zone or at the
uropod, line scans (1 m) were obtained. Fluorescence intensity was plot-
ted as function of distance along this line, and the integrated areas under the
curves representing the fluorescence intensity were calculated as ratio be-
tween the immunological synapse vs the uropod. Thirty conjugates were
analyzed per experiment. To assess TCR-induced clustering of LFA-1,
Jurkat T cells were incubated with biotinylated anti-UCHT-1 in the pres-
ence of streptavidin at 4°C. After washing, the cells were stimulated at
37°C for 30 min on poly(L-lysine)-coated slides, fixed with 3.5% PFA in
PBS, and then blocked with 5% horse serum in PBS. The cells were stained
5 The online version of this article contains supplemental material.
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with FITC-conjugated anti-MEM48 and imaged, as described above. For
each experiment, a minimum of at least 40 cells with LFA-1 polarized to
one side of the cell was regarded as polarized, whereas those cells showing
equal distribution of LFA-1 were considered not to be polarized. The per-
centage of polarized cells in each field was determined.
Results
Loss of SLP-76 impairs TCR-mediated activation of LFA-1 and
T cell-APC conjugation
By using a small peptide that disrupts the constitutive interaction
between SLP76 and Gads, we recently provided evidence that
formation of the LAT/Gads/SLP76 signaling platform at the
plasma membrane is required for TCR-mediated integrin activa-
tion (22). However, we formally could not exclude the possibility
that the functional effects exerted by the Gads-binding fragment
were not due to targeting the SLP76/Gads complex, but rather to
disruption of a distinct signaling pathway that regulates intergrin
activation in response to TCR stimulation. To assess this point
more specifically, we reduced the expression of SLP76 in primary
human T cells by RNAi. As shown in Fig. 1, A and B, SLP76
siRNA treatment lowered the expression levels of endogenous
SLP76 up to 80%, whereas the expression levels of ADAP,
SKAP55, and RIAM remained unaffected.
FIGURE 1. SLP76 is crucial for TCR-induced adhesion to ICAM-1 and conjugate formation. A, Purified human T cells were transfected with control
siRNA (siC) or the indicated concentrations of siRNAs against SLP76 (siSLP76). After 72 h, whole-cell extracts were analyzed by Western blotting with
the indicated Abs. B, In parallel, cells transfected with 50 nM siC or siSLP76 were analyzed by flow cytometry for the intracellular expression of SLP76,
ADAP, SKAP55, and RIAM (black line). The preimmune sheep serum and the anti-GST mAb were used as isotype controls (dashed line). C, Human T
cells transfected as described in A were left untreated or stimulated with anti-CD3 mAbs (TCR) for the indicated period of time. Lysates were analyzed
by Western blotting using the indicated Abs. Moreover, the same transfectants were cultured on plate-bound anti-CD3 mAbs (TCR) or in the presence of
PMA for 18 h, stained with anti-CD69 mAbs, and analyzed by flow cytometry. Data are representative of three individual experiments. Note that
the total expression of LAT, ZAP70, PLC1, or ERK1/2 was not affected (data not shown). D, Human T cells transfected as described above were
left untreated or stimulated with anti-CD3 mAb (TCR), PMA, or MnCl2 for 30 min, and subsequently analyzed for their ability to adhere to
Fc-ICAM-1. Suppression of SLP76 expression for each experiment was assessed by flow cytometry, and the percentage of SLP76-expressing cells
was calculated. Data represent the mean and SE of three independently performed experiments. E, In parallel, transfectants were analyzed for the
surface expression of CD18 or the TCR (black line), and control IgG were used as isotype controls (dashed line). One representative experiment
of three is shown. F, Equal numbers of the same cells as described in A were stained with CFSE and incubated for 30 min without SA (SA) or
with SA-pulsed (SA) DDAO-SE-labeled B cells. The percentage of conjugate formation was assessed by flow cytometry. Data represent the mean
and SE of three independently performed experiments. Representative histograms of SA-pulsed DDAO-SE B cells conjugated with CFSE-stained
T cells in the presence or absence of SLP76 are shown.
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Previously, it had been reported that SLP76 is required for
phosphorylation of PLC1, activation of ERK1/2, as well as for
expression of CD69 upon TCR stimulation. To first address
whether loss of SLP76 interferes with these SLP76-mediated
functions also in primary human T cells, we analyzed the ability
of SLP76-deficient human T cells to activate PLC1 and
ERK1/2 in response to TCR stimulation by Western blotting
and to up-regulate CD69 expression by flow cytometry. As
shown in Fig. 1C, loss of SLP76 strongly attenuated TCR-me-
diated phosphorylation of PLC1 at Y783, activation of
ERK1/2, and up-regulation of CD69. As expected, more prox-
imal signaling events such as the phosphorylation of ZAP70 at
Y319 or tyrosine phosphorylation of LAT (either global or at
Y171) were not affected in the absence of SLP76 (Fig. 1C). Note
that similar data were obtained, when we suppressed the expres-
sion of SLP76 by shRNA in Jurkat T cells (supplemental Fig. 2).
Thus, with regard to well-established SLP76-regulated signaling
processes, SLP76-deficient primary human T cells behave like
their corresponding Jurkat T cell counterparts (3).
Using the siRNA approach, we next analyzed the capability of
T cells to adhere to ICAM-1-coated dishes in response to various
stimuli. As shown in Fig. 1D and supplemental Fig. 3A, control
transfected human T cells and Jurkat T cells readily adhered to
ICAM-1 upon TCR or PMA treatment. In contrast, loss of SLP76
substantially attenuated both PMA- and TCR-induced adhesion to
ICAM-1 (left panel), whereas the cells showed no defect in their
adhesiveness in response to Mn2 (middle panel). The defect in
TCR- or PMA-induced adhesion to ICAM-1 was not due to an
altered expression of the 2 integrin (or the TCR) as determined by
flow cytometry (Fig. 1E and supplemental Fig. 3B).
Because the interaction of LFA-1 with ICAM-1 is important
for the establishment and maintenance of T cell/APC interac-
tions (5), we next analyzed whether SLP76 is required for con-
jugate formation between human T cells and SA-loaded B cells.
Fig. 1F shows that in contrast to control transfected T cells, loss
of SLP76 substantially blunted conjugate formation. Similarly,
SLP76low Jurkat T cells failed to interact with SA-loaded B
cells (supplemental Fig. 3C). Collectively, the experiments
shown in Fig. 1 indicate that SLP76 is mandatory for both TCR-
mediated adhesion to ICAM-1 and conjugate formation.
Loss of SLP76 attenuates TCR-mediated affinity/avidity
regulation of LFA-1
TCR-mediated inside-out signaling alters both LFA-1 affinity
(conformation) and avidity (clustering) (6). To determine the role
of SLP76 for LFA-1 affinity modulation, we assessed the ability of
soluble Fc-ICAM-1 to bind to SLP76-proficient and SLP76-defi-
cient T cells after TCR stimulation by means of flow cytometry.
Fig. 2A shows that knockdown of SLP76 in human T cells abro-
gates binding of soluble Fc-ICAM-1 after TCR stimulation (for
Jurkat T cells, please see supplemental Fig. 3D). In contrast, both
transfectants were able to bind similar amounts of Fc-ICAM-1
after treatment with Mg2/EDTA, which directly induces the high-
affinity conformation of LFA-1.
Next, we investigated avidity regulation of LFA-1 by analyz-
ing clustering of CD18 (the 2 chain of LFA-1) to the IS in
response to TCR stimulation. Fig. 2B shows that localization of
CD18 to the IS occurred readily in SLP76-expressing T cells
after incubation with SA-pulsed B cells, whereas it was se-
verely impaired in SLP76low T cells. In line with these data,
SLP76low Jurkat T cells also displayed no typical clustering of
CD18 upon cross-linking of the TCR (supplemental Fig. 3E).
Taken together, SLP76 is required for both affinity and avidity
regulation of LFA-1 after stimulation of the TCR.
TCR-mediated activation of Rac and actin dynamics require
SLP76
Reorganization of the actin cytoskeleton is required for TCR-me-
diated integrin activation and conjugate formation (33, 34), and the
small GTPase Rac is a major regulator regulating this process. In
T cells, activation of Rac is mediated via the nucleotide exchange
factor Vav1, which is recruited to and activated by SLP76 upon T
cell activation (32). Therefore, it seemed likely that loss of SLP76
also leads to alterations in actin dynamics upon TCR stimulation.
As depicted in Fig. 3, this is indeed the case. TCR-mediated ac-
tivation of Rac (Fig. 3A), formation of F-actin (Fig. 3B), as well as
accumulation of F-actin at the IS (Fig. 3C, upper right panel) are
severely impaired in SLP76-deficient T cells. Note that similar
data were obtained when the F-actin content after TCR triggering
was assessed in SLP76low Jurkat T cells (data not shown). Hence,
loss of SLP76 induces a failure to activate Rac and a defect in
F-actin remodeling upon TCR stimulation.
Because the scaffolding protein talin links newly synthesized
F-actin branches to LFA-1 and, hence, stabilizes the position of
LFA-1 in the IS (7, 47), we also investigated whether SLP76 is
required for targeting of talin to the IS after TCR stimulation.
FIGURE 2. TCR-induced affinity/avidity regulation of LFA-1 depends on
SLP76. A, Human T cells were transfected with either 50 nM control siRNA
(siC) or siRNAs against SLP76 (siSLP76). After 72 h, cells were analyzed for
their ability to bind soluble Fc-ICAM-1 in response to anti-CD3 mAb (TCR)
or Mg2/EDTA stimulation for 5 min. Suppression of SLP76 expression was
evaluated by flow cytometry. One representative experiment of three is shown.
B, Human T cells transfected as described in A were allowed to form conju-
gates with SA-pulsed B cells for 30 min. Fixed cells were stained for the 2
subunit of LFA-1 (green) to determine IS localization of LFA-1. Fluorescence
intensity of LFA-1 at the contact zone or the uropod was quantified and cal-
culated as ratio of intensity at the IS vs the uropod. Knockdown efficiency of
SLP76 expression was assessed by flow cytometry. Data present the average
of three independently performed experiments.
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Fig. 3C (lower right panel) shows that SLP76low T cells also
fail to target talin to the IS upon incubation with SA-pulsed B
cells. Thus, SLP76 appears to also regulate LFA-1-dependent
adhesion processes in activated T cells through its ability to
recruit talin to the IS.
Activation of Rap1 and localization of the SKAP55/RIAM
module to the IS depend on SLP76
Both the activation and the transport of Rap1 to the plasma mem-
brane are known to regulate LFA-1 activation (6, 17, 48). There-
fore, we next investigated whether loss of SLP76 affects TCR-
mediated activation of Rap1. Fig. 4A demonstrates that control
transfected cells exhibited strong activation of Rap1 within 2–10
min after TCR stimulation, whereas in SLP76low Jurkat T cells,
TCR-induced Rap1 was strongly suppressed. These results dem-
onstrate that SLP76 is critically involved in Rap1 activation in
response to TCR triggering.
We have recently shown that formation and membrane re-
cruitment of a signaling module consisting of the cytosolic
adapter proteins ADAP and SKAP55 and the Rap1 effector mol-
ecule RIAM (ADAP/SKAP55/RIAM module) regulate TCR-
mediated LFA-1 activation through recruitment of Rap1 to the
plasma membrane (17, 21). Moreover, an inducible association
between SLP76 and ADAP following TCR stimulation had
been suggested in several previous studies, but the question of
whether SLP76 links the TCR via the ADAP/SKAP55/RIAM
module to integrin activation has to date not been addressed
directly. To clarify this point, we immunoprecipitated SLP76
from resting or TCR-stimulated T cells and subsequently ana-
lyzed the precipitates for coprecipitation of ADAP, SKAP55,
RIAM, and Rap1 by means of Western blotting. Fig. 4B depicts
that SLP76 inducibly associates with both the ADAP/SKAP55/
RIAM complex and Rap1 upon TCR stimulation of Jurkat T
cells (Fig. 4B, left panel) as well as of primary T cells (Fig. 4B,
right panel). Analysis of SKAP55 immunoprecipitates that
were prepared from either SLP76-proficient or SLP76-deficient
T cells further revealed that Rap1 only associates with the
ADAP/SKPAP55//RIAM module if SLP76 is present (Fig. 4C).
Because only active Rap1 can interact with RIAM (12), this
finding is most likely due to the attenuated activation of Rap1
in the absence of SLP76 (see Fig. 4A).
The immunoprecipitation data shown in Fig. 4, B and C, were
further substantiated by cellular subfractionation experiments that
showed that TCR-mediated plasma membrane recruitment of
ADAP, SKAP55, RIAM, and Rap1 (Fig. 4D) and, consequently,
targeting of SKAP55, RIAM, and Rap1 to the IS (Fig. 4E) were
strongly impaired in SLP76low T cells. In summary, the data
shown in Fig. 4 indicate that SLP76 is required for both activation
and plasma membrane/IS targeting through the ADAP/SKAP55/
RIAM/Rap1 module of Rap1 after TCR triggering.
SLP76 is dispensable for CXCR4-mediated adhesion to ICAM-1
and affinity regulation of LFA-1
Similar to the TCR, triggering of the chemokine receptor CXCR4
leads to activation of LFA-1 and T cell adhesion to ICAM-1 (6).
Above we have shown that SLP76 is mandatory for TCR-mediated
integrin activation (Figs. 1 and 2). Therefore, we were interested to
investigate whether SLP76 is also required for CXCR4-mediated
adhesion. To assess this point, we down-regulated SLP76 expression
by siRNA and subsequently analyzed the capability of SLP76low T
cells to adhere to ICAM-1 in response to CXCL12 in an adhesion
assay. Surprisingly, these experiments revealed that SLP76low T cells
were as capable to adhere to Fc-ICAM-1 in response to CXCL12 as
their SLP76high counterparts (Fig. 5A). Similarly, neither the binding
of soluble Fc-ICAM-1 (Fig. 5B) nor of the conformation-sensitive
anti-LFA-1 mAb KIM127 (data not shown) was altered in SLP76low
T cells. Hence, we conclude that, in contrast to TCR stimulation, the
presence of SLP76 is dispensable for T cell adhesion and affinity
regulation in response to CXCL12 stimulation.
FIGURE 3. TCR-mediated actin remodeling, Rac activation, and recruit-
ment of talin to the IS require the presence of SLP76. A, Jurkat T cells were
transfected with either control vector (shC) or SLP76-suppression vector
(shSLP76). After 48 h, cells were either left untreated or stimulated with anti-
CD3 mAbs (TCR) for the indicated periods of time. GTP-loaded Rac was
precipitated using the GST-PBD fusion protein. Precipitates and aliquots of
whole-cell extracts were analyzed using the indicated Abs by means of West-
ern blotting. One representative experiment of two is shown. B, Purified hu-
man T cells were transfected with either control siRNA (siC) or siRNA against
SLP76 (siSLP76). After 72 h, cells were left untreated or stimulated with
anti-CD3 mAbs (TCR) for 5 min and stained with FITC-coupled phalloidin.
Reduction of SLP76 expression in human T cells was assessed by flow cy-
tometry. Data are representative of three individual experiments. C, Human T
cells transfected as described above were allowed to form conjugates with
SA-loaded B cells for 30 min. Cells were fixed, permeabilized, and stained
with TRITC-phalloidin (red) or talin (green). Fluorescence intensity of F-actin
and talin at IS or uropod was quantified and calculated as ratio of intensity for
the individual molecules at the IS vs the uropod. The knockdown efficiency of
SLP76 was evaluated by flow cytometry. Data present the average results of
three independent experiments.
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SLP76 is dispensable for CXCR4-mediated Rac activation, actin
dynamics, and migration
Similar to TCR stimulation, remodeling of the actin cytoskeleton
through Rac is crucial for inducing T cell adhesion, polarization,
and chemotaxis following CXCR4 stimulation (33). Our above
findings led us to ask whether the presence of SLP76 might be
dispensable for Rac activation in response to CXCL12 triggering.
As shown in Fig. 6A, SLP76low Jurkat T cells indeed display no
obvious defect in CXCL12-mediated activation of Rac. Moreover,
both SLP76high and SLP76low T cells revealed comparable levels
of F-actin formation in response to CXCL12 (Fig. 6B). These data
strongly suggest that SLP76 is indeed dispensable for signaling
events that are critically involved in CXCR4-mediated activation
of Rac and actin polymerization.
To prove whether expression of SLP76 is required for CXCR4-
induced T cell chemokinesis, we determined the lateral locomotion of
T cells by live cell imaging on Fc-ICAM-1-coated coverslips. As
shown in Fig. 6C, both SLP76high and SLP76low T cells showed com-
parable basal and CXCL12-induced velocities. In contrast, and in line
with previously published data (31), Vav1-deficient T cells displayed
FIGURE 4. The inducible interaction between ADAP and SLP-76 is mandatory for the recruitment of SKAP55, RIAM, and Rap1 to the plasma membrane.
A, Jurkat T cells were transfected with either control vector (shC) or SLP76-suppression vector (shSLP76). After 48 h, cells were either left untreated or stimulated
with anti-CD3 mAbs (TCR) for the indicated periods of time. GTP-loaded Rap1 was precipitated using the GST-RalGDS-RBD fusion protein. Precipitates and
aliquots of whole-cell extracts were analyzed with the indicated Abs by Western blotting. One representative experiment of three is shown. B, Jurkat T cells or
human T cells (hT-cells) were left untreated or stimulated with anti-CD3 mAbs (). Immunoprecipitations were performed using anti-SLP76 or preimmune sheep
serum (anti-PIS), and precipitates were analyzed by Western blotting with the indicated Abs. One representative experiment of two is shown. C, Jurkat T cells were
transfected as described in A. SKAP55 was immunoprecipitated from untreated or stimulated cells, and proteins interacting with SKAP55 were detected by Western
blotting using the indicated Abs. Data are representative for two individual experiments. D, Jurkat T cells were transfected as described in A, and plasma membrane
or cytosolic fractions were prepared from untreated () or TCR-stimulated cells (). The individual fractions were analyzed by Western blotting using the
indicated Abs. Fractionation efficiency was assessed by Western blotting using anti-LAT (plasma membrane) or anti-ERK1/2 (cytosol) Abs, respectively. One
representative experiment of two is shown. E, Human T cells transfected with control siRNA (siC) or siRNA against SLP76 (siSLP76) were allowed to form
conjugates with SA-loaded B cells for 30 min. Fixed and permeabilized cells were stained with mAbs to SKAP55, RIAM, or Rap1 (green) and TRITC-phalloidin
(red). Fluorescence intensity of SKAP55, RIAM, or Rap1 at IS or uropod was quantified and calculated as ratio of intensity for the individual protein at the IS vs the uropod.
Loss of SLP76 expression for each experiment was analyzed by flow cytometry. Data present the average results of three independently performed experiments.
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a strongly reduced motility upon CXCR4 triggering (Fig. 6C). It is
also important to note that nearly all SPL76low T cells displayed a
polarized phenotype upon chemokine stimulation, whereas the ma-
jority of Vav1-depleted T cells remained a round, nonpolarized shape
(Fig. 6C). Fig. 6D further demonstrates that the absence of SLP76
does not alter CXCR4-induced chemotaxis of human primary T cells
in response to a CXCL12 gradient in vitro. In summary, it appears as
if SLP76 is not mandatory for migratory steps triggered by CXCL12.
The ADAP/SKAP55/RIAM module is recruited to the plasma
membrane independently of SLP76
Upon T cell activation, the Gads/SLP76 complex is recruited to
phosphorylated LAT, thereby coupling the TCR to the intracellular
signaling machinery (2, 49). Given the above data, we next inves-
tigated whether the LAT/Gads/SLP76 signaling platform would be
assembled after CXCR4 stimulation. To test this, we stimulated hu-
man T cells for various periods of time with CXCL12 and subse-
quently analyzed global tyrosine phosphorylation of LAT by Western
blotting. In contrast to TCR stimulation, phosphorylation of LAT was
only very weakly induced upon CXCR4 triggering (Fig. 7A). Similar
results were obtained when the phosphorylation status of LAT at Y171
(which is important for Gads binding) was assessed (Fig. 7A). These
data suggested that the Gads/SLP76 complex might not associate with
LAT following CXCR4 triggering. To investigate this point in more
detail, we immunoprecipitated the Gads/SLP76 complex from un-
treated, TCR-stimulated, or CXCR4-triggered T cells. Fig. 7B shows
that an inducible interaction among Gads/SLP76, LAT, and Vav1 was
readily detectable after TCR stimulation. In contrast, neither LAT nor
Vav1 was found to be associated with the Gads/SLP76 complex in
FIGURE 5. SLP76 is dispensable for CXCL12-mediated adhesion to
ICAM-1, affinity maturation of LFA-1. A, Human T cells were trans-
fected with control siRNA (siC) or siRNAs against SLP76 (siSLP76).
Cells were left untreated or stimulated with immobilized CXCL12 (10
min) or anti-CD3 mAbs (TCR) for 30 min. Subsequently, cells were
analyzed for their ability to adhere to Fc-ICAM-1. Suppression of
SLP76 expression was assessed by flow cytometry, and the percentage
of SLP76-expressing cells was calculated. Data represent the mean and
SE of three independently performed experiments. B, Human T cells
transfected as described in A were analyzed for their ability to bind
soluble Fc-ICAM-1 upon anti-CD3 (TCR), CXCL12, or Mg2/EGTA
(positive control) treatment for 5 min. Suppression of SLP76 expression
was evaluated by flow cytometry. One individual experiment of three is
shown.
FIGURE 6. The presence of SLP76 is not required for Rac activation, actin polymerization, motility, and chemotaxis in response to CXCL12. A, Jurkat
T cells were transfected with either control vector (shC) or SLP76-suppression vector (shSLP76). After 48 h, cells were either left untreated, or stimulated
with CXCL12 or anti-CD3 mAbs (TCR) for the indicated time points. Activated Rac was precipitated using the GST-PBD fusion protein. Precipitates and
aliquots of whole-cell extracts were analyzed by Western blotting using the indicated Abs. One representative experiment of three is shown. B, Human T
cells were transfected with control siRNA (siC) or siRNA against SLP76 (siSLP76). After 72 h, cells were left untreated, stimulated with anti-CD3 mAbs
(TCR, for 5 min) or CXCL12 for 1 min, and stained with FITC-coupled phalloidin. Reduction of SLP76 expression in human T cells was assessed by flow
cytometry. Data are representative of three independent experiments. C, Human T cells were transfected with control siRNA (siC), siRNA against SLP76
(siSLP76), or siRNA against Vav1 (siVav1). After 72 h, motility of T cells in the absence or presence of CXCL12 was determined on Fc-ICAM-1-coated
coverslips, as described in Materials and Methods. In parallel, transfectants were stimulated on Fc-ICAM-1-coated coverslips with CXCL12 for 30 min.
Cells were fixed, permeabilized, and stained with TRITC-phalloidin. Whole-cell extracts were analyzed by Western blotting for the expression of SLP76,
Vav1, and -actin. One individual experiment of three is shown. D, Chemotaxis of human T cells transfected as described in A was addressed using a
Transwell assay, as described in Materials and Methods. After 2 h, the number of migrated cells into the lower chamber was counted. Suppression of SLP76
expression was assessed by flow cytometry, and the percentage of SLP76-expressing cells was calculated. Data represent the mean and SE of three
independently performed experiments.
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response to CXCL12 stimulation (Fig. 7B). These experiments indi-
cate that the LAT/Gads/SLP76 signaling platform is not assembled in
response to CXCL12 in T cells.
Above we have shown that the ADAP/SKAP55/RIAM module
inducibly interacts with SLP76 upon TCR-mediated T cell activa-
tion, and that SLP76 is mandatory for membrane targeting of the
ADAP/SKAP55/RIAM module and for activation of Rap1 (Fig.
4). In marked contrast, CXCL12 stimulation of T cells did not lead
to an inducible interaction between the LAT/Gads/SLP76 complex
and the ADAP/SKAP55/RIAM module (Fig. 7B). However, the
ADAP/SKAP55/RIAM module (and also Rap1) was properly re-
cruited to the plasma membrane in response to CXCR4 stimulation
in both SLP76-proficient and -deficient T cells (Fig. 7, C and D).
Moreover, SLP76low Jurkat T cells displayed no obvious defect in
CXCL12-mediated activation of Rap1 (Fig. 7E). These data sug-
gest that SLP76 is not required for CXCR4-mediated Rap1 acti-
vation and plasma membrane targeting of ADAP, SKAP55,
RIAM, and Rap1.
To exclude the possibility that ADAP and SKAP55 them-
selves are dispensable for CXCR4-regulated adhesion and mi-
gration, we down-regulated ADAP expression in human T cells
by siRNA and subsequently assessed both the adhesiveness and
migratory capacity of these cells in response to CXCL12. Fig.
7F shows that loss of ADAP strongly attenuated CXCR4-in-
duced adhesion and chemotaxis in human T cells. Similar data
were obtained when we assessed CXCR4-induced migration of
ADAPlow Jurkat T cells or of T cells obtained from ADAP-
deficient mice (data not shown). In summary, our data show that
in contrast to TCR stimulation, SLP76 is not involved in mem-
brane recruitment of the ADAP/SKAP55/RIAM module, the
activation of Rac or Rap1, and the induction of adhesion or
migration in response to CXCR4 stimulation.
Discussion
Together with the transmembrane adapter protein LAT, the cyto-
solic adapter protein SLP76 facilitates the formation of a signaling
platform (LAT/Gads/SLP76) following TCR stimulation that leads to
the activation of multiple intracellular signaling pathways (49). Our
previous data suggested that the signaling pathways controlled by the
Gads/SLP76 complex also include those regulating adhesion pro-
cesses (22). In this study, we confirm this hypothesis by showing that
suppression of SLP76 expression by RNAi in human T cells or the
FIGURE 7. The SLP76/Gads complex is not associated with LAT or transported to the plasma membrane upon CXC12 stimulation. A, Human T cells were
either left untreated, or stimulated with anti-CD3 mAbs (TCR) or CXCL12 for the indicated periods of time. Lysates were analyzed by Western blotting using
the indicated Abs. B, The cell extracts as described in A were used for immunoprecipitation using anti-Gads Ab. Precipitates were analyzed by Western blotting
using the indicated Abs. C, Plasma membrane or cytosolic fractions were prepared from untreated () or CXCR4-stimulated human T cells (). The individual
fractions were analyzed by Western blotting using the indicated Abs. Fractionation efficiency was assessed by Western blotting using anti-LAT (plasma membrane)
or anti-ERK1/2 (cytosol) Abs, respectively. One representative experiment of two is shown. D, Jurkat T cells were transfected with either control vector (shC) or
SLP76-suppression vector (shSLP76). After 48 h, plasma membrane or cytosolic fractions were prepared from untreated () or CXCR4-stimulated cells (). The
individual fractions were analyzed by Western blotting using the indicated Abs. Fractionation efficiency was assessed by Western blotting using anti-LAT (plasma
membrane) or anti-ERK1/2 (cytosol) Abs, respectively. One representative experiment of two is shown. E, Jurkat T cells were transfected with either control vector
(shC) or SLP76-suppression vector (shSLP76). After 48 h, cells were either left untreated, or stimulated with CXCL12 or anti-CD3 mAbs (TCR) for the indicated
time points. GTP-loaded Rap1 was precipitated using the GST-RalGDS-RBD fusion protein. Precipitates and aliquots of whole-cell extracts were analyzed by
Western blotting using the indicated Abs. One representative experiment of three is shown. F, Human T cells were transfected with control siRNA (siC) or siRNA
against ADAP (siADAP). After 72 h, transfectants were left untreated or stimulated with CXCL12 (for 10 min) or MnCl2 (for 30 min) and subsequently analyzed
for their ability to adhere to Fc-ICAM-1. Chemotaxis of the same cells was analyzed using a Transwell assay, as described in Materials and Methods. After 2 h,
the number of migrated cells into the lower chamber was determined. Suppression of ADAP and SKAP55 expression was determined by flow cytometry, and the
percentage of ADAP/SKAP55-expressing cells was calculated. Note that loss of ADAP abrogates SKAP55 expression (17). Data represent the mean and SE of
three independently performed experiments.
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Jurkat T cell line abrogates TCR-mediated conjugate formation, ad-
hesion to ICAM-1, and affinity/avidity maturation of LFA-1. Consis-
tent with previously published data (50, 51), we also found that loss
of SLP76 attenuates adhesion to fibronectin (the ligand of 1 inte-
grins; VLA-4) in response to TCR stimulation (J. Horn and S. Kliche,
unpublished data). Thus, SLP76 regulates TCR-induced inside-out
signaling, leading to the activation of 1 and 2 integrins.
Reorganization of the actin cytoskeleton is critically involved in
TCR-mediated integrin activation (33, 34). Moreover, it has previ-
ously been demonstrated that overexpression of SLP76 enhances F-
actin formation in response to TCR stimulation (52). In addition to
these overexpression data, we show in this study that loss of SLP76
attenuates TCR-mediated polymerization of F-actin. Together these
findings suggest that SLP76 is one of the (if not the) central molecule
that links the TCR to remodeling of the actin cytoskeleton.
The defect in actin dynamics most likely results from an ab-
rogated activation of the small GTPase Rac. Activation of Rac
depends on membrane recruitment and activation of the GEF
Vav1 and the Tec kinase Itk (20, 32). Both Vav1 and Itk asso-
ciate with SLP76 upon TCR stimulation, and both molecules
are required for F-actin formation at the IS, activation of Rac,
clustering of LFA-1, adhesion to ICAM-1, and conjugate for-
mation (20, 32). In this scenario, the role of Vav1 is to generate
sufficient pools of activated Rac to promote F-actin polymer-
ization through activation of proteins of the Wiskott-Aldrich
syndrome protein/Wiskott-Aldrich syndrome-Verprolin-homo-
logues protein family (33, 34). Our data showing attenuated
actin reorganization in SLP76low cells are in line with a model
in which loss of SLP76 blocks activation of Rac (and conse-
quently signaling events downstream of Rac) by impairing the
functions of Vav1 and Itk.
We are, however, aware that another group recently reported
that TCR-mediated actin remodeling is not attenuated in the
SLP76-deficient Jurkat T cell line J14 (53). In addition, no de-
fect in Rac activation upon TCR stimulation was observed in
this Jurkat variant (54). The reasons for these discrepant find-
ings in SLP76-deficient Jurkat T cells vs SLP76low human T
cells are unclear at present. A possible explanation may come
from compensatory mechanisms that developed in line J14 to
escape the selection pressure that cannot develop in short-term
manipulated T cells.
Besides the reorganization of the actin cytoskeleton, one critical
regulator of TCR-mediated conjugate formation and inside-out sig-
naling is the small GTPase Rap1 (6). Several studies have reported
that Rap1 activation critically depends on the expression of PLC1
(13, 26, 55). PLC1 signaling to Rap1 occurs via the nucleotide ex-
change factor calcium and diacylglycerol-regulated guanine nucleo-
tide exchange factor I that is activated by the second messengers cal-
cium and diacylglycerol (which both are generated following
phosphatidylinositol 4,5-bisphosphate hydrolysis by PLC1). Thus, a
defect in PLC1 activation in SLP76-suppressed T cells (see Fig. 1C
and supplemental Fig. 2, C and D) and consequently a failure to ac-
tivate CalDAG-GEFI might be largely responsible for the attenuated
activation of Rap1 after TCR triggering in the absence of SLP76.
However, additional mechanisms controlled by SLP76 may also con-
tribute to the block in Rap1 activation. For example, SLP76 is man-
datory for activation and membrane targeting of protein kinase C,
which has recently been identified to control TCR-induced Rap1 ac-
tivity by phosphorylation of Rap1-GEF2 (56, 57). Hence, loss of
SLP76 might affect several signaling pathways that are critical for
TCR-induced activation of Rap1.
We had previously shown that the ADAP/SKAP55/RIAM com-
plex is required for plasma membrane targeting of Rap1. More-
over, we had demonstrated that this event is crucial for inside-out
signaling and for the activation of integrins in response to TCR
stimulation. However, loss of ADAP and/or SKAP55 selectively
abrogated plasma membrane recruitment of Rap1, although TCR-
mediated activation of Rap1 was not affected (17, 21). In contrast,
the data presented in this study show that SLP76 is mandatory for
both membrane targeting and activation of Rap1 after TCR trig-
gering. The former event most likely involves the ADAP/SKAP55/
RIAM module, whereas the activation of Rap1 might be regulated
through the PLC1- or the protein kinase C-signaling pathways
that were discussed above. Hence, our data support a model in
which plasma membrane targeting and activation of Rap1 are two
interrelated, but distinctly controlled signaling events that are or-
ganized at the level of SLP76.
The activation of Rap1 and Rac as well as changes in F-actin
dynamics are also mandatory for affinity modulation of LFA-1,
T cell adhesion, and migration in response to CXCR4 stimula-
tion (6, 58). Given the central role of SLP76 in TCR-mediated
signaling, it was totally unexpected for us to find that loss of
SLP76 did not affect these events after CXCR4 stimulation and
that the SLP76/Gads complex was not recruited to LAT in re-
sponse to CXCR4 stimulation. The latter observation is proba-
bly due to the fact that the tyrosine residue within LAT that is
responsible for recruiting the Gads/SLP76 complex (Y171) is
not phosphorylated in response to CXCL12 triggering.
Our data also showed that SLP76 is not involved in the recruitment
(and consequently the activation) of downstream effector molecules
(e.g., Vav1) that are important for mediating adhesion and migration
processes of T cells in response to CXCL12 triggering (58). Indeed,
whereas Vav1-deficient T cells failed to polarize in response to
CXCL12 stimulation, SLP76low T cells showed no defect in this pro-
cess. Moreover, CXCL12-induced lateral migration velocity and che-
motaxis were unaffected in SLP76low T cells. Hence, it appears as if
SLP76 is dispensable for both adhesive and migratory processes in
response to CXCL12 stimulation.
In line with the functional data, we found that membrane re-
cruitment of the ADAP/SKAP55/RIAM module that is critical for
CXCR4-mediated adhesion and migration of T cells was not af-
fected by loss of SLP76. Although this finding strongly supports
our above discussed hypothesis that membrane targeting of Rap1
and activation of this GTPase are distinct processes that are indi-
vidually regulated by different signaling receptors, it opens the
question as to which signaling molecule provides the molecular
link between CXCR4 and the ADAP/SKAP55/RIAM module.
In this regard, it has recently been shown that the cytosolic
adapter protein Shc is phosphorylated upon CXCR4 stimula-
tion and assembles into a complex that includes Lck, ZAP70,
Vav1, and LAT (59). Moreover, Shc-deficient Jurkat T cells
show an attenuated migratory capacity and impaired F-actin
dynamics upon CXCR4 stimulation, and mutation of critical
tyrosine residues of Shc (YY238/240 or Y317) results in defective
phosphorylation of Vav1 and Itk (59). Thus, Shc might be an
attractive candidate to connect CXCR4 with the Vav1-Itk-de-
pendent pathway of F-actin polymerization and T cell migration
(59). It will be important to assess the role of Shc in CXCR4-
induced inside-out signaling, adhesion, and Rap1 activation in
future studies. Similarly, it needs to be analyzed whether, and if
so how, LAT is involved in this process. Experiments are cur-
rently set up in our laboratory to assess these points. Neverthe-
less, our data collectively and surprisingly indicate that, in con-
trast to TCR signaling, SLP76 is not a key component
connecting the chemokine receptor CXCR4 with the activation
of integrins and the induction of T cell adhesion and migration.
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Abstract
Transmembrane adaptor proteins (TRAPs) organize signaling complexes at the plasma membrane, and thus function as
critical linkers and integrators of signaling cascades downstream of antigen receptors. We have previously shown that the
transmembrane adaptor protein SIT regulates the threshold for thymocyte selection. Moreover, T cells from SIT-deficient
mice are hyperresponsive to CD3 stimulation and undergo enhanced lymphopenia-induced homeostatic proliferation, thus
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inactivation of Foxo1, a transcription factor of the Forkhead family that inhibits cell cycle progression and regulates T-cell
homeostasis. We have also shown that CD4+ T cells from SIT-deficient mice display increased CD69 and CD40L expression
indicating an altered activation status. Additional biochemical analyses further revealed that suppression of SIT expression
by RNAi in human T cells resulted in an enhanced proximal TCR signaling. In summary, the data identify SIT as an important
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Introduction
Transmembrane adaptor proteins (TRAPs) are a group of
molecules involved in immune cell activation [1]. Among these,
LAT, PAG/Cbp, NTAL/LAB and LIME are mainly localized in
the lipid rafts; while TRIM, SIT and LAX are excluded from the
raft fraction of the plasma membrane (reviewed in 1).
The common characteristic of TRAPs is the presence of several
tyrosine-based signaling motifs (TBSMs) within their cytoplasmic
tails. These are phosphorylated by protein tyrosine kinases of the
Src and Syk families, thereby, enabling the TRAPs to recruit SH2-
containing cytoplasmic signaling and/or effector proteins to the
plasma membrane. Thus, TRAPs function as important regulators
of signal transduction, connecting signal transducing cell-surface
receptors with downstream cellular signaling pathways [1].
During the last years, several groups have generated knockout
mice to investigate the in vivo function of these molecules. The data
demonstrate that TRAPs play an important role in the regulation
of immune-cell homeostasis. For example, LAT-deficient mice
display a severe alteration of the immune system and T-cell
development is completely blocked at the DN3 stage [2]. NTAL-
deficient mice develop a spontaneous autoimmune disease
characterized by splenomegaly, elevated levels of anti-double-
stranded DNA autoantibodies, and deposition of immune
complexes within the glomeruli [3]. Moreover, LAX-deficient
mice display hyperactive T, B and mast cells [4,5].
We have shown that SIT-deficient mice have altered thymic
selection and decreased numbers of peripheral naı¨ve T cells [6–8].
Moreover, T cells from SIT2/2mice also display hyperresponsiveness
to CD3 stimulation and undergo enhanced lymphopenia-induced
expansion [6,7]. Finally, we showed that the clinical course of experi-
mental autoimmune encephalomyelitis (EAE) is more severe in
SIT2/2 mice [6]. Thus, these data suggest that SIT plays an im-
portant role in T-cell homeostasis and in the establishment of tolerance.
In the present study, we extended our previous investigations on
the function of SIT. We focused particularly on how SIT regulates
signaling in T cells. We provide further evidence that SIT
negatively regulates proximal TCR signaling and TCR-mediated
phosphorylation of Akt in vitro. We additionally show that the
phosphorylation/inactivation of Foxo1, a transcription factor
downstream of Akt that inhibits cell cycle progression and
regulates T-cell homeostasis [9,10], is significantly enhanced in
SIT2/2 T cells. Moreover, CD4+ T cells within the secondary
lymphoid organs of SIT2/2 mice show signs of mild hyperactiva-
tion. In summary, our studies demonstrate that SIT is an
important inhibitory molecule of T-cell activation.
Methods
Human Ethics
Approval for these studies involving the analysis of TCR-
mediated signaling in human T cells was obtained from the Ethics
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e23761
Committee of the Medical Faculty at the Otto-von-Guericke
University, Magdeburg, Germany with the permission number
[107/09]. Informed consent was obtained in writing in accordance
with the Declaration of Helsinki.
Animal Ethics
All experiments were performed with samples taken from
euthanized animals in accordance with the German National
Guidelines for the Use of Experimental Animals (Animal
Protection Act, Tierschutzgesetz, TierSchG). Animals were
handled in accordance with the European Communities Council
Directive 86/609/EEC. All possible efforts were made to
minimize animal suffering and the number of animals used.
Mice
SIT2/2 mice were previously described [6]. The mice were
maintained in a pathogen free condition.
Flow cytometry
Single cell suspensions were prepared from spleen. Subsequent-
ly, 16106 cells were stained with different monoclonal antibodies
for 15 min at 4uC, washed and then analyzed on a FACSCalibur
using the CellQuest software (Becton Dickinson). Antibodies were
purchased from BD Pharmingen. Anti-CD40L (MR1) Abs was
from eBioscience.
The analysis of Annexin V, Bcl-2, and BrdU was performed as
previously described [7].
Cell culture
Peripheral blood mononuclear cells were isolated by Ficoll
gradient (Biochrom) centrifugation of heparinized blood collected
from healthy volunteers. Human T cells were further purified by
non-T cell depletion using the Pan T cell isolation kit II (Miltenyi
Biotec). The purity of T cells, determined by flow cytometry, was
usually more then 96%. Cells were maintained in RPMI 1640
medium containing 10% FBS, stable L-glutamine, and 1000 U/
ml penicillin/streptomycin at 37uC with 5% CO2 over night
before transfection. Jurkat T cells (ATCC) were maintained in
RPMI 1640 medium supplemented with 10% FBS (PAN) and
stable L-glutamine at 37uC with 5% CO2.
RNA interference, plasmids and cell transfection
The following SIT siRNA duplex containing 25 nucleotides
were purchased from Invitrogen: 59-GGC UGC AGA GGA GGU
GAU GUG CUA U-39, 59-GGG CUG UGA CGC UGC UAU
UUC UCA U-39 and 59-GCC AGA CCA GCA GGA UCC AAC
UCU U-39. As negative control we used a Renilla Luciferase
siRNA duplex from Invitrogen. To achieve efficient SIT
downregulation, primary human T cells (36106) were transfected
with a mix of siRNA (120 nM for each duplex) using the
Nucleofection Kit (Amaxa) according to the manufacturer’s
instruction or the Gene Pulser Xcell (Bio-Rad) as previously
described [11]. Cells were harvested 72 h after electroporation.
206106 Jurkat T cells were resuspended in 0.4 ml of PBS
containing Ca2+ and Mg2+ and incubated with a mix of siRNA
(200 nM for each duplex). Cells were transfected using Gene
Pulser II (Bio-Rad) set at 230 mV, 950 mF. Cells were cultured for
48 h after electroporation.
Cell stimulation, Immunoblotting, and
immunoprecipitation
Purified mouse CD4+ T cells were stimulated at 37uC with
5 mg/ml soluble anti-mouse CD3e (145-2C11; BD Biosciences)
without cross-linking for the indicated time points. Human T cells
were stimulated at 37uC by using OKT3 mAb without cross-
linking for the indicated time points. Cell lysates were prepared
and analyzed as previously described [12]. Anti-pS473Akt (PKB),
anti-pY319ZAP70, anti-pY191LAT, anti-pS256Foxo1, (all from Cell
Signaling Technology), anti-pY783PLCc-1, CD3e (Santa Cruz
Biotechnology), anti-pY145SLP-76 (BD Biosciences), anti-b-actin
(clone AC-15) (Sigma-Aldrich), anti-p-Tyr (4G10) (Upstate
Biotechnology), anti-ZAP-70 (Transduction Laboratories), and
anti-SIT [13] antibodies were used for Western blotting. The
intensity of the detected bands was acquired using the Kodak
Image station 2000R and analysis was performed using ID Image
software (Kodak).
In immunoprecipitation experiments, 106106 Jurkat T cells
were either left unstimulated or stimulated with 5 mg/ml purified
OKT3 mAb without cross-linking for 5 min at 37uC. Cell lysates
were immunoprecipitated with agarose-conjugated CD3f (Santa
Cruz Biotechnology) (Santa Cruz Biotechnology) antibody fol-
lowed by recombinant protein G-Sepharose 4B (Zymed Labora-
tories Inc.) at 4uC overnight. After washing, CD3f immunopre-
cipitates were resolved by SDS-PAGE, transferred to a membrane,
and analyzed by immunoblotting with the indicated antibodies.
Statistics
Statistical analyses were performed using GraphPad Prism
(GraphPad Software Inc., San Diego, CA). p values were
determined by an unpaired two-tailed Student’s t test.
Results
Loss of SIT results in an enhanced activation of the TCR-
mediated Akt-Foxo pathway
Recently, we have shown that SIT is an important modulator of
T-lymphocyte functions. SIT negatively regulates selection
processes within the thymus, peripheral T-cell activation and T-
cell homeostasis [6–8]. Moreover, SIT-deficient mice are more
susceptible to the development of EAE, a mouse model of Multiple
Sclerosis [6]. As the data suggest that SIT plays an inhibitory role
in T cells, we have next attempted to investigate whether SIT
influences TCR-mediated signaling. However, we have found that
SIT-deficient T cells develop sensory adaptation and are
refractory to stimulation upon extensive crosslinking of the
TCR/CD3 complex [7], Therefore, we used an alternative
stimulation condition that induces only a minimal crosslinking of
the antigen receptor on T cells, thus better mimicking the
physiological situation. Under these conditions of stimulation, we
found that SIT-deficient T cells show enhanced Akt phosphory-
lation (figure 1). We next investigated which intracellular signaling
pathways might be affected by the augmented Akt activation in
SIT-deficient T cells. We have shown that the loss of SIT results in
an enhanced T-cell proliferation [6,7]. Therefore, as a putative
target of Akt, we chose Foxo1, a member of the Forkhead family of
transcription factors, which is implicated in cell cycle regulation
[9]. One of the known functions of Foxo is to activate the
transcription of the cell cycle inhibitor p27kip1. Members of the
Foxo family are phosphorylated by Akt. Phosphorylation by Akt
results in the sequestration of Foxo1 into the cytosol, thus
preventing p27kip1 transcription and cell cycle inhibition. Although
well characterized in other cellular systems, it is poorly understood
how the Akt-Foxo pathway is activated in T cells. Recently, it has
been shown in T cells that Vav1 activates the PI3K-Akt-Foxo1
pathway, thus regulating cell cycle progression [14]. Loss of Vav1
resulted in reduced activation of Akt, blunted Foxo1 phosphor-
ylation, and cell cycle arrest. Conversely to Vav12/2 T cells, SIT-
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deficient T cells are hyperproliferative and display enhanced Akt
activation. Thus, we expected to observe an enhanced phosphory-
lation of Foxo1 in SIT2/2 T cells. As shown in figure 1, we found
that the level of phospho-Foxo1 is indeed higher in lysates from SIT-
deficient CD4+ T cells than in wild type cells. These results suggest
that SIT inhibits TCR-mediated Akt activation and Foxo1
phosphorylation, thus likely negatively regulating T-cell proliferation.
Suppression of SIT expression enhanced proximal TCR
signaling
As mentioned above, SIT-deficient mouse T cells develop
compensatory mechanisms that alter proximal TCR signaling [7].
Therefore, the enhanced phosphorylation of Akt observed in SIT-
deficient T cells could be due to the altered status of SIT-deficient
mouse T cells. To confirm that SIT regulates Akt activation, we
Figure 1. Enhanced phosphorylation of Akt and Foxo1 in SIT2/2 CD4+ T cells. Purified splenic CD4+ T cells from 3–4 month-old SIT2/2 or
WT mice were stimulated with non-crosslinked CD3 (clone 145-2C11) mAb for the indicated times. Samples were analyzed by Western blotting using
the indicated Abs. The phosphorylated Akt and Foxo1 bands were quantified using the ImageQuant software and values were normalized to the
corresponding b-actin signal. Graphs show the phosphorylation levels of Akt and Foxo1 shown as of arbitrary units 6 SEM of at least 3 independent
experiments. Statistical significance * p,0.05.
doi:10.1371/journal.pone.0023761.g001
Figure 2. Downregulation of SIT results in an enhanced TCR-mediated signaling in primary human T cells. A) Primary human T cells
were transfected with control or SIT-specific siRNA and 72 h later were stimulated with non-crosslinked CD3 (clone OKT3) mAb for the indicated
times. Cell lysates were analyzed by immunoblotting using phosphospecific antibodies for ZAP-70, PLCc-1, and Akt. Immunoblots verifying SIT
downregulation are shown. B) Phosphorylated bands were quantified using the ImageQuant software and values were normalized to the
corresponding b-actin signal. Graphs show the phosphorylation levels of ZAP-70, PLCc-1, and Akt shown as of arbitrary units 6 SEM of 2, 4, and 6
independent experiments, respectively. Statistical significance in B) * p,0.05 and **p,0.01.
doi:10.1371/journal.pone.0023761.g002
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performed RNA interference in primary human T cells. The
results shown in figure 2 demonstrate that, similar to mouse T
cells, downregulation of SIT in human primary T cells results in
an enhanced TCR-mediated Akt phosphorylation.
Collectively, these data suggest that SIT regulates T-cell
activation likely by inhibiting proximal TCR signaling events
leading to Akt activation. Therefore, we next analyzed proximal
TCR signaling in primary human T cells upon downregulation of
Figure 3. Suppression of SIT expression results in an enhanced proximal TCR signaling. siRNA duplex for SIT or control were introduced
in Jurkat T cells by electroporation. Cells were stimulated 48 h after transfection with non-cross-linked CD3 Ab for the indicated times. Total cell
lysates (A–B) or TCRf immunoprecipitates (C) were prepared and analyzed by Western blotting using the indicated Abs. The data are representative
of at least 3 independent experiments. Immunoblots verifying SIT downregulation are shown. Equal loading is shown by reprobing immunoblots
with antibodies specific for b-actin (A–B) or TCRf (C). The phosphorylated bands were quantified using ImageQuant software and values were
normalized to the corresponding b-actin signal. Graphs show the phosphorylation levels shown as of arbitrary units 6 SEM of at least 3 independent
experiments. Statistical significance * p,0.05 and **p,0.01.
doi:10.1371/journal.pone.0023761.g003
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SIT. As shown in figure 2, we found that the phosphorylation of
both ZAP-70 and PLCc-1 was enhanced. Thus, it appears that
SIT suppresses proximal TCR signaling.
In primary human T cells, the downregulation efficiency of SIT
is approximately 50% (figure 2A). In order to obtain a more
efficient suppression of SIT, we used the Jurkat T-cell line. As
shown in figure 3, we were able to downregulate up to 70–90% of
SIT in Jurkat T cells. Therefore, we used this well-characterized
T-cell line to further analyze the role of SIT on proximal TCR
signaling. The data presented in figure 3A show that, similar to the
downregulation of SIT in primary human T cells, also suppression
of SIT in Jurkat T cells results in an enhanced proximal TCR
signaling. SIT-depleted Jurkat T cells showed an augmented
TCR-mediated phosphorylation of ZAP-70, LAT, SLP-76 and
PLCc-1 (figure 3A). We additionally found that suppression of SIT
strongly enhanced Akt phosphorylation upon CD3 stimulation
even in a system where Akt is already constitutively activated
(figure 3B) [15,16].
To further elucidate the mechanism responsible for the
enhanced proximal TCR signaling, we investigated TCRf
phosphorylation and TCRf/ZAP-70 association. In agreement
with the enhanced phosphorylation of ZAP-70, LAT, SLP-76, and
PLCc-1, the phosphorylation of TCRf was also enhanced upon
suppression of SIT expression (figure 3C). Additionally, analysis of
Figure 4. Analysis of activation markers in SIT2/2mice. A) Splenic CD4+ T cells from 1 year-old SIT-deficient and wild-type mice were analyzed
for CD69 expression. Numbers within histograms indicate the percentage of cells. One representative profile per group is shown. B) Comparison of
CD40L expression on CD4+ T cells isolated from SIT-deficient (empty histogram) and wild-type (filled histogram) mice. Mean fluorescent intensity
(MFI) from one representative mouse per group is indicated. C) Comparison of CD5 expression on CD4+ T cells isolated from SIT-deficient (empty
histogram) and wild-type (filled histogram) mice. Bar graphs in A), B), and C) represent statistical analyses of CD69, CD40L, and CD5 expression,
respectively. Data derive from at least 5 mice per group. Statistical significance * p,0.05 and ***p,0.0001.
doi:10.1371/journal.pone.0023761.g004
Table 1. T-cell subsets in lymph nodes.
Genotype bTCR+CD45RB+ bTCR+CD62L+ CD4+CD25+ CD4+CD103+
SIT+/+ 32.863.5 (n = 6) 66.367.0 (n = 4) 7.560.2 (n = 3) 2.860.5 (n = 10)
SIT2/2 27.261.8 (n = 6) 60.367.5 (n = 4) 7.660.6 (n = 3) 2.860.4 (n = 10)
% of lymph node cells 6 SEM. n =number of examined mice.
doi:10.1371/journal.pone.0023761.t001
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immunoprecipitated TCRf showed that the association with ZAP-
70 was also increased in SIT dim T cells (figure 3C). Thus, these
data suggest that suppression of SIT expression enhanced
proximal TCR signaling at the level of TCRf phosphorylation.
Increased proportion of activated CD4+ T cells in aged
SIT-deficient mice
The PI3K-Akt pathway regulates a variety of cellular processes
including proliferation and apoptosis. Therefore, we next
investigated whether SIT2/2 mice developed any dysfunction
within the lymphocyte compartment. We found that CD4+ T cells
from aged SIT2/2 mice showed a modest but consistent increase
in the expression of CD69 and CD40L (figure 4A, 4B). Moreover,
these cells also express increased levels of CD5 (figure 4C), which
we have previously shown to be altered also in thymocytes and
CD8+ T cells [6,7]. We additionally analyzed the expression of a
variety of other surface markers, including CD3, CD4, CD25,
CD44, CD45RB, CD62L, and CD103, but we did not observe
significant differences between WT and SIT-deficient mice ([6,7],
table 1, and table 2). We also did not observe significant
differences in the size of secondary lymphoid organs. In fact, the
numbers of total splenocytes, total splenic CD4+ T cells, and
effector/memory CD4+ T cells in the spleen were not affected
(table 2). We found only a modest decrease in the number of CD4+
T cells in lymph nodes [6]. Finally, we also did not observe
significant differences in BrdU incorporation (figure 5A), in the
intracellular expression of the antiapoptotic molecules Bcl-2
(figure 5B), and in Annexin V expression (figure 5C) on ex vivo
isolated CD4+ T cells from SIT-deficient mice. Thus, these data
indicate that loss of SIT results in a partial alteration of the
activation status of CD4+ T cells without affecting their steady-
state proliferation or apoptosis. We hypothesize that the
compensatory mechanism displayed by SIT-deficient mice may
prevent the development of a more severe hyperactivation of T
cells and lymphoproliferative diseases.
Discussion
In this study, we provide new insights into the function of the
transmembrane adaptor protein SIT. We show that SIT inhibits
TCR-mediated signaling. This is an important finding as the
mechanism by which SIT inhibits T-cell activation was not clear.
We have previously shown that overexpression of SIT suppressed
transcription of an NFAT-driven reporter gene in the Jurkat T-cell
line [13]. However, we did not find obvious alterations of more
proximal TCR signaling events in this T-cell line upon strong
stimulation of the antigen receptor. Here, we now show that SIT
negatively regulates the phosphorylation/activation of crucial
signaling molecules such as ZAP-70, LAT, PLCc-1, and Akt
upon weak T-cell stimulation. Potential clues to the mechanisms
underlying the inhibitory effect of SIT on TCR-mediated signaling
may be provided by recent unexpected observations suggesting
that Grb2 amplifies TCR signaling by regulating Lck activation
[17]. SIT possesses two Grb2 consensus binding motifs and indeed
inducibly binds Grb2 upon TCR stimulation [13,18]. It has been
suggested that non-raft TRAPs inhibit antigen-receptor-mediated
signaling by sequestering signaling molecules away from the lipid
rafts [1]. Thus, we propose a scenario whereby SIT, by
functioning as a dosage regulator of Grb2 at the plasma
membrane, may in turn dampen proximal TCR signaling.
We have additionally uncovered a link between the transmem-
brane adaptor SIT and the Akt-Foxo1 pathway. Whether SIT
inhibits the phosphorylation of Akt-Foxo1 directly or indirectly
(i.e. by negatively regulating proximal signaling) requires further
investigation. Nevertheless, our study adds new insights into the
regulation of Foxo1 in T cells. We show that low affinity ligands
induced Foxo1 phosphorylation/inactivation in mouse T cells and
that the loss of SIT enhances the TCR-mediated inactivation of
Foxo1. Thus, SIT could modulate cell cycle progression (e.g.
triggered by low affinity ligands) via Foxo1. Intriguingly, similar to
SIT2/2 mice [6,7] Foxo12/2 mice display reduced numbers of
naı¨ve cells and an accumulation of CD44hi memory-like T cells
[10]. It will be interesting to determine whether SIT is involved in
the regulation of other members of the Foxo family such as Foxo4
and Foxo3a. In fact, the characterization of Foxo3a-deficient mice
revealed a phenotype resembling that of SIT-deficient mice, such
as T-cell hyperactivation, enhanced production of IL-2 and Th1
and Th2 cytokines [19].
We have previously shown that SIT regulates thymocyte
selection [6,8]. It is tempting to speculate that an altered Foxo-
mediated pathway also accounts for the defects in thymic
development in SIT-deficient mice. Indeed, it has been recently
Figure 5. Normal survival and steady-state proliferation of SIT-deficient CD4+ T cells. Lymph node cells were isolated and stained with
CD4 and CD8 mAbs. A) BrdU incorporation was measured for CD4+ T cells. Bar graphs indicate mean values6 SEM from 3 SIT2/2 and 5 SIT+/+ mice. B)
Intracellular Bcl-2 expression in CD4+ T cells from SIT2/2 (empty histogram) and SIT+/+ (filled histogram) mice. Isotype control is shown as a gray line.
C) Annexin V expression on CD4+ T cells. Bar graphs indicate mean values 6 SEM from 3 SIT2/2 and 3 SIT+/+ mice.
doi:10.1371/journal.pone.0023761.g005
Table 2. T-cell subpopulations in the spleen.
Genotype Splenocytes CD4+ CD4+CD44hiCD62lo
SIT+/+ (n = 8) 111.3624.6 19.666.5 8.6463.8
SIT2/2 (n = 8) 98.8626.1 19.664.1 11.4462.5
Number of cells in the spleen (6106) 6 SEM. n =number of examined mice.
doi:10.1371/journal.pone.0023761.t002
Negative Feedback Regulation by SIT
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e23761
shown that the adaptor protein SLP-65 regulates B-cell develop-
ment via Akt-Foxo3a [20]. How Foxo family members regulate
lymphocyte development is not yet clear. They may be involved in
the regulation of transcriptional activation of genes required in
developmental processes.
Our data suggest that the loss of SIT also results in an altered
function of CD4+ T cells. In fact, both TCR-mediated signaling
and the expression levels of CD69 and CD40L are augmented.
Moreover, we have previously shown that SIT-deficient T cells
were hyperresponsive to CD3 stimulation, produced higher
amount of cytokines in vitro, and more importantly, displayed a
more severe clinical course of the experimentally induced
autoimmunity EAE [6]. Thus, it appears that the loss of SIT
generally enhances the activation status of T lymphocytes. Despite
the fact that T cells are hyperactivated, SIT-deficient mice do not
develop signs of chronic inflammation or lymphoproliferation. We
propose that the development of compensatory mechanisms in
SIT-deficient mice [7] could serve to prevent autoimmunity or
chronic inflammatory processes, thus preserving immune func-
tions. However, whether sensory adaptation is completely effective
is currently under investigations. In fact, we have recently found
that SIT-deficient mice spontaneously develop anti-nuclear
antibodies and glomerulonephritis (Arndt and Simeoni, unpub-
lished observations).
In summary, the data presented here together with previous
studies demonstrate a critical function for SIT in fine-tuning
signals emanating from the TCR leading to proliferation,
differentiation and tolerance and further emphasize the important
role that TRAPs play in regulating homeostasis within the immune
system.
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Sos proteins are ubiquitously expressed activators of Ras.
Lymphoid cells also express RasGRP1, another Ras activator.
Sos and RasGRP1 are thought to cooperatively control full
Ras activation upon T-cell receptor triggering. Using RNA
interference, we evaluated whether this mechanism operates in
primary human T cells. We found that T-cell antigen receptor
(TCR)-mediated Erk activation requires RasGRP1, but not Grb2/
Sos. Conversely, Grb2/Sos—but not RasGRP1—are required for
IL2-mediated Erk activation. Thus, RasGRP1 and Grb2/Sos are
insulators of signals that lead to Ras activation induced by
different stimuli, rather than cooperating downstream of the TCR.
Keywords: T cells; Sos; Grb2; RasGRP1; Erk
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INTRODUCTION
Signalling via the Erk cascade is essential for cell-fate decisions
in many cell types including T lymphocytes [1]. On ligation
of the T-cell antigen receptor (TCR), the activation of the Erk
cascade is thought to occur through the action of two
distinct GEFs, RasGRP1 and the ubiquitously expressed Sos
proteins [2]. The activation of both RasGRP1 and Sos depends
on the transmembrane adaptor linker for activation of T cells
(LAT), which might therefore activate Ras via two distinct
pathways: (i) PLCg1-DAG-RasGRP1 and (ii) Grb2-Sos.
A key finding on Ras-Erk regulation in T cells came from recent
studies based on lymphoid cell lines, thymocytes and in silico
simulations showing that Ras activation is further controlled by an
unusual interplay between RasGRP1 and Sos [3,4]. This model has
important implications for T-cell function, as it helps to explain
how antigenic peptide/major histocompatibility complexes,
which are usually rare during in vivo infections, induce productive
T-cell activation [4]. These studies propose that, on initial receptor
triggering, Ras is exclusively activated by RasGRP1. Successively,
RasGTP will prime Sos thereby activating a positive feedback loop
and allowing full T-cell activation [4].
Thus, the current model postulates that the coordinated action of
RasGRP1 and Sos regulates the magnitude of Ras-Erk activation.
However, it has not yet been demonstrated whether this model for
TCR-mediated Ras-Erk is also valid in primary human T cells. Given
the central role of Erk activation in cell-fate specification processes
induced by TCR triggering, we have examined the molecular events
leading to Erk activation in peripheral human T cells in more detail.
Surprisingly, we found that Sos proteins and Grb2 are not
limiting for full Erk activation upon TCR stimulation in primary
human T cells. Thus, this study shows that the contribution of
Sos to the regulation of the magnitude of Erk activation in
primary human T cells is considerably different from that
predicted by the current model.
RESULTS
Sos and Grb2 are not limiting for Erk activation
On the basis of overexpression experiments in Jurkat T cells and
computer simulations, it has been postulated that Sos is important in
inducing robust Ras signalling in T cells [3,4]. To evaluate whether
Sos also has a similar role in primary T cells, we performed short
interfering RNA (siRNA)-mediated downregulation of Sos. We
initially evaluated the role of Sos1. As shown in Fig 1A, transfection
with RNA duplex efficiently suppressed Sos1 expression in peripheral
human T cells. Next, human T cells were treated with two different
CD3e monoclonal antibodies, MEM92 or OKT3. As expected,
suppression of Sos1 did not alter the activation status of the upstream
signalling molecules LAT, PLCg1 and ZAP-70 (data not shown).
However, when we analysed Erk activation we surprisingly found
that Erk phosphorylation was not reduced upon TCR stimulation in
primary T lymphocytes (Fig 1A). In the case of stimulation with
MEM92, Erk phosphorylation was even slightly enhanced (Fig 1A).
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To check whether the highly homologous Sos2 might compen-
sate for Sos1, we suppressed both Sos1 and Sos2 expression. As
shown in Fig 1B, downregulation of both Sos proteins also did not
affect but rather slightly enhanced Erk activation. Similar results
were obtained by analysing the level of phosphorylated Erk by flow
cytometry (supplementary Fig S1 online). Thus, these data indicate
that, in contrast to the proposed model, Sos proteins are not limiting
for full Ras-Erk activation in primary human T lymphocytes.
Sos constitutively binds the adaptor protein Grb2 by its two SH3
domains [5]. It is well established that, during T-cell activation, this
constitutive interaction recruits Sos to the plasma membrane upon
binding of the Grb2-SH2 domain to phosphorylated LAT [6]. The
interaction between Sos and Grb2 is also required to activate the
Ras-Erk cascade by binding of the Grb2-SH2 domain to phosphory-
lated Shc, an adaptor protein that directly binds to phosphorylated
TCR-z immunoreceptor tyrosine-based activation motifs [7]. In
addition to Sos, Grb2 could regulate Erk activation via Themis [8].
Hence, given the crucial role of Grb2 in regulating the activation of
Ras, we evaluated whether suppression of Grb2 expression in
primary human T cells would result in defective Erk activation.
The results presented in Fig 2 show that, similarly to Sos, the
downregulation of Grb2 did not reduce Erk activation. Rather, Erk
activation was slightly enhanced on strong TCR stimulation. Similar
results were obtained by using another set of siRNA duplex targeting
another region of Grb2 mRNA (data not shown).
To evaluate whether residual expression of Grb2 and Sos might
still be sufficient to activate Erk, we simultaneously downregulated
Sos1, Sos2 and Grb2. Also under this condition we did not
observe a reduction in Erk activation (supplementary Fig S2
online). In addition, we tested the hypothesis that Grb2 and Sos
might have a role in Ras activation in different T-cell subsets. To
assess this possibility, the expression of Grb2 and Sos1/Sos2 was
suppressed in CD4þ naive (supplementary Fig S3 online)
and memory T cells (supplementary Fig S4 online). Also in
these cells the downregulation of Grb2 and Sos1/Sos2 did not
reduce Erk activation.
As our data showed that Sos1 and Grb2 are not crucial for the
activation of Erk in primary human T cells, we next analysed
whether they might have a role in the activation of other mitogen-
activated protein kinases (MAPK). These investigations were
motivated by the observation that Grb2/ thymocytes [9] and
thymocytes with Grb2 haploid insufficiency clearly showed
weakened TCR-mediated JNK and p38, but normal Erk activation
[10]. Therefore, Grb2 and Sos1 might be required for JNK or
p38 activation rather than for Erk upon TCR stimulation.
However, we found that both molecules also do not influence
the activation of JNK and p38 in primary human T cells
(supplementary Fig S5 online).
According to the proposed model, Sos1 might function as an
amplifier of the Ras-Erk cascade in Jurkat T cells. Therefore, to
further test the validity of our approach, we suppressed the
expression of Sos1 and Grb2 in Jurkat T cells in an attempt to
recapitulate the current model. In marked contrast to primary
T cells, we found that downregulation of Sos1 (supplementary
Fig S6A online) or Grb2 (supplementary Fig S6B online) resulted in
a reduction of Erk activation on both strong and weak TCR
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stimulation in Jurkat T cells, thus confirmed that the prediction
made by the model are valid in the Jurkat T cell line.
Altogether, our data demonstrate that, conversely to Jurkat
T cells, Sos and Grb2 do not significantly contribute to full
TCR-mediated Ras-Erk activation in primary human T cells.
Surprisingly, both Sos and Grb2 seem to have a modest inhibitory
effect on Erk phosphorylation.
RasGRP1 regulates TCR-mediated Erk activation
To assess how Erk is activated on TCR triggering in primary human
T cells, we next investigated the role of another important Ras
activator, RasGRP1. To this end, we suppressed RasGRP1
expression by RNA-mediated interference. The data shown in
Fig 3A indicate that knockdown of RasGRP1 results in a severe
reduction of Erk phosphorylation, but not of another MAPK, p38
upon TCR stimulation (data not shown). The analysis of the
intracellular levels of phospho-Erk by flow cytometry confirmed
this result (supplementary Fig S1 online). Thus, in addition to be
involved in Erk activation in murine thymocytes [11], peripheral
CD8þ [12,13] and Jurkat T cells [3,14], RasGRP1 is also an
important regulator of Ras-Erk activation on TCR stimulation in
primary human T lymphocytes.
Interestingly, we found that Erk activation on CD3xCD28
stimulation is less dependent on RasGRP1, as suppression of
RasGRP1 only modestly affected Erk phosphorylation (Supple-
mentary Fig S7 online). This indicates that CD28 costimulation
either triggers RasGRP1-independent pathways to activate Erk (for
example, by activating a PKC-Raf axis) or that it enhances the
activation of the residual RasGRP1.
It has been proposed that, to be activated, Sos requires a
priming by active Ras produced by RasGRP1 [3]. Therefore, it is
possible that Sos function is masked by the dominant action of
RasGRP1 in primary human T cells, and hence, the effect of Sos
on Ras-Erk activation cannot be detected when sufficient amount
of RasGRP1 are expressed. To address this possibility, we
simultaneously suppressed both Sos1 and RasGRP1. If Sos1 and
RasGRP1 cooperate to regulate Ras activation, the suppression of
both Sos1 and RasGRP1 should affect Erk activation in a more
pronounced manner compared with RasGRP1 alone. Surprisingly,
we found that the further suppression of Sos1 neutralizes the effect
seen with RasGRP1 (Fig 3B). Similar results were obtained when
we suppressed both Grb2 and RasGRP1 (supplementary
Fig S8 online). Thus, these results suggest that rather than
cooperatively, Sos1 and RasGRP1 antagonize one another to
regulate Ras activation.
Sos and Grb2 regulate IL-2R-mediated Erk activation
As our data show that Sos and Grb2 are not crucial for
TCR-mediated Erk activation in primary human T cells, we next
analysed whether they have a role in the activation of Erk
downstream of other receptors such as the IL-2R, which is also
essential for T-cell activation. Therefore, we generated T-cell
blasts in which the expression of Grb2, Sos1/Sos2 and RasGRP1
was suppressed by RNA-mediated interference. Erk activation was
analysed on IL-2 stimulation. As shown in Fig 4A,B,D, suppression
of Grb2 and Sos1/Sos2 expression significantly reduced IL-2-
mediated Erk phosphorylation. Consistent with previously
published data [13], we found that the downregulation of
RasGRP1 did not affect IL-2-mediated Erk activation (Fig 4C,D).
The data in Fig 4 also show that the phosphorylation of STAT3,
which does not depend on Grb2/Sos, is not affected.
Collectively, these results show that Grb2/Sos and RasGRP1 are
involved in the activation of the Ras-Erk cascade downstream
of different receptors. Whereas Grb2/Sos are required for
IL2- but not TCR-mediated Erk activation, RasGRP1 is an activator
of Ras downstream of the TCR, but it is not required for
IL2 receptor signalling.
Finally, we tested whether suppression of Grb2, Sos1/Sos2 and
RasGRP1 affect T-cell activation. In agreement with previously
published data [12], we found that suppression of RasGRP1
expression markedly reduced CD3-mediated proliferation (Fig 5).
Similarly, also the suppression of Grb2 and Sos1/Sos2 reduced
proliferation. However, the effect of Sos1/Sos2 was more
pronounced than that of Grb2. It is possible that during
proliferation T cells might compensate the loss of Grb2 by other
adaptor molecules. In summary, the data indicate that both Grb2/
Sos and RasGRP1 are required for T-cell activation, albeit
downstream of different receptors.
DISCUSSION
Erk functions as a hub that directs signals coming from different
cell-surface receptors (for example, growth factor, chemokine,
cytokine and antigen receptors) towards the receptor-specific
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cellular response. How Erk performs its function has now begun to
be understood. It seems that signalling through the Erk module is
controlled by several upstream regulators that determine
the duration, the magnitude and the compartmentalization of
Erk activation [15]. Thus, by eliciting different modes of Erk
activation, the generation of a receptor- or ligand-specific cellular
outcome is ensured.
By using lymphoid cell lines and in silico simulations, it has
recently been proposed that RasGRP1 and Sos synergistically
function as upstream activators of the Ras-Erk cascade and
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cooperatively regulate the magnitude of Erk activation on TCR
stimulation [3,4,16]. The mechanism described by this model might
have important consequences for our understanding of how T cells
are selected in the thymus and how they are activated during an
immune response. Recently, conditional Grb2/ [9] and Sos1/
[17] mice have been generated. The data suggest that both Grb2 and
Sos1 are required at different stages during thymocyte development.
However, whereas Sos1 contributes to TCR-mediated Erk activation
in immature T cells, Grb2 seems to be dispensable.
Here, we have assessed the role of Sos and Grb2 in TCR-
mediated Erk activation in mature human T cells isolated from
peripheral blood. We found that the Grb2/Sos signalling module
does not appear essential for full Erk activation on TCR stimulation
in primary human T cells. Our data corroborate recent observations
showing that CD4þ peripheral T cells from conditional Sos1/
mice also display normal TCR-mediated Erk activation [17].
In addition, we show that Sos1 and Grb2 are required for Erk
activation in Jurkat T cells. Thus, our data demonstrate that the
prediction made by the current model of Ras-Erk activation is valid
for Jurkat, but not in primary human T cells. The reason for the
differential requirement of Grb2/Sos in primary versus Jurkat T cells
is not yet clear. Jurkat T cells seem to have the characteristic of
immature double-negative thymocytes. It is possible that the
requirement of Sos to activate Ras might differ in immature versus
mature T cells. This hypothesis seems to be in line with recent
observations by Kortum et al [17] suggesting that immature T cells
require Sos1 to activate Erk, whereas mature T cells are largely
Sos1 independent. However, it should also be kept in mind
that, although being the best characterized model system to study
TCR-mediated signalling, Jurkat are a transformed T-cell line that
are known to carry mutations in different genes which could
account for the observed differences to primary T cells.
Whereas RasGRP1 is the major activator of Ras in immature
CD4þCD8þ thymocytes [11,12], it seems that mature T cells use
both RasGRP1-dependent and -independent pathways to activate
Erk. In fact, despite the strong depletion (80%) of RasGRP1 that we
were able to archive in our experiments, Erk phosphorylation was
reduced by only about 50%. In line with our findings, recent data
show that RasGRP1 deficiency partially affects, but does not
completely abrogate TCR-mediated Erk activation, CD69 and
CD25 upregulation in peripheral mouse T lymphocytes [12,13].
One of the RasGRP1-independent pathways could be mediated
by RasGRF2. However, recent data suggest that loss of RasGRF2
induces no major changes in Erk activation in TCR-stimulated
splenic T cells [18]. Thus, it is currently not clear which RasGRP1-
independent signalling pathways contribute to Erk activation
in primary T lymphocytes.
Our experiments also show that, in addition to being not
crucial for TCR-mediated Ras-Erk activation, Sos1 and Grb2 are
not limiting for TCR-mediated JNK or p38 activation in primary
human T cells. These results were unexpected in light of recent
data demonstrating defective TCR-mediated JNK and p38 activa-
tion in Grb2/ [9] and Grb2þ / [10] thymocytes. This once again
indicates that thymocytes and peripheral T cells differentially use
signalling pathways to activate MAPKs upon TCR stimulation.
Another surprising observation of our study was that down-
regulation of Grb2 or Sos slightly enhanced TCR-mediated
activation of Erk. This suggests that Grb2 and Sos might function
as inhibitory signalling molecules in primary human T cells. In line
with this assumption, it has been proposed that Grb2 is required
for the assembly of an inhibitory signalling complex in T cells with
the lipid phosphatase SHIP1 and the adaptor protein Dok2, which
might inhibit Ras upon binding to RasGAP [19]. We have found
that the inhibitory effect on TCR-mediated Erk activation was
more evident on Grb2 knockdown compared with Sos1 or Sos1/
Sos2 suppression. Thus, it is likely that Grb2 performs parts of its
inhibitory signalling functions independently of Sos proteins.
An important question arising from our study is whether Sos
activity is required for the activation of Ras in mature T cells. We
explored the possibility that Sos1 and/or Sos2 regulates Ras
activation in signalling pathways mediated by other receptors,
such as the IL-2R. This hypothesis is in line with the observation
that cytokine receptors can also activate Ras-Erk on recruitment of
the Grb2/Sos complex to the phosphorylated receptor by the
adaptor protein Shc [20]. We found that Grb2/Sos is indeed
required to regulate IL-2-mediated Erk activation, whereas
RasGRP1 appears to be dispensable, which in line with recently
published data [13]. Thus, RasGRP1 and Grb2/Sos do not function
as integrators, but they might rather function as insulators allowing
the cells to distinguish the source of the input. Understanding the
spatio-temporal contribution of signals from different receptors
such as the TCR, the IL-2R and perhaps also by costimulatory
molecules, such as integrins, is essential to predict cellular
behaviour in a physiological context [21].
METHODS
Approval for these studies was obtained from the Ethics
Committee of the Medical Faculty at the Otto-von-Guericke
University, Magdeburg, Germany. Informed consent was obtained
in accordance with the Declaration of Helsinki Principles.
Cell culture. Peripheral blood T cells were isolated as
previously described [22]. T-cell blasts were generated
as previously described [21].
siRNA duplex and transfection. siRNA duplex containing 19
nucleotides with 2 thymidine 30 overhangs were purchase from
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Fig 5 | Grb2/Sos and RasGRP1 are required for T-cell activation.
Peripheral human T cells were transfected with siRNA duplex for Grb2,
Sos1/Sos2, RasGRP1 or siRNA Ctrl. Subsequently, cells were stimulated
with plate-bound CD3 for 2 days, pulsed with [3H]-thymidine and
processed for standard scintillation counting. Graphs show proliferation
expressed as arbitrary units±s.e.m. of Grb2-, Sos1/Sos2- and RasGRP1-
low T cells compared with Ctrls. Results are from at least three
independent experiments. Statistical significance ***Po0.001, *Po0.05.
Ctrl, control; siRNA, short interfering RNA.
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Invitrogen. The sequences were as follow: for Sos1: 50-UUGCCC
AUUUAUCAAUUGGTT-30, for Grb2: 50-CAUGUUUCCCCGCA
AUUAUTT-30, for RasGRP1: 50-GGGUGAGGAGUUACAUUG
CTT-30, and as negative control we used a Renilla luciferase
siRNA duplex 50-CCAAGUAAUGUAGGAUCAATT-30. For Sos2
downregulation, a STEALTH pool of three siRNAs (Invitrogen) was
used. To achieve efficient downregulation, primary human T cells
or T-cell blasts were transfected with siRNA duplex using either
the Nucleofection Kit (Amaxa) according to the manufacturer’s
instruction or the Gene Pulser Xcell (Bio-Rad) as previously
described [22]. Cells were collected 72 h after electroporation.
Cell stimulation and western blot analysis. Cell stimulations and
cell lysates were prepared as previously described [22]. Anti-CD3
OKT3 (ATCC) and anti-CD3 MEM92 (kindly provided by
V. Horejsi, Academy of Sciences of the Czech Republic, Czech
Republic) were used for stimulation as hybridoma supernatants.
Before experiments, hybridoma supernatants were titrated by
two-fold dilution (from 1:1 to 1:64) to determine the appropriate
monoclonal antibody concentration resulting in optimal T-cell
stimulation (judged by phosphorylated Erk staining). T-cell blasts
were stimulated as previously described [21]. Human recombi-
nant IL-2 (Peprotech) was used at 100U/ml. Western blots were
conducted with the following antibodies: anti-phosphospecific
antibodies (all from Cell Signaling Technology), anti-b-actin
(clone AC-15; Sigma-Aldrich), anti-RasGRP1 [23], anti-Sos1
(C-23), anti-Sos2 and anti-Grb2 (C-23; Santa Cruz Biotechnology).
Membranes were probed with the appropriate horseradish
peroxidase-conjugated secondary antibodies and developed using
the ECL detection system (Amersham Pharmacia).
Proliferation assay. To assess the proliferative capacity, cells
were transfected with siRNA duplex as described above, rested
overnight and stimulated in 96-well round-bottomed tissue
culture plates (Costar; Corning Life Sciences, Acton, MA) coated
with CD3 monoclonal antibody (MEM92). Cells were plated at
5 104 cells per well in quadruplicates and cultured for 2 days.
[3H]-Thymidine (0.3mCi per well; specific activity, 50Ci/mmol)
was added for the last 8 h, and the plates were collected using
a PHD cell harvester (Inotech AG, Basel, Switzerland). Thymidine
incorporation was measured by liquid scintillation counting.
Statistics. Statistical analyses were performed using GraphPad
Prism (GraphPad Software Inc., San Diego, CA). P-values were
determined by an unpaired two-tailed Student’s t-test. Statistical
significance is indicated by asterisks.
Supplementary information is available at EMBO reports online
(http://www.emboreports.org).
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Abstract 
Signaling through the TCR is crucial for the generation of different cellular responses 
including proliferation, differentiation, and apoptosis. A growing body of evidence indicates 
that differences in the magnitude and the duration of the signal are critical determinants in 
eliciting cellular responses. Here, we have analyzed signaling dynamics induced upon 
TCR/CD28 ligation in primary human T cells. We used CD3xCD28 antibodies either cross-
linked in solution (sAbs) or immobilized on microbeads (iAbs), two widely employed 
methods to stimulate T cells in vitro. It is well-established that sAbs induce only a transient 
signal but no productive T-cell responses (unresponsiveness). Conversely, iAbs induce T-cell 
activation and proliferation. A comparative analysis of the signaling properties of iAbs and 
sAbs revealed that, under proliferation-inducing conditions, feedback regulation is markedly 
different from that leading to an unresponsive state. In fact, whereas TCR-mediated signaling 
is prolonged by a positive feedback loop involving Erk upon iAbs stimulation, sAbs strongly 
activate inhibitory molecules that likely terminate signaling. In summary, our analysis 
documents TCR signaling kinetics and feedback regulation under proliferation-inducing 
conditions. As iAbs appear to mimic signaling dynamics triggered by antigen specific 
systems, we propose that iAbs are better suited for studying TCR-mediated signaling. 
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Introduction 
Triggering of the T cell receptor (TCR) by pathogens activates an intricate network of 
signaling cascades that are both temporally and spatially regulated. These signaling events 
will lead to transcriptional activation, proliferation, and differentiation of T cells that will 
ultimately culminate in an immune response. Defects in signal transduction may lead to either 
T-cell hyperresponsiveness or impaired T-cell activation, which result in autoimmunity or 
immunodeficiency, respectively. Thus, the study of how TCR signaling is initiated, 
propagated, and translated into a cellular response is important for the understanding not only 
of physiological processes, but also of the molecular mechanisms underlying human diseases. 
To reproduce in vitro the signaling events occurring during physiological T-cell activation, 
immunologists need to pay particular attention in the choice of an appropriate stimulus. In 
vivo, T cells are activated upon contact with APCs expressing the agonistic peptide in the 
context of MHC-molecules. Therefore, the ideal method to activate T cells in vitro e.g. for 
biochemical analyses should mimic these conditions. Antigen-based systems, however, can 
only be used for the in vitro stimulation of monoclonal T-cell populations expressing a 
specific TCR, usually expressed on transgenic T cells, and are thus limited to mouse models. 
Alternative methods such as artificial antigen-presenting systems employing both cell-based 
and acellular technologies have been developed and are now being used to different extents in 
immunotherapy (1). However, to assess biochemical events during T-cell activation, soluble 
polyclonal stimuli such as agonistic antibodies against the TCR/CD3 complex, the 
coreceptors and/or the costimulatory molecule CD28 are still largely used. For more than 30 
years, this method has been extensively employed and indeed, has provided significant insight 
into the molecular events occurring during T-cell activation. However, stimulations with 
soluble ligands have clear limitations, as they fail to reproduce the extra dimension of a cell-
cell contact and, more importantly, they do not induce T-cell responses (2, 3). Thus, it is 
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questionable whether TCR signaling induced upon stimulation with soluble Abs mirrors the 
physiologic signaling cascade leading to productive T-cell responses. Moreover, it appears 
somehow surprising that, despite the availability of tools that trigger T-cell activation, mimic 
APCs, and induce proliferation, the analyses of intracellular signaling pathways are still 
mainly performed by applying soluble ligands. 
Microbeads coated with functional antibodies, such as CD3 and CD28, are an efficient tool 
that can be used to expand T cells ex vivo especially for immunotherapeutic applications (4-
6). To date, there are no studies that directly compare the signaling properties and the 
functional effects of conventional stimuli such as CD3xCD28 Abs cross-linked in solution 
(sAbs), to those of attractive alternative systems that might more closely mimic cell-cell 
contact such as CD3xCD28 Abs immobilized on microbeads (iAbs). Therefore, we performed 
a systematic analysis of the signaling signatures induced by CD3xCD28 Abs either cross-
linked in solution or immobilized on microbeads. 
Our studies show that, conversely to sAbs that induce transient signaling, but not 
proliferation, iAbs trigger sustained TCR-mediated signaling, activate a positive regulatory 
circuit involving Erk phosphorylation of Lck, resulting in proliferation. Most importantly, 
signaling features of iAbs appear similar to those of antigen-driven systems. Our analysis 
document signaling kinetics and feedback regulation of iAbs and show that they are better 
suited than sAbs for studying TCR-mediated signaling. 
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Materials and Methods 
Human Ethics. Approval for these studies involving the analysis of TCR-mediated signaling 
in human T cells was obtained from the Ethics Committee of the Medical Faculty at the Otto-
von-Guericke University, Magdeburg, Germany with the permission number [107/09]. 
Informed consent was obtained in writing in accordance with the Declaration of Helsinki. 
T-cell purification. Peripheral blood mononuclear cells were isolated by Ficoll gradient 
(Biochrom) centrifugation of heparinized blood collected from healthy volunteers. Human T 
cells were further purified by non-T cell depletion using T cell isolation kits (Miltenyi 
Biotec). The purity of T cells, determined by flow cytometry, was usually more then 96%.  
T-cell stimulation. After isolation, T cells were cultured overnight in RPMI 1640 medium 
containing 10% FCS (PAN Biotech), 100 U/ml penicillin, 100 µg/ml streptomycin (all from 
Biochrom AG). Successively, T cells were stimulated with either soluble or immobilized 
CD3xCD28 mAbs as follow. For soluble Ab stimulation, 2x10⁶ cells were loaded with 10 
µg/ml biotinylated anti-human CD3 (clone UCHT1, eBioscience) and 10 µg/ml biotinylated 
anti-human CD28 (clone CD28.2, eBioscience) mAbs in 100 µl RPMI 1640 and incubated for 
10 min on ice. After washing, receptors were cross-linked by adding 25 µg/ml 
NeutraAvidin™ (Pierce). For microbead stimulation, SuperAvidin™-coated polystyrene 
microspheres (Ø=10.48 µm, 1.566e+7/ml density, Bangs laboratories, Inc./Polysciences 
Europe) were coated with biotinylated CD3 and CD28 mAbs (10 µg/ml each) for 30 min at 37 
°C in PBS. Antibody-coated microbeads were washed twice with PBS, resuspended in RPMI 
1640 and incubated with T cells in a 1:1 ratio. Stimulation of T cells was facilitated and 
synchronized by centrifugating samples for about 5 sec at 1000 rpm. 
Biotinylated IgG2a and IgG1 mouse immunoglobulins (eBioscience) were used as a control. 
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Stimulations in the presence of either the MEK1/2 inhibitor, UO126 (Cell Signaling 
Technology) or DMSO (Sigma-Aldrich) were performed by pre-incubating T-cells for 30 min 
with 10µM of the compounds before stimulation with soluble Abs. For microbead 
stimulation, 10µM of either UO126 or DMSO were added 30 min after stimulation. 
Western blotting. T cells were lysed in buffer containing 1% lauryl maltoside (N-dodecyl β-
maltoside), 1% NP-40, 1 mM Na3VO4, 1 mM PMSF, 10 mM NaF, 10 mM EDTA, 50 mM 
Tris pH 7.5, and 150 mM NaCl. Postnuclear lysates were separated by SDS-PAGE and 
transferred onto nitrocellulose membranes. Membranes were probed with the indicated 
primary antibodies and the appropriate HRP-conjugated secondary antibodies (Dianova) and 
developed using the ECL detection system (Amersham Pharmacia). The following antibodies 
were used for Western blotting in this study: anti-phospho(p)-T202/Y204 ERK1/2, anti-
pS473Akt, anti-pY319ZAP-70, anti-pY171LAT, anti-pY783PLC-γ1, anti-pS9GSK-3β, anti-pS338-
c-Raf, anti-pS217/221MEK1/2, anti-pS380p90RSK, anti-pY731-c-Cbl, anti-pY351-p56Dok-2 (all 
from Cell Signaling Technology), anti-Lck (from BD Transduction laboratories), anti-ZAP70 
(Santa Cruz Biotechnology), anti-pTyr (clone 4G10)-HRP conjugate (Millipore), and anti-β-
actin (clone AC-15) (Sigma-Aldrich). For quantifications of the Western blots, the intensity of 
the detected bands was acquired using the Kodak Image Station 2000R and analysis was 
performed using 1D ImageQuant software (Kodak). 
In vitro assays. Proliferation experiments were carried out in 96-well plates (Costar). Purified 
human T cells were labelled with 0,1 µM CFSE (Molecular Probes) for 10 min at 37°C. After 
washing, 2 x 105 cells were seeded in a total volume of 200 µl to each well and cultured in 
RPMI (supplemented with 10% FCS, antibiotics and β-Mercaptoethanol). T cells were either 
left unstimulated or were stimulated with soluble or immobilized CD3xCD28 mAbs as 
indicated above (see T-cell stimulation). For stimulation with plate-bound mAbs, 10µg/ml 
CD3 and 10µg/ml CD28 mAbs were incubated overnight in 96-well plates (Costar). T cells 
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were cultured for 72 h at 37°C, 5% CO2. Proliferation was assessed by CFSE dilution using a 
FACS-Calibur and the CellQuest software (BD, Biosciences). 
To determine T-cell activation, T cells were stimulated as described above. After 24h, T cells 
were stained with either FITC- or PE-labelled mAbs against CD25 and CD69 (BD, 
Biosciences), respectively. Cell associated fluorescence was analysed by flow cytometry. 
To quantify cell survival under different stimulation conditions, T cells were stimulated with 
either soluble or immobilized mAbs as described above, and resuspended in RPMI 
supplemented with 10% FCS at a density of 1x10⁶ cells/ml in a 24-well tissue culture plate. 
Cells were harvested after 24 h and the percentage of cells undergoing apoptosis was 
measured by flow cytometry using FITC-annexin V and propidium iodide (PI) (rh annexin 
V/FITC kit; Bender MedSystems) according to manufacturer’s instructions. Cell-associated 
fluorescence was acquired using a FACS Calibur and the data was analyzed using the 
CellQuest software (BD Biosciences). 
TCR internalization. To determine TCR internalization, 1x106 cells were stimulated with 
sAbs or iAbs as mentioned above at 37°C for 0–60 min. Cells were stained with PE-
conjugated TCRαβ mAb (BD Biosciences) for 15 min at 4°C and analyzed by flow 
cytometry. 
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Results 
iAbs induce activation and proliferation, whereas, sAbs result in T-cell 
unresponsiveness. 
It is generally accepted that soluble antibodies cannot induce productive T-cell responses. 
Indeed, we and others have demonstrated that OT-I transgenic T cells and cytotoxic T-
lymphocyte clones are not activated and do not differentiate upon stimulation with antibodies 
cross-linked in suspension (2, 3). Here, we have stimulated primary human T cells with either 
sAbs or iAbs and analyzed their functional responses. Figure 1A-B (middle panels) shows 
that treatment of T cells with iAbs led to a rapid expression of CD25 and CD69 and to a 
strong proliferative response. Conversely, treatment with sAbs failed to induce T-cell 
activation as indicated by the absence of CD69 and CD25 expression (Fig. 1A). In agreement 
with these data, proliferation assays revealed that T cells stimulated with sAbs also did not 
proliferate (Figure 1B). In contrast to sAbs, when CD3 (either OKT3, UCHT-1, or MEM92) 
mAbs were immobilized on plastic together with CD28, T-cell activation and proliferation 
were observed (Fig. 1A-B and data not shown).
Finally, similar to human T cells, also the stimulation of mouse T cells with TCRβxCD28 
mAbs either immobilized on microbeads or on a plastic surface resulted in proliferation, 
whereas, stimulation with the same antibodies cross-linked in suspension did not induce 
proliferation (Supplementary Fig.1A). 
We have previously shown that cross-linked soluble CD3xCD8 antibodies induce apoptosis 
rather than proliferation in OT-I TCR transgenic CD8+ mouse T cells (2). To analyze whether 
stimulation of human T cells with sAbs may also induce apoptosis, peripheral T cells were 
stimulated overnight and assayed for annexin V expression. Figure 1C shows that, in contrast 
to mouse, stimulation of human T cells with sAbs did not induce apoptosis. 
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Thus, despite the fact that sAbs are commonly used to activate proximal and distal TCR-
mediated signaling pathways, they are unable to induce productive T-cell activation and 
proliferation. 
CD3xCD28 antibodies immobilized on microbeads efficiently stimulate T cells. 
To date, little is known about the signaling properties of CD3xCD28 mAbs coated to 
microbeads. Therefore, we systematically compared proximal TCR signaling induced by 
either sAbs or iAbs. We initially established a protocol to efficiently stimulate T cells with 
iAbs. For stimulation, we employed 10µm microbeads that were coated with supravidine. 
This gives the possibility to bind any biotin-labeled antibody or recombinant protein on the 
surface of the microbeads. For this investigation, we used biotinylated CD3ε and CD28 mAbs 
unless indicated otherwise. Microbeads were coated with 10 µg/ml biotinylated CD3 and 
CD28 mAbs. Microbeads loaded with non-relevant antibodies of the same isotype were used 
as control. To induce rapid and synchronous cell contact with the beads, we performed a brief 
centrifugation (5 seconds at 1000 rpm) in a small volume (100 μl). Aliquots of the samples 
were taken at regular time intervals and analyzed on a FACS Calibur. Supplementary Figure 
2A shows that T cells and microbeads have clearly different physical parameters and can be 
easily visualized in FSC/SSC dot plots. The data also demonstrate that a significant number of 
cells associated with microbeads coated with CD3xCD28 Abs and appeared as a new 
population indicated in the gate RTc+m (Supplementary Fig. 2B). Conversely, in the control 
samples the emergence of a new population in the RTc+m gate is not detected (Supplementary 
Fig. 2B, upper panels), thus indicating that microbeads loaded with isotype controls do not 
bind to T cells. Successively, to quantify T cell-microbead association, we calculated the ratio 
Ra of the number of T cell/microbead conjugates (events in the RTc+m gate) to the total number 
of T cells (events in the RTc gate). We found that a high fraction of the cells was in contact 
with microbeads already after 5 min incubation, with Ra approximately 0.2 (Supplementary 
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Fig. 2C). After 15 min incubation, the proportion of T cells in contact with microbeads 
increased up to 50% (Ra=0.5). Afterwards, the Ra slightly decreased and stabilized at values 
close to 0.3. A similar association rate between Jurkat T cells and CD3-coated micrometric 
particles has been recently described (7). To further address this issue and to check whether 
mechanical stress during flow cytometry measurements resulted in the disruption of T 
cell/bead conjugates, we performed additional analyses. We initially assessed cell/bead 
conjugates using light microscopy (Supplementary Fig. 2D). We found that a high number of 
T cells rapidly established contact with iAbs. We next quantified cell/bead conjugates by 
manual counting in a haemocytometer. The data depicted in supplementary Figure 2E show 
that around 50-70 % of the cells conjugate with beads. As the proportion of T cell/microbead 
conjugates were slightly higher than those presented in supplementary Figure 2C, this 
suggests that some contacts with beads were lost during flow cytometry. Collectively, these 
data demonstrate that a very high number of iAbs interact with T cells, thus ensuring a focal 
stimulation.  
We next quantified the effectiveness of the stimulation by analyzing the proportion of cells 
displaying phosphorylated Erk1/2. The data presented in supplementary Figure 2F confirmed 
that the cell/bead contact indeed resulted in T-cell stimulation as the proportions of T cells in 
contact with beads and those displaying intracellular phospho-Erk1/2 were similar. Similar 
proportions of activated T cells were also obtained upon stimulation with sAbs 
(Supplementary Fig. 2G). Thus, the efficiency of iAbs and sAbs in stimulating T cells appears 
to be comparable. 
Sustained versus transient activation kinetics in TCR-mediated signaling induced by 
iAbs and sAbs, respectively. 
As sAbs and iAbs induce markedly different cellular outcomes, we next performed a 
comparative analysis of their signaling signatures in primary human T cells. In agreement 
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with the current knowledge, Figure 2 shows that stimulation with sAbs resulted in a strong 
and transient induction not only of global tyrosine phosphorylation (Fig. 2A), but also of 
ZAP-70, LAT, and PLCγ-1 (Fig. 2B, 2E). In contrast, when primary human T cells were 
treated with iAbs, global tyrosine phosphorylation (Fig. 2A) as well as the phosphorylation of 
ZAP70, LAT and PLCγ-1 (Fig. 2B, 2E) were very weak, but sustained. Thus, despite the fact 
that both iAbs and sAbs displayed efficient activation of downstream signaling molecules 
such as Erk (Supplementary Fig. 2F-G), focal stimulation of primary human T cells by iAbs 
resulted in a weak but sustained activation of proximal TCR signaling. 
We next analyzed signaling kinetics of more distal pathways. Surprisingly, we found that 
AKT- (Fig. 2C, 2F) and Erk1/2-mediated pathways (Fig. 2D, 2G) were very strongly 
activated under both conditions of stimulation. However, the activation induced by iAbs was 
sustained and lasted up to 90 minutes. An extended kinetic analysis revealed that Erk1/2 
phosphorylation was still detectable after 12h of iAbs stimulation (data not shown). Thus, 
despite the weak activation of proximal signaling molecules, iAbs are capable of inducing 
strong and prolonged activation of downstream signaling pathways. Conversely, the 
activation kinetics of the AKT- (Fig. 2C, 2F) and Erk1/2- mediated pathways (Fig. 2D, 2G) 
upon stimulation with sAbs were transient, peaked at 5-10 minutes, and rapidly declined 
thereafter. Cells that were treated with microbeads loaded with isotype controls failed to 
induce any detectable activation of TCR-mediated signaling, thus demonstrating that 
microbeads alone or irrelevant antibodies do not stimulate human T cells (Supplementary Fig. 
2F). 
Next, we compared activation kinetics of purified naïve and memory CD4+ T cells upon 
stimulation with sAbs and iAbs. Similar to unfractionated T cells, both CD4+ T-cell subsets 
displayed a transient activation upon sAbs stimulation, but sustained signaling upon treatment 
with iAbs (Fig. 3). Thus, it appears that the signaling signatures of sAbs and iAbs are 
independent of the differentiation status of the cells. 
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Moreover, similar activation kinetics were also observed when purified mouse splenic T cells 
were stimulated with TCRβxCD28 Abs immobilized on microbeads or cross-linked in 
solution (Supplementary Fig. 1B-C), suggesting that TCR-mediated signaling induced by 
antibodies immobilized on beads are not dependent on the antibody clones used for 
stimulation. 
We next analyzed the signaling kinetics induced by physiological stimuli. We used CD4  T 
cells isolated from OT-II transgenic mice that were stimulated with APCs alone as control or 
with APCs loaded with the 
+
OVA323–339 peptide. Supplementary Figure 3 shows that only 
stimulation with peptide loaded APCs, but not with control APCs induces phosphorylation of 
Erk1/2 in OT-II transgenic T cells. More importantly, phosphorylation of Erk1/2 seems to be 
weak, but sustained upon physiological stimulation. These data further corroborate our 
previous observations showing that the stimulation of CD8  T cells from + OT-I transgenic 
mice with physiological ligands also induced weak and sustained phosphorylation of 
signaling molecules such as Erk, PLCγ-1, and Akt (2). It is important to note that, similar to 
iAbs, physiological stimulation of OT-II and OT-I transgenic T cells also induces T-cell 
responses (data not shown and (2)).
Finally, we analyzed the signaling signatures induced by plate-bound antibodies 
(Supplementary Fig. 4), which also induce T-cell activation and proliferation (Fig. 1 A-B, 
lower panels). As shown in Supplementary Figure 4, we found that plate-bound Abs have 
signaling kinetics similar to iAbs. 
Collectively, these data show that stimulation of human T cells with immobilized Abs induce 
activation kinetics similar to those induced by physiological ligands in mouse TCR transgenic 
systems and that sustained activation of TCR signaling correlates with proliferation. 
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Feedback regulation of TCR-mediated signaling is markedly different upon stimulation 
with iAbs versus sAbs. 
The data presented above, show that sAbs induced a rapid, but transient TCR-mediated 
signaling kinetics, whereas stimulation with iAbs resulted in a sustained activation of a variety 
of signaling molecules. We next investigated how TCR-mediated signaling is differentially 
regulated under the two conditions of stimulation. We hypothesized that a fast internalization 
of the available TCR molecules upon stimulation with sAbs could provide an explanation for 
the rapid termination of TCR-mediated signaling. Therefore, we compared the expression 
levels of the TCR after stimulation with either sAbs or iAbs by flow cytometry. The data 
presented in Figure 4A show that stimulation with iAbs does not reduce, but rather slightly 
increases TCR levels. This is likely due to the fact that Abs bound to a solid matrix limit TCR 
internalization, but do not interfere with TCR expression. On the other hand, Figure 4A shows 
that sAbs induce a slow rate of TCR downregulation, which became evident after 30 minutes 
of stimulation. It is important to note that the majority of the signaling molecules that we have 
tested reverted to the dephosphorylated/inactive state already 15 minutes after sAbs 
stimulation (Fig. 2). Therefore, termination of TCR-mediated signaling occurs before TCR 
internalization. Moreover, we have previously shown that sustained TCR-mediated signaling 
and proliferation can occur under conditions of stimulation inducing TCR downregulation (2). 
Thus, on the basis of these observations, we exclude that TCR internalization induced by 
sAbs is the cause of transient signaling. 
Having ruled out this possibility, we next focused on the analysis of feedback regulation 
events, which have been shown to play a crucial role in T-cell activation (8-10). Proximal 
negative feedback loops can be activated by the TCR signalosome and can regulate the 
amplitude, the duration, and the specificity of the signal (reviewed in Acuto et al. (10)). We 
asked the question of whether the stimulation with sAbs induced the activation of negative 
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regulatory molecules that may terminate signaling, thus resulting in the transient signal 
observed above. Among the many inhibitory molecules organizing inhibitory regulatory 
circuits, we decided to focus on c-Cbl, an E3 ubiquitin ligase belonging to the CBL family, 
and the adaptor protein DOK2, which regulate TCR-mediated signaling through two different 
mechanisms. Whereas members of the CBL family are involved in the down-regulation of 
signaling molecules via ubiquitination (11), DOK2 and its homolog DOK1 inhibit the 
activation of signaling pathways by competing for binding to SH2 domains or by recruiting 
other negative regulators such as SHIP1 or RasGAP to the TCR signalosome (12). The 
activity of both c-Cbl and DOK2 has been reported to be regulated by tyrosine 
phosphorylation (12-14) and can be easily monitored by using anti-c-Cbl and anti-DOK2 
phosphospecific antibodies, respectively. Figure 4A and B shows that upon sAbs stimulation, 
T cells very rapidly and strongly phosphorylated both c-Cbl and DOK2, whereas, treatment of 
human T cells with iAbs resulted only in a very weak phosphorylation of both molecules. 
c-Cbl targets many signaling molecules for degradation, including ZAP-70 (15). Thus, we 
next tested whether sAbs in addition to inducing strong c-Cbl phosphorylation would also 
induce ZAP-70 ubiquitination and degradation, as we have previously shown in mouse OT-I 
T cells that ubiquitination of ZAP-70 results in the appearance of ZAP-70 bands displaying 
retarded migration in SDS-PAGE (2). We checked whether stimulation with soluble 
CD3xCD28 Abs also resulted in the appearance of ZAP-70 bands running at a higher 
molecular weight in primary human T cells and we found that activation/phosphorylation of 
c-Cbl upon stimulation with sAbs indeed correlates with retarded ZAP-70 migration (Fig. 
4C). Additionally, the data presented in Figure 4C suggest that stimulation with sAbs also 
induced ZAP-70 degradation. Conversely, stimulation with iAbs did not significantly induce 
either c-Cbl phosphorylation or retarded migration and degradation of ZAP-70 (Fig. 4B, 4C). 
Thus, it appears that stimulation with sAbs activates inhibitory feedback loops that may be 
responsible for terminating TCR-mediated signaling. 
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We next investigated whether positive feedback loops may be triggered by iAbs, thus leading 
to sustained activation of TCR-mediated signaling. In particular, we explored the regulatory 
circuit involving Lck phosphorylation by activated Erk (8). This model is based on 
observations showing that the Erk-mediated phosphorylation of Lck on serine 59 alters the 
ability of the SH2 domain of Lck to bind phosphotyrosines (16). Stefanova et al. further 
demonstrated that Erk-mediated phosphorylation of Lck prevents SHP-1 binding, thus 
interfering with SHP-1-mediated Lck inactivation (8). According to this model, active Erk 
would feedback to Lck to sustain signaling. To assess whether stimulation with iAbs triggers 
this Erk-mediated positive feedback loop, T cells were stimulated with iAbs and sAbs and the 
phosphorylation of Lck on S59 was detected by the appearance of a new Lck band running at 
59 kDa by Western blot (8). As shown in Figure 5A, stimulation of T cells with iAbs clearly 
resulted in the formation of p59 Lck whereas this shift in the molecular weight of Lck was 
only barely detectable upon sAbs treatment. Quantification of the proportion of p56 and p59 
Lck revealed that the majority of Lck is serine phosphorylated upon iAbs stimulation (Fig. 
5B). To demonstrate that the appearance of p59 Lck indeed depends on Erk-mediated 
phosphorylation, T cells were stimulated with iAbs for 30 min to allow Erk to become 
activated and subsequently incubated with UO126, an inhibitor of the Erk activator MEK. 
This treatment has previously been shown to abolish the conversion of Lck to the p59 form 
(8). In agreement with these observations, we also found that treatment of iAbs-stimulated T 
cells with UO126 completely abolished both Erk activation and the shift of Lck to the p59 
form (Fig. 5C-D). To check whether the inhibition of Erk-mediated Lck phosphorylation also 
resulted in a reduction of its activity, we investigated phosphorylation levels of downstream 
signaling molecules that are substrate of Lck, such as the tyrosine kinase ZAP-70, and the 
adaptor protein LAT whose phosphorylation depends on ZAP-70. The data presented in 
Figure 5C-D show that the phosphorylation of both ZAP-70 and LAT is reduced upon MEK 
inhibition, thus indicating that Erk-mediated Lck phosphorylation may enhance its response. 
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Conversely, preincubation of sAbs-stimulated T cells with the MEK inhibitor reduced Erk 
phosphorylation, as expected, but not ZAP-70 or LAT phosphorylation (Fig. 5E-F). 
Collectively, these data suggest that only stimulation with iAbs activates an Erk-mediated 
positive feedback loop. Importantly, the regulatory circuit induced by iAbs seems to mimic a 
previously described mechanism that is induced in T cells upon physiological stimulation (8). 
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Discussion 
Current stimulation protocols to study T-cell signaling are mainly based on agonistic 
antibodies cross-linked in solution. This method has several advantages such as low costs, 
easy handling, high reproducibility, effective activation of signaling molecules, polyclonal 
activity and, most of all, it is well-characterized. However, despite its routine use to study 
signaling during T-cell activation, it is known that sAbs induce only a transient activation 
signal that results in an abortive response. Moreover, soluble antibodies do not reproduce the 
cell-cell contact induced by an APC and therefore fail to mimic at least one crucial event 
occurring during T-cell activation.  
Here, we have analyzed whether Abs immobilized on microbeads, which mimic APCs and 
induce proliferation, represent an alternative and more suitable method to sAbs for the 
stimulation of T cells for signaling studies. We further compared the kinetics of central 
signaling events induced by CD3xCD28 Abs immobilized on microbeads to those generated 
by CD3xCD28 Abs cross-linked in solution. We document profound signaling differences 
between these methods of stimulation.  
One of the most important findings is that the sustained activation and feedback regulation 
induced by iAbs recapitulated signaling events observed in antigen-specific systems. In fact, 
we have previously shown that H-2Kb molecules loaded with the SIINFEKEL peptide 
triggered prolonged activation of ZAP-70, LAT, PLCγ-1, Erk1/2, and Akt and also induced 
proliferation in OT-I transgenic T cells (2). Further, Stefanova et al. had demonstrated that the 
sustained signaling, which is necessary for transcriptional activation triggered upon 
stimulation with agonist peptides, is supported by a positive feedback loop involving 
phosphorylation of Lck by activated Erk in 5C.C7 transgenic T cells (8). 
In addition to the immobilization on beads, Abs can also be bound to cell culture plates. 
Similarly to iAbs, also plate-bound antibodies induce functional responses. Previous studies 
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have shown that plate-bound, but not soluble CD3 Abs induce sustained TCR-mediated 
tyrosine phosphorylation and MAPK activation in murine CTL clones (3, 17, 18). However, 
the relevance of these studies is limited. First, they utilize CD8+ T-cell clones, which were 
expanded in the presence of IL-2 and were stimulated with CD3 Abs alone in the absence of 
costimulation. Therefore, it is questionable whether these data also apply to primary human T 
cells. Second, the authors do not provide insight into the mechanisms regulating the different 
activation kinetics. Conversely, in our studies we have provided an extensive biochemical 
characterization of signaling networks upon stimulation with either sAbs or iAbs in total 
human peripheral T cells as well as in naïve and memory CD4+ T cells. To our knowledge 
similar studies describing the signaling properties of Abs immobilized either on beads or cell 
culture plates have not been performed. Despite the fact that both iAbs and plate-bound 
antibodies induce functional responses and likely similar signaling kinetics, antibodies 
immobilized on microbeads allow an easier handling of the samples during stimulation 
compared to plate-bound antibodies. Therefore, we believe that iAbs are a valid method of 
stimulation that allows easy and large scale biochemical analyses of TCR-mediated signaling 
events. 
The availability of a method that mimic antigen-specific systems is of particular importance to 
study primary human T-cells, which can not be stimulated on a large scale by antigen-specific 
systems. Data from primary human T cells are still scarce and the bulk of our knowledge on 
signaling in human T cells is based upon data obtained from the analysis of lymphoid cell 
lines that were stimulated with cross-linked soluble mAbs. Experiments employing primary 
human cells stimulated with more physiological systems are necessary not only to study the 
basis of T-cell function, but are also essential to understand the molecular basis of human 
diseases such as autoimmunity and cancerogenesis. 
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We have further shown that iAbs allowed the analysis of the dynamics and feedback control 
of signaling cascades that correlate with a productive response in primary human T cells. As 
an example, we analyzed the regulation of the Erk signaling pathway, which has been 
demonstrated to be crucial for the translation of input signals into specific cellular responses 
in different cell types (19, 20). We have found major differences in the regulation of Erk 
activation between sAbs and iAbs. TCR-mediated Erk activation upon stimulation with iAbs 
appears to be not only quantitatively, but also qualitatively different from that induced by 
sAbs. It has been shown that Erk activation in cytotoxic mouse T lymphocytes after 
stimulation with immobilized antibodies depends on nPKCs, whereas, sAbs stimulation 
activates Erk also via cPKCs (18). Thus, it will be important in the future to investigate 
whether other qualitative and also quantitative differences in TCR-mediated signaling exist 
between iAbs and sAbs. This may lead to a substantial revision of the current knowledge on 
signaling in human T cells. We also believe that the data presented here may also help to 
explain why in vitro biochemical data, which are usually obtained by employing sAbs that 
may trigger pathways not active under physiological conditions, do not always correlate with 
functional responses. 
In summary, our studies clearly show that iAbs are a valid alternative to sAbs for stimulation 
of T cells for signaling analysis. First, iAbs are easy and ready-to use. Second, iAbs trigger 
signaling pathways correlating with T-cell activation and proliferation. Third, we show that 
TCR signaling kinetics and feedback regulation under proliferation-inducing conditions 
(iAbs) are markedly different from those leading to unresponsiveness (sAbs). 
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Legends to the figures 
Figure 1. Analysis of the functional effects of sAbs and iAbs. 
Purified human T cells were treated as indicated. A) 24h after stimulation, the activation of T 
cells was analyzed by staining with CD25 and CD69 and flow cytometry. B) T cells were 
labeled with CFSE and stimulated as indicated. Proliferation was assed after 72h by analyzing 
CFSE content on a FACS Calibur. C) T cells were stimulated as indicated for 24h. Cell 
survival was assessed by FITC-annexin V and PI staining. One representative experiment of 
at least three independent experiments is shown here. 
Figure 2. sAbs induce transient, whereas, iAbs induce sustained signaling. 
A-D) Purified human T cells were treated with either soluble (sAbs) or immobilized (iAbs) 
CD3xCD28 mAbs for the indicated time periods. Samples were analyzed by Western blotting 
using the Abs indicated. One representative immunoblot is shown. Phosphorylated bands in 
B, C, and D were quantified using the ImageQuant software and values were normalized to 
the corresponding β-actin signal. Data in E-G represent the mean of the phosphorylation 
levels shown as arbitrary units ± SEM of 5 independent experiments. 
Figure 3. sAbs induce transient, whereas, iAbs induce sustained signaling in human 
naïve and memory CD4+ T cells. 
Human naïve A-B) and memory C-D) CD4+ T cells were treated with either soluble (sAbs) or 
immobilized (iAbs) CD3xCD28 mAbs for the indicated time points. Samples were analyzed 
by Western blotting using the indicated Abs. One representative immunoblot is shown. 
Phosphorylated bands in A) and C) were quantified as described in Figure 2 and data are 
shown in B) and D), respectively. Graphs show the mean of the phosphorylation levels shown 
as arbitrary units ± SEM from 1 to 5 experiments. 
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 Figure 4. sAbs, but not iAbs, induce strong activation of negative regulatory molecules 
and ZAP-70 degradation. 
Purified human T cells were treated with either soluble (sAbs) or immobilized (iAbs) 
CD3xCD28 mAbs for the indicated time points. A) Measurement of TCR internalization. The 
expression of the TCR was assessed by PE-conjugated anti-TCRαβ mAb staining analysis by 
flow cytometry. Data represent the % of the mean fluorescence intensity (MFI) of the TCR 
expression relative to time 0 of 4 independent experiments. B) The phosphorylation of c-Cbl 
on Y731 and Dok2 on Y351 was determined by Western blotting. The phosphorylated c-Cbl and 
Dok2 bands were quantified using the ImageQuant software and the values normalized to the 
corresponding β-actin signal. Data represent the mean of the phosphorylation levels shown as 
arbitrary units ± SEM of at least 4 independent experiments. C) The expression of ZAP-70 
was determined by Western blotting. Equal loading is shown by reprobing immunoblots with 
antibodies specific for β-actin. ZAP-70 bands were quantified as above. Data represent the 
mean of the expression levels shown as arbitrary units ± SEM of 6 independent experiments. 
Figure 5. iAbs induce an Erk-mediated positive feedback loop. 
A) Purified human T cells were treated with either soluble (sAbs) or immobilized (iAbs) 
CD3xCD28 mAbs for the indicated time points. Lck expression was detected in cell lysates 
by anti-Lck immunoblotting. B) Bands corresponding to p56 or p59 Lck were quantified as 
described in Figure 3. Data represent the mean of the levels of p56, p59 and total (p56+p59) 
Lck shown as arbitrary units ± SEM of 5 independent experiments. C) Purified human T cells 
were treated with iAbs alone for 30 min and then either DMSO or the MEK inhibitor UO126 
was added and incubated for an additional 30 to 60 min. Samples were analyzed by Western 
blotting using the indicated Abs. D) Bands in C) were quantified and the values normalized as 
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described. Graphs show the mean of the phosphorylation levels of Erk1/2, ZAP-70, and LAT 
or the level of p59 Lck as arbitrary units ± SEM of 4 independent experiments. E) Purified 
human T cells were preincubated either in the presence of DMSO or the MEK inhibitor 
UO126 and successively stimulated with sAbs for the indicated time points. Sample were 
analyzed by Western blotting using the indicated Abs. F) Bands in E) were quantified as 
described above and the data from two independent experiments are shown. 
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Legends to the Supplementary Figures 
Supplementary Figure 1. Analysis of the biochemical and functional effects of sAbs and 
iAbs in mouse splenic T cells. 
Purified mouse splenic T cells were treated as indicated. A) Proliferation was assed after 72h 
by analyzing CFSE content on a FACS Calibur. One representative experiment of three 
independent experiments is shown here. B) Samples were analyzed by Western blotting using 
the indicated Abs. One representative immunoblots is shown. C) Phosphorylated bands in B) 
were quantified as described in Figure 2. Data represent the mean of the phosphorylation 
levels shown as arbitrary units ± SEM from 5 independent experiments. 
Supplementary Figure 2. Analyses of the binding and stimulation efficiency of 
Tcell/microbead. 
A) T cells and microbeads alone were analyzed by side scattering versus forward scattering 
dot plots. B) Subsequently, T cells and microbeads loaded either with isotype controls 
(isotypes, upper panels) or CD3xCD28 mAbs (iAbs, lower panels) were brought into contact 
for the indicated time periods. T cell/microbeads conjugates (RTc+m) are clearly distinct from 
free T cells (RTc) and microbeads (Rm). C) Statistical analysis of the ratio (Ra) between the 
numbers of T cell/microbead conjugates (events in the RTc+m gate) to the total number of T 
cells (events in the RTc gate) is presented. D) Transmission light images of T cells incubated 
with microbeads loaded either with isotype controls (isotypes, upper panels) or CD3xCD28 
mAbs (iAbs, lower panels) are shown. E) T cell/microbeads conjugates were diluted and 
manually counted in a haemocytometer. The graph shows statistical analysis of the ratio (Ra) 
between the numbers of T cell/microbead conjugates to the total number of T cells from three 
independent experiments. F) Human T cells were purified and stimulated with beads loaded 
either with CD3xCD28 mAbs (iAbs) or isotype control (isotypes) for the indicated time 
points. The level of pErk1/2 as marker of activation was measured by intracellular staining. 
Data represent the mean proportions of pErk1/2 positive cells ± SEM of 3 independent 
experiments. G) Human T cells were purified and either left unstimulated (medium) or were 
treated with CD3xCD28 mAbs cross-linked in solution (sAbs) for 2 min. The graph shows the 
mean proportions of pErk1/2 positive cells ± SEM from 3 independent experiments. 
Supplementary Figure 3. Stimulation of OT-II transgenic T cells with APCs loaded with 
the agonist peptide OVA323–339 induces sustained Erk1/2 activation. 
Purified mouse splenic OT-II transgenic T cells were stimulated with APCs either left 
unloaded or loaded with the agonist peptide OVA323–339 for the indicated time points. Samples 
were analyzed by Western blotting using the indicated Abs. One representative immunoblot is 
shown. 
Supplementary Figure 4. Stimulation of primary human T cells with plate-bound 
CD3xCD28 Abs induces sustained signaling. 
Purified human peripheral T cells were stimulated with plate-bound CD3xCD28 Abs for the 
indicated time points. Samples were analyzed by Western blotting using the indicated Abs. 
One representative immunoblot is shown. 
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Abstract 
Lymphocyte activation is crucial for the generation of immune responses. In vitro 
studies have demonstrated that transmembrane adaptor proteins (TRAPs) are critical 
regulators of lymphocyte activation. However, more recent in vivo studies have 
demonstrated that, with the exception of LAT, TRAPs such as SIT, NTAL, and LAX 
only minimally affect immune cell function. Additional studies have suggested that the 
mild or the apparent lack of a phenotype displayed by most TRAP knockout mice may 
be explained by the existence of functional redundancy among this family of adaptors. 
In fact, it has been shown that the phenotype of NTAL/LAT or SIT/TRIM double-
deficient mice is more severe than that of the single knockouts. Here, we have evaluated 
whether SIT and the related transmembrane adaptor LAX have overlapping functions 
by generating SIT/LAX double-knockout (DKO) mice. We show that DKO, in contrast 
to single-knockout mice, accumulate large numbers of activated CD4+ T cells in the 
spleen. Moreover, conventional B cells from DKO mice are hyperproliferative upon 
CD40 stimulation. Additionally, we found that DKO mice displayed an expansion of the 
B1 cell pool in the peritoneal cavity, hypergammaglobulinaemia, and an enhanced 
immune response to the T1-independent antigen TNP-LPS. Finally, we demonstrate that 
SIT/LAX double deficiency resulted in a more pronounced breakdown of peripheral 
tolerance and the development of autoimmunity characterized by antinuclear antibodies 
(ANAs), and renal disease (glomerulonephritis and proteinuria). Collectively, our data 
indicate that SIT and LAX are important negative regulators of immune responses that 
functionally cooperate. 
 
  4 
Introduction 
Transmembrane adaptor proteins (TRAPs) represent a family of molecules that organize 
membrane-proximal signaling. To date, seven TRAPs have been identified. Among these, 
LAT, PAG/Cbp, NTAL/LAB and LIME are mainly localized in the lipid rafts, while TRIM, 
SIT, and LAX are excluded from the raft fraction of the plasma membrane (reviewed in 1). 
The common features of all known transmembrane adapters are the presence of a short 
extracellular domain, a single membrane-spanning region, and multiple tyrosine-based 
signaling motifs (TBSMs) within the cytoplasmatic tail [1, 2]. These TBSMs become 
phosphorylated after antigen receptor engagement and allow inducible protein-protein 
interactions. Therefore, by recruiting other signal transducing molecules, TRAPs represent 
important regulators of signaling cascades that are required for the propagation and fine-
tuning of the signal from the antigen receptor. 
During the last years, the physiological role of TRAPs has been highlighted in studies using 
cell lines and knockout mice. The generation of LAT-/- mice revealed its essential role in T-
cell development. LAT-deficient mice lack peripheral T cells, whereas the generation of B 
cells and NK cells was not altered [3]. In addition to LAT, other TRAPs are also important for 
proper immune function. However, loss of these adaptors only modestly affects immune 
functions. For example, NTAL-deficient mice developed an autoimmune disease with age [4], 
whereas LAX-deficient mice show abnormally activated lymphocytes, spontaneous germinal 
center formation in the spleen of unimmunized mice, hypergammaglobulinemia, and 
hyperreactive mast cells [5, 6]. Moreover, we have shown that SIT-deficient mice displayed 
an enhanced positive selection in the thymus, hyperactivated peripheral T cells, and an 
increased homeostatic proliferation. [7-9]. Conversely, mice lacking TRIM [10], PAG [11, 
12], and LIME [13] have no significant alteration of the immune system. 
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The observation that TBSMs are highly conserved among transmembrane adaptors and that 
knockout mice have no phenotype or only a mild alteration of the immune system has led to 
the hypothesis that TRAPs are functionally redundant [1]. Indeed, by generating SIT/TRIM 
double-deficient mice, we have shown that SIT and TRIM (which share the two TBSMs: 
YGNL and YASV/L, respectively) modulate T-cell development by setting the threshold for 
thymocyte activation [14]. In addition, the analysis of LAT/NTAL double-deficient mast cells 
revealed that they display a more severe defect in FcεRI-mediated activation than mast cells 
lacking LAT alone, thus demonstrating that LAT and NTAL function in a complementary 
manner [15, 16]. 
In the present study, we have evaluated whether SIT and LAX cooperate during lymphocyte 
development and activation by generating SIT/LAX double-knockout (DKO). The rational 
basis for this approach was given by several structural and functional similarities between the 
two adaptors: (i) SIT and LAX are both non-raft associated TRAPs (ii) they both negatively 
regulate antigen receptor mediated signaling, (iii) they share canonical Grb2-binding motifs 
(YxN) and associate with Grb2 upon antigen receptor stimulation, and finally, (iv) they 
possess an overlapping tissue distribution in lymphocytes [4, 7-9, 17, 18]. 
We show that aged DKO mice accumulated larger numbers of activated CD4+ T cells in the 
spleen. In addition, we also demonstrated that, despite the fact that SIT and LAX do not 
overlap during thymic selection and during the development of conventional B cells, they 
cooperatively regulate the generation of B1 B cells and immune functions, such as basal 
serum immunoglobulin levels and T-I immune responses. Finally, we found that DKO mice 
develop elevated levels of anti-nuclear antibodies (ANAs) in the sera and further develop 
glomerulonephritis and proteinuria. This lupus-like disease appears to be more severe than in 
age-matched SIT- or LAX-single knockout mice. 
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In summary, our studies shed further light on the role of non-raft transmembrane adaptors in 
lymphocytes and demonstrate that SIT and LAX are important regulators of immune function 
that partially overlap. 
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Material and methods 
Animal Ethics. All experiments were performed with samples taken from euthanized animals 
in accordance with the German National Guidelines for the Use of Experimental Animals 
(Animal Protection Act, Tierschutzgesetz, TierSchG ). Animals were handled in accordance 
with the European Communities Council Directive 86/609/EEC. All possible efforts were 
made to minimize animal suffering and the number of animals used. 
Mice. SIT-/- and LAX-/- mice were previously described [5, 7]. LAX-/- mice were kindly 
provided by W. Zhang. SIT-/- mice were mated with LAX-/- to generate SIT+/-LAX+/- mice, 
which were then crossed to generate SIT-/-LAX-/- double-deficient (DKO) mice. Mice were 
genotyped for SIT and LAX mutations as previously described [5, 7]. All mice used in this 
study were between 4 and 10 weeks of age, when not otherwise indicated.  
Flow cytometry. Single cell suspensions were prepared from thymus, spleen, lymph nodes, 
bone marrow, and peritoneal cavity. Subsequently, 1x106 cells were stained with different 
monoclonal antibodies for 15 min at 4°C, washed, and then analyzed on a FACS Calibur 
using the CellQuest software (Becton Dickinson). Antibodies against CD3ε (145-2C11); CD4 
(RM4-5); CD5 (53-7.3); CD8 (53-6.7); CD21 (7G6); CD23 (B3B4); CD25 (7D4); CD40 
(3/23); CD44 (IM7); CD62L (MEL-14); CD69 (H1.2F3); CD86 (GL1); β-TCR (H57-597); 
B220 (RA3-6B2); IgM (11/41); IgD (11-26c.2a); MAC-1 (M1/70); were purchased from BD 
Bioscience. CD40L (MR1) were purchased from eBioscience. 
Proliferation assay. Splenic B lymphocytes or CD4+ cells were purified using a B-cell 
isolation kit or a CD4+ isolation kit (Miltenyi Biotech) on an AutoMACS magnetic separation 
system. The purity that we obtained during the isolation process was usually >94% and was 
confirmed by flow cytometry. Purified B cells (5x104 cells/well) and purified CD4+ cells 
(2x105 cells/well) were cultured in RPMI medium (supplemented with 10% fetal calf serum, 
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antibiotics, and β-mercaptoethanol) and either left unstimulated or activated with the 
following mitogens: anti-IgM F(ab)’2 fragment, CD40, LPS, CD3 and PMI and Ionomycin. 
Anti-IgM F(ab)’2 was added in solution, whereas CD40 and CD3 were coated to the plate. 
LPS was used at 1 µg/ml. Cells were cultured for 72 hours at 37°C with 5% CO2. During the 
last 8 hours, cells were pulsed with 0.5µCi/well of [3H]-thymidine. Subsequently, cells were 
harvested and [3H]-thymidine incorporation was measured by using the microplate liquid 
scintillation counter Wallac MicroBeta® TriLux from Perkin Elmer. 
Mouse immunization and ELISA. For T-independent (TI) immune responses, mice were 
immunized intraperitoneally with 50µg TNP-LPS (Sigma). Sera were collected before 
immunization and at day 10 after immunization. Immunoglobulin levels were determined as 
previously described [19]. Basal IgE levels were determined by using a Mouse-IgE 
Quantitation-Kit (Bethyl-Laboratories). 
Anti-nuclear antibody (ANA) production. The presence of anti-nuclear antibodies was 
analyzed by using a 12-well microscope slide (Innogenetics) covered with human HEp-2 
cells. HEp-2 cells were blocked and then incubated with the indicated mouse serum dilutions 
for 30 min. Successively, the slides were washed and incubated for additional 30 min with a 
FITC-labeled goat anti-mouse IgM antibody (Sigma) or donkey anti-mouse IgG antibody 
(Dianova). Slides were analyzed by fluorescence microscopy. 
Histology. Kidneys from 12 month old C57BL/6 wild-type and mutant mice were fixed in 
formalin and embedded in paraffin for histological studies. Sections were stained with 
hematoxylin and eosin (H&E) and additionally with periodic acid-Schiff (PAS). Slides were 
analyzed by light microscopy in a blinded fashion. 
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Immunofluorescence. For immunohistochemistry, kidneys were quickly frozen in liquid 
nitrogen. Sections were stained with FITC-conjugated goat anti-mouse IgG and analyzed by 
fluorescence microscopy. 
Proteinuria. Proteinuria was measured by using urine analysis sticks (Bayer). 
Statistics. Statistical analyses were performed using GraphPad Prism (GraphPad Software 
Inc., San Diego, CA). p values were determined by an unpaired two-tailed Student's t test. 
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Results 
Accumulation of activated CD4+ T cells in DKO mice. 
Recently, it has been shown that SIT and LAX are important negative regulators of 
lymphocyte activation [5, 7, 9]. As SIT-/- and LAX-/- mice display only a mild alteration in 
immune function, we have investigated whether the loss of both SIT or LAX results in a more 
severe phenotype. To assess this issue, we generated SIT-/-/LAX-/- double-knockout mice 
(DKO). We have previously shown that loss of SIT altered thymic selection. Conversely, 
LAX is dispensable for lymphocyte development [5]. To assess whether the concomitant 
ablation of LAX further aggravates the defective thymic development of SIT-deficient mice, 
we analyzed primary and secondary lymphoid organs from SIT-/-, LAX-/-, and DKO mice. The 
numbers as well as the CD4/CD8 profiles of thymocytes from DKO were comparable to those 
of SIT-deficient mice (data not shown). Moreover, detailed analyses of both positive and 
negative selection in TCR transgenic models also revealed no difference between SIT-
deficient and DKO mice (data not shown). Thus, it appears that SIT and LAX do not overlap 
during T-cell development. Also the size of the spleen and lymph nodes were comparable 
between mutant and wild type mice, thus indicating that DKO, similar to single mutant mice, 
do not develop lymphopenia or lymphoproliferative disease (data not shown). However, a 
detailed analysis of lymphocyte subsets revealed that aged, but not young, DKO mice have 
clearly elevated numbers of CD4+ T cells in the spleen (Table 1). The expansion of CD4+ T 
cells was not detected in either LAX-/- or SIT-/- mice. Successively, we examined whether 
CD4+ T cells from aged DKO mice showed additional abnormalities. FACS analyses revealed 
that CD4+ T cells from DKO mice express a significantly higher level of CD69 compared to 
the single mutant mice (Figure 1A). In contrast to CD4+ T cells from LAX-/- and SIT-/- mice, 
those from DKO also displayed elevated expression levels of the IL-2 receptor alpha chain 
CD25 (Figure 1A). Moreover, aged DKO mice, but not single mutant mice, also displayed a 
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striking increase in the numbers of CD4+ T cells that express high levels of CD44 and low 
levels of CD62L corresponding to activated/effector T cells (Figure 1B and Table 1). We 
additionally investigated a variety of surface markers and found that CD4+ T cells of all 
mutant mice express higher amounts of CD40L compared to WT mice (Figure 1C). 
Conversely to CD69 and CD25, we did not find any enhancement of SIT/LAX double-
deficiency on CD40L expression. 
Given the fact that T cells from aged DKO and SIT-/- appear to be expanded in vivo, we 
investigated their proliferative capability in vitro. As shown in Figure 2 and in agreement with 
our previously published data [7], loss of SIT enhanced CD3-mediated proliferation. 
Moreover, the data presented in Figure 2 also suggest that CD4+ T cells from 12 month-old 
DKO mice proliferate stronger in response to the applied stimuli in comparison to cells from 
either single knockout mice or WT controls. Taken together, it appears that SIT and LAX 
synergize to regulate the activation status of CD4+ T cells. 
Normal development of conventional B cells but increased numbers of B1 B cells in 
SIT/LAX double-deficient mice. 
We next evaluated the role of SIT and LAX in the B-cell compartment. We found that the 
development of conventional B cells is not affected by either single or double deletion of the 
two transmembrane adaptors (data not shown). In agreement with this observation, we found 
normal B-cell numbers in all mutant mice (data not shown). To assess whether other B-cell 
subsets, such as B1 cells that appear to have a distinct origin than conventional B cells [20], 
were affected by the loss of SIT and LAX, B1 cells were prepared from the spleen and 
peritoneal lavages, stained with IgM and CD5 Abs and analyzed by flow cytometry. As 
shown in Figure 3A-B, DKO mice possess a two-fold higher proportion of B1 cells compared 
to wild type mice both in the peritoneal cavity and the spleen. It is important to note that the 
proportion of B1 cells is normal in both SIT and LAX single-knockout mice. Thus, our data 
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reveal that, although SIT and LAX do not possess redundant function during the development 
of conventional B lymphocytes, they collaborate in regulating the size of the peripheral B1-
cell pool. 
B cells from DKO mice express higher levels of CD40 and are hyperproliferative upon 
CD40 stimulation 
We next investigated the function of the peripheral B-cell pool. We found that splenic B cells 
from all mutant mice displayed normal expression of the activation markers CD69 and CD86 
(Figure 4A and 4B). Figure 4C and D show that SIT-/- and LAX-/- mice also display normal 
levels of CD40 expression, while in contrast, splenic B cells from DKO mice have a marked 
increase in CD40 expression. CD40 is constitutively expressed on B cells. Crosslinking of 
CD40 initiates proliferation, differentiation, and Ig production.  
Next, we wanted to investigate whether SIT and LAX regulate the proliferative capability of 
B cells in vitro. Freshly purified splenic B cells were cultured and stimulated with different 
concentrations of anti-IgM F[ab’]2, CD40, and LPS. B cells from DKO mice displayed an 
equal proliferation potential compared to single knock-out mice upon anti-IgM F[ab’]2 
stimulation (data not shown). In contrast, upon stimulation with anti-CD40, B cells from 
DKO mice proliferated strongly (Figure 5). Taken together, these results demonstrate that SIT 
and LAX alone do not regulate proliferative response in vitro upon antigen receptor 
stimulation in B cells. In contrast, both adaptors together appear to regulate CD40 expression 
and hence proliferation upon CD40 stimulation in B cells in a redundant manner. 
SIT/LAX double-deficient mice display hypergammaglobulinemia and enhanced TI 
immune responses. 
Having demonstrated that SIT and LAX cooperatively regulate the activation status of CD4+ 
T cells and the number of B1 B cells, we wanted to evaluate whether the absence of both SIT 
and LAX also affects the immune response in vivo. We have previously shown that the 
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absence of SIT does not alter the basal serum immunoglobulin levels. Moreover, T-dependent 
(TD) and T-independent (TI) responses were also normal in SIT-/- mice [7]. Conversely to 
SIT-/- mice, LAX-deficient mice have been reported to possess elevated levels of basal 
immunoglobulins [5]. In agreement with these data, we found that SIT-/- mice possess normal 
levels of serum immunoglobulins, whereas LAX-deficient mice display higher levels of IgG1, 
IgG3, IgM, and IgE (Figure 6A). When we investigated the immunoglobulin levels in the sera 
of DKO mice, we observed that the production of IgG3, IgE, and particularly IgM is further 
enhanced in the DKOs compared to LAX-/- mice (Figure 6A). As SIT-deficient mice possess 
normal levels of immunoglobulins, the augmented concentration of IgG3, IgE, and IgM in the 
sera of DKO mice appears to indicate that SIT and LAX function in a cooperative manner in 
regulating immunoglobulin production in vivo. 
The augmented basal immunoglobulin levels observed in DKO mice prompted us to examine 
the humoral immune responses in these mice. To address this point, mice were immunized 
with the T-dependent antigen DNP-KLH and the T-independent antigen TNP-LPS. The 
concentration of anti-hapten antibodies after primary and secondary immunization with the 
DNP-KLH antigen was indistinguishable among SIT-, LAX-deficient, SIT/LAX double-
deficient, and wild type mice (data not shown). These observations confirm previous data and 
demonstrate that SIT and LAX are dispensable for TD immune responses [5, 7]. However, 
when mice were immunized with the TI-1 antigen TNP-LPS DKO mice showed a slight, but 
significant enhancement of the antibody titer (Figure 6B). Conversely, single mutant mice 
generated a normal antibody response against the TI-1 antigen TNP-LPS (Figure 6B). 
Collectively, these data suggest that SIT and LAX cooperatively regulate TI antibody 
production. 
SIT and LAX cooperate to limit autoimmunity. 
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The data presented above indicate that T and B cells from DKO have an altered function. We 
next analyzed whether our mutant mice spontaneously develop autoimmune diseases. We 
initially determined the constitutive production of autoantibodies by analyzing sera from aged 
SIT-/-, LAX-/-, DKO mice, and wild type littermates for the presence of antinuclear antibodies 
(ANAs). HEp-2 epithelial cells were permeabilized and incubated with sera from mutant and 
control mice. The immunofluorescence data presented in Figure 7A show that sera collected 
from 12 month-old SIT-/- and LAX-/- mice display an homogeneous antinuclear staining 
similar to what is observed in human Systemic Lupus Erythematosus (SLE) [21]. We next 
determined the ANA titer in SIT-/- and LAX-/- mice through serial dilution of the serum and 
found a titer of 247.3 ± 53.3 in SIT-/- and 221.8 ± 55.9 in LAX-/- mice whereas the mean of 
ANA titer in control mice was only 16.7 ± 9.1 (Figure 7B). On the other hand, DKO mice 
also showed an homogeneous antinuclear staining (Figure 7A) and displayed an antibody titer 
that was approximately two fold higher than in either single knockout (480 ± 97) (Figure 7B). 
Kidneys from DKO mice were markedly abnormal and displayed a more severe 
glomerulonephritis and an augmented IgG deposition compared to single knockout mice 
(Figure 7C). Moreover, glomeruli showing pathological signs were more frequent in DKO 
mice (data not shown). Additionally, DKO mice also displayed significantly enhanced 
proteinuria compared to single-mutant mice (Figure 7D). Thus, it appears that DKO mice 
suffer from a more severe disease than the single-knockout mice, as they display higher ANA 
titers and a more severe kidney disease. However, this seems to be an additive effect of the 
two phenotypes observed in single knockout mice. Thus, we propose that SIT and LAX 
cooperate to limit autoimmunity. 
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Discussion 
SIT and LAX possess similar structure, function, tissue distribution, and membrane 
localization. Here, we have investigated whether these two TRAPs also share overlapping 
functions in lymphocytes. The principal finding of our study is that SIT and LAX negatively 
regulate several aspects of the immune system in a cooperative manner. First, SIT and LAX 
appear to cooperate to limit autoimmunity. The clinical features of the lupus-like disease in 
our mice are similar to those seen in knockout mice for other adaptor molecules such as 
NTAL and TSAd [4, 22], as the disease is late in onset and does not affect 
mortality/morbidity. In NTAL- and TSAd-deficient mice the disease appears to be triggered 
by an abnormal T-cell function. However, in the case of SIT-/-, LAX-/-, and DKO mice, it is 
not clear whether T cells play a major role in the development of the lupus-like disease. We 
favor the hypothesis that an altered T-cell function is responsible for the development of 
autoantibodies. In fact, it has been shown that both SIT- and LAX-deficient T cells are 
hyperactive [5, 7, 9]. Here, we additionally show that LAX-deficient T cells display enhanced 
CD69 and CD40L expression. The intensity of CD40L expression seems to correlate with the 
susceptibility of the mice to develop Systemic Lupus Erythematosus. In fact, increased 
expression of CD40L was found on CD4+ T cells from lupus patients [23, 24]. Moreover, 
crossing MRL/lpr mice onto CD40L-deficient mice resulted in a decreased level of IgG 
autoantibodies, and a less severe renal disease [25]. Additionally, in SWR × NZB F1 mice, 
another murine lupus model, the administration of antibodies against CD40L (CD154) 
delayed the onset of the disease [26]. 
Thus, it may be that the increased CD40L expression observed in SIT-/-, LAX-/-, and DKO 
mice also contributes to the autoimmune syndrome, e.g. by supporting the production of high 
affinity IgG autoantibodies. Nevertheless, as SIT and LAX are also expressed in B cells, it is 
possible that B cells could also contribute to the development of the disease. Indeed, B-cell 
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functions are markedly altered in LAX-deficient mice [5]. Here, we have shown that DKO 
mice have enhanced TI-1 immune responses and display more B1 cells. However, additional 
experiments are required to asses the contribution of T and B cells to the development of the 
lupus-like disease in these mice. 
Second, our data suggest that SIT and LAX synergistically regulate the development of B-1 
cells, a peculiar subset of B lymphocytes. B1 cells express different surface markers (e.g. 
CD5) and also have different functions compared to conventional B2 cells [27]. In fact, B1 
cells are resistant to anti-IgM induced proliferation and apoptosis, produce low affinity 
antibodies with a broad specificity, and mediate mainly T-independent immune responses 
[27]. The importance of B1 cells is emphasized by the discovery that this lymphocyte 
subpopulation is implicated in the pathogenesis of many human diseases, such as 
autoimmunity and malignant transformation [20, 28].The origin of B1 cells is still under 
debate, but several studies indicate that the development of B1 cells appears to be critically 
dependent upon BCR signal strength. Disruption of genes that decrease BCR-mediated 
signaling results in a reduction of B-1 cells, whereas mutations that enhance BCR-mediated 
signal strength results in an expansion of B-1 cells [29]. Thus, mice lacking or carrying 
mutations in negative regulators of BCR-mediated signaling such as CD22, Lyn, PD-1, and 
SHP-1 show increased numbers of B1 cells. As SIT and LAX also represent negative 
regulators of antigen receptor-mediated signaling, the observation that B1-cell numbers are 
increased in DKO mice is in line with the idea that signals emanating from the BCR critically 
regulate B1 cell numbers. Our data further corroborate the hypothesis that the lack of negative 
regulators of BCR-mediated signaling leads to the expansion of the B-1 cell pool. 
How could SIT and LAX regulate the expansion of B1 cells? It has been shown that the 
development of B-1 cells depends critically on the transcription factor NFAT [30]. Indeed, the 
absence of NFATc1 resulted in a severe depletion of B1 cells by more than seven fold. 
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Berland and Wortis also demonstrated that B1 cells express five times more NFATc1 than 
conventional B2 cells [30]. Interestingly, both SIT and LAX were shown to regulate NFAT 
activity in Jurkat T cells in a dose-dependent manner [18, 31]. 
Third, we have shown that together SIT and LAX regulate basal Ig levels and TI-1 immune 
responses. It is possible that the increased levels of IgM and IgG3 in DKO may be due to the 
increased number of B1 cells in these mice. In fact, B1 cells are believed to be the primary 
source of natural IgM and IgG3 [32, 33]. These natural antibodies react weakly with self 
antigens, but strongly with many common pathogen-associated carbohydrate antigens. Almost 
all of the natural antibodies that react with LPS are produced by B1 cells [34]. These 
antibodies are very important for the clearance of LPS and, therefore, for protection against 
endotoxin-mediated sepsis. Thus, these data suggest that also the elevated antibody titer to 
TNP-LPS immunization in DKO mice may be due to the expanded B1-cell population. 
Despite the fact that our in vivo data suggest that SIT and LAX are important regulators of 
lymphocyte function, how SIT and LAX together fine-tune antigen receptor signaling is not 
yet clear. Previously published biochemical studies have revealed that LAX negatively 
regulates antigen receptor signaling by inhibiting PI3K signaling [5]. More recently, we have 
shown that SIT inhibits TCR-ζ phosphorylation, thus affecting proximal TCR signaling [9]. 
However, our extensive biochemical analysis of both T and B cells did not reveal any 
additional effect in DKO mice compared to the single mutants (data not shown). As both 
adaptors do not associate with membrane rafts, where signaling complexes are organized, we 
suggest that SIT and LAX may regulate the availability of cytoplasmic adaptors and effector 
molecules by sequestering them into the non-raft compartment. By acting as dosage-
dependent regulators of signaling pathways, SIT and LAX could control signals that are not 
only transduced via antigen receptors, but also through other surface receptors and could 
therefore modulate the general activation threshold of lymphocytes. 
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Collectively, our data suggest that lymphocytes are endowed with a set of TRAPs that exert 
subtle effects in regulating antigen receptor-mediated signaling. Thus, the question arises why 
lymphocytes need to express several TRAPs. Our data suggest that it is not the action of a 
single TRAP, but rather the coordinated action of multiple TRAPs that finely tunes the 
immune response. This regulation seems to be important not only for peripheral immune 
functions, but also for lymphocyte development. Indeed, we show here that SIT and LAX 
regulate the number of peripheral B1 cells and additional data from our laboratory suggest 
that the two transmembrane adaptor molecules SIT and TRIM concomitantly regulate T-cell 
development [14]. As suggested by studies demonstrating that NTAL and LAT function in a 
complementary manner to regulate FcεRI-mediated signaling in mast cells, it thus appears as 
if TRAPs possess a redundant role not only in lymphocytes, but also in other cell types within 
the immune system [16, 35]. 
It is tempting to speculate that functional redundancy is not only limited to the adaptor pairs 
SIT/LAX, NTAL/LAT, and SIT/TRIM, but indeed might apply to all TRAPs. In fact, the 
structural similarities between LAX and TRIM (note that both molecules are capable of 
binding PI3K and are strongly expressed in CD4+ T cells) or between NTAL and LAX (which 
both carry several Grb2-binding site and both are expressed in B cells and mast cells) are 
suggestive of the existence of sophisticated and redundant mechanisms that regulate antigen 
receptor-mediated signaling. Interestingly, it has been published that aged NTAL-deficient 
mice show hyperactivation of CD4+ T cells, anti-nuclear antibodies and develop a lupus-like 
autoimmune disease [4]. This phenotype strikingly resembles the alteration of the immune 
system that we observe in the SIT/LAX double-deficient mice. It will now be important to 
assess whether SIT/LAX/NTAL-triple deficient mice show an even more aggravated 
autoimmune phenotype. Similarly, the generation of additional double or even triple knockout 
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mice will help to assess how TRAPs control the intricate signal transduction network within 
immune cells. 
Nevertheless, it is striking to note that NTAL, SIT, TRIM, and LAX all appear to primarily 
exert negative regulatory signaling functions within the immune system. Similarly, although 
PAG/Cbp-deficient mice do not show an obvious phenotype [11, 12], siRNA studies 
demonstrate that PAG is an important negative regulatory protein in T cells [36]. Thus, it 
appears as if the strong positive regulatory function of LAT is balanced by a plethora of 
negative regulatory TRAPs that help to maintain homeostasis within the immune system. 
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Legend to figures. 
Figure 1. Analysis of T-cell activation markers 
A) Histograms show the expression of the activation markers CD69 or CD25. Numbers 
within the histograms indicate the percentage of CD4+ T cells that express CD69 or CD25. 
Graphs show statistical analyses of CD69 and CD25 expression. Bars represent the mean ± 
SEM from four mice. Statistical significance is indicated (* p<0,05). B) CD4+ T cells were 
analyzed for the expression of CD44 and CD62L. Numbers indicate the percentage of cells in 
the region. C) Histograms compare the expression of CD40L on CD4+ T cells from WT 
(shaded) and mutant mice (black line). Left panel: comparison between WT and SIT-/- mice; 
middle panel: comparison between WT and LAX-/- mice; right panel: comparison between 
WT and DKO mice. Bar graphs on the right represent statistical analysis from five mice. 
Statistical significance is indicated (* p<0,05). 
Figure 2. T cells from DKO mice are hyperactivated 
Purified splenic CD4+ T cells from aged mutant and control mice were stimulated in a 96-well 
plate with the indicated doses of coated CD3 or PMA plus ionomycin (P&I) (2 ng/ml PMA 
and 0,5 µg/ml Ionomycin) for 72 hours. Cells were pulsed with [3H]-thymidine and processed 
for standard scintillation counting. Data represent mean counts per minute (cpm) ± SEM from 
five mice. * p < 0.05; ** p < 0.01; *** p < 0.0001; ns=not significant. 
Figure 3. Increased numbers of B1 cells in DKO mice 
A) Peritoneal cells were stained with mAbs against CD5 and IgM. B1 cells were defined as 
IgMhi and CD5+. Numbers indicate the percentages of living cells that reside in the 
corresponding gate. One representative mouse out of ten per each group is shown. B) Bar 
graphs show the absolute numbers of B1 cells in the peritoneal cavity (left) and spleen (right). 
* p < 0.05; ** p < 0.01. 
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Figure 4. Analysis of B-cell activation markers in aged mice. 
A) Histograms display the expression of the activation marker CD69 on B220+-gated cells 
from aged DKO, SIT-/- or LAX-/- and WT mice. Numbers indicate the percentage of living 
cells that express CD69. B and C) B220+-gated splenic cells were analyzed for the expression 
of CD86 and of CD40. One representative mouse of four is shown. D) Statistical analysis of 
CD40 expression. Data show the MFI ± SEM from four mice. *** p < 0.001. 
Figure 5: Hyperproliferation of B cells from DKO mice upon CD40 stimulation 
Purified splenic B cells from aged mutant and control mice were stimulated with the indicated 
concentrations of plate-bound CD40 mAb or LPS in a 96-well plate for 72 hours. 
Proliferation was assessed by [H3]-thymidine incorporation for the last 6-8 hours. Data 
represent mean counts per minute (cpm) ± SEM from triplicate cultures of four mice per each 
group. Statistical significance is indicated * p < 0.05; ** p < 0.01. 
Figure 6. Hypergammaglobulinemia in DKO mice 
A) Basal immunoglobulin levels in the sera from ten DKO, SIT-/-, LAX-/- and WT mice were 
determined by ELISA. (B) T cell-independent immune response. Mice were immunized with 
50µg TNP-LPS, sera were collected before (Day 0) and after (Day 10) immunization and 
analyzed for TNP-specific antibodies. A total of 11 mice per group were analyzed. Asterisks 
indicate the statistical significance * p < 0.05; ** p < 0.01; *** p < 0.0001. 
Figure 7. Development of ANAs and glomerulonephritis in DKO, SIT-/- and LAX-/- mice 
A) The presence of autoantibodies (ANAs) in sera from aged mutant and WT mice was 
determined by immunofluorescent staining of HEp-2 epithelial cells. The pattern of nuclear 
staining of HEp-2 cells using 1:80 dilution is shown. ANAs were detected with FITC-
conjugated secondary antibody against mouse IgG. B) Statistical analysis of ANA titer in 
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mutant and wild type mice. The bars represent the mean values of ANA titers. C) Kidney 
sections from 1 year-old mutant and wild type mice were stained with periodic acid-Schiff 
(PAS), hematoxylin and eosin (H&E) or with FITC-conjugated goat anti-mouse IgG. Sections 
were analyzed in a blinded fashion by light microscopy and scored for mesangial cellularity, 
increased mesangial matrix, infiltration of inflammatory cells and thickness of basal 
membranes or capillary walls. Representative glomeruli from control and mutant mice are 
shown (1 x 400). Kidney cryosections were also stained with FITC-conjugated goat anti-
mouse IgG and the presence of immune complexes was visualized by fluorescence 
microscopy. D) Statistical analysis of proteinuria in mutant and wild type mice. The bars 
represent the mean values of proteinuria. Proteinuria was measured by using urine analysis 
sticks and graded according to the following scale: negative, 0 mg/dl; 1, < 30mg/dl; 2, < 
100mg/dl and 3, > 100mg/dl. Asterisks in B) and D) indicate statistical significance (* 
p<0,05; ** p<0.01; *** p<0.0001). 
 
 
 
 
 
 
Table 1: Cellularity of peripheral T-cell subsets from aged mutant and wild type mice. 
The numbers of lymphocyte subsets were determined on the basis of the total cell numbers 
and flow cytometric analysis. Data represent means ± standard errors (SD) of the mean. 
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Genotype Number of 
examined 
mice 
Number (1x106) of Spleenocytes ±SD 
Total CD4+ CD4+ CD44hi 
CD62low 
CD8+ 
DKO 12 113.3±29.0 27.3±6.9 19.2±5.2 8.2±2.8 
LAX-/- 6 109.5±22.0 20.6±5.6 10.1±2.5 12.1±4.8 
SIT-/- 6 98.8±26.1 19.6±4.1 11.4±2.0 8.5±1.8 
WT 8 111.3±24.6 19.6±6.5 8.6±3.8 13.0±3.5 
p values   DKO vs LAX 0.04 
DKO vs SIT 0.01 
DKO vs WT 0.01 
DKO vs LAX 0.0008 
DKO vs SIT 0.0034 
DKO vs WT 0.0001 
DKO vs LAX 0.11 
DKO vs SIT 0.87 
DKO vs WT 0.02 
 
Table 1 
 
